PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ				Golubitsky, M; Stewart, I; Buono, PL; Collins, JJ			Symmetry in locomotor central pattern generators and animal gaits	NATURE			English	Article							COUPLED OSCILLATORS; QUADRUPEDAL GAITS; TRANSITIONS; CHAINS	Animal locomotion is controlled, in part, by a central pattern generator (CPG), which is an intraspinal network of neurons capable of generating a rhythmic output(1-4). The spatio-temporal symmetries of the quadrupedal gaits walk, trot and pace(5-8) lead to plausible assumptions about the symmetries of locomotor CPGs(9-11). These assumptions imply that the CPG of a quadruped should consist of eight nominally identical subcircuits, arranged in an essentially unique matter. Here we apply analogous arguments to myriapod CPGs. Analyses based on symmetry applied to these networks lead to testable predictions, including a distinction between primary and secondary gaits, the existence of a new primary gait called 'jump', and the occurrence of half-integer wave numbers in myriapod gaits. For bipeds, our analysis also predicts two gaits with the out-of-phase symmetry of the walk and two gaits with the in-phase symmetry of the hop. We present data that support each of these predictions. This work suggests that symmetry can be used to infer a plausible dass of CPG network architectures from observed patterns of animal gaits.	Univ Houston, Dept Math, Houston, TX 77204 USA; Univ Warwick, Inst Math, Coventry CV4 7AL, W Midlands, England; Boston Univ, Dept Biomed Engn, Ctr Biodynam, Boston, MA 02215 USA	University of Houston System; University of Houston; University of Warwick; Boston University	Golubitsky, M (corresponding author), Univ Houston, Dept Math, Houston, TX 77204 USA.			Buono, Pietro-Luciano/0000-0003-1460-4465				Alexander R. M., 1977, MECH ENERGETICS ANIM, P168; ALEXANDER RM, 1983, J ZOOL, V201, P135, DOI 10.1111/j.1469-7998.1983.tb04266.x; BUONO PL, UNPUB J MATH BIOL; BUONO PL, 1998, THESIS U HOUSTON; COLLINS FS, 1993, HUM GENOME NEWS, V5, P3; COLLINS JJ, 1992, J MATH BIOL, V30, P827; COLLINS JJ, 1993, BIOL CYBERN, V68, P287, DOI 10.1007/BF00201854; COLLINS JJ, 1994, BIOL CYBERN, V71, P95, DOI 10.1007/BF00197312; DELCOMYN F, 1980, SCIENCE, V210, P492, DOI 10.1126/science.7423199; DEUEL NR, 1987, J BIOMECH, V20, P645, DOI 10.1016/0021-9290(87)90285-5; FULL RJ, 1991, J EXP BIOL, V158, P369; Gambaryan P.P., 1974, MAMMALS RUN ANATOMIC; Golubitsky M, 1998, PHYSICA D, V115, P56, DOI 10.1016/S0167-2789(97)00222-4; GOLUBITSKY M, 1988, SINGULARITIES GROUPS, V2, P275; HILDEBRA.M, 1965, SCIENCE, V150, P701, DOI 10.1126/science.150.3697.701; HILDEBRAND M, 1989, BIOSCIENCE, V39, P766, DOI 10.2307/1311182; Hildebrand M., 1976, NEURAL CONTROL LOCOM, V18, P202, DOI DOI 10.1007/978-1-4757-0964-3_9; KOPELL N, 1990, SIAM J APPL MATH, V50, P1014, DOI 10.1137/0150062; KOPELL N, 1986, COMMUN PUR APPL MATH, V39, P623, DOI 10.1002/cpa.3160390504; Kopell N., 1988, MATH BIOSCI, V89, P14; LEACH DH, 1979, J EQUINE MED SURG, V3, P436; Mann R, 1982, DISORDERS OF THE FOO, P37; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; MANTON S. M., 1965, J LINN SOC LONDON ZOOL, V45, P251; SCHONER G, 1990, J THEOR BIOL, V142, P359, DOI 10.1016/S0022-5193(05)80558-2; SELVERSTON AI, 1980, BEHAV BRAIN SCI, V3, P535, DOI 10.1017/S0140525X00006580; SHIK ML, 1976, PHYSIOL REV, V56, P465, DOI 10.1152/physrev.1976.56.3.465	27	282	287	0	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					693	695		10.1038/44416	http://dx.doi.org/10.1038/44416			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537106				2022-12-24	WOS:000083207400055
J	Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW				Serdula, MK; Mokdad, AH; Williamson, DF; Galuska, DA; Mendlein, JM; Heath, GW			Prevalence of attempting weight loss and strategies for controlling weight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAT-CONTENT; ADULTS; OVERWEIGHT; EXERCISE; WOMEN	Context Overweight and obesity are increasing in the United States. Changes in diet and physical activity are important for weight control. Objectives To examine the prevalence of attempting to lose or to maintain weight and to describe weight control strategies among US adults. Design The Behavioral Risk Factor Surveillance System, a random-digit telephone survey conducted in 1996 by state health departments. Setting The 49 states (and the District of Columbia) that participated in the survey. Participants Adults aged 18 years and older (N = 107 804). Main Outcome Measures Reported current weights and goal weights, prevalence of weight loss or maintenance attempts, and strategies used to control weight (eating fewer calories, eating less fat, or using physical activity) by population subgroup. Results The prevalence of attempting to lose and maintain weight was 28.8% and 35.1% among men and 43.6% and 34.4% among women, respectively. Among those attempting to lose weight, a common strategy was to consume less fat but not fewer calories (34.9% of men and 40.0% of women); only 21.5% of men and 19.4% of women reported using the recommended combination of eating fewer calories and engaging in at least 150 minutes of leisure-time physical activity per week. Among men trying to lose weight, the median weight was 90.4 kg with a goal weight of 81.4 kg. Among women, the median weight was 70.3 kg with a goal weight of 59.0 kg. Conclusions Weight loss and weight maintenance are common concerns for US men and women. Most persons trying to lose weight are not using the recommended combination of reducing calorie intake and engaging in leisure-time physical activity 150 minutes or more per week.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Serdula, MK (corresponding author), Ctr Dis Control & Prevent, Div Nutr & Phys Act, Chron Dis Nutr Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K26, Atlanta, GA 30341 USA.		Heath, Gregory Wayne/AAE-2464-2020	Heath, Gregory Wayne/0000-0003-2864-5225				ALLRED JB, 1995, J AM DIET ASSOC, V95, P417, DOI 10.1016/S0002-8223(95)00111-5; [Anonymous], 1998, CLIN GUID ID EV TREA; Bouchard C, 1993, Obes Res, V1, P133; BROWNELL KD, 1995, INT J OBESITY, V19, pS122; CAPUTO FA, 1993, INT J OBESITY, V17, P237; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P199; CLELAND R, 1998, COMMERCIAL WEIGHT LO; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JAKICIC JM, 1995, INT J OBESITY, V19, P893; JEFFERY RW, 1995, OBES RES, V3, pS283, DOI 10.1002/j.1550-8528.1995.tb00475.x; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; NELSON DE, 1998, P SECT SURV METH AM; Pronk N P, 1994, Obes Res, V2, P587; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHULMAN J, 1999, 16 ANN BRFSS C MAY 1; SERDULA MK, 1994, AM J PUBLIC HEALTH, V84, P1821, DOI 10.2105/AJPH.84.11.1821; Shah BV, 1997, SUDAAN USERS MANUAL; SHIDE DJ, 1995, J AM DIET ASSOC, V95, P993, DOI 10.1016/S0002-8223(95)00273-1; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; [No title captured]	22	351	354	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1353	1358		10.1001/jama.282.14.1353	http://dx.doi.org/10.1001/jama.282.14.1353			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527182	Bronze			2022-12-24	WOS:000083000800030
J	Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC				Wilson, CL; Ouellette, AJ; Satchell, DP; Ayabe, T; Lopez-Boado, YS; Stratman, JL; Hultgren, SJ; Matrisian, LM; Parks, WC			Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense	SCIENCE			English	Article							PANETH CELL DEFENSINS; ANTIMICROBIAL PEPTIDES; EPITHELIAL-CELLS; GENE-EXPRESSION; MOUSE; CRYPTDIN; PURIFICATION; VERTEBRATES; DEGRADATION; COMPONENTS	Precursors of alpha-defensin peptides require activation for bactericidal activity. In mouse small intestine, matrilysin colocalized with alpha-defensins (cryptdins) in Paneth cell granules, and in vitro it cleaved the pro segment from cryptdin precursors. Matrilysin-deficient (MAT(-/-)) mice Lacked mature cryptdins and accumulated precursor molecules. Intestinal peptide preparations from MAT(-/-) mice had decreased antimicrobial activity. Orally administered bacteria survived in greater numbers and were more virulent in MAT(-/-) mice than in MAT(+/+) mice Thus, matrilysin functions in intestinal mucosal defense by regulating the activity of defensins, which may be a common role for this metalloproteinase in its numerous epithelial sites of expression.	Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Washington Univ, Sch Med, Dept Mol Microbiol & Microbial Pathogenesis, St Louis, MO 63110 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Washington University (WUSTL); University of California System; University of California Irvine; University of California System; University of California Irvine; Washington University (WUSTL); Vanderbilt University	Wilson, CL (corresponding author), Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO 63110 USA.		Parks, William C./AAH-6786-2021; Ayabe, Tokiyoshi/F-5264-2011	Ayabe, Tokiyoshi/0000-0002-8631-5593				AYABE T, UNPUB; BEVINS CL, 1994, CIBA F SYMP, V186, P250; CANOGAUCI DF, 1993, EXP CELL RES, V208, P344, DOI 10.1006/excr.1993.1255; Darmoul D, 1996, AM J PHYSIOL-GASTR L, V271, pG68, DOI 10.1152/ajpgi.1996.271.1.G68; EISENHAUER PB, 1992, INFECT IMMUN, V60, P3556, DOI 10.1128/IAI.60.9.3556-3565.1992; Gad S.C., 1989, PRINCIPLES METHODS T, P463; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; GANZ T, 1990, EUR J HAEMATOL, V44, P1; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Ganz T, 1997, SEMIN HEMATOL, V34, P343; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; LOPEZBOADO YS, UNPUB; MARCOTTE PA, 1992, J BIOL CHEM, V267, P13803; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OUELLETTE AJ, 1992, FEBS LETT, V304, P146, DOI 10.1016/0014-5793(92)80606-H; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; Quayle AJ, 1998, AM J PATHOL, V152, P1247; SATOH Y, 1995, GASTROENTEROLOGY, V108, P1345, DOI 10.1016/0016-5085(95)90681-9; SATOH Y, 1988, CELL TISSUE RES, V253, P397; SATOH Y, 1986, DIGESTION, V34, P115, DOI 10.1159/000199319; SATOH Y, 1988, CELL TISSUE RES, V251, P87, DOI 10.1007/BF00215451; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1986, ANAL BIOCHEM, V155, P270, DOI 10.1016/0003-2697(86)90436-7; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SELSTED ME, 1989, J BIOL CHEM, V264, P4003; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Svinarich DM, 1997, AM J OBSTET GYNECOL, V176, P470, DOI 10.1016/S0002-9378(97)70517-9; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; WELKOS S, 1994, METHOD ENZYMOL, V235, P29; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	40	871	903	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					113	117		10.1126/science.286.5437.113	http://dx.doi.org/10.1126/science.286.5437.113			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506557				2022-12-24	WOS:000082907400047
J	Cheng, CHC; Chen, LB				Cheng, CHC; Chen, LB			Evolution of an antifreeze glycoprotein	NATURE			English	Article									Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Cheng, CHC (corresponding author), Univ Illinois, Dept Ecol Ethol & Evolut, Urbana, IL 61801 USA.			, liangbiao/0000-0002-0717-8536				Chen LB, 1997, P NATL ACAD SCI USA, V94, P3811, DOI 10.1073/pnas.94.8.3811; Chen LB, 1997, P NATL ACAD SCI USA, V94, P3817, DOI 10.1073/pnas.94.8.3817; Cheng Chi-Hing C., 1998, P311; CLARKE A, 1996, TRENDS ECOL EVOL, V11, P187; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; Eastman J.T., 1993, ANTARCTIC FISH BIOL; HSIAO KC, 1990, P NATL ACAD SCI USA, V87, P9265, DOI 10.1073/pnas.87.23.9265; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEWIN B, 1994, GENES, V5	9	110	122	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					443	444		10.1038/46721	http://dx.doi.org/10.1038/46721			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519545				2022-12-24	WOS:000082981200042
J	Truman, JW; Riddiford, LM				Truman, JW; Riddiford, LM			The origins of insect metamorphosis	NATURE			English	Article							COCKROACH NAUPHOETA-CINEREA; JUVENILE HORMONE-III; MANDUCA-SEXTA; EMBRYONIC-DEVELOPMENT; LOCUSTA-MIGRATORIA; ECDYSTEROID TITER; TOBACCO HORNWORM; PIONEER NEURONS; NERVOUS-SYSTEM; EMBRYOGENESIS	Insect metamorphosis is a fascinating and highly successful biological adaptation, but there is much uncertainty as to how it evolved. Ancestral insect species did not undergo metamorphosis and there are stilt some existing species that lack metamorphosis or undergo only partial metamorphosis. Based on endocrine studies and morphological comparisons of the development of insect species with and without metamorphosis, a novel hypothesis for the evolution of metamorphosis is proposed. changes in the endocrinology of development are central to this hypothesis The three stages of the ancestral insect species-pronymph, nymph and adult-are proposed to be equivalent to the larva, pupa and adult stages of insects with complete metamorphosis. This proposal has general implications far insect developmental biology.	Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Truman, JW (corresponding author), Univ Washington, Dept Zool, Box 351800, Seattle, WA 98195 USA.	jwt@u.washington.edu						Asahina S, 1954, MORPHOLOGICAL STUDY; AZAM KM, 1969, ANN ENTOMOL SOC AM, V62, P549, DOI 10.1093/aesa/62.3.549; BAKER FC, 1987, INSECT BIOCHEM, V17, P989, DOI 10.1016/0020-1790(87)90108-9; BATE CM, 1976, NATURE, V260, P54, DOI 10.1038/260054a0; Bergot B. J., 1981, JUVENILE HORMONE BIO, P33; Berlese A., 1913, Redia Firenze, V9; BERNAYS EA, 1971, Z MORPHOL TIERE, V70, P183; BOLLENBACHER WE, 1981, GEN COMP ENDOCR, V44, P302, DOI 10.1016/0016-6480(81)90005-8; BROADIE KS, 1991, ROUX ARCH DEV BIOL, V199, P327, DOI 10.1007/BF01705925; BRUNING E, 1985, INT J INVER REP DEV, V8, P269; BRYANT PJ, 1970, DEV BIOL, V22, P389, DOI 10.1016/0012-1606(70)90160-0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CARPENTER FM, 1992, ARTHROPODA R, V3, P1; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Champlin DT, 1998, DEVELOPMENT, V125, P2009; CORBET PHILIP S., 1955, ENT GAZ, V6, P189; Couso JP, 1998, INT J DEV BIOL, V42, P345; Dewitz, 1878, Z WISS ZOOL, V30, P78; DORN A, 1981, TISSUE CELL, V13, P461, DOI 10.1016/0040-8166(81)90019-7; DORN A, 1983, ENTOMOL GEN, V8, P193; Durston AJ, 1998, CURR TOP DEV BIOL, V40, P111, DOI 10.1016/S0070-2153(08)60366-X; EDWARDS JS, 1979, ROUX ARCH DEV BIOL, V186, P151, DOI 10.1007/BF00848176; FAIN MJ, 1975, BIOL BULL-US, V149, P506, DOI 10.2307/1540383; Grueber WB, 1999, J COMP NEUROL, V404, P127, DOI 10.1002/(SICI)1096-9861(19990201)404:1<127::AID-CNE10>3.0.CO;2-M; Heeley W, 1941, P ZOOL SOC LOND B-SY, V111, P79; Heming BS, 1996, CAN J ZOOL, V74, P1008, DOI 10.1139/z96-114; HINTON H. E., 1955, TRANS ROY ENT SOC LONDON, V106, P455; Hinton H. E., 1948, Transactions of the Royal Entomological Society of London, V99, P395; Hinton H.E., 1981, BIOL INSECT EGGS, V1; IMBODEN H, 1978, GEN COMP ENDOCR, V36, P628, DOI 10.1016/0016-6480(78)90104-1; KARAWAIEW W, 1898, Z WISS ZOOL, V64, P385; KREMEN C, J INSECT PHYSL, V44, P287; KRISHNAN KN, 1975, INDIAN J TECHNOL, V13, P1; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KURUSHIMA M, 1975, J INSECT PHYSIOL, V21, P1705, DOI 10.1016/0022-1910(75)90183-3; KUTSCH W, 1987, DEV BIOL, V123, P517, DOI 10.1016/0012-1606(87)90410-6; LAGUEUX M, 1979, J INSECT PHYSIOL, V25, P709, DOI 10.1016/0022-1910(79)90123-9; LAWRENCE JF, 1982, ANNU REV ECOL SYST, V13, P261, DOI 10.1146/annurev.es.13.110182.001401; Lindsay E., 1940, Proceedings of the Royal Society of Victoria N S, V52, P35; MEIER T, 1991, DEVELOPMENT, V112, P241; MERCER WF, 1900, NEW YORK ENTOMOL SOC, V8, P1; MEYER DR, 1980, J EXP ZOOL, V213, P185, DOI 10.1002/jez.1402130205; MICCIARELLI AS, 1977, ACTA EMBRYOL EXP, P295; Monsma SA, 1996, J COMP NEUROL, V367, P10, DOI 10.1002/(SICI)1096-9861(19960325)367:1<10::AID-CNE2>3.0.CO;2-M; Needham JG, 1935, BIOL MAYFLIES; NEUMANN D, 1991, J INSECT PHYSIOL, V37, P101, DOI 10.1016/0022-1910(91)90095-H; Nijhout H.F., 1994, INSECT HORMONES; NOVAK VJA, 1969, J EMBRYOL EXP MORPH, V21, P1; NOVAK VJA, 1975, INSECT HORMONES; Oberlander H., 1985, COMPREHENSIVE INSECT, V1st, P151; Powell P. B., 1904, J NY ENTOMOL SOC, V12, P237; Powell PB., 1905, J N Y ENTOMOL SOC, V13, P5; Poyarkoff E., 1914, Archives de Zoologie Paris, V54; PRATT HS, 1897, PSYCHE, V8, P15; QUENNEDEY A, 1990, TISSUE CELL, V22, P721, DOI 10.1016/0040-8166(90)90067-J; REDDY G, 1980, EXPERIENTIA, V36, P461, DOI 10.1007/BF01975148; RIDDIFOR.LM, 1967, P NATL ACAD SCI USA, V57, P595, DOI 10.1073/pnas.57.3.595; Riddiford L.M., 1972, P95; RIDDIFORD LM, 1994, ADV INSECT PHYSIOL, V24, P213, DOI 10.1016/S0065-2806(08)60084-3; RIDDIFORD LM, 1978, INSECT BIOCHEM, P307; ROHDENDORF EB, 1973, J INSECT PHYSIOL, V19, P37, DOI 10.1016/0022-1910(73)90220-5; SBRENNA G, 1991, MORPHOGENETIC HORMON, V3, P44; SBRENNAMICCIARE.A, 1972, J INSECT PHYSIOL, V18, P1027; SEHNAL F, 1985, COMPREHENSIVE INSECT, V2, P1; Sehnal Frantisek, 1996, P3, DOI 10.1016/B978-012283245-1/50003-8; SMITH RF, 1975, J INSECT PHYSIOL, V21, P723, DOI 10.1016/0022-1910(75)90004-9; SVACHA P, 1992, DEV BIOL, V154, P101, DOI 10.1016/0012-1606(92)90052-I; TEMIN G, 1986, INT J INVER REP DEV, V9, P105, DOI 10.1080/01688170.1986.10510184; Tiegs O. W., 1922, Transactions and Proceedings Royal Society South Australia, V46, P319; TOWER WL, 1903, ZOOL JB, V17, P515; van der Hammen L., 1989, INTRO COMP ARACHNOLO; VAUGHT GL, 1974, ANN ENTOMOL SOC AM, V67, P167, DOI 10.1093/aesa/67.2.167; WATSON JAL, 1967, BIOL BULL, V132, P277, DOI 10.2307/1539895; WEISMANN A, 1864, Z WISS ZOOL, V14, P101; Whiting MF, 1997, SYST BIOL, V46, P1, DOI 10.1093/sysbio/46.1.1; WIESMAN A, 1966, Z WISS ZOOL, V16, P1; Williams C.M., 1980, P369; ZACHARUK RY, 1991, ANNU REV ENTOMOL, V36, P331, DOI 10.1146/annurev.en.36.010191.001555	78	354	369	6	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					447	452		10.1038/46737	http://dx.doi.org/10.1038/46737			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519548				2022-12-24	WOS:000082981200047
J	Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS				Dunn, DE; Tanawattanacharoen, P; Boccuni, P; Nagakura, S; Green, SW; Kirby, MR; Kumar, MSA; Rosenfeld, S; Young, NS			Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED APLASTIC-ANEMIA; MYELODYSPLASTIC SYNDROMES; FLOW-CYTOMETRY; MONOCLONAL-ANTIBODIES; ANCHORED PROTEINS; PATHOGENETIC LINK; PNH PHENOTYPE; DEFICIENCY; DIAGNOSIS; DISEASE	Background: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem-cell disorder in which the affected cells are deficient in glycosylphosphatidylinositol (GPI)-anchored proteins. Paroxysmal nocturnal hemoglobinuria is frequently associated with aplastic anemia, although the basis of this relation is unknown. Objective: To assess the PNH status of patients with diverse marrow failure syndromes. Design: Correlation of cytofluorometric data with clinical features. Setting: Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, Maryland. Patients: 115 patients with aplastic anemia, 39 patients with myelodysplasia, 28 patients who had recently undergone bone marrow transplantation, 18 patients with cancer that was treated with chemotherapy, 13 patients with large granular lymphocytosis, 20 controls who had received renal allografts, and 21 healthy participants. Intervention: Patients with aplastic anemia, myelodysplasia, or renal allografts received antithymocyte globulin. Measurements: Flow cytometry was used to assess expression of GPI-anchored proteins on granulocytes. Results: Evidence of PNH was found in 25 of 115 (22%) patients with aplastic anemia. No patient with normal CPI-anchored protein expression at presentation developed PNH after therapy (n = 16). Nine of 39 (23%) patients with myelodysplasia had CPI-anchored protein-deficient cells. Abnormal cells were not detected in patients with constitutional or other forms of bone marrow failure or in renal allograft recipients who had received antithymocyte globulin. Aplastic anemia is known to respond to immunosuppressive therapy; in myelodysplasia, the presence of a PNH population was strongly correlated with hematologic improvement after administration of antithymocyte globulin (P = 0.0015). Conclusions: Flow cytometric analysis is superior to the Ham test and permits concomitant diagnosis of PNH in about 20% of patients with myelodysplasia (a rate similar to that seen in patients with aplastic anemia). The presence of GPI-anchored protein-deficient cells in myelodysplasia predicts responsiveness to immunosuppressive therapy. Early emergence of GPI-anchored protein-deficient hematopoiesis in a patient with marrow failure may point to an underlying immune pathogenesis.	NHLBI, Bethesda, MD 20892 USA; MCP Hahnemann Univ Hosp, Philadelphia, PA USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Drexel University	Dunn, DE (corresponding author), 309 E Osceola St,Suite 208, Stuart, FL 34994 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002315, ZIAHL002315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfinito F, 1996, LEUKEMIA, V10, P1326; Araten DJ, 1999, P NATL ACAD SCI USA, V96, P5209, DOI 10.1073/pnas.96.9.5209; Aul C, 1998, LEUKEMIA RES, V22, P93, DOI 10.1016/S0145-2126(97)00089-1; CONRAD ME, 1979, AM J HEMATOL, V7, P61, DOI 10.1002/ajh.2830070108; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; Dunn DE, 1996, P NATL ACAD SCI USA, V93, P7938, DOI 10.1073/pnas.93.15.7938; Dunn DE, 1997, BLOOD, V90, P1811; GRAHAM DL, 1992, AM J MED, V93, P671, DOI 10.1016/0002-9343(92)90201-L; GRISCELLIBENNACEUR A, 1995, BLOOD, V85, P1354, DOI 10.1182/blood.V85.5.1354.bloodjournal8551354; Hall SE, 1996, BLOOD, V87, P5332, DOI 10.1182/blood.V87.12.5332.bloodjournal87125332; HERTENSTEIN B, 1995, BLOOD, V86, P1487, DOI 10.1182/blood.V86.4.1487.bloodjournal8641487; IWAMOTO N, 1995, BLOOD, V85, P2228, DOI 10.1182/blood.V85.8.2228.bloodjournal8582228; Iwanaga M, 1998, BRIT J HAEMATOL, V102, P465, DOI 10.1046/j.1365-2141.1998.00794.x; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; Kawagoe K, 1996, BLOOD, V87, P3600, DOI 10.1182/blood.V87.9.3600.bloodjournal8793600; Kinoshita T, 1996, ANNU REV MED, V47, P1; LEWIS SM, 1967, BRIT J HAEMATOL, V13, P236, DOI 10.1111/j.1365-2141.1967.tb08736.x; LOUGHRAN TP, 1993, BLOOD, V82, P1; Luzzatto L, 1996, Curr Opin Hematol, V3, P101; Molldrem JJ, 1997, BRIT J HAEMATOL, V99, P699, DOI 10.1046/j.1365-2141.1997.4423249.x; Nagakura S, 1997, INT J HEMATOL, V65, P187; NAKAKUMA H, 1995, BLOOD, V85, P1371, DOI 10.1182/blood.V85.5.1371.bloodjournal8551371; NISSEN C, 1986, BRIT J HAEMATOL, V64, P355, DOI 10.1111/j.1365-2141.1986.tb04129.x; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; Raza A, 1996, LEUKEMIA, V10, P1648; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Rosse WF, 1997, MEDICINE, V76, P63, DOI 10.1097/00005792-199703000-00001; Rosti V, 1997, J CLIN INVEST, V100, P1028, DOI 10.1172/JCI119613; ROTOLI B, 1989, SEMIN HEMATOL, V26, P201; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; SCHREZENMEIER H, 1995, EXP HEMATOL, V23, P81; SCHUBERT J, 1991, BRIT J HAEMATOL, V79, P487, DOI 10.1111/j.1365-2141.1991.tb08060.x; SHICHISHIMA T, 1993, BRIT J HAEMATOL, V85, P378, DOI 10.1111/j.1365-2141.1993.tb03182.x; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; TERSTAPPEN LWMM, 1992, J LEUKOCYTE BIOL, V52, P652, DOI 10.1002/jlb.52.6.652; VANDERSCHOOT CE, 1990, BLOOD, V76, P1853; VANKAMP H, 1994, BRIT J HAEMATOL, V87, P399, DOI 10.1111/j.1365-2141.1994.tb04929.x; WARE RE, 1991, NEW ENGL J MED, V325, P991, DOI 10.1056/NEJM199110033251403; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Young NS, 1999, JAMA-J AM MED ASSOC, V282, P271, DOI 10.1001/jama.282.3.271; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385	41	210	219	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					401	408		10.7326/0003-4819-131-6-199909210-00002	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498555				2022-12-24	WOS:000082641100001
J	Treasure, T				Treasure, T			Rethink on biological aortic valves for the elderly	LANCET			English	Editorial Material							HEART-VALVE		Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England	St Georges University London	Treasure, T (corresponding author), Univ London St Georges Hosp, Cardiothorac Unit, London SW17 0QT, England.							BLOOMFIELD P, 1991, NEW ENGL J MED, V324, P573, DOI 10.1056/NEJM199102283240901; Bouma BJ, 1999, HEART, V82, P143, DOI 10.1136/hrt.82.2.143; Gilbert T, 1999, HEART, V82, P138, DOI 10.1136/hrt.82.2.138; HAMMERMEISTER KE, 1993, NEW ENGL J MED, V328, P1289, DOI 10.1056/NEJM199305063281801; HUYSMANS HA, 1999, STENTLESS BIOPROSTHE; Peterseim DS, 1999, J THORAC CARDIOV SUR, V117, P890, DOI 10.1016/S0022-5223(99)70368-5; Senthilnathan V, 1999, CARDIOVASC SURG, V7, P393, DOI 10.1016/S0967-2109(99)00026-5; TREASURE T, 1990, LANCET, V336, P1115, DOI 10.1016/0140-6736(90)92583-4; TREASURE T, 1995, CURR OPIN CARDIOL, V10, P144, DOI 10.1097/00001573-199503000-00008; *UK HEART VALV REG, 1999, UK HEART VALV REG RE	10	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					964	965		10.1016/S0140-6736(99)00198-1	http://dx.doi.org/10.1016/S0140-6736(99)00198-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501351				2022-12-24	WOS:000082596000002
J	Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S				Huang, ZJ; Kirkwood, A; Pizzorusso, T; Porciatti, V; Morales, B; Bear, MF; Maffei, L; Tonegawa, S			BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex	CELL			English	Article							LONG-TERM POTENTIATION; GAMMA-AMINOBUTYRIC-ACID; NERVE GROWTH-FACTOR; DEVELOPING NEUROMUSCULAR SYNAPSES; EXPERIENCE-DEPENDENT PLASTICITY; NEUROTROPHIC FACTOR; MONOCULAR DEPRIVATION; SYNAPTIC PLASTICITY; MESSENGER-RNA; RAT-BRAIN	Maturation of the visual cortex is influenced by visual experience during an early postnatal period. The factors that regulate such a critical period remain unclear. We examined the maturation and plasticity of the visual cortex in transgenic mice in which the postnatal rise of brain-derived neurotrophic factor (BDNF) was accelerated. In these mice, the maturation of GABAergic innervation and inhibition was accelerated. Furthermore, the age-dependent decline of cortical longterm potentiation induced by white matter stimulation, a form of synaptic plasticity sensitive to cortical inhibition, occurred earlier. Finally, transgenic mice showed a precocious development of visual acuity and an earlier termination of the critical period for ocular dominance plasticity. We propose that BDNF promotes the maturation of cortical inhibition during early postnatal life, thereby regulating the critical period for visual cortical plasticity.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; MIT, Ctr Learning & Memory, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA; CNR, Ist Neurofisiol, I-56127 Pisa, Italy; Scuola Normale Super Pisa, I-56127 Pisa, Italy; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Scuola Normale Superiore di Pisa; Brown University	Tonegawa, S (corresponding author), MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA.	tonegawa@mit.edu	; Pizzorusso, Tommaso/D-1399-2013	Bear, Mark/0000-0002-9903-2541; Porciatti, Vittorio/0000-0002-1592-3532; Pizzorusso, Tommaso/0000-0001-5614-0668; Huang, Z. Josh/0000-0003-0592-028X	NATIONAL EYE INSTITUTE [R01EY012124] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032925] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY12124-01] Funding Source: Medline; NINDS NIH HHS [NS32925] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaneya Y, 1997, J NEUROSCI, V17, P6707; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BENEVENTO LA, 1992, BRAIN RES, V572, P198, DOI 10.1016/0006-8993(92)90470-T; BENEVENTO LA, 1995, BRAIN RES, V689, P172, DOI 10.1016/0006-8993(95)00553-3; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BIRCH D, 1979, VISION RES, V19, P933, DOI 10.1016/0042-6989(79)90029-4; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Bonhoeffer T, 1996, CURR OPIN NEUROBIOL, V6, P119, DOI 10.1016/S0959-4388(96)80017-1; BOOTHE RG, 1985, ANNU REV NEUROSCI, V8, P495, DOI 10.1146/annurev.ne.08.030185.002431; BOZZI Y, 1995, NEUROSCIENCE, V69, P1133, DOI 10.1016/0306-4522(95)00321-9; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; CAMPBELL FW, 1965, J PHYSIOL-LONDON, V181, P576, DOI 10.1113/jphysiol.1965.sp007784; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; Cellerino A, 1996, EUR J NEUROSCI, V8, P1190, DOI 10.1111/j.1460-9568.1996.tb01287.x; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; COHENCORY S, 1991, J NEUROSCI, V11, P462; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DELRIO JA, 1994, DEV BRAIN RES, V81, P247, DOI 10.1016/0165-3806(94)90311-5; DELRIO JA, 1992, J COMP NEUROL, V326, P501, DOI 10.1002/cne.903260403; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DRAGER UC, 1975, J COMP NEUROL, V160, P269, DOI 10.1002/cne.901600302; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; Dupuy ST, 1996, J NEUROSCI, V16, P6919; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ESCLAPEZ M, 1994, J NEUROSCI, V14, P1834, DOI 10.1523/JNEUROSCI.14-03-01834.1994; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; FREEMAN DN, 1975, NATURE, V254, P614, DOI 10.1038/254614a0; Galuske RAW, 1996, EUR J NEUROSCI, V8, P1554, DOI 10.1111/j.1460-9568.1996.tb01618.x; GHOSH A, 1995, NEURON, V15, P89, DOI 10.1016/0896-6273(95)90067-5; Gianfranceschi L, 1999, VISION RES, V39, P569, DOI 10.1016/S0042-6989(98)00169-2; Gonchar Y, 1997, CEREB CORTEX, V7, P347, DOI 10.1093/cercor/7.4.347; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gorba T, 1999, EUR J NEUROSCI, V11, P1179, DOI 10.1046/j.1460-9568.1999.00551.x; Gordon JA, 1996, J NEUROSCI, V16, P3274; HATA Y, 1994, SCIENCE, V265, P1732, DOI 10.1126/science.8085163; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; HICKS TP, 1983, BRAIN RES, V274, P160, DOI 10.1016/0006-8993(83)90533-4; Huber KM, 1998, NEUROPHARMACOLOGY, V37, P571, DOI 10.1016/S0028-3908(98)00050-1; IP NY, 1993, J NEUROSCI, V13, P3394; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; Liu XB, 1996, P NATL ACAD SCI USA, V93, P7332, DOI 10.1073/pnas.93.14.7332; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Marty S, 1997, TRENDS NEUROSCI, V20, P198, DOI 10.1016/S0166-2236(96)01026-0; Marty S, 1996, J NEUROSCI, V16, P675; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCALLISTER AK, 1995, NEURON, V15, P791, DOI 10.1016/0896-6273(95)90171-X; Micheva KD, 1997, CAN J PHYSIOL PHARM, V75, P470, DOI 10.1139/cjpp-75-5-470; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; NAWA H, 1994, J NEUROSCI, V14, P3751; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; PERKINS AT, 1988, BRAIN RES, V439, P222; PORCIATTI V, 1999, IN PRESS VISION RES; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Rutherford LC, 1998, NEURON, V21, P521, DOI 10.1016/S0896-6273(00)80563-2; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Sambrook JFE, 1989, MOL CLONING LAB MANU; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WANG T, 1995, J NEUROSCI, V15, P4796; WIDMER HR, 1994, DEV BRAIN RES, V80, P279, DOI 10.1016/0165-3806(94)90114-7; WOLFF JR, 1984, NEUROSCI LETT, V47, P207, DOI 10.1016/0304-3940(84)90515-9; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6	86	896	904	2	56	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					739	755		10.1016/S0092-8674(00)81509-3	http://dx.doi.org/10.1016/S0092-8674(00)81509-3			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499792	Bronze			2022-12-24	WOS:000082679200002
J	Moore, T				Moore, T			Shape representations and visual guidance sf saccadic eye movements	SCIENCE			English	Article							CORTEX; MACAQUE; CONNECTIONS; POSITION; FIELD	One hallmark of primate vision is that the direction of gaze is constantly shifting to position objects of interest appropriately on the fovea, where visual acuity is greatest. This process most involve the close cooperation of oculomotor and Visual recognition mechanisms because visual details must be translated into specific motor commands. This paper describes the correspondence between the presaccadic activity of V4 neurons and the degree of visual guidance of saccadic eye movements to objects of different form. The results suggest that neurons that participate in coding visual stimuli are also involved in guiding the eyes to prominent features of objects.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Moore, T (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.	tirin@princeton.edu			NEI NIH HHS [EY0067] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; DESIMONE R, 1985, VISION RES, V25, P441, DOI 10.1016/0042-6989(85)90069-0; DESIMONE R, 1980, BRAIN RES, V184, P41, DOI 10.1016/0006-8993(80)90586-7; FISCHER B, 1981, EXP BRAIN RES, V44, P129; FRIES W, 1984, J COMP NEUROL, V230, P55, DOI 10.1002/cne.902300106; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Groh JM, 1997, J NEUROSCI, V17, P4312; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; Moore T, 1998, P NATL ACAD SCI USA, V95, P8981, DOI 10.1073/pnas.95.15.8981; ROBINSON DA, 1964, J PHYSIOL-LONDON, V174, P245, DOI 10.1113/jphysiol.1964.sp007485; SCHALL JD, 1995, J NEUROSCI, V15, P4464; Thier P, 1998, J NEUROPHYSIOL, V80, P1713, DOI 10.1152/jn.1998.80.4.1713; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; VITU F, 1990, PERCEPT PSYCHOPHYS, V47, P583, DOI 10.3758/BF03203111; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; Zipser K, 1996, J NEUROSCI, V16, P7376	18	67	67	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1914	1917		10.1126/science.285.5435.1914	http://dx.doi.org/10.1126/science.285.5435.1914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489371				2022-12-24	WOS:000082638300051
J	Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P				Pietrangelo, A; Montosi, G; Totaro, A; Garuti, C; Conte, D; Cassanelli, S; Fraquelli, M; Sardini, C; Vasta, F; Gasparini, P			Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IRON OVERLOAD	Background and Methods Hereditary hemochromatosis in adults is usually characterized by mutations in the hemochromatosis (HFE) gene on the short arm of chromosome 6. Most patients have a substitution of tyrosine for cysteine at position 282 (C282Y). We studied a large family from Italy that includes persons who have a hereditary iron-overload condition indistinguishable from hemochromatosis but without apparent pathogenic mutations in the HFE gene. We performed biochemical, histologic, and genetic studies of 53 living members of the family, including microsatellite analysis of chromosome 6 and direct sequencing of the HFE gene, Results Of the 53 family members, 15 had abnormal serum ferritin levels, values for transferrin saturation that were higher than 50 percent, or both. Thirteen of the 15 had elevated body iron levels, diagnosed on the basis of the clinical evaluation and liver biopsy, and underwent iron-removal therapy. The other two, both children, did not undergo liver biopsy or iron-removal therapy. None of the 15 members had the C282Y mutation of the HFE gene; 5 of the 15 (as well as 5 healthy relatives) had another mutation of this gene, a substitution of aspartate for histidine at position 63, but none were homozygous for it. No other mutations were found after sequencing of the entire HFE gene for all family members. Microsatellite analysis showed no linkage of the hemochromatosis phenotype with the short arm of chromosome 6, the site of the HFE gene. Conclusions Hereditary hemochromatosis can occur in adults who do not have pathogenic mutations in the hemochromatosis gene. (N Engl J Med 1999;341:725-32,) (C)1999, Massachusetts Medical Society.	Univ Modena, Policlin, Dept Internal Med, I-41100 Modena, Italy; Osped San Giovanni Rotondo, Foggia, Italy; Univ Milan, Dept Gastroenterol, Milan, Italy	Universita di Modena e Reggio Emilia; University of Milan	Pietrangelo, A (corresponding author), Univ Modena, Policlin, Dept Internal Med, Via Pozzo 71, I-41100 Modena, Italy.		Gasparini, Paolo/B-6173-2014; Cassanelli, Stefano/D-7631-2015; Pietrangelo, Antonello/K-1517-2016	Cassanelli, Stefano/0000-0001-5929-4689; Pietrangelo, Antonello/0000-0002-7411-935X; Gasparini, Paolo/0000-0002-0859-0856	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Beutler E, 1997, AM J HUM GENET, V61, P762; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Camaschella C, 1997, EUR J HUM GENET, V5, P371, DOI 10.1159/000484794; Camaschella C, 1999, HEPATOLOGY, V29, P1563, DOI 10.1002/hep.510290509; Carella M, 1997, AM J HUM GENET, V60, P828; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; McNamara L, 1998, BRIT J HAEMATOL, V102, P1176; PERKINS KW, 1965, AM J MED, V39, P118, DOI 10.1016/0002-9343(65)90251-2; Piperno A, 1998, GASTROENTEROLOGY, V114, P996, DOI 10.1016/S0016-5085(98)70319-1; ROCCHI E, 1986, J LAB CLIN MED, V107, P36; Sanchez M, 1998, GENE, V225, P77, DOI 10.1016/S0378-1119(98)00519-8; SIMON M, 1976, GUT, V17, P332, DOI 10.1136/gut.17.5.332; VONRECKLINGHAUS.FD, 1889, HAEMOCHROMATOSE, P324	16	209	220	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					725	732		10.1056/NEJM199909023411003	http://dx.doi.org/10.1056/NEJM199909023411003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471458				2022-12-24	WOS:000082291900003
J	Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH				Mohn, AR; Gainetdinov, RR; Caron, MG; Koller, BH			Mice with reduced NMDA receptor expression display behaviors related to schizophrenia	CELL			English	Article							DOPAMINE-RECEPTORS; ANTIPSYCHOTIC AGENTS; TARGETED DISRUPTION; LOCOMOTOR-ACTIVITY; NUCLEUS-ACCUMBENS; NEONATAL DEATH; PCP SITE-2; PHENCYCLIDINE; AMPHETAMINE; SUBUNIT	N-methyl-D-aspartate receptors (NMDARs) represent a subclass of glutamate receptors that play a critical role in neuronal development and physiology. We report here the generation of mice expressing only 5% of normal levels of the essential NMDAR1 (NR1) subunit. Unlike NR1 null mice, these mice survive to adulthood and display behavioral abnormalities, including increased motor activity and stereotypy and deficits in social and sexual interactions. These behavioral alterations are similar to those observed in pharmacologically induced animal models of schizophrenia and can be ameliorated by treatment with haloperidol or clozapine, antipsychotic drugs that antagonize dopaminergic and serotonergic receptors. These findings support a model in which reduced NMDA receptor activity results in schizophrenic-like behavior and reveals how pharmacological manipulation of monoaminergic pathways can affect this phenotype.	Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol & Med, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Koller, BH (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA.	treawouns@aol.com	Gainetdinov, Raul R/G-5875-2011	Gainetdinov, Raul R/0000-0003-2951-6038; Ramsey, Amy/0000-0002-2717-5279	NIGMS NIH HHS [T32GM07092] Funding Source: Medline; NINDS NIH HHS [NS19576] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abi-Saab WM, 1998, PHARMACOPSYCHIATRY, V31, P104, DOI 10.1055/s-2007-979354; AKUNNE HC, 1992, NEUROCHEM RES, V17, P261, DOI 10.1007/BF00966668; ANDEN NE, 1970, EUR J PHARMACOL, V11, P303, DOI 10.1016/0014-2999(70)90006-3; ANGRIST B, 1974, J PSYCHIAT RES, V11, P13, DOI 10.1016/0022-3956(74)90064-8; BAN TA, 1984, PSYCHIAT DEV, V2, P179; *BRANB C GEN BACKG, 1997, NEURON, V20, P755; Carlsson A, 1997, LIFE SCI, V61, P75, DOI 10.1016/S0024-3205(97)00228-2; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; CORBETT R, 1995, PSYCHOPHARMACOLOGY, V120, P67, DOI 10.1007/BF02246146; CORBETT R, 1993, PHARMACOL BIOCHEM BE, V45, P9, DOI 10.1016/0091-3057(93)90079-9; Coyle JT, 1996, HARVARD REV PSYCHIAT, V3, P241, DOI 10.3109/10673229609017192; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; DIXON AK, 1994, J CLIN PSYCHIAT, V55, P4; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Druhan JP, 1996, SYNAPSE, V24, P135, DOI 10.1002/(SICI)1098-2396(199610)24:2<135::AID-SYN5>3.0.CO;2-G; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; ELLISON G, 1995, BRAIN RES REV, V20, P250, DOI 10.1016/0165-0173(94)00014-G; ERESHEFSKY L, 1989, CLIN PHARMACY, V8, P691; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Franklin K. B. J., 1996, MOUSE BRAIN STEREOTA; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gleason SD, 1997, PSYCHOPHARMACOLOGY, V129, P79, DOI 10.1007/s002130050165; Goff DC, 1997, SCHIZOPHR RES, V27, P157, DOI 10.1016/S0920-9964(97)00079-0; GRIFFITH JD, 1972, ARCH GEN PSYCHIAT, V26, P97; HOFFMAN DC, 1995, PSYCHOPHARMACOLOGY, V120, P128, DOI 10.1007/BF02246184; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HYTTEL J, 1978, PSYCHOPHARMACOLOGY, V59, P211, DOI 10.1007/BF00426624; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; IMPERATO A, 1990, EUR J PHARMACOL, V187, P555, DOI 10.1016/0014-2999(90)90387-L; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; Kelly MA, 1998, J NEUROSCI, V18, P3470; KNABLE MB, 1994, BIOL PSYCHIAT, V36, P827, DOI 10.1016/0006-3223(94)90593-2; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Lahti RA, 1996, NEUROREPORT, V7, P1945, DOI 10.1097/00001756-199608120-00016; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; Malhotra AK, 1997, NEUROPSYCHOPHARMACOL, V17, P141; Martin P, 1998, J NEURAL TRANSM, V105, P365, DOI 10.1007/s007020050064; Masters WG, 1996, LAB ANIM SCI, V46, P663; MELTZER HY, 1991, SCHIZOPHRENIA BULL, V17, P263, DOI 10.1093/schbul/17.2.263; Miller DW, 1996, BRAIN RES BULL, V40, P57, DOI 10.1016/0361-9230(95)02144-2; Moghaddam B, 1998, SCIENCE, V281, P1349, DOI 10.1126/science.281.5381.1349; MOHN AR, 1995, DNA CLONING, V4, P141; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Nakanishi S, 1998, BRAIN RES REV, V26, P230, DOI 10.1016/S0165-0173(97)00033-7; Nankai M, 1996, NEUROCHEM INT, V29, P529, DOI 10.1016/0197-0186(96)00010-1; Nieoullon A., 1983, EXP BRAIN RES S, V7, P54; Nimgaonkar VL, 1997, ACTA PSYCHIAT SCAND, V95, P364, DOI 10.1111/j.1600-0447.1997.tb09647.x; ODEGARD O, 1980, ACTA PSYCHIAT SCAND, V62, P212, DOI 10.1111/j.1600-0447.1980.tb00609.x; Pierce RC, 1997, PSYCHOPHARMACOLOGY, V133, P188, DOI 10.1007/s002130050390; ROSENBAUER K A, 1980, Folia Morphologica (Prague), V28, P126; ROTHMAN RB, 1994, NEUROTOXICOL TERATOL, V16, P343, DOI 10.1016/0892-0362(94)90022-1; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAUGSTAD LF, 1989, SCHIZOPHRENIA BULL, V15, P9, DOI 10.1093/schbul/15.1.9; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5	62	826	869	0	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					427	436		10.1016/S0092-8674(00)81972-8	http://dx.doi.org/10.1016/S0092-8674(00)81972-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481908	Bronze			2022-12-24	WOS:000082174900004
J	Armstrong, K; Schwartz, JS; Asch, DA				Armstrong, K; Schwartz, JS; Asch, DA			Direct sale of sildenafil (Viagra) to consumers over the Internet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL INFORMATION; QUALITY		Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center	Armstrong, K (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X	NCI NIH HHS [CA73619] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger A, 1998, BMJ, V317, P824; CAPPASSO T, 1999, STATE J REGISTE 0506, P9; Cheitlin MD, 1999, CIRCULATION, V99, P168, DOI 10.1161/01.CIR.99.1.168; Dorozynski A, 1996, BRIT MED J, V313, P1033; DOULIN T, 1999, COLUMBUS DISPA 0513, pA1; Dyer C, 1996, BRIT MED J, V313, P645; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Greenaway NJ, 1999, LANCET, V353, P330, DOI 10.1016/S0140-6736(05)74889-3; HADDON J, 1999, MORNING EDITION 0511; KASSIRER JP, 1995, NEW ENGL J MED, V332, P52, DOI 10.1056/NEJM199501053320110; LEE TH, 1999, HARVARD HEART LETT, V9, P7; Marwick C, 1999, JAMA-J AM MED ASSOC, V281, P975, DOI 10.1001/jama.281.11.975; McDonald CJ, 1998, JAMA-J AM MED ASSOC, V280, P1325, DOI 10.1001/jama.280.15.1325; OSTROM CM, 1999, SEATTLE TIMES   0512, pA1; PERRIN J, 1998, PHARM J, V260, P707; Seaboldt JA, 1997, AM J HEALTH-SYST PH, V54, P1732, DOI 10.1093/ajhp/54.15.1732; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Skolnick AA, 1997, JAMA-J AM MED ASSOC, V278, P1723; SLIVKA J, 1999, SEATTLE POST IN 0507, pC1; TAYLOR C, 1999, TIME            0524, P73; Wang T, 1997, Methods Mol Biol, V72, P1	22	69	71	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1389	1392		10.1056/NEJM199910283411810	http://dx.doi.org/10.1056/NEJM199910283411810			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536133				2022-12-24	WOS:000083357800010
J	Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ				Bisharat, N; Agmon, V; Finkelstein, R; Raz, R; Ben-Dror, G; Lerner, L; Soboh, S; Colodner, R; Cameron, DN; Wykstra, DL; Swerdlow, DL; Farmer, JJ		Israel Vibrio Study Grp	Clinical, epidemiological, and microbiological features of Vibrio vulnificus biogroup 3 causing outbreaks of wound infection and bacteraemia in Israel	LANCET			English	Article							GULF-COAST; BENECKEA VULNIFICUS; FISH; MANIFESTATIONS; ENVIRONMENT; FLORIDA	Background Vibrio vulnificus is a gram-negative bacterium that causes septicaemia and wound infection. Cases occur sporadically, and no previous outbreaks due to a common source or a clonal strain have been reported. In the summer and autumn of 1996 and 1997, an outbreak of invasive V vulnificus infection occurred in Israel in people who had recently handled fresh, whole fish purchased from artificial fish-ponds. Methods We reviewed clinical and epidemiological information, and undertook an environmental investigation to assess disease characteristics, modes of transmission, phenotypic characteristics of the bacterium, and fish-marketing policy. The clonal nature of 19 isolates was studied by biotyping, pulsed-field gel electrophoresis, and restriction-fragment length polymorphism (RFLP) analysis of a PCR fragment. Findings During 1996-97, 62 cases of wound infection and bacteraemia occurred. 57 patients developed cellulitis, four had necrotising fasciitis, and one developed osteomyelitis. In all cases, the fish were cultivated in inland fish-ponds. In the summer of 1996, fish-pond managers initiated a new marketing policy, in which fish were sold alive instead of being packed in ice. Phenotypically, the isolates had five atypical biochemical test results. The isolates were non-typeable by pulsed-field gel electrophoresis, and all had the same PCR-RFLP pattern which had not been seen previously. Interpretation The cause of the outbreak was a new strain of V vulnificus, classified as biogroup 3. A new fish-marketing policy that began in 1996 may have exposed susceptible people to the organism.	HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel; HaEmek Med Ctr, Microbiol Lab, IL-18101 Afula, Israel; Govt Cent Labs, Jerusalem, Israel; Rambam Med Ctr, Infect Dis Unit, Haifa, Israel; Poriah Med Ctr, Dept Med, Tiberias, Israel; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Lab Sect, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA	Emek Medical Center; Emek Medical Center; Rambam Health Care Campus; Technion Israel Institute of Technology; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Bisharat, N (corresponding author), HaEmek Med Ctr, Infect Dis Unit, IL-18101 Afula, Israel.			Colodner, Raul/0000-0001-9752-1053				[Anonymous], MANUAL CLIN MICROBIO; Bisharat N, 1996, LANCET, V348, P1585, DOI 10.1016/S0140-6736(05)66199-5; BLAKE PA, 1979, NEW ENGL J MED, V300, P1, DOI 10.1056/NEJM197901043000101; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; Brenner D J, 1978, Prog Clin Pathol, V7, P71; BURRAS N, 1985, APPL ENVIRON MICROB, V50, P989; CAMERON D, 1997, 97 C AM SOC MICR; CAMERON D, 1998, INT C EM INF DIS; Centers for Disease Control and Prevention (CDC), 1993, MMWR MORB MORTAL WKL, V42, P405; CHUANG YC, 1992, CLIN INFECT DIS, V15, P271, DOI 10.1093/clinids/15.2.271; Dalsgaard A, 1996, EUR J CLIN MICROBIOL, V15, P227, DOI 10.1007/BF01591359; DEPAOLA A, 1994, APPL ENVIRON MICROB, V60, P984, DOI 10.1128/AEM.60.3.984-988.1994; ELLIOT EL, 1992, FOOD DRUG ADM BACTER, P111; FANG FC, 1992, CLIN INFECT DIS, V15, P1071, DOI 10.1093/clind/15.6.1071; Farmer J. J., 1992, The Prokaryotes. A handbook on the biology of bacteria: ecophysiology, isolation, identification, applications. Volume III.., P2952; FARMER JJ, 1979, LANCET, V2, P903; FARMER JJ, 1985, MANUAL CLIN MICROBIO, P282; Hlady WG, 1996, J INFECT DIS, V173, P1176, DOI 10.1093/infdis/173.5.1176; HOLLIS DG, 1976, J CLIN MICROBIOL, V3, P425; HOWARD RJ, 1985, SURGERY, V98, P126; KELLY MT, 1982, APPL ENVIRON MICROB, V44, P820, DOI 10.1128/AEM.44.4.820-824.1982; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; LEVINE WC, 1993, J INFECT DIS, V167, P479, DOI 10.1093/infdis/167.2.479; MORRIS JG, 1987, APPL ENVIRON MICROB, V53, P193, DOI 10.1128/AEM.53.1.193-195.1987; Oliver J., 1989, FOODBORNE BACTERIAL, P569; OLIVER JD, 1983, APPL ENVIRON MICROB, V45, P985, DOI 10.1128/AEM.45.3.985-998.1983; OVERMAN T, 1986, J CLIN MICROBIOL, V24, P715; SERA H, 1972, B JPN SOC SCI FISH, V38, P853; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; Tamplin M., 1995, P 1994 VIBR VULN WOR, P75; TISON DL, 1982, APPL ENVIRON MICROB, V44, P640, DOI 10.1128/AEM.44.3.640-646.1982; Weinstein MR, 1997, NEW ENGL J MED, V337, P589, DOI 10.1056/NEJM199708283370902; WRIGHT AC, 1981, INFECT IMMUN, V34, P503, DOI 10.1128/IAI.34.2.503-507.1981	33	228	236	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1421	1424		10.1016/S0140-6736(99)02471-X	http://dx.doi.org/10.1016/S0140-6736(99)02471-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543668				2022-12-24	WOS:000083277400011
J	Reilly, JJ; Dorosty, AR; Emmett, PM				Reilly, JJ; Dorosty, AR; Emmett, PM			Prevalence of overweight and obesity in British children: cohort study	BRITISH MEDICAL JOURNAL			English	Article							INDEX	Estimates of the prevalence of obesity among children are necessary so that the need for preventive measures can be assessed, secular trends monitored, and high risk population groups identified.(1) The aim of this study was therefore to provide current estimates of the prevalence of obesity among British children.	Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, ALSPAC Study Team, Bristol BS8 1TH, Avon, England	University of Glasgow; University of Bristol	Reilly, JJ (corresponding author), Univ Glasgow, Dept Human Nutr, Yorkhill Hosp, Glasgow G3 8SJ, Lanark, Scotland.		Dorosty-Motlagh, Ahmad-Reza/E-1003-2018; Emmett, Pauline/AAL-6815-2021	Dorosty-Motlagh, Ahmad-Reza/0000-0002-6937-7776; Emmett, Pauline/0000-0003-1076-4779	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ALSPAC, 1998, CHILDR 90S; Barlow SE, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e29; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Reilly JJ, 1999, INT J OBESITY, V23, P217, DOI 10.1038/sj.ijo.0800804	5	127	135	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1039	1039		10.1136/bmj.319.7216.1039	http://dx.doi.org/10.1136/bmj.319.7216.1039			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521196	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000083210100027
J	Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM				Watson, M; Haviland, JS; Greer, S; Davidson, J; Bliss, JM			Influence of psychological response on survival in breast cancer: a population-based cohort study	LANCET			English	Article							MAC SCALE; QUESTIONNAIRE MEASURE; MENTAL ADJUSTMENT; EMOTIONAL CONTROL	Background The psychological response to breast cancer, such as a fighting spirit or an attitude of helplessness and hopelessness toward the disease, has been suggested as a prognostic factor with an influence on survival. We have investigated the effect of psychological response on disease outcome in a large cohort of women with early-stage breast cancer. Methods 578 women with early-stage breast cancer were enrolled in a prospective survival study. Psychological response was measured by the mental adjustment to cancer (MAC) scale, the Courtauld emotional control (CEC) scale, and the hospital anxiety and depression (HAD) scale 4-12 weeks and 12 months after diagnosis. The women were followed up for at least 5 years. Cox's proportional-hazards regression was used to obtain the hazard ratios for the measures of psychological response, with adjustment for known clinical factors associated with survival. Findings At 5 years, 395 women were alive and without relapse, 50 were alive with relapse, and 133 had died. There was a significantly increased risk of death from all causes by 5 years in women with a high score on the HAD scale category of depression (hazard ratio 3.59 [95% CI 1.39-9.24]). There was a significantly increased risk of relapse or death at 5 years in women with high scores on the helplessness and hopelessness category of the MAC scale compared with those with a low score in this category (1.55 [1.07-2.25]). There were no significant results found for the category of "fighting spirit". Interpretation For 5-year event-free survival a high helplessness/hopelessness score has a moderate but detrimental effect. A high score for depression is linked to a significantly reduced chance of survival; however, this result is based on a small number of patients and should be interpreted with caution.	Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp NHS Trust, London, England; Inst Canc Res, Sutton, Surrey, England; St Raphaels Hosp, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Watson, M (corresponding author), Royal Marsden Hosp NHS Trust, Sutton SM2 5PT, Surrey, England.			Bliss, Judith/0000-0001-7957-7424; Haviland, Joanne/0000-0001-5728-3636				BUDDEBERG C, 1991, PSYCHOTHER PSYCHOSOM, V55, P151, DOI 10.1159/000288423; Clarke M, 1998, LANCET, V351, P1451; COPPER CL, 1993, PSYCHOL MED, V23, P653; GOLDSTEIN DA, 1989, PSYCHOL HEALTH, V3, P245, DOI DOI 10.1080/08870448908400384; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; GREER S, 1989, J PSYCHOSOM RES, V33, P373, DOI 10.1016/0022-3999(89)90027-5; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; HOLLAND J C, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P237; JAMISON RN, 1987, J CLIN ONCOL, V5, P768, DOI 10.1200/JCO.1987.5.5.768; LEVY SM, 1988, PSYCHOSOM MED, V50, P520, DOI 10.1097/00006842-198809000-00008; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; MORRIS T, 1980, CANCER DETECTION PRE, V3, P102; Nordin K, 1999, PSYCHO-ONCOLOGY, V8, P250, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<250::AID-PON379>3.3.CO;2-A; PETTINGALE KW, 1985, LANCET, V1, P750; Schnoll RA, 1998, PSYCHO-ONCOLOGY, V7, P424, DOI 10.1002/(SICI)1099-1611(1998090)7:5<424::AID-PON322>3.0.CO;2-2; WATSON M, 1991, PSYCHOL MED, V21, P51, DOI 10.1017/S0033291700014641; WATSON M, 1984, J PSYCHOSOM RES, V28, P467, DOI 10.1016/0022-3999(84)90080-1; WATSON M, 1983, J PSYCHOSOM RES, V27, P299, DOI 10.1016/0022-3999(83)90052-1; WATSON M, 1988, PSYCHOL MED, V18, P203, DOI 10.1017/S0033291700002026; Watson M, 1989, MENTAL ADJUSTMENT CA; WEISMAN AD, 1977, COPING VULNERABILITY; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	474	482	0	24	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1331	1336		10.1016/S0140-6736(98)11392-2	http://dx.doi.org/10.1016/S0140-6736(98)11392-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	246DV	10533861	Green Accepted			2022-12-24	WOS:000083149900010
J	Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H				Celli, J; Duijf, P; Hamel, BCJ; Bamshad, M; Kramer, B; Smits, APT; Newbury-Ecob, R; Hennekam, RCM; Van Buggenhout, G; van Haeringen, B; Woods, CG; van Essen, AJ; de Waal, R; Vriend, G; Haber, DA; Yang, A; McKeon, F; Brunner, HG; van Bokhoven, H			Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome	CELL			English	Article							SPLIT FOOT LOCUS; LIMB DEVELOPMENT; GENE; PROTEIN; EXPRESSION; SEQUENCE; DATABASE; COMPLEX; DEFECTS; MODEL	EEC syndrome is an autosomal dominant disorder characterized by ectrodactyly, ectodermal dysplasia, and facial clefts. We have mapped the genetic defect in several EEC syndrome families to a region of chromosome 3q27 previously implicated in the EEC-like disorder, limb mammary syndrome (LMS). Analysis of the p63 gene, a homolog of p53 located in the critical LMS/EEC interval, revealed heterozygous mutations in nine unrelated EEC families. Eight mutations result in amino acid substitutions that are predicted to abolish the DNA binding capacity of p63. The ninth is a frameshift mutation that affects the p63 alpha, but not p63 beta and p63 gamma isotypes. Transactivation studies with these mutant p63 isotypes provide a molecular explanation for the dominant character of p63 mutations in EEC syndrome.	Univ Nijmegen Hosp, Dept Human Genet 417, NL-6500 HB Nijmegen, Netherlands; Univ Utah, Hlth Sci Ctr, Dept Pediat, Salt Lake City, UT 84112 USA; Shriners Hosp Children, Intermt Unit, Salt Lake City, UT 84112 USA; Royal Hosp Sick Children, United Bristol Healthcare NHS Trust Clin Genet Se, Bristol BS2 8BJ, Avon, England; Univ Amsterdam, Acad Med Ctr, Inst Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2333 SA Leiden, Netherlands; St James Univ Hosp, Dept Clin Genet, Leeds LS9 7TF, W Yorkshire, England; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Nijmegen Hosp, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, CMBI, NL-6500 GL Nijmegen, Netherlands; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Radboud University Nijmegen; Utah System of Higher Education; University of Utah; Bristol Royal Hospital For Children; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; University Hospital Leuven; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Saint James's University Hospital; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	van Bokhoven, H (corresponding author), Univ Nijmegen Hosp, Dept Human Genet 417, Box 9101, NL-6500 HB Nijmegen, Netherlands.		van Bokhoven, Hans/D-8764-2012; woods, christopher g/A-1361-2010; Brunner, Han/C-9928-2013; Vriend, G./H-8112-2014; Waal, R.M.W./L-4739-2015; Vriend, Gert/D-6730-2011; Duijf, Pascal H.G./E-7110-2012; Bokhoven, J.H.L.M. van van/H-8015-2014	Duijf, Pascal H.G./0000-0001-8646-9843; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254				AHMAD M, 1987, HUM GENET, V75, P169, DOI 10.1007/BF00591081; CHINEA G, 1995, PROTEINS, V23, P415, DOI 10.1002/prot.340230315; Chitayat D, 1996, AM J MED GENET, V61, P45, DOI 10.1002/(SICI)1096-8628(19960102)61:1<45::AID-AJMG9>3.0.CO;2-W; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EVANS JA, 1994, AM J MED GENET, V49, P52, DOI 10.1002/ajmg.1320490111; Gorlin RJ, 1990, PLAST RECONSTR SURG; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON KR, 1995, GENOMICS, V29, P457, DOI 10.1006/geno.1995.9981; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREMER H, 1994, HUM MOL GENET, V3, P299, DOI 10.1093/hmg/3.2.299; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Niswander L, 1997, CURR OPIN GENET DEV, V7, P530, DOI 10.1016/S0959-437X(97)80082-2; NUNES ME, 1995, HUM MOL GENET, V4, P2165, DOI 10.1093/hmg/4.11.2165; O'Quinn JR, 1998, AM J HUM GENET, V62, P130, DOI 10.1086/301687; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Roelfsema NM, 1996, CLIN DYSMORPHOL, V5, P115, DOI 10.1097/00019605-199604000-00003; ROTHSCHILD AR, 1996, J MED GENET, V33, P996; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHERER SW, 1994, HUM MOL GENET, V3, P1345; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Seto ML, 1997, TERATOLOGY, V56, P262, DOI 10.1002/(SICI)1096-9926(199710)56:4<262::AID-TERA5>3.0.CO;2-0; Shimada A, 1999, CANCER RES, V59, P2781; SHUBER AP, 1993, HUM MOL GENET, V2, P153, DOI 10.1093/hmg/2.2.153; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; van Bokhoven H, 1999, AM J HUM GENET, V64, P538, DOI 10.1086/302246; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	43	528	546	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					143	153		10.1016/S0092-8674(00)81646-3	http://dx.doi.org/10.1016/S0092-8674(00)81646-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535733	Green Published, Bronze			2022-12-24	WOS:000083159700005
J	Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES				Golub, TR; Slonim, DK; Tamayo, P; Huard, C; Gaasenbeek, M; Mesirov, JP; Coller, H; Loh, ML; Downing, JR; Caligiuri, MA; Bloomfield, CD; Lander, ES			Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring	SCIENCE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ALVEOLAR RHABDOMYOSARCOMA; SACCHAROMYCES-CEREVISIAE; BURKITT-LYMPHOMA; SURFACE-ANTIGENS; TRANSLOCATION; CELLS; MICROARRAY; FUSION	Although cancer classification has improved over the past 30 years, there has been no general approach for identifying new cancer classes (class discovery) or for assigning tumors to known classes (class prediction). Here, a generic approach to cancer classification based on gene expression monitoring by DNA microarrays is described and applied to human acute Leukemias as a test case. A class discovery procedure automatically discovered the distinction between acute myeloid Leukemia (AML) and acute Lymphoblastic Leukemia (ALL) without previous knowledge of these classes. An automatically derived class predictor was able to determine the class of new leukemia cases. The results demonstrate the feasibility of cancer classification based solely on gene expression monitoring and suggest a general strategy for discovering and predicting cancer classes for other types of cancer, independent of previous biological knowledge.	MIT, Whitehead Inst, Ctr Genome Res, Cambridge, MA 02139 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Canc & Leukemia Grp B, Columbus, OH 43210 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; St Jude Children's Research Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Massachusetts Institute of Technology (MIT)	Golub, TR (corresponding author), MIT, Whitehead Inst, Ctr Genome Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	golub@genome.wi.mit.edu; lander@genome.wi.mit.edu	Peng, Bo/A-6920-2009; Mesirov, Jill/AGF-7626-2022; Downing, James R./N-8102-2018	Peng, Bo/0000-0001-8225-2284; Slonim, Donna/0000-0003-3357-437X; Loh, Mignon/0000-0003-4099-4700				BALABANMALENBAUM G, 1977, SCIENCE, V198, P739, DOI 10.1126/science.71759; BENNETT JM, 1969, BLOOD-J HEMATOL, V33, P341, DOI 10.1182/blood.V33.2.341.341; Bishop JF, 1999, MED J AUSTRALIA, V170, P39, DOI 10.5694/j.1326-5377.1999.tb126866.x; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUCCHERI V, 1993, BLOOD, V82, P853; Cole KA, 1999, NAT GENET, V21, P38, DOI 10.1038/4466; CRAWFORD AW, 1991, J BIOL CHEM, V266, P5847; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELATTRE O, 1994, NEW ENGL J MED, V331, P294, DOI 10.1056/NEJM199408043310503; DeRisi J, 1996, NAT GENET, V14, P457; DINNDORF PA, 1992, MED PEDIATR ONCOL, V20, P192, DOI 10.1002/mpo.2950200303; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; FORKNER CE, 1938, LEUKEMIA ALLIED DISO; FREI E, 1961, BLOOD, V18, P431, DOI 10.1182/blood.V18.4.431.431; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, UNPUB; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150; Huang SY, 1997, BRIT J HAEMATOL, V96, P682, DOI 10.1046/j.1365-2141.1997.d01-2100.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Khan J, 1999, ELECTROPHORESIS, V20, P223, DOI 10.1002/(SICI)1522-2683(19990201)20:2<223::AID-ELPS223>3.0.CO;2-A; Khan J, 1998, CANCER RES, V58, P5009; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MASTER PS, 1989, BLUT, V59, P221, DOI 10.1007/BF00320851; McLean TW, 1996, BLOOD, V88, P4252; *MED RES COUNC, 1963, BRIT MED J, V1, P7; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PESANDO JM, 1979, BLOOD, V54, P1240; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; QUAGLINO D, 1959, J PATHOL BACTERIOL, V78, P521, DOI 10.1002/path.1700780219; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROPER M, 1983, BLOOD, V61, P830; ROSS W, 1984, CANCER RES, V44, P5857; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; SALLAN SE, 1980, BLOOD, V55, P395; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHLOSSMAN SF, 1976, P NATL ACAD SCI USA, V73, P1288, DOI 10.1073/pnas.73.4.1288; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STEPHENSON CF, 1992, HUM PATHOL, V23, P1270, DOI 10.1016/0046-8177(92)90295-E; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P47, DOI 10.1016/S0889-8588(18)30257-0; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Triche T J, 1988, Prog Clin Biol Res, V271, P475; TSUKIMOTO I, 1976, NEW ENGL J MED, V294, P245, DOI 10.1056/NEJM197601292940503; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517	52	7959	9684	22	792	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					531	537		10.1126/science.286.5439.531	http://dx.doi.org/10.1126/science.286.5439.531			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521349				2022-12-24	WOS:000083121200061
J	Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D				Chowdhury, TR; Basu, GK; Mandal, BK; Biswas, BK; Samanta, G; Chowdhury, UK; Chanda, CR; Lodh, D; Lal Roy, S; Saha, KC; Roy, S; Kabir, S; Quamruzzaman, Q; Chakraborti, D			Arsenic poisoning in the Ganges delta	NATURE			English	Article							WEST-BENGAL; 6 DISTRICTS; GROUNDWATER; INDIA; BANGLADESH; CALAMITY; DRINKING; WATER		Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India; Dhaka Community Hosp Trust, Dhaka 1217, Bangladesh	Jadavpur University	Chowdhury, TR (corresponding author), Jadavpur Univ, Sch Environm Studies, Calcutta 700032, W Bengal, India.			Roychowdhury, Tarit/0000-0001-6515-5634				AKAI J, 1998, C P 3 FOR ARS CONT G, P51; CHOWDHURY R, 1999, THESIS JADAVPUR U CA; Das D, 1996, ENVIRON GEOCHEM HLTH, V18, P5, DOI 10.1007/BF01757214; DAS D, 1995, ANALYST, V120, P917, DOI 10.1039/an9952000917; DAS D, 1995, THESIS JADAVPUR U CA; Dhar RK, 1997, CURR SCI INDIA, V73, P48; *M MACD LTD, 1999, BRIT GEOL SURV FIN R; Mandal BK, 1998, SCI TOTAL ENVIRON, V218, P185, DOI 10.1016/S0048-9697(98)00220-4; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; NICKSON R, 1997, THESIS U COLL LONDON; Samanta G, 1999, MICROCHEM J, V62, P174, DOI 10.1006/mchj.1999.1713	11	277	299	5	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					545	546		10.1038/44056	http://dx.doi.org/10.1038/44056			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524620				2022-12-24	WOS:000083054900035
J	McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR				McDonald, LC; Archibald, LK; Rheanpumikankit, S; Tansuphaswadikul, S; Eampokalap, B; Nwanyanawu, O; Kazembe, P; Dobbie, H; Reller, LB; Jarvis, WR			Unrecognised Mycobacterium tuberculosis bacteraemia among hospital inpatients in less developed countries	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BACTEC 12B BOTTLES; INFECTION; BACTEREMIA; DIAGNOSIS; EXTRAPULMONARY; NAIROBI; SYSTEM	Background Nosocomial transmission of Mycobacterium tuberculosis is a global public-health concern. Although early clinical recognition of M tuberculosis in hospital inpatients is critical for effective infection control, such recognition may be difficult in patients with HIV infection. To find out whether M tuberculosis bacteraemia frequently goes unrecognised, we did a prospective blood-culture survey in an infectious-diseases hospital in Thailand and a general hospital in Malawi, Methods Consecutive febrile (greater than or equal to 37.5 degrees C axillary or greater than or equal to 38.0 degrees C orally) hospital inpatients (aged greater than or equal to 18 years) were enrolled; blood was obtained for mycobacterial culture and HIV testing. Simple diagnostic tests, such as chest radiographs and sputum smears, were ordered by clinicians as deemed necessary, and were carried out with existing local resources. Findings Of 344 patients enrolled, 255 (74%) were HIV infected, the median age was 33 years (range 18-87), and 208 (61%) were male. 34 (10%) patients had NI tuberculosis bacteraemia; five of these patients were already on antituberculosis therapy. Only HIV-infected patients had M tuberculosis bacteraemia. Of the 29 patients with M tuberculosis bacteraemia who were not already receiving antituberculosis therapy, 13 (45%) had an abnormal chest radiograph or a positive sputum smear. 16 (55%) patients had no additional diagnostic test results to indicate M tuberculosis infection; 18 (81%) of these had a cough. Interpretation In less developed countries where both M tuberculosis and HIV infections are prevalent, M tuberculosis bacteraemia may frequently go unrecognised among febrile hospital inpatients.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Bamrasnaradura Hosp, Bangkok, Thailand; Lilongwe Cent Hosp, Lilongwe, Malawi; Duke Univ, Med Ctr, Durham, NC USA	Centers for Disease Control & Prevention - USA; Duke University	Archibald, LK (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.			McDonald, L. Clifford/0000-0003-3044-5572				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BARNES PF, 1988, CHEST, V94, P316, DOI 10.1378/chest.94.2.316; BARNES PF, 1987, J INFECT DIS, V156, P377, DOI 10.1093/infdis/156.2.377; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; DOERN GV, 1994, J CLIN MICROBIOL, V32, P2576, DOI 10.1128/JCM.32.10.2576-2577.1994; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; Fandinho FCO, 1997, B WORLD HEALTH ORGAN, V75, P361; Fox J, 1998, ASM NEWS, V64, P73; GILKS CF, 1990, AIDS, V4, P981, DOI 10.1097/00002030-199010000-00006; Grinsztejn B, 1997, ARCH INTERN MED, V157, P2359, DOI 10.1001/archinte.157.20.2359; Inderlied Clark B., 1995, P1385; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; Mattar S, 1992, Enferm Infecc Microbiol Clin, V10, P29; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; NUNN P, 1992, TUBERCLE LUNG DIS, V73, P45, DOI 10.1016/0962-8479(92)90079-Y; REIMER LG, 1994, CLIN LAB MED, V14, P99, DOI 10.1016/S0272-2712(18)30397-4; SHAFER RW, 1989, AM REV RESPIR DIS, V140, P1611, DOI 10.1164/ajrccm/140.6.1611; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; WASILAUSKAS B, 1994, J CLIN MICROBIOL, V32, P654, DOI 10.1128/JCM.32.3.654-657.1994; *WHO, 1998, TUB FACT SHEET	22	75	78	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1159	1163		10.1016/S0140-6736(98)12325-5	http://dx.doi.org/10.1016/S0140-6736(98)12325-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513709				2022-12-24	WOS:000082954100011
J	Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R				Fisslthaler, B; Popp, R; Kiss, L; Potente, M; Harder, DR; Fleming, I; Busse, R			Cytochrome P4502C is an EDHF synthase in coronary arteries	NATURE			English	Article							ARACHIDONIC-ACID METABOLITE; HYPERPOLARIZING FACTOR; EPOXYEICOSATRIENOIC ACIDS; K+ CHANNELS; MICROCIRCULATION; ENZYMES	In most arterial beds a significant endothelium-dependent dilation to various stimuli persists even after inhibition of nitric oxide synthase and cyclo-oxygenase. This dilator response is preceded by an endothelium-dependent hyperpolarization of vascular smooth muscle cells, which is sensitive to a combination of the calcium-dependent potassium-channel inhibitors charybdotoxin and apamin, and is assumed to be mediated by an unidentified endothelium-derived hyperpolarizing factor (EDHF)(1,2). Here we show that the induction of cytochrome P450 (CYP) 2C8/34 in native porcine coronary artery endothelial cells by beta-naphthoflavone enhances the formation of 11,12-epoxyeicosatrienoic acid, as well as EDHF-mediated hyperpolarization and relaxation. Transfection of coronary arteries with CYP 2C8/34 antisense oligonucleotides results in decreased levels of CYP 2C and attenuates EDHF-mediated vascular responses. Thus, a CYP-epoxygenase product is an essential component of EDHF-mediated relaxation in the porcine coronary artery, and CYP 2C8/34 fulfils the criteria for the coronary EDHF synthase.	Univ Frankfurt Klinikum, Inst Kardiovask Physiol, D-60590 Frankfurt, Germany; Univ Giessen, Zentrum Inneren Med, D-35392 Giessen, Germany; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Justus Liebig University Giessen; Medical College of Wisconsin	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovask Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; BAUERSACHS J, 1994, BRIT J PHARMACOL, V113, P1548, DOI 10.1111/j.1476-5381.1994.tb17172.x; Bauersachs J, 1996, CIRCULATION, V94, P3341, DOI 10.1161/01.CIR.94.12.3341; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CHEN G, 1988, BRIT J PHARMACOL, V95, P1165, DOI 10.1111/j.1476-5381.1988.tb11752.x; Edwards G, 1998, NATURE, V396, P269, DOI 10.1038/24388; FULTON D, 1995, BRIT J PHARMACOL, V114, P99, DOI 10.1111/j.1476-5381.1995.tb14911.x; GUENGERICH FP, 1992, FASEB J, V6, P745, DOI 10.1096/fasebj.6.2.1537465; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; Kiss L, 1998, ANAL BIOCHEM, V261, P16, DOI 10.1006/abio.1998.2674; KOMORI K, 1990, BLOOD VESSELS, V27, P238; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Miura H, 1998, CIRC RES, V83, P501, DOI 10.1161/01.RES.83.5.501; Oltman CL, 1998, CIRC RES, V83, P932; PINTO A, 1987, J PHARMACOL EXP THER, V240, P856; Popp R, 1996, J PHYSIOL-LONDON, V497, P699, DOI 10.1113/jphysiol.1996.sp021801; PRITCHARD KA, 1990, AM J PATHOL, V136, P1381; Puntarulo S, 1998, FREE RADICAL BIO MED, V24, P1324, DOI 10.1016/S0891-5849(97)00463-2; Quilley J, 1997, BIOCHEM PHARMACOL, V54, P1059, DOI 10.1016/S0006-2952(97)00039-7; ROSOLOWSKY M, 1993, AM J PHYSIOL, V264, pH327, DOI 10.1152/ajpheart.1993.264.2.H327; RUBANYI GM, 1987, CIRC RES, V61	22	772	799	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					493	497		10.1038/46816	http://dx.doi.org/10.1038/46816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519554				2022-12-24	WOS:000082981200060
J	Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR				Oddy, WH; Holt, PG; Sly, PD; Read, AW; Landau, LI; Stanley, FJ; Kendall, GE; Burton, PR			Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE FOLLOW-UP; ATOPIC DISEASE; HUMAN-MILK; CHILDHOOD; ALLERGY; INFANTS; PROPHYLAXIS; LIFE; AGE	Objectives To investigate the association between the duration of exclusive breast feeding and the development of asthma related outcomes in children at age 6 years. Design Prospective cohort study, Setting Western Australia. Subjects 2187 children ascertained through antenatal clinics at the major tertiary obstetric hospital in Perth and followed to age 6 years. Main outcome measures Unconditional logistic regression to model the association between duration of exclusive breast feeding and outcomes related ro asthma or atopy at 6 years of age, allowing for several important confounders: sex, gestational age, smoking in the household, and early childcare, Results. After adjustment for confounders, the introduction of milk other than breast milli before ii months of age was a significant risk factor for all asthma and atopy related outcomes in children aged 6) ears: asthma diagnosed by a doctor (odds ratio 1.25, 95% confidence interval 1.02 to 1.52); wheeze three or more rimes since 1 year bf age (1.41, 1.14 to 1.76); wheeze in the past year (1.31, 1.05 to 1.64); sleep disturbance due to wheeze within the past year (1.42, 1.07 to 1.89), age when doctor diagnosed asthma (hazard ratio 1.22, 1.03 to 1.43); age at first wheeze (1.36, 1.17 to 1.59); and positive skin prick test reaction to at least one common aeroallergen (1.30, 1.04 to 1.61). Conclusion A significant reduction in the risk of childhood asthma at age 6 years occurs if exclusive breast feeding is continued for at least the 4 months after birth. These findings are important for our understanding of the cause of childhood asthma and suggest that public health interventions to optimise breast feeding may help to reduce the community burden of childhood asthma and its associated traits.	TVW Telethon, Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Fac Med & Dent, Nedlands, WA 6009, Australia; Univ Western Australia, Princess Margaret Hosp Children, Dept Paediat, Div Biostat & Genet Epidemiol, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Oddy, WH (corresponding author), TVW Telethon, Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	Wendyo@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Study, Raine/K-4517-2013; Sly, Peter D/F-1486-2010; Burton, Paul R/H-7527-2016	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Golding J, 1997, EARLY HUM DEV, V49, pS121, DOI 10.1016/S0378-3782(97)00058-3; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; Hamosh M, 1998, BIOL NEONATE, V74, P163, DOI 10.1159/000014021; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; Hide D W, 1991, Adv Exp Med Biol, V310, P475; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MCCULLAGH P., 1991, GEN LINEAR MODELS; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Pabst HF, 1997, PEDIATR INFECT DIS J, V16, P991, DOI 10.1097/00006454-199710000-00017; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robertson CF, 1998, MED J AUSTRALIA, V168, P434, DOI 10.5694/j.1326-5377.1998.tb139022.x; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Strachan DP, 1995, LANCET, V346, P1714, DOI 10.1016/S0140-6736(95)92884-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587, DOI 10.1016/S0091-6749(98)70164-2; Wilson AC, 1998, BMJ-BRIT MED J, V316, P21, DOI 10.1136/bmj.316.7124.21; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758, DOI 10.1001/archpedi.1995.02170200048006; Xanthou M, 1998, BIOL NEONATE, V74, P121, DOI 10.1159/000014018	24	357	367	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					815	819		10.1136/bmj.319.7213.815	http://dx.doi.org/10.1136/bmj.319.7213.815			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496824	Green Published, Bronze			2022-12-24	WOS:000082865200022
J	Skidmore, SJ				Skidmore, SJ			Factors in spread of hepatitis E	LANCET			English	Editorial Material							E VIRUS; INFECTION		Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England		Skidmore, SJ (corresponding author), Princess Royal Hosp, Publ Hlth Lab Serv, PHLS Midlands, Telford TF6 6TF, Shrops, England.							Balayan MS, 1997, J VIRAL HEPATITIS, V4, P155, DOI 10.1046/j.1365-2893.1997.00145.x; BRADLEY DW, 1995, J HEPATOL, V22, P140; Corwin AL, 1999, T ROY SOC TROP MED H, V93, P255, DOI 10.1016/S0035-9203(99)90014-7; Hau CH, 1999, AM J TROP MED HYG, V60, P277, DOI 10.4269/ajtmh.1999.60.277; Hussaini SH, 1997, J VIRAL HEPATITIS, V4, P51, DOI 10.1046/j.1365-2893.1997.00123.x; Lu FM, 1996, CHINESE MED J-PEKING, V109, P919; SCHARSCHMIDT BF, 1995, LANCET, V346, P519, DOI 10.1016/S0140-6736(95)91376-9; SKIDMORE SJ, 1995, BRIT MED J, V310, P414, DOI 10.1136/bmj.310.6977.414; Zhang YF, 1997, CLIN DIAGN LAB IMMUN, V4, P423, DOI 10.1128/CDLI.4.4.423-428.1997	9	22	23	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1049	1050		10.1016/S0140-6736(99)00241-X	http://dx.doi.org/10.1016/S0140-6736(99)00241-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509491				2022-12-24	WOS:000082777500005
J	Zhou, YQ; Karplus, M				Zhou, YQ; Karplus, M			Interpreting the folding kinetics of helical proteins	NATURE			English	Article							MOLECULAR-DYNAMICS; SIMULATIONS; SYSTEMS	The detailed mechanism of protein folding is one of the major problems in structural biology(1,2). Its solution is of practical as well as fundamental interest because of its possible role in utilizing the many sequences becoming available from genomic analysis(3). Although the Levinthal paradox(4) (namely, that a polypeptide chain can find its unique native state in spite of the astronomical number of configurations in the denatured state) has been resolved(4-7), the reasons for the differences in the folding behaviour of individual proteins remain to be elucidated. Here a C-alpha-based three-helix-bundle-like protein model with a realistic thermodynamic phase diagram is used to calculate several hundred folding trajectories. By varying a single parameter, the difference between the strength of native and non-native contacts, folding is changed from a diffusion-collision mechanism(8) to one that involves simultaneous collapse and partial secondary-structure formation, followed by reorganization to the native structure. Non-obligatory intermediates are important in the former, whereas there is an obligatory on-pathway intermediate in the latter. Our results provide a basis for understanding the range of folding behaviour that is observed in helical proteins.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Univ Strasbourg, ISIS, Lab Chim Biophys, F-67000 Strasbourg, France	Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu	Zhou, Yaoqi/B-3284-2009	Zhou, Yaoqi/0000-0002-9958-5699				Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Burton RE, 1998, BIOCHEMISTRY-US, V37, P5337, DOI 10.1021/bi980245c; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; Cavagnero S, 1999, J MOL BIOL, V285, P269, DOI 10.1006/jmbi.1998.2273; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FERRENBERG AM, 1989, PHYS REV LETT, V63, P1195, DOI 10.1103/PhysRevLett.63.1195; Fersht A., 1998, ENZYME STRUCTURE MEC; Frauenfelder H, 1998, P NATL ACAD SCI USA, V95, P4795, DOI 10.1073/pnas.95.9.4795; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Guo ZY, 1997, P NATL ACAD SCI USA, V94, P10161, DOI 10.1073/pnas.94.19.10161; KARPLUS M, 1995, CURR OPIN STRUC BIOL, V5, P58, DOI 10.1016/0959-440X(95)80010-X; KARPLUS M, 1976, NATURE, V260, P404, DOI 10.1038/260404a0; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; LI AJ, 1994, P NATL ACAD SCI USA, V91, P10430, DOI 10.1073/pnas.91.22.10430; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; Sali Andrej, 1998, Nature Structural Biology, V5, P1029, DOI 10.1038/4136; Schlunegger F, 1997, BASIN RES, V9, P1, DOI 10.1046/j.1365-2117.1997.00029.x; Socci ND, 1998, PROTEINS, V32, P136, DOI 10.1002/(SICI)1097-0134(19980801)32:2<136::AID-PROT2>3.3.CO;2-5; TAKETOMI H, 1975, INT J PEPT PROT RES, V7, P445; Zhou YQ, 1999, J MOL BIOL, V285, P1371, DOI 10.1006/jmbi.1998.2374; Zhou YQ, 1997, P NATL ACAD SCI USA, V94, P14429, DOI 10.1073/pnas.94.26.14429; Zhou YQ, 1997, J CHEM PHYS, V107, P10691, DOI 10.1063/1.474186	30	244	246	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					400	403		10.1038/43937	http://dx.doi.org/10.1038/43937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517642				2022-12-24	WOS:000082822600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Net tip - Lab search engine	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1869						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-24	WOS:000082638300037
J	Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI				Esteban, CR; Capdevila, J; Economides, AN; Pascual, J; Ortiz, A; Belmonte, JCI			The novel Cer-like protein Caronte mediates the establishment of embryonic left-right asymmetry	NATURE			English	Article							HOMEOBOX GENE; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; HEART DEVELOPMENT; NODAL EXPRESSION; SECRETED FACTOR; ORGANIZER; CERBERUS; PATHWAY; CELLS	In the chick embryo, left-right asymmetric patterns of gene expression in the lateral plate mesoderm are initiated by signals located in and around Hensen's node, Here we show that Caronte (Gar), a secreted protein encoded by a member of the Cerberus/Dan gene family, mediates the Sonic hedgehog (Shh)-dependent induction of left-specific genes in the lateral plate mesoderm, Car is induced by Shh and repressed by fibroblast growth factor-8 (FGF-8), Car activates the expression of Nodal by antagonizing a repressive activity of bone morphogenic proteins (BMPs), Our results define a complex network of antagonistic molecular interactions between Activin, FGF-8, Lefty-1, Nodal, BMPs and Car that cooperate to control left-right asymmetry in the chick embryo.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Salk Institute; Regeneron; Scripps Research Institute	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	pascual, jaime/D-4566-2009	pascual, jaime/0000-0001-8992-7475; Economides, Aris/0000-0002-6508-8942				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Campione M, 1999, DEVELOPMENT, V126, P1225; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1999, CURR BIOL, V9, pR18, DOI 10.1016/S0960-9822(99)80036-0; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Merino R, 1999, DEV BIOL, V206, P33, DOI 10.1006/dbio.1998.9129; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OZAKI T, 1993, P NATL ACAD SCI USA, V90, P2593, DOI 10.1073/pnas.90.7.2593; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Pizette S, 1999, DEVELOPMENT, V126, P883; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Schneider A, 1999, CURR BIOL, V9, P911, DOI 10.1016/S0960-9822(99)80397-2; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; STANLEY E, MECH DEV, V77, P173; Streit A, 1998, DEVELOPMENT, V125, P507; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Thisse C, 1999, DEVELOPMENT, V126, P229; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Tribioli C, 1997, MECH DEVELOP, V65, P145, DOI 10.1016/S0925-4773(97)00067-1; TSUKUI T, IN PRESS P NATL ACAD; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; YOKOUCHI Y, IN PRESS CELL; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	168	175	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					243	251		10.1038/45738	http://dx.doi.org/10.1038/45738			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499580				2022-12-24	WOS:000082678400044
J	Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM				Wiesmann, C; Ultsch, MH; Bass, SH; de Vos, AM			Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor	NATURE			English	Article							IMMUNOGLOBULIN-LIKE DOMAIN; TYROSINE KINASE RECEPTORS; LEUCINE-RICH MOTIF; NEUROTROPHIN RECEPTORS; AFFINITY RECEPTOR; NGF; RESOLUTION; SITE; DIFFERENTIATION; SPECIFICITY	Nerve growth factor (NGF) is involved in a variety of processes involving signalling, such as cell differentiation and survival, growth cessation and apoptosis of neurons'. These events are mediated by NGF as a result of binding to its two cell-surface receptors,TrkA and p75 (ref. 2). TrkA is a receptor with tyrosine kinase activity that forms a high-affinity binding site for NGF(3). Of the five domains comprising its extracellular portion, the immunoglobulin-like domain proximal to the membrane (TrkA-d5 domain) is necessary and sufficient for NGF binding(4). Here we present the crystal structure of human NGF in complex with human TrkA-d5 at 2.2 Angstrom resolution. The ligand-receptor interface consists of two patches of similar size. One patch involves the central beta-sheet that forms the core of the homodimeric NGF molecule and the loops at the carboxy-terminal pole of TrkA-d5. The second patch comprises the amino-terminal resudes of NGF, which adopt a helical conformation upon complex formation, packing against the 'ABED' sheet of TrkA-d5. The structure is consistent with results from mutagenesis experiments for all neurotrophins, and indicates that the first patch may constitute a conserved binding motif for all family members, whereas the second patch is specific for the interaction between NGF and TrkA.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	de Vos, AM (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.			Wiesmann, Christian/0000-0002-4092-9880				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; DECHANT G, 1997, J NEUROSCI, V17, P5271; GOTZ R, 1994, NATURE, V372, P366; IBANEZ CF, 1991, EMBO J, V10, P2105, DOI 10.1002/j.1460-2075.1991.tb07743.x; IBANEZ CF, 1993, EMBO J, V12, P2281, DOI 10.1002/j.1460-2075.1993.tb05882.x; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KULLANDER K, 1994, J NEUROSCI RES, V39, P195, DOI 10.1002/jnr.490390210; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; O'Leary PD, 1998, J NEUROCHEM, V70, P1712; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Ryden M, 1997, J BIOL CHEM, V272, P33085, DOI 10.1074/jbc.272.52.33085; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urfer R, 1997, BIOCHEMISTRY-US, V36, P4775, DOI 10.1021/bi962877+; Urfer R, 1998, J BIOL CHEM, V273, P5829, DOI 10.1074/jbc.273.10.5829; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	30	303	331	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					184	188		10.1038/43705	http://dx.doi.org/10.1038/43705			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490030				2022-12-24	WOS:000082458800059
J	Henney, JE				Henney, JE			Endotoxin-like reactions to gentamicin sulfate	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-24	WOS:000082335900006
J	Rice, TW				Rice, TW			Superficial oesophageal carcinoma: is there a need for three-field lymphadenectomy?	LANCET			English	Editorial Material									Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Rice, TW (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA.							CHRISTIE NA, IN PRESS J THORAC CA; Matsubara T, 1999, BRIT J SURG, V86, P669, DOI 10.1046/j.1365-2168.1999.01067.x; Nigro JJ, 1999, J THORAC CARDIOV SUR, V117, P16, DOI 10.1016/S0022-5223(99)70464-2; Rice TW, 1998, ANN THORAC SURG, V65, P787, DOI 10.1016/S0003-4975(97)01387-8	4	45	47	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					792	794						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485718				2022-12-24	WOS:000082400700005
J	Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC				Lin, JY; Qi, R; Aston, C; Jing, JP; Anantharaman, TS; Mishra, B; White, O; Daly, MJ; Minton, KW; Venter, JC; Schwartz, DC			Whole-genome shotgun optical mapping of Deinococcus radiodurans	SCIENCE			English	Article							ORDERED RESTRICTION MAPS; IONIZING-RADIATION; FORCE MICROSCOPY; DNA-MOLECULES; PHYSICAL MAP; CHROMOSOME; RECOMBINATION; SURFACES; REPAIR	A whole-genome restriction map of Deinococcus radiodurans, a radiation-resistant bacterium able to survive up to 15,000 grays of ionizing radiation, was constructed without using DNA Libraries, the polymerase chain reaction, or electrophoresis. Very Large, randomly sheared, genomic DNA fragments were used to construct maps from individual DNA molecules that were assembled into two circular overlapping maps (2.6 and 0.415 megabases), without gaps. A third smaller chromosome (176 kilobases) was identified and characterized. Aberrant nonlinear DNA structures that may define chromosome structure and organization, as well as intermediates in DNA repair, were directly visualized by optical mapping techniques after gamma irradiation.	NYU, Dept Chem, WM Keck Lab Biomol Imaging, New York, NY 10003 USA; NYU, Courant Inst Math Sci, Dept Comp Sci, New York, NY 10012 USA; Inst Genome Res, Rockville, MD 20850 USA; Celera Genom, Rockville, MD 20850 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	New York University; New York University; J. Craig Venter Institute; Uniformed Services University of the Health Sciences - USA	Schwartz, DC (corresponding author), Univ Wisconsin, Ctr Biotechnol, Dept Chem, 425 Henry Mall, Madison, WI 53706 USA.				NHGRI NIH HHS [HG0025-08] Funding Source: Medline; NIGMS NIH HHS [GM 39933] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman TS, 1997, J COMPUT BIOL, V4, P91, DOI 10.1089/cmb.1997.4.91; ANANTHARAMAN TS, IN PRESS 7 INT C INT; ANANTHARAMAN TS, 1998, 760 NEW YORK U COUR; Aston C, 1999, METHOD ENZYMOL, V303, P55; BAUTSCH W, 1997, GENOME MAPPING PRACT, P281; BEDERSON BB, 1998, HUMAN FACTORS WEB DE, P255; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLATTNER FR, UNPUB; CAI WW, 1995, P NATL ACAD SCI USA, V92, P5164, DOI 10.1073/pnas.92.11.5164; Cai WW, 1998, P NATL ACAD SCI USA, V95, P3390, DOI 10.1073/pnas.95.7.3390; Daly MJ, 1997, GENE, V187, P225, DOI 10.1016/S0378-1119(96)00755-X; DALY MJ, 1995, SCIENCE, V270, P1318, DOI 10.1126/science.270.5240.1318; Daly MJ, 1996, J BACTERIOL, V178, P4461, DOI 10.1128/jb.178.15.4461-4471.1996; DALY MJ, 1995, J BACTERIOL, V177, P5505; DALY MM, UNPUB; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HANSEN MT, 1978, J BACTERIOL, V134, P71, DOI 10.1128/JB.134.1.71-75.1978; Jing JP, 1999, GENOME RES, V9, P175; KIKUCHI M, 1994, RADIAT RES, V139, P123, DOI 10.2307/3578742; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LAI Z, UNPUB; Lee E, UNPUB; LINK AJ, 1991, GENETICS, V127, P681; LIOUTAS C, 1995, EXP PARASITOL, V80, P349, DOI 10.1006/expr.1995.1045; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MENG X, 1995, NAT GENET, V9, P432, DOI 10.1038/ng0495-432; Minton KW, 1996, MUTAT RES-DNA REPAIR, V363, P1, DOI 10.1016/0921-8777(95)00014-3; MINTON KW, 1995, BIOESSAYS, V17, P457, DOI 10.1002/bies.950170514; Reed J, 1998, ANAL BIOCHEM, V259, P80, DOI 10.1006/abio.1998.2640; SAMAD AH, 1995, NATURE, V378, P516, DOI 10.1038/378516a0; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; Schwartz DC, 1997, CURR OPIN BIOTECH, V8, P70, DOI 10.1016/S0958-1669(97)80160-7; Wang WN, 1998, BIOPHYS J, V75, P513, DOI 10.1016/S0006-3495(98)77540-X; WHITE O, UNPUB	35	143	167	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1558	1562		10.1126/science.285.5433.1558	http://dx.doi.org/10.1126/science.285.5433.1558			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477518				2022-12-24	WOS:000082359500063
J	Hansen, D; Moller, H; Olsen, J				Hansen, D; Moller, H; Olsen, J			Severe periconceptional life events and the sex ratio in offspring: follow up study based on five national registers	BRITISH MEDICAL JOURNAL			English	Article							BIRTH		John F Kennedy Inst, DK-2600 Glostrup, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark; Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danmarks Grundforskningsfond; Aarhus University	Hansen, D (corresponding author), John F Kennedy Inst, G1 Landevej 7, DK-2600 Glostrup, Denmark.			Moller, Henrik/0000-0001-8200-5929				Fenster L, 1997, J ANDROL, V18, P194; Fukuda M, 1998, HUM REPROD, V13, P2321, DOI 10.1093/humrep/13.8.2321; James WH, 1996, J THEOR BIOL, V180, P271, DOI 10.1006/jtbi.1996.0102; LYSTER WR, 1974, J OBSTET GYN BR COMM, V81, P626; PRATT NC, 1989, J REPROD FERTIL, V87, P736	5	112	113	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					548	549		10.1136/bmj.319.7209.548	http://dx.doi.org/10.1136/bmj.319.7209.548			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463895	Green Published, Bronze			2022-12-24	WOS:000082347200022
J	Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO				Dowsing, AT; Yong, EL; Clark, M; McLachlan, RI; de Kretser, DM; Trounson, AO			Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene	LANCET			English	Article							DOMINANT CEREBELLAR-ATAXIA; CAG REPEAT; MEN; CHROMOSOME; DISEASE; SPERM; TRANSACTIVATION; INSENSITIVITY; AZOOSPERMIA; MUTATIONS	Background Androgens acting via the androgen receptor bring about stimulation and maintenance of spermatogenesis. If mutations in the androgen-receptor gene interfere with the receptor's function, this effect may partly account for impaired spermatogenesis. We aimed to find out whether expansion of a trinucleotide repeat in the androgen-receptor gene is associated with male infertility. Methods We analysed 67 coded semen and blood samples from a predominantly white group of male infertility patients and controls. Clinical analyses included cause of infertility, sperm count, and reproductive hormone concentrations. Analysis of trinucleotide (CAG) repeal length and point mutations in the androgen-receptor gene was done by PCR, single-stranded conformational polymorphism, and DNA sequencing. Findings Screening and characterisation of the androgen-receptor gene in 35 patients and 32 controls showed no point mutations in the gene. 30 of the infertile patients had idiopathic azoospermia or oligozoospermia, and these men had significantly longer CAG repeat tracts than controls (mean 23.2 [SE 0.7] vs 20.5 [0.3], p=0.0001). The odds of having CAG repeat lengths of 20 were six-fold higher for fertile men than for men with a spermatogenic disorder. Interpretation Our results indicate a relation between CAG repeat length in the androgen-receptor gene and the risk of defective spermatogenesis. With the use of intracytoplasmic sperm injection, this mutation could be inherited. possibly leading to an increase in male infertility in future generations. Should further elongation of the CAG repeat occur in these future generations, there is an added risk of increased severity of male infertility, and potentially an increased incidence of neurodegenerative disease.	Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Dept Math & Stat, Clayton, Vic 3168, Australia; Monash Univ, Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore, Singapore	Monash University; Monash University; Monash University; Prince Henry's Institute of Medical Research; National University of Singapore	Trounson, AO (corresponding author), Monash Univ, Monash Med Ctr, Ctr Early Human Dev, Inst Reprod & Dev, Level 5,246 Clayton Rd, Clayton, Vic 3168, Australia.			Yong, Eu-Leong/0000-0001-6511-770X; Trounson, Alan/0000-0001-5469-0500				AIMAN J, 1982, J CLIN ENDOCR METAB, V54, P725, DOI 10.1210/jcem-54-4-725; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; David G, 1998, HUM MOL GENET, V7, P165, DOI 10.1093/hmg/7.2.165; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LIU DY, 1994, HUM REPROD, V9, P1694, DOI 10.1093/oxfordjournals.humrep.a138776; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; McLachlan RI, 1996, J ENDOCRINOL, V148, P1, DOI 10.1677/joe.0.1480001; Najmabadi H, 1996, J CLIN ENDOCR METAB, V81, P1347, DOI 10.1210/jc.81.4.1347; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PUSCHECK EE, 1994, FERTIL STERIL, V62, P1035; Tincello DG, 1997, MOL HUM REPROD, V3, P941, DOI 10.1093/molehr/3.11.941; Tut TG, 1997, J CLIN ENDOCR METAB, V82, P3777, DOI 10.1210/jc.82.11.3777; *WHO, 1987, INT J ANDROL S, V7, P3; *WHO, 1996, 2 WHO LAB MAN EX HUM; YONG EL, 1994, FERTIL STERIL, V61, P856; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	25	217	222	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					640	643		10.1016/S0140-6736(98)08413-X	http://dx.doi.org/10.1016/S0140-6736(98)08413-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466666				2022-12-24	WOS:000082214500013
J	Ni, M; Tepperman, JM; Quail, PH				Ni, M; Tepperman, JM; Quail, PH			Binding of phytochrome B to its nuclear signalling partner PIF3 is reversibly induced by light	NATURE			English	Article							REGULATORY ACTIVITY; TERMINAL-DOMAIN; TRANSDUCTION; PROTEIN	The phytochrome photoreceptor family directs plant gene expression by switching between biologically inactive and active conformers in response to the sequential absorption of red and far-red photons(1,2). Several intermediates that act late in the phytochrome signalling pathway have been identified, but fewer have been identified that act early in the pathway(3,4). We have cloned a nuclear basic helix-loop-helix protein, PIF3, which can bind to non-photoactive carboxy-terminal fragments of phytochromes A and B and functions in phytochrome signalling in vivo(5). Here we show that full-length photoactive phytochrome B binds PIF3 in vitro only upon light-induced conversion to its active form, and that photoconversion back to its inactive form causes dissociation from PIF3. We conclude that photosensory signalling by phytochrome B involves light-induced, conformer-specific recognition of the putative transcriptional regulator PIF3, providing a potential mechanism for direct photoregulation of gene expression.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; USDA ARS, Ctr Plant Gene Express, Albany, CA 94710 USA	University of California System; University of California Berkeley; United States Department of Agriculture (USDA)	Quail, PH (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Ni, Maria/GVT-4942-2022					Chory J, 1996, P NATL ACAD SCI USA, V93, P12066, DOI 10.1073/pnas.93.22.12066; DENG XW, IN PRESS SEMIN CELL; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; Quail PH, 1998, PHILOS T R SOC B, V353, P1399, DOI 10.1098/rstb.1998.0294; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sakamoto K, 1996, PLANT J, V10, P859, DOI 10.1046/j.1365-313X.1996.10050859.x; Scheer H., 1984, TECHNIQUES PHOTOMORP, P227, DOI [10.5282/ubm/epub.2167, DOI 10.5282/UBM/EPUB.2167]; SOMERS DE, 1991, PLANT CELL, V3, P1263, DOI 10.1105/tpc.3.12.1263; TERZAGHI WB, 1995, ANNU REV PLANT PHYS, V46, P445, DOI 10.1146/annurev.pp.46.060195.002305; Tobin Elaine M., 1994, Seminars in Cell Biology, V5, P335, DOI 10.1006/scel.1994.1040; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Wei N, 1996, PLANT PHYSIOL, V112, P871, DOI 10.1104/pp.112.3.871; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	17	350	388	2	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					781	784		10.1038/23500	http://dx.doi.org/10.1038/23500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466729				2022-12-24	WOS:000082131100054
J	Grace, AA				Grace, AA			Brugada syndrome	LANCET			English	Editorial Material							UNEXPLAINED-DEATH-SYNDROME; ST-SEGMENT ELEVATION; BUNDLE-BRANCH BLOCK; VENTRICULAR-FIBRILLATION; HEART-DISEASE; SUDDEN-DEATH; MARKER		Papworth Hosp, Cambridge CB3 8RE, England; Univ Cambridge, Dept Biochem, Sect Cardiovasc Biol, Cambridge CB2 1QW, England	Papworth Hospital; University of Cambridge	Grace, AA (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.							Alings M, 1999, CIRCULATION, V99, P666, DOI 10.1161/01.CIR.99.5.666; Brugada J, 1998, CIRCULATION, V97, P457; Chen QY, 1998, NATURE, V392, P293, DOI 10.1038/32675; Corrado D, 1996, J AM COLL CARDIOL, V27, P443, DOI 10.1016/0735-1097(95)00485-8; Gussak I, 1999, J AM COLL CARDIOL, V33, P5, DOI 10.1016/S0735-1097(98)00528-2; Kasanuki H, 1997, CIRCULATION, V95, P2277, DOI 10.1161/01.CIR.95.9.2277; Matsuo K, 1999, EUR HEART J, V20, P465, DOI 10.1053/euhj.1998.1332; Nademanee K, 1997, CIRCULATION, V96, P2595, DOI 10.1161/01.CIR.96.8.2595; Priori SG, 1999, EUR HEART J, V20, P174, DOI 10.1053/euhj.1998.1220; Priori SG, 1997, CIRCULATION, V95, P265; SAUMAREZ RC, 1995, CIRCULATION, V92, P2565, DOI 10.1161/01.CIR.92.9.2565; WEVER EFD, 1993, CIRCULATION, V88, P1021, DOI 10.1161/01.CIR.88.3.1021; WONG ML, 1992, TROP GEOGR MED, V44, pS1; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334	14	12	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 7	1999	354	9177					445	446		10.1016/S0140-6736(99)90032-6	http://dx.doi.org/10.1016/S0140-6736(99)90032-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465166				2022-12-24	WOS:000081896100006
J	Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL				Huang, JF; Yang, Y; Sepulveda, H; Shi, WX; Hwang, I; Peterson, PA; Jackson, MR; Sprent, J; Cai, ZL			TCR-mediated internalization of peptide-MHC complexes acquired by T cells	SCIENCE			English	Article							CLASS-II MOLECULES; TRANSGENIC MICE; LYMPHOCYTES-T; RECEPTOR; ANTIGEN; ACTIVATION; VIRUS; PROTEIN; REQUIREMENTS; RECOGNITION	Peptide-major histocompatibility complex protein complexes (pMHCs) on antigen-presenting cells (APCs) are central to T cell activation. Within minutes of peptide-specific T cells interacting with APCs, pMHCs on APCs formed clusters at the site of T cell contact. Thereafter, these clusters were acquired by T cells and internalized through T cell receptor-mediated endocytosis. During this process, T cells became sensitive to peptide-specific Lysis by neighboring T cells (fratricide). This form of immunoregulation could explain the "exhaustion" of T cell responses that is induced by high viral Loads and may serve to downregulate immune responses.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Res Inst, Dept Immunol, IMM4, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Cai, ZL (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.			Hwang, Inkyu/0000-0001-8997-6090				BORROW P, 1991, J EXP MED, V174, P203, DOI 10.1084/jem.174.1.203; Buchmeier M J, 1980, Adv Immunol, V30, P275, DOI 10.1016/S0065-2776(08)60197-2; Cai ZL, 1997, J EXP MED, V185, P641, DOI 10.1084/jem.185.4.641; Cai ZL, 1996, P NATL ACAD SCI USA, V93, P14736, DOI 10.1073/pnas.93.25.14736; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HWANG I, UNPUB; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LORBER MI, 1982, J IMMUNOL, V128, P2798; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; NEPOM JT, 1981, J IMMUNOL, V127, P888; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Preckel T, 1997, J EXP MED, V185, P1803, DOI 10.1084/jem.185.10.1803; PULLEN JK, 1991, J IMMUNOL, V146, P2145; SAIZAWA MK, 1992, J CELL BIOCHEM, V16, P54; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; Shen ZH, 1997, J IMMUNOL, V158, P2723; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Valitutti S, 1997, J EXP MED, V185, P1859, DOI 10.1084/jem.185.10.1859; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	31	367	379	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					952	954		10.1126/science.286.5441.952	http://dx.doi.org/10.1126/science.286.5441.952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542149				2022-12-24	WOS:000083368500044
J	Hartman, JJ; Vale, RD				Hartman, JJ; Vale, RD			Microtubule disassembly by ATP-dependent oligomerization of the AAA enzyme katanin	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; NSF; CENTROSOME; DYNAMICS; COMPLEX; SPINDLE	Katanin, a member of the AAA adenosine triphosphatase (ATPase) superfamily, uses nucleotide hydrolysis energy to sever and disassemble microtubules. Many AAA enzymes disassemble stable protein-protein complexes, but their mechanisms are not well understood. A fluorescence resonance energy transfer assay demonstrated that the p60 subunit of katanin oligomerized in an adenosine triphosphate (ATP)- and microtubule-dependent manner. Oligomerization increased the affinity of katanin for microtubules and stimulated its ATPase activity. After hydrolysis of ATP, microtubule-bound katanin oligomers disassembled microtubules and then dissociated into free katanin monomers. Coupling a nucleotide-dependent oligomerization cycle to the disassembly of a target protein complex may be a general feature of ATP-hydrolyzing AAA domains.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	vale@phy.ucsf.edu						Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Leonhard K, 1999, NATURE, V398, P348, DOI 10.1038/18704; MCNALLY FJ, 1993, CELL, V75, P419, DOI 10.1016/0092-8674(93)90377-3; MCNALLY FJ, UNPUB; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TSIEN R, COMMUNICATION; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yu RC, 1998, NAT STRUCT BIOL, V5, P803, DOI 10.1038/1843; Zhai Y, 1996, J CELL BIOL, V135, P201, DOI 10.1083/jcb.135.1.201	28	176	182	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					782	785		10.1126/science.286.5440.782	http://dx.doi.org/10.1126/science.286.5440.782			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531065				2022-12-24	WOS:000083303200057
J	Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME				Mao, ZX; Bonni, A; Xia, F; Nadal-Vicens, M; Greenberg, ME			Neuronal activity-dependent cell survival mediated by transcription factor MEF2	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; GENE-EXPRESSION; CREB PHOSPHORYLATION; ACTIVATION; NUCLEUS; CALCIUM; DEATH; DROSOPHILA; MYOGENESIS; APOPTOSIS	During mammalian development, electrical activity promotes the calcium-dependent survival of neurons that have made appropriate synaptic connections. However, the mechanisms by which calcium mediates neuronal survival during development are not well characterized. A transcription-dependent mechanism was identified by which calcium influx into neurons promoted cell survival. The transcription factor MEF2 was selectively expressed in newly generated postmitotic neurons and was required for the survival of these neurons. Calcium influx into cerebellar granule neurons Led to activation of p38 mitogen-activated protein kinase-dependent phosphorylation and activation of MEF2. Once activated, MEF2 regulated neuronal survival by stimulating MEF2-dependent gene transcription. These findings demonstrate that MEF2 is a calcium-regulated transcription factor and define a function for MEF2 during nervous system development that is distinct from previously Well-characterized functions of MEF2 during muscle differentiation.	Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Charlestown, MA 02129 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Greenberg, ME (corresponding author), Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA.		Xia, Fen/G-3708-2013		NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NINDS NIH HHS [NS28829, 5T32NS07112] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007112, R01NS028829, R37NS028829] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; FRANKLIN JL, 1994, ANN NY ACAD SCI, V747, P195; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GEISERT EE, 1989, NEUROSCI LETT, V102, P137, DOI 10.1016/0304-3940(89)90068-2; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; IKESHIMA H, 1995, NEUROSCI LETT, V200, P117, DOI 10.1016/0304-3940(95)12092-I; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin MH, 1997, DEV BIOL, V182, P240, DOI 10.1006/dbio.1996.8484; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lin X, 1996, MOL BRAIN RES, V42, P307, DOI 10.1016/S0169-328X(96)00135-0; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MAO Z, UNPUB; Miller TM, 1997, J BIOL CHEM, V272, P9847; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MONTMINY MR, 1986, J NEUROSCI, V6, P1171; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; Santella L, 1997, FASEB J, V11, P1091, DOI 10.1096/fasebj.11.13.9367344; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	32	432	449	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					785	790		10.1126/science.286.5440.785	http://dx.doi.org/10.1126/science.286.5440.785			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531066				2022-12-24	WOS:000083303200058
J	Bodenheimer, T				Bodenheimer, T			Long-term care for frail elderly people - The On Lok model	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROGRAM											Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8; Binstock RH, 1997, HEALTH SERV RES, V32, P715; CHATTERJI P, 1998, IMPACT PACE PARTICIP; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Eng C., 1996, CURR CONCEPTS GERIAT, V2, P4; Fisher Ian, 1998, N Y Times Web, P30; GRUENBERG L, 1993, ANAL EXPECTED MED CO; HARRINGTON C, 1991, JAMA-J AM MED ASSOC, V266, P3023, DOI 10.1001/jama.266.21.3023; IRVIN CV, 1999, NEW ENGL J MED, V340, P1283; Kassirer JP, 1998, NEW ENGL J MED, V339, P1925, DOI 10.1056/NEJM199812243392609; KUNZ E, 1996, AM J MANAGE CARE, V2, P301; Levit KR, 1998, HEALTH AFFAIR, V17, P35, DOI 10.1377/hlthaff.17.1.35; MCLEOD D, 1998, AARP B           APR; NEWCOMER R, 1996, ANNU REV GERONTOL, V16, P1; RIMER S, 1998, NY TIMES        0315, P1; Vladeck B.C., 1980, UNLOVING CARE NURSIN; White A.J., 1998, EFFECT PACE COSTS ME; [No title captured]; [No title captured]	19	78	82	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1324	1328		10.1056/NEJM199910213411722	http://dx.doi.org/10.1056/NEJM199910213411722			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247NF	10528046				2022-12-24	WOS:000083226300034
J	Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA				Elliott, AM; Smith, BH; Penny, KI; Smith, WC; Chambers, WA			The epidemiology of chronic pain in the community	LANCET			English	Article							GENERAL-POPULATION; PERSISTENT PAIN; PREVALENCE; HEALTH; CARE	Background Chronic pain is recognised as an important problem in the community but our understanding of the epidemiology of chronic pain remains limited. We undertook a study designed to quantify and describe the prevalence and distribution of chronic pain in the community. Methods A random sample of 5036 patients, aged 25 and over, was drawn from 29 general practices in the Grampian region of the UK and surveyed by a postal self-completion questionnaire. The questionnaire included case-screening questions, a question on the cause of the pain, the chronic pain grade questionnaire, the level of expressed needs questionnaire, and sociodemographic questions. Findings 3605 questionnaires were returned completed. 1817 (50.4%) of patients self reported chronic pain, equivalent to 46.5% of the general population. 576 reported back pain and 570 reported arthritis; these were the most common complaints and accounted for a third of all complaints. Backward stepwise logistic-regression modelling identified age, sex, housing tenure, and employment status as significant predictors of the presence of chronic pain in the community. 703 (48.7%) individuals with chronic pain had the least severe grade of pain, and 228 (15.8%) the most severe grade. Of those who reported chronic pain, 312 (17.2%) reported no expressed need, and 509 (28.0%) reported the highest expressed need. Interpretation Chronic pain is a major problem in the community and certain groups within the population are more likely to have chronic pain. A detailed understanding of the epidemiology of chronic pain is essential for efficient management of chronic pain in primary care.	Univ Aberdeen, Sch Med, Dept Gen Practice, Aberdeen AB9 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Publ Hlth, Aberdeen AB9 2ZD, Scotland; Aberdeen Royal Infirm, Dept Anaesthet, Aberdeen, Scotland; Univ Edinburgh, Sch Med, Med Stat Unit, Edinburgh, Midlothian, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Edinburgh	Elliott, AM (corresponding author), Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland.		Smith, Blair H/G-2834-2012; G, G/A-3459-2012	Smith, Blair H/0000-0002-5362-9430; 				Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Blaxter M., 1990, HLTH LIFESTYLES; BOWSHER D, 1991, Pain Clinic, V4, P223; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; CROFT P, 1993, J RHEUMATOL, V20, P710; Croft PR, 1998, BRIT MED J, V316, P1356, DOI 10.1136/bmj.316.7141.1356; Crombie IK, 1998, PAIN, V74, P1; CROOK J, 1989, PAIN, V36, P49, DOI 10.1016/0304-3959(89)90111-5; CROOK J, 1984, PAIN, V18, P299, DOI 10.1016/0304-3959(84)90824-8; Davies Huw T. O., 1992, Pain Clinic, V5, P129; DIAMOND A, 1991, ANAESTHESIA, V46, P83, DOI 10.1111/j.1365-2044.1991.tb09343.x; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; International Association for the Study of Pain: Subcommittee on Taxonomy, 1986, PAIN S, V3, pS1, DOI DOI 10.1016/0304-3959(86)90106-5; Latham J, 1994, Disabil Rehabil, V16, P39; Locker David, 1983, DISABILITY DISADVANT; MAGNI G, 1993, PAIN, V53, P163, DOI 10.1016/0304-3959(93)90076-2; Purves AM, 1998, PAIN CLINIC, V10, P139; Rothman K., 1998, MODERN EPIDEMIOLOGY; Smith BH, 1997, PAIN, V71, P141, DOI 10.1016/S0304-3959(97)03347-2; Smith BH, 1996, J ROY SOC MED, V89, P181, DOI 10.1177/014107689608900402; TURK DC, 1988, J CONSULT CLIN PSYCH, V56, P233, DOI 10.1037/0022-006X.56.2.233; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; Von Korff M, 1990, PAIN, V279, P91, DOI DOI 10.1016/0304-3959(90)91125-3; VONKORFF M, 1991, PSYCHOSOM MED, V53, P61, DOI 10.1097/00006842-199101000-00006; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4	25	813	851	0	49	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1248	1252		10.1016/S0140-6736(99)03057-3	http://dx.doi.org/10.1016/S0140-6736(99)03057-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520633				2022-12-24	WOS:000083010400010
J	Henney, JE				Henney, JE			New drug for sleeplessness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-24	WOS:000082901100007
J	Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF				Bisang, C; Long, PF; Cortes, J; Westcott, J; Crosby, J; Matharu, AL; Cox, RJ; Simpson, TJ; Staunton, J; Leadlay, PF			A chain initiation factor common to both modular and aromatic polyketide synthases	NATURE			English	Article							ACYL CARRIER PROTEINS; ENGINEERED BIOSYNTHESIS; IN-VITRO; STREPTOMYCES-GLAUCESCENS; RATIONAL DESIGN; PURIFICATION; SPECIFICITY; EXPRESSION; RECONSTITUTION; COMPONENTS	Antibiotic-producing polyketide synthases (PKSs) are enzymes responsible for the biosynthesis in Streptomyces and related filamentous bacteria of a remarkably broad range of bioactive metabolites, including antitumour aromatic compounds such as mithramycin(1) and macrolide antibiotics such as erythromycin(2). The molecular basis for the selection of the starter unit on aromatic PKSs is unknown(3). Here we show that a component of aromatic PKS, previously named 'chain-length factor'(4), is a factor required for polyketide chain initiation and that this factor has decarboxylase activity towards malonyl-ACP (acyl carrier protein). We have re-examined the mechanism of initiation on modular PKSs and have identified as a specific initiation factor a domain of previously unknown function named KSQ, which operates like chain-length factor. Both KSQ and chain-length factor are similar to the ketosynthase domains that catalyse polyketide chain extension in modular multifunctional PKSs and in aromatic PKSs, respectively, except that the ketosynthase domain active-site cysteine residue is replaced by a highly conserved glutamine in KSQ and in chain-length factor. The glutamine residue is important both for decarboxylase activity and for polyketide synthesis.	Dept Biochem, Cambridge CB2 1GA, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England	University of Cambridge	Leadlay, PF (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Cox, Russell John/F-9190-2015; Simpson, Thomas J/P-5058-2015	Cox, Russell John/0000-0002-1844-0157; Leadlay, Peter/0000-0002-3247-509X; Cortes, Jesus/0000-0002-2475-6983				Bao WL, 1998, BIOCHEMISTRY-US, V37, P8132, DOI 10.1021/bi980466i; Carreras CW, 1998, BIOCHEMISTRY-US, V37, P2084, DOI 10.1021/bi972919+; CROSBY J, 1995, BBA-PROTEIN STRUCT M, V1251, P32, DOI 10.1016/0167-4838(95)00053-W; Hitchman TS, 1998, CHEM BIOL, V5, P35, DOI 10.1016/S1074-5521(98)90085-0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Joshi AK, 1997, BIOCHEMISTRY-US, V36, P2316, DOI 10.1021/bi9626968; Kao CM, 1996, BIOCHEMISTRY-US, V35, P12363, DOI 10.1021/bi9616312; KIM ES, 1995, J BACTERIOL, V177, P1202, DOI 10.1128/jb.177.5.1202-1207.1995; Kramer PJ, 1997, J AM CHEM SOC, V119, P635, DOI 10.1021/ja962888q; KRESZE GB, 1977, EUR J BIOCHEM, V79, P191, DOI 10.1111/j.1432-1033.1977.tb11797.x; Lombo F, 1997, J BACTERIOL, V179, P3354, DOI 10.1128/jb.179.10.3354-3357.1997; Marsden AFA, 1998, SCIENCE, V279, P199, DOI 10.1126/science.279.5348.199; Matharu AL, 1998, CHEM BIOL, V5, P699, DOI 10.1016/S1074-5521(98)90663-9; MCDANIEL R, 1994, P NATL ACAD SCI USA, V91, P11542, DOI 10.1073/pnas.91.24.11542; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; MEURER G, 1995, J BACTERIOL, V177, P477, DOI 10.1128/jb.177.2.477-481.1995; Pieper R, 1997, BIOCHEMISTRY-US, V36, P1846, DOI 10.1021/bi962324z; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; Rowe CJ, 1998, GENE, V216, P215, DOI 10.1016/S0378-1119(98)00327-8; SHEN B, 1995, J AM CHEM SOC, V117, P6811, DOI 10.1021/ja00131a002; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; Staunton J, 1998, TOP CURR CHEM, V195, P49; Weissman KJ, 1998, BIOCHEMISTRY-US, V37, P11012, DOI 10.1021/bi9806246; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658; Zawada RJX, 1997, J BIOL CHEM, V272, P16184, DOI 10.1074/jbc.272.26.16184	27	225	264	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					502	505		10.1038/46829	http://dx.doi.org/10.1038/46829			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519556				2022-12-24	WOS:000082981200062
J	Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP				Di Cristofano, A; Kotsi, P; Peng, YF; Cordon-Cardo, C; Elkon, KB; Pandolfi, PP			Impaired Fas response and autoimmunity in Pten(+/-) mice	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENE; PROSTATE-CANCER; COWDEN-DISEASE; CELL-DEATH; PTEN GENE; PTEN/MMAC1; MUTATIONS; APOPTOSIS; BREAST; FREQUENT	Inactivating mutations in the PTEN tumor suppressor gene, encoding a phosphatase, occur in three related human autosomal dominant disorders characterized by tumor Susceptibility. Here it is shown that Pten heterozygous (Pten(+/-)) mutants develop a lethal polyclonal autoimmune disorder with features reminiscent of those observed in Fas-deficient mutants. Fas-mediated apoptosis was impaired in Pten(+/-) mice, and T Lymphocytes from these mice show reduced activation-induced cell death and increased proliferation upon activation. Phosphatidylinositol (PI) 3-kinase inhibitors restored Fas responsiveness in Pten(+/-) cells. These results indicate that Pten is an essential mediator of the Fas response and a repressor of autoimmunity and thus implicate the PI 3-kinase/Akt pathway in Fas-mediated apoptosis.	Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Hosp Special Surg, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Human Genet, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Di Cristofano, Antonio/B-4148-2016; di cristofano, antonio/AAJ-3796-2020; kotsi, paraskevi/GRR-7445-2022	di cristofano, antonio/0000-0003-2537-3228; kotsi, paraskevi/0000-0003-3696-6731	NATIONAL CANCER INSTITUTE [R01CA082328, P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045482] Funding Source: NIH RePORTER; NCI NIH HHS [CA-82328, CA-08748] Funding Source: Medline; NIAMS NIH HHS [AR45482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Cairns P, 1997, CANCER RES, V57, P4997; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Elkon KB, 1996, CURR OPIN IMMUNOL, V8, P852, DOI 10.1016/S0952-7915(96)80015-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; Levine JS, 1999, SEMIN NEPHROL, V19, P34; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, J MED GENET, V35, P881, DOI 10.1136/jmg.35.11.881; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Penninger JM, 1998, ADV IMMUNOL, V68, P51, DOI 10.1016/S0065-2776(08)60558-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; Rhei E, 1997, CANCER RES, V57, P3657; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Tashiro H, 1997, CANCER RES, V57, P3935; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Weintraub JP, 1997, J IMMUNOL, V159, P4117; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	33	439	452	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2122	2125		10.1126/science.285.5436.2122	http://dx.doi.org/10.1126/science.285.5436.2122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497129				2022-12-24	WOS:000082734300041
J	Barr, MM; Sternberg, PW				Barr, MM; Sternberg, PW			A polycystic kidney-disease gene homologue required for male mating behaviour in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN; INSIGHTS; NEURON; PKD1	The stereotyped mating behaviour of the Caenorhabditis elegans male is made up of several substeps: response, backing, turning, vulva location, spicule insertion and sperm transfer. The complexity of this behaviour is reflected in the sexually dimorphic anatomy and nervous system(1). Behavioural functions have been assigned to most of the male-specific sensory neurons by means of cell ablations; for example, the hook sensory neurons HOA and HOB are specifically required for vulva location(2). We have investigated how sensory perception of the hermaphrodite by the C. elegans male controls mating behaviours. Here we identify a gene, lov-1 (for location of vulva), that is required for two male sensory behaviours: response and vulva location. lov-1 encodes a putative membrane protein with a mucin-like, serine-threonine-rich amino terminus' followed by two blocks of homology to human polycystins, products of the autosomal dominant polycystic kidney-disease loci PKD1 and PKD2 (ref 4). LOV-1 is the closest C. elegans homologue of PKD1. lov-1 is expressed in adult males in sensory neurons of the rays, hook and head, which mediate response, vulva location, and potentially chemotaxis to hermaphrodites, respectively(2,5). PKD-2, the C. elegans homologue of PKD2, is localized to the same neurons as LOV-1, suggesting that they function in the same pathway.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.			Sternberg, Paul/0000-0002-7699-0173				Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BRENNER S, 1974, GENETICS, V77, P71; CARRAWAY KL, 1995, TRENDS GLYCOSCI GLYC, V7, P31, DOI 10.4052/tigg.7.31; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Collet J, 1998, GENETICS, V148, P187; DRISCOLL M, 1997, NEMATODE C ELEGANS, V2, P645; Hodgkin J, 1997, GENETICS, V146, P149; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; PERKINS LA, 1986, DEV BIOL, V117, P456, DOI 10.1016/0012-1606(86)90314-3; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; SANFORD R, 1997, HUM MOL GENET, V9, P1483; SCHNABEL H, 1990, SCIENCE, V250, P686, DOI 10.1126/science.250.4981.686; Sullivan LP, 1998, PHYSIOL REV, V78, P1165, DOI 10.1152/physrev.1998.78.4.1165; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Torres VE, 1998, CURR OPIN NEPHROL HY, V7, P159, DOI 10.1097/00041552-199803000-00004; Tsiokas L, 1999, P NATL ACAD SCI USA, V96, P3934, DOI 10.1073/pnas.96.7.3934; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; WARD S, 1975, J COMP NEUROL, V160, P313, DOI 10.1002/cne.901600305; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618	30	386	434	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					386	389		10.1038/43913	http://dx.doi.org/10.1038/43913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517638	Bronze			2022-12-24	WOS:000082822600054
J	Kelly, TR; De Silva, H; Silva, RA				Kelly, TR; De Silva, H; Silva, RA			Unidirectional rotary motion in a molecular system	NATURE			English	Article							MOTORS; MUSCLE; F1-ATPASE; MACHINES; SHUTTLE; COMPLEX; RATCHET; SEARCH; WORK	The conversion of energy into controlled motion plays an important role in both man-made devices and biological systems. The principles of operation of conventional motors are well established, but the molecular processes used by 'biological motors' such as muscle fibres, flagella and cilia(1-9) to convert chemical energy into co-ordinated movement remain poorly understood(10-12). Although Brownian ratchets'(13-16) are known to permit thermally activated motion in one direction only, the concept of channelling random thermal energy into controlled motion has not pet been extended to the molecular level. Here we describe a molecule that uses chemical energy to activate and bias a thermally induced isomerization reaction, and thereby achieve unidirectional intramolecular rotary motion. The motion consists of a 120 degrees rotation around a single bond connecting a three-bladed subunit to the bulky remainder of the molecule, and unidirectional motion is achieved by reversibly introducing a tether between the two units to energetically favour one of the two possible rotation directions. Although our system does not achieve continuous and fast rotation, the design principles that we have used may prove relevant for a better understanding of biological and synthetic molecular motors producing unidirectional rotary motion.	Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA	Boston College	Kelly, TR (corresponding author), Boston Coll, Dept Chem, EF Merkert Chem Ctr, Chestnut Hill, MA 02467 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BENNISTON AC, 1993, ANGEW CHEM INT EDIT, V32, P1459, DOI 10.1002/anie.199314591; Berg HC, 1998, NATURE, V394, P324, DOI 10.1038/28506; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Block SM, 1997, NATURE, V386, P217, DOI 10.1038/386217a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Huxley A, 1998, NATURE, V391, P239, DOI 10.1038/34567; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; KELLY TR, 1994, J AM CHEM SOC, V116, P3657, DOI 10.1021/ja00087a085; Kelly TR, 1998, J ORG CHEM, V63, P3655, DOI 10.1021/jo9723218; Mao CD, 1999, NATURE, V397, P144, DOI 10.1038/16437; Mislow K, 1988, CHEMTRACTS ORG CHEM, V2, P151; Musser G, 1999, SCI AM, V280, P24; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; STRYER L, 1995, BIOCHEMISTRY-US, pCH15; TRAVIS J, 1995, SCIENCE, V267, P1593, DOI 10.1126/science.267.5204.1593; Vale R D, 1990, Adv Biophys, V26, P97, DOI 10.1016/0065-227X(90)90009-I	28	679	691	2	201	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					150	152		10.1038/43639	http://dx.doi.org/10.1038/43639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490021				2022-12-24	WOS:000082458800049
J	Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL				Koumura, N; Zijlstra, RWJ; van Delden, RA; Harada, N; Feringa, BL			Light-driven monodirectional molecular rotor	NATURE			English	Article							UNIQUE CHIRAL OLEFINS; ABSOLUTE STEREOCHEMISTRY; ROTATION; TRANS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; CIS-1,1',2,2',3,3',4,4'-OCTAHYDRO-3,3'-DIMETHYL-4,4'-BIPHENANTHRYLIDENE; MACHINES	Attempts to fabricate mechanical devices on the molecular level(1,2) have yielded analogues of rotors(3), gears(4) switches(5), shuttles(6,7), turnstiles(8) and ratchets(9). Molecular motors, however, have not yet been made, even though they are common in biological systems(10) Rotary motion as such has been induced in interlocked systems(11-13) and directly visualized for single molecules(14), but the controlled conversion of energy into unidirectional rotary motion has remained difficult to achieve. Here we report repetitive, monodirectional rotation around a central carbon-carbon double bond in a chiral, helical alkene, with each 360 degrees rotation involving four discrete isomerization steps activated by ultraviolet light or a change in the temperature of the system. We find that axial chirality and the presence of two chiral centres are essential for the observed monodirectional behaviour of the molecular motor. Two light-induced cis-trans isomerizations are each associated with a 180 degrees rotation around the carbon-carbon double bond and are each followed by thermally controlled helicity inversions, which effectively block reverse rotation and thus ensure that the four individual steps add up to one full rotation in one direction only. As the energy barriers of the helicity inversion steps can be adjusted by structural modifications, chiral alkenes based on our system may find use as basic components for 'molecular machinery' driven by light.	Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, NL-9747 AG Groningen, Netherlands; Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	University of Groningen; Tohoku University	Feringa, BL (corresponding author), Univ Groningen, Stratingh Inst, Dept Organ & Mol Inorgan Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Koumura, Nagatoshi/M-4947-2018; Feringa, Ben L./C-1665-2013	Koumura, Nagatoshi/0000-0002-2141-0741; 				Armaroli N, 1999, J AM CHEM SOC, V121, P4397, DOI 10.1021/ja984051w; Ashton PR, 1998, J AM CHEM SOC, V120, P11932, DOI 10.1021/ja982167m; Balzani V, 1998, ACCOUNTS CHEM RES, V31, P405, DOI 10.1021/ar970340y; BEDARD TC, 1995, J AM CHEM SOC, V117, P10662, DOI 10.1021/ja00148a008; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Clayden J, 1998, ANGEW CHEM INT EDIT, V37, P1937, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14<1937::AID-ANIE1937>3.0.CO;2-4; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; Drexler K.E., 1992, NANOSYSTEMS MOL MACH; Feynman RP, 1961, MINIATURIZATION; Gimzewski JK, 1998, SCIENCE, V281, P531, DOI 10.1126/science.281.5376.531; Harada N, 1997, J AM CHEM SOC, V119, P7256, DOI 10.1021/ja970669e; Huck NPM, 1996, SCIENCE, V273, P1686, DOI 10.1126/science.273.5282.1686; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Koumura N, 1998, CHEM LETT, P1151, DOI 10.1246/cl.1998.1151; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schoevaars AM, 1997, J ORG CHEM, V62, P4943, DOI 10.1021/jo962210t	17	1386	1400	26	924	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					152	155		10.1038/43646	http://dx.doi.org/10.1038/43646			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490022	Green Submitted			2022-12-24	WOS:000082458800050
J	Grum, VL; Li, DN; MacDonald, RI; Mondragon, A				Grum, VL; Li, DN; MacDonald, RI; Mondragon, A			Structures of two repeats of spectrin suggest models of flexibility	CELL			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; MEMBRANE SKELETON; CRYSTAL-STRUCTURE; ALPHA-SPECTRIN; TEMPERATURE-DEPENDENCE; CONFORMATIONAL UNIT; MOLECULAR-STRUCTURE; PLASMA-MEMBRANE; CELL MEMBRANE; SITE	Spectrin is a vital component of the cytoskeleton, conferring flexibility on cells and providing a scaffold for a variety of proteins. It is composed of tandem, antiparallel coiled-coil repeats. We report four related crystal structures at 1.45 Angstrom, 2.0 Angstrom 3.1 Angstrom and 4.0 Angstrom resolution of two connected repeats of chicken brain a-spectrin. In all of the structures, the linker region between adjacent units is or-helical without breaks, kinks, or obvious boundaries. Two features observed in the structures are (1) conformational rearrangement in one repeat, resulting in movement of the position of a loop, and (2) varying degrees of bending at the linker region. These features form the basis of two different models of flexibility: a conformational rearrangement and a bending model. These models provide novel atomic details of spectrin flexibility.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	a-mondragon@nwu.edu			NIGMS NIH HHS [GM57692, GM51350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057692, R01GM051350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BABCOCK MS, 1994, J MOL BIOL, V237, P125, DOI 10.1006/jmbi.1994.1213; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLOCH R J, 1992, Trends in Cell Biology, V2, P186, DOI 10.1016/0962-8924(92)90231-B; Brown JH, 1996, PROTEINS, V26, P134; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P3898, DOI 10.1021/bi00468a016; DESILVA TM, 1992, BIOCHEMISTRY-US, V31, P10872, DOI 10.1021/bi00159a030; DeSilva TM, 1997, BIOCHEMISTRY-US, V36, P3991, DOI 10.1021/bi962412j; Devarajan P, 1996, CURR TOP MEMBR, V43, P97; Djinovic-Carugo K, 1999, CELL, V98, P537, DOI 10.1016/S0092-8674(00)81981-9; Dubreuil RR, 1996, CURR TOP MEMBR, V43, P147; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG LWM, 1989, LIFE SCI, V44, P735, DOI 10.1016/0024-3205(89)90385-8; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GRUM VL, 1998, THESIS NW U EVANSTON; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEARMONTH RP, 1989, BIOCHIM BIOPHYS ACTA, V987, P124, DOI 10.1016/0005-2736(89)90463-X; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; Lusitani D, 1998, BIOCHEMISTRY-US, V37, P16546, DOI 10.1021/bi9811462; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MACDONALD RI, 1994, P NATL ACAD SCI USA, V91, P1299, DOI 10.1073/pnas.91.4.1299; MARCHESI SL, 1991, CURR TOP MEMBR, V38, P155; MCGOUGH AM, 1990, P NATL ACAD SCI USA, V87, P5208, DOI 10.1073/pnas.87.13.5208; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKKELSEN A, 1981, BIOCHIM BIOPHYS ACTA, V668, P74, DOI 10.1016/0005-2795(81)90150-1; MOHANDAS N, 1994, ANNU REV BIOPH BIOM, V23, P787, DOI 10.1146/annurev.bb.23.060194.004035; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas G, 1998, BIOCHEM J, V332, P81, DOI 10.1042/bj3320081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pantazatos DP, 1997, J BIOL CHEM, V272, P21052, DOI 10.1074/jbc.272.34.21052; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; Pascual J, 1996, FEBS LETT, V383, P201, DOI 10.1016/0014-5793(96)00251-7; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Repasky EA, 1996, CURR TOP MEMBR, V43, P313; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; Steck T. L., 1989, CELL SHAPE DETERMINA, P205; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P111, DOI 10.1016/0005-2736(85)90399-2; STOKKE BT, 1985, BIOCHIM BIOPHYS ACTA, V816, P102, DOI 10.1016/0005-2736(85)90398-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; SVOBODA K, 1992, BIOPHYS J, V63, P784, DOI 10.1016/S0006-3495(92)81644-2; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WAUGH RE, 1982, BIOPHYS J, V39, P273, DOI 10.1016/S0006-3495(82)84517-7; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	72	213	214	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					523	535		10.1016/S0092-8674(00)81980-7	http://dx.doi.org/10.1016/S0092-8674(00)81980-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481916	Bronze			2022-12-24	WOS:000082174900012
J	Jarecki, J; Johnson, E; Krasnow, MA				Jarecki, J; Johnson, E; Krasnow, MA			Oxygen regulation of airway branching in Drosophila is mediated by branchless FGF	CELL			English	Article							TRACHEAL CELL-MIGRATION; RECEPTOR HOMOLOG; BETA-GALACTOSIDASE; FUSION PROTEIN; EXPRESSION; BREATHLESS; GROWTH; SYSTEM; MORPHOGENESIS; ANGIOGENESIS	The Drosophila tracheal (respiratory) system is a tubular epithelial network that delivers oxygen to internal tissues. Sprouting of the major tracheal branches is stereotyped and controlled by hard-wired developmental cues. Here we show that ramification of the fine terminal branches is variable and regulated by oxygen, and that this process is controlled by a local signal or signals produced by oxygen-starved cells. We provide evidence that the critical signal is Branchless (Bnl) FGF, the same growth factor that patterns the major branches during embryogenesis. During larval life, oxygen deprivation stimulates expression of Bnl, and the secreted growth factor functions as a chemoattractant that guides new terminal branches to the expressing cells. Thus, a single growth factor is reiteratively used to pattern each level of airway branching, and the change in branch patterning results from a switch from developmental to physiological control of its expression.	Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Krasnow, MA (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Howard Hughes Med Inst, Stanford, CA 94305 USA.	krasnow@cmgm.stanford.edu						AFFOLTER M, 1994, DEVELOPMENT, V120, P743; Arias A.M., 1993, DEV DROSOPHILA, P609; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; CUNNINGHAM EL, 1974, J APPL PHYSIOL, V37, P362, DOI 10.1152/jappl.1974.37.3.362; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Guillemin K, 1996, DEVELOPMENT, V122, P1353; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOCKE M, 1958, Q J MICROSC SCI, V99, P373; MEINHARDT H, 1976, DIFFERENTIATION, V6, P117, DOI 10.1111/j.1432-0436.1976.tb01478.x; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Nagao M, 1996, FEBS LETT, V387, P161, DOI 10.1016/0014-5793(96)00484-X; ONEILL JW, 1994, BIOTECHNIQUES, V17, P870; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Pignoni F, 1997, DEVELOPMENT, V124, P271; Pihan J.C., 1972, Bulletin de la Societe Zoologique de France, V97, P351; PIHAN JC, 1971, J EMBRYOL EXP MORPH, V26, P497; REICHMANFRIED M, 1995, MECH DEVELOP, V52, P265, DOI 10.1016/0925-4773(95)00407-R; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruhle H, 1932, Z WISS ZOOL ABT A, V141, P159; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; Shilo BZ, 1997, COLD SPRING HARB SYM, V62, P241; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Smith EL, 1996, BONE, V18, pS45, DOI 10.1016/8756-3282(95)00379-7; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; Vincent S, 1997, DEVELOPMENT, V124, P2741; WALGENBACH KJ, 1995, NAT MED, V1, P453, DOI 10.1038/nm0595-453; WIGGLESWORTH VB, 1954, Q J MICROSC SCI, V95, P115; XU T, 1993, DEVELOPMENT, V117, P1223; [No title captured]	42	189	190	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					211	220		10.1016/S0092-8674(00)81652-9	http://dx.doi.org/10.1016/S0092-8674(00)81652-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535739	Bronze			2022-12-24	WOS:000083159700011
J	Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K				Aritomi, M; Kunishima, N; Okamoto, T; Kuroki, R; Ota, Y; Morikawa, K			Atomic structure of the GCSF-receptor complex showing a new cytokine-receptor recognition scheme	NATURE			English	Article							COLONY-STIMULATING FACTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; GROWTH-HORMONE; LIGAND-BINDING; GRANULOCYTE; CSF; IDENTIFICATION; DIMERIZATION; REGION	Granulocyte colony-stimulating factor (GCSF) is the principal growth factor regulating the maturation, proliferation and differentiation of the precursor cells of neutrophilic granulocytes' and is used to treat neutropenia(2), GCSF is a member of the long-chain subtype of the class 1 cytokine superfamily, which includes growth hormone, erythropoietin, interleukin 6 and oncostatin M (ref. 3), Here we have determined the crystal structure of GCSF complexed to the BN-BC domains, the principal ligand-binding region of the GCSF receptor (GCSFR). The two receptor domains form a complex in a 2:2 ratio with the ligand, with a noncrystallographic pseudo-twofold axis through primarily the interdomain region and secondarily the BC domain. This structural view of a gp130-type receptor-ligand complex presents a new molecular basis for cytokine-receptor recognition.	Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan	Kirin Brewery Company Limited	Morikawa, K (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.	morikawa@beri.co.jp	Kunishima, Naoki/N-7464-2015	Kunishima, Naoki/0000-0001-9826-9902; Aritomi, Masaharu/0000-0003-3002-8779				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Covell DG, 1997, J MOL BIOL, V269, P281, DOI 10.1006/jmbi.1997.1028; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HILL CP, 1993, P NATL ACAD SCI USA, V90, P5167, DOI 10.1073/pnas.90.11.5167; Hiraoka O, 1995, BIOSCI BIOTECH BIOCH, V59, P2351, DOI 10.1271/bbb.59.2351; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; Horan T, 1996, BIOCHEMISTRY-US, V35, P4886, DOI 10.1021/bi9525841; Horan TP, 1998, PROTEIN EXPRES PURIF, V14, P45, DOI 10.1006/prep.1998.0942; KUGA T, 1994, Patent No. 8317; Layton JE, 1997, J BIOL CHEM, V272, P29735, DOI 10.1074/jbc.272.47.29735; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ReidhaarOlson JF, 1996, BIOCHEMISTRY-US, V35, P9034, DOI 10.1021/bi952705x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Yamasaki K, 1997, NAT STRUCT BIOL, V4, P498, DOI 10.1038/nsb0697-498; Yamasaki M, 1998, BIOSCI BIOTECH BIOCH, V62, P1528, DOI 10.1271/bbb.62.1528	30	118	130	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					713	718		10.1038/44394	http://dx.doi.org/10.1038/44394			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537111				2022-12-24	WOS:000083207400060
J	Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B				Chan, TA; Hermeking, H; Lengauer, C; Kinzler, KW; Vogelstein, B			14-3-3 sigma is required to prevent mitotic catastrophe after DNA damage	NATURE			English	Article							NUCLEAR EXPORT; G(2) CHECKPOINT; CYCLIN B1; ARREST; P21; LOCALIZATION; KINASE; PHASE; CELLS; CRM1	14-3-3 sigma is a member of a family of proteins that regulate cellular activity by binding and sequestering phosphorylated proteins. It has been suggested that 14-3-3 sigma promotes pre-mitotic cell-cycle arrest following DNA damage, and that its expression can be controlled by the p53 tumour suppressor gene(1). Here we describe an improved approach to the generation of human somatic-cell knockouts, which we have used to generate human colorectal cancer cells in which both 14-3-3 sigma alleles are inactivated. After DNA damage, these cells initially arrested in the G2 phase of the cell cycle, but, unlike Cells containing 14-3-3 sigma, the 14-3-3 sigma(-/-) cells were unable to maintain cell-cycle arrest. The 14-3-3 sigma(-/-) cells died ('mitotic catastrophe') as they entered mitosis. This process was associated with a failure of the 14-3-3 sigma-deficient cells to sequester the proteins (cyclin B1 and cdc2) that initiate mitosis and prevent them from entering the nucleus. These results may indicate a mechanism for maintaining the G2 checkpoint and preventing mitotic death.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Vogelstein, B (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.		Chan, Timothy A/ABD-5850-2021					Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busler DE, 1996, BIOTECHNIQUES, V21, P1002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, BIOCHEM BIOPH RES CO, V230, P262, DOI 10.1006/bbrc.1996.5933; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	20	781	814	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					616	620		10.1038/44188	http://dx.doi.org/10.1038/44188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524633				2022-12-24	WOS:000083054900058
J	Cortes, D; Visfeldt, J; Moller, H; Thorup, J				Cortes, D; Visfeldt, J; Moller, H; Thorup, J			Testicular neoplasia in cryptorchid boys at primary surgery: case series	BRITISH MEDICAL JOURNAL			English	Article							TESTIS; CANCER; COHORT; RISK		Rigshosp, Dept Paediat Surg, DK-2100 Copenhagen O, Denmark; Rigshosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen O, Denmark	Rigshospitalet; Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Thorup, J (corresponding author), Rigshosp, Dept Paediat Surg, 4072, DK-2100 Copenhagen O, Denmark.			Cortes, Dina/0000-0002-6852-6530; Thorup, Jorgen/0000-0003-3550-1107; Moller, Henrik/0000-0001-8200-5929				CORTES D, 1994, J UROLOGY, V151, P722, DOI 10.1016/S0022-5347(17)35071-1; CORTES D, 1998, SCAND J UROL NE S196, V32, P54; Moller H, 1998, BMJ-BRIT MED J, V317, P729, DOI 10.1136/bmj.317.7160.729; MULLER J, 1985, J PEDIATR-US, V106, P431, DOI 10.1016/S0022-3476(85)80670-3; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507	5	15	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					888	889		10.1136/bmj.319.7214.888	http://dx.doi.org/10.1136/bmj.319.7214.888			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506044	Green Published, Bronze			2022-12-24	WOS:000082975600024
J	Brewer, LR; Corzett, M; Balhorn, R				Brewer, LR; Corzett, M; Balhorn, R			Protamine-induced condensation and decondensation of the same DNA molecule	SCIENCE			English	Article							BACTERIOPHAGE HEADS; BINDING; MICROSCOPY; COMPLEXES; COLLAPSE; PACKING; PROTEIN; POLYMER; SPERM	The DNA sperm and certain viruses is condensed by arginine-rich proteins into toroidal subunits, a form of packaging that inactivates their entire genome. Individual DNA molecules were manipulated with an optical trap to examine the kinetics of torus formation induced by the binding of protamine and a subset of its DNA binding domain, Arg(6). Condensation and decondensation experiments with lambda-phage DNA show that toroid formation and stability are influenced by the number of arginine-rich anchoring domains in protamine. The results explain why protamines contain so much arginine and suggest that these proteins must be actively removed from sperm chromatin after fertilization.	Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Brewer, LR (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA.		Brewer, Laurence/G-4056-2012					ARSCOTT PG, 1990, BIOPOLYMERS, V30, P619, DOI 10.1002/bip.360300514; Balhorn R., 1989, P366; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Baumann CG, 1997, P NATL ACAD SCI USA, V94, P6185, DOI 10.1073/pnas.94.12.6185; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; BUSTAMANTE C, 1991, ANNU REV BIOPHYS BIO, V20, P415, DOI 10.1146/annurev.bb.20.060191.002215; CAO TM, 1982, BIOCH BIOPHYS RES CO, V108; HUD NV, 1995, BIOPHYS J, V69, P1355, DOI 10.1016/S0006-3495(95)80002-0; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KLIMENKO SM, 1967, J MOL BIOL, V23, P523, DOI 10.1016/S0022-2836(67)80122-0; MAEDA S, 1991, VIROLOGY, V180, P807, DOI 10.1016/0042-6822(91)90096-T; NAKANO M, 1989, J BIOCHEM-TOKYO, V105, P133, DOI 10.1093/oxfordjournals.jbchem.a122607; OSTROVSKY B, 1995, BIOPHYS J, V68, P1694, DOI 10.1016/S0006-3495(95)80347-4; PERKINS TT, 1995, SCIENCE, V268, P83, DOI 10.1126/science.7701345; PORSCHKE D, 1991, J MOL BIOL, V222, P423, DOI 10.1016/0022-2836(91)90220-Z; POST CB, 1982, BIOPOLYMERS, V21, P2139, DOI 10.1002/bip.360211105; RICHARDS KE, 1973, J MOL BIOL, V78, P255, DOI 10.1016/0022-2836(73)90114-9; RuizLara SA, 1996, EUR J BIOCHEM, V240, P186, DOI 10.1111/j.1432-1033.1996.0186h.x; Ueda M, 1996, PHYS REV LETT, V77, P2133, DOI 10.1103/PhysRevLett.77.2133; WATANABE F, 1983, J MOL BIOL, V163, P485, DOI 10.1016/0022-2836(83)90070-0; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7	23	198	203	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					120	123		10.1126/science.286.5437.120	http://dx.doi.org/10.1126/science.286.5437.120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506559	Green Submitted			2022-12-24	WOS:000082907400049
J	Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS				Eckert, DM; Malashkevich, VN; Hong, LH; Carr, PA; Kim, PS			Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMEMBRANE GLYCOPROTEIN; LEUCINE-ZIPPER; ENVELOPE GLYCOPROTEIN; MUTATIONAL ANALYSIS; ATOMIC-STRUCTURE; PROTEIN; FUSION; SUBDOMAIN; DOMAIN	The HIV-1 gp41 protein promotes viral entry by mediating the fusion of viral and cellular membranes. A prominent pocket on the surface of a central trimeric coiled coil within gp41 was previously identified as a potential target for drugs that inhibit HIV-1 entry. We designed a peptide, IQN17, which properly presents this pocket. Utilizing IQN17 and mirror-image phage display, we identified cyclic, D-peptide inhibitors of HIV-1 infection that share a sequence motif. A1.5 Angstrom cocrystal structure of IQN17 in complex with a D-peptide, and NMR studies, show that conserved residues of these inhibitors make intimate contact with the gp41 pocket. Our studies validate the pocket per se as a target for drug development. IQN17 and these D-peptide inhibitors ave likely to be useful for development and identification of a new class of orally bioavailable anti-HIV drugs.	MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	Kim, PS (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol,Cambridge Ctr 9, Cambridge, MA 02142 USA.				NIGMS NIH HHS [P01 GM56552] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056552] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Bovey F. A., 1988, NUCL MAGNETIC RESONA; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; CAVANAGH J, 1993, J MAGN RESON SER A, V105, P328; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN BK, 1994, J VIROL, V68, P654, DOI 10.1128/JVI.68.2.654-660.1994; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FIELDS C G, 1991, Peptide Research, V4, P95; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; HARBURY PB, 1995, P NATL ACAD SCI USA, V92, P8408, DOI 10.1073/pnas.92.18.8408; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; OSAPAY K, 1991, J AM CHEM SOC, V113, P9436, DOI 10.1021/ja00025a002; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Schumacher TNM, 1996, SCIENCE, V271, P1854, DOI 10.1126/science.271.5257.1854; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	50	402	446	3	81	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					103	115		10.1016/S0092-8674(00)80066-5	http://dx.doi.org/10.1016/S0092-8674(00)80066-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520998	Bronze			2022-12-24	WOS:000082981600012
J	Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG				Shukla, D; Liu, J; Blaiklock, P; Shworak, NW; Bai, XM; Esko, JD; Cohen, GH; Eisenberg, RJ; Rosenberg, RD; Spear, PG			A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry	CELL			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; RECEPTOR-RELATED PROTEIN-1; GLYCOPROTEIN-D; POLIOVIRUS RECEPTOR; PSEUDORABIES VIRUS; MOLECULAR-CLONING; CELLS; BINDING; TYPE-1; INFECTION	Herpes simplex virus type 1 (HSV-1) binds to cells through interactions of viral glycoproteins gB and gC with heparan sulfate chains on cell surface proteoglycans. This binding is not sufficient for viral entry, which requires fusion between the viral envelope and cell membrane. Here, we show that heparan sulfate modified by a subset of the multiple D-glucosaminyl 3-O-sulfotransferase isoforms provides sites for the binding of a third viral glycoprotein, go, and for initiation of HSV-1 entry. We conclude that susceptibility of cells to HSV-1 entry depends on (1) presence of heparan sulfate chains to which virus can bind and (2) 3-O-sulfation of specific glucosamine residues in heparan sulfate to generate gD-binding sites or the expression of other previously identified gD-binding receptors.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Beth Israel Deaconess Med Ctr, Angiogenesis Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Dept Med, Boston, MA 02215 USA; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Oral Hlth Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Philadelphia, PA 19104 USA	Northwestern University; Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California San Diego; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Spear, PG (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	rdrrosen@mit.edu; p-spear@nwu.edu	Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634; Shukla, Deepak/0000-0002-3039-6953	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031494, R01AI036293] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 59479] Funding Source: Medline; NIAID NIH HHS [U01 AI 31494, R01 AI 36293] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1989, J BIOL CHEM, V264, P8059; Brynes AP, 1998, J VIROL, V72, P7349, DOI 10.1128/JVI.72.9.7349-7356.1998; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; DEAN HJ, 1994, VIROLOGY, V199, P67, DOI 10.1006/viro.1994.1098; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; HEROLD BC, 1994, J GEN VIROL, V75, P1211, DOI 10.1099/0022-1317-75-6-1211; Herold BC, 1996, J VIROL, V70, P3461, DOI 10.1128/JVI.70.6.3461-3469.1996; HEROLD BC, 1991, J VIROL, V65, P1090, DOI 10.1128/JVI.65.3.1090-1098.1991; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; Jackson T, 1996, J VIROL, V70, P5282, DOI 10.1128/JVI.70.8.5282-5287.1996; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; KRUMMENACHER C, 1999, IN PRESS J VIROL; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LEE MK, 1991, P NATL ACAD SCI USA, V88, P2768, DOI 10.1073/pnas.88.7.2768; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; LIU J, 1999, IN PRESS J BIOL CHEM; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Mauri DN, 1998, IMMUNITY, V8, P21, DOI 10.1016/S1074-7613(00)80455-0; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; Schmidt J, 1997, J VIROL, V71, P17, DOI 10.1128/JVI.71.1.17-24.1997; Schroder C, 1997, J VIROL, V71, P25; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SPEAR PG, 1993, SEMIN VIROL, V4, P167, DOI 10.1006/smvy.1993.1012; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Summerford C, 1998, J VIROL, V72, P1438, DOI 10.1128/JVI.72.2.1438-1445.1998; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998	48	809	838	0	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					13	22		10.1016/S0092-8674(00)80058-6	http://dx.doi.org/10.1016/S0092-8674(00)80058-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520990	Bronze			2022-12-24	WOS:000082981600004
J	Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD				Little, SJ; Daar, ES; D'Aquila, RT; Keiser, PH; Connick, E; Whitcomb, JM; Hellmann, NS; Petropoulos, CJ; Sutton, L; Pitt, JA; Rosenberg, ES; Koup, RA; Walker, BD; Richman, DD			Reduced antiretroviral drug susceptibility among patients with primary HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE RESISTANCE; REVERSE-TRANSCRIPTASE; NUCLEOSIDE ANALOGS; THERAPY; LAMIVUDINE; TRANSMISSION; NEVIRAPINE; INDINAVIR; VIREMIA	Context The transmission of drug-resistant hu man immunodeficiency virus (HIV) has been documented, but the prevalence of such transmission is unknown. Objective To assess the spectrum and frequency of antiretroviral susceptibility among subjects with primary HIV infection. Design, Setting, and Patients Retrospective analysis of 141 subjects identified from clinical research centers in 5 major metropolitan areas, enrolled from 1989 to 1998, with HIV seroconversion within the preceding 12 months and no more than 7 days' prior antiretroviral (ARV) therapy. Main Outcome Measures Phenotypic and genotypic ARV susceptibility of HIV from plasma samples. Results The transmission of drug-resistant HIV as assessed by a greater than 10-fold reduction in ARV susceptibility to 1 or more drugs was observed in 3 (2%) of 141 subjects, including to a nonnucleoside reverse transcriptase inhibitor in 1 patient and to a nucleoside reverse transcriptase inhibitor and a protease inhibitor in 2 patients. Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L10I/V, K20R, M36I, M46I, G48V, L63P, A71T, V77I, V82T, I84V, L90M) in the 2 latter patient samples, along with numerous polymorphisms. A reduction in susceptibility of greater than 2.5- to 10-fold to 1 or more drugs was observed in viral isolates from 36 patients (26%). Sequence analysis of these 36 samples identified well-characterized drug resistance mutation in reverse transcriptase and protease in only 1 of these patients. Conclusions Reductions in drug susceptibility of more than 10-fold were rare among this cohort of recently HIV-infected subjects and were distributed among each of the 3 major classes of ARV drugs tested. Reductions in susceptibility of more than 2.5- to 10-fold to certain ARV drugs of unknown clinical significance were highly prevalent among newly infected patients. Resistance testing may be warranted to monitor the frequency of drug resistance over time and to assess the potential for geographic variability.	Univ Calif San Diego, Treatment Ctr, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Dept Vet Affairs Med Ctr, San Diego, CA USA; Cedars Sinai Burns & Allen Res Inst, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, Los Angeles, CA USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; Dept Vet Affairs Med Ctr, Denver, CO USA; ViroLog Inc, San Francisco, CA USA; Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA; Merck & Co Inc, Blue Bell, PA USA; Bristol Myers Squibb Co, Glaxo Wellcome, Princeton, NJ USA; Agouron Inst, La Jolla, CA 92037 USA; Roxane, Columbus, OH USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Massachusetts General Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; GlaxoSmithKline; Merck & Company; Bristol-Myers Squibb; GlaxoSmithKline	Little, SJ (corresponding author), Univ Calif San Diego, Treatment Ctr, Dept Med, 2760 5th Ave,Suite 300, San Diego, CA 92103 USA.	slittle@ucsd.edu	Little, Susan/AAA-6116-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, K08AI001541, P30AI036214] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Conway B, 1999, CLIN INFECT DIS, V28, P910, DOI 10.1086/515225; DAAR E, 1999, 6 C RETR OPP INF JAN; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Goudsmit J, 1996, J VIROL, V70, P5662, DOI 10.1128/JVI.70.8.5662-5664.1996; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1998, J VIROL, V72, P3773, DOI 10.1128/JVI.72.5.3773-3778.1998; HARRIGAN R, 1998, 38 INT C ANT AG CHEM; HECHT F, 1998, 12 INT C AIDS JUN 28; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HELLMAN N, 1999, 3 INT WORKSH DRUG RE; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; HUANG W, 1999, 3 INT WORKSH DRUG RE; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Imrie A, 1996, J INFECT DIS, V174, P195, DOI 10.1093/infdis/174.1.195; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Martinez-Picado J, 1999, J VIROL, V73, P3744, DOI 10.1128/JVI.73.5.3744-3752.1999; MILLER MD, 1999, 3 INT WORKSH DRUG RE; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Parkin NT, 1999, J INFECT DIS, V180, P865, DOI 10.1086/314928; PARKIN NT, 1999, 3 INT WORKSH DRUG RE; Piketty C, 1999, AIDS, V13, pF71, DOI 10.1097/00002030-199907300-00001; Rey D, 1998, J ACQ IMMUN DEF SYND, V17, P203, DOI 10.1097/00042560-199803010-00003; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SKOWRON G, 1999, 3 INT WORKSH DRUG RE; Vanhems P, 1997, CLIN INFECT DIS, V24, P965, DOI 10.1093/clinids/24.5.965; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; YERLY S, 1998, 12 INT C AIDS JUN 26	39	266	275	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1142	1149		10.1001/jama.282.12.1142	http://dx.doi.org/10.1001/jama.282.12.1142			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501117	Bronze			2022-12-24	WOS:000082596200029
J	Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M				Cao, TT; Deacon, HW; Reczek, D; Bretscher, A; von Zastrow, M			A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta 2-adrenergic receptor	NATURE			English	Article							BETA(2)-ADRENERGIC RECEPTOR; NA+/H+-EXCHANGER; PHOSPHORYLATION SITES; PROTEIN; MEMBRANE; DESENSITIZATION; BINDING; RESENSITIZATION; INTERNALIZATION; IDENTIFICATION	A fundamental question in cell biology is how membrane proteins are sorted in the endocytic pathway, The sorting of internalized beta 2-adrenergic receptors between recycling endosomes and lysosomes is responsible for opposite effects on signal transduction and is regulated by physiological stimuli(1,2). Here we describe a mechanism that controls this sorting operation, which is mediated by a family of conserved protein-interaction modules called PDZ domains(3). The phosphoprotein EBP50 (for ezrin-radixin-moesin(ERM)-binding phosphoprotein-50)(4) binds to the cytoplasmic tail of the beta 2-adrenergic receptor through a PDZ domain and to the cortical actin cytoskeleton through an ERM-binding domain. Disrupting the interaction of EBP50 with either domain or depolymerization of the actin cytoskeleton itself causes missorting of endocytosed beta 2-adrenergic receptors but does not affect the recycling of transferrin receptors. A serine residue at position 411 in the tail of the beta 2-adrenergic receptor is a substrate for phosphorylation by GRK-5 (for G-protein-coupled-receptor kinase-5) (ref. 5) and is required for interaction with EBP50 and for proper recycling of the receptor. Our results identify a new role for PDZ-domain-mediated protein interactions and for the actin cytoskeleton in endocytic sorting, and suggest a mechanism by which GRK-mediated phosphorylation could regulate membrane trafficking of G-protein-coupled receptors after endocytosis.	Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cornell University	von Zastrow, M (corresponding author), Univ Calif San Francisco, Program Cell Biol Cellular & Mol Pharmacol & Psyc, San Francisco, CA 94143 USA.							Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Durrbach A, 1996, J CELL SCI, V109, P457; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; Klein U, 1997, J BIOL CHEM, V272, P19099, DOI 10.1074/jbc.272.31.19099; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Reczek D, 1998, J BIOL CHEM, V273, P18452, DOI 10.1074/jbc.273.29.18452; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	26	551	558	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					286	290		10.1038/45816	http://dx.doi.org/10.1038/45816			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499588				2022-12-24	WOS:000082678400056
J	Wan, JJ; Poo, MM				Wan, JJ; Poo, MM			Activity-induced potentiation of developing neuromuscular synapses	SCIENCE			English	Article							LONG-TERM POTENTIATION; CALCIUM-RELEASE CHANNEL; HETEROSYNAPTIC SUPPRESSION; SARCOPLASMIC-RETICULUM; SYNAPTIC TRANSMISSION; SILENT SYNAPSES; SKELETAL-MUSCLE; DEPRESSION; CALMODULIN; PROTEIN	Electrical activity plays a critical role in shaping the structure and function of synaptic connections in the nervous system. In Xenopus nerve-muscle cultures, a brief burst of action potentials in the presynaptic neuron induced a persistent potentiation of neuromuscular synapses that exhibit immature synaptic functions. Induction of potentiation required an elevation of postsynaptic Ca2+ and expression of potentiation appeared to involve an increased probability of transmitter secretion from the presynaptic nerve terminal. Thus, activity-dependent persistent synaptic enhancement may reflect properties characteristic of immature synaptic connections, and bursting activity in developing spinal neurons may promote functional maturation of the neuromuscular synapse.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cash S, 1996, SCIENCE, V272, P998, DOI 10.1126/science.272.5264.998; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CHOW I, 1985, J NEUROSCI, V5, P1076; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; EVERS J, 1989, J NEUROSCI, V9, P1523; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KIDOKORO Y, 1982, P NATL ACAD SCI-BIOL, V79, P6727, DOI 10.1073/pnas.79.21.6727; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; KULLBERG RW, 1977, DEV BIOL, V60, P101, DOI 10.1016/0012-1606(77)90113-0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Donovan MJ, 1998, ANN NY ACAD SCI, V860, P130; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; Tabti N, 1998, CULTURING NERVE CELL, P237; WAN J, UNPUB; XIE Z, 1986, P NATL ACAD SCI USA, V83, P4069; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665	35	30	30	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1725	1728		10.1126/science.285.5434.1725	http://dx.doi.org/10.1126/science.285.5434.1725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481007				2022-12-24	WOS:000082472600033
J	Powell, JW; Barber-Foss, KD				Powell, JW; Barber-Foss, KD			Traumatic brain injury in high school athletes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOTBALL PLAYERS; CONCUSSION	Context The potential seriousness of mild traumatic brain injury (MTBI) is increasingly recognized; however, information on the frequency of MTBI among high school athletes is limited. Objective To identify the type, frequency, and severity of MTBI in selected high school sports activities. Design Observational cohort study.. Setting and Participants Two hundred forty-six certified athletic trainers recorded injury and exposure data for high school varsity athletes participating in boys' football, wrestling, baseball and field hockey, girls' volleyball and softball, boys' and girls' basketball, and boys' and girls' soccer at 235 US high schools during 1 or more of the 1995-1997 academic years. Main Outcome Measures Rates of reported MTBI, defined as a head-injured player who was removed from participation and evaluated by an athletic trainer or physician prior to returning to participation. National incidence figures for MTBI also were estimated. Results Of 23 566 reported injuries in the 10 sports during the 3-year study period, 1219 (5.5 %) were MTBIs. Of the MTBIs, football accounted for 773 (63.4%) of cases; wrestling, 128 (10.5%); girls' soccer, 76 (6.2%); boys' soccer, 69 (5.7%); girls' basketball, 63 (5.2%); boys' basketball, 51 (4.2%); softball, 25 (2.1%); baseball, 15 (1.2%); field hockey, 13 (1.1%); and volleyball, 6 (0.5%). The injury rates per 100 player-seasons were 3.66 for football, 1.58 for wrestling, 1.14 for girls' soccer, 1.04 for girls' basketball, 0.92 for boys' soccer, 0.75 for boys' basketball, 0.46 for softball, 0.46 for field hockey, 0.23 for baseball, and 0.14 for volleyball. The median time lost from participation for all MTBIs was 3 days. There were 6 cases of subdural hematoma and intracranial injury reported in football. Based on these data, an estimated 62 816 cases of MTBI occur annually among high school varsity athletes participating in these sports, with football accounting for about 63 % of cases. Conclusions Rates of MTBI vary among sports and none of the 10 popular high school sports we studied is without the occurrence of an MTBI. Continued involvement of high school sports sponsors, researchers, medical professionals, coaches, and sports participants is essential to help minimize the risk of MTBI.	Med Sports Syst, Iowa City, IA USA		Powell, JW (corresponding author), Michigan State Univ, Dept Kinesiol, IM Sports Circle, E Lansing, MI 48824 USA.							Barth J.T., 1989, MILD HEAD INJURY, P257; BUCKLEY WE, 1985, THESIS PENNSYLVANIA; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; CLARKE KS, 1979, MED SCI SPORTS EXERC, V2, P138; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; GAHLINGER PM, 1993, RATRES2 VERSION 1 4C; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; *NAT ATHL TRAIN AS, 1991, P MILD BRAIN INJ NAT; *NAT CTR ED STAT, 1994, US DHEW NCES PUBL; Powell JW, 1999, J ATHL TRAINING, V34, P277; POWELL JW, 1988, AM J SPORTS MED S, V16, P134; *QUAL STAND SUBC A, 1997, NEUROBIOLOGY, V48, P1	21	408	413	0	59	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					958	963		10.1001/jama.282.10.958	http://dx.doi.org/10.1001/jama.282.10.958			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485681				2022-12-24	WOS:000082335900034
J	Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH				Chen, CC; Luo, CL; Wang, SJ; Chern, CM; Fuh, JL; Lin, SH; Hu, HH			Colour doppler imaging for diagnosis of intracranial hypotension	LANCET			English	Article							BLOOD-FLOW; ENHANCEMENT; HEADACHES; ANATOMY; ORBIT	Background Measurement of CSF pressure is the only known way to confirm the diagnosis of intracranial hypotension. We aimed to assess colour doppler flow imaging (CDFI) for measurement of blood flow of the superior ophthalmic vein for the diagnosis of intracranial hypotension. Methods We enrolled 25 consecutive patients with orthostatic headache who had clinical features of intracranial hypotension. We defined low-pressure headache as cerebrospinal-fluid pressure below 60 mm H2O. We used CDFI to measure the diameter and maximum flow velocity of the superior ophthalmic vein in all patients. Magnetic resonance imaging of the brain and lumbar puncture with measurement of cerebrospinal-fluid pressure within 24 h were also done after sonographic examination. The control group comprised 13 healthy individuals of a similar age; in addition, those patients who had orthostatic headache without low pressure served as a control group for the patients. Findings Of the 25 patients recruited for this study, 13 satisfied the criteria for low-pressure headache. The remaining 12 patients with normal cerebrospinal-fluid pressure had transformed migraine (five patients) or chronic tension-type headache (seven patients), and therefore served as the control group for the patients. The mean diameter of the superior ophthalmic vein was substantially larger in the patients with intracranial hypotension (3.9 [SD 0.2] mm) than in the healthy controls (2.6 [0.4] mm) and the controls from the patients' group (2.7 [0.2] mm) (p<0.0001). The mean maximum flow velocity was significantly higher in the intracranial-hypotension group (17.0 [SD 3.4] cm/s) than in the healthy controls (7.9 [1.1] cm/s) and the other patients (7.3 [1.7] cm/s) (p<0.0001). Seven patients with intracranial hypotension were reassessed after treatment with epidural blood patch. After this treatment the clinical symptoms were relieved and there was a striking reversal of the superior ophthalmic vein flow. Interpretation CDFI to measure blood flow of the superior ophthalmic vein provides a practical, simple, and non-invasive diagnostic method for suspected intracranial hypotension.	Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Dept Anesthesiol, Taipei, Taiwan	National Yang Ming Chiao Tung University	Hu, HH (corresponding author), Vet Gen Hosp, Neurol Inst, Taipei 11217, Taiwan.			Fuh, Jong-Ling/0000-0001-9135-3351				Benzon HT, 1996, ANESTHESIOLOGY, V85, P920, DOI 10.1097/00000542-199610000-00029; Blank SC, 1997, CLIN NEUROL NEUROSUR, V99, P199, DOI 10.1016/S0303-8467(97)00015-2; CARRIE LES, 1993, BRIT J ANAESTH, V71, P179, DOI 10.1093/bja/71.2.179; Costa VP, 1997, J CLIN ULTRASOUND, V25, P448, DOI 10.1002/(SICI)1097-0096(199710)25:8<448::AID-JCU7>3.0.CO;2-J; ERICKSON SJ, 1989, RADIOLOGY, V173, P511, DOI 10.1148/radiology.173.2.2678264; Ettl A, 1997, OPHTHALMOLOGY, V104, P869, DOI 10.1016/S0161-6420(97)30219-X; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; Fishman RA, 1992, CEREBROSPINAL FLUID, P71; GUILIONI M, 1988, NEUROSURGERY, V22, P807; HIRASHITA M, 1992, EUR J APPL PHYSIOL, V64, P92, DOI 10.1007/BF00376447; HU HH, 1993, STROKE, V24, P1196, DOI 10.1161/01.STR.24.8.1196; Khanna RK, 1997, J NEUROSURG, V86, P893, DOI 10.3171/jns.1997.86.5.0893; Klotzsch C, 1996, NEURORADIOLOGY, V38, P555; LIEB WE, 1991, ARCH OPHTHALMOL-CHIC, V109, P527, DOI 10.1001/archopht.1991.01080040095036; MOKRI B, 1995, NEUROLOGY, V45, P1801, DOI 10.1212/WNL.45.10.1801; Mokri B, 1997, MAYO CLIN PROC, V72, P400, DOI 10.4065/72.5.400; Mokri B, 1998, NEUROLOGY, V51, P786, DOI 10.1212/WNL.51.3.786; POMERANZ S, 1993, ACTA NEUROCHIR, V122, P113, DOI 10.1007/BF01446996; Schievink WI, 1996, J NEUROSURG, V84, P598, DOI 10.3171/jns.1996.84.4.0598; Silberstein SD, 1996, NEUROLOGY, V47, P871, DOI 10.1212/WNL.47.4.871; Spektor S, 1997, NEUROSURGERY, V40, P532, DOI 10.1097/00006123-199703000-00022	21	31	32	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					826	829						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485725				2022-12-24	WOS:000082400700012
J	Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ				Tang, YP; Shimizu, E; Dube, GR; Rampon, C; Kerchner, GA; Zhuo, M; Liu, GS; Tsien, JZ			Genetic enhancement of learning and memory in mice	NATURE			English	Article							LONG-TERM POTENTIATION; HETEROMERIC NMDA RECEPTORS; SYNAPTIC PLASTICITY; GLUTAMATE RECEPTORS; VISUAL-CORTEX; HIPPOCAMPUS; BRAIN; FEAR; ANTAGONIST; AMYGDALA	Hebb's rule (1949) states that learning and memory are based on modifications of synaptic strength among neurons that are simultaneously active. This implies that enhanced synaptic coincidence detection would lead to better learning and memory. If the NMDA (N-methyl-D-aspartate) receptor, a synaptic coincidence detector(1-4), acts as a graded switch for memory formation, enhanced signal detection by NMDA receptors should enhance learning and memory. Here we show that overexpression of NMDA receptor 2B (NR2B) in the forebrains of transgenic mice leads to enhanced activation of NMDA receptors, facilitating synaptic potentiation in response to stimulation at 10-100 Hz. These mice exhibit superior ability in learning and memory in various behavioural tasks, showing that NR2B is critical in gating the age-dependent threshold for plasticity and memory formation. NMDA-receptor-dependent modifications of synaptic efficacy, therefore, represent a unifying mechanism for associative learning and memory. Our results suggest that genetic enhancement of mental and cognitive attributes such as intelligence and memory in mammals is feasible.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; MIT, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurobiol, St Louis, MO 63110 USA	Princeton University; Massachusetts Institute of Technology (MIT); Washington University (WUSTL); Washington University (WUSTL)	Tsien, JZ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Zhuo, Min/A-2072-2008; Shimizu, Eiji/K-4637-2017; Tang, Ya-Ping/A-1035-2011	Zhuo, Min/0000-0001-9062-3241; Shimizu, Eiji/0000-0002-6741-9338; rampon, claire/0000-0001-8551-8682; Tang, Ya-Ping/0000-0002-0445-4072				Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; DAVIS M, 1987, PSYCHOL LEARNING MEM; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FALLS WA, 1992, J NEUROSCI, V12, P854; HARRIS KM, 1984, J PHYSIOL-LONDON, V346, P27, DOI 10.1113/jphysiol.1984.sp015005; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; KIM JJ, 1992, BEHAV NEUROSCI, V106, P591, DOI 10.1037/0735-7044.106.4.591; KONISHI M, 1989, NEURON, V3, P541, DOI 10.1016/0896-6273(89)90264-X; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Morris RG, 1982, NATURE, V2, P681; Mumby DG, 1996, BEHAV NEUROSCI, V110, P266, DOI 10.1037/0735-7044.110.2.266; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Okabe S, 1998, J NEUROSCI, V18, P4177; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Reed JM, 1997, BEHAV NEUROSCI, V111, P667, DOI 10.1037/0735-7044.111.4.667; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Stevens CF, 1998, CURR BIOL, V8, pR151, DOI 10.1016/S0960-9822(98)70097-1; STUBLI U, 1996, J NEUROSCI, V16, P853; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7	30	1434	1541	3	190	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					63	69		10.1038/43432	http://dx.doi.org/10.1038/43432			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485705				2022-12-24	WOS:000082374400041
J	Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V				Clemons, WM; May, JLC; Wimberly, BT; McCutcheon, JP; Capel, MS; Ramakrishnan, V			Structure of a bacterial 30S ribosomal subunit at 5.5 angstrom resolution	NATURE			English	Article							RNA-BINDING-SITE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; PROTEIN S15; CRYSTAL-STRUCTURE; BACILLUS-STEAROTHERMOPHILUS; NMR-SPECTROSCOPY; CROSS-LINKING; MESSENGER-RNA; 16S RNA	The 30S ribosomal subunit binds messenger RNA and the anticodon stem-loop of transfer RNA during protein synthesis. A crystallographic analysis of the structure of the subunit from the bacterium Thermos thermophilus is presented, At a resolution of 5.5 Angstrom, the phosphate backbone of the ribosomal RNA is visible, as are the cu-helices of the ribosomal proteins, enabling double-helical regions of RNA to be identified throughout the subunit, all seven of the small-subunit proteins of known crystal structure to be positioned in the electron density map, and the fold of the entire central domain of the small-subunit ribosomal RNA to be determined.	MRC, Mol Biol Lab, Structural Studies Div, Cambridge CB2 2QH, England; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84103 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	MRC Laboratory Molecular Biology; Utah System of Higher Education; University of Utah; United States Department of Energy (DOE); Brookhaven National Laboratory	Ramakrishnan, V (corresponding author), MRC, Mol Biol Lab, Structural Studies Div, Hills Rd, Cambridge CB2 2QH, England.		Clemons, William M/D-1026-2009	Clemons, William M/0000-0002-0021-889X; Ramakrishnan, V/0000-0002-4699-2194; McCutcheon, John/0000-0002-5489-6039	NIGMS NIH HHS [F31 GM019384] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM019384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agafonov DE, 1997, P NATL ACAD SCI USA, V94, P12892, DOI 10.1073/pnas.94.24.12892; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Alberts B, 1995, MOL BIOL CELL; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; ALLEN G, 1979, J BIOL CHEM, V254, P9800; ATMADJA J, 1986, NUCLEIC ACIDS RES, V14, P659, DOI 10.1093/nar/14.2.659; Batey RT, 1996, J MOL BIOL, V261, P536, DOI 10.1006/jmbi.1996.0481; Berglund H, 1997, NAT STRUCT BIOL, V4, P20, DOI 10.1038/nsb0197-20; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Clemons WM, 1998, STRUCT FOLD DES, V6, P429, DOI 10.1016/S0969-2126(98)00045-8; Davies C, 1998, EMBO J, V17, P4545, DOI 10.1093/emboj/17.16.4545; Davies C, 1996, STRUCTURE, V4, P1093, DOI 10.1016/S0969-2126(96)00115-3; GREGORY RJ, 1984, J MOL BIOL, V178, P287, DOI 10.1016/0022-2836(84)90145-1; GREUER B, 1987, NUCLEIC ACIDS RES, V15, P3241, DOI 10.1093/nar/15.8.3241; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; Jaishree TN, 1996, BIOCHEMISTRY-US, V35, P2845, DOI 10.1021/bi951062i; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kalurachchi K, 1997, P NATL ACAD SCI USA, V94, P2139, DOI 10.1073/pnas.94.6.2139; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Lee KS, 1997, J MOL BIOL, V269, P732, DOI 10.1006/jmbi.1997.1092; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Markus MA, 1998, EMBO J, V17, P4559, DOI 10.1093/emboj/17.16.4559; McCutcheon JP, 1999, P NATL ACAD SCI USA, V96, P4301, DOI 10.1073/pnas.96.8.4301; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; Moine H, 1997, RNA, V3, P255; Mueller F, 1997, J MOL BIOL, V271, P566, DOI 10.1006/jmbi.1997.1212; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Mueller F, 1997, J MOL BIOL, V271, P545, DOI 10.1006/jmbi.1997.1211; Nevskaya N, 1998, J MOL BIOL, V279, P233, DOI 10.1006/jmbi.1998.1758; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POWERS T, 1995, RNA, V1, P194; RAMAKRISHNAN V, 1992, NATURE, V358, P768, DOI 10.1038/358768a0; RAMAKRISHNAN VR, 1981, J MOL BIOL, V153, P739, DOI 10.1016/0022-2836(81)90416-2; Serganov AA, 1996, RNA, V2, P1124; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; UNGEWICKELL E, 1975, EUR J BIOCHEM, V51, P165, DOI 10.1111/j.1432-1033.1975.tb03917.x; Urlaub H, 1997, J BIOL CHEM, V272, P14547, DOI 10.1074/jbc.272.23.14547; VANACKEN U, 1975, MOL GEN GENET, V140, P61, DOI 10.1007/BF00268989; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WINBERLY BT, 1997, STRUCTURE, V5, P1187; WITTMANNLIEBOLD B, 1978, FEBS LETT, V95, P91, DOI 10.1016/0014-5793(78)80059-3; WU H, 1994, NUCLEIC ACIDS RES, V22, P1687, DOI 10.1093/nar/22.9.1687; YONATH A, 1988, J MOL BIOL, V203, P831, DOI 10.1016/0022-2836(88)90216-1; Yonath A, 1998, ACTA CRYSTALLOGR A, V54, P945, DOI 10.1107/S010876739800991X; YUSUPOV MM, 1988, FEBS LETT, V238, P113, DOI 10.1016/0014-5793(88)80237-0	50	305	328	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					833	840		10.1038/23631	http://dx.doi.org/10.1038/23631			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476960				2022-12-24	WOS:000082233200035
J	Forrester, WC; Dell, M; Perens, E; Garriga, G				Forrester, WC; Dell, M; Perens, E; Garriga, G			A C-elegans Ror receptor tyrosine kinase regulates cell motility and asymmetric cell division	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NEUROMUSCULAR-JUNCTION; GENES; MIGRATION; LINEAGE; FAMILY; MUSK	Ror kinases are a family of orphan receptors with tyrosine kinase activity that are related to muscle specific kinase (MuSK), a receptor tyrosine kinase that assembles acetylcholine receptors at the neuromuscular junction(1,2). Although the functions of Ror kinases are unknown, similarities between Ror and MuSK kinases have led to speculation that Ror kinases regulate synaptic development. Here we show that the Caenorhabditis elegans gene cam-1 encodes a member of the Ror kinase family that guides migrating cells and orients the polarity of asymmetric cell divisions and axon outgrowth. We find that tyrosine kinase activity is required for some of the functions of CAM-1, but not for its role in cell migration. CAM-1 is expressed in cells that require its function, and acts cell autonomously in migrating neurons. Overexpression and loss of cam-1 function result in reciprocal cell-migration phenotypes, indicating that levels of CAM-1 influence the final positions of migrating cells. Our results raise the possibility that Ror kinases regulate cell motility and asymmetric cell division in organisms as diverse as nematodes and mammals.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Garriga, G (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.			Perens, Elliot/0000-0003-3377-7708				Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Forrester WC, 1997, DEVELOPMENT, V124, P1831; Forrester WC, 1998, GENETICS, V148, P151; HANKS SK, 1988, SCIENCE, V241, P47; Hawkins N, 1998, GENE DEV, V12, P3625, DOI 10.1101/gad.12.23.3625; HEDECOCK EM, 1995, GENETICS, V141, P989; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HERMAN RK, 1984, GENETICS, V108, P165; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109	25	130	135	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					881	885		10.1038/23722	http://dx.doi.org/10.1038/23722			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476968				2022-12-24	WOS:000082233200048
J	Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P				Arstila, TP; Casrouge, A; Baron, V; Even, J; Kanellopoulos, J; Kourilsky, P			A direct estimate of the human alpha beta T cell receptor diversity	SCIENCE			English	Article							ANTIGEN RECEPTOR; REPERTOIRE; SELECTION; LYMPHOCYTES; RECOGNITION; CHAINS	Generation and maintenance of an effective repertoire of T cell antigen receptors are essential to the immune system, yet the number of distinct T cell receptors (TCRs) expressed by the estimated 10(12) T cells in the human body is not known. In this study, TCR gene amplification and sequencing showed that there are about 10(6) different beta chains in the blood, each pairing, on the average, with at Least 25 different alpha chains. In the memory subset, the diversity decreased to 1 x 10(5) to 2 x 10(5) different beta chains, each pairing with only a single alpha chain. Thus, the naive repertoire is highly diverse, whereas the memory compartment, here one-third of the T cell population, contributes Less than 1 percent of the total diversity.	Inst Pasteur, INSERM, U277, Unite Biol Mol Gene, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Arstila, TP (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	petteri.arstila@helsinki.fi	Yang, Chen/G-1379-2010					ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arden Bernhard, 1995, Immunogenetics, V42, P501; ARGAET VP, 1994, J EXP MED, V180, P2335, DOI 10.1084/jem.180.6.2335; BENIT C, 1995, J IMMUNOL, V154, P5103; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; CASROUGE A, 1998, J EXP MED, V187, P1871; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DUDLEY EC, 1994, IMMUNITY, V1, P83, DOI 10.1016/1074-7613(94)90102-3; FERRADINI L, UNPUB; HALL MA, 1995, HUM IMMUNOL, V43, P207, DOI 10.1016/0198-8859(95)00013-T; McMahan CJ, 1998, IMMUNITY, V9, P637, DOI 10.1016/S1074-7613(00)80661-5; Nanki T, 1998, J IMMUNOL, V161, P228; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016/0167-5699(95)80117-0; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROSENBERG WMC, 1992, EUR J IMMUNOL, V22, P541, DOI 10.1002/eji.1830220237; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Trigueros C, 1998, J EXP MED, V188, P1401, DOI 10.1084/jem.188.8.1401; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447	26	646	704	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					958	961		10.1126/science.286.5441.958	http://dx.doi.org/10.1126/science.286.5441.958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542151				2022-12-24	WOS:000083368500046
J	Steiner, MJ				Steiner, MJ			Contraceptive effectiveness - What should the counseling message be?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Family Hlth Int, Res Triangle Pk, NC 27709 USA		Steiner, MJ (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	msteiner@fhi.org						Fu HS, 1999, FAM PLANN PERSPECT, V31, P56, DOI 10.2307/2991640; GODWIN K, 1999, BR J FAM PLANN, V93, P896; Raymond E, 1999, OBSTET GYNECOL, V93, P896, DOI 10.1016/S0029-7844(99)00002-2; Steiner M, 1996, OBSTET GYNECOL, V88, pS24, DOI 10.1016/0029-7844(96)00251-7; Trussell J, 1999, FAM PLANN PERSPECT, V31, P64, DOI 10.2307/2991641; TRUSSELL J, 1998, CONTRACEPTIVE TECHNO, P211	6	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1405	1407		10.1001/jama.282.15.1405	http://dx.doi.org/10.1001/jama.282.15.1405			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535416				2022-12-24	WOS:000083111000001
J	Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W				Jones, TF; Craig, AS; Valway, SE; Woodley, CL; Schaffner, W			Transmission of tuberculosis in a jail	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	36th Annual Meeting of the Infectious-Diseases-Society-of-America	NOV 11-15, 1998	DENVER, CO	Infect Dis Soc Amer		disease outbreaks; tuberculosis; prisoners; infection control; tuberculin test	CORRECTIONAL HEALTH-CARE; YORK-STATE PRISON; RESISTANT TUBERCULOSIS; INFECTION; POLYMORPHISM; ASSOCIATION; POPULATION; ADMISSION; OUTBREAK; FACILITY	Background: Outbreaks of tuberculosis are uncommonly recognized in jails. In 1996, an increase in active tuberculosis cases was noted among inmates of a large urban jail. Objectives: To determine the source and extent of a tuberculosis outbreak in an urban jail and to recommend control measures. Design: Retrospective cohort study. Setting: Urban jail. Patients: Inmates and guards with tuberculosis. Intervention: Outbreak evaluation and control. Measurements: Medical records of inmates and guards with tuberculosis were reviewed, and inmates were interviewed. DNA fingerprinting was performed on Mycobacterium tuberculosis isolates. Results: From 1 January 1995 through 31 December 1997, active tuberculosis was diagnosed in 38 inmates and 5 guards from the jail. Nineteen (79%) of the 24 culture-positive inmates had isolates with DNA fingerprints matching those of other inmates. Isolates from both culture-positive guards matched the predominant inmate strain; only 6 (14%) of 43 isolates from infected persons in the community had this pattern. The median length of incarceration of all inmates in the jail was 1 day; the median length of continuous incarceration before diagnosis of tuberculosis in inmates was 138 days. Inmates with tuberculosis had been incarcerated a median of 15 times. Forty-three percent of persons in this city with tuberculosis diagnosed from January 1995 through July 1997 had been incarcerated in the jail at some time before diagnosis. Conclusions: Traditional and molecular epidemiologic investigations suggest that tuberculosis was transmitted among inmates and guards in an urban jail. Aggressive measures to screen for active tuberculosis upon incarceration are important for preventing spread of disease in jails and to the surrounding community.	Tennessee Dept Hlth, CEDS, Nashville, TN 37247 USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div TB Eliminat, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA	Tennessee Department Health; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Vanderbilt University; Vanderbilt University	Jones, TF (corresponding author), Tennessee Dept Hlth, CEDS, Cordell Hull Bldg,4th Floor,425 5th Ave N, Nashville, TN 37247 USA.	bhudson@mail.acponline.org						ABELES H, 1970, AM REV RESPIR DIS, V101, P706; BELLIN EY, 1993, JAMA-J AM MED ASSOC, V269, P2228, DOI 10.1001/jama.269.17.2228; BergmireSweat D, 1996, EPIDEMIOL INFECT, V117, P485, DOI 10.1017/S095026880005915X; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; *BUR JUST STAT, 1995, BJS B; *BUR JUST STAT, 1998, PROF JAIL INM; *CAS DEF INF COND, 1997, MMWR-MORBID MORTAL W, V46, P1; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Conklin TJ, 1998, AM J PUBLIC HEALTH, V88, P1249; *CONTR TB CORR FAC, 1995, ATL CDCP; DEAN AD, 1994, ATLANTA CDCP; Fountain F F Jr, 1997, Tenn Med, V90, P138; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; HAMMETT T, 1994, TUBERCULOSIS CORRECT; HUTTON MD, 1993, PUBLIC HEALTH REP, V108, P305; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; Koo DT, 1997, AM J PUBLIC HEALTH, V87, P279, DOI 10.2105/AJPH.87.2.279; Layton MC, 1997, AM J PUBLIC HEALTH, V87, P1335, DOI 10.2105/AJPH.87.8.1335; MacIntyre CR, 1997, CLIN INFECT DIS, V24, P1060, DOI 10.1086/513632; PELLETIER AR, 1993, ARCH INTERN MED, V153, P2692, DOI 10.1001/archinte.153.23.2692; Prevention CfDCa, 1996, MMWR-MORBID MORTAL W, V45, P1; Puisis M, 1996, PUBLIC HEALTH REP, V111, P330; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3175, DOI 10.1001/jama.268.22.3175; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; Sreevatsan S, 1997, P NATL ACAD SCI USA, V94, P9869, DOI 10.1073/pnas.94.18.9869; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; *TUB TRANSM STAT C, 1992, MMWR-MORBID MORTAL W, V41, P927; VALWAY SE, 1994, J INFECT DIS, V170, P151, DOI 10.1093/infdis/170.1.151; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; WILCOCK K, 1996, TUBERCULOSIS CORRECT	31	71	74	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					557	+		10.7326/0003-4819-131-8-199910190-00002	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	246ZR	10523215				2022-12-24	WOS:000083196600001
J	Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB				Liu, JE; Roman, MJ; Pini, R; Schwartz, JE; Pickering, TG; Devereux, RB			Cardiac and arterial target organ damage in adults with elevated ambulatory and normal office blood pressure	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; blood pressure monitoring, ambulatory; hypertrophy, left ventricular; coronary arteriosclerosis; blood pressure	LEFT-VENTRICULAR MASS; WHITE COAT HYPERTENSION; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; HYPERTROPHY; VARIABILITY; MORBIDITY; MORTALITY; THICKNESS; CHILDREN	Background: Ambulatory blood pressure may be higher or lower than clinic blood pressure. Attention has focused on "white coat hypertension" (normal ambulatory blood pressure elevated in the clinic). The converse phenomenon of high ambulatory blood pressure but normal office blood pressure-"white coat normotension"-has not been studied. Objective: To assess whether white coat normotension (awake ambulatory blood pressure > 134/90 mm Hg and clinic blood pressure < 140/90 mm Hg) is associated with target organ damage. Design: Cross-sectional observational study. Setting: University hospital hypertension center and participant work sites. Patients: 295 clinically normotensive adults and 64 patients with sustained hypertension (elevated clinic and ambulatory blood pressure). Measurements: Target organ abnormalities were measured by echocardiography and arterial ultrasonography in 61 patients with white coat normotension, 234 with sustained normotension (normal clinic and ambulatory blood pressure), and 64 with sustained hypertension. Results: Patients with white coat normotension were older; had higher body mass indices, serum creatinine concentrations, and glucose levels; and a higher prevalence of current smokers. Left ventricular mass index and relative wall thickness were higher by 13 g/m(2) (Cl, 8 to18 g/m(2)) and by 0.03 (Cl, 0.01 to 0.04), respectively, in patients with white coat normotension compared with those who had sustained normotension. Patients with white coat normotension and those with sustained hypertension did not differ significantly for left ventricular mass index (4 g/m(2) [Cl, -3 to 10 g/m(2)) or relative wall thickness (0.01 [Cl, -0.01 to 0.03]). The prevalence of discrete atherosclerotic plaques was similar in patients with white coat normotension (17 of 61, or 28% [Cl, 17% to 39%]) and those with sustained hypertension (17 of 64, or 27% [Cl, 16% to 38%]), but the difference lost significance after adjustment for age. Conclusions: White coat normotension is associated with left ventricular mass and carotid wall thickness similar to those in sustained hypertension. The association of white coat normotension with prognostically important target organ damage may partly explain the ability of high normal left ventricular mass and high normal clinic blood pressure to predict subsequent hypertension and cardiovascular events in patients with clinical normotension.	Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, New York, NY 10021 USA; Univ Florence, Div Gerontol & Geriatr, I-50141 Florence, Italy	Cornell University; NewYork-Presbyterian Hospital; University of Florence	Devereux, RB (corresponding author), Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Cardiol, Box 222,525 E 68th St, New York, NY 10021 USA.	rbdevere@mail.med.cornell.edu		Schwartz, Joseph/0000-0002-8944-3566; Pini, Riccardo/0000-0002-7940-7908	NHLBI NIH HHS [HL 47540, P01 HL047540, HL 30606, HL 18323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047540, P50HL018323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1980, CARDIOLOGY REV REPOR, V1, P509; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; DESIMONE G, 1995, J AM COLL CARDIOL, V25, P1056, DOI 10.1016/0735-1097(94)00540-7; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; Devereux RB, 1997, CIRCULATION, V96, P1416, DOI 10.1161/01.CIR.96.5.1416; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; Devereux RB, 1996, AM J CARDIOL, V78, P61, DOI 10.1016/S0002-9149(96)00228-7; Devereux RB, 1991, BLOOD PRESSURE MEASU, P261; FAGARD R, 1995, AM J HYPERTENS, V8, P533, DOI 10.1016/0895-7061(95)00043-O; GANAU A, 1990, CIRCULATION, V81, P25, DOI 10.1161/01.CIR.81.1.25; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GOSSE P, 1986, J HYPERTENS, V4, pS297; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Jones EC, 1997, J AM COLL CARDIOL, V29, P1303, DOI 10.1016/S0735-1097(97)82755-6; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KANNEL WB, 1974, PROG CARDIOVASC DIS, V17, P5, DOI 10.1016/0033-0620(74)90034-6; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LARKIN KT, 1998, BLOOD PRESS MONIT, V3, P247; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PALATINI P, 1985, J HYPERTENS, V3, pS425; Palmieri V, 1998, CIRCULATION, V98, P29; PERLOFF D, 1989, J HYPERTENS, V7, pS3; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; PRISANT LM, 1990, AM J HYPERTENS, V3, P81, DOI 10.1093/ajh/3.2.81; RAVOGLI A, 1990, HYPERTENSION, V16, P491, DOI 10.1161/01.HYP.16.5.491; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROSENMAN RH, 1976, CIRCULATION, V54, P51, DOI 10.1161/01.CIR.54.1.51; ROWLANDS DB, 1982, LANCET, V1, P467; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNALL PL, 1992, HYPERTENSION, V19, P488, DOI 10.1161/01.HYP.19.5.488; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; VERDECCHIA P, 1992, HYPERTENSION, V20, P555, DOI 10.1161/01.HYP.20.4.555; VERDECCHIA P, 1995, J HYPERTENS, V13, P1209, DOI 10.1097/00004872-199510000-00016; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793	42	284	301	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					564	+		10.7326/0003-4819-131-8-199910190-00003	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523216				2022-12-24	WOS:000083196600002
J	Duke, T				Duke, T			Decline in child health in rural Papua New guinea	LANCET			English	Editorial Material									Goroka Base Hosp, Dept Paediat, Goroka, Eastern Highlan, Papua N Guinea		Duke, T (corresponding author), Goroka Base Hosp, Dept Paediat, POB 392, Goroka, Eastern Highlan, Papua N Guinea.	duke@global.net.pg						Alto William A., 1996, Papua New Guinea Medical Journal, V39, P315; Decosas J, 1999, LANCET, V353, P143, DOI 10.1016/S0140-6736(98)11454-X; *DEP HLTH, 1996, PNG NAT HLTH PLAN, P40; *DEP HLTH PAP NEW, 1997, DHS SURV; PATAKISCHWEIZER KJ, 1983, PAPUA NEW GUINEA MED, V26, P178; REILLY Q, 1990, ACHIEVING HLTH ALL Y, P213; Shann F, 1979, P N G Med J, V22, P170; Summerfield D, 1998, LANCET, V351, P1955, DOI 10.1016/S0140-6736(98)06056-5; *UNICEF, 1999, STAT WORLDS CHILDR 1, P91; World Bank, 2013, WOR DEV REP, P1, DOI 10.1596/978-0-8213-9575-2	10	22	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1291	1294		10.1016/S0140-6736(99)00335-9	http://dx.doi.org/10.1016/S0140-6736(99)00335-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520651				2022-12-24	WOS:000083010400046
J	Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C				Molster, FJ; Yamamura, I; Waters, LBFM; Tielens, AGGM; de Graauw, T; de Jong, T; de Koter, A; Malfait, K; van den Ancker, ME; van Winckel, H; Voors, RHM; Waelkens, C			Low-temperature crystallization of silicate dust in circumstellar disks	NATURE			English	Article							SPECTRUM; GRAINS; COMETS; STARS	Silicate dust in the interstellar medium is observed to be amorphous(1), yet silicate dust in comets(2,3) and interplanetary dust particles(4) is sometimes partially crystalline. The dust in young stars(5,6) also appears to be partially crystalline. These clouds to a planetary system, it must undergo some processing, Here we report observations of highly crystalline silicate dust in the disks surrounding binary red-giant stars. The dust was created in amorphous form in the outer atmospheres of the red giants, and therefore must be processed in the disks to become crystalline. The temperatures in these disks are too low for the grains to anneal; therefore, some low-temperature process must be responsible. As the physical properties of the disks around young stars and red giants are similar, our results suggest that low-temperature crystallization of silicate grains also can occur in protoplanetary systems.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; SRON, Lab Space Res Groningen, NL-9700 AV Groningen, Netherlands; SRON, Space Res Lab, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Astron Inst, NL-3508 TA Utrecht, Netherlands	University of Amsterdam; KU Leuven; Utrecht University	Molster, FJ (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.		Van Winckel, Hans/I-7863-2013	Van Winckel, Hans/0000-0001-5158-9327; van den Ancker, Mario/0000-0001-6992-3100				Bradley J. P., 1999, Solid interstellar matter: the ISO revolution, P297; BRADLEY JP, 1994, SCIENCE, V265, P925, DOI 10.1126/science.265.5174.925; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; deGraauw T, 1996, ASTRON ASTROPHYS, V315, pL49; Dorschner J, 1995, ASTRON ASTROPHYS REV, V6, P271, DOI 10.1007/BF00873686; Elliman R. G., 1986, MATER RES SOC S P, V51, P319; Gail HP, 1998, ASTRON ASTROPHYS, V332, P1099; GALVIN GJ, 1982, PHYS REV LETT, V48, P33, DOI 10.1103/PhysRevLett.48.33; Grun J, 1997, PHYS REV LETT, V78, P1584, DOI 10.1103/PhysRevLett.78.1584; Hallenbeck S, 1998, ASTROPHYS SPACE SCI, V255, P427; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; JONES TW, 1976, ASTROPHYS J, V209, P509, DOI 10.1086/154746; JURA M, 1995, ASTROPHYS J, V453, P721, DOI 10.1086/176433; Kessler MF, 1996, ASTRON ASTROPHYS, V315, pL27; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; MOLSTER PJ, IN PRESS ASTRON ASTR; Shu FH, 1996, SCIENCE, V271, P1545, DOI 10.1126/science.271.5255.1545; Shu FH, 1997, SCIENCE, V277, P1475, DOI 10.1126/science.277.5331.1475; THIEL K, 1991, NUCL TRACKS RAD MEAS, V19, P709; TIELENS AGGM, 1994, ASTROPHYS J, V431, P321, DOI 10.1086/174488; Van Winckel H, 1998, ASTRON ASTROPHYS, V336, pL17; VANDENANCKER ME, IN PRESS ASTRON ASTR; Waelkens C, 1998, ASTROPHYS SPACE SCI, V255, P25; WATERS LBF, 1999, IAU S, V191, P209; Waters LBFM, 1996, ASTRON ASTROPHYS, V315, pL361; WILLIAMS JS, 1985, PHYS REV LETT, V55, P1482, DOI 10.1103/PhysRevLett.55.1482; WOOD JA, 1985, PROTOSTARS PLANETS, V2, P687; YAMAMURA I, 1997, ESA, P313	28	162	164	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					563	565		10.1038/44085	http://dx.doi.org/10.1038/44085			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524623				2022-12-24	WOS:000083054900042
J	Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC				Joshipura, KJ; Ascherio, A; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Hennekens, CH; Spiegelman, D; Willett, WC			Fruit and vegetable intake in relation to risk of ischemic stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; CARDIOVASCULAR-DISEASE; PLASMA HOMOCYSTEINE; MEN; REPRODUCIBILITY; CONSUMPTION; POTASSIUM; MORTALITY; VALIDITY	Context Few studies have evaluated the relationship between fruit and vegetable intake and cardiovascular disease. Objective To examine the associations between fruit and vegetable intake and ischemic stroke. Design, Setting, and Subjects Prospective cohort studies, including 75 596 women aged 34 to 59 years in the Nurses' Health Study with 14 years of follow-up (1980-1994), and 38 683 men aged 40 to 75 years in the Health Professionals' Follow-up Study with 8 years of follow-up (1986-1994). All individuals were free of cardiovascular disease, cancer, and diabetes at baseline. Main Outcome Measure Incidence of ischemic stroke by quintile of fruit and vegetable intake. Results A total of 366 women and 204 men had an ischemic stroke. After controlling for standard cardiovascular risk factors, persons in the highest quintile of fruit and vegetable intake (median of 5.1 servings per day among men and 5.8 servings per day among women) had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.52-0.92) compared with those in the lowest quintile. An increment of 1 serving per day of fruits or vegetables was associated with a 6% tower risk of ischemic stroke (RR, 0.94; 95% CI, 0.90-0.99; P = .01, test for trend). Cruciferous vegetables (RR, 0.68 for an increment of 1 serving per day; 95% CI, 0.49-0.94), green leafy vegetables (RR, 0.79; 95% CI, 0.62-0.99), citrus fruit including juice (RR, 0.81; 95% CI, 0.68-0.96), and citrus fruit juice (RR, 0.75; 95% CI, 0.61-0.93) contributed most to the apparent protective effect of total fruits and vegetables. Legumes or potatoes were not associated with lower ischemic stroke risk. The multivariate pooled RR for total stroke was 0.96 (95% CI, 0.93-1.00) for each increment of 2 servings per day. Conclusions These data support a protective relationship between consumption of fruit and vegetables-particularly cruciferous and green leafy vegetables and citrus fruit and juice-and ischemic stroke risk.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Prevent Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Joshipura, KJ (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, 188 Longwood Ave, Boston, MA 02115 USA.		Joshipura, Kaumudi J/AAA-3852-2020	Joshipura, Kaumudi/0000-0003-1964-7579	NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL35464, HL34595] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL034595] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GAZIANO JM, 1995, ANN EPIDEMIOL, V5, P225; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hirayama T, 1986, Prog Clin Biol Res, V206, P299; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KNEKT P, 1994, AM J EPIDEMIOL, V139, P180; LEE CN, 1988, NEW ENGL J MED, V318, P995; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STEINMETZ KA, 1993, CANCER RES, V53, P536; Ward M, 1997, QJM-MON J ASSOC PHYS, V90, P519, DOI 10.1093/qjmed/90.8.519; Weinfeld, 1981, STROKE S1, V12, pI13; *WHO STUD GROUP, 1990, WHO TECHNICAL REPORT, V797; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY	27	731	760	2	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1233	1239		10.1001/jama.282.13.1233	http://dx.doi.org/10.1001/jama.282.13.1233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517425	Bronze			2022-12-24	WOS:000082901100030
J	Bos, JD				Bos, JD			Reappraisal of dermatoses of pregnancy	LANCET			English	Editorial Material							ATOPIC-DERMATITIS; CRITERIA; SKIN		Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Bos, JD (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Dermatol AO235, NL-1100 DE Amsterdam, Netherlands.							Aractingi S, 1998, LANCET, V352, P1898, DOI 10.1016/S0140-6736(98)05121-6; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; HOLMES RC, 1983, J AM ACAD DERMATOL, V8, P405, DOI 10.1016/S0190-9622(83)70046-0; Jones SAV, 1999, BRIT J DERMATOL, V141, P71; PROVOST TT, 1973, J CLIN INVEST, V52, P1779, DOI 10.1172/JCI107359; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WINSTON G, 1982, J AM ACAD DERMATOL, V6, P977	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1140	1140		10.1016/S0140-6736(99)00244-5	http://dx.doi.org/10.1016/S0140-6736(99)00244-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513703				2022-12-24	WOS:000082954100005
J	Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR				Wigmore, SJ; Seeney, FM; Pleass, HCC; Praseedom, RK; Forsythe, JLR		Kidney Advisory Grp	Kidney damage during organ retrieval: data from UK National Transplant Database	LANCET			English	Article								Background Kidney damage at organ retrieval is believed to be an increasing problem that is under reported. We aimed to identify the true rate of such damage and assess the effects on transplant survival. Methods Data from the UK National Transplant Database were analysed on all cadaveric kidneys donated over a 5-year period in the UK. Records indicated whether kidneys had been retrieved by a liver or renal surgical team and whether damage was noted at the time of retrieval or at the transplant procedure. Multivariate Cox's regression models were fitted to 1-year and 3-year transplant-survival data in those kidneys that were transplanted between 1992 and 1994. Findings Of 9014 kidneys retrieved, 96 could not be transplanted because of damage sustained at retrieval. Damage was reported in 1726 (19%) kidneys although by both donor and recipient centres iri only 270 (3%). 1070 (62%) of the damaged organs were from donors aged 40 years or older. Reported kidney damage was more likely for retrievals of kidney only by a renal team (503 [26%]) than for multiorgan retrieval (454 [21%]), the proportion was lower when a liver team retrieved both liver and kidneys (415 [17%]). 794 (14%) kidneys retrieved and retained locally were reported as damaged, compared with 932 (29%) kidneys which had been exported. Donors' age had a significant effect on both 1-year and 3-year transplant survival (p<0.01 for both) but kidney damage did not (1 year p=0.40; 3 year p=0.81). Interpretation Despite the high rate of damage to kidneys at retrieval, most of the organs can be transplanted with no adverse effect on transplant survival. Kidney damage is least likely to occur with kidneys from young donors, and when liver teams or centres undertaking more than 50 retrievals per year do the retrieval.	Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland; United Kingdom Transplant Support Serv Author, Stoke Gifford, England	Royal Infirmary of Edinburgh; University of Edinburgh	Forsythe, JLR (corresponding author), Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Scottish Liver Transplant Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Wigmore, Stephen/AAF-3562-2019	Wigmore, Stephen/0000-0002-3614-8002				Cecka J M, 1988, Clin Transpl, P399; GENTLEMAN D, 1990, BMJ-BRIT MED J, V301, P1203, DOI 10.1136/bmj.301.6762.1203; Grossman MD, 1996, TRANSPLANTATION, V62, P1828, DOI 10.1097/00007890-199612270-00026; Lee CM, 1996, TRANSPLANTATION, V62, P1832, DOI 10.1097/00007890-199612270-00027; Nicholls J, 1996, TRANSPLANT P, V28, P142; NYGAARD CE, 1990, J TRAUMA, V30, P728, DOI 10.1097/00005373-199006000-00013; 1995, UNOS UPDATE, V11, P30	7	39	39	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1143	1146		10.1016/S0140-6736(98)09409-4	http://dx.doi.org/10.1016/S0140-6736(98)09409-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513706				2022-12-24	WOS:000082954100008
J	Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM				Takahashi, T; Fournier, A; Nakamura, F; Wang, LH; Murakami, Y; Kalb, RG; Fujisawa, H; Strittmatter, SM			Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors	CELL			English	Article							GROWTH CONE COLLAPSE; PERIPHERAL-NERVE PROJECTION; NEUROPILIN; FAMILY; PROTEIN; TRANSMEMBRANE; MOLECULES; GUIDANCE; SIGNALS; SYSTEM	Class 1 and 3 semaphorins repulse axons but bind to different cell surface proteins. We find that the two known semaphorin-binding proteins, plexin 1 (Plex 1) and neuropilin-1 (NP-1), form a stable complex. Plex 1 alone does not bind semaphorin-3A (Sema3A), but the NP-1/Plex 1 complex has a higher affinity for Sema3A than does NP-1 alone. While Sema3A binding to NP-1 does not alter nonneuronal cell morphology, Sema3A interaction with NP-1/Plex 1 complexes induces adherent cells to round up. Expression of a dominant-negative Plex 1 in sensory neurons blocks Sema3A-induced growth cone collapse. Sema3A treatment leads to the redistribution of growth cone NP-1 and plexin into clusters. Thus, physiologic Sema3A receptors consist of NP-1/plexin complexes.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Cellular & Dev Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Nagoya Univ, Grad Sch Sci, Grp Dev Neurobiol, Div Biol Sci, Nagoya, Aichi 4648602, Japan	Yale University; Yale University; Yale University; Yale University; Nagoya University	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.		Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092				Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Jin Z, 1997, J NEUROSCI, V17, P6256; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Takahashi T, 1997, J NEUROSCI, V17, P9183; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	31	666	694	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					59	69		10.1016/S0092-8674(00)80062-8	http://dx.doi.org/10.1016/S0092-8674(00)80062-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520994	Bronze			2022-12-24	WOS:000082981600008
J	Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM				Tamagnone, L; Artigiani, S; Chen, H; He, ZG; Ming, GL; Song, HJ; Chedotal, A; Winberg, ML; Goodman, CS; Poo, MM; Tessier-Lavigne, M; Comoglio, PM			Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates	CELL			English	Article							HEPATOCYTE GROWTH-FACTOR; CELL-SURFACE MOLECULE; MET RECEPTOR; SIGNAL TRANSDUCTION; IDENTIFICATION; NEUROPILIN; NEURONS; GUIDANCE; COLLAPSE; PROTEINS	In Drosophila, plexin A is a functional receptor for semaphorin-1a. Here we show that the human plexin gene family comprises at least nine members in four subfamilies. Plexin-B1 is a receptor for the transmembrane semaphorin Sema4D (CD100), and plexin-C1 is a receptor for the GPI-anchored semaphorin Sema7A (Sema-K1). Secreted (class 3) semaphorins do not bind directly to plexins, but rather plexins associate with neuropilins, coreceptors for these semaphorins. Plexins are widely expressed: in neurons, the expression of a truncated plexin-A1 protein blocks axon repulsion by Sema3A. The cytoplasmic domain of plexins associates with a tyrosine kinase activity. Plexins may also act as ligands mediating repulsion in epithelial cells in vitro. We conclude that plexins are receptors for multiple (and perhaps all) classes of semaphorins, either alone or in combination with neuropilins, and trigger a novel signal transduction pathway controlling cell repulsion.	Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Hop La Pitie Salpetriere, INSERM U106, F-75013 Paris, France	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California San Diego; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Tamagnone, L (corresponding author), Univ Turin, Inst Canc Res & Treatment, I-10060 Candiolo, Italy.		Tamagnone, Luca/J-8948-2018; Ming, Guo-li/J-7880-2013; Chedotal, Alain/F-2750-2017	Tamagnone, Luca/0000-0002-2884-7946; Chedotal, Alain/0000-0001-7577-3794; Ming, Guo-li/0000-0002-2517-6075; Comoglio, Paolo/0000-0002-7056-5328	NINDS NIH HHS [NS 22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Christensen CRL, 1998, CANCER RES, V58, P1238; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; Hall KT, 1996, P NATL ACAD SCI USA, V93, P11780, DOI 10.1073/pnas.93.21.11780; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P396, DOI 10.1006/bbrc.1996.1367; Kameyama T, 1996, BIOCHEM BIOPH RES CO, V226, P524, DOI 10.1006/bbrc.1996.1388; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; OHTA K, 1995, NEURON, V14, P1189, DOI 10.1016/0896-6273(95)90266-X; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SHINOURA N, 1995, CANCER LETT, V89, P215, DOI 10.1016/0304-3835(95)03690-X; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	40	898	965	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					71	80		10.1016/S0092-8674(00)80063-X	http://dx.doi.org/10.1016/S0092-8674(00)80063-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520995	Bronze			2022-12-24	WOS:000082981600009
J	Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA				Lebioda, L; LaCount, MW; Zhang, EL; Chen, YP; Han, KP; Whitton, MM; Lincoln, DE; Woodin, SA			Protein structure - An enzymatic globin from a marine worm	NATURE			English	Article							PEROXIDASE		Univ S Carolina, Dept Chem, Columbia, SC 29208 USA; Univ S Carolina, Dept Biochem & Biol Sci, Columbia, SC 29208 USA; Parke Davis Pharmaceut Res, Ann Arbor, MI 48105 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Pfizer	Lebioda, L (corresponding author), Univ S Carolina, Dept Chem, Columbia, SC 29208 USA.	lebioda@psc.sc.edu	Woodin, Sarah A/K-8481-2014	Woodin, Sarah A/0000-0001-5615-2212				ATOR MA, 1987, J BIOL CHEM, V262, P1542; Chen YP, 1996, J BIOL CHEM, V271, P4609; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; WOODIN SA, 1993, J CHEM ECOL, V19, P517, DOI 10.1007/BF00994322	6	75	75	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					445	445		10.1038/46728	http://dx.doi.org/10.1038/46728			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519547				2022-12-24	WOS:000082981200044
J	Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F				Altmann, P; Cunningham, J; Dhanesha, U; Ballard, M; Thompson, J; Marsh, F			Disturbance of cerebral function in people exposed to drinking water contaminated with aluminium sulphate: retrospective study of the Camelford water incident	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; GASTROINTESTINAL ABSORPTION; DIALYSIS ENCEPHALOPATHY; ENVIRONMENTAL ALUMINUM; HEMODIALYSIS-PATIENTS; CEREBROSPINAL-FLUID; PRESENILE-DEMENTIA; NORTH CORNWALL; METABOLISM; POLLUTION	Objective To establish whether people exposed to drinking water contaminated with 20 tonnes of aluminium sulphate in the Camelford area of Cornwall in the south west of England in July 1988 had suffered organic brain damage as opposed to psychological trauma only. Design Retrospective study of affected people. Participants 55 affected people and 15 siblings nearest in age to one of the group but who had not been exposed to the contaminated water were studied. Main outcome measures Various clinical and psychological tests to determine medical condition and anxiety levels in affected people. Assessment of premorbid IQ (pFSIQ) with the national adult reading test, a computerised battery of psychomotor testing, and measurement of the difference in latencies between the flash and pattern visual evoked potentials in all participants. Results The mean (SE) pFSIQ was above average at 114.4 (1.1). The most sensitive of the psychomotor tests for organic brain disease was the symbol digit coding (SDC) test (normal score 100, abnormal <85). Participants performed less well on this test (54.5 (6.0)) than expected from their pFSIQ (P < 0.0001) and a little less poorly on the averaged less discriminating tests within the battery (86.1 (2.5), P < 0.0001). In a comparison with the 15 sibling pairs (affected people's age 41.0 (3.3) years v sibling age of 42.7 (3.1) years (P = 0.36) the exposed people had similar pFSIQ (114.7 (2.1)) to their siblings (116.3 (2.1), (P = 0.59) but performed badly on the symbol digit coding test (51.8 (16.6)) v (87.5 (4.9) for siblings, P = 0.03), The flash-pattern differences in exposed people were greater than in 42 unrelated control subjects of similar age (27.33 (1.64) ms v 18.57 (1.47) ms, P = 0.0002). The 15 unexposed siblings had significantly better flash-pattern differences than their affected siblings (13.4 (2.4) ms v 29.6 (2.9) ms, P = 0.0002). No effect of anxiety could be shown on these measurements from the analysis of the anxiety scores of exposed people. Conclusion People who were exposed to the contaminated water at Camelford suffered considerable damage to cerebral function, which was not related to anxiety. Follow up studies would be required to determine the longer term prognosis for affected individuals.	Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England; Royal London Hosp, London E1 1BB, England; Coventry & Warwickshire Hosp, Paybody Eye Unit, Coventry CV1 4FH, W Midlands, England; Priory Hosp, London SW15 5JJ, England; UCL, Sch Med, London W1N 8AA, England	University of Oxford; Barts Health NHS Trust; Royal London Hospital; University of London; University College London; UCL Medical School	Altmann, P (corresponding author), Oxford Radcliffe Hosp, Oxford Kidney Unit, Oxford OX3 7LJ, England.	paul.altmann@orh.anglox.nhs.uk						ACKER W, 1982, B MAUDSLEY AUTOMATED; Acker W., 1982, BEXLEY MAUDSLEY AUTO; ALFREY AC, 1976, NEW ENGL J MED, V294, P184, DOI 10.1056/NEJM197601222940402; ALLEN WM, 1989, VET REC, V124, P479, DOI 10.1136/vr.124.18.479; ALTMANN P, 1989, LANCET, V2, P7, DOI 10.1016/S0140-6736(89)90254-7; ALTMANN P, 1987, KIDNEY INT, V32, P710, DOI 10.1038/ki.1987.264; ALTMANN P, 1987, NEW ENGL J MED, V317, P80, DOI 10.1056/NEJM198707093170204; ALTMANN P, 1991, THESIS U LONDON LOND; BARLOW PJ, 1986, J ROY SOC MED, V79, P581, DOI 10.1177/014107688607901007; BASUN H, 1991, J NEURAL TRANSM-PARK, V3, P231; BIRCHALL JD, 1988, LANCET, V2, P1008, DOI 10.1016/S0140-6736(88)90754-4; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BRUN A, 1981, ACTA PATH MICRO IM A, V89, P193; Cacabelos R, 1996, ACTA NEUROL SCAND, V93, P72; CLAYTON B, 1991, WATER POLLUTION LOWE; Clayton B., 1989, WATER POLLUTION LOWE; COGGON D, 1991, BRIT MED J, V303, P1280, DOI 10.1136/bmj.303.6813.1280; CRAPPER DR, 1973, SCIENCE, V180, P511, DOI 10.1126/science.180.4085.511; DAVID AS, 1995, J PSYCHOSOM RES, V39, P1, DOI 10.1016/0022-3999(94)00085-J; DELABAR JM, 1987, SCIENCE, V235, P1390, DOI 10.1126/science.2950593; DEROGATIS LR, 1977, S CHECKL 90 R ADM SC; DHAESE PC, 1985, CLIN CHEM, V31, P24; DOLL R, 1993, AGE AGEING, V22, P138, DOI 10.1093/ageing/22.2.138; ELLIOTT HL, 1978, BRIT MED J, V1, P1101, DOI 10.1136/bmj.1.6120.1101; Exley C, 1996, J TOXICOL ENV HEALTH, V48, P569, DOI 10.1080/009841096161078; FARRAR G, 1990, LANCET, V335, P747, DOI 10.1016/0140-6736(90)90868-6; Flaten TP, 1996, J TOXICOL ENV HEALTH, V48, P527, DOI 10.1080/009841096161050; GURLING HMD, 1980, 3 INT C TWIN STUD JE; GURLING HMD, 1980, 3 INT C TWIN STUD; HANTSON P, 1994, LANCET, V344, P1647, DOI 10.1016/S0140-6736(94)90446-4; Haycock KH, 1992, STATVIEW; JACQMIN H, 1994, AM J EPIDEMIOL, V139, P48, DOI 10.1093/oxfordjournals.aje.a116934; KAEHNY WD, 1977, NEW ENGL J MED, V296, P1389, DOI 10.1056/NEJM197706162962407; KAPAKI EN, 1993, BIOL PSYCHIAT, V33, P679, DOI 10.1016/0006-3223(93)90114-S; KELLETT JM, 1986, LANCET, V1, P682; Lezak M., 1976, NEUROPSYCHOLOGICAL A; MARTYN CN, 1989, LANCET, V1, P59; MAYEUX R, 1995, AM J PUBLIC HEALTH, V85, P1280, DOI 10.2105/AJPH.85.9.1280; MAYONWHITE RT, 1993, BRIT MED J, V307, P398, DOI 10.1136/bmj.307.6901.398; MCMILLAN TM, 1993, HUM EXP TOXICOL, V12, P37, DOI 10.1177/096032719301200108; MCMILLAN TM, 1993, J CHILD PSYCHOL PSYC, V34, P1449, DOI 10.1111/j.1469-7610.1993.tb02102.x; MEHTA RP, 1979, CAN MED ASSOC J, V120, P1112; MICHEL P, 1990, NEUROBIOL AGING, V11, P264; Mjoberg B, 1997, ACTA ORTHOP SCAND, V68, P511, DOI 10.3109/17453679708999016; Moore PB, 1997, BIOL PSYCHIAT, V41, P488, DOI 10.1016/S0006-3223(96)00045-5; Nelson HE., 1982, NATL ADULT READING T; OWEN PJ, 1995, J PUBLIC HEALTH MED, V17, P200, DOI 10.1093/oxfordjournals.pubmed.a043093; PERL DP, 1980, SCIENCE, V208, P297, DOI 10.1126/science.7367858; PLATTS MM, 1981, CLIN NEPHROL, V15, P223; PLATTS MM, 1977, BRIT MED J, V2, P657, DOI 10.1136/bmj.2.6088.657; POWELL JJ, 1995, ANALYST, V120, P793, DOI 10.1039/an9952000793; Priest ND, 1996, BIOMETALS, V9, P221, DOI 10.1007/BF00817919; PRIEST ND, 1995, HUM EXP TOXICOL, V14, P287, DOI 10.1177/096032719501400309; PRIEST ND, 1993, P NUTR SOC, V52, P231, DOI 10.1079/PNS19930055; RIFAT SL, 1990, LANCET, V336, P1162, DOI 10.1016/0140-6736(90)92775-D; SHARP CA, 1993, EUR J CLIN INVEST, V23, P554, DOI 10.1111/j.1365-2362.1993.tb00965.x; Spofforth J, 1921, LANCET, V1, P1301; TALBOT RJ, 1995, HUM EXP TOXICOL, V14, P595, DOI 10.1177/096032719501400707; TAYLOR GA, 1992, AGE AGEING, V21, P81, DOI 10.1093/ageing/21.2.81; TERRY RD, 1965, NEUROPATHOL EXP NEUR, V23, P200; VONDOLLKEN, 1897, ARCH EXP PATHOL PH, V40, P98; WHALLEY LJ, 1985, LANCET, V1, P578; WHITE DM, 1992, ARCH INTERN MED, V152, P1443, DOI 10.1001/archinte.152.7.1443; WHITE DM, 1992, ARCH INTERN MED, V153, P2796; WRIGHT CE, 1984, ELECTROEN CLIN NEURO, V57, P405, DOI 10.1016/0013-4694(84)90069-5; ZAPATERO MD, 1995, BIOL TRACE ELEM RES, V47, P235, DOI 10.1007/BF02790122	66	82	88	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					807	+		10.1136/bmj.319.7213.807	http://dx.doi.org/10.1136/bmj.319.7213.807			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241CR	10496822	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000082865200020
J	Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW				Freeman, TB; Vawter, DE; Leaverton, PE; Godbold, JH; Hauser, RA; Goetz, CG; Olanow, CW			Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FETAL NIGRAL TRANSPLANTATION; LONG-TERM SURVIVAL; DOUBLE-BLIND; DOPAMINERGIC GRAFTS; CLINICAL RESEARCH; GENE-THERAPY; PATIENT; IMPLANTS; LEVODOPA; PET		Univ S Florida, Tampa, FL 33606 USA; Minnesota Ctr Hlth Care Eth, Minneapolis, MN 55454 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA	State University System of Florida; University of South Florida; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Rush University	Freeman, TB (corresponding author), Univ S Florida, Tampa, FL 33606 USA.		Hauser, Robert/I-5372-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033772] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS32842, R01 NS33772] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 1998, FED REGISTER, V63, P26744; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; BAUM M, 1999, LANCET S1, V353, pS16, DOI DOI 10.1016/S0140-6736(99)90220-9]; BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BONCHEK LI, 1979, NEW ENGL J MED, V301, P44, DOI 10.1056/NEJM197907053010110; BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Defer GL, 1996, BRAIN, V119, P41, DOI 10.1093/brain/119.1.41; Delbanco TL, 1996, JAMA-J AM MED ASSOC, V275, P716; DIMOND EG, 1958, CIRCULATION, V18, P712; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; Freeman TB, 1997, EXP NEUROL, V144, P47, DOI 10.1006/exnr.1996.6387; GUTTMAN M, 1989, CAN J NEUROL SCI, V16, P305, DOI 10.1017/S0317167100029139; HARBAUGH RE, 1989, J NEUROSURG, V71, P481, DOI 10.3171/jns.1989.71.4.0481; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; HAUSER RA, 1992, SCI BASIS TREATMENT, P275; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Kordower JH, 1998, MOVEMENT DISORD, V13, P383, DOI 10.1002/mds.870130303; LAW PK, 1991, ACTA CARDIOMIOLOGICA, V3, P281; LEAPE LL, 1991, JRA02 RAND, pR5; LEVINE RJ, 1986, ETHICS REGULATION CL; Levit K R, 1985, Health Care Financ Rev, V7, P1; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lotz B, 1996, NEUROLOGY, V46, P1244; LOVE JW, 1975, JAMA-J AM MED ASSOC, V232, P37, DOI 10.1001/jama.232.1.37; McCarthy M, 1996, LANCET, V348, P323, DOI 10.1016/S0140-6736(05)64475-3; Moseley JB, 1996, AM J SPORT MED, V24, P28, DOI 10.1177/036354659602400106; Nutt JG, 1996, ANN NEUROL, V39, P561, DOI 10.1002/ana.410390504; Olanow CW, 1996, TRENDS NEUROSCI, V19, P102, DOI 10.1016/S0166-2236(96)80038-5; OLANOW CW, 1994, MOVEMENT DISORD, V9, P40, DOI 10.1002/mds.870090107; OLANOW CW, 1990, ARCH NEUROL-CHICAGO, V47, P1286, DOI 10.1001/archneur.1990.00530120030006; OLANOW CW, 1995, ANN NEUROL, V38, P771, DOI 10.1002/ana.410380512; Pocock SJ, 1983, CLIN TRIALS PRACTICA; Prentice Ernest D, 1989, IRB, V11, P6, DOI 10.2307/3563825; Reeves B, 1999, LANCET S1, V353, pS13; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SAWLE GV, 1992, ANN NEUROL, V31, P166, DOI 10.1002/ana.410310207; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SPODICK DH, 1971, AM HEART J, V81, P149, DOI 10.1016/0002-8703(71)90125-6; STANLEY B, 1988, PSYCHOPHARMACOL BULL, V24, P18; TAYLOR JR, 1995, CELL TRANSPLANT, V4, P13, DOI 10.1016/0963-6897(94)00035-I; THOMSEN J, 1981, ARCH OTOLARYNGOL, V107, P271; TURNER JA, 1994, JAMA-J AM MED ASSOC, V271, P1609, DOI 10.1001/jama.271.20.1609; Wagner M, 1996, LANCET, V348, P1394, DOI 10.1016/S0140-6736(05)67494-6; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115	52	174	178	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					988	992		10.1056/NEJM199909233411311	http://dx.doi.org/10.1056/NEJM199909233411311			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498497				2022-12-24	WOS:000082658100011
J	Spruck, CH; Won, KA; Reed, SI				Spruck, CH; Won, KA; Reed, SI			Deregulated cyclin E induces chromosome instability	NATURE			English	Article							BREAST-CANCER; CELL-CYCLE; DNA-REPLICATION; S-PHASE; EXPRESSION; KINASE; PROLIFERATION; CARCINOMAS; ACTIVATION; INDUCTION	Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (Cdk2), is an important regulator of entry into S phase in the mammalian cell cycle. In normal dividing cells, cyclin E accumulates at the G(1)/S-phase boundary and is degraded as cells progress through S phase(1,2). However, in many human tumours cyclin E is overexpressed(3) and the levels of protein and kinase activity are often deregulated relative to the cell cycle(4-7). It is not understood how alterations in expression of cyclin E contribute to tumorigenesis. Here we show that constitutive cyclin-E overexpression in both immortalized rat embryo fibroblasts and human breast epithelial cells results in chromosome instability (CIN). In contrast, analogous expression of cyclin D1 or A does not increase the frequency of GIN. Cyclin-E-expressing cells that exhibit CIN have normal centrosome numbers. However, constitutive overexpression of cyclin E impairs S-phase progression, indicating that aberrant regulation of this process may be responsible for the CIN observed. These results indicate that downregulation of cyclin-E/Cdk2 kinase activity following the G(1)/S-phase transition may be necessary for the maintenance of karyotypic stability.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, MB-7,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Bito T, 1997, J CUTAN PATHOL, V24, P305, DOI 10.1111/j.1600-0560.1997.tb00796.x; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; ELBLE R, 1992, MOL BIOL CELL, V3, P971, DOI 10.1091/mbc.3.9.971; Erlanson M, 1998, BLOOD, V92, P770; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hua XH, 1997, J CELL BIOL, V137, P183, DOI 10.1083/jcb.137.1.183; Keyomarsi K, 1997, Prog Cell Cycle Res, V3, P171; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mumberg D, 1996, ONCOGENE, V13, P2493; Nielsen NH, 1998, ANAL CELL PATHOL, V17, P177, DOI 10.1155/1998/659712; Pihan GA, 1998, CANCER RES, V58, P3974; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Simpson G.G., 1960, QUANTITATIVE ZOOLOGY; Walter J, 1998, MOL CELL, V1, P519, DOI 10.1016/S1097-2765(00)80052-0; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	28	587	606	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					297	300		10.1038/45836	http://dx.doi.org/10.1038/45836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499591				2022-12-24	WOS:000082678400059
J	Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y				Sahara, S; Aoto, M; Eguchi, Y; Imamoto, N; Yoneda, Y; Tsujimoto, Y			Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation	NATURE			English	Article							CASPASE-ACTIVATED DNASE; LAMIN-A; IMPORT; CELLS; FRAGMENTATION; COMPLEX	Apoptosis is defined by several unique morphological nuclear changes, such as chromatin condensation and nuclear fragmentation(1). These changes are triggered by the activation of a family of cysteine proteases called caspases(2,3), and caspase-activated DNase (CAD/DPP40)(4,5) and Iamin protease (caspase-6)(6,7) have been implicated in some of these changes. CAD/DFF40 induces chromatin condensation in purified nuclei, but distinct caspase-activated factor(s) may be responsible for chromatin condensations. Here we use an in vitro system to identify a new nuclear factor, designated Acinus, which induces apoptotic chromatin condensation after cleavage by caspase-3 without inducing DNA fragmentation. Immunodepletion experiments showed that Acinus is essential for apoptotic chromatin condensation in vitro, and an antisense study revealed that Acinus is also important in the induction of apoptotic chromatin condensation in cells.	Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Anat, Osaka 5650871, Japan; Japan Sci & Technol Corp JST, CREST, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Biomed Res Ctr, Dept Med Genet, 202 Yamadaoka, Osaka 5650871, Japan.		Imamoto, Naoko/A-7458-2015	Imamoto, Naoko/0000-0002-2886-3022				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Iwahashi H, 1997, NATURE, V390, P413, DOI 10.1038/37144; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Matsudaira PT., 1993, PRACTICAL GUIDE PROT; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tachibana T, 1996, FEBS LETT, V397, P177, DOI 10.1016/S0014-5793(96)01180-5; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	26	346	354	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					168	173		10.1038/43678	http://dx.doi.org/10.1038/43678			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490026				2022-12-24	WOS:000082458800055
J	Horton, R				Horton, R			Future of European cardiology: continentally isolated or globally integrated?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Horton, R (corresponding author), The Lancet, London WC1B 3SL, England.							Chockalingam A, 1999, IMPENDING GLOBAL PAN; de Luna AB, 1999, J AM COLL CARDIOL, V33, P1427; De Luna AB, 1999, EUR HEART J, V20, P562, DOI 10.1053/euhj.1998.1392; Fuster V, 1999, CIRCULATION, V99, P1132, DOI 10.1161/01.CIR.99.9.1132; Institute of Medicine, 1998, CONTR CARD DIS DEV C; King SB, 1998, J AM COLL CARDIOL, V32, P2100; Lechat P, 1999, LANCET, V353, P9; Masera G, 1998, LANCET, V352, P1923, DOI 10.1016/S0140-6736(98)07077-9; Ryden L, 1999, EUR HEART J, V20, P319; Tunstall-Pedoe H, 1999, LANCET, V353, P1547, DOI 10.1016/S0140-6736(99)04021-0	10	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					791	792						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485717				2022-12-24	WOS:000082400700004
J	Joubin, K; Stern, CD				Joubin, K; Stern, CD			Molecular interactions continuously define the organizer during the cell movements of gastrulation	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; PRIMITIVE STREAK FORMATION; EARLY XENOPUS DEVELOPMENT; EARLY CHICK-EMBRYO; NEURAL INDUCTION; SPEMANNS ORGANIZER; MESODERM INDUCTION; MARGINAL ZONE; AVIAN EMBRYOS; HENSENS NODE	The organizer is a unique region in the gastrulating embryo that induces and patterns the body axis. It arises before gastrulation under the influence of the Nieuwkoop center. We show that during gastrulation, cell movements bring cells into and out of the chick organizer, Hensen's node. During these movements, cells acquire and lose organizer properties according to their position. A "node inducing center," which emits Vg1 and Wnt8C, is located in the middle of the primitive streak. Its activity is inhibited by ADMP produced by the node and by BMPs at the periphery. These interactions define the organizer as a position in the embryo, whose cellular makeup is constantly changing, and explain the phenomenon of organizer regeneration.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Columbia University	Stern, CD (corresponding author), Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA.	cds20@columbia.edu	Stern, Claudio/AAZ-7381-2021; Stern, Claudio D/C-6265-2008	Stern, Claudio/0000-0002-9907-889X; Stern, Claudio D/0000-0002-9907-889X	NIGMS NIH HHS [GM53456] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053456] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABERCROMBIE M, 1954, J EMBRYOL EXP MORPH, V2, P55; ALTABA AR, 1995, DEV BIOL, V170, P299; Bachvarova RF, 1998, DEVELOPMENT, V125, P3521; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Brannon M, 1996, DEV BIOL, V180, P344, DOI 10.1006/dbio.1996.0306; BUTROS J, 1967, J EMBRYOL EXP MORPH, V17, P119; Connolly DJ, 1997, INT J DEV BIOL, V41, P389; CONNOLLY DJ, 1995, DEV GENET, V17, P65, DOI 10.1002/dvg.1020170108; COOKE J, 1973, J EMBRYOL EXP MORPH, V30, P283; COOKE J, 1975, J EMBRYOL EXP MORPH, V33, P147; Crease DJ, 1998, P NATL ACAD SCI USA, V95, P4398, DOI 10.1073/pnas.95.8.4398; Cui YZ, 1996, DEV BIOL, V180, P22, DOI 10.1006/dbio.1996.0281; DALE L, 1992, DEVELOPMENT, V115, P573; DU SJ, 1995, MOL CELL BIOL, V15, P2625; GALLERA J, 1974, EXPERIENTIA, V30, P183, DOI 10.1007/BF01927723; Gerhart J.C., 1980, Biological Regulation and Development, V2, P133; GRABOWSKI CT, 1956, J EXP ZOOL, V133, P301, DOI 10.1002/jez.1401330207; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARA K, 1978, ORG MILESTONE HALF C, P221; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATADA Y, 1994, DEVELOPMENT, V120, P2879; Hoang BH, 1998, DEV DYNAM, V212, P364, DOI 10.1002/(SICI)1097-0177(199807)212:3<364::AID-AJA4>3.0.CO;2-F; Hoppler S, 1998, MECH DEVELOP, V71, P119, DOI 10.1016/S0925-4773(98)00004-5; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUME CR, 1993, DEVELOPMENT, V119, P1147; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; Jones CM, 1996, DEVELOPMENT, V122, P1545; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kodjabachian L, 1998, CURR BIOL, V8, pR918, DOI 10.1016/S0960-9822(98)00009-8; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lin KM, 1997, P NATL ACAD SCI USA, V94, P11196, DOI 10.1073/pnas.94.21.11196; Moos M, 1995, DEVELOPMENT, V121, P4293; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Nicholas JS, 1942, J EXP ZOOL, V90, P127, DOI 10.1002/jez.1400900108; Nicolas JF, 1996, DEVELOPMENT, V122, P2933; NICOLET G, 1970, Journal of Embryology and Experimental Morphology, V23, P79; Nicolet G., 1971, Adv Morphogen, V9, P231; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; Pannett CA, 1924, LANCET, V1, P381; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Psychoyos D, 1996, DEVELOPMENT, V122, P1523; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROSENQUIST GLENN C., 1966, CARNEGIE INST WASH PUBL, V38, P71; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Seleiro EAP, 1996, CURR BIOL, V6, P1476, DOI 10.1016/S0960-9822(96)00752-X; SELLECK MAJ, 1992, NATO ADV SCI I A-LIF, V231, P23; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; Shah SB, 1997, DEVELOPMENT, V124, P5127; Shih J, 1996, DEVELOPMENT, V122, P1313; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smith JL, 1998, CURR TOP DEV BIOL, V40, P79, DOI 10.1016/S0070-2153(08)60365-8; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN S, 1995, MECH DEVELOP, V49, P37, DOI 10.1016/0925-4773(94)00300-C; STEINBEISSER H, 1995, EMBO J, V14, P5230, DOI 10.1002/j.1460-2075.1995.tb00208.x; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; STERN CD, 1981, ANAT EMBRYOL, V163, P245, DOI 10.1007/BF00315703; STOREY KG, 1995, DEVELOPMENT, V121, P417; Streit A, 1997, DEVELOPMENT, V124, P1191; Streit A, 1998, DEVELOPMENT, V125, P507; Streit A, 1999, MECH DEVELOP, V82, P51, DOI 10.1016/S0925-4773(99)00013-1; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Tonegawa A, 1997, DEVELOPMENT, V124, P1975; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; Watanabe Y, 1996, MECH DEVELOP, V57, P69, DOI 10.1016/0925-4773(96)00534-5; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; WU M, 1991, METHOD CELL BIOL, V36, P3; YUAN SP, 1995, DEV GENET, V17, P38, DOI 10.1002/dvg.1020170106; Yuan SP, 1999, DEVELOPMENT, V126, P2461; Yuan SP, 1998, DEVELOPMENT, V125, P201; Yuan SP, 1995, DEV BIOL, V172, P567, DOI 10.1006/dbio.1995.8064; ZOM AM, 1999, DEV BIOL, V209, P282	85	119	122	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					559	571		10.1016/S0092-8674(00)80044-6	http://dx.doi.org/10.1016/S0092-8674(00)80044-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490096	hybrid			2022-12-24	WOS:000082433500004
J	Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A				Oldstone, MBA; Lewicki, H; Thomas, D; Tishon, A; Dales, S; Patterson, J; Manchester, M; Homann, D; Naniche, D; Holz, A			Measles virus infection in a transgenic model: Virus-induced immunosuppression and central nervous system disease	CELL			English	Article							DEPENDENT DIABETES-MELLITUS; SINDBIS VIRUS; MOUSE MODEL; T-CELLS; PROTEIN; MICE; CD46; EXPRESSION; RECEPTOR; STRAIN	Measles virus (MV) infects 40 million persons and kills one million per year primarily by suppressing the immune system and afflicting the central nervous system (CNS). The lack of a suitable small animal model has impeded progress of understanding how MV causes disease and the development of novel therapies and improved vaccines. We tested a transgenic mouse line in which expression of the MV receptor CD46 closely mimicked the location and amount of CD46 found in humans. Virus replicated in and was recovered from these animals' immune systems and was associated with suppression of humoral and cellular immune responses. infectious virus was recovered from the CNS, replicated primarily in neurons, and spread to distal sites presumably by fast axonal transport. Thus, a small animal model is available for analysis of MV pathogenesis.	Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, La Jolla, CA 92037 USA; Rockefeller Univ, Dept Cell Biol, New York, NY 10024 USA	Scripps Research Institute; Rockefeller University	Oldstone, MBA (corresponding author), Scripps Res Inst, Res Inst, Dept Neuropharmacol, Div Virol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mbaobo@scripps.edu	Naniche, Denise S/S-1814-2018	Naniche, Denise S/0000-0002-4495-6325; Holz, Andreas/0000-0002-8886-0915; Homann, Dirk/0000-0002-7622-5754	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019185] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36222] Funding Source: Medline; NIA NIH HHS [AG00080] Funding Source: Medline; NIMH NIH HHS [MH19185] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baskar JF, 1996, J VIROL, V70, P3207, DOI 10.1128/JVI.70.5.3207-3214.1996; Blixenkrone-Moller M, 1998, VIROLOGY, V249, P238, DOI 10.1006/viro.1998.9301; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; EASTMAN CL, 1994, EXP NEUROL, V125, P119, DOI 10.1006/exnr.1994.1015; Evans CF, 1996, J EXP MED, V184, P2371, DOI 10.1084/jem.184.6.2371; FugierVivier I, 1997, J EXP MED, V186, P813, DOI 10.1084/jem.186.6.813; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Griffin D., 1996, FIELDS VIROLOGY, V3rd ed., P1267; Griffin DE, 1999, TRENDS MICROBIOL, V7, P155, DOI 10.1016/S0966-842X(99)01470-5; Grosjean I, 1997, J EXP MED, V186, P801, DOI 10.1084/jem.186.6.801; Holz A, 1996, J NEUROSCI, V16, P467; Homann D, 1998, J VIROL, V72, P9208, DOI 10.1128/JVI.72.11.9208-9216.1998; Horvat B, 1996, J VIROL, V70, P6673, DOI 10.1128/JVI.70.10.6673-6681.1996; Horwitz MS, 1999, LAB INVEST, V79, P235; JOHNSON RT, 1972, J INFECT DIS, V125, P257, DOI 10.1093/infdis/125.3.257; Lawrence DMP, 1999, J VIROL, V73, P1795, DOI 10.1128/JVI.73.3.1795-1801.1999; LIEBERT UG, 1995, CURR TOP MICROBIOL, V191, P149; LIPKIN WI, 1989, CURR TOP MICROBIOL, V143, P33; LISZEWSKI MK, 1991, ANNU REV IMMUNOL, V9, P431, DOI 10.1146/annurev.iy.09.040191.002243; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LONG EO, 1989, IMMUNOL TODAY, V10, P45, DOI 10.1016/0167-5699(89)90303-4; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Markowitz LE, 1994, VACCINES, P229; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MOSIER DE, 1974, J IMMUNOL, V112, P305; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; OLDSTONE MB, 1973, J IMMUNOL, V110, P1268; Oldstone MBA, 1997, VIROLOGY, V234, P179, DOI 10.1006/viro.1997.8674; OLDSTONE MBA, 1986, NATURE, V321, P239, DOI 10.1038/321239a0; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OLDSTONE MBA, 1998, VIRUSES PLAGUES HIST, P73; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Rall GF, 1997, P NATL ACAD SCI USA, V94, P4659, DOI 10.1073/pnas.94.9.4659; RIMA BK, 1995, CURR TOP MICROBIOL, V191, P65; ROCKENSTEIN EM, 1995, J BIOL CHEM, V270, P28257; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROZENBLATT S, 1979, J VIROL, V32, P329, DOI 10.1128/JVI.32.1.329-333.1979; RUSSELL SM, 1992, EUR J IMMUNOL, V22, P1513, DOI 10.1002/eji.1830220625; Schnorr JJ, 1997, P NATL ACAD SCI USA, V94, P5326, DOI 10.1073/pnas.94.10.5326; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; TERMEULEN V, 1983, COMPR VIROL, V18, P105; Thorley BR, 1997, EUR J IMMUNOL, V27, P726, DOI 10.1002/eji.1830270322; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TISHON A, 1988, J IMMUNOL, V140, P1280; Trgovcich J, 1997, VIROLOGY, V227, P234, DOI 10.1006/viro.1996.8289; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; Yannoutsos N, 1996, GENES CELLS, V1, P409, DOI 10.1046/j.1365-2443.1996.d01-244.x; Zingoni A, 1998, J IMMUNOL, V161, P547	51	125	127	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					629	640		10.1016/S0092-8674(00)80050-1	http://dx.doi.org/10.1016/S0092-8674(00)80050-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490102	Bronze			2022-12-24	WOS:000082433500010
J	Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS				Boekema, EJ; van Breemen, JFL; Brisson, A; Ubbink-Kok, T; Konings, WN; Lolkema, JS			Biological motors - Connecting stalks in V-type ATPase	NATURE			English	Article							ROTATIONAL CATALYSIS; ELECTRON-MICROSCOPY; SYNTHASE		Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands	University of Groningen	Boekema, EJ (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands.		Konings, Wilhelmus N./C-7063-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boekema EJ, 1998, PHOTOSYNTH RES, V57, P267, DOI 10.1023/A:1006044931980; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOYER PD, 1995, FASEB J, V9, P559, DOI 10.1096/fasebj.9.7.7737466; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	10	76	76	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					37	38		10.1038/43369	http://dx.doi.org/10.1038/43369			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485704	Green Published			2022-12-24	WOS:000082374400031
J	Romashkova, JA; Makarov, SS				Romashkova, JA; Makarov, SS			NF-kappa B is a target of AKT in anti-apoptotic PDGF signalling	NATURE			English	Article							KINASE-C-ZETA; GROWTH-FACTOR; CELL-DEATH; PROTEIN; ACTIVATION; PHOSPHORYLATION; FIBROBLASTS; INDUCTION; RAS; TRANSDUCTION	The mechanisms of cell proliferation and transformation are intrinsically linked to the process of apoptosis: the default of proliferating cells is to die unless specific survival signals are provided(1,2). Platelet-derived growth factor (PDGF) is a principal survival factor that inhibits apoptosis and promotes proliferation(1), but the mechanisms mediating its anti-apoptotic properties are not completely understood. Here we show that the transcription factor NF-kappa B3-5 is important in PDGF signalling. NF-kappa B transmits two signals: one is required for the induction of proto-oncogene c-myc and proliferation, and the second, an anti-apoptotic signal, counterbalances c-Myc cytotoxicity. We have traced a putative pathway whereby PDGF activates NF-kappa B through pas and phospatidylinositol-3-kinase (PI(3)K) to the PKB/Akt protein kinase and the I kappa B kinase (IKK); NF-kappa B thus appears to be a target of the anti-apoptotic Ras/PI(3)K/Akt pathway(6,7). We show that, upon PDGF stimulation, Akt transiently associates in vivo with IKK and induces IKK activation. These findings establish a role for NF-kappa B in growth factor signalling and define an anti-apoptotic Ras/PI(3)K/Akt/IKK/NF-kappa B pathway, thus linking anti-apoptotic signalling with transcription machinery.	Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Makarov, SS (corresponding author), Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA.							Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Evan G, 1997, INT J CANCER, V71, P709, DOI 10.1002/(SICI)1097-0215(19970529)71:5<709::AID-IJC2>3.0.CO;2-V; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I; Foo SY, 1999, TRENDS GENET, V15, P229; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HARRIS CC, 1994, CANCER EPIDEM BIOMAR, V3, P1; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Makarov SS, 1996, P NATL ACAD SCI USA, V93, P402, DOI 10.1073/pnas.93.1.402; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296	30	1620	1672	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					86	90		10.1038/43474	http://dx.doi.org/10.1038/43474			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485711				2022-12-24	WOS:000082374400047
J	Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK				Sinha, A; Sazawal, S; Kumar, R; Sood, S; Reddaiah, VP; Singh, B; Rao, M; Naficy, A; Clemens, JD; Bhan, MK			Typhoid fever in children aged less than 5 years	LANCET			English	Article							VI-CAPSULAR POLYSACCHARIDE; SALMONELLA-TYPHI; VACCINE; YOUNGER	Background Calculation of the incidence of typhoid fever during preschool years is important to define the optimum age of immunisation and the choice of vaccines for public-health programmes in developing countries. Hospital-based studies have suggested that children younger than 5 years do not need vaccination against typhoid fever, but this view needs to be re-examined in community-based longitudinal studies. We undertook a prospective follow-up study of residents of a low-income urban area of Delhi, India, with active surveillance for case detection. Methods A baseline census was undertaken in 1995, Between Nov 1, 1995, and Oct 31, 1996, we visited 8172 residents of 1820 households in Kalkaji, Delhi, twice weekly to detect febrile cases. Blood samples were obtained from febrile patients, and those who tested positive for Salmonella typhi were treated with ciprofloxacin, Findings 63 culture-positive typhoid fever cases were detected. Of these, 28 (44%) were in children aged under 5 years. The incidence rate of typhoid per 1000 person-years was 27.3 at age under 5 years, 11.7 at 5-19 years, and 1.1 between 19 and 40 years. The difference in the incidence of typhoid fever between those under 5 years and those aged 5-19 years (15.6 per 1000 person-years [95% CI 4.7-26.5]), and those aged 19-40 years (26.2 [16.0-36.3]) was significant (p<0.001 for both). The difference between the incidence of typhoid at 5-19 years and the incidence at 19-40 years was also significant (10.6 [6.3-14.8], p<0.001). Morbidity in those under 5 and in older people was similar in terms of duration of fever, signs and symptoms, and need for hospital admission. Interpretation Our findings challenge the common view that typhoid fever is a disorder of school-age children and of adults. Typhoid is a common and significant cause of morbidity between 1 and 5 years of age. The optimum age of typhoid immunisation and the choice of vaccines needs to be reassessed.	All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India; All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India; All India Inst Med Sci, Ctr Community Med, New Delhi 110029, India; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; NICHHD, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	All India Institute of Medical Sciences (AIIMS) New Delhi; Indian Council of Medical Research (ICMR); All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bhan, MK (corresponding author), All India Inst Med Sci, Dept Pediat, Div Paediat Gastroenterol, Adv Ctr Diarrhoeal Dis Res,Indian Council Med Res, New Delhi 110029, India.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002528] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; ARORA R K, 1992, Indian Pediatrics, V29, P61; CHUTTANI CS, 1972, INT J EPIDEMIOL, V1, P39, DOI 10.1093/ije/1.1.39; EDELMAN R, 1986, REV INFECT DIS, V8, P329; FERRECCIO C, 1984, J PEDIATR-US, V104, P899, DOI 10.1016/S0022-3476(84)80492-8; FERRECCIO C, 1989, J INFECT DIS, V159, P766, DOI 10.1093/infdis/159.4.766; Gupta A, 1994, Indian J Pediatr, V61, P321, DOI 10.1007/BF02751884; HACKETT J, 1990, VACCINE, V8, P5, DOI 10.1016/0264-410X(90)90169-M; IVANOFF B, 1994, B WORLD HEALTH ORGAN, V72, P957; KAPOOR J P, 1985, Indian Pediatrics, V22, P811; KLUGMAN KP, 1987, LANCET, V2, P1165; LEVINE MM, 1997, NEW GENERATION VACCI, P437; LEVINE MM, 1994, VACCINES, P601; MAHLE WT, 1993, PEDIATR INFECT DIS J, V12, P627, DOI 10.1097/00006454-199308000-00001; MIDDELKAMP J N, 1965, Med Times, V93, P956; MISHRA S, 1991, Indian Pediatrics, V28, P1171; MULLIGAN TO, 1971, BRIT MED J, V4, P665, DOI 10.1136/bmj.4.5788.665; PATNAIK KC, 1967, INDIAN J MED RES, V55, P228; PLOTKIN SA, 1995, ARCH INTERN MED, V155, P2293, DOI 10.1001/archinte.155.21.2293; Sen S K, 1972, Indian J Pediatr, V39, P354, DOI 10.1007/BF02753167; SIMANJUNTAK CH, 1991, LANCET, V338, P1055, DOI 10.1016/0140-6736(91)91910-M; SMITH PG, 1991, METHODS FIELDS TRIAL, P292	22	285	291	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					734	737		10.1016/S0140-6736(98)09001-1	http://dx.doi.org/10.1016/S0140-6736(98)09001-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475185				2022-12-24	WOS:000082233000013
J	Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A				Birketvedt, GS; Florholmen, J; Sundsfjord, J; Osterud, B; Dinges, D; Bilker, W; Stunkard, A			Behavioral and neuroendocrine characteristics of the night-eating syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBESITY SURGERY PATIENTS; GENERAL-POPULATION; MELATONIN LEVELS; NOCTURNAL RISE; BINGE; DISORDERS; LEPTIN; SLEEP; PROTEIN; DEPRESSION	Context Investigators first described the night-eating syndrome (NES), which consists of morning anorexia, evening hyperphagia, and insomnia, in 1955, but, to our knowledge, this syndrome has never been subjected to careful clinical study. Objective To characterize NES on the basis of behavioral characteristics and neuroendocrine data. Design and Setting A behavioral observational study was conducted between January 1996 and June 1997 in a weight and eating disorders program at the University of Pennsylvania. A neuroendocrine study was conducted from May through August 1997 at the Clinical Research Center of the University Hospital, Tromso, Norway, Subjects The behavioral study included 10 obese subjects who met criteria for NES and 10 matched control subjects. The neuroendocrine study included 12 night eaters and 21 control subjects. Behavioral study subjects were observed for 1 week on an outpatient basis, and neuroendocrine study subjects were observed during a 24-hour period in the hospital. Main Outcome Measures The behavioral study measured timing of energy intake, mood level, and sleep disturbances. The neuroendocrine study measured circadian levels of plasma melatonin, leptin, and cortisol, Results In the behavioral study, compared with control subjects, night eaters had more eating episodes in the 24 hours (mean [SD], 9.3 [0.6] vs 4.2 [0.2]; P<.001) and consumed significantly more of their daily energy intake at night than did control subjects (56% vs 15%; P<.001), They averaged 3.6 (0.9) awakenings per night compared with 0.3 (0.3) by controls (P<.001). In night eaters, 52% of these awakenings were associated with food intake, with a mean intake per ingestion of 1134 (1197) kJ, None of the controls ate during their awakenings. In the neuroendocrine study, compared with control subjects, night eaters had attenuation of the nocturnal rise in plasma melatonin and leptin levels (P<.001 for both) and higher circadian levels of plasma cortisol (P = .001). Conclusion A coherent pattern of behavioral and neuroendocrine characteristics was found in subjects with NES.	Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Tromso, Inst Clin Med, Lab Gastroenterol, Tromso, Norway; Univ Tromso, Inst Med Biochem, Tromso, Norway; Univ Tromso Hosp, Dept Clin Chem, N-9012 Tromso, Norway	University of Pennsylvania; University of Pennsylvania; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway	Birketvedt, GS (corresponding author), Univ Penn, Sch Med, Dept Psychiat, 3600 Market St,Suite 736, Philadelphia, PA 19104 USA.	gsb42nor@aol.com	Bilker, Warren/AAS-3515-2021; Dinges, David/P-7183-2019					American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; BERRY EM, 1991, NEUROLOGY, V41, P1295, DOI 10.1212/WNL.41.8.1295; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Diggle PJ, 2002, ANAL LONGITUDINAL DA; Fairburn CG, 1993, BINGE EATING NATURE; GREENO CG, 1995, INT J EAT DISORDER, V18, P343, DOI 10.1002/1098-108X(199512)18:4&lt;343::AID-EAT2260180407&gt;3.0.CO;2-P; GRILO CM, 1994, J CONSULT CLIN PSYCH, V62, P611, DOI 10.1037/0022-006X.62.3.611; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; HAIMOV I, 1995, SLEEP, V18, P598, DOI 10.1093/sleep/18.7.598; Hajak G, 1995, J PINEAL RES, V19, P116, DOI 10.1111/j.1600-079X.1995.tb00179.x; HANSEN T, 1987, ACTA PSYCHIAT SCAND, V75, P428, DOI 10.1111/j.1600-0447.1987.tb02811.x; Heiman ML, 1997, ENDOCRINOLOGY, V138, P3859, DOI 10.1210/en.138.9.3859; HEINRICHS SC, 1995, STRESS BASIC MECHANI, P93; Kellner M, 1997, NEUROENDOCRINOLOGY, V65, P284, DOI 10.1159/000127186; KENNEDY SH, 1989, ARCH GEN PSYCHIAT, V46, P73; Manni R, 1997, SLEEP, V20, P734, DOI 10.1093/sleep/20.9.734; Matkovic V, 1997, J CLIN ENDOCR METAB, V82, P1368, DOI 10.1210/jc.82.5.1368; RAND CSW, 1993, INT J OBESITY, V17, P657; Rand CSW, 1997, INT J EAT DISORDER, V22, P65, DOI 10.1002/(SICI)1098-108X(199707)22:1&lt;65::AID-EAT8&gt;3.0.CO;2-0; ROSEN JC, 1986, INT J EAT DISORDER, V5, P255, DOI 10.1002/1098-108X(198602)5:2<255::AID-EAT2260050206>3.0.CO;2-D; ROSSITER EM, 1990, INT J EAT DISORDER, V9, P513, DOI 10.1002/1098-108X(199009)9:5&lt;513::AID-EAT2260090506&gt;3.0.CO;2-T; SADEH A, 1989, J AMBULATORY MONITOR, V25, P305; SCHENCK CH, 1993, SLEEP, V16, P457; SCHENCK CH, 1994, INT J EAT DISORDER, V15, P343, DOI 10.1002/eat.2260150405; Sinha MK, 1996, J CLIN INVEST, V97, P1344, DOI 10.1172/JCI118551; SPAGGIARI MC, 1994, SLEEP, V17, P339, DOI 10.1093/sleep/17.4.339; Stratakis CA, 1995, ANN NY ACAD SCI, V771, P1, DOI 10.1111/j.1749-6632.1995.tb44666.x; Stunkard A, 1996, INT J OBESITY, V20, P1; STUNKARD AJ, 1955, AM J MED, V19, P78, DOI 10.1016/0002-9343(55)90276-X; STUNKARD AJ, 1959, PSYCHIAT QUART, V33, P284, DOI 10.1007/BF01575455; Turnbull AV, 1997, P SOC EXP BIOL MED, V215, P1; VONEN B, 1992, SCAND J CLIN LAB INV, V52, P107, DOI 10.3109/00365519209088773; WINKELMAN JW, 1993, SLEEP RES, V22, P291; WISBERG J, 1990, J SLEEP RES, V19, P384; YOKOGOSHI H, 1986, METABOLISM, V35, P837, DOI 10.1016/0026-0495(86)90225-8; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhdanova IV, 1996, SLEEP, V19, P423, DOI 10.1093/sleep/19.5.423	37	270	278	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					657	663		10.1001/jama.282.7.657	http://dx.doi.org/10.1001/jama.282.7.657			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517719	Bronze			2022-12-24	WOS:000082033700025
J	Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M				Hermans, PWM; Hibberd, ML; Booy, R; Daramola, O; Hazelzet, JA; de Groot, R; Levin, M		Meningococcal Res Grp	4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; PROTEIN-C; PURPURA FULMINANS; SEPTIC SHOCK; PLASMA ENDOTOXIN; ASSOCIATION; COAGULATION; CHILDREN; INTERLEUKIN-1; ANTITHROMBIN	Background Intravascular coagulation with infarction of skin, digits, and limbs is a characteristic feature of meningococcal sepsis. Children with meningococcal sepsis have higher than normal concentrations of plasminogen activator inhibitor 1 (PAI-1) in plasma. Combined with the widespread venous thrombosis, this finding suggests an impairment of fibrinolysis. A common functional insertion/deletion (4G/5G) polymorphism exists in the promoter region of the PAI-1. gene. We tested the hypothesis that children with the 4G/4G genotype produce higher concentrations of PAI-1, develop more severe coagulopathy, and are at greater risk of death during meningococcal sepsis. Methods The relation between meningococcal disease outcome, PAI-1 concentration, ana PAI-1 genotype was investigated in 175 children with meningococcal disease (37 from Rotterdam, the Netherlands, and 138 from London, UK) and 226 controls (137 from Rotterdam, 89 from London). PAI-1 concentrations in plasma were measured by ELISA, and the 4G/5G PAI-1 polymorphism was detected by PCR and hybridisation. Findings Concentrations of PAI-1 on admission correlated with presentation (sepsis or meningitis) and outcome. The median PAI-1 concentration in children who died was substantially higher than that in survivors (2448 [IQR 1115-3191] vs 370 [146-914] ng/mL; p<0.0001). Patients with the 4G/4G genotype had significantly higher PAI-1 concentrations than those with the 4G/5G or 5G/5G genotype (1051 [550-2440] vs 436 [198-1225] ng/mL; p=0.03), and had an increased risk of death (relative risk 2.0 [1.0-3.8] for the two cohorts combined, and 4.8 [1.8-13] for the London cohort). Interpretation A genetic predisposition to produce high concentrations of PAI-1 is associated with poor outcome of meningococcal sepsis. This finding suggests that impaired fibrinolysis is an important factor in the pathophysiology of meningococcal sepsis.	Erasmus Univ, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Sch Med, Dept Paediat, London, England; Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital; Imperial College London; University of London; University College London	Hermans, PWM (corresponding author), Erasmus Univ, Lab Paediat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hazelzet, Jan A/L-2888-2015; Hermans, Peter W.M./H-8042-2014; Hermans, Peter P.W.M./F-4655-2010; Hibberd, Martin L/D-5050-2009	Levin, Michael/0000-0003-2767-6919; Hibberd, Martin/0000-0001-8587-1849; Hazelzet, Jan/0000-0002-9414-5539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achtman M, 1995, MENINGOCOCCAL DIS, P159; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; DAY KC, 1990, BLOOD, V76, P1538; Derkx B, 1999, CLIN INFECT DIS, V28, P770, DOI 10.1086/515184; DRAPKIN MS, 1989, PEDIATR INFECT DIS J, V8, P399, DOI 10.1097/00006454-198906000-00015; Duncan A, 1997, LANCET, V350, P1565, DOI 10.1016/S0140-6736(05)64007-X; ENGEBRETSEN LF, 1986, THROMB RES, V42, P713, DOI 10.1016/0049-3848(86)90351-8; ESMON CT, 1991, THROMB HAEMOSTASIS, V66, P160; FOURRIER F, 1990, INTENS CARE MED, V16, P121, DOI 10.1007/BF01699858; GLADSON CL, 1989, BLOOD, V74, P173; Hazelzet JA, 1996, THROMB HAEMOSTASIS, V76, P932; HEYDERMAN RS, 1991, ARCH DIS CHILD, V66, P1296, DOI 10.1136/adc.66.11.1296; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; KUPPERMANN N, 1994, PEDIATR INFECT DIS J, V13, P867, DOI 10.1097/00006454-199410000-00004; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NADEL S, 1995, MENINGOCOCCAL DIS, P207; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POWARS DR, 1987, NEW ENGL J MED, V317, P571; Ryan MP, 1996, BIOCHEM J, V314, P1041, DOI 10.1042/bj3141041; Smith OP, 1997, LANCET, V350, P1590, DOI 10.1016/S0140-6736(97)06356-3; SPEER CP, 1987, J PEDIATR-US, V111, P667, DOI 10.1016/S0022-3476(87)80240-8; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; ZENZ W, 1995, PEDIATRICS, V96, P144	30	218	226	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					556	560		10.1016/S0140-6736(99)02220-5	http://dx.doi.org/10.1016/S0140-6736(99)02220-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470700				2022-12-24	WOS:000081991000013
J	Javedan, SP; Dickman, CA				Javedan, SP; Dickman, CA			Cause of adjacent-segment disease after spinal fusion	LANCET			English	Editorial Material							ANTERIOR; INSTRUMENTATION		Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA	Barrow Neurological Institute	Javedan, SP (corresponding author), Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ 85013 USA.							AOTA Y, 1995, J SPINAL DISORD, V8, P464, DOI 10.1097/00002517-199512000-00008; Cunningham BW, 1997, SPINE, V22, P2655, DOI 10.1097/00007632-199711150-00014; Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163; FRYMOYER J W, 1978, Spine, V3, P1, DOI 10.1097/00007632-197803000-00001; GOFFIN J, 1995, J SPINAL DISORD, V8, P500; Hilibrand AS, 1997, SPINE, V22, P1574, DOI 10.1097/00007632-199707150-00009; Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009; LEE CK, 1981, SPINE, V6, P118, DOI 10.1097/00007632-198103000-00002; LUNSFORD LD, 1980, J NEUROSURG, V53, P1, DOI 10.3171/jns.1980.53.1.0001; PENTA M, 1995, SPINE, V20, P743, DOI 10.1097/00007632-199503150-00018; ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223; Shono Y, 1998, SPINE, V23, P1550, DOI 10.1097/00007632-199807150-00009; WHITEHILL R, 1987, SPINE, V12, P959, DOI 10.1097/00007632-198712000-00001; Wimmer C, 1997, ACTA ORTHOP SCAND, V68, P269, DOI 10.3109/17453679708996699; Wu W, 1996, ACTA RADIOL, V37, P614; YANG SW, 1986, SPINE, V11, P937	16	36	41	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					530	531		10.1016/S0140-6736(99)00201-9	http://dx.doi.org/10.1016/S0140-6736(99)00201-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470693				2022-12-24	WOS:000081991000006
J	Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW				Di Sebastiano, P; Fink, T; di Mola, FF; Weihe, E; Innocenti, P; Friess, H; Buchler, MW			Neuroimmune appendicitis	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASOACTIVE INTESTINAL POLYPEPTIDE; GROWTH-ASSOCIATED PROTEIN-43; RECEPTOR-BINDING SITES; CHRONIC-PANCREATITIS; SUBSTANCE-P; ULCERATIVE-COLITIS; CROHNS-DISEASE; NERVE-FIBERS; INNERVATION	Background 15-25% of appendices removed from patients with suspected appendicitis appear normal on histological examination. The cause of pain in such patients is unknown. Since the content of neuropeptides seems to be altered in chronic inflammation, we investigated possible changes in peptidergic innervation for substance P (SP), vasoactive intestinal peptide (VIP), and growth-associated protein-43 (GAP-43). Methods Appendices classified as showing acute appendicitis, non-acute appendicitis (clinical signs of acute appendicitis, but histologically not inflamed), or normal were processed for SP, VIP, and GAP-43 immunocytochemistry. The density of SP immunostaining was assessed by digitised morphometry. Findings 31 appendix specimens were studied (16 acute, 15 non-acute). 16 specimens were used as controls. Expression of GAP-43 was increased in the non-acute appendices. We observed larger amounts of SP-immunoreactive and VIP-immunoreactive nerves in the mucosal layer of the appendix in patients with non-acute appendicitis than in controls and patients with acute appendicitis (mean % area SP-immunoreactive 0.0496 [SD 0.0113] non-acute, 0.0221 [0.0049] acute, 0.0229 [0.0068] controls). In addition, a close spatial relation between SP-immunoreactive and VIP-immunoreactive nerve fibres and lymphoid cells was detected in the outer zone of lymph follicles. Interpretation Neuroproliferation in the appendix, in association with an increase in neurotransmitters SP and VIP, may be involved in the pathophysiology of acute right abdominal pain in the absence of an acute inflammation of the appendix. Our data, together with increasing knowledge about the way in which the nervous system and immune cells interact, suggest that neuroimmune appendicitis is a distinct pathological entity.	Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland; Univ G DAnnunzio, Surg Unit, Chieti, Italy; Univ Mainz, Inst Legal Med, D-6500 Mainz, Germany; Univ Marburg, Dept Anat & Cell Biol, D-35032 Marburg, Germany	University of Bern; G d'Annunzio University of Chieti-Pescara; Johannes Gutenberg University of Mainz; Philipps University Marburg	Buchler, MW (corresponding author), Univ Bern, Dept Visceral & Transplantat Surg, Inselspital, CH-3010 Bern, Switzerland.		di Mola, Fabio Francesco/J-3082-2018; di sebastiano, pierluigi/I-9851-2018	di Mola, Fabio Francesco/0000-0001-9877-2946; di sebastiano, pierluigi/0000-0002-9386-8241				AUBOCK L, 1982, J PATHOL, V136, P217, DOI 10.1002/path.1711360305; BISHOP AE, 1980, GASTROENTEROLOGY, V79, P853; BUCHLER M, 1992, PANCREAS, V7, P183; CHONG MS, 1992, EUR J NEUROSCI, V4, P883, DOI 10.1111/j.1460-9568.1992.tb00115.x; DiSebastiano P, 1997, GASTROENTEROLOGY, V112, P1648, DOI 10.1016/S0016-5085(97)70047-7; DISEBASTIANO P, 1995, DIGEST DIS SCI, V4, P333; FINK T, 1994, NEUROSCIENCE, V63, P249, DOI 10.1016/0306-4522(94)90020-5; GOLDIN E, 1989, DIGEST DIS SCI, V34, P754, DOI 10.1007/BF01540348; HORSCH D, 1993, J COMP NEUROL, V335, P381, DOI 10.1002/cne.903350308; KUBOTA Y, 1992, GASTROENTEROLOGY, V102, P1242; LAU WY, 1986, SURG GYNECOL OBSTET, V162, P256; LEMBECK F, 1985, SUBSTANCE P METABOLI, P137; MAGGI CA, 1990, NEUROSCIENCE, V39, P833, DOI 10.1016/0306-4522(90)90266-7; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MANTYH PW, 1989, PEPTIDES, V10, P627, DOI 10.1016/0196-9781(89)90154-X; MANTYH PW, 1988, NEUROSCIENCE, V25, P817, DOI 10.1016/0306-4522(88)90038-3; MASSON P, 1921, PARIS, V173, P262; MEYERMARCOTTY W, 1986, LANGENBECK ARCH CHIR, V369, P187, DOI 10.1007/BF01274349; MIETTINEN P, 1995, ANN CHIR GYNAECOL FE, V84, P267; OLSEN BS, 1987, HISTOPATHOLOGY, V11, P843, DOI 10.1111/j.1365-2559.1987.tb01887.x; OMORAIN C, 1984, GUT, V25, P57, DOI 10.1136/gut.25.1.57; PERNOW B, 1985, SUBSTANCE P METABOLI, P187; SAMELSON SL, 1987, ARCH SURG-CHICAGO, V122, P691; SHAW PAV, 1990, HISTOPATHOLOGY, V17, P117, DOI 10.1111/j.1365-2559.1990.tb00681.x; SJOLUND K, 1983, GUT, V24, P724, DOI 10.1136/gut.24.8.724; STEAD RH, 1990, J PATHOL, V161, P209, DOI 10.1002/path.1711610307; Wang Y, 1996, LANCET, V347, P1076, DOI 10.1016/S0140-6736(96)90279-2; WEIHE E, 1988, AGENTS ACTIONS, V25, P255, DOI 10.1007/BF01965027; WEIHE E, 1991, ANN NY ACAD SCI, V632, P283, DOI 10.1111/j.1749-6632.1991.tb33116.x; 1987, LANCET, V1, P198	30	97	98	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					461	466		10.1016/S0140-6736(98)10463-4	http://dx.doi.org/10.1016/S0140-6736(98)10463-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465170				2022-12-24	WOS:000081896100010
J	Lyons, RA; Sibert, J; McCabe, M				Lyons, RA; Sibert, J; McCabe, M			Sharing data to prevent injuries	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales; Univ Wales Coll Med, Dept Child Hlth, Cardiff CF64 2XX, S Glam, Wales; Morriston Hosp, Swansea NHS Trust, Swansea SA6 6NL, W Glam, Wales	Cardiff University; Morriston Hospital	Lyons, RA (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				*DEP HLTH, 1998, OUR HLTH NAT CONTR H; Department of Health, 1992, HLTH NAT STRAT HLTH; Lyons R A, 1995, Inj Prev, V1, P173, DOI 10.1136/ip.1.3.173; *WELSH HLTH PLANN, 1992, PROT INV HLTH GAIN I; *WELSH HLTH PLANN, 1989, STRAT INT DIR NHS WA; Welsh Office, 1995, 1992 WELSH SOC SURV	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					372	373		10.1136/bmj.319.7206.372	http://dx.doi.org/10.1136/bmj.319.7206.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490321				2022-12-24	WOS:000082001700027
J	Lahn, BT; Page, DC				Lahn, BT; Page, DC			Four evolutionary strata on the human X chromosome	SCIENCE			English	Article							HUMAN Y-CHROMOSOME; MAMMALIAN SEX-CHROMOSOMES; KALLMANN SYNDROME GENE; PROTEIN-KINASE GENE; RNA-BINDING PROTEIN; PSEUDOAUTOSOMAL REGION; HUMAN GENOME; MARSUPIAL-X; INACTIVATION; HOMOLOG	Human sex chromosomes evolved from autosomes. Nineteen ancestral autosomal genes persist as differentiated homologs on the X and Y chromosomes. The ages of individual X-Y gene pairs (measured by nucleotide divergence) and the Locations of their X members on the X chromosome were found to be highly correlated. Age decreased in stepwise fashion from the distal long arm to the distal short arm in at least four "evolutionary strata." Human sex chromosome evolution was probably punctuated by at Least four events, each suppressing X-Y recombination in one stratum, without disturbing gene order on the X chromosome. The first event, which marked the beginnings of X-Y differentiation, occurred about 240 to 320 million years ago, shortly after divergence of the mammalian and avian lineages.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lahn, BT (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	dcpage@wi.mit.edu			NHGRI NIH HHS [HG00257] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000257] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AGULNIK AI, 1994, HUM MOL GENET, V3, P879, DOI 10.1093/hmg/3.6.879; BENGTSSON BO, 1987, ANN HUM GENET, V51, P57, DOI 10.1111/j.1469-1809.1987.tb00865.x; BLAIR HJ, 1994, GENOMICS, V19, P215, DOI 10.1006/geno.1994.1050; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Bull J. J., 1983, EVOLUTION SEX DETERM; CHANDRA HS, 1985, P NATL ACAD SCI USA, V82, P6947, DOI 10.1073/pnas.82.20.6947; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; DEVER TE, 1994, J BIOL CHEM, V269, P3212; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FOSTER JW, 1994, P NATL ACAD SCI USA, V91, P1927, DOI 10.1073/pnas.91.5.1927; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Fridolfsson AK, 1998, P NATL ACAD SCI USA, V95, P8147, DOI 10.1073/pnas.95.14.8147; GONDO H, 1987, J IMMUNOL, V139, P3840; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Jegalian K, 1998, NATURE, V394, P776, DOI 10.1038/29522; Jones MH, 1996, HUM MOL GENET, V5, P1695, DOI 10.1093/hmg/5.11.1695; KLINK A, 1995, HUM MOL GENET, V4, P869, DOI 10.1093/hmg/4.5.869; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Lahn BT, 1997, SCIENCE, V278, P675, DOI 10.1126/science.278.5338.675; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; Li W-H, 1997, MOL EVOLUTION; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; Mazeyrat S, 1999, NAT GENET, V22, P224, DOI 10.1038/10282; Meroni G, 1996, HUM MOL GENET, V5, P423, DOI 10.1093/hmg/5.4.423; Mitchell MJ, 1998, HUM MOL GENET, V7, P429, DOI 10.1093/hmg/7.3.429; MITCHELL MJ, 1992, NATURE, V359, P528, DOI 10.1038/359528a0; Mu J, 1997, J BIOL CHEM, V272, P27589, DOI 10.1074/jbc.272.44.27589; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PILBEAM D, 1984, SCI AM, V250, P84, DOI 10.1038/scientificamerican0384-84; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; Schiebel K, 1997, HUM MOL GENET, V6, P1985, DOI 10.1093/hmg/6.11.1985; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; SPENCER JA, 1991, GENOMICS, V9, P598, DOI 10.1016/0888-7543(91)90352-F; SPENCER JA, 1991, GENOMICS, V11, P339, DOI 10.1016/0888-7543(91)90141-Z; STEVANOVIC M, 1993, HUM MOL GENET, V2, P2013, DOI 10.1093/hmg/2.12.2013; SUN C, IN PRESS NATURE GENE; TODER R, 1995, HUM GENET, V95, P22; Toder R, 1998, MAMM GENOME, V9, P373, DOI 10.1007/s003359900772; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WATSON JM, 1992, GENOMICS, V14, P785, DOI 10.1016/S0888-7543(05)80187-9; WELLER PA, 1995, HUM MOL GENET, V4, P859, DOI 10.1093/hmg/4.5.859; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7	58	652	675	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					964	967		10.1126/science.286.5441.964	http://dx.doi.org/10.1126/science.286.5441.964			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542153				2022-12-24	WOS:000083368500048
J	Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J				Ridker, PM; Hennekens, CH; Buring, JE; Kundsin, R; Shih, J			Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women	ANNALS OF INTERNAL MEDICINE			English	Article						cardiovascular diseases; Chlamydia pneumoniae; Helicobacter pylori; simplexvirus; cytomegalovirus; antibodies, anti-adiotypic	CORONARY HEART-DISEASE; INFECTION; ATHEROSCLEROSIS; SEROPOSITIVITY; MORTALITY; EVENTS	Background: Results of cross-sectional and retrospective studies have suggested that chronic infection may be a risk factor for cardiovascular disease. However, prospective data evaluating the relation between baseline antibody titers against various plausible agents and risk for cardiovascular disease are sparse, particularly among women. Objective: To determine whether previous exposure to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, or cytomegalovirus is associated with increased risk for cardiovascular events. Design: Prospective, nested, case-control study. Setting: Women's Health Study. Participants: Apparently healthy postmenopausal women. Measurements: IgG antibody titers against C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus were measured in baseline blood samples obtained from 122 study participants who subsequently reported a first cardiovascular event (case-patients) and 244 participants matched for age and smoking status who did not report a cardiovascular event (controls) during 3 years of follow-up. Results: Little evidence was found of an association between risk for cardiovascular events and baseline IgG sero-positivity for antibodies against C. pneumoniae (rate ratio, 1.1 [95% CI, 0.7 to 1.8]), H. pylori (rate ratio, 0.90 ICI, 0.6 to 1.4]), herpes simplex virus (rate ratio, 1.2 [CI, 0.6 to 2.1]), and cytomegalovirus (rate ratio, 0.9 [CI, 0.6 to 1.5]). In addition, there was little evidence of an association between a participant's total number of infections and subsequent cardiovascular risk (P > 0.2). Conclusion: In apparently healthy postmenopausal women, little evidence was found that previous infection, as measured by IgG antibody titers to C. pneumoniae, H. pylori, herpes simplex virus, and cytomegalovirus, is associated with subsequent risk for cardiovascular disease.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Abbott Laboratories	Ridker, PM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	bhudson@mail.acponline.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davidson M, 1998, CIRCULATION, V98, P628, DOI 10.1161/01.CIR.98.7.628; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; Libby P, 1997, CIRCULATION, V96, P4095; Miettinen H, 1996, EUR HEART J, V17, P682; Ridker PM, 1999, JAMA-J AM MED ASSOC, V281, P1817, DOI 10.1001/jama.281.19.1817; Ridker PM, 1998, CIRCULATION, V97, P1671, DOI 10.1161/01.CIR.97.17.1671; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1998, CIRCULATION, V98, P2796, DOI 10.1161/01.CIR.98.25.2796; Ridker PM, 1999, CIRCULATION, V99, P1161, DOI 10.1161/01.CIR.99.9.1161; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P346; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; Strachan DP, 1999, BMJ-BRIT MED J, V318, P1035, DOI 10.1136/bmj.318.7190.1035; Strachan DP, 1998, CIRCULATION, V98, P1286, DOI 10.1161/01.CIR.98.13.1286; Strandberg TE, 1997, BRIT MED J, V314, P1317, DOI 10.1136/bmj.314.7090.1317; Wald NJ, 1997, BMJ-BRIT MED J, V315, P1199, DOI 10.1136/bmj.315.7117.1199; WANG SP, 1984, 1983 INT S MED VIR, P87; Whincup PH, 1996, HEART, V75, P568, DOI 10.1136/hrt.75.6.568; ZHU J, 1998, CIRCULATION, V98, P1	20	102	103	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					573	+		10.7326/0003-4819-131-8-199910190-00004	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523217				2022-12-24	WOS:000083196600003
J	Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS				Dietz, PH; Spitz, AM; Anda, RF; Williamson, DF; McMahon, PM; Santelli, JS; Nordenberg, DF; Felitti, VJ; Kendrick, JS			Unintended pregnancy among adult women exposed to abuse or household dysfunction during their childhood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SEXUAL ABUSE; ADOLESCENT PREGNANCY; PREVALENCE; ABORTION; RISK	Context Studies have identified childhood sexual and physical abuse as a risk factor for adolescent pregnancy but the relationship between exposure to childhood abuse and unintended pregnancy in adulthood has, to our knowledge, not been studied. Objective To assess whether unintended pregnancy during adulthood is associated with exposure to psychological, physical, or sexual abuse or household dysfunction during childhood. Design and Setting Analysis of data from the Adverse Childhood Experiences Study, a survey mailed to members of a large health maintenance organization who visited a clinic in San Diego, Calif, between August and November 1995 and January and March 1996, The survey had a 63.4% response rate among the target population for this study. Participants A total of 1193 women aged 20 to 50 years whose first pregnancy occurred at or after age 20 years. Main Outcome Measure Risk of unintended first pregnancy by type of abuse (psychological, physical, or sexual abuse; peer sexual assault) and type of household dysfunction (physical abuse of mother by her partner, substance abuse by a household member, mental illness of a household member). Results More than 45% of the women reported that their first pregnancy was unintended, and 65.8% reported exposure to 2 or more types of childhood abuse or household dysfunction. After adjustment for confounders (marital status at first pregnancy and age at first pregnancy), the strongest associations between childhood experiences and unintended first pregnancy included frequent psychological abuse (risk ratio [RR], 1.4; 95% confidence interval [CI], 1.2-1.6), frequent physical abuse of the mother by her partner (RR, 1.4, 95% CI, 1.1-1.7), and frequent physical abuse (RR, 1.5; 95% CI, 1.2-1.8). Women who experienced 4 or more types of abuse during their childhood were 1.5 times (95% CI, 1.2-1.8) more likely to have an unintended first pregnancy during adulthood than women who did not experience any abuse. Conclusions This study indicates that there may be a dose-response association between exposure to childhood abuse or household dysfunction and unintended first pregnancy in adulthood. Additional research is needed to fully understand the causal pathway of this association.	Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; So Calif Permanente Med Grp, Dept Prevent Med, San Diego, CA 92120 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Spitz, AM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, MS K-35,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	AMS2@cdc.gov	Santelli, John/AAG-3046-2021		ATSDR CDC HHS [TS-44-10/12] Funding Source: Medline	ATSDR CDC HHS		BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; Evins G, 1996, WOMEN HEALTH ISS, V6, P204, DOI 10.1016/1049-3867(95)00012-7; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; FINKELHOR D, 1990, CHILD ABUSE NEGLECT, V14, P19, DOI 10.1016/0145-2134(90)90077-7; Glander SS, 1998, OBSTET GYNECOL, V91, P1002, DOI 10.1016/S0029-7844(98)00089-1; Glei DA, 1999, FAM PLANN PERSPECT, V31, P73, DOI 10.2307/2991642; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; KOST K, 1995, FAM PLANN PERSPECT, V27, P11, DOI 10.2307/2135971; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MARSIGLIO W, 1988, J MARRIAGE FAM, V50, P1023, DOI 10.2307/352112; NAGY S, 1995, PEDIATRICS, V96, P944; *NAT CTR HLTH STAT, 1991, EXP ALC FAM US 1988, P205; PARKER B, 1994, OBSTET GYNECOL, V84, P323; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P53; STEVENSSIMON C, 1994, CHILD ABUSE NEGLECT, V18, P569, DOI 10.1016/0145-2134(94)90083-3; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; WYATT GE, 1985, CHILD ABUSE NEGLECT, V9, P507, DOI 10.1016/0145-2134(85)90060-2; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	19	199	201	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1359	1364		10.1001/jama.282.14.1359	http://dx.doi.org/10.1001/jama.282.14.1359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	243MB	10527183	Bronze			2022-12-24	WOS:000083000800031
J	Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK				Prasad, BVV; Hardy, ME; Dokland, T; Bella, J; Rossmann, MG; Estes, MK			X-ray crystallographic structure of the Norwalk virus capsid	SCIENCE			English	Article							TURNIP CRINKLE VIRUS; 3-DIMENSIONAL STRUCTURE; RESOLUTION; CALICIVIRUS; ORGANIZATION; PROTEINS; SEQUENCE; TU	Norwalk virus, a noncultivatable human calicivirus, is the major cause of epidemic gastroenteritis in humans. The first x-ray structure of a calicivirus capsid, which consists of 180 copies of a single protein, has been determined by phase extension from a Low-resolution electron microscopy structure. The capsid protein has a protruding (P) domain connected by a flexible hinge to a shell (S) domain that has a classical eight-stranded P-sandwich motif. The structure of the P domain is unlike that of any other viral protein with a subdomain exhibiting a fold similar to that of the second domain in the eukaryotic translation elongation factor-Tu. This subdomain, Located at the exterior of the capsid, has the Largest sequence variation among Norwalk-Like human calici-viruses and is Likely to contain the determinants of strain specificity and cell binding.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA; Purdue Univ, Dept Life Sci, W Lafayette, IN 47907 USA	Baylor College of Medicine; Baylor College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Prasad, BVV (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA.	vprasad@bcm.tmc.edu	Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Prasad, B.V.Venkataram/0000-0002-1172-2071				ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; Estes Mary K., 1995, P1009; Fankhauser RL, 1998, J INFECT DIS, V178, P1571, DOI 10.1086/314525; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; GLASS P, UNPUB; GREENBERG HB, 1981, J VIROL, V37, P994, DOI 10.1128/JVI.37.3.994-999.1981; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HARRISON SC, 1996, VIROLOGY, V1, P59; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hornung V, 1998, BIOCHEMISTRY-US, V37, P7260, DOI 10.1021/bi972969e; JIANG X, 1990, Science (Washington D C), V250, P1580; JIANG X, 1993, VIROLOGY, V195, P51, DOI 10.1006/viro.1993.1345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPIKIAN AZ, 1996, FIELDS VIROLOGY, V1, P783; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; LAMBDEN PR, 1993, SCIENCE, V259, P516, DOI 10.1126/science.8380940; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUO M, 1987, SCIENCE, V235, P182, DOI 10.1126/science.3026048; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; PALMENBERG AC, 1989, MOL ASPECTS PICORNAV, P211; PRASAD BVV, 1994, J VIROL, V68, P5117, DOI 10.1128/JVI.68.8.5117-5125.1994; PRASAD BVV, 1994, J MOL BIOL, V240, P256, DOI 10.1006/jmbi.1994.1439; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P341; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P225, DOI 10.1107/S0021889879012218; ROSSMANN MG, 1992, J APPL CRYSTALLOGR, V25, P166, DOI 10.1107/S002188989101141X; ROSSMANN MG, 1979, J APPL CRYSTALLOGR, V12, P570, DOI 10.1107/S0021889879013273; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; ROSSMMANN M G, 1983, Journal of Molecular Biology, V166, P37, DOI 10.1016/S0022-2836(83)80049-7; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; Thouvenin E, 1997, J MOL BIOL, V270, P238, DOI 10.1006/jmbi.1997.1095; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; WERY JP, 1994, J MOL BIOL, V235, P565, DOI 10.1006/jmbi.1994.1014; WHITE L, 1997, THESIS BAYLOR COLLEG; White LJ, 1996, J VIROL, V70, P6589, DOI 10.1128/JVI.70.10.6589-6597.1996; Wirblich C, 1996, J VIROL, V70, P7974, DOI 10.1128/JVI.70.11.7974-7983.1996; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992	40	666	716	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					287	290		10.1126/science.286.5438.287	http://dx.doi.org/10.1126/science.286.5438.287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514371				2022-12-24	WOS:000083024400043
J	Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS				Choi, G; Yi, H; Lee, J; Kwon, YK; Soh, MS; Shin, BC; Luka, Z; Hahn, TR; Song, PS			Phytochrome signalling is mediated through nucleoside diphosphate kinase 2	NATURE			English	Article							LIGHT CONTROL; TRANSDUCTION; ARABIDOPSIS; GENE; PURIFICATION; MUTANTS; PROTEIN	Because plants are sessile, they have developed intricate strategies to adapt to changing environmental variables, including light, Their growth and development, from germination to flowering, is critically influenced by Light, particularly at red (660 nm) and far-red (730 mn) wavelengths(1,2). Higher plants perceive red and far-red Light by means of specific light sensors called phytochromes(A-E)(3), However, very little is known about how light signals are transduced to elicit responses in plants. Here we report that nucleoside diphosphate kinase 2 (NDPK2) is an upstream component in the phytochrome signalling pathway in the plant Arabidopsis thaliana. In animal and human cells, NDPK acts as a tumour suppressor(4). We show that recombinant NDPK2 in Arabidopsis preferentially binds to the red-light-activated form of phytochrome in vitro and that this interaction increases the activity of recombinant NDPK2. Furthermore, a mutant lacking NDPK2 showed a partial defect in responses to both red and far-red light, including cotyledon opening and greening. These results indicate that NDPK2 is a positive signalling component of the phytochrome-mediated light-signal-transduction pathway in Arabidopsis.	Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea; Kyung Hee Univ, Dept Genet Engn, Suwon 449701, South Korea; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; Kwangju Inst & Technol, Dept Life Sci, Kwangju 500712, South Korea	Kyung Hee University; University of Nebraska System; University of Nebraska Lincoln; Gwangju Institute of Science & Technology (GIST)	Choi, G (corresponding author), Kumho Life & Environm Sci Lab, Kwangju 500712, South Korea.		Choi, Giltsu/C-1601-2011	SOH, MOON-SOO/0000-0002-4430-516X				Ahmad M, 1996, PLANT J, V10, P1103, DOI 10.1046/j.1365-313X.1996.10061103.x; Barnes SA, 1996, PLANT J, V10, P1155, DOI 10.1046/j.1365-313X.1996.10061155.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; DEAROLF CR, 1988, DEV BIOL, V13, P203; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; Hoecker U, 1998, PLANT CELL, V10, P19, DOI 10.1105/tpc.10.1.19; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Kwok SF, 1996, PLANT PHYSIOL, V110, P731, DOI 10.1104/pp.110.3.731; LAPKO VN, 1995, PHOTOCHEM PHOTOBIOL, V62, P194, DOI 10.1111/j.1751-1097.1995.tb05258.x; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Soh MS, 1998, PLANT J, V16, P411, DOI 10.1046/j.1365-313x.1998.00307.x; SOMMER D, 1994, BBA-MOL CELL RES, V1222, P464, DOI 10.1016/0167-4889(94)90055-8; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Wagner D, 1996, P NATL ACAD SCI USA, V93, P4011, DOI 10.1073/pnas.93.9.4011; Wagner D, 1997, PLANT CELL, V9, P731, DOI 10.1105/tpc.9.5.731; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Zimmermann S, 1999, J BIOL CHEM, V274, P17017, DOI 10.1074/jbc.274.24.17017	29	242	261	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					610	613		10.1038/44176	http://dx.doi.org/10.1038/44176			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524631				2022-12-24	WOS:000083054900056
J	Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H				Aaby, P; Gomes, J; Fernandes, M; Djana, Q; Lisse, I; Jensen, H			Nutritional status and mortality of refugee and resident children in a non-camp setting during conflict: follow up study in Guinea-Bissau	BRITISH MEDICAL JOURNAL			English	Article							MEASLES	Objective To study the effects on children of humanitarian aid agencies restricting help to refugee families (internally displaced people). Design Follow up study of 3 months. Setting Prabis peninsular outside Bissau, the capital of Guinea-Bissau, which has functioned as a refugee area for internally displaced people in the ongoing war, and the study area of the Bandim health project in Bissau. Participants 422 children aged 9-23 months in 30 clusters. Main outcome measures Mid upper arm circumference and survival in relation to residence status. Results During the refugee situation all children deteriorated nutritionally, and mortality was high (3.0% in a 6 week period). Rice consumption was higher in families resident in Prabis than in refugees from Bissau but there was no difference in food expenditure. Nutritional status, measured by mid-upper arm circumference, was not associated with rice consumption levels in the family and the decline in circumference was significantly worse for resident than for refugee children, the mid-upper arm circumference of refugee children increased faster than that of resident children, For resident children, mortality was 4.5 times higher (95% confidence interval 1.1 to 30.0) than for refugee children. Mortality for both resident and refugee children was 7.2 times higher (1.3 to 133.9) during the refugee's stay in Prabis compared with the period after the departure of the refugees. Conclusion In a non-camp setting, residents may be more malnourished and have higher mortality than refugees. Major improvements in nutritional status and a reduction in mortality occurred in resident and refugee children as soon as refugees returned home despite the fact that there was no improvement in food availability.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Bandim Hlth Project, Bissau, Guinea Bissau	Aarhus University; Statens Serum Institut	Aaby, P (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark.			Aaby, Peter/0000-0001-8331-1389				Aaby P, 1998, LANCET, V352, P1229, DOI 10.1016/S0140-6736(05)60575-2; AABY P, 1984, AM J EPIDEMIOL, V120, P49, DOI 10.1093/oxfordjournals.aje.a113874; AABY P, 1997, PROSPECTIVE COMMUNIT, P276; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; VANDAMME W, 1995, LANCET, V346, P360	6	40	41	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 2	1999	319	7214					878	881		10.1136/bmj.319.7214.878	http://dx.doi.org/10.1136/bmj.319.7214.878			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506040	Bronze, Green Published			2022-12-24	WOS:000082975600020
J	Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J				Rudenko, G; Nguyen, T; Chelliah, Y; Sudhof, TC; Deisenhofer, J			The structure of the ligand-binding domain of neurexin I beta: Regulation of LNS domain function by alternative splicing	CELL			English	Article							PROTEIN SECONDARY STRUCTURE; CELL-SURFACE PROTEINS; CRYSTAL-STRUCTURE; ALPHA-LATROTOXIN; A-CHAIN; AGRIN; RECEPTOR; LECTIN; DYSTROGLYCAN; LAMININ	Neurexins are expressed in hundreds of isoforms on the neuronal cell surface, where they may function as cell recognition molecules. Neurexins contain LNS domains, folding units found in many proteins like the G domain of laminin A, agrin, and slit. The crystal structure of neurexin I beta, a single LNS domain, reveals two seven-stranded beta sheets forming a jelly roll fold with unexpected structural similarity Po lectins. The LNS domains of neurexin and agrin undergo alternative splicing that modulates their affinity for protein ligands in a neuron-specific manner. These splice sites are localized within loops at one edge of the jelly roll, suggesting a distinct protein interaction surface in LNS domains that is regulated by alternative splicing.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	johann.deisenhofer@email.swmed.edu	Rudenko, Gabrielle (Gabby)/O-7938-2018	Rudenko, Gabrielle (Gabby)/0000-0002-7372-0530				Ay J, 1998, P NATL ACAD SCI USA, V95, P6613, DOI 10.1073/pnas.95.12.6613; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Campanelli JT, 1996, DEVELOPMENT, V122, P1663; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRENNELL S, 1994, STRUCTURE, V2, P535, DOI 10.1016/S0969-2126(00)00053-8; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; DIVNE C, 1994, SCIENCE, V265, P524, DOI 10.1126/science.8036495; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gesemann M, 1998, J BIOL CHEM, V273, P600, DOI 10.1074/jbc.273.1.600; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; Hata Y, 1996, J NEUROSCI, V16, P2488; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH DR, 1992, FASEB J, V6, P2477, DOI 10.1096/fasebj.6.7.1532944; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kleiman RJ, 1996, CELL, V85, P461, DOI 10.1016/S0092-8674(00)81245-3; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1992, JOINT CCP4 ESFEACBM; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lu GG, 1999, J APPL CRYSTALLOGR, V32, P365, DOI 10.1107/S0021889898015052; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Missler M, 1998, J NEUROSCI, V18, P3630; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Petrenko AG, 1996, J NEUROSCI, V16, P4360; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Ruegg MA, 1998, TRENDS NEUROSCI, V21, P22, DOI 10.1016/S0166-2236(97)01154-5; Sanes JR, 1998, J PHYSIOLOGY-PARIS, V92, P167, DOI 10.1016/S0928-4257(98)80004-1; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Song JY, 1999, P NATL ACAD SCI USA, V96, P1100, DOI 10.1073/pnas.96.3.1100; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301	60	113	116	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					93	101		10.1016/S0092-8674(00)80065-3	http://dx.doi.org/10.1016/S0092-8674(00)80065-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520997	Bronze			2022-12-24	WOS:000082981600011
J	Haase, SB; Reed, SI				Haase, SB; Reed, SI			Evidence that a free-running oscillator drives G1 events in the budding yeast cell cycle	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; POSITIVE FEEDBACK; KINASE; PHOSPHORYLATION; IDENTIFICATION; TRANSITION; GENES; G(1); DEGRADATION	In yeast and somatic cells, mechanisms ensure cell-cycle events are initiated only when preceding events have been completed(1). In contrast, interruption of specific cell-cycle processes in early embryonic cells of many organisms does not affect the timing of subsequent events(2), indicating that cell-cycle events are triggered by a free-running cell-cycle oscillator. Here we present evidence for an independent cell-cycle oscillator in the budding yeast Saccharomyces cerevisiae. We observed periodic activation of events normally restricted to the G1 phase of the cell cycle, in cells lacking mitotic cyclin-dependent kinase activities that are essential far cell-cycle progression, As in embryonic cells, G1 events cycled on schedule, in the absence of S phase or mitosis, with a period similar to the cell-cycle time of wild-type cells. Oscillations of similar periodicity were observed in cells responding to mating pheromone in the absence of G1 cyclin (Cln)- and mitotic cyclin (Clb)-associated kinase activity, indicating that the oscillator may function independently of cyclin-dependent kinase dynamics. We also show that Clb-associated kinase activity is essential for ensuring dependencies by preventing the initiation of new G1 events when cell-cycle progression is delayed.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 94303 USA	Scripps Research Institute	Reed, SI (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 94303 USA.	sreed@scripps.edu		Haase, Steve/0000-0001-8127-8992				ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CHENEVERT J, 1994, GENETICS, V136, P1287; COLLART MA, 1993, CURRENT PROTOCOLS MO, V2; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; GEHRUNG S, 1990, J CELL BIOL, V111, P1451, DOI 10.1083/jcb.111.4.1451; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; Ngo LG, 1997, EUR J BIOCHEM, V245, P182, DOI 10.1111/j.1432-1033.1997.00182.x; NOVAK B, 1986, J CELL SCI, V86, P191; REED S, 1992, COLD SPRING HARB SYM, V56, P61; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; WHITAKER M, 1990, DEVELOPMENT, V108, P525; XU HX, 1992, MOL CELL BIOL, V12, P5249, DOI 10.1128/MCB.12.11.5249	30	91	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					394	397		10.1038/43930	http://dx.doi.org/10.1038/43930			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517640	Bronze			2022-12-24	WOS:000082822600056
J	Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA				Cappuccio, FP; Meilahn, E; Zmuda, JM; Cauley, JA		Study Osteoporotic Fractures Res Grp	High blood pressure and bone-mineral loss In elderly white women: a prospective study	LANCET			English	Article							ESSENTIAL-HYPERTENSION; CALCIUM-METABOLISM; URINARY CALCIUM; HIP FRACTURE; OSTEOPOROTIC FRACTURES; YOUNG-PEOPLE; THIAZIDE; DENSITY; POPULATION; PREVENTION	Background High blood pressure is associated with abnormalities in calcium metabolism. Sustained calcium loss may lead to increased bone-mineral loss in people with high blood pressure. We investigated the prospective association between blood pressure and bone-mineral loss over time in elderly white women. Methods We studied 3676 women who were initially assessed in 1988-90 (mean age 73 years [SD 4, range 66-91 years]; mean bodyweight 65.3 kg [11.5]; blood pressure 137/75 mm Hg [17/9]) who were not on thiazide diuretics. Mean follow-up was 3.5 years. Anthropometry, blood pressure, and bone-mineral density at the femoral neck were measured at baseline and bone densitometry was repeated after 3.5 years by dual-energy X-ray absorptiometry. Findings After adjustment for age, initial hone-mineral density, weight and weight change, smoking, and regular use of hormone-replacement therapy, the rate of bone loss at the femoral neck increased with blood pressure at baseline. In the quartiles of systolic blood pressure, yearly bone losses increased from 2.26 mg/cm(2) (95% CI 1.48-3.04) in the first quartile to 3.79 mg/cm(2) in the fourth quartile (3.13-4.45; test for heterogeneity, p=0.03; test for linear trend, p=0.01), equivalent to yearly changes of 0.34% (0.20-0.46) and 0.59% (0.49-0.69; test for heterogeneity, p=0.02; test for linear trend, p=0.005). There was no significant interaction with age. The exclusion of women on antihypertensive drugs did not alter the results, For diastolic blood pressure, there was an association with bone loss in women younger than 75 years. Interpretation Higher blood pressure in elderly white women is associated with increased bone loss at the femoral neck. This association may reflect greater calcium losses associated with high blood pressure, which may contribute to the risk of hip fractures.	St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Epidemiol Unit, London, England; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA	St Georges University London; University of London; London School of Hygiene & Tropical Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Cappuccio, FP (corresponding author), St George Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England.	f.cappuccio@sghms.ac.uk	Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009; Cauley, Jane A/N-4836-2015	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Cauley, Jane A/0000-0003-0752-4408				BRICKMAN AS, 1990, HYPERTENSION, V16, P515, DOI 10.1161/01.HYP.16.5.515; BROWNER WS, 1993, STROKE, V24, P940, DOI 10.1161/01.STR.24.7.940; BROWNER WS, 1991, LANCET, V338, P355, DOI 10.1016/0140-6736(91)90489-C; Cappuccio FP, 1997, LANCET, V350, P850, DOI 10.1016/S0140-6736(97)02264-2; CAULEY JA, 1993, ANN INTERN MED, V118, P666, DOI 10.7326/0003-4819-118-9-199305010-00002; CIRILLO M, 1989, AM J HYPERTENS, V2, P741, DOI 10.1093/ajh/2.10.741; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; *DEP DRUGS DIV DRU, 1991, DRUG EV ANN 1991, P683; DEVINE A, 1995, AM J CLIN NUTR, V62, P740, DOI 10.1093/ajcn/62.4.740; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; Ensrud KE, 1997, ARCH INTERN MED, V157, P857, DOI 10.1001/archinte.157.8.857; ENSRUD KE, 1995, J BONE MINER RES, V10, P1778; GADALLAH M, 1991, AM J HYPERTENS, V4, P404, DOI 10.1093/ajh/4.5.404; Geleijnse JM, 1996, J HYPERTENS, V14, P1491, DOI 10.1097/00004872-199612000-00018; GROBBEE DE, 1988, BRIT MED J, V296, P814, DOI 10.1136/bmj.296.6625.814; HVARFNER A, 1987, J HYPERTENS, V5, P451; IZAWA Y, 1985, CALCIFIED TISSUE INT, V37, P605, DOI 10.1007/BF02554916; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MACGREGOR GA, 1993, J HYPERTENS, V11, P781, DOI 10.1097/00004872-199308000-00003; MATKOVIC V, 1995, AM J CLIN NUTR, V62, P417, DOI 10.1093/ajcn/62.2.417; MCCARRON DA, 1980, HYPERTENSION, V2, P162, DOI 10.1161/01.HYP.2.2.162; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; STEIGER P, 1992, J BONE MINER RES, V7, P625; STRAZZULLO P, 1983, CLIN SCI, V65, P137, DOI 10.1042/cs0650137; STRAZZULLO P, 1987, J HUM HYPERTENS, V1, P155; Strazzullo P., 1991, NUTR METABOLISM CARD, V1, P98; Tsuda K, 1998, J HYPERTENS, V16, pS209; UMEMURA S, 1986, J HYPERTENS, V4, P19, DOI 10.1097/00004872-198602000-00004; VANHOOFT IMS, 1993, HYPERTENSION, V21, P267, DOI 10.1161/01.HYP.21.3.267; WASNICH R, 1990, BRIT MED J, V301, P1303, DOI 10.1136/bmj.301.6764.1303; WASNICH RD, 1983, NEW ENGL J MED, V309, P344, DOI 10.1056/NEJM198308113090605; WONDERRECKE P, 1999, AM J MED, V106, P273; YAMAKAWA H, 1992, HYPERTENSION, V19, P528, DOI 10.1161/01.HYP.19.6.528; YOUNG EW, 1992, J LAB CLIN MED, V120, P624	35	267	287	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					971	975		10.1016/S0140-6736(99)01437-3	http://dx.doi.org/10.1016/S0140-6736(99)01437-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501357				2022-12-24	WOS:000082596000008
J	Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H				Roose, J; Huls, G; van Beest, M; Moerer, P; van der Horn, K; Goldschmeding, R; Logtenberg, T; Clevers, H			Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1	SCIENCE			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; COLORECTAL-CANCER; AXIS FORMATION; FUNCTIONAL INTERACTION; XENOPUS EMBRYOS; TRANSCRIPTION; GENE; ASSOCIATION; ACTIVATION	Mutations in APC or beta-catenin inappropriately activate the transcription factor Tcf4, thereby transforming intestinal epithelial cells. Here it is shown that one of the target genes of Tcf4 in epithelial cells is Tcf1, The most abundant Tcf1 isoforms Lack a beta-catenin interaction domain. Tcf1(-/-) mice develop adenomas in the gut and mammary glands. Introduction of a mutant APC allele into these mice substantially increases the number of these adenomas. Tcf1 may act as a feedback repressor of beta-catenin-Tcf4 target genes and thus may cooperate with APC to suppress malignant transformation of epithelial cells.	Univ Utrecht, Med Ctr, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University	Clevers, H (corresponding author), Univ Utrecht, Med Ctr, Dept Immunol, POB 85500, NL-3508 GA Utrecht, Netherlands.	h.clevers@lab.azu.nl	Goldschmeding, Roel/I-1723-2014					Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAKRER N, 1999, AM J PATHOL, V154, P29; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CASTROP J, 1995, BLOOD, V86, P3050, DOI 10.1182/blood.V86.8.3050.bloodjournal8683050; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JEN J, 1994, CANCER RES, V54, P5523; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mayer K, 1997, INT J CANCER, V72, P625, DOI 10.1002/(SICI)1097-0215(19970807)72:4<625::AID-IJC13>3.0.CO;2-A; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schilham MW, 1998, J IMMUNOL, V161, P3984; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANBEEST M, UNPUB; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	50	392	417	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1923	1926		10.1126/science.285.5435.1923	http://dx.doi.org/10.1126/science.285.5435.1923			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489374				2022-12-24	WOS:000082638300054
J	Henney, JE				Henney, JE			Approval of TMJ prosthesis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-24	WOS:000082335900007
J	Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM				Chen, HW; Lin, RJ; Xie, W; Wilpitz, D; Evans, RM			Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase	CELL			English	Article							BREAST-CANCER-CELLS; RECEPTOR COACTIVATOR COMPLEX; NUCLEAR-RECEPTOR; ESTROGEN-RECEPTOR; RETINOIC ACID; IN-VIVO; TRANSCRIPTIONAL ACTIVATION; ACETYLTRANSFERASE ACTIVITY; CHROMATIN STRUCTURE; LEUKEMIA-CELLS	Nuclear receptors have been postulated to regulate gene expression via their association with histone acetylase (HAT) or deacetylase complexes. We report that hormone induces dramatic hyperacetylation at endogenous target genes through the HAT activity of p300/CBP. Unexpectedly, this hyperacetylation is transient and coincides with attenuation of hormone-induced gene activation. In exploring the underlying mechanism, we found that the acetylase ACTR can be acetylated by p300/CBP. The acetylation neutralizes the positive charges of two lysine residues adjacent to the core LXXLL motif and disrupts the association of HAT coactivator complexes with promoter-bound estrogen receptors. These results provide strong in vivo evidence that histone acetylation plays a key role in hormone-induced gene activation and define cofactor acetylation as a novel regulatory mechanism in hormonal signaling.	Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Mol Pathol, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Xie, Wen/M-1768-2016; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880	NIGMS NIH HHS [GM26444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1988, NUCLEIC ACIDS RES, V16, P1903, DOI 10.1093/nar/16.5.1903; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Hyder SM, 1997, CANCER RES, V57, P2547; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; JIANG HP, 1994, ONCOGENE, V9, P3397; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Pratt MAC, 1996, J BIOL CHEM, V271, P20346, DOI 10.1074/jbc.271.34.20346; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SASAKI K, 1984, J BIOL CHEM, V259, P5242; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WADE PA, 1997, CURR BIOL, V7, P82; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027	63	534	548	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					675	686		10.1016/S0092-8674(00)80054-9	http://dx.doi.org/10.1016/S0092-8674(00)80054-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490106	Bronze			2022-12-24	WOS:000082433500014
J	Redelmeier, DA; Tibshirani, RJ				Redelmeier, DA; Tibshirani, RJ			Why cars in the next lane seem to go faster	NATURE			English	Article							PERCEPTION		Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Stanford, CA 94305 USA	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Stanford University; Stanford University	Redelmeier, DA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, G-151,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Angrilli A, 1997, PERCEPT PSYCHOPHYS, V59, P972, DOI 10.3758/BF03205512; Feller W., 1966, INTRO PROBABILITY TH, VII; GILOVICH T, 1985, COGNITIVE PSYCHOL, V17, P295, DOI 10.1016/0010-0285(85)90010-6; Helbing D, 1998, NATURE, V396, P738, DOI 10.1038/25499; LARSON RC, 1987, OPER RES, V35, P895, DOI 10.1287/opre.35.6.895; Snowden RJ, 1998, NATURE, V392, P450, DOI 10.1038/33049; TVERSKY A, 1991, Q J ECON, V106, P1039, DOI 10.2307/2937956; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; *US BUR CENS, 1997, STAT ABSTR US 1996; Walton D, 1998, ACCIDENT ANAL PREV, V30, P821, DOI 10.1016/S0001-4575(98)00035-9	10	12	12	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					35	35		10.1038/43360	http://dx.doi.org/10.1038/43360			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	232MK	10485702	Bronze			2022-12-24	WOS:000082374400028
J	Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S				Funa, N; Ohnishi, Y; Fujii, I; Shibuya, M; Ebizuka, Y; Horinouchi, S			A new pathway for polyketide synthesis in microorganisms	NATURE			English	Article							STREPTOMYCES-GRISEUS; CHALCONE SYNTHASE; GENE; BIOSYNTHESIS; ANTIBIOTICS; VANCOMYCIN; SEQUENCE; SITE	Chalcone synthases, which biosynthesize chalcones (the starting materials for many flavonoids(1,2)), have been believed to be specific to plants. However, the rppA gene from the Gram-positive, soil-living filamentous bacterium Streptomyces griseus encodes a 372-amino-acid protein that shows significant similarity to chalcone synthases'. Several rppA-like genes are known, but their functions and catalytic properties have not been described. Here we show that a homodimer of RppA catalyses polyketide synthesis: it selects malonyl-coenzyme-A as the starter, carries out four successive extensions and releases the resulting pentaketide to cyclize to 1,3,6,8-tetrahydroxynaphthalene (THN). Site-directed mutagenesis revealed that, as in other chalcone synthases(4,5), a cysteine residue is essential for enzyme activity. Disruption of the chromosomal rppA gene in S. griseus abolished melanin production in hyphae, resulting in 'albino' mycelium. THN was readily oxidized to form 2,5,7-trihydroxy-1,4-naphthoquinone(flaviolin), which then randomly polymerized to form various coloured compounds. THN formed by RppA appears to be an intermediate in the biosynthetic pathways for not only melanins but also various secondary metabolites containing a naphthoquinone ring. Therefore, RppA is a chalcone-synthase-related synthase that synthesizes polyketides and is found in the Streptomyces and other bacteria.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.			Ohnishi, Yasuo/0000-0001-7633-9236				Ando N, 1997, MICROBIOL-UK, V143, P2715, DOI 10.1099/00221287-143-8-2715; Bangera MG, 1996, MOL PLANT MICROBE IN, V9, P83, DOI 10.1094/MPMI-9-0083; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BELL AA, 1986, ANNU REV PHYTOPATHOL, V24, P411, DOI 10.1146/annurev.py.24.090186.002211; BLANCO G, 1993, GENE, V130, P107, DOI 10.1016/0378-1119(93)90352-4; DIMROTH P, 1976, EUR J BIOCHEM, V68, P591, DOI 10.1111/j.1432-1033.1976.tb10847.x; Eckermann S, 1998, NATURE, V396, P387, DOI 10.1038/24652; Fujii I, 1999, BIOSCI BIOTECH BIOCH, V63, P1445, DOI 10.1271/bbb.63.1445; FUNAYAMA S, 1990, J ORG CHEM, V55, P1132, DOI 10.1021/jo00291a003; HAMMOND SJ, 1982, J CHEM SOC CHEM COMM, P344, DOI 10.1039/c39820000344; Hopwood D. A., 1985, GENETIC MANIPULATION; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; LANZ T, 1991, J BIOL CHEM, V266, P9971; Maniatis T., 1982, MOL CLONING LAB MANU; MAYORGA ME, 1992, MOL GEN GENET, V235, P205, DOI 10.1007/BF00279362; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; PATHIRANA C, 1992, TETRAHEDRON LETT, V33, P7663, DOI 10.1016/0040-4039(93)88010-G; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Schroder J., 1999, COMPREHENSIVE NATURA, V1, P749, DOI DOI 10.1016/b978-0-08-091283-7.00029-1; SHIN-YA K, 1990, Tetrahedron Letters, V31, P6025, DOI 10.1016/S0040-4039(00)98019-5; SHIOMI K, 1986, J ANTIBIOT, V39, P494, DOI 10.7164/antibiotics.39.494; TAKANO Y, 1995, MOL GEN GENET, V249, P162, DOI 10.1007/BF00290362; TROPF S, 1995, J BIOL CHEM, V270, P7922, DOI 10.1074/jbc.270.14.7922; UEDA K, 1995, J ANTIBIOT, V48, P638, DOI 10.7164/antibiotics.48.638; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Yu TW, 1998, J AM CHEM SOC, V120, P7749, DOI 10.1021/ja9803658	28	230	250	6	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					897	899		10.1038/23748	http://dx.doi.org/10.1038/23748			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476972				2022-12-24	WOS:000082233200052
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Folding to green	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Peters, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1229	1229		10.1126/science.285.5431.1229	http://dx.doi.org/10.1126/science.285.5431.1229			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10484733				2022-12-24	WOS:000082130200032
J	Kim, KK; Yokota, H; Kim, SH				Kim, KK; Yokota, H; Kim, SH			Four-helical-bundle structure of the cytoplasmic domain of a serine chemotaxis receptor	NATURE			English	Article							DISULFIDE CROSS-LINKING; LIGAND-BINDING DOMAIN; ASPARTATE RECEPTOR; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; ALPHA-HELIX; CHEMORECEPTOR; MODEL; DIMER; MUTAGENESIS	The bacterial chemotaxis receptors are transmembrane receptors with a simple signalling pathway which has elements relevant to the general understanding of signal recognition and transduction across membranes, how signals are relayed between molecules in a pathway, and how adaptation to a persistent signal is achieved(1). In contrast to many mammalian receptors which signal by oligomerizing upon ligand binding(2), the chemotaxis receptors are dimeric even in the absence of their ligands, and their signalling does not depend on a monomer-dimer equilibrium(3). Bacterial chemotaxis receptors are composed of a ligand-binding domain, a transmembrane domain consisting of two helices TM1 and TM2, and a cytoplasmic domain. All known bacterial chemotaxis receptors have a highly conserved cytoplasmic domain, which unites signals from different ligand domains into a single signalling pathway to flagella motors. Here we report the crystal structure of the cytoplasmic domain of a serine chemotaxis receptor of Escherichia coli, which reveals a 200 Angstrom-long coiled-coil of two antiparallel helices connected by a 'U-turn'. Two of these domains form a long, supercoiled, four-helical bundle in the cytoplasmic portion of the receptor.	Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Phys Biosci Div, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kim, SH (corresponding author), Univ Calif Berkeley, Melvin Calvin Lab 220, Berkeley, CA 94720 USA.	shkim@LBL.gov						AMES P, 1988, COLD SPRING HARB SYM, V53, P59, DOI 10.1101/SQB.1988.053.01.010; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; Ames P, 1996, MOL MICROBIOL, V19, P737, DOI 10.1046/j.1365-2958.1996.408930.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bass RB, 1998, J BIOL CHEM, V273, P25006, DOI 10.1074/jbc.273.39.25006; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BRUNGER AT, 1993, X PLOR VERSION 3 1; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1994, PROTEIN SCI, V3, P159; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MADDOCK JR, 1993, SCIENCE, V259, P1717; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	30	381	386	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					787	792		10.1038/23512	http://dx.doi.org/10.1038/23512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466731				2022-12-24	WOS:000082131100056
J	Mole, SE				Mole, SE			Batten's disease: eight genes and still counting?	LANCET			English	Editorial Material							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; MUTATIONS		UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England	University of London; University College London; UCL Medical School	Mole, SE (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat, London WC1E 6JJ, England.		Mole, Sara/C-2024-2008	Mole, Sara/0000-0003-4385-4957				BERKOVIC SF, 1988, BRAIN, V111, P27, DOI 10.1093/brain/111.1.27; CAMP LA, 1993, J BIOL CHEM, V268, P22566; Das AK, 1998, J CLIN INVEST, V102, P361, DOI 10.1172/JCI3112; Goebel H, 1999, NEURONAL CEROID LIPO; Greene NDE, 1999, MOL GENET METAB, V66, P309, DOI 10.1006/mgme.1999.2828; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; LU JY, 1996, P NATL ACAD SCI USA, V93, P1046; Mitchison HM, 1998, HUM MOL GENET, V7, P291, DOI 10.1093/hmg/7.2.291; MOLE SE, IN PRESS HUM MUTAT; Pearce DA, 1999, NAT GENET, V22, P55, DOI 10.1038/8861; Ranta S, 1997, GENOME RES, V7, P887, DOI 10.1101/gr.7.9.887; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Savukoski M, 1998, NAT GENET, V19, P286, DOI 10.1038/975; Sharp JD, 1997, HUM MOL GENET, V6, P591, DOI 10.1093/hmg/6.4.591; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Wheeler RB, 1999, MOL GENET METAB, V66, P337, DOI 10.1006/mgme.1999.2804	19	45	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					443	445		10.1016/S0140-6736(99)00173-7	http://dx.doi.org/10.1016/S0140-6736(99)00173-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465165				2022-12-24	WOS:000081896100005
J	Turner, S				Turner, S			Place of pharmacotherapy in post-traumatic stress disorder	LANCET			English	Editorial Material									Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England; UCL, London W1P 1LB, England	University of London; University College London; University of London; University College London	Turner, S (corresponding author), Camden & Islington Community Trust, Traumat Stress Clin, London W1P 1LB, England.							American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; Connor KM, 1999, BRIT J PSYCHIAT, V175, P17, DOI 10.1192/bjp.175.1.17; Foa EB, 1999, J CLIN PSYCHIAT S16, V60; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Shapiro F., 2018, EYE MOVEMENT DESENSI, V2; Van Etten ML, 1998, CLIN PSYCHOL PSYCHOT, V5, P126, DOI 10.1002/(SICI)1099-0879(199809)5:3<126::AID-CPP153>3.3.CO;2-8; Yehuda R, 1998, REV PSYCHIAT SER, V17, P97	7	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1404	1405		10.1016/S0140-6736(99)00245-7	http://dx.doi.org/10.1016/S0140-6736(99)00245-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	248LY	10543663				2022-12-24	WOS:000083277400006
J	Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG				Gould, E; Reeves, AJ; Graziano, MSA; Gross, CG			Neurogenesis in the neocortex of adult primates	SCIENCE			English	Article							HUMAN CEREBRAL-CORTEX; DENTATE GYRUS; PREFRONTAL CORTEX; HIPPOCAMPAL-NEURONS; RHESUS-MONKEY; CELL-CYCLE; YOUNG NEURONS; BRAIN; RAT; REPLACEMENT	In primates, prefrontal, inferior temporal, and posterior parietal cortex are important for cognitive function. It is shown that in adult macaques, new neurons are added to these three neocortical association areas, but not to a primary sensory area (striate cortex). The new neurons appeared to originate in the subventricular zone and to migrate through the white matter to the neocortex, where they extended axons, These new neurons, which are continually added in adulthood, may play a role in the functions of association neocortex.	Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA	Princeton University	Gould, E (corresponding author), Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA.				NATIONAL EYE INSTITUTE [R01EY011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH052423] Funding Source: NIH RePORTER; NEI NIH HHS [EY11347-29] Funding Source: Medline; NIMH NIH HHS [MH52423-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALTMAN J, 1963, ANAT REC, V145, P573, DOI 10.1002/ar.1091450409; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; ALTMAN J, 1967, NEUROSCIENCES STUDY, P723; ALVAREZBUYLLA A, 1988, NATURE, V335, P353, DOI 10.1038/335353a0; ALVAREZBUYLLA A, 1995, STEM CELLS, V13, P263, DOI 10.1002/stem.5530130307; ALVAREZBUYLLA A, 1992, J NEUROBIOL, V23, P396, DOI 10.1002/neu.480230406; ANDERSEN RA, 1985, J COMP NEUROL, V232, P443, DOI 10.1002/cne.902320403; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARBAS H, 1989, J COMP NEUROL, V286, P353, DOI 10.1002/cne.902860306; BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; Barnea A, 1996, P NATL ACAD SCI USA, V93, P714, DOI 10.1073/pnas.93.2.714; BARNEA A, 1994, P NATL ACAD SCI USA, V91, P11217, DOI 10.1073/pnas.91.23.11217; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BOURGEOIS JP, 1994, CEREB CORTEX, V4, P78, DOI 10.1093/cercor/4.1.78; Cajal SRY., 1995, HISTOLOGY NERVOUS SY, V1; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; COLOMBEL M, 1992, CANCER RES, V52, P4313; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feinendegen LE, 1967, TRITIUM LABELED MOL; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, TRENDS COGN SCI, V3, P186, DOI 10.1016/S1364-6613(99)01310-8; GOULD E, 1992, J NEUROSCI, V12, P3642; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; GOULD E, UNPUB; Gross C. G., 1973, HDB SENSORY PHYSIOLO, P451; Honig LS, 1996, CEREB CORTEX, V6, P794, DOI 10.1093/cercor/6.6.794; KAPLAN MS, 1981, J COMP NEUROL, V195, P323, DOI 10.1002/cne.901950211; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kolb B, 1998, BEHAV BRAIN RES, V91, P127, DOI 10.1016/S0166-4328(97)00112-5; LOPEZGARCIA C, 1988, BRAIN RES, V471, P167; Magiakou MA, 1996, CLIN ENDOCRINOL, V44, P419, DOI 10.1046/j.1365-2265.1996.683505.x; Martin RF, 1996, NEUROIMAGE, V4, P119, DOI 10.1006/nimg.1996.0036; Melchitzky DS, 1998, J COMP NEUROL, V390, P211, DOI 10.1002/(SICI)1096-9861(19980112)390:2<211::AID-CNE4>3.0.CO;2-4; Miller EK, 1996, J NEUROSCI, V16, P5154; MINTURN JE, 1995, J COMP NEUROL, V355, P369, DOI 10.1002/cne.903550304; Nauta WJ, 1970, NEUROSCIENCES, P7; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; NOTTEBOHM F, 1989, NEURAL CONTROL REPRO, P583; NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; Pincus D W, 1997, Clin Neurosurg, V44, P17; RAKIC P, 1985, ANN NY ACAD SCI, V457, P193, DOI 10.1111/j.1749-6632.1985.tb20806.x; Rakic P, 1998, NAT NEUROSCI, V1, P645, DOI 10.1038/3643; RAKIC P, 1985, SCIENCE, V227, P1054, DOI 10.1126/science.3975601; RAKIC P, 1978, POSTGRAD MED J, V54, P25; Rosselli-Austin L, 1979, J Dev Physiol, V1, P295; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; SCHWARTZ ML, 1984, J COMP NEUROL, V226, P403, DOI 10.1002/cne.902260309; Shankle WR, 1998, J THEOR BIOL, V191, P115, DOI 10.1006/jtbi.1997.0570; Sugita N, 1918, J COMP NEUROL, V29, P61, DOI 10.1002/cne.900290202; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	60	933	1011	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					548	552		10.1126/science.286.5439.548	http://dx.doi.org/10.1126/science.286.5439.548			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521353				2022-12-24	WOS:000083121200065
J	Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK				Luecke, H; Schobert, B; Richter, HT; Cartailler, JP; Lanyi, JK			Structural changes in bacteriorhodopsin during ion transport at 2 Angstrom resolution	SCIENCE			English	Article							ORIENTED PURPLE MEMBRANES; LIPIDIC CUBIC PHASES; RETINAL SCHIFF-BASE; LOCAL-ACCESS MODEL; X-RAY-DIFFRACTION; REPROTONATION SWITCH; PROTON-TRANSFER; N-INTERMEDIATE; CHROMOPHORE ISOMERIZATION; DIFFERENCE SPECTROSCOPY	Crystal structures of the Asp(96) to Asn mutant of the light-driven proton pump bacteriorhodopsin and its M photointermediate produced by illumination at ambient temperature have been determined to 1.8 and 2.0 angstroms resolution, respectively. The trapped photoproduct corresponds to the Late M state in the transport cycle-that is, after proton transfer to Asp(85) and release of a proton to the extracellular membrane surface, but before reprotonation of the deprotonated retinal Schiff base. Its density map describes displacements of side chains near the retinal induced by its photoisomerization to 13-cis, 15-anti and an extensive rearrangement of the three-dimensional network of hydrogen-bonded residues and bound water that accounts for the changed pK(a) values (where K-a is the acid constant) of the Schiff base and Asp(85). The structural changes detected suggest the means for conserving energy at the active site and for ensuring the directionality of proton translocation.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, UCI Program Macromol Struct, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Luecke, H (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Cartailler, Jean-Philippe/D-2543-2010; Lanyi, Janos/C-3808-2011; Luecke, Hartmut/F-4712-2012	Cartailler, Jean-Philippe/0000-0002-0312-2391; Luecke, Hartmut/0000-0002-4938-0775	NIGMS NIH HHS [R01-GM59970, R01-GM29498, R01-GM56445] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056445, R01GM029498, R01GM059970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Borucki B, 1998, J PHYS CHEM B, V102, P3821, DOI 10.1021/jp980433c; BRAIMAN MS, 1991, P NATL ACAD SCI USA, V88, P2388, DOI 10.1073/pnas.88.6.2388; Braiman MS, 1996, BIOPHYS J, V70, P939, DOI 10.1016/S0006-3495(96)79637-6; Brown LS, 1996, P NATL ACAD SCI USA, V93, P1731, DOI 10.1073/pnas.93.4.1731; Brown LS, 1998, BIOPHYS J, V75, P1455, DOI 10.1016/S0006-3495(98)74064-0; Brown LS, 1998, BIOCHEMISTRY-US, V37, P3982, DOI 10.1021/bi9728396; Brown LS, 1995, BIOPHYS J, V69, P2103, DOI 10.1016/S0006-3495(95)80081-0; CAO Y, 1991, BIOCHEMISTRY-US, V30, P10972, DOI 10.1021/bi00109a023; Dickopf S, 1997, BIOPHYS J, V73, P3171, DOI 10.1016/S0006-3495(97)78343-7; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P9889, DOI 10.1021/bi980934o; EARNEST TN, 1986, BIOCHEMISTRY-US, V25, P7793, DOI 10.1021/bi00372a002; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; GERWERT K, 1986, EMBO J, V5, P805, DOI 10.1002/j.1460-2075.1986.tb04285.x; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; HESSLING B, 1993, BIOPHYS J, V65, P1929, DOI 10.1016/S0006-3495(93)81264-5; HOLZ M, 1989, P NATL ACAD SCI USA, V86, P2167, DOI 10.1073/pnas.86.7.2167; Kamikubo H, 1996, P NATL ACAD SCI USA, V93, P1386, DOI 10.1073/pnas.93.4.1386; Kandori H, 1997, BIOCHEMISTRY-US, V36, P5134, DOI 10.1021/bi9629788; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; Lanyi JK, 1995, ISR J CHEM, V35, P365; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Moltke S, 1998, BIOCHEMISTRY-US, V37, P11821, DOI 10.1021/bi980676v; Nagel G, 1998, BIOPHYS J, V74, P403, DOI 10.1016/S0006-3495(98)77797-5; OESTERHELT D, 1986, EUR BIOPHYS J BIOPHY, V14, P123, DOI 10.1007/BF00263069; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Richter HT, 1996, BIOCHEMISTRY-US, V35, P4054, DOI 10.1021/bi952883q; Rodig C, 1999, FEBS LETT, V445, P14, DOI 10.1016/S0014-5793(99)00088-5; Rummel G, 1998, J STRUCT BIOL, V121, P82, DOI 10.1006/jsbi.1997.3952; SASAKI J, 1992, J BIOL CHEM, V267, P20782; Sass HJ, 1997, EMBO J, V16, P1484, DOI 10.1093/emboj/16.7.1484; SCHARNAGL C, 1995, J PHYS CHEM-US, V99, P7787, DOI 10.1021/j100019a068; SCHULTEN K, 1978, NATURE, V272, P85, DOI 10.1038/272085a0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SUBRAMANIAM S, 1991, P NATL ACAD SCI USA, V88, P6873, DOI 10.1073/pnas.88.15.6873; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TITTOR J, 1989, EMBO J, V8, P3477, DOI 10.1002/j.1460-2075.1989.tb08512.x; VARO G, 1991, BIOPHYS J, V59, P313, DOI 10.1016/S0006-3495(91)82225-1; VARO G, 1991, BIOCHEMISTRY-US, V30, P5016, DOI 10.1021/bi00234a025; Vonck J, 1996, BIOCHEMISTRY-US, V35, P5870, DOI 10.1021/bi952663c; WELDLICH O, 1996, BIOCHEMISTRY-US, V35, P10807; ZIMANYI L, 1992, BIOCHEMISTRY-US, V31, P8535, DOI 10.1021/bi00151a022	50	491	540	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					255	260		10.1126/science.286.5438.255	http://dx.doi.org/10.1126/science.286.5438.255			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514362				2022-12-24	WOS:000083024400034
J	Hertel, P; Fagerquist, MV; Svensson, TH				Hertel, P; Fagerquist, MV; Svensson, TH			Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha(2) adrenoceptor blockade	SCIENCE			English	Article							INCREASES EXTRACELLULAR DOPAMINE; MEDIAL PREFRONTAL CORTEX; D-1 RECEPTOR AGONIST; IN-VIVO; ALPHA(2)-ADRENOCEPTOR ANTAGONISM; NUCLEUS-ACCUMBENS; FRONTAL-CORTEX; HIGH-AFFINITY; RAT-BRAIN; SCHIZOPHRENIA	Clozapine exerts superior clinical efficacy and markedly enhances cortical dopamine output compared with classical antipsychotic drugs, Here the alpha(2) adrenoceptor antagonist idazoxan was administered to rats alone or in combination with the D-2/3 dopamine receptor antagonist raclopride. Dopamine efflux in the medial prefrontal cortex and conditioned avoidance responding were analyzed. Idazoxan selectively potentiated the cortical output of dopamine and augmented the suppression of conditioned avoidance responding induced by raclopride. These results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action.	Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet	Svensson, TH (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, Sect Neuropsychopharmacol, S-17177 Stockholm, Sweden.							Abi-Dargham A, 1997, J NEUROPSYCH CLIN N, V9, P1; AHLENIUS S, 1986, PHARMACOL BIOCHEM BE, V24, P1409, DOI 10.1016/0091-3057(86)90203-0; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; ARNT J, 1982, ACTA PHARMACOL TOX, V51, P321; Ashby CR, 1996, SYNAPSE, V24, P349, DOI 10.1002/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D; BALDESSARINI RJ, 1991, NEW ENGL J MED, V324, P746; BROWNING JL, 1998, SOC NEUR ABSTR, V28, P1741; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; CARBONI E, 1990, J NEUROCHEM, V55, P1067, DOI 10.1111/j.1471-4159.1990.tb04599.x; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; Coull JT, 1996, PSYCHOPHARMACOLOGY, V123, P239, DOI 10.1007/BF02246578; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; DOXEY JC, 1983, BRIT J PHARMACOL, V78, P489, DOI 10.1111/j.1476-5381.1983.tb08809.x; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; GARRATT JC, 1991, EUR J PHARMACOL, V193, P87, DOI 10.1016/0014-2999(91)90204-4; Green MF, 1996, AM J PSYCHIAT, V153, P321; GRESCH PJ, 1995, J NEUROCHEM, V65, P111; Harvey PD, 1998, AM J PSYCHIAT, V155, P1080, DOI 10.1176/ajp.155.8.1080; HERNANDEZ L, 1995, PHARMACOL BIOCHEM BE, V52, P581, DOI 10.1016/0091-3057(95)00144-L; Hertel P, 1997, NEUROPSYCHOPHARMACOL, V17, P44; Hertel P, 1996, PSYCHOPHARMACOLOGY, V124, P74, DOI 10.1007/BF02245607; JANSSEN PAJ, 1965, J PHARMACOL EXP THER, V244, P684; Jentsch JD, 1997, SCIENCE, V277, P953, DOI 10.1126/science.277.5328.953; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KOHLER C, 1985, BIOCHEM PHARMACOL, V34, P2251, DOI 10.1016/0006-2952(85)90778-6; KURIBARA H, 1981, PHARMACOL BIOCHEM BE, V14, P181; Kuroki T, 1999, J PHARMACOL EXP THER, V288, P774; LEYSEN JE, 1993, PSYCHOPHARMACOLOGY, V112, pS40, DOI 10.1007/BF02245006; Litman RE, 1996, BRIT J PSYCHIAT, V168, P571, DOI 10.1192/bjp.168.5.571; MOGHADDAM B, 1990, J NEUROCHEM, V54, P1755, DOI 10.1111/j.1471-4159.1990.tb01230.x; NOMIKOS GG, 1994, PSYCHOPHARMACOLOGY, V115, P147, DOI 10.1007/BF02244765; NUTT DJ, 1994, J PSYCHOPHARMACOL, V8, P193, DOI 10.1177/026988119400800401; POZZI L, 1994, J NEUROCHEM, V63, P195; Prinssen EPM, 1996, PSYCHOPHARMACOLOGY, V128, P191, DOI 10.1007/s002130050124; Salmi P, 1996, EUR J PHARMACOL, V307, P27, DOI 10.1016/0014-2999(96)00181-1; SANBERG PR, 1988, BEHAV NEUROSCI, V102, P748, DOI 10.1037/0735-7044.102.5.748; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515, DOI 10.1152/jn.1994.71.2.515; SCHNEIDER JS, 1994, BRAIN RES, V663, P140, DOI 10.1016/0006-8993(94)90471-5; SVARTENGREN J, 1994, EUR J PHARMACOL, V254, P73, DOI 10.1016/0014-2999(94)90372-7; Tanda G, 1996, PSYCHOPHARMACOLOGY, V123, P127, DOI 10.1007/BF02246169; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; Volonte M, 1997, J NEUROCHEM, V69, P182; WADENBERG ML, 1990, BIOL PSYCHIAT, V28, P297, DOI 10.1016/0006-3223(90)90657-N; WADENBERG ML, 1991, J NEURAL TRANSM-GEN, V83, P43, DOI 10.1007/BF01244451; Wadenberg ML, 1996, EUR NEUROPSYCHOPHARM, V6, P305, DOI 10.1016/S0924-977X(96)00035-1; WEINBERGER DR, 1994, J NEUROPSYCH CLIN N, V6, P419; Yamamoto BK, 1998, J NEUROCHEM, V71, P274; Youngren KD, 1999, NEUROPSYCHOPHARMACOL, V20, P403, DOI 10.1016/S0893-133X(98)00082-7	49	165	166	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					105	107		10.1126/science.286.5437.105	http://dx.doi.org/10.1126/science.286.5437.105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506554				2022-12-24	WOS:000082907400044
J	Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J				Chen, XZ; Vassilev, PM; Basora, N; Peng, JB; Nomura, H; Segal, Y; Brown, EM; Reeders, ST; Hediger, MA; Zhou, J			Polycystin-L is a calcium-regulated cation channel permeable to calcium ions	NATURE			English	Article							XENOPUS-LAEVIS OOCYTES; KIDNEY-DISEASE; GENE; PROTEINS; CHLORIDE; CELLS; PKD1; INHIBIT; ENCODES; ENTRY	Polycystic kidney diseases are genetic disorders in which the renal parenchyma is progressively replaced by fluid-filled cysts(1). Two members of the polycystin family (polycystin-1 and -2) are mutated in autosomal dominant polycystic kidney disease (ADPKD)(2-5), and polycystin-L is deleted in mice with renal and retinal defects(6), Polycystins are membrane proteins that share significant sequence homology(6,7), especially polycystin-2 and -L (50% identity and 71% similarity). The functions of the polycystins remain unknown. Here we show that polycystin-L is a calcium-modulated nonselective cation channel that is permeable to sodium, potassium and calcium ions. Patch-clamp experiments revealed single-channel activity with a unitary conductance of 137 pS. Channel activity was substantially increased when either the extracellular or intracellular calcium-ion concentration was raised, indicating that polycystin-L may act as a transducer of calcium-mediated signalling in vivo. Its large single-channel conductance and regulation by calcium ions distinguish it from other structurally related cation channels.	Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zhou, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.			Hediger, Matthias/0000-0003-1946-027X				Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; Chen XZ, 1999, J BIOL CHEM, V274, P2773, DOI 10.1074/jbc.274.5.2773; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P105; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Jorgensen AJ, 1997, PFLUG ARCH EUR J PHY, V434, P261; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kunze DL, 1997, AM J PHYSIOL-CELL PH, V272, pC27, DOI 10.1152/ajpcell.1997.272.1.C27; LANE JW, 1993, BRIT J PHARMACOL, V108, P116, DOI 10.1111/j.1476-5381.1993.tb13449.x; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Saadi I, 1998, KIDNEY INT, V54, P48, DOI 10.1046/j.1523-1755.1998.00956.x; Sullivan LP, 1998, J AM SOC NEPHROL, V9, P903; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WARD CJ, 1994, CELL, V77, P881; Wu GQ, 1998, GENOMICS, V54, P564, DOI 10.1006/geno.1998.5618; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287	30	191	203	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					383	386		10.1038/43907	http://dx.doi.org/10.1038/43907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517637				2022-12-24	WOS:000082822600053
J	Muhlbauer, RC; Li, F				Muhlbauer, RC; Li, F			Nutrition - Effect of vegetables on bone metabolism	NATURE			English	Article							OVARIECTOMIZED RATS; DIURNAL RHYTHM; RESORPTION		Univ Bern, Dept Clin Res, Bone Biol Grp, CH-3010 Bern, Switzerland	University of Bern	Muhlbauer, RC (corresponding author), Univ Bern, Dept Clin Res, Bone Biol Grp, Murtenstr 35, CH-3010 Bern, Switzerland.							Anderson JJB, 1997, NUTR RES, V17, P1617, DOI 10.1016/S0271-5317(97)00156-5; Antic VN, 1996, CALCIFIED TISSUE INT, V58, P443, DOI 10.1007/s002239900073; Cecchini MG, 1997, CALCIFIED TISSUE INT, V61, pS9, DOI 10.1007/s002239900377; Kanis JA, 1999, BONE, V24, P279, DOI 10.1016/S8756-3282(99)00010-1; Li F, 1999, J BONE MINER RES, V14, P1457, DOI 10.1359/jbmr.1999.14.8.1457; MUHLBAUER RC, 1990, AM J PHYSIOL, V259, pR679, DOI 10.1152/ajpregu.1990.259.4.R679; MUHLBAUER RC, 1995, J CLIN INVEST, V95, P1933, DOI 10.1172/JCI117875; SILVERMAN SL, 1998, BONE, V23, P1108; White P, 1998, OSTEOPOROSIS CLIN CO; WRONSKI TJ, 1986, BONE, V7, P119, DOI 10.1016/8756-3282(86)90683-6	10	93	96	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					343	344		10.1038/43824	http://dx.doi.org/10.1038/43824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517630				2022-12-24	WOS:000082822600040
J	Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C				Beard, BL; Johnson, CM; Cox, L; Sun, H; Nealson, KH; Aguilar, C			Iron isotope biosignatures	SCIENCE			English	Article								The Fe-56/Fe-54 of Fe-bearing phases precipitated in sedimentary environments varies by 2.5 per mil (delta(56)Fe values of +0.9 to -1.6 per mil). In contrast, the Fe-56/Fe-54 of Fe-bearing phases in igneous rocks from Earth and the moon does not vary measurably (delta(56)Fe = 0.0 +/- 0.3 per mil). Experiments with dissimilatory Fe-reducing bacteria of the genus Shewanella algae grown on a ferrihydrite substrate indicate that the delta(56)Fe of ferrous Fe in solution is isotopically Lighter than the ferrihydrite substrate by 1.3 per mil. Therefore, the range in delta(56)Fe values of sedimentary rocks may reflect biogenic fractionation, and the isotopic composition of Fe may be used to trace the distribution of microorganisms in modern and ancient Earth.	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Wisconsin, Inst Great Lakes Study, Milwaukee, WI 53204 USA	University of Wisconsin System; University of Wisconsin Madison; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Wisconsin System; University of Wisconsin Milwaukee	Beard, BL (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.							BEARD BL, IN PRESS GEOCHIM COS; Bullen T.D., 1998, MINERAL MAG A, V62, P255; Bullen T. D., 1997, EOS, V78, pS173; CALDEIRA K, 1990, EXTINCTION EVENTS EA, P333, DOI DOI 10.1007/BFB0011156; DIXON PR, 1992, WATER ROCK INTERACTI, V2, P915; Friedman I., 1977, DATA GEOCHEMISTRY; JOHNSON CM, 1999, INT J MASS SPECTROM, V63, P1653; LIN CF, 1990, ENVIRON SCI TECHNOL, V24, P126, DOI 10.1021/es00071a016; LITTLE B, 1997, CORROSION 97; Marechal CN, 1999, CHEM GEOL, V156, P251, DOI 10.1016/S0009-2541(98)00191-0; Morgan E. H., 1994, IRON METABOLISM HLTH, P63; MYERS CR, 1994, J APPL BACTERIOL, V76, P253, DOI 10.1111/j.1365-2672.1994.tb01624.x; NEALSON KH, 1990, AM J SCI, V290A, P35; Schidlowski M., 1983, P149; Schwertmann U, 1991, IRON OXIDES LAB PREP; STOOKEY LL, 1970, ANAL CHEM, V42, P779, DOI 10.1021/ac60289a016	16	304	334	6	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1889	1892		10.1126/science.285.5435.1889	http://dx.doi.org/10.1126/science.285.5435.1889			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489362				2022-12-24	WOS:000082638300042
J	Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G				Bernard, A; Hermans, C; Broeckaert, F; De Poorter, G; De Cock, A; Houins, G			Food contamination by PCBs and dioxins	NATURE			English	Article							POLYCHLORINATED-BIPHENYLS		Catholic Univ Louvain, Toxicol Unit, B-1200 Brussels, Belgium; Belgian Fed Minist Agr, B-1000 Brussels, Belgium	Universite Catholique Louvain	Bernard, A (corresponding author), Catholic Univ Louvain, Toxicol Unit, 30-54 Clos Chapelle Champs, B-1200 Brussels, Belgium.		BERNARD, Alfred M/A-6511-2010	BERNARD, Alfred M/0000-0003-3171-3743				ASPLUND L, 1994, ARCH ENVIRON HEALTH, V49, P477, DOI 10.1080/00039896.1994.9955004; GILBERTSON M, 1991, J TOXICOL ENV HEALTH, V33, P455, DOI 10.1080/15287399109531538; HARRIS JR, 1972, J AM VET MED ASSOC, V161, P1584; KOHANAWA M, 1969, NATL I ANIM HEALTH Q, V9, P220; MASUDA Y, 1994, DIOXINS HLTH, V1, P633; Papke O, 1998, ENVIRON HEALTH PERSP, V106, P723, DOI 10.2307/3433826	6	133	141	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					231	232		10.1038/45717	http://dx.doi.org/10.1038/45717			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499576				2022-12-24	WOS:000082678400038
J	Miralles, R; Gerrish, PJ; Moya, A; Elena, SF				Miralles, R; Gerrish, PJ; Moya, A; Elena, SF			Clonal interference and the evolution of RNA viruses	SCIENCE			English	Article							SPONTANEOUS MUTATION; FITNESS; POPULATIONS; ADAPTATION; RATES	In asexual populations, beneficial mutations that occur in different lineages compete with one another. This phenomenon, known as clonal interference, ensures that those beneficial mutations that do achieve fixation are of Large effect. Clonal interference also increases the time between fixations, thereby stowing the adaptation of asexual populations. The effects of clonal interference were measured in the asexual RNA virus vesicular stomatitis virus; rates and average effects of beneficial mutations were quantified.	Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Valencia 46071, Spain; Univ Valencia, Dept Genet, Valencia 46071, Spain; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	University of Valencia; University of Valencia; Centers for Disease Control & Prevention - USA	Elena, SF (corresponding author), Univ Valencia, Inst Cavanilles Biodiversitat & Biol Evolut, Apartado 22085, Valencia 46071, Spain.		Gerrish, Philip/AAE-7346-2019; Moya, Andrés/A-8190-2008; Elena, Santiago F./A-4191-2011	Moya, Andrés/0000-0002-2867-1119; Elena, Santiago F./0000-0001-8249-5593; Gerrish, Philip/0000-0001-6393-0553				Burch CL, 1999, GENETICS, V151, P921; CROW JAMES F., 1965, AMER NATUR, V99, P439, DOI 10.1086/282389; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; DELATORRE JC, 1990, J VIROL, V64, P6278, DOI 10.1128/JVI.64.12.6278-6281.1990; Drake JW, 1998, GENETICS, V148, P1667; DRAKE JW, 1993, P NATL ACAD SCI USA, V90, P4171, DOI 10.1073/pnas.90.9.4171; Elena SF, 1998, EVOLUTION, V52, P309, DOI 10.1111/j.1558-5646.1998.tb01633.x; Escarmis C, 1999, J MOL BIOL, V285, P495, DOI 10.1006/jmbi.1998.2366; Fisher R. A., 1930, GENETICAL THEORY NAT, DOI 10.5962/bhl.title.27468; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Gillespie J. H., 1991, CAUSES MOL EVOLUTION; Hogg R.V., 1995, INTRO MATH STAT; HOLLAND JJ, 1991, J VIROL, V65, P2960, DOI 10.1128/JVI.65.6.2960-2967.1991; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Miralles R, 1999, J GEN VIROL, V80, P2051, DOI 10.1099/0022-1317-80-8-2051; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Novella IS, 1996, MOL GEN GENET, V252, P733, DOI 10.1007/BF02173980; Novella IS, 1999, J VIROL, V73, P1668, DOI 10.1128/JVI.73.2.1668-1671.1999; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; Orr HA, 1998, EVOLUTION, V52, P935, DOI [10.1111/j.1558-5646.1998.tb01823.x, 10.2307/2411226]; Otto SP, 1997, GENETICS, V147, P879; VANDEPOL SB, 1986, VIROLOGY, V148, P312, DOI 10.1016/0042-6822(86)90328-4	23	207	208	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1745	1747		10.1126/science.285.5434.1745	http://dx.doi.org/10.1126/science.285.5434.1745			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481012				2022-12-24	WOS:000082472600038
J	Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N				Peters, M; Petros, A; Dixon, G; Inwald, D; Klein, N			Acquired immunoparalysis in paediatric intensive care: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							MONOCYTE		Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England; Great Ormond St Hosp Children NHS Trust, Paediat Intens Care Unit, London WC1N 3JH, England; Inst Child Hlth, Immunobiol Unit, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Peters, M (corresponding author), Inst Child Hlth, Portex Dept Anaesthesia Intens Therapy & Resp Med, London WC1N 3EH, England.			Inwald, David/0000-0001-9518-7821; Klein, Nigel/0000-0003-3925-9258; Peters, Mark/0000-0003-3653-4808; Dixon, Garth/0000-0001-8165-3094				ASADULLAH K, 1995, CRIT CARE MED, V23, P1976, DOI 10.1097/00003246-199512000-00006; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Schinkel C, 1998, J TRAUMA, V44, P743, DOI 10.1097/00005373-199805000-00001; WILKINSON JD, 1986, CRIT CARE MED, V14, P271, DOI 10.1097/00003246-198604000-00002; Wise R, 1998, BMJ-BRIT MED J, V317, P609, DOI 10.1136/bmj.317.7159.609	5	20	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					609	610		10.1136/bmj.319.7210.609	http://dx.doi.org/10.1136/bmj.319.7210.609			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473475	Bronze, Green Published			2022-12-24	WOS:000082460300019
J	Richards, AM; Nicholls, MG				Richards, AM; Nicholls, MG			Aldosterone antagonism in heart failure	LANCET			English	Editorial Material							SECONDARY		Christchurch Sch Med, Cardioendocrine Res Grp, Christchurch, New Zealand	University of Otago	Richards, AM (corresponding author), Christchurch Sch Med, Cardioendocrine Res Grp, POB 4345, Christchurch, New Zealand.							BARR CS, 1995, AM J CARDIOL, V76, P1259, DOI 10.1016/S0002-9149(99)80353-1; BRILLA CG, 1993, J MOL CELL CARDIOL, V25, P563, DOI 10.1006/jmcc.1993.1066; Hjalmarson A, 1999, LANCET, V353, P2001; Lechat P, 1999, LANCET, V353, P9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pitt B, 1996, AM J CARDIOL, V78, P902; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Struthers A D, 1996, J Card Fail, V2, P47, DOI 10.1016/S1071-9164(96)80009-1; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Volpe M, 1997, HYPERTENSION, V30, P168, DOI 10.1161/01.HYP.30.2.168	11	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					789	790						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485716				2022-12-24	WOS:000082400700003
J	Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E				Jomaa, H; Wiesner, J; Sanderbrand, S; Altincicek, B; Weidemeyer, C; Hintz, M; Turbachova, I; Eberl, M; Zeidler, J; Lichtenthaler, HK; Soldati, D; Beck, E			Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs	SCIENCE			English	Article							1-DEOXY-D-XYLULOSE 5-PHOSPHATE REDUCTOISOMERASE; MEVALONATE-INDEPENDENT PATHWAY; PARASITE TOXOPLASMA-GONDII; TERPENOID BIOSYNTHESIS; HIGHER-PLANTS; ISOPENTENYL DIPHOSPHATE; APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; ERYTHROCYTES; FOSMIDOMYCIN	A mevalonate-independent pathway of isoprenoid biosynthesis present in Plasmodium falciparum was shown to represent an effective target for chemotherapy of malaria. This pathway includes 1-deoxy-D-xylulose 5-phosphate (DOXP) as a key metabolite. The presence of two genes encoding the enzymes DOXP synthase and DOXP reductoisomerase suggests that isoprenoid biosynthesis in P. falciparum depends on the DOXP pathway. This pathway is probably Located in the apicoplast. The recombinant P, falciparum DOXP reductoisomerase was inhibited by fosmidomycin and its derivative, FR-900098. Both drugs suppressed the in vitro growth of multidrug-resistant P. falciparum strains. After therapy with these drugs, mice infected with the rodent malaria parasite P. vinckei were cured.	Univ Giessen, Acad Hosp Ctr, Inst Biochem, D-35392 Giessen, Germany; Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Karlsruhe, Inst Bot 1, D-76128 Karlsruhe, Germany	Justus Liebig University Giessen; Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology	Jomaa, H (corresponding author), Univ Giessen, Acad Hosp Ctr, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	hassan.jomaa@biochemie.med.uni-giessen.de	Altincicek, Boran/C-1191-2009; Eberl, Matthias/A-5970-2009; Soldati-Favre, Dominique/A-2999-2009	Altincicek, Boran/0000-0003-2019-452X; Eberl, Matthias/0000-0002-9390-5348; 				Ancelin ML, 1998, BLOOD, V91, P1426, DOI 10.1182/blood.V91.4.1426; Arigoni D, 1997, P NATL ACAD SCI USA, V94, P10600, DOI 10.1073/pnas.94.20.10600; BEYTIA ED, 1976, ANNU REV BIOCHEM, V45, P113, DOI 10.1146/annurev.bi.45.070176.000553; Disch A, 1998, BIOCHEM J, V333, P381, DOI 10.1042/bj3330381; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; GRELLIER P, 1994, ANTIMICROB AGENTS CH, V38, P1144, DOI 10.1128/AAC.38.5.1144; KAMIYA T, 1980, Patent No. 4206156; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; KUEMMERLE HP, 1987, CHEMIOTERAPIA, V6, P113; Kuzuyama T, 1998, TETRAHEDRON LETT, V39, P7913, DOI 10.1016/S0040-4039(98)01755-9; Lange BM, 1998, P NATL ACAD SCI USA, V95, P2100, DOI 10.1073/pnas.95.5.2100; Lichtenthaler HK, 1997, PHYSIOL PLANTARUM, V101, P643, DOI 10.1111/j.1399-3054.1997.tb01049.x; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Lichtenthaler HK, 1997, FEBS LETT, V400, P271, DOI 10.1016/S0014-5793(96)01404-4; Lois LM, 1998, P NATL ACAD SCI USA, V95, P2105, DOI 10.1073/pnas.95.5.2105; Mandel MA, 1996, PLANT J, V9, P649, DOI 10.1046/j.1365-313X.1996.9050649.x; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; MURAKAWA T, 1982, ANTIMICROB AGENTS CH, V21, P224, DOI 10.1128/AAC.21.2.224; OHLER E, 1995, SYNTHESIS-STUTTGART, P539; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; PETERS W, 1980, MALARIA, V1, P160; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Schwender J, 1997, FEBS LETT, V414, P129, DOI 10.1016/S0014-5793(97)01002-8; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Sprenger GA, 1997, P NATL ACAD SCI USA, V94, P12857, DOI 10.1073/pnas.94.24.12857; Takahashi S, 1998, P NATL ACAD SCI USA, V95, P9879, DOI 10.1073/pnas.95.17.9879; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VACEROAKBANI A, IN PRESS METHODS EN; VIAL HJ, 1984, MOL BIOCHEM PARASIT, V13, P53, DOI 10.1016/0166-6851(84)90101-4; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Zeidler J, 1998, Z NATURFORSCH C, V53, P980	33	940	983	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1573	1576		10.1126/science.285.5433.1573	http://dx.doi.org/10.1126/science.285.5433.1573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477522				2022-12-24	WOS:000082359500067
J	Smith, O				Smith, O			Nota bene: Neuroscience - For time is the longest distance between two places	SCIENCE			English	Editorial Material																		Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Teng E, 1999, NATURE, V400, P675, DOI 10.1038/23276	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1504	1504		10.1126/science.285.5433.1504	http://dx.doi.org/10.1126/science.285.5433.1504			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10498536				2022-12-24	WOS:000082359500039
J	Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD				Suh, YA; Arnold, RS; Lassegue, B; Shi, J; Xu, XX; Sorescu, D; Chung, AB; Griendling, KK; Lambeth, JD			Cell transformation by the superoxide-generating oxidase Mox1	NATURE			English	Article							CHRONIC GRANULOMATOUS-DISEASE; PHAGOCYTE NADPH OXIDASE; HYDROGEN-PEROXIDE; ANGIOTENSIN-II; MAMMALIAN-CELLS; ANION; CYTOCHROME-B558; HYPERTROPHY; FIBROBLASTS; EXPRESSION	Reactive oxygen species (ROS) generated in some non-phagocytic cells are implicated in mitogenic signalling and cancer(1-6). Many cancer cells show increased production of ROS7, and normal cells exposed to hydrogen peroxide or superoxide show increased proliferations and express growth-related genes(9-11). ROS are generated in response to growth factors, and may affect cell growth(2,3,12,13), for example in vascular smooth-muscle cells(6,13-15) Increased ROS in Ras-transformed fibroblasts correlates with increased mitogenic rate(16). Here we describe the cloning of mox1, which encodes a homologue of the catalytic subunit of the superoxide-generating NADPH oxidase of phagocytes(17,18), gp91phox. mox1 messenger RNA is expressed in colon, prostate, uterus and vascular smooth muscle, but not in peripheral blood leukocytes. In smooth-muscle cells, platelet-derived growth factor induces mox1 mRNA production, while antisense mox1 mRNA decreases superoxide generation and serum-stimulated growth. Overexpression of mox1 in NIH3T3 cells increases superoxide generation and cell growth, Cells expressing mox1 have a transformed appearance, show,anchorage-independent growth and produce tumours in athymic mice. These data link ROS production by Mox1 to growth control in non-phagocytic cells.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA	Emory University; Emory University	Lambeth, JD (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.			Lassegue, Bernard/0000-0003-4924-6506; Griendling, Kathy/0000-0002-9456-8582				Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BERK BC, 1990, J BIOL CHEM, V265, P19632; Bjorgvinsdottir H, 1996, BLOOD, V87, P2005, DOI 10.1182/blood.V87.5.2005.bloodjournal8752005; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CRAWFORD D, 1988, ONCOGENE, V3, P27; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FLINT DH, 1994, ARCH BIOCHEM BIOPHYS, V311, P509, DOI 10.1006/abbi.1994.1269; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MATSUBARA T, 1986, J IMMUNOL, V137, P3295; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; WOLIN MS, 1991, KLIN WOCHENSCHR, V69, P1046, DOI 10.1007/BF01645156; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	29	1226	1289	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					79	82		10.1038/43459	http://dx.doi.org/10.1038/43459			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485709				2022-12-24	WOS:000082374400045
J	Thomson, M				Thomson, M			Helicobacter pylori - the story so far	BRITISH MEDICAL JOURNAL			English	Editorial Material							CAMPYLOBACTER-PYLORI; INFECTION; DISEASE		Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England	University of London; University College London	Thomson, M (corresponding author), Univ London, Royal Free Hosp NHS Trust, Dept Paediat Gastroenterol & Nutr, London, England.							COGHLAN JG, 1987, LANCET, V2, P109; FORMAN D, 1993, GUT, V34, P1672, DOI 10.1136/gut.34.12.1672; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; MACARTHUR C, 1995, JAMA-J AM MED ASSOC, V273, P729, DOI 10.1001/jama.273.9.729; Malfertheiner P, 1997, EUR J GASTROEN HEPAT, V9, P1; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; OCONNOR HJ, 1987, LANCET, V2, P633; Talley NJ, 1999, BMJ-BRIT MED J, V318, P833, DOI 10.1136/bmj.318.7187.833; TATSUTA M, 1990, GUT, V31, P973, DOI 10.1136/gut.31.9.973; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	12	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					541	541						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10523085				2022-12-24	WOS:000082347200018
J	Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T				Whitehouse, I; Flaus, A; Cairns, BR; White, MF; Workman, JL; Owen-Hughes, T			Nucleosome mobilization catalysed by the yeast SWI/SNF complex	NATURE			English	Article							REMODELING FACTOR; HOLLIDAY JUNCTION; MOBILITY; BINDING; TRANSCRIPTION; RESOLUTION; ISWI; RSC; DNA	The generation of a local chromatin topology conducive to transcription is a key step in gene regulation(1). The yeast SWI/SNF complex is the founding member of a family of ATP-dependent remodelling activities capable of altering chromatin structure both in vitro and in vivo(2). Despite its importance, the pathway by which the SWI/SNF complex disrupts chromatin structure is unknown. Here we use a model system to demonstrate that the yeast SWI/SNF complex can reposition nucleosomes in an ATP-dependent reaction that favours attachment of the histone octamer to an acceptor site on the same molecule of DNA (in cis), We show that SWI/SNF-mediated displacement of the histone octamer is effectively blocked by a barrier introduced into the DNA, suggesting that this redistribution involves sliding or tracking of nucleosomes along DNA, and that it is achieved by a catalytic mechanism. We conclude that SWI/SNF catalyses the redistribution of nucleosomes along DNA in cis, which may represent a general mechanism by which ATP-dependent chromatin remodelling occurs.	Univ Dundee, Div Gene Regulat, Dundee DD1 5EH, Scotland; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Huntsman Canc Inst, Salt Lake City, UT 84108 USA; Penn State Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	University of Dundee; University of Dundee; Huntsman Cancer Institute; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Owen-Hughes, T (corresponding author), Univ Dundee, Div Gene Regulat, Wellcome Trust Bldg, Dundee DD1 5EH, Scotland.		White, Malcolm F/A-6055-2010; Flaus, Andrew/D-5076-2011	White, Malcolm F/0000-0003-1543-9342; Flaus, Andrew/0000-0002-5720-7139; Whitehouse, Iestyn/0000-0003-0385-3116; Owen-Hughes, Tom/0000-0002-0618-8185	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grigoriev M, 1997, MOL CELL BIOL, V17, P7139, DOI 10.1128/MCB.17.12.7139; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; van Holde KE, 1985, STRUCTURE FUNCTION G, P35, DOI DOI 10.1007/978-1-4684-5024-8_4; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	29	268	275	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					784	787		10.1038/23506	http://dx.doi.org/10.1038/23506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466730				2022-12-24	WOS:000082131100055
J	Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD				Stein, R; Sherrill, D; Morgan, WJ; Holberg, CJ; Halonen, M; Taussig, LM; Wright, AL; Martinez, FD			Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years	LANCET			English	Article							LUNG-FUNCTION; EARLY-CHILDHOOD; 1ST YEAR; AIRWAY RESPONSIVENESS; TRACT ILLNESS; SERUM IGE; ASTHMA; BRONCHIOLITIS; CHILDREN; RESPONSES	Background The relation between lower respiratory tract illnesses in early life caused by the respiratory syncytial virus (RSV) and the subsequent development of wheezing acid atopy in childhood is not well understood. We studied this relation in children who had lower respiratory tract illnesses that occurred before 3 years of age. Methods Children were enrolled at birth and cases of lower respiratory tract illness were ascertained by a physician. Viral tests were done for specimens collected at the time of the illness. Children were classified into five groups according to type and cause of lower respiratory tract illness. Children were then followed prospectively up to age 13, and we measured frequency of wheezing, pulmonary function, and atopic status (allergy skin-prick tests, serum IgE concentrations). Findings RSV lower respiratory tract illnesses were associated with an increased risk of infrequent wheeze (odds ratio 3.2 [95% CI 2.0-5.0], p<0.001), and an increased risk of frequent wheeze (4.3 [2.2-8.7], p less than or equal to 0.001) by age 6, Risk decreased markedly with age and was not significant by age 13. There was no association between RSV lower respiratory tract illnesses and subsequent atopic status. RSV lower respiratory tract illnesses were associated with significantly lower measurements of forced expiratory volume (2.11 [2.05-2.15], p less than or equal to 0.001) when compared with those of children with no lower respiratory tract illnesses, but there was no difference in forced expiratory volume after inhalation of salbutamol. Interpretation RSV lower respiratory tract illnesses in early childhood are an independent risk factor for the subsequent development of wheezing up to age 11 years but not at ape 13. This association is not caused by an increased risk of allergic sensitisation.	Pontiflcia Univ Catolica RS, Dept Pediat, Pediat Pulm Sect, Porto Alegre, RS, Brazil; Univ Arizona, Resp Sci Ctr, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Martinez, FD (corresponding author), POB 245030, Tucson, AZ 85724 USA.		Stein, Renato T/G-2975-2012; Stein, Renato Tetelbom/K-2568-2014	Halonen, Marilyn/0000-0001-9606-935X; STEIN, RENATO/0000-0003-0269-0757	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056177] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-56177, HL-03154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1302, DOI 10.1164/ajrccm.152.4.7551386; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Colasurdo GN, 1998, AM J RESP CRIT CARE, V157, P1506, DOI 10.1164/ajrccm.157.5.9705026; COLASURDO GN, 1995, AM J PHYSIOL-LUNG C, V268, pL1006, DOI 10.1152/ajplung.1995.268.6.L1006; GLEZEN WP, 1981, J PEDIATR, V98, P702; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; HALONEN M, 1999, IN PRESS AM J RESP C; Hanrahan JP, 1996, AM J RESP CRIT CARE, V154, P670, DOI 10.1164/ajrccm.154.3.8810604; HENDERSON FW, 1992, AM REV RESPIR DIS, V145, P283, DOI 10.1164/ajrccm/145.2_Pt_1.283; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Larsen GL., 1998, RSV ASTHMA IS THERE, P17; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MCCONNOCHIE KM, 1985, AM J DIS CHILD, V139, P625, DOI 10.1001/archpedi.1985.02140080095042; MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PULLAN CR, 1982, BRIT MED J, V284, P165; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SIGURS N, 1995, PEDIATRICS, V95, P500; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655, DOI 10.1164/ajrccm/144.3_Pt_1.655; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811, DOI 10.1164/ajrccm/147.4.811; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219, DOI 10.1093/oxfordjournals.aje.a115242; TAUSSIG LM, 1993, AM REV RESPIR DIS, V147, pA375; TEPPER RS, 1992, PEDIATR PULM, V13, P6, DOI 10.1002/ppul.1950130104; VOTER KZ, 1988, AM REV RESPIR DIS, V137, P302, DOI 10.1164/ajrccm/137.2.302; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; WELLIVER RC, 1998, RSV ASTHMA IS THERE, P21; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232, DOI 10.1093/oxfordjournals.aje.a115243	34	1104	1150	2	55	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					541	545		10.1016/S0140-6736(98)10321-5	http://dx.doi.org/10.1016/S0140-6736(98)10321-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470697				2022-12-24	WOS:000081991000010
J	Rohani, P; Earn, DJD; Grenfell, BT				Rohani, P; Earn, DJD; Grenfell, BT			Opposite patterns of synchrony in sympatric disease metapopulations	SCIENCE			English	Article							INSECT POPULATION; MEASLES DYNAMICS; TIME-SERIES; CHAOS; VACCINATION; PERTUSSIS; TRANSMISSION; PERSISTENCE; ENGLAND; WALES	Measles epidemics in UK cities, which were regular and highly synchronous before vaccination, are known to have become irregular and spatially uncorrelated in the vaccine era. Whooping cough shows the reverse pattern, namely a shift from spatial incoherence and irregularity before vaccination to regular, synchronous epidemics afterward. Models show that these patterns can arise from disease-specific responses to dynamical noise. This analysis has implications for vaccination strategies and illustrates the power of comparative dynamical studies of sympatric metapopulations.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England	University of Cambridge	Rohani, P (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	pej@zoo.cam.ac.uk		rohani, pejman/0000-0002-7221-3801; Earn, David/0000-0002-7562-1341				AGUR Z, 1993, P NATL ACAD SCI USA, V90, P11698, DOI 10.1073/pnas.90.24.11698; ANDERSON R M, 1991; ARON JL, 1990, THEOR POPUL BIOL, V38, P58, DOI 10.1016/0040-5809(90)90003-E; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bjornstad ON, 1999, ECOLOGY, V80, P622, DOI 10.2307/176640; Bjornstad ON, 1998, J ANIM ECOL, V67, P110, DOI 10.1046/j.1365-2656.1998.00168.x; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; CLARKSON JA, 1985, INT J EPIDEMIOL, V14, P153, DOI 10.1093/ije/14.1.153; Costantino RF, 1997, SCIENCE, V275, P389, DOI 10.1126/science.275.5298.389; Earn DJD, 1998, P ROY SOC B-BIOL SCI, V265, P7, DOI 10.1098/rspb.1998.0256; EARN DJD, UNPUB; ELLNER S, 1995, AM NAT, V145, P343, DOI 10.1086/285744; FINE PEM, 1982, LANCET, V1, P666; Grenfell B, 1997, TRENDS ECOL EVOL, V12, P395, DOI 10.1016/S0169-5347(97)01174-9; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; GRENFELL BT, 1992, J ROY STAT SOC B MET, V54, P383; GRENFELL BT, 1989, PROC R SOC SER B-BIO, V236, P213, DOI 10.1098/rspb.1989.0022; Grenfell BT, 1998, ECOL LETT, V1, P63; GRENFELL BT, 1999, CHAOS REAL DATA ANAL; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1977, J ANIM ECOL, V46, P249, DOI 10.2307/3959; Hethcote HW, 1997, MATH BIOSCI, V145, P89, DOI 10.1016/S0025-5564(97)00014-X; Higgins K, 1997, SCIENCE, V276, P1431, DOI 10.1126/science.276.5317.1431; LEVINS R, 1969, Bulletin of the Entomological Society of America, V15, P237; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; Miller E, 1997, DEV BIOLOGICALS, V89, P15; Miller E, 1992, Commun Dis Rep CDR Rev, V2, pR152; NOKES DJ, 1997, J MATH APPL MED BIOL, V12, P29; Rohani P, 1998, P ROY SOC B-BIOL SCI, V265, P2033, DOI 10.1098/rspb.1998.0537; ROHANI P, UNPUB; SCHENZLE D, 1984, J MATH APPL MED BIOL, V1, P169; Scott PT, 1997, AM FAM PHYSICIAN, V56, P1121; Shulgin B, 1998, B MATH BIOL, V60, P1123, DOI 10.1016/S0092-8240(98)90005-2; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0	35	229	234	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					968	971		10.1126/science.286.5441.968	http://dx.doi.org/10.1126/science.286.5441.968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542154				2022-12-24	WOS:000083368500049
J	Shamoo, Y; Steitz, TA				Shamoo, Y; Steitz, TA			Building a replisome from interacting pieces: Sliding clamp complexed to a peptide from DNA polymerase and a polymerase editing complex	CELL			English	Article							3'-5' EXONUCLEASE ACTIVITY; I KLENOW FRAGMENT; CRYSTAL-STRUCTURE; REPLICATION COMPLEX; CONSERVED REGION; BINDING-PROTEIN; III HOLOENZYME; BACTERIOPHAGE-T4; SUBUNIT; SITES	We have solved the crystal structures of the bacteriophage RB69 sliding clamp, its complex with a peptide essential for DNA polymerase interactions, and the DNA polymerase complexed with primer-template DNA. The editing complex structure shows a partially melted duplex DNA exiting from the exonuclease domain at an unexpected angle and significant changes in the protein structure. The clamp complex shows the C-terminal 11 residues of polymerase bound in a hydrophobic pocket, and it allows docking of the editing and clamp structures together. The peptide binds to the sliding clamp at a position identical to that of a replication inhibitor peptide bound to PCNA, suggesting that the replication inhibitor protein p21(CIP1) functions by competing with eukaryotic polymerases for the same binding pocket on the clamp.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009	Shamoo, Yousif/0000-0001-9241-8962	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Berdis AJ, 1996, P NATL ACAD SCI USA, V93, P12822, DOI 10.1073/pnas.93.23.12822; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; COWART M, 1989, BIOCHEMISTRY-US, V28, P1975, DOI 10.1021/bi00431a004; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Goodrich LD, 1997, BIOCHEMISTRY-US, V36, P10474, DOI 10.1021/bi9708949; GOPALAKRISHNAN V, 1994, J BIOL CHEM, V269, P21123; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOUNG I, 1991, VIROLOGY, V184, P235, DOI 10.1016/0042-6822(91)90840-8; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KABOORD BF, 1993, P NATL ACAD SCI USA, V90, P10881, DOI 10.1073/pnas.90.22.10881; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN TC, 1994, J BIOL CHEM, V269, P19286; MORRIS CF, 1979, J BIOL CHEM, V254, P6787; NICHOLLS KA, 1993, BIOPHYS J, V64, pA166; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REDDY MK, 1993, P NATL ACAD SCI USA, V90, P3211, DOI 10.1073/pnas.90.8.3211; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; Rice LM, 1998, J APPL CRYSTALLOGR, V31, P798, DOI 10.1107/S0021889898006645; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; Soumillion P, 1998, BIOCHEMISTRY-US, V37, P1819, DOI 10.1021/bi972526a; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P438; SPICER EK, 1982, J BIOL CHEM, V257, P8972; STOCKI SA, 1995, J MOL BIOL, V254, P15, DOI 10.1006/jmbi.1995.0595; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TINKER RL, 1995, J BIOL CHEM, V270, P15899, DOI 10.1074/jbc.270.26.15899; WANG CC, 1995, J BIOL CHEM, V270, P26558, DOI 10.1074/jbc.270.44.26558; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Wu P, 1998, BIOCHEMISTRY-US, V37, P14748, DOI 10.1021/bi980835a; Yeh LS, 1998, J BACTERIOL, V180, P2005, DOI 10.1128/JB.180.8.2005-2013.1998	54	305	322	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					155	166		10.1016/S0092-8674(00)81647-5	http://dx.doi.org/10.1016/S0092-8674(00)81647-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535734	hybrid			2022-12-24	WOS:000083159700006
J	Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R				Venkataraman, G; Shriver, Z; Raman, R; Sasisekharan, R			Sequencing complex polysaccharides	SCIENCE			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; ENZYMATIC DEGRADATION; GLYCOSAMINOGLYCANS; OLIGOSACCHARIDES; BINDING	Although rapid sequencing of polynucleotides and polypeptides has become commonplace, it has not been possible to rapidly sequence femto- to picomole amounts of tissue-derived complex polysaccharides. Heparin-like glycosaminoglycans (HLGAGs) were readily sequenced by a combination of matrix-assisted Laser desorption ionization mass spectrometry and a notation system for representation of polysaccharide sequences. This will enable identification of sequences that are critical to HLGAG biological activities in anticoagulation, cell growth, and differentiation.	Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; MIT, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057073] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57073] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; Conrad H. E., 1998, HEPARIN BINDING PROT; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1998, P NATL ACAD SCI USA, V95, P4182, DOI 10.1073/pnas.95.8.4182; Hung SL, 1999, VIROLOGY, V257, P156, DOI 10.1006/viro.1999.9633; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; Jacquet A, 1998, VIRUS RES, V53, P197, DOI 10.1016/S0168-1702(97)00149-4; Joyce JG, 1999, J BIOL CHEM, V274, P5810, DOI 10.1074/jbc.274.9.5810; JUHASZ P, 1994, P NATL ACAD SCI USA, V91, P4333, DOI 10.1073/pnas.91.10.4333; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; LANE DL, 1989, HEPARIN CHEM BIOL PR; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1995, THROMB RES, V75, P1; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Rapraeger AC, 1993, CURR OPIN CELL BIOL, V5, P844, DOI 10.1016/0955-0674(93)90034-N; Rhomberg AJ, 1998, P NATL ACAD SCI USA, V95, P4176, DOI 10.1073/pnas.95.8.4176; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sporn M. B., 1990, PEPTIDE GROWTH FACTO; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; TURNBULL JH, 1999, P NATL ACAD SCI USA, V96, P2703; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Vives RR, 1999, BIOCHEM J, V339, P767, DOI 10.1042/0264-6021:3390767; Waksman G, 1998, NAT STRUCT BIOL, V5, P527, DOI 10.1038/778; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	29	209	248	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					537	542		10.1126/science.286.5439.537	http://dx.doi.org/10.1126/science.286.5439.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521350				2022-12-24	WOS:000083121200062
J	Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS				Shih, NY; Li, J; Karpitskii, V; Nguyen, A; Dustin, ML; Kanagawa, O; Miner, JH; Shaw, AS			Congenital nephrotic syndrome in mice lacking CD2-associated protein	SCIENCE			English	Article							PODOCYTES; CONTACTS; GENES	CD2-associated protein (CD2AP) is an 80-kilodalton protein that is critical for stabilizing contacts between T cells and antigen-presenting cells. In CD2AP-deficient mice, immune function was compromised, but the mice died at 6 to 7 weeks of age from renal failure. In the kidney, CD2AP was expressed primarily in glomerular epithelial cells. Knockout mice exhibited defects in epithelial tell foot processes, accompanied by mesangial cell hyperplasia and extracellular matrix deposition. Supporting a role for CD2AP in the specialized cell junction known as the slit diaphragm, CD2AP associated with nephrin, the primary component of the slit diaphragm.	Washington Univ, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Dept Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Shih, NY (corresponding author), Washington Univ, Ctr Immunol, St Louis, MO 63110 USA.		Shih, Neng-Yao/D-2086-2010; Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389				Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; GAUEN LT, 1992, MOL CELL BIOL, V38, P5438; KATO M, 1988, J CELL BIOL, V106, P2203, DOI 10.1083/jcb.106.6.2203; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MUNDEL P, 1991, J HISTOCHEM CYTOCHEM, V39, P1047, DOI 10.1177/39.8.1856454; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SHIH N, UNPUB	14	628	683	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					312	315		10.1126/science.286.5438.312	http://dx.doi.org/10.1126/science.286.5438.312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514378				2022-12-24	WOS:000083024400050
J	Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF				Loisel, TP; Boujemaa, R; Pantaloni, D; Carlier, MF			Reconstitution of actin-based motility of Listeria and Shigella using pure proteins	NATURE			English	Article							FILAMENT TURNOVER; CELL MOTILITY; MONOCYTOGENES; SURFACE; DYNAMICS; FLEXNERI; POLYMERIZATION; SUFFICIENT; NUCLEATION; COMPLEX	Actin polymerization is essential for cell locomotion and is thought to generate the force responsible for cellular protrusions. The Arp2/3 complex is required to stimulate actin assembly at the leading edge in response to signalling(1-6). The bacteria Listeria and Shigella bypass the signalling pathway and harness the Arp2/3 complex to induce actin assembly and to propel themselves in living cells(7-10). However, the Arp2/3 complex alone is insufficient to promote movement. Here we have used pure components of the actin cytoskeleton to reconstitute sustained movement in Listeria and Shigella in vitro. Actin-based propulsion is driven by the free energy released by ATP hydrolysis linked to actin polymerization, and does not require myosin. In addition to actin and activated Arp2/3 complex, actin depolymerizing factor (ADF, or cofilin) and capping protein are also required for motility as they maintain a high steady-state level of G-actin, which controls the rate of unidirectional growth of actin filaments at the surface of the bacterium. The movement is more effective when profilin, alpha-actinin and VASP (for Listeria) are also included. These results have implications for our understanding of the mechanism of actin-based motility in cells.	CNRS, LEBS, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Carlier, MF (corresponding author), CNRS, LEBS, Gif Sur Yvette, France.	carlier@lebs.caps-gif.fr		Boujemaa-Paterski, Rajaa/0000-0001-9645-387X				Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; GOLDBERG MB, 1995, P NATL ACAD SCI USA, V92, P6572, DOI 10.1073/pnas.92.14.6572; Goldberg MB, 1997, CELL MOTIL CYTOSKEL, V37, P44, DOI 10.1002/(SICI)1097-0169(1997)37:1<44::AID-CM5>3.3.CO;2-S; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; KOCKS C, 1995, MOL MICROBIOL, V18, P413, DOI 10.1111/j.1365-2958.1995.mmi_18030413.x; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; Lasa I, 1997, EMBO J, V16, P1531, DOI 10.1093/emboj/16.7.1531; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MARCHAND JB, 1995, J CELL BIOL, V130, P331, DOI 10.1083/jcb.130.2.331; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NANAVATI D, 1994, CELL MOTIL CYTOSKEL, V28, P346, DOI 10.1002/cm.970280408; Ressad F, 1999, J BIOL CHEM, V274, P20970, DOI 10.1074/jbc.274.30.20970; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Sun J P, 1995, J Am Soc Echocardiogr, V8, P29, DOI 10.1016/S0894-7317(05)80355-4; Suzuki T, 1998, EMBO J, V17, P2767, DOI 10.1093/emboj/17.10.2767; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8; Yarar D, 1999, CURR BIOL, V9, P555, DOI 10.1016/S0960-9822(99)80243-7	31	787	800	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					613	616		10.1038/44183	http://dx.doi.org/10.1038/44183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524632				2022-12-24	WOS:000083054900057
J	Millstone, E; Brunner, E; Mayer, S				Millstone, E; Brunner, E; Mayer, S			Beyond 'substantial equivalence'	NATURE			English	Editorial Material									Univ Sussex, Sci Policy Res Unit, Brighton BN1 9RF, E Sussex, England; UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; GeneWatch UK, Buxton SK17 8NY, Derby, England	University of Sussex; University of London; University College London	Millstone, E (corresponding author), Univ Sussex, Sci Policy Res Unit, Mantell Bldg, Brighton BN1 9RF, E Sussex, England.	e.p.millstone@sussex.ac.uk	Kesim, Haydar K/B-4662-2010; Brunner, Eric/H-2114-2011	Brunner, Eric/0000-0002-0595-4474				Bowers J, 1999, SCIENCE, V285, P1562, DOI 10.1126/science.285.5433.1562; *EUR COMM, 1980, FOOD ADD CONS, P41; KUIPER H, 1998, FOOD SAFETY EVALUATI; LYDON J, 1989, PESTIC SCI, V25, P361, DOI 10.1002/ps.2780250406; Masood E, 1999, NATURE, V398, P98, DOI 10.1038/18086; *OECD, 1993, SAF EV FOODS DER MOD; Padgette SR, 1996, J NUTR, V126, P702, DOI 10.1093/jn/126.3.702; WHO, 1991, STRAT ASS SAF FOODS	8	200	226	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					525	526		10.1038/44006	http://dx.doi.org/10.1038/44006			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524614				2022-12-24	WOS:000083054900020
J	Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC				Jalan, R; Damink, SWMO; Deutz, NEP; Lee, A; Hayes, PC			Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure	LANCET			English	Article							FULMINANT HEPATIC-FAILURE; CEREBRAL BLOOD-FLOW; TOTAL HEPATECTOMY; BODY-TEMPERATURE; CONTROLLED TRIAL; BRAIN EDEMA; GLUTAMINE; RAT; METABOLISM; AMMONIA	Background Increased intracranial pressure as a complication of acute liver failure has a mortality of about 90% in patients who do not respond to treatment with mannitol and ultrafiltration. We investigated the safety and efficacy of moderate hypothermia for uncontrolled increase in intracranial pressure in patients with acute liver failure. Methods We studied seven consecutive patients aged 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver failure who fulfilled criteria for poor-prognosis liver failure and had increased intracranial pressure that was unresponsive to two treatments with mannitol and ultrafiltration. We used cooling blankets to lower the patients' core temperature to 32-33 degrees C. Patients who were not suitable candidates for OLT (patients 1-3) were cooled for 8 h and then gradually rewarmed over 1 h to 8 baseline temperature of 37 degrees C. Patients who were suitable candidates for OLT (patients 4-7) were cooled before and during the OLT procedure; We measured cerebral blood flow and metabolic indices before and after cooling. Findings The four patients who were candidates for OLT were successfully maintained until transplantation with 13 (range 10-14) h of hypothermia. The three patients who were unsuitable candidates for OLT died after rewarming. Intracranial pressure before cooling was 45 (25-49) mm Hg and was reduced in all patients to 16 (13-17) mm Hg (p<0.05). Cerebral blood flow decreased from 103 (25-134) mt 100 g(-1) min(-1) before cooling to 44 (24-75) mt 100 g(-1) min(-1) after cooling (p<005). The corresponding changes for cerebral perfusion pressure was an increase from 45 (37-56) mm Hg to 70 (60-78) mm Hg (p<0.05) and for cardiac index a decrease from 9.8 (7-13) to 5.1 (4.3-6.1) L per min per m(2) of body surface area. During hypothermia there was no significant relapse of increased intracranial pressure. Arterial ammonia and cerebral uptake of ammonia were significantly reduced with cooling. No adverse effects of hypothermia were observed. Interpretation Moderate hypothermia is useful in the treatment of uncontrolled increase in intracranial pressure in patients with acute liver failure and may serve as a bridge to OLT.	Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Scottish Liver Transplantat Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Dept Anaesthet, Edinburgh EH3 9YW, Midlothian, Scotland; Royal Infirm Edinburgh, Intens Care Unit, Edinburgh EH3 9YW, Midlothian, Scotland; Maastricht Univ, Dept Surg, Maastricht, Netherlands	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; Maastricht University	Jalan, R (corresponding author), Royal Infirm Edinburgh, Liver Unit, Edinburgh EH3 9YW, Midlothian, Scotland.		Deutz, Nicolaas E/J-5200-2012; Damink, Steven WM Olde/U-7919-2019	Damink, Steven WM Olde/0000-0002-5202-9345; Deutz, Nicolaas/0000-0001-5845-6447	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGGARWAL S, 1994, HEPATOLOGY, V19, P80, DOI 10.1002/hep.1840190114; ASCHER NL, 1993, ARCH SURG-CHICAGO, V128, P677; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; COOPER AJL, 1987, PHYSIOL REV, V67, P440, DOI 10.1152/physrev.1987.67.2.440; DEJONG CHC, 1993, J CLIN INVEST, V92, P2834, DOI 10.1172/JCI116903; EDE RJ, 1986, J HEPATOL, V2, P43, DOI 10.1016/S0168-8278(86)80007-1; Eguchi S, 1996, HEPATOLOGY, V24, P1452; EJLERSEN E, 1994, TRANSPLANT P, V26, P1794; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; Hirata T, 1996, STROKE, V27, P729, DOI 10.1161/01.STR.27.4.729; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; JACOBSEN M, 1989, J CEREB BLOOD FLOW M, V9, P717; KEAYS R, 1991, BRIT MED J, V303, P1026, DOI 10.1136/bmj.303.6809.1026; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; Larsen FS, 1996, SEMIN LIVER DIS, V16, P281, DOI 10.1055/s-2007-1007241; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCCONNELL JR, 1995, HEPATOLOGY, V22, P69, DOI 10.1016/0270-9139(95)90354-2; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; OLAFSSON S, 1995, GASTROENTEROLOGY, V108, P1097, DOI 10.1016/0016-5085(95)90208-2; PEIGNOUX M, 1982, CLIN SCI, V62, P273, DOI 10.1042/cs0620273; Philips BJ, 1998, HEPATOLOGY, V27, P369, DOI 10.1002/hep.510270209; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Rao VLR, 1998, METAB BRAIN DIS, V13, P175, DOI 10.1023/A:1023281307660; TAKAHASHI H, 1991, AM J PHYSIOL, V261, P825; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trey C, 1970, Prog Liver Dis, V3, P282; WENDON JA, 1994, HEPATOLOGY, V19, P1407, DOI 10.1016/0270-9139(94)90235-6; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9	30	255	265	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1164	1168		10.1016/S0140-6736(98)12440-6	http://dx.doi.org/10.1016/S0140-6736(98)12440-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513710				2022-12-24	WOS:000082954100012
J	Micchelli, CA; Blair, SS				Micchelli, CA; Blair, SS			Dorsoventral lineage restriction in wing imaginal discs requires Notch	NATURE			English	Article							DORSAL-VENTRAL BOUNDARY; GENE-EXPRESSION; VESTIGIAL GENE; DROSOPHILA; SERRATE; FRINGE; ACTIVATION; CELLS; COMPARTMENT; SIGNAL	The formation of boundaries that prevent the intermixing of cells is an important developmental patterning mechanism. The compartmental lineage restrictions that appear in the developing imaginal discs of Drosophila are striking examples of such boundaries(1). However, little is known about the cellular mechanism underlying compartmental lineage restrictions. The dorsoventral (D/V) lineage restriction that arises late in the developing wing imaginal disc requires the dorsal expression of the transcription factor Apterous and it has been hypothesized that apterous (ap) maintains compartmentalization by directly regulating the expression of molecules that modify cell adhesion or affinity(2). However, ap expression also regulates signalling between dorsal and ventral compartments, resulting in high levels of Notch signalling at the D/V boundary(3-17). Here we show that the formation of Notch-dependent boundary cells ig required for the D/V lineage restriction.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Blair, SS (corresponding author), Univ Wisconsin, Dept Zool, 250 N Mills St, Madison, WI 53706 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; Blair SS, 1997, CURR BIOL, V7, pR686, DOI 10.1016/S0960-9822(06)00356-3; BLAIR SS, 1999, DEV GENETICS EPIGENE, P347; Brennan K, 1997, GENETICS, V147, P177; BROWER DL, 1985, DEV BIOL, V108, P120, DOI 10.1016/0012-1606(85)90014-4; Couso JP, 1995, CURR BIOL, V5, P1437, DOI 10.1016/S0960-9822(95)00281-8; DECELIS JF, 1994, MECH DEVELOP, V46, P109, DOI 10.1016/0925-4773(94)90080-9; deCelis JF, 1996, DEVELOPMENT, V122, P359; deCelis JF, 1997, DEVELOPMENT, V124, P3241; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; Doherty D, 1996, GENE DEV, V10, P421, DOI 10.1101/gad.10.4.421; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; Gho M, 1996, DEVELOPMENT, V122, P1673; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Klein T, 1998, DEVELOPMENT, V125, P2951; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Neumann CJ, 1996, DEVELOPMENT, V122, P3477; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9	30	87	89	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					473	476		10.1038/46779	http://dx.doi.org/10.1038/46779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519549				2022-12-24	WOS:000082981200055
J	Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M				Boden, D; Hurley, A; Zhang, LQ; Cao, YZ; Guo, Y; Jones, E; Tsay, J; Ip, J; Farthing, C; Limoli, K; Parkin, N; Markowitz, M			HIV-1 drug resistance in newly infected individuals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; ANTIRETROVIRAL THERAPY; ZIDOVUDINE-RESISTANCE; PROTEASE INHIBITORS; TYPE-1; TRANSMISSION; MUTATIONS; CELL; INDINAVIR	Context There is concern that the widespread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may result in the increased transmission of drug-resistant virus. Objective To determine the prevalence of drug resistance-conferring mutations and phenotypic resistance to antiretroviral agents in a cohort of individuals newly infected with HIV-1. Design Case series with genetic analyses of the HIV-1 plasma-derived pol gene using reverse transcriptase polymerase chain reaction followed by direct sequencing of polymerase chain reaction products. Phenotypic analysis was performed with a recombinant virus assay. Setting and Patients Eighty individuals referred, on average, 1.7 months after infection with HIV-1 to the Aaron Diamond AIDS Research Center between July 1995 and April 1999, Subjects were from large urban areas (65 from New York, NY; 11 from Los Angeles, Calif); 60 (75%) were white, and 75 (93.8%) were homosexual men. Main Outcome Measures Prevalence of known resistance-conferring genotypes and reduced susceptibility to individual antiviral agents by phenotype. Results Thirteen individuals (16.3%) had genotypes associated with drug resistance to any antiretroviral agent. Virus with known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subjects, and to any protease inhibitors in 2 cases. Multidrug-resistant Virus was identified in 3 individuals (3.8%), Extensive polymorphism in the protease gene was identified. Interpretation of genotypes and phenotypes was concordant in 57 (85%) of the 67 cases in which both studies were performed. Conclusion The prevalence of HIV-1 variants with known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected individuals is 16.3%., These data support expanded use of resistance testing in the setting of primary HIV-1 infection. Clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical tri pie combination antiretroviral therapy, provides additional virological and immunological benefit when treating primary HIV-1 infection. Further efforts to expand the study of transmission of drug-resistant HIV-1 variants, particularly in cohorts with different epidemiological profiles, are indicated.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; AIDS Healthcare Fdn, Los Angeles, CA USA; ViroLog Inc, San Francisco, CA USA	Rockefeller University	Markowitz, M (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.	mmarkowitz@adarc.org	Parkin, Neil/P-2724-2019; Ip, James E./I-1235-2019; Guo, Yong/ABF-9338-2020	Ip, James E./0000-0002-3461-505X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848, U01AI041534] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIAID NIH HHS [AI-41534, P30AI42848] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGARANO G, 1994, AIDS, V8, P1013, DOI 10.1097/00002030-199407000-00023; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Condra JH, 1996, J VIROL, V70, P8270, DOI 10.1128/JVI.70.12.8270-8276.1996; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CONLON CP, 1994, J INFECT DIS, V169, P411, DOI 10.1093/infdis/169.2.411; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; DUNCOMBE C, 1998, 5 C RETR OPP INF FEB; Eastman PS, 1998, J VIROL, V72, P5154, DOI 10.1128/JVI.72.6.5154-5164.1998; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269, DOI 10.1093/jac/42.2.269; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Jena PK, 1996, J IMMUNOL METHODS, V190, P199, DOI 10.1016/0022-1759(95)00277-4; Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PARKIN N, 1997, 37 INT C ANT AG CHEM; Patick AK, 1998, ANTIMICROB AGENTS CH, V42, P2637, DOI 10.1128/AAC.42.10.2637; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Quigg M, 1997, AIDS, V11, P835; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008; Shi CF, 1997, ANTIMICROB AGENTS CH, V41, P2781, DOI 10.1128/AAC.41.12.2781; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SONNERBORG A, 1993, AIDS, V7, P1684, DOI 10.1097/00002030-199312000-00027; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	37	368	381	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1135	1141		10.1001/jama.282.12.1135	http://dx.doi.org/10.1001/jama.282.12.1135			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501116	Bronze			2022-12-24	WOS:000082596200028
J	Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP				Harris, TJ; Cook, DG; Wicks, PD; Cappuccio, FP			Ethnic differences in use of hormone replacement therapy: community based survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Med, Blood Pressure Unit, London SW17 0RE, England	St Georges University London; St Georges University London; St Georges University London	Cook, DG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Cappuccio, Francesco Paolo/ABF-1094-2020; Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493; Harris, Tess/0000-0002-8671-1553; Cook, Derek/0000-0002-9723-5759				BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Cappuccio FP, 1997, HEART, V78, P555, DOI 10.1136/hrt.78.6.555; GRIFFITHS F, 1995, FAM PRACT, V12, P163, DOI 10.1093/fampra/12.2.163; TOBIAS JH, 1994, CLIN SCI, V87, P587, DOI 10.1042/cs0870587	5	11	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					610	611		10.1136/bmj.319.7210.610	http://dx.doi.org/10.1136/bmj.319.7210.610			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10473476	Green Published, Bronze			2022-12-24	WOS:000082460300020
J	Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW				Ko, AI; Reis, MG; Dourado, CMR; Johnson, WD; Riley, LW		Salvador Leptospirosis Study Grp	Urban epidemic of severe leptospirosis in Brazil	LANCET			English	Article							INNER-CITY; ANTIBODIES; ASSAY	Background Leptospirosis has, traditionally, been considered a sporadic rural disease. We describe a large urban outbreak of leptospirosis. Methods Active surveillance for leptospirosis was established in an infectious-disease referral hospital in Salvador, Brazil, between March 10 and Nov 2, 1996. Patients meeting case criteria for severe manifestations of leptospirosis were recruited into the study. The diagnosis was confirmed in the laboratory with the microagglutination test and identification of leptospires in blood or urine. Risk factors for death were examined by multivariate analyses. Findings Surveillance identified 326 cases of which 193 (59%) were laboratory-confirmed (133) or probable (60) cases. Leptospira interrogans serovar copenhageni was isolated from 87% of the cases with positive blood cultures. Most of the cases were adult (mean age 35.9 years [SD 15.9]), and 80% were male. Complications included jaundice (91%), oliguria (35%), and severe anaemia (26%). 50 cases died (case-fatality rate 15%) despite aggressive supportive care including dialysis (in 23%). Altered mental status was the strongest independent predictor of death (odds ratio 9.12 [95% CI 4.28-20.3]), age over 37 years, renal insufficiency, and respiratory insufficiency were also significant predictors of death. Before admission to hospital, 42% were misdiagnosed as having dengue fever in the outpatient clinic; an outbreak of dengue fever was taking place concurrently. Interpretation An epidemic of leptospirosis has become a major urban health problem, associated with high mortality. Diagnostic confusion with dengue fever, another emerging infectious disease with a similar geographic distribution, prevents timely intervention that could minimise mortality.	Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, BR-40295001 Salvador, BA, Brazil; Hosp Couto Maia, Secretary Hlth State Bahia, Salvador, BA, Brazil; Cornell Univ Med Coll, Div Int Med & Infect Dis, New York, NY USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Fundacao Oswaldo Cruz; Cornell University; University of California System; University of California Berkeley	Ko, AI (corresponding author), Brazilian Minist Hlth, Ctr Pesquisas Goncalo Moniz, Fdn Oswaldo Cruz MS, Rua Waldemar Falcao 121, BR-40295001 Salvador, BA, Brazil.		Ko, Albert/P-2343-2015	Ko, Albert/0000-0001-9023-2339; Pedreira, Clarissa/0000-0003-1267-3344	FIC NIH HHS [D43 TW00919, D43 TW00905, D43 TW00018] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000018, D43TW000919, D43TW000905] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		CACCIAPUOTI B, 1994, EUR J EPIDEMIOL, V10, P173, DOI 10.1007/BF01730367; CASTRO JSM, 1997, B EPIDEMIOL SESAB, V5, P2; CHEN Y, 1990, CHUNG HUA SHEN CHING, V23, P226; CHILDS JE, 1992, AM J PUBLIC HEALTH, V82, P597, DOI 10.2105/AJPH.82.4.597; DEMERS RY, 1983, J FAM PRACTICE, V17, P1007; Dupont H, 1997, CLIN INFECT DIS, V25, P720, DOI 10.1086/513767; EDWARDS FA, 1964, MEDICINE, V36, P117; Faine S., 1982, GUIDELINES CONTROL L; Faine S., 1993, LEPTOSPIRA LEPTOSPIR; FARR RW, 1995, CLIN INFECT DIS, V21, P1, DOI 10.1093/clinids/21.1.1; FORWELL MA, 1984, BRIT MED J, V289, P1583, DOI 10.1136/bmj.289.6458.1583; Goncalves A J, 1992, Rev Soc Bras Med Trop, V25, P261; GRAVEKAMP C, 1993, J GEN MICROBIOL, V139, P1691, DOI 10.1099/00221287-139-8-1691; Gussenhoven GC, 1997, J CLIN MICROBIOL, V35, P92, DOI 10.1128/JCM.35.1.92-97.1997; KORVER H, 1988, Israel Journal of Veterinary Medicine, V44, P15; LESSA I, 1981, LANCET, V2, P1113, DOI 10.1016/S0140-6736(81)91315-5; MERIEN F, 1992, J CLIN MICROBIOL, V30, P2219; NOGUCHI H, 1924, MONOGRAPHS ROCKEFELL, V20, P1; PARK SK, 1989, AM J TROP MED HYG, V41, P345, DOI 10.4269/ajtmh.1989.41.345; SAKATA EE, 1992, REV I MED TROP, V34, P217, DOI 10.1590/S0036-46651992000300006; Vinetz JM, 1996, ANN INTERN MED, V125, P794, DOI 10.7326/0003-4819-125-10-199611150-00002; Winslow WE, 1997, J CLIN MICROBIOL, V35, P1938, DOI 10.1128/JCM.35.8.1938-1942.1997; Zaki SR, 1996, LANCET, V347, P535, DOI 10.1016/S0140-6736(96)91167-8; 1991, ANUARIO ESTATISTICO; 1997, MMWR MORB MORTAL WKL, V46, P577; 1998, RELATORIO GESTAO; 1998, MMWR MORB MORTAL WKL, V47, P585	27	529	559	1	115	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 4	1999	354	9181					820	825		10.1016/S0140-6736(99)80012-9	http://dx.doi.org/10.1016/S0140-6736(99)80012-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485724				2022-12-24	WOS:000082400700011
J	Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN				Marine, JC; Topham, DJ; McKay, C; Wang, DM; Parganas, E; Stravopodis, D; Yoshimura, A; Ihle, JN			SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality	CELL			English	Article							CHRONIC ACTIVE HEPATITIS; MICE LACKING JAK3; INTERFERON-GAMMA; INDUCIBLE GENE; CELL-DEATH; EXPRESSION; LIVER; THYMOCYTES; INHIBITOR; RECEPTORS	SOCS1. is an SH2-containing protein that is primarily expressed in thymocytes in a cytokine- and T cell receptor-independent manner. SOCS1 deletion causes perinatal lethality with death by 2-3 weeks. During this period thymic changes include a loss of cellularity and a switch from predominantly CD4(+)CD8(+) to single positive cells. Peripheral T cells express activation antigens and proliferate to IL-2 in the absence of anti-CD3. In addition, IFN gamma is present in the serum. Reconstitution of the lymphoid lineage of JAK3-deficient mice with SOCS1-deficient stem cells recapitulates the lethality and T cell alterations. Introducing a RAG2 or IFN gamma deficiency eliminates lethality. The results demonstrate that lymphocytes are critical to SOCS1-associated perinatal lethality and implicate SOCS1 in lymphocyte differentiation or regulation.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Dept Biochem, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wang, Demin/AAX-4449-2020; Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015; Yoshimura, Akihiko/K-5515-2013	Wang, Demin/0000-0001-5549-3795; Marine, Jean-Christophe/0000-0003-2433-9837; Stravopodis, Dimitrios/0000-0002-9535-2134	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GRESSER I, 1981, AM J PATHOL, V102, P396; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Lerner A, 1996, EMBO J, V15, P5876, DOI 10.1002/j.1460-2075.1996.tb00974.x; MATTSSON R, 1992, BIOL REPROD, V46, P1176, DOI 10.1095/biolreprod46.6.1176; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Okamoto T, 1996, BIOCHEM BIOPH RES CO, V226, P762, DOI 10.1006/bbrc.1996.1426; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SHI YF, 1991, J IMMUNOL, V146, P3340; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; SUDA T, 1990, J IMMUNOL, V144, P3039; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Young HA, 1997, BLOOD, V89, P583, DOI 10.1182/blood.V89.2.583	26	432	446	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					609	616		10.1016/S0092-8674(00)80048-3	http://dx.doi.org/10.1016/S0092-8674(00)80048-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490100	Bronze			2022-12-24	WOS:000082433500008
J	Brennand, JK				Brennand, JK			"I wish I'd got my new ears last year, mum"'	LANCET			English	Editorial Material									Perth Royal Infirm, Perth PH1 1NX, Scotland		Brennand, JK (corresponding author), Perth Royal Infirm, Taymount Terrace, Perth PH1 1NX, Scotland.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					676	676		10.1016/S0140-6736(99)04026-X	http://dx.doi.org/10.1016/S0140-6736(99)04026-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466688				2022-12-24	WOS:000082214500048
J	Maiden, MCJ; Spratt, BG				Maiden, MCJ; Spratt, BG			Meningococcal conjugate vaccines: new opportunities and new challenges	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; ET-37 COMPLEX; VACCINATION; CARRIAGE; DISEASE		Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3FY, England	University of Oxford	Maiden, MCJ (corresponding author), Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, S Parks Rd, Oxford OX1 3FY, England.		Spratt, Brian G/A-1676-2009; Maiden, Martin C J/C-5055-2014; Maiden, Martin/N-6805-2019	Maiden, Martin C J/0000-0001-6321-5138; Maiden, Martin/0000-0001-6321-5138				CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; Gupta S, 1999, PHILOS T R SOC B, V354, P711, DOI 10.1098/rstb.1999.0424; Kwara A, 1998, TROP MED INT HEALTH, V3, P742, DOI 10.1046/j.1365-3156.1998.00300.x; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Slack MPE, 1998, PEDIATR INFECT DIS J, V17, pS204, DOI 10.1097/00006454-199809001-00026; Stephens DS, 1999, LANCET, V353, P941, DOI 10.1016/S0140-6736(98)00279-7; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010; VEDROS NA, 1987, EVOLUTION MENINGOCOC, P33; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320	16	87	90	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					615	616						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466659				2022-12-24	WOS:000082214500006
J	Mahanty, SK; Wang, YM; Farley, FW; Elion, EA				Mahanty, SK; Wang, YM; Farley, FW; Elion, EA			Nuclear shuttling of yeast scaffold Ste5 is required for its recruitment to the plasma membrane and activation of the mating MAPK cascade	CELL			English	Article							PHEROMONE RESPONSE PATHWAY; BETA-GAMMA COMPLEX; SACCHAROMYCES-CEREVISIAE; KINASE CASCADE; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TRANSCRIPTION FACTOR; CELL-CYCLE; FUS3; TRANSPORT	Localization of Ste5 to G beta at the plasma membrane is essential for transmission of the pheromone signal to associated MAP kinase cascade enzymes. Here, we show that this crucial localization requires prior shuttling of Ste5 through the nucleus. Ste5 shuttles through the nucleus constitutively during vegetative growth. Pheromone enhances nuclear export of Ste5, and this pool translocates vectorial ly to the cell periphery. Remarkably, Ste5 that cannot transit the nucleus is unable to localize at the periphery and activate the pathway, while Ste5 with enhanced transit through the nucleus has enhanced ability to localize to the periphery and activate the pathway. This novel regulatory scheme may ensure that cytoplasmic Ste5 does not activate downstream kinases in the absence of pheromone and could be applicable to other membrane-recruited signaling proteins.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Elion, EA (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	elion@bcmp.med.harvard.edu			NIGMS NIH HHS [GM46962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; [Anonymous], 1991, Methods Enzymol, V194, P1; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; Choi KY, 1999, MOL BIOL CELL, V10, P1553, DOI 10.1091/mbc.10.5.1553; CHOI KY, 1994, CELL, V78, P499; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; ELION EA, 1991, COLD SH Q B, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Farley FW, 1999, GENETICS, V151, P1425; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; KAISER CA, 1997, MOL CELLULAR BIOL YE, V3, P91; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyons DM, 1996, MOL CELL BIOL, V16, P4095; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHLENSTEDT G, 1993, J CELL BIOL, V123, P785, DOI 10.1083/jcb.123.4.785; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	57	127	130	1	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					501	512		10.1016/S0092-8674(00)81978-9	http://dx.doi.org/10.1016/S0092-8674(00)81978-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481914	Bronze			2022-12-24	WOS:000082174900010
J	Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L				Forsberg, E; Pejler, G; Ringvall, M; Lunderius, C; Tomasini-Johansson, B; Kusche-Gullberg, M; Eriksson, I; Ledin, J; Hellman, L; Kjellen, L			Abnormal mast cells in mice deficient in a heparin-synthesizing enzyme	NATURE			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; SERINE PROTEASES; SULFATE; MOUSE; BIOSYNTHESIS; EXPRESSION; PROTEOGLYCANS; DROSOPHILA	Heparin is a sulphated polysaccharide, synthesized exclusively by connective-tissue-type mast cells(1) and stored in the secretory granules in complex with histamine and various mast-cell proteases(2). Although heparin has long been used as an antithrombotic drug, endogenous heparin is not present in the blood, so it cannot have a physiological role in regulating blood coagulation. The biosynthesis of heparin involves a series of enzymatic reactions, including sulphation at various positions(1,3). The initial modification step, catalysed by the enzyme glucosaminyl N-deacetylase/N-sulphotransferase-2, NDST-2 (refs 4-7), is essential for the subsequent reactions. Here we report that mice carrying a targeted disruption of the gene encoding NDST-2 are unable to synthesize sulphated heparin. These NDST-2-deficient mice are viable and fertile but have fewer connective-tissue-type mast cells; these cells have an altered morphology and contain severely reduced amounts of histamine and mast-cell proteases. Our results indicate that one site of physiological action for heparin could be inside connective-tissue-type mast cells, where its absence results in severe defects in the secretory granules.	Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Cell & Mol Biol, S-75123 Uppsala, Sweden; Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences; Uppsala University; Uppsala University	Kjellen, L (corresponding author), Swedish Univ Agr Sci, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.		Kusche-Gullberg, Marion/P-4466-2016; Kjellen, Lena/F-1362-2011	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ledin, Johan/0000-0002-7319-7735				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Galli SJ, 1996, NATURE, V381, P21, DOI 10.1038/381021a0; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Huang CF, 1998, J CLIN IMMUNOL, V18, P169, DOI 10.1023/A:1020574820797; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, BIOCHEM J, V253, P885, DOI 10.1042/bj2530885; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PASSLER R, 1995, GENE DEV, V9, P1896; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458	25	393	397	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					773	776		10.1038/23488	http://dx.doi.org/10.1038/23488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466727				2022-12-24	WOS:000082131100052
J	Cavalli, G; Paro, R				Cavalli, G; Paro, R			Epigenetic inheritance of active chromatin after removal of the main transactivator	SCIENCE			English	Article							DROSOPHILA BITHORAX COMPLEX; POLYCOMB-PROTEIN; DOMAIN BOUNDARY; MELANOGASTER; TRITHORAX; GENE; EXPRESSION; ELEMENTS; BINDING	The Drosophila Polycomb and trithorax group proteins act through chromosomal elements such as Fab-7 to maintain repressed or active gene expression, respectively. A Fab-7 element is switched from a silenced to a mitotically heritable active state by an embryonic pulse of transcription. Here, histone H4 hyperacetylation was found to be associated with Fab-7 after activation, suggesting that H4 hyperacetylation may be a heritable epigenetic tag of the activated element, Activated Fab-7 enables transcription of a gene even after withdrawal of the primary transcription factor. This feature may allow epigenetic maintenance of active states of developmental genes after decay of their early embryonic regulators.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Inst Human Genet, F-34396 Montpellier, France	Ruprecht Karls University Heidelberg; Universite de Montpellier	Paro, R (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.		cavalli, giacomo/Z-2754-2019; Cavalli, Giacomo/A-7958-2008	cavalli, giacomo/0000-0003-3709-3469; Cavalli, Giacomo/0000-0003-3709-3469				BREILING A, IN PRESS MOL CELL BI; BUSTURIA A, 1993, EMBO J, V12, P1415, DOI 10.1002/j.1460-2075.1993.tb05785.x; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FAUVARQUE MO, 1995, MECH DEVELOP, V52, P343, DOI 10.1016/0925-4773(95)00412-T; Gellon G, 1998, BIOESSAYS, V20, P116, DOI 10.1002/(SICI)1521-1878(199802)20:2<116::AID-BIES4>3.3.CO;2-N; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hagstrom K, 1997, GENETICS, V146, P1365; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Orlando V, 1998, EMBO J, V17, P5141, DOI 10.1093/emboj/17.17.5141; Paro R., 1996, EPIGENETIC MECH GENE, P507; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773; Tillib S, 1999, MOL CELL BIOL, V19, P5189; ZINK B, 1989, NATURE, V337, P468, DOI 10.1038/337468a0; ZINK B, 1991, EMBO J, V10, P153, DOI 10.1002/j.1460-2075.1991.tb07931.x; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	24	198	209	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					955	958		10.1126/science.286.5441.955	http://dx.doi.org/10.1126/science.286.5441.955			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542150				2022-12-24	WOS:000083368500045
J	Mathews, S; Donoghue, MJ				Mathews, S; Donoghue, MJ			The root of angiosperm phylogeny inferred from duplicate phytochrome genes	SCIENCE			English	Article							SEED PLANT PHYLOGENY; DATA SETS; SEQUENCES; EVOLUTION; ORIGIN; DIVERSIFICATION; PARSIMONY; DIVERSITY; FAMILY	An analysis of duplicate phytochrome genes (PHYA and PHYC) is used to root the angiosperms, thereby avoiding the inclusion of highly diverged outgroup sequences. The results unambiguously place the root near Amborella tone species, New Caledonia) and resolve water Lilies (Nymphaeales, similar to 70 species, cosmopolitan), followed by Austrobaileya tone species, Australia), as early branches. These findings bear directly on the interpretation of morphological evolution and diversification within angiosperms.	Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA	Harvard University	Mathews, S (corresponding author), Harvard Univ Herbaria, Dept Organism & Evolutionary Biol, 22 Divin Ave, Cambridge, MA 02138 USA.	smathews@oeb.harvard.edu	Mathews, Sarah/A-6513-2015	Mathews, Sarah/0000-0002-5518-7541				BOWE LM, IN PRESS P NATL ACAD; CARLQUIST S, 1992, AM J BOT, V79, P660, DOI 10.2307/2444882; Carlquist S, 1975, ECOLOGICAL STRATEGIE; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHAW SM, IN PRESS P NATL ACAD; Donoghue MJ, 1998, MOL PHYLOGENET EVOL, V9, P489, DOI 10.1006/mpev.1998.0511; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; DOYLE JA, 1993, PALEOBIOLOGY, V19, P141, DOI 10.1017/S0094837300015840; Doyle JA, 1996, INT J PLANT SCI, V157, pS3, DOI 10.1086/297401; ENDRESS PK, UNPUB; Farris JS, 1995, SYST BIOL, V44, P570, DOI 10.2307/2413663; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GRAHAM SV, UNPUB; Hansen A, 1999, MOL BIOL EVOL, V16, P1006, DOI 10.1093/oxfordjournals.molbev.a026176; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Howe GT, 1998, MOL BIOL EVOL, V15, P160, DOI 10.1093/oxfordjournals.molbev.a025912; Igersheim A, 1997, BOT J LINN SOC, V124, P213, DOI 10.1006/bojl.1997.0102; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; Larson A., 1994, Experientia Supplementum (Basel), V69, P371; Lavin M, 1998, AM J BOT, V85, P412, DOI 10.2307/2446334; MATHEWS S, 1995, ANN MO BOT GARD, V82, P296, DOI 10.2307/2399882; Mathews S, 1997, PLANT CELL ENVIRON, V20, P666, DOI 10.1046/j.1365-3040.1997.d01-117.x; MATHEWS SM, UNPUB; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; PARKINSON CJ, UNPUB; QIU YL, IN PRESS NATURE; Renner SS, 1999, AM J BOT, V86, P1301, DOI 10.2307/2656778; SANDERSON MJ, 1994, SCIENCE, V264, P1590, DOI 10.1126/science.264.5165.1590; Sang T, 1997, MOL BIOL EVOL, V14, P994, DOI 10.1093/oxfordjournals.molbev.a025716; Schneider EL, 1996, AM J BOT, V83, P1236, DOI 10.2307/2446207; Schneider-Poetsch HAW, 1998, PHYSIOL PLANTARUM, V102, P612, DOI 10.1034/j.1399-3054.1998.1020417.x; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS PS, IN PRESS NATURE; SWOFFORD D, 1999, PAUP 4 0; THEIN LB, UNPUB; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355; WHITEHOUSE HLK, 1950, ANN BOT-LONDON, V14, P199, DOI 10.1093/oxfordjournals.aob.a083243; Winter KU, 1999, P NATL ACAD SCI USA, V96, P7342, DOI 10.1073/pnas.96.13.7342; YOUNG DA, 1981, SYST BOT, V6, P313, DOI 10.2307/2418445	40	347	362	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					947	950		10.1126/science.286.5441.947	http://dx.doi.org/10.1126/science.286.5441.947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542147				2022-12-24	WOS:000083368500042
J	Sestan, N; Artavanis-Tsakonas, S; Rakic, P				Sestan, N; Artavanis-Tsakonas, S; Rakic, P			Contact-dependent inhibition of cortical neurite growth mediated by notch signaling	SCIENCE			English	Article							MAMMALIAN NUMB; IN-VITRO; NEUROGENESIS; DIFFERENTIATION; SYNAPTOGENESIS; TRANSCRIPTION; LOCALIZATION; ACTIVATION; DISEASE; PATHWAY	The exuberant growth of neurites during development becomes markedly reduced as cortical neurons mature. In vitro studies of neurons from mouse cerebral cortex revealed that contact-mediated Notch signaling regulates the capacity of neurons to extend and elaborate neurites, Up-regulation of Notch activity was concomitant with an increase in the number of interneuronal contacts and cessation of neurite growth. In neurons with low Notch activity, which readily extend neurites, up-regulation of Notch activity either inhibited extension or caused retraction of neurites. Conversely, in more mature neurons that had ceased their growth after establishing numerous connections and displayed high Notch activity,inhibition of Notch signaling promoted neurite extension. Thus, the formation of neuronal contacts results in activation of Notch receptors, Leading to restriction of neuronal growth and a subsequent arrest in maturity.	Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Yale University; Harvard University; Massachusetts General Hospital	Rakic, P (corresponding author), Yale Univ, Sch Med, Neurobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.	pasko.rakic@yale.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS014841, R01NS026084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS14841, NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHMAD I, 1995, MECH DEVELOP, V53, P73, DOI 10.1016/0925-4773(95)00425-4; AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 1997, J BIOL CHEM, V272, P11336; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Berezovska O, 1999, MOL BRAIN RES, V69, P273, DOI 10.1016/S0169-328X(99)00119-9; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUNN GA, 1971, J COMP NEUROL, V143, P491, DOI 10.1002/cne.901430406; FLETCHER TL, 1994, J NEUROSCI, V14, P6695; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Gray GE, 1999, AM J PATHOL, V154, P785, DOI 10.1016/S0002-9440(10)65325-4; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gridley T, 1997, MOL CELL NEUROSCI, V9, P103, DOI 10.1006/mcne.1997.0610; Horch HW, 1999, NEURON, V23, P353; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jarriault S, 1998, MOL CELL BIOL, V18, P7423, DOI 10.1128/MCB.18.12.7423; Kimble J, 1997, ANNU REV CELL DEV BI, V13, P333, DOI 10.1146/annurev.cellbio.13.1.333; Lecourtois M, 1998, CURR BIOL, V8, P771, DOI 10.1016/S0960-9822(98)70300-8; Li LH, 1998, IMMUNITY, V8, P43, DOI 10.1016/S1074-7613(00)80457-4; Lu FM, 1996, P NATL ACAD SCI USA, V93, P5663, DOI 10.1073/pnas.93.11.5663; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Olson EC, 1998, MOL CELL NEUROSCI, V12, P281, DOI 10.1006/mcne.1998.0712; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; PERRY VH, 1982, NATURE, V297, P683, DOI 10.1038/297683a0; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; RAKIC P, 1982, DEV MODIFIABILITY CE; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SESTAN N, 1999, THESIS YALE U; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Vamum-Finney B, 1998, BLOOD, V91, P4084; Van den Pol AN, 1998, J COMP NEUROL, V399, P541; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; Yavari R, 1998, HUM MOL GENET, V7, P1161, DOI 10.1093/hmg/7.7.1161; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	50	476	498	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					741	746		10.1126/science.286.5440.741	http://dx.doi.org/10.1126/science.286.5440.741			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531053				2022-12-24	WOS:000083303200045
J	Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M				Vassar, R; Bennett, BD; Babu-Khan, S; Kahn, S; Mendiaz, EA; Denis, P; Teplow, DB; Ross, S; Amarante, P; Loeloff, R; Luo, Y; Fisher, S; Fuller, L; Edenson, S; Lile, J; Jarosinski, MA; Biere, AL; Curran, E; Burgess, T; Louis, JC; Collins, F; Treanor, J; Rogers, G; Citron, M			beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE	SCIENCE			English	Article							TRANSGENIC MICE; DISEASE; PEPTIDE; CELLS; MUTATION; RELEASE; PURIFICATION; GENERATION; INHIBITION; RECEPTOR	Cerebral deposition of amyloid beta peptide (A beta) is an early and critical feature of Alzheimer's disease. A beta generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: beta-secretase and gamma-secretase. These proteases are prime therapeutic targets. A transmembrane aspartic protease with all the known characteristics of beta-secretase was cloned and characterized. Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta-secretase positions. Antisense inhibition of endogenous BACE messenger RNA decreased the amount of beta-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as beta-secretase. Finally, the expression pattern and subcellular Localization of BACE were consistent with that expected for beta-secretase. Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.	Amgen Inc, Thousand Oaks, CA 91320 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Amgen; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Citron, M (corresponding author), Amgen Inc, 1 Amgen Ctr Dr,M-S 29-2-B, Thousand Oaks, CA 91320 USA.							Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 1996, AMYLOID, V3, P150, DOI 10.3109/13506129609045514; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CURRAN EJ, 1995, J COMP NEUROL, V361, P57, DOI 10.1002/cne.903610106; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Gouras GK, 1998, J NEUROCHEM, V71, P1920; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P105; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Younkin SG, 1998, J PHYSIOLOGY-PARIS, V92, P289, DOI 10.1016/S0928-4257(98)80035-1; Zhao J, 1996, J BIOL CHEM, V271, P31407, DOI 10.1074/jbc.271.49.31407; ZHONG ZY, 1994, J BIOL CHEM, V269, P627	32	3153	3422	10	464	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					735	741		10.1126/science.286.5440.735	http://dx.doi.org/10.1126/science.286.5440.735			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531052	Green Published			2022-12-24	WOS:000083303200044
J	Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ				Yawn, BP; Yawn, RA; Hodge, D; Shaughnessy, WJ; Ilstrup, D; Jacobsen, SJ			A population-based study of school scoliosis screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADOLESCENT IDIOPATHIC SCOLIOSIS; NATURAL-HISTORY; EPIDEMIOLOGY	Context Although school-based screening programs for adolescent idiopathic scoliosis are mandated in 26 states in the United States, few program outcomes data exist regarding the effectiveness of such programs. Objective To determine the effectiveness of a community-based school scoliosis screening program. Design, Setting, and Participants Retrospective cohort study of children who attended kindergarten or first grade at public or private schools in Rochester, Minn, during 1979-1982. Children were followed up until age 19 years or until they left the school district. Main Outcome Measures Number of children diagnosed and treated for scoliosis, based on results from scoliosis screenings performed annually in grades 5 through 9, linked to community medical records data; performance characteristics of the screening program. Results Of the 2242 children screened, 92 (4.1%) were referred for further evaluation. Of these, 68 (74%) had documented medical or chiropractic evaluation of scoliosis. School screening identified 5 of the 9 children treated for scoliosis but resulted in referrals for another 87 children who were not treated. The cumulative incidence of diagnosed scoliosis in this population was 1.8% (95% confidence interval [CI], 1.2%-2.3 %) for curves of more than 10 degrees, 1.0% (95% CI, 0.6%-1.5%) for curves of at least 20 degrees, and 0.4% (95% CI, 0.1%-0.6%) for curves of 40 degrees or more; 0.4% (0.5% of girls and 0.3% of boys) were treated for scoliosis. The positive predictive value of the school screening program for the identification of treated scoliosis was 0.05 (95% CI, 0.048-0.052), with 448 children needed to screen to identify 1 child who subsequently received treatment. The percent positive agreement across consecutive years of screening varied from 7% to 30%. Conclusion In this population, school scoliosis screening identified some children who went on to receive treatment but referred many more who did not. These data should be considered in making decisions regarding school scoliosis screening.	Olmsted Med Ctr, Dept Res, Rochester, MN 55904 USA; Mayo Clin, Biostat Sect, Rochester, MN USA; Mayo Clin, Clin Epidemiol Sect, Rochester, MN USA; Mayo Clin, Dept Orthoped, Rochester, MN USA	Olmsted Medical Center; Mayo Clinic; Mayo Clinic; Mayo Clinic	Yawn, BP (corresponding author), Olmsted Med Ctr, Dept Res, 210 9th St SE, Rochester, MN 55904 USA.		shaughnessy, william/AAJ-4458-2020	Jacobsen, Steven/0000-0002-8174-8533	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMENDT LE, 1990, PHYS THER, V70, P108, DOI 10.1093/ptj/70.2.108; ASHWORTH MA, 1988, SPINE, V13, P1187, DOI 10.1097/00007632-198810000-00024; BERG O, 1993, J AM BOARD FAM PRACT, V6, P497; BERWICK DM, 1985, PEDIAT REV, V5, P238; BUNNELL WP, 1984, J BONE JOINT SURG AM, V66A, P1381, DOI 10.2106/00004623-198466090-00010; BUNNELL WP, 1986, SPINE, V11, P773, DOI 10.1097/00007632-198610000-00003; BUNNELL WP, 1993, SPINE, V18, P1572, DOI 10.1097/00007632-199309000-00001; BURWELL RG, 1988, SPINE, V13, P1192; DICKSON RA, 1980, BRIT MED J, V281, P265, DOI 10.1136/bmj.281.6235.265; DIGUISEPPI C, 1996, US PREVENTIVE SERVIC; GORE DR, 1981, PEDIATRICS, V67, P196; LEAVER JM, 1982, INT J EPIDEMIOL, V11, P101, DOI 10.1093/ije/11.2.101; LONSTEIN JE, 1982, J BONE JOINT SURG AM, V64, P481, DOI 10.2106/00004623-198264040-00002; LONSTEIN JE, 1988, SPINE, V13, P1198, DOI 10.1097/00007632-198810000-00029; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MONTGOMERY SA, 1990, INT CLIN PSYCHOPHARM, V5, P67; MORAIS T, 1985, AM J PUBLIC HEALTH, V75, P1377, DOI 10.2105/AJPH.75.12.1377; NACHEMSON AL, 1995, J BONE JOINT SURG AM, V77A, P815, DOI 10.2106/00004623-199506000-00001; OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008; PRUIJS JEH, 1992, SPINE, V17, P431, DOI 10.1097/00007632-199204000-00009; RENSHAW TS, 1988, CLIN ORTHOP RELAT R, P26; ROBITAILLE Y, 1984, INT J EPIDEMIOL, V13, P319, DOI 10.1093/ije/13.3.319; ROGALA EJ, 1978, J BONE JOINT SURG AM, V60, P173, DOI 10.2106/00004623-197860020-00005; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P153; Skaggs DL, 1996, J BONE JOINT SURG AM, V78A, P151, DOI 10.2106/00004623-199601000-00024; SMYRNIS T, 1987, ORTHOPEDICS, V10, P921; Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006; WILLNER S, 1982, ACTA ORTHOP SCAND, V53, P233, DOI 10.3109/17453678208992208; WOOLF SH, 1993, JAMA-J AM MED ASSOC, V269, P2664; Yawn BP, 1996, J SCHOOL HEALTH, V66, P171, DOI 10.1111/j.1746-1561.1996.tb06269.x	30	101	106	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1427	1432		10.1001/jama.282.15.1427	http://dx.doi.org/10.1001/jama.282.15.1427			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535432	Bronze			2022-12-24	WOS:000083111000027
J	Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR				Marcil, M; Brooks-Wilson, A; Clee, SM; Roomp, K; Zhang, LH; Yu, L; Collins, JA; van Dam, M; Molhuizen, HOF; Loubster, O; Ouellette, BFF; Sensen, CW; Fichter, K; Mott, S; Denis, M; Boucher, B; Pimstone, S; Genest, J; Kastelein, JJP; Hayden, MR			Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux	LANCET			English	Article							SUBSTRATE-SPECIFICITY; TANGIER-DISEASE; APOA-I; LIPOPROTEIN; HYPERCATABOLISM; TRANSPORTER; FIBROBLASTS; DYSTROPHY; POSITION; LIPASE	Background A low concentration of HDL cholesterol is the most common lipoprotein abnormality in patients with premature atherosclerosis. We have shown that Tangier disease, a rare and severe form of HDL deficiency characterised by a biochemical defect in cellular cholesterol efflux, is caused by mutations in the ATP-binding-cassette (ABC1) gene. This gene codes for the cholesterol-efflux regulatory protein (CERP). We investigated the presence of mutations in this gene in patients with familiar HDL deficiency. Methods Three French-Canadian families and one Dutch family with familial HDL deficiency were studied. Fibroblasts from the proband of each family were defective in cellular cholesterol efflux. Genomic DNA of each proband was used for mutation detection with primers flanking each exon of the ABC1 gene, and for sequencing of the entire coding region of the gene. PCR and restriction-fragment length polymorphism assays specific to each mutation were used to investigate segregation of the mutation in each family, and to test for absence of the mutation in DNA from normal controls. Findings A different mutation was detected in ABC1 in each family studied. Each mutation either created a stop codon predicted to result in truncation of CERP, or altered a conserved aminoacid residue. Each mutation segregated with low concentrations of HDL-cholesterol in the family, and was not observed in more than 500 control chromosomes tested. Interpretation These data show that mutations in ABC1 are the major cause of familial HDL deficiency associated with defective cholesterol efflux, and that CERP has an essential role in the formation of HDL. Our findings highlight the potential of modulation of ABC1 as a new route for increasing HDL concentrations.	Xenon Biores Inc, NRC Innovat Ctr, Vancouver, BC, Canada; Univ British Columbia, Womens & Childrens Hosp, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 1M9, Canada; Acad Med Ctr, Dept Vasc Med, NL-1005 AZ Amsterdam, Netherlands; Clin Res Inst Montreal, Cardiovasc Genet Lab, Montreal, PQ H2W 1R7, Canada; NRC, Inst Marine Biosci, Halifax, NS, Canada	National Research Council Canada; University of British Columbia; University of Amsterdam; Academic Medical Center Amsterdam; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; National Research Council Canada	Hayden, MR (corresponding author), Ctr Mol Med & Therapeut, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	mrh@cmmt.ubc.ca	van Dam, Marjel/AFT-3071-2022; Kastelein, John/AAF-7950-2020; Collins, Jennifer/AAE-1895-2020; Brooks-Wilson, Angela/E-9399-2012; Sensen, Christoph W./C-1798-2013; Clee, Susanne/AAC-4278-2020; Hayden, Michael R/D-8581-2011; Clee, Susanne/F-7312-2010	Brooks-Wilson, Angela/0000-0003-1009-6408; Sensen, Christoph W./0000-0001-9604-8962; Hayden, Michael R/0000-0001-5159-1419; Clee, Susanne/0000-0001-7946-688X; Ouellette, B. F. Francis/0000-0003-4676-675X; van Dam, Marjel/0000-0001-9802-7516				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; Eberhart GP, 1998, J CLIN ENDOCR METAB, V83, P836, DOI 10.1210/jc.83.3.836; EISENBERG S, 1984, J LIPID RES, V25, P1017; EMMERICH J, 1993, ARTERIOSCLER THROMB, V13, P1299, DOI 10.1161/01.ATV.13.9.1299; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1997, ARTERIOSCL THROM VAS, V17, P560, DOI 10.1161/01.ATV.17.3.560; MARCIL M, 1995, ARTERIOSCL THROM VAS, V15, P1015, DOI 10.1161/01.ATV.15.8.1015; Marcil M, 1999, ARTERIOSCL THROM VAS, V19, P159, DOI 10.1161/01.ATV.19.1.159; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; REYMER PWA, 1995, NAT GENET, V10, P28, DOI 10.1038/ng0595-28; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Schuler GD, 1998, METHOD BIOCHEM ANAL, V39, P145; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Taguchi Y, 1997, BIOCHEMISTRY-US, V36, P8883, DOI 10.1021/bi970553v; Taguchi Y, 1997, FEBS LETT, V413, P142, DOI 10.1016/S0014-5793(97)00899-5; TALMUD P, 1982, GENET EPIDEMIOL, V45, P161; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toh S, 1999, AM J HUM GENET, V64, P739, DOI 10.1086/302292; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	35	299	316	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1341	1346		10.1016/S0140-6736(99)07026-9	http://dx.doi.org/10.1016/S0140-6736(99)07026-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533863				2022-12-24	WOS:000083149900012
J	Posnett, J				Posnett, J			The hospital of the future - Is bigger better? Concentration in the provision of secondary care	BRITISH MEDICAL JOURNAL			English	Editorial Material							VOLUME		Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England	University of York - UK	Posnett, J (corresponding author), Univ York, York Hlth Econ Consortium, York YO1 5DD, N Yorkshire, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ALETRAS V, 1997, CONCENTRATION CHOICE, P23; Bentham G, 1995, Soc Sci Med, V40, P131, DOI 10.1016/0277-9536(94)E0048-W; Carr-Hill R, 1997, CONCENTRATION CHOICE, P37; *EFF HLTH CAR B, 1996, HOSP VOL HLTH CAR OU; GODDARD M, 1997, HLTH EC SERIES; HOWLAND G, 1997, IHSM HLTH SOCIAL SER; Jones J, 1995, INT J TECHNOL ASSESS, V11, P762, DOI 10.1017/S0266462300009193; SOWDEN A, 1997, CONCENTRATION CHOICE, P9; SOWDEN AJ, 1995, BMJ-BRIT MED J, V311, P151, DOI 10.1136/bmj.311.6998.151	9	55	57	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1063	1065		10.1136/bmj.319.7216.1063	http://dx.doi.org/10.1136/bmj.319.7216.1063			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10521207	Green Published			2022-12-24	WOS:000083210100037
J	Boguski, MS				Boguski, MS			Biosequence exegesis	SCIENCE			English	Editorial Material							SEQUENCE	Annotation of Large-scale gene sequence data will benefit from comprehensive and consistent application of well-documented, standard analysis methods and from progressive and vigilant efforts to ensure quality and utility and to keep the annotation up to date. However, it is imperative to Learn how to apply information derived from functional genomics and proteomics technologies to conceptualize and explain the behaviors of biological systems. Quantitative and dynamical models of systems behaviors will supersede the Limited and static forms of single-gene annotation that are now the norm. Molecular biological epistemology will increasingly encompass both teleological and causal explanations.	NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Boguski, MS (corresponding author), NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, 8600 Rockville Pike, Bethesda, MD 20894 USA.							BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Doolittle RF, 1997, J MOL MED-JMM, V75, P239; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Hayles Katherine, 1999, CYBERNETICS LIT INFO; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; INSLOW RL, 1999, CIRC RES, V84, P571; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Judson H. F., 1996, 8 DAY CREATION; SANGER F, 1988, ANNU REV BIOCHEM, V57, P1, DOI 10.1146/annurev.bi.57.070188.000245; SHAW S, 1998, BRIT SOC IMM ANN M H; Sober E, 1993, PHILOS BIOL; Weiner J., 1999, TIME LOVE MEMORY GRE; Wheelan SJ, 1998, GENOME RES, V8, P168, DOI 10.1101/gr.8.3.168	14	44	48	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					453	455		10.1126/science.286.5439.453	http://dx.doi.org/10.1126/science.286.5439.453			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521334				2022-12-24	WOS:000083121200045
J	Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC				Tabara, H; Sarkissian, M; Kelly, WG; Fleenor, J; Grishok, A; Timmons, L; Fire, A; Mello, CC			The rde-1 gene, RNA interference, and transposon silencing in C-elegans	CELL			English	Article							DOUBLE-STRANDED-RNA; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; ANTISENSE RNA; MESSENGER-RNA; SEQUENCE; EXPRESSION; ELEMENTS; GERMLINE; EMBRYOS	Double-stranded (ds) RNA can induce sequence-specific inhibition of gene function in several organisms. However, both the mechanism and the physiological role of the interference process remain mysterious. In order to study the interference process, we have selected C. elegans mutants resistant to dsRNA-mediated interference (RNAi). Two loci, rde-1 and rde-4, are defined by mutants strongly resistant to RNAi but with no obvious defects in growth or development. We show that rde-1 is a member of the piwi/sting/argonaute/zwille/elF2C gene family conserved from plants to vertebrates. Interestingly, several, but not all, RNAi-deficient strains exhibit mobilization of the endogenous transposons. We discuss implications for the mechanism of RNAi and the possibility that one natural function of RNAi is transposon silencing.	Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA; Carnegie Inst Sci, Dept Embryol, Baltimore, MD 21210 USA	University of Massachusetts System; University of Massachusetts Worcester; Carnegie Institution for Science	Mello, CC (corresponding author), Univ Massachusetts, Ctr Canc, Program Mol Med, Dept Cell Biol, Worcester, MA 01605 USA.	craig.mello@ummed.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058800] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08353] Funding Source: Medline; NIGMS NIH HHS [GM37706, GM58800, R01 GM037706] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Beclin C, 1998, VIROLOGY, V252, P313, DOI 10.1006/viro.1998.9457; Benfey PN, 1999, CURR BIOL, V9, pR171, DOI 10.1016/S0960-9822(99)80105-5; Birchler JA, 1999, NAT GENET, V21, P148, DOI 10.1038/5926; Bohmert K, 1998, EMBO J, V17, P170, DOI 10.1093/emboj/17.1.170; Boyd L, 1996, DEVELOPMENT, V122, P3075; BRENNER S, 1974, GENETICS, V77, P71; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; Elmayan T, 1998, PLANT CELL, V10, P1747, DOI 10.1105/tpc.10.10.1747; FIRE A, 1991, DEVELOPMENT, V113, P503; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Henikoff S, 1998, BIOESSAYS, V20, P532, DOI 10.1002/(SICI)1521-1878(199807)20:7<532::AID-BIES3>3.3.CO;2-0; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kelly WG, 1997, GENETICS, V146, P227; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lynn K, 1999, DEVELOPMENT, V126, P469; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; MOERMAN DG, 1986, P NATL ACAD SCI USA, V83, P2579, DOI 10.1073/pnas.83.8.2579; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; MORI I, 1988, GENETICS, V120, P397; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Moussian B, 1998, EMBO J, V17, P1799, DOI 10.1093/emboj/17.6.1799; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; ROY AL, 1988, BIOCHEMISTRY-US, V27, P8203, DOI 10.1021/bi00421a033; Schmidt A, 1999, GENETICS, V151, P749; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Tabara H, 1999, DEVELOPMENT, V126, P1; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; VANDERKEYL H, 1994, DEV DYNAM, V201, P86, DOI 10.1002/aja.1002010109; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; WILLIAMS BD, 1992, GENETICS, V131, P609; YUAN JY, 1991, P NATL ACAD SCI USA, V88, P3334, DOI 10.1073/pnas.88.8.3334; Zou C, 1998, GENE, V211, P187, DOI 10.1016/S0378-1119(98)00107-3	57	951	1088	3	77	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					123	132		10.1016/S0092-8674(00)81644-X	http://dx.doi.org/10.1016/S0092-8674(00)81644-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535731	Bronze			2022-12-24	WOS:000083159700003
J	Lockless, SW; Ranganathan, R				Lockless, SW; Ranganathan, R			Evolutionarily conserved pathways of energetic connectivity in protein families	SCIENCE			English	Article							HORMONE RECEPTOR COMPLEX; K+ CHANNEL; PDZ-DOMAIN; CRYSTAL-STRUCTURE; SIGNALING COMPLEXES; POTASSIUM CHANNEL; MUTANT CYCLES; LONG-RANGE; BINDING; RECOGNITION	For mapping energetic interactions in proteins, a technique was developed that uses evolutionary data for a protein family to measure statistical interactions between amino acid positions, For the PDZ domain family, this analysis predicted a set of energetically coupled positions for a binding site residue that includes unexpected Long-range interactions. Mutational studies confirm these predictions, demonstrating that the statistical energy function is a good indicator of thermodynamic coupling in proteins. Sets of intracting residues form connected pathways through the protein fold that may be the basis for efficient energy conduction within proteins.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ranganathan, R (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	rama@chop.swmed.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brenman JE, 1998, J NEUROSCI, V18, P8805; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doolittle R., 1996, METHOD ENZYMOL, V266, P1; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ESSER L, UNPUB; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Hedstrom L, 1996, BIOL CHEM, V377, P465; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOLT JM, 1995, FASEB J, V9, P210, DOI 10.1096/fasebj.9.2.7781923; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LICATA VJ, 1995, BIOCHEMISTRY-US, V34, P3133, DOI 10.1021/bi00010a001; Lichtarge O, 1996, J MOL BIOL, V257, P342, DOI 10.1006/jmbi.1996.0167; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEHER E, 1994, P NATL ACAD SCI USA, V91, P98, DOI 10.1073/pnas.91.1.98; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PERRY KM, 1989, BIOCHEMISTRY-US, V28, P7961, DOI 10.1021/bi00445a061; PETTIGREW DW, 1982, P NATL ACAD SCI-BIOL, V79, P1849, DOI 10.1073/pnas.79.6.1849; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Ranganathan R, 1997, CURR BIOL, V7, pR770, DOI 10.1016/S0960-9822(06)00401-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1993, NEURON, V11, P67; SOCOLICH M, UNPUB; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tolman RC, 1938, PRINCIPLES STAT MECH; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WELLS JA, 1995, BIO-TECHNOL, V13, P647, DOI 10.1038/nbt0795-647; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1	49	1012	1028	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					295	299		10.1126/science.286.5438.295	http://dx.doi.org/10.1126/science.286.5438.295			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514373				2022-12-24	WOS:000083024400045
J	Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP				Salvemini, D; Wang, ZQ; Zweier, JL; Samouilov, A; Macarthur, H; Misko, TP; Currie, MG; Cuzzocrea, S; Sikorski, JA; Riley, DP			A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats	SCIENCE			English	Article							NITRIC-OXIDE; LIPID-PEROXIDATION; IN-VIVO; PEROXYNITRITE; INFLAMMATION; INJURY; COMPLEXES; EDEMA; MICE	Many human diseases are associated with the overproduction of oxygen free radicals that inflict cell damage. A manganese(II) complex with a bis(cyclohexylpyridine)-substituted macrocyclic Ligand (M40403) was designed to be a functional mimic of the superoxide dismutase (SOD) enzymes that normally remove these radicals. M40403 had high catalytic SOD activity and was chemically and biologically stable in vivo. injection of M40403 into rat models of inflammation and ischemia-reperfusion injury protected the animals against tissue damage, Such mimics may result in better clinical therapies for diseases mediated by superoxide radicals.	MetaPhore Pharmaceut, St Louis, MO 63114 USA; Monsanto Co, GD Searle & Co, Discovery Pharmacol, St Louis, MO 63167 USA; Johns Hopkins Univ, Sch Med, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy; Monsanto Co, GD Searle & Co, Discovery Med Chem, St Louis, MO 63198 USA	Monsanto; Johns Hopkins University; Saint Louis University; University of Messina; Monsanto	Salvemini, D (corresponding author), MetaPhore Pharmaceut, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com	Samouilov, Alexandre/B-5824-2014; Samouilov, Alexandre/E-4010-2011	Misko, Thomas/0000-0001-7917-422X				BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BITTERMAN H, 1988, P SOC EXP BIOL MED, V188, P265; CABELLI DE, IN PRESS BIOMIMETIC; Deshmukh DR, 1997, AM J PHYSIOL-CELL PH, V273, pC1130, DOI 10.1152/ajpcell.1997.273.4.C1130; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HIRSCHELMANN R, 1981, EXPERIENTIA, V37, P1313, DOI 10.1007/BF01948381; Horie Y, 1998, CIRC RES, V83, P691, DOI 10.1161/01.RES.83.7.691; IANARO A, 1994, IMMUNOLOGY, V82, P370; JADOT G, 1995, CLIN PHARMACOKINET, V28, P17, DOI 10.2165/00003088-199528010-00003; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; PETKAU A, 1986, CANCER TREAT REV, V13, P17, DOI 10.1016/0305-7372(86)90012-5; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Riley DP, 1997, J AM CHEM SOC, V119, P6522, DOI 10.1021/ja964271e; Riley DP, 1996, INORG CHEM, V35, P5213, DOI 10.1021/ic960262v; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; Riley DP, 1999, INORG CHEM, V38, P1908, DOI 10.1021/ic981319b; RILEY DP, 1997, CATTECH, V1, P41; ROSA MD, 1971, J PHARM PHARMACOL, V23, P297, DOI 10.1111/j.2042-7158.1971.tb08661.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SCHRAUFSTATTER IU, 1987, INT J TISSUE REACT, V9, P317; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SQUADRITO F, 1995, BRIT J PHARMACOL, V115, P395, DOI 10.1111/j.1476-5381.1995.tb16346.x; WARREN JS, 1990, FREE RADICAL BIO MED, V8, P163, DOI 10.1016/0891-5849(90)90089-2; Weiss RH, 1996, J BIOL CHEM, V271, P26149, DOI 10.1074/jbc.271.42.26149; WEISS RH, 1993, J BIOL CHEM, V268, P23049	29	448	494	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					304	306		10.1126/science.286.5438.304	http://dx.doi.org/10.1126/science.286.5438.304			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514375				2022-12-24	WOS:000083024400047
J	Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M				Nutt, SL; Heavey, B; Rolink, AG; Busslinger, M			Commitment to the B-lymphoid lineage depends on the transcription factor Pax5	NATURE			English	Article							MOUSE BONE-MARROW; MURINE FETAL LIVER; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; STEM-CELLS; DENDRITIC CELLS; FACTOR BSAP; C-FOS; PRO-B; MACROPHAGES	The Pax5 gene encoding the B-cell-specific activator protein (BSAP) is expressed within the haematopoietic system exclusively in the B-lymphoid lineage, where it is required in vivo for progression beyond the pro-B-cell stage. However, Pax5 is not essential for in vitro propagation of pro-B cells in the presence of interleukin-ir and stromal cells. Here we show that pro-B cells lacking Pax5 are also incapable of in vitro B-cell differentiation unless Pax5 expression is restored by retroviral transduction, Pax5(-/-) pro-B cells ape not restricted in their lineage fate, as stimulation with appropriate cytokines induces them to differentiate into functional macrophages, osteoclasts, dendritic cells, granulocytes and natural killer cells. As expected far a clonogenic haematopoietic progenitor with lymphomyeloid developmental potential, the Pax5(-/-) pro-B cell expresses genes of different lineage-affiliated programmes, and restoration of Pax5 activity represses this lineage-promiscuous transcription. Pax5 therefore plays an essential role in B-lineage commitment by suppressing alternative lineage choices.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Basel Inst Immunol, CH-4005 Basel, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Busslinger, M (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	busslinger@nt.imp.univie.ac.at	Busslinger, Meinrad J./J-1249-2016; Nutt, Stephen L/C-9256-2013	Busslinger, Meinrad J./0000-0002-9111-9351; Nutt, Stephen L/0000-0002-0020-6637				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Aiba Y, 1997, BLOOD, V90, P3923, DOI 10.1182/blood.V90.10.3923; AKASHI K, 1991, J CELL PHYSIOL, V148, P446, DOI 10.1002/jcp.1041480317; Akerblad P, 1999, MOL CELL BIOL, V19, P392; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Borrello MA, 1996, IMMUNOL TODAY, V17, P471, DOI 10.1016/0167-5699(96)20031-B; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; Busslinger Meinrad, 1998, P83; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hu M, 1997, GENE DEV, V11, P774, DOI 10.1101/gad.11.6.774; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacaud G, 1998, IMMUNITY, V9, P827, DOI 10.1016/S1074-7613(00)80648-2; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Liu FL, 1997, BLOOD, V90, P2583, DOI 10.1182/blood.V90.7.2583.2583_2583_2590; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NAT GENET, V21, P390, DOI 10.1038/7720; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; Raulet DH, 1999, CURR OPIN IMMUNOL, V11, P129, DOI 10.1016/S0952-7915(99)80023-5; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Sigvardsson M, 1997, IMMUNITY, V7, P25, DOI 10.1016/S1074-7613(00)80507-5; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Thevenin C, 1998, J EXP MED, V188, P735, DOI 10.1084/jem.188.4.735; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yamane T, 1997, BLOOD, V90, P3516, DOI 10.1182/blood.V90.9.3516; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	50	867	890	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					556	562		10.1038/44076	http://dx.doi.org/10.1038/44076			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524622				2022-12-24	WOS:000083054900041
J	Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K				Zangaladze, A; Epstein, CM; Grafton, ST; Sathian, K			Involvement of visual cortex in tactile discrimination of orientation	NATURE			English	Article							MAGNETIC BRAIN-STIMULATION; COIL SUPPRESSION; BLIND HUMANS; PERCEPTION; ACTIVATION; TOUCH; SITE; EYE; LIP	The primary sense modalities (vision, touch and so on) are generally thought of as distinct. However, visual imagery is implicated in the normal tactile perception of some object properties, such as orientation(1), shape and size(2). Furthermore, certain tactile tasks, such as discrimination of grating orientation(1) and object recognition: are associated with activity in areas of visual cortex. Here we show that disrupting function of the occipital cortex using focal transcranial magnetic stimulation (TMS) interferes with the tactile discrimination of grating orientation. The specificity of this effect is illustrated by its time course and spatial restriction over the scalp, and by the failure of occipital TMS to affect either detection of an electrical stimulus applied to the fingerpad or tactile discrimination of grating texture. In contrast, TMS over the somatosensory cortex blocked discrimination of grating texture as well as orientation. We also report that, during tactile discrimination of grating orientation, an evoked potential is recorded over posterior scalp regions with a latency corresponding to the peak of the TMS interference effect (about 180 ms). The findings indicate that visual cortex is closely involved in tactile discrimination of orientation. To our knowledge, this is the first demonstration that visual cortical processing is necessary for normal tactile perception.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA	Emory University	Sathian, K (corresponding author), Emory Univ, Sch Med, Dept Neurol, WMRB-6000,PO Drawer 5,1639 Pierce Dr, Atlanta, GA 30322 USA.			Sathian, Krish/0000-0001-9495-2499				Buchel C, 1998, BRAIN, V121, P409, DOI 10.1093/brain/121.3.409; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Deibert E, 1999, NEUROLOGY, V52, P1413, DOI 10.1212/WNL.52.7.1413; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P247, DOI 10.1097/00004691-199605000-00009; EPSTEIN CM, 1990, NEUROLOGY, V40, P666, DOI 10.1212/WNL.40.4.666; Epstein CM, 1996, NEUROLOGY, V47, P1590, DOI 10.1212/WNL.47.6.1590; Epstein CM, 1996, J CLIN NEUROPHYSIOL, V13, P242, DOI 10.1097/00004691-199605000-00008; GALLETTI C, 1991, EUR J NEUROSCI, V3, P452, DOI 10.1111/j.1460-9568.1991.tb00832.x; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; JOHNSON KO, 1992, ANNU REV NEUROSCI, V15, P227, DOI 10.1146/annurev.ne.15.030192.001303; KLATZKY RL, 1987, J EXP PSYCHOL GEN, V116, P356; KUJALA T, 1995, NEUROSCI LETT, V183, P143, DOI 10.1016/0304-3940(94)11135-6; Mellet E, 1996, J NEUROSCI, V16, P6504; PASCUALLEONE A, 1993, ELECTROEN CLIN NEURO, V89, P120, DOI 10.1016/0168-5597(93)90094-6; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Sadato N, 1998, BRAIN, V121, P1213, DOI 10.1093/brain/121.7.1213; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Sathian K, 1996, NEUROLOGY, V46, P1464, DOI 10.1212/WNL.46.5.1464; Sathian K, 1997, NEUROREPORT, V8, P3877, DOI 10.1097/00001756-199712220-00008; Sathian K, 1997, PERCEPT PSYCHOPHYS, V59, P119, DOI 10.3758/BF03206854; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; VANBOVEN RW, 1994, NEUROLOGY, V44, P2361, DOI 10.1212/WNL.44.12.2361; VEGABERMUDEZ F, 1991, J NEUROPHYSIOL, V65, P531, DOI 10.1152/jn.1991.65.3.531; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734	24	325	330	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					587	590		10.1038/44139	http://dx.doi.org/10.1038/44139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524625				2022-12-24	WOS:000083054900050
J	Waterlow, J				Waterlow, J			Treatment of children with malnutrition and diarrhoea	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Waterlow, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1E 7HT, England.							Ahmed T, 1999, LANCET, V353, P1919, DOI 10.1016/S0140-6736(98)07499-6; Schofield C, 1996, B WORLD HEALTH ORGAN, V74, P223; SMITH R, 1963, LANCET, V1, P771; WATERLOW JC, 1978, NUTRITION CLIN MANAG, P49; Waterlow JC, 1992, PROTEIN ENERGY MALNU; WATERLOW JC, 1992, NUTR CLIN MANAGEMENT; World Health Organization, 1999, MAN SEV MALN MAN PHY	7	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 2	1999	354	9185					1142	1142		10.1016/S0140-6736(99)00329-3	http://dx.doi.org/10.1016/S0140-6736(99)00329-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513705				2022-12-24	WOS:000082954100007
J	Evans, SK; Lundblad, V				Evans, SK; Lundblad, V			Est1 and Cdc13 as comediators of telomerase access	SCIENCE			English	Article							DNA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; REVERSE-TRANSCRIPTASE; IN-VITRO; YEAST; SENESCENCE; LENGTH; MAINTENANCE; MUTANTS; DEFECT	Cdc13 and Est1 are single-strand telomeric DNA binding proteins that contribute to telomere replication in the yeast Saccharomyces cerevisiae. Here it is shown that fusion of Cdc13 to the telomerase-associated Est1 protein results in greatly elongated telomeres. Fusion proteins consisting of mutant versions of Cdc13 or Est1 confer similar telomere elongation, indicating that close physical proximity can bypass telomerase-defective mutations in either protein. Fusing Cdc13 directly to the catalytic core of telomerase allows stable telomere maintenance in the absence of Est1, consistent with a role for Est1 in mediating telomerase access. Telomere length homeostasis therefore is maintained in part by restricting access of telomerase to chromosome termini, but this limiting situation can be overcome by directly tethering telomerase to the telomere.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Lundblad, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055867] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM55867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHANDRA A, UNPUB; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; EVANS S, UNPUB; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; HUGHES TJ, UNPUB; Lendvay TS, 1996, GENETICS, V144, P1399; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Marcand S, 1999, EMBO J, V18, P3509, DOI 10.1093/emboj/18.12.3509; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; NUGENT CI, UNPUB; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094	21	363	376	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					117	120		10.1126/science.286.5437.117	http://dx.doi.org/10.1126/science.286.5437.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506558				2022-12-24	WOS:000082907400048
J	Gil, D; Graves, J; Hazon, N; Wells, A				Gil, D; Graves, J; Hazon, N; Wells, A			Male attractiveness and differential testosterone investment in zebra finch eggs	SCIENCE			English	Article							EXTRA-PAIR PATERNITY; GENETIC QUALITY; MATERNAL TESTOSTERONE; ULTRAVIOLET VISION; BODY-MASS; IMMUNOCOMPETENCE; INDICATOR; ORNAMENTATION; POPULATIONS; VIABILITY	Good-genes hypotheses of sexual selection predict that offspring fathered by preferred males should have increased viability resulting from superior genetic quality. Several studies of birds have reported findings consistent with this prediction, but maternal effects are an important confounding variable. Those studies that have attempted to control for maternal effects have only considered differential maternal investment after egg laying. However, female birds differentially deposit testosterone in the eggs, and this influences the development of the chick. This study shows that female birds deposit higher amounts of testosterone and 5 alpha-dihydrotestosterone in their eggs when mated to more attractive males.	Univ St Andrews, Sch Environm & Evolutionary Biol, St Andrews KY16 9TS, Fife, Scotland	University of St Andrews	Gil, D (corresponding author), Univ Paris 10, Lab Psychophysiol & Ethol, UPRESA CNRS 7025, F-92001 Nanterre, France.	Diego.Gil@u-paris10.fr	Gil, Diego/L-1666-2014	Gil, Diego/0000-0003-3179-1987				Al-Afaleq AI, 1998, IMMUNOPHARM IMMUNOT, V20, P315, DOI 10.3109/08923979809038547; Andersson Malte, 1994; Bennett ATD, 1996, NATURE, V380, P433, DOI 10.1038/380433a0; BURLEY N, 1986, EVOLUTION, V40, P1191, DOI 10.1111/j.1558-5646.1986.tb05744.x; BURLEY N, 1988, AM NAT, V132, P611, DOI 10.1086/284877; Cuthill IC, 1997, P ROY SOC B-BIOL SCI, V264, P1093, DOI 10.1098/rspb.1997.0151; DELOPE F, 1993, EVOLUTION, V47, P1152, DOI 10.1111/j.1558-5646.1993.tb02142.x; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; GAUSE WC, 1986, CLIN IMMUNOL IMMUNOP, V39, P464, DOI 10.1016/0090-1229(86)90174-1; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; Hasselquist D, 1999, BEHAV ECOL SOCIOBIOL, V45, P167, DOI 10.1007/s002650050550; HEGNER RE, 1986, HORM BEHAV, V20, P313, DOI 10.1016/0018-506X(86)90040-1; Hillgarth Nigella, 1997, P78; Hoikkala A, 1998, P ROY SOC B-BIOL SCI, V265, P503, DOI 10.1098/rspb.1998.0323; Hunt S, 1997, ANIM BEHAV, V54, P1383, DOI 10.1006/anbe.1997.0540; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Lipar JL, 1999, AUK, V116, P231, DOI 10.2307/4089471; Mock D. W., 1997, EVOLUTION SIBLING RI; MOLLER AP, 1994, P NATL ACAD SCI USA, V91, P6929, DOI 10.1073/pnas.91.15.6929; NORRIS K, 1993, NATURE, V362, P537, DOI 10.1038/362537a0; PETRIE M, 1994, NATURE, V371, P598, DOI 10.1038/371598a0; Ros AFH, 1997, AM NAT, V150, P201, DOI 10.1086/286063; Saino N, 1995, BEHAV ECOL, V6, P397, DOI 10.1093/beheco/6.4.397; SCHUURS AHWM, 1992, INT ARCH ALLERGY IMM, V97, P337, DOI 10.1159/000236142; Schwabl H, 1997, NATURE, V386, P231, DOI 10.1038/386231a0; Schwabl H, 1996, J EXP ZOOL, V276, P157, DOI 10.1002/(SICI)1097-010X(19961001)276:2<157::AID-JEZ9>3.3.CO;2-Y; SCHWABL H, 1993, P NATL ACAD SCI USA, V90, P11446, DOI 10.1073/pnas.90.24.11446; Schwabl H, 1996, COMP BIOCHEM PHYS A, V114, P271, DOI 10.1016/0300-9629(96)00009-6; SEARCY WA, 1988, ECOLOGY, V69, P85, DOI 10.2307/1943163; Sheldon BC, 1997, P ROY SOC B-BIOL SCI, V264, P297, DOI 10.1098/rspb.1997.0042; Staub NL, 1997, GEN COMP ENDOCR, V108, P1, DOI 10.1006/gcen.1997.6962; Verhulst S, 1999, P NATL ACAD SCI USA, V96, P4478, DOI 10.1073/pnas.96.8.4478; Welch AM, 1998, SCIENCE, V280, P1928, DOI 10.1126/science.280.5371.1928; Wilkinson GS, 1998, NATURE, V391, P276, DOI 10.1038/34640; ZANN RA, 1966, ZEBRA FINCH	35	424	427	0	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					126	128		10.1126/science.286.5437.126	http://dx.doi.org/10.1126/science.286.5437.126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506561				2022-12-24	WOS:000082907400051
J	Solomon, SC; Bullock, MA; Grinspoon, DH				Solomon, SC; Bullock, MA; Grinspoon, DH			Climate change as a regulator of tectonics on Venus	SCIENCE			English	Article							ATMOSPHERE; HISTORY	Tectonics, volcanism, and climate on Venus may be strongly coupled. Large excursions in surface temperature predicted to follow a global or near-global volcanic event diffuse into the interior and introduce thermal stresses of a magnitude sufficient to influence widespread tectonic deformation. This sequence of events accounts for the timing and many of the characteristics of deformation in the ridged plains of Venus, the most widely preserved volcanic terrain on the planet.	Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; SW Res Inst, Dept Space Studies, Boulder, CO 80302 USA	Carnegie Institution for Science	Solomon, SC (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.							Basilevsky AT, 1996, GEOPHYS RES LETT, V23, P1497, DOI 10.1029/96GL00975; Basilevsky AT, 1998, J GEOPHYS RES-PLANET, V103, P8531, DOI 10.1029/98JE00487; Bilotti F, 1999, ICARUS, V139, P137, DOI 10.1006/icar.1999.6092; BIRCH F, 1948, AM J SCI, V246, P729; BULLOCK MA, 1994, ICARUS, V107, P142, DOI 10.1006/icar.1994.1012; Bullock MA, 1996, J GEOPHYS RES-PLANET, V101, P7521, DOI 10.1029/95JE03862; BULLOCK MA, 1993, GEOPHYS RES LETT, V20, P2147, DOI 10.1029/93GL02505; BULLOCK MA, UNPUB; COFFIN MF, 1994, REV GEOPHYS, V32, P1, DOI 10.1029/93RG02508; COLLINS GC, 1997, LUNAR PLANET SCI, V28, P243; FEGLEY B, 1989, NATURE, V337, P55, DOI 10.1038/337055a0; GRINSPOON DH, 1993, NATURE, V363, P428, DOI 10.1038/363428a0; Guest JE, 1999, ICARUS, V139, P55, DOI 10.1006/icar.1999.6091; Hansen VL, 1996, ICARUS, V123, P296, DOI 10.1006/icar.1996.0159; HASHIMOTO GL, 1999, LUNAR PLANET SCI, V30, P1867; Head JW, 1998, GEOLOGY, V26, P35, DOI 10.1130/0091-7613(1998)026<0035:SOTDIT>2.3.CO;2; Ivanov MA, 1996, J GEOPHYS RES-PLANET, V101, P14861, DOI 10.1029/96JE01245; IVANOV MA, 1998, LUNAR PLANET SCI, V29, P1653; KRASNOPOLSKY VA, 1994, ICARUS, V109, P58, DOI 10.1006/icar.1994.1077; Kreslavsky MA, 1998, J GEOPHYS RES-PLANET, V103, P11103, DOI 10.1029/98JE00360; KRESLAVSKY MA, 1999, LUNAR PLANET SCI, V30, P1192; MCGILL GE, 1993, GEOPHYS RES LETT, V20, P2047; McKinnon W. B., 1997, VENUS, P969; Phillips RJ, 1998, SCIENCE, V279, P1492, DOI 10.1126/science.279.5356.1492; PHILLIPS RJ, 1992, J GEOPHYS RES, V97, P15921; Sandwell DT, 1997, ICARUS, V129, P232, DOI 10.1006/icar.1997.5721; SCHABER GG, 1992, J GEOPHYS RES-PLANET, V97, P13257, DOI 10.1029/92JE01246; SCHULTZ RA, 1993, J GEOPHYS RES-PLANET, V98, P10883, DOI 10.1029/93JE00691; SOLOMON SC, 1992, J GEOPHYS RES-PLANET, V97, P13199, DOI 10.1029/92JE01418; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; Timoshenko S., 1970, THEORY ELASTICITY, P433; TURCOTTE DL, 1982, GEODYNAMICS, P158; TURCOTTE DL, 1983, J GEOPHYS RES S, V88, pA585, DOI DOI 10.1029/JB088IS02P0A585	33	61	62	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					87	90		10.1126/science.286.5437.87	http://dx.doi.org/10.1126/science.286.5437.87			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506565				2022-12-24	WOS:000082907400038
J	Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL				Wells, AL; Lin, AW; Chen, LQ; Safer, D; Cain, SM; Hasson, T; Carragher, BI; Milligan, RA; Sweeney, HL			Myosin VI is an actin-based motor that moves backwards	NATURE			English	Article							SMOOTH-MUSCLE MYOSIN; UNCONVENTIONAL MYOSIN; CRYOELECTRON MICROSCOPY; MOLECULAR MOTOR; IMAGE-ANALYSIS; ADP RELEASE; GENE; NCD; DIRECTION; DEAFNESS	Myosins and kinesins are molecular motors that hydrolyse ATP to track along actin filaments and microtubules, respectively. Although the kinesin family includes motors that move towards either the plus or minus ends of microtubules(1), all characterized myosin motors move towards the barbed (+) end of actin filaments(2). Crystal structures of myosin II (refs 3-6) have shown that small movements within the myosin motor core are transmitted through the 'converter domain' to a 'lever arm' consisting of a light-chain-binding helix and associated light chains(5,6), The lever arm further amplifies the motions of the converter domain into large directed movements(3,5-7). Here we report that myosin VI, an unconventional myosin(8-12), moves towards the pointed (-) end of actin. We visualized the myosin VI construct bound to actin using cryo-electron microscopy and image analysis, and found that an ADP-mediated conformational change in the domain distal to the motor, a structure likely to be the effective lever arm, is in the opposite direction to that observed for other myosins, Thus, it appears that myosin VI achieves reverse-direction movement by rotating its lever arm in the opposite direction to conventional myosin lever arm movement.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Illinois, Beckman Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Pennsylvania; Scripps Research Institute; University of California System; University of California San Diego; University of Illinois System; University of Illinois Urbana-Champaign	Sweeney, HL (corresponding author), Univ Penn, Sch Med, Dept Physiol, 3700 Hamilton Walk, Philadelphia, PA 19104 USA.	Lsweeney@mail.med.upenn.edu	Sweeney, H Lee/F-1862-2010	Carragher, Bridget/0000-0002-0624-5020; HASSON, TAMA/0000-0002-5405-662X				Avraham KB, 1997, HUM MOL GENET, V6, P1225, DOI 10.1093/hmg/6.8.1225; AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; Hasson T, 1997, J CELL BIOL, V137, P1287, DOI 10.1083/jcb.137.6.1287; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirose K, 1998, J MOL BIOL, V278, P389, DOI 10.1006/jmbi.1998.1709; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, J CELL BIOL, V139, P683, DOI 10.1083/jcb.139.3.683; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; MERMALL V, 1994, NATURE, V369, P560, DOI 10.1038/369560a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; POLLARD TD, 1982, METHOD ENZYMOL, V85, P123; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1995, J CELL SCI, V108, P1489	30	532	543	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					505	508		10.1038/46835	http://dx.doi.org/10.1038/46835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519557				2022-12-24	WOS:000082981200063
J	Wigle, JT; Oliver, G				Wigle, JT; Oliver, G			Prox1 function is required for the development of the murine lymphatic system	CELL			English	Article							ANGIOGENESIS; GENE; IDENTIFICATION; CAPILLARIES; EXPRESSION; RECEPTOR; PROSPERO	The lack of specific markers has raised problems in documenting the precise manner by which the lymphatic system develops. Here we report that the homeobox gene Prox1 is expressed in a subpopulation of endothelial cells that by budding and sprouting give rise to the lymphatic system. The initial localization of these cells in the veins and their subsequent budding are both polarized, suggesting that unidentified guidance signals regulate this process. In Prox1 null mice, budding and sprouting is arrested, although vasculogenesis and angiogenesis of the vascular system is unaffected. These findings suggest that Prox1 is a specific and required regulator of the development of the lymphatic system and that the vascular and lymphatic systems develop independently.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Oliver, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.		Wigle, J.t./G-2005-2014	Wigle, J.t./0000-0002-4985-7684	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058462] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NEI NIH HHS [EY12162] Funding Source: Medline; NIGMS NIH HHS [GM58462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; BOBER E, 1994, DEVELOPMENT, V120, P603; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; EZAKI T, 1990, ARCH HISTOL CYTOL, V53, P77, DOI 10.1679/aohc.53.Suppl_77; FRALEY EE, 1961, AM J ANAT, V109, P85, DOI 10.1002/aja.1001090107; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; GRAY H, 1985, ANATOMY HUMAN BODY, P866; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Huntington GS, 1910, AM J ANAT, V10, P177, DOI 10.1002/aja.1000100108; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; LEAK LV, 1968, J CELL BIOL, V36, P129, DOI 10.1083/jcb.36.1.129; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; NERLICH AG, 1991, HISTOCHEMISTRY, V96, P449, DOI 10.1007/BF00316003; OLIVER G, 1993, MECH DEVELOP, V44, P3, DOI 10.1016/0925-4773(93)90012-M; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Sabin FR, 1904, AM J ANAT, V3, P183, DOI 10.1002/aja.1000030205; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wigle JT, 1999, NAT GENET, V21, P318, DOI 10.1038/6844	27	1132	1183	2	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					769	778		10.1016/S0092-8674(00)81511-1	http://dx.doi.org/10.1016/S0092-8674(00)81511-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499794	Bronze			2022-12-24	WOS:000082679200004
J	Sugita, Y				Sugita, Y			Grouping of image fragments in primary visual cortex	NATURE			English	Article							ILLUSORY CONTOURS; PERCEPTION; MECHANISMS; MONKEY; INHIBITION; RESPONSES	In the visual world, objects are partially occluded by nearer objects, separating them into image fragments. However, the image fragments of the object can easily be grouped and organized together by the visual system(1-4). Psychophysical data(1-4) and theoretical analysis(5) indicate that such perceptual grouping might be mediated in the early stages of visual processing. Here I show that some orientation-selective cells in the primary visual cortex (V1) have response properties that can mediate the grouping of image fragments. These cells stopped responding to a stimulus bar when it was partly occluded by a small patch. The cells also did not respond when the patch had uncrossed disparity so that it appeared to be behind the bar. However, the cells began responding again when the patch had crossed disparity so that it appeared to be in front of the bar. These results indicate that cells as early as V1 have the computational power to make inferences about the nature of partially invisible forms seen behind occluding structures.	Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Tsukuba, Ibaraki 3058566, Japan; Japan Sci & Technol Corp, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Sugita, Y (corresponding author), Natl Inst Biosci & Human Technol, Lab Neural Informat Proc, Higashi 1-1, Tsukuba, Ibaraki 3058566, Japan.							ANDERSON BL, 1995, PSYCHOL REV, V102, P705, DOI 10.1037/0033-295X.102.4.705; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREGORY RL, 1972, NATURE, V238, P51, DOI 10.1038/238051a0; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; Grossberg S, 1997, TRENDS NEUROSCI, V20, P106, DOI 10.1016/S0166-2236(96)01002-8; Kanizsa G., 1955, RIV PSICOL, V49, P7; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; LAMME VAF, 1995, J NEUROSCI, V15, P1605; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Nakayama K, 1996, P NATL ACAD SCI USA, V93, P634, DOI 10.1073/pnas.93.2.634; NAKAYAMA K, 1992, SCIENCE, V257, P1357, DOI 10.1126/science.1529336; NAKAYAMA K, 1989, PERCEPTION, V18, P55, DOI 10.1068/p180055; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; PETERHANS E, 1989, J NEUROSCI, V9, P1749; ROCK I, 1979, PERCEPTION, V8, P665, DOI 10.1068/p080665; SHIMOJO S, 1990, PERCEPTION, V19, P285, DOI 10.1068/p190285; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; VONDERHEYDT R, 1984, SCIENCE, V224, P1260, DOI 10.1126/science.6539501; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Zipser K, 1996, J NEUROSCI, V16, P7376	21	179	181	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					269	272		10.1038/45785	http://dx.doi.org/10.1038/45785			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499583				2022-12-24	WOS:000082678400051
J	Finkel, TH				Finkel, TH			Potential use of a caspase against HIV - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Natl Jewish Med & Res Ctr, Div Basic Sci, Denver, CO USA	National Jewish Health	Finkel, TH (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Rheumatol, Philadelphia, PA 19104 USA.							Casella C R, 1997, Curr Opin Hematol, V4, P24; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FINKEL TH, 1998, CELL DEATH SIGNIFICA, P289; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Schulz TF, 1996, LANCET, V348, P587, DOI 10.1016/S0140-6736(95)11033-X; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1021	1022		10.1001/jama.282.11.1021	http://dx.doi.org/10.1001/jama.282.11.1021			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493188				2022-12-24	WOS:000082512300002
J	Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E				Leitzmann, MF; Rimm, EB; Willett, WC; Spiegelman, D; Grodstein, F; Stampfer, MJ; Colditz, GA; Giovannucci, E			Recreational physical activity and the risk of cholecystectomy in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOGISTIC-REGRESSION; GLUCOSE-TOLERANCE; GALLSTONE DISEASE; REPRODUCIBILITY; CHOLESTEROL; VALIDITY; CHOLELITHIASIS; QUESTIONNAIRE; OBESITY; PIGMENT	Background Physical activity may be an important determinant of the risk of gallstone disease in women, both independently and as a result of its role in maintaining body weight. Methods We prospectively studied recreational physical activity (such as jogging, running, and bicycling) and sedentary behavior (such as spending hours watching television) in relation to the risk of cholecystectomy, a surrogate for symptomatic cholelithiasis, in a cohort of 60,290 women who were 40 to 65 years of age in 1986 and had no history of gallstone disease. As part of the Nurses' Health Study, the women reported on questionnaires mailed to them every two years both their activity level and whether they had undergone cholecystectomy. During a 10-year follow-up period (1986 to 1996), 3257 cases of cholecystectomy were documented. Results Recreational physical activity was inversely related to the risk of cholecystectomy. The multivariate relative risk for women in the highest as compared with the lowest quintile of physical activity was 0.69 (95 percent confidence interval, 0.61 to 0.78). In contrast, sedentary behavior was independently related to an increased risk of cholecystectomy. As compared with women who spent less than 6 hours per week sitting while at work or driving, women who spent 41 to 60 hours per week sitting had a multivariate relative risk of 1.42 (95 percent confidence interval, 1.06 to 1.89), and women who spent more than 60 hours per week sitting while at work or driving had a multivariate relative risk of 2.32 (95 percent confidence interval, 1.26 to 4.26). These associations persisted after we controlled for body weight and weight change. Conclusions In women, recreational physical activity is associated with a decreased risk of cholecystectomy. The association is independent of other risk factors for gallstone disease, such as obesity and recent weight loss. (N Engl J Med 1999;341:777-84.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; PHS HHS [T45 09856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANGELICO M, 1988, HEPATOLOGY, V8, P907; Apstein MD, 1996, EUR J CLIN INVEST, V26, P343, DOI 10.1046/j.1365-2362.1996.148287.x; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BENNION LJ, 1978, NEW ENGL J MED, V299, P1161, DOI 10.1056/NEJM197811232992104; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; DiPietro L, 1998, J AM GERIATR SOC, V46, P875, DOI 10.1111/j.1532-5415.1998.tb02722.x; ELLISON PT, 1986, AM J OBSTET GYNECOL, V154, P100; HOFMANN AF, 1993, AM J SURG, V165, P541, DOI 10.1016/S0002-9610(05)80958-4; KALSER SC, 1993, AM J SURG, V165, P390; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; Misciagna G, 1999, AM J CLIN NUTR, V69, P120; OETTLE GJ, 1991, GUT, V32, P941, DOI 10.1136/gut.32.8.941; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Rothman K., 1998, MODERN EPIDEMIOLOGY; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SEALS DR, 1984, JAMA-J AM MED ASSOC, V252, P645, DOI 10.1001/jama.252.5.645; SOUTHGATE DA, 1969, J SCI FOOD AGR, V20, P331, DOI 10.1002/jsfa.2740200603; TROTMAN BW, 1975, AM J DIG DIS, V20, P735, DOI 10.1007/BF01070831; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390	31	141	147	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					777	784		10.1056/NEJM199909093411101	http://dx.doi.org/10.1056/NEJM199909093411101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477775				2022-12-24	WOS:000082534000001
J	Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ				Alexander, WS; Starr, R; Fenner, JE; Scott, GL; Handman, E; Sprigg, NS; Corbin, JE; Cornish, AL; Darwiche, R; Owczarek, CM; Kay, TWH; Nicola, NA; Hertzog, PJ; Metcalf, D; Hilton, DJ			SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine	CELL			English	Article							JAK-STAT PATHWAY; MUTANT-CELL LINE; IFN-GAMMA; TARGETED DISRUPTION; TYROSINE PHOSPHORYLATION; SUCKLING MICE; RECEPTOR; PROTEIN; GENE; ACTIVATION	Mice lacking suppressor of cytokine signaling-1 (SOCS1) develop a complex fatal neonatal disease. In this study, SOCS1(-/-) mice were shown to exhibit excessive responses typical of those induced by interferon gamma (IFN gamma), were hyperresponsive to viral infection, and yielded macrophages with an enhanced IFN gamma-dependent capacity to kill L. major parasites. The complex disease in SOCS1(-/-) mice was prevented by administration of anti-IFN gamma antibodies and did not occur in SOCS1(-/-) mice also lacking the IFN gamma gene. Although IFN gamma is essential for resistance to a variety of infections, the potential toxic action of IFN gamma, particularly in neonatal mice, appears to require regulation. Our data indicate that SOCS1 is a key modulator of IFN gamma action, allowing the protective effects of this cytokine to occur without the risk of associated pathological responses.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Monash Med Ctr, Inst Reprod & Dev, Ctr Funct Gen & Human Dis, Clayton, Vic 3165, Australia	Walter & Eliza Hall Institute; Monash University	Hilton, DJ (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	hilton@wehi.edu.au	Nicola, Nicos/D-2989-2011; Hertzog, Paul J/G-6734-2013; Hilton, Douglas J/C-7250-2013; Hertzog, Paul J/I-7053-2013	Nicola, Nicos/0000-0003-1054-7889; Hertzog, Paul J/0000-0002-1373-8472; Hilton, Douglas J/0000-0002-7698-2392; Hertzog, Paul J/0000-0002-1373-8472	NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; ANDO K, 1993, J EXP MED, V178, P1541, DOI 10.1084/jem.178.5.1541; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; BILLIAU A, 1991, EUR J CLIN INVEST, V21, P559, DOI 10.1111/j.1365-2362.1991.tb01410.x; Billiau A, 1996, ADV IMMUNOL, V62, P61, DOI 10.1016/S0065-2776(08)60428-9; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DAMELL JE, 1994, SCIENCE, V264, P1415; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Maeyer Edward, 1998, P491; De Sepulveda P, 1999, EMBO J, V18, P904; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRESSER I, 1981, AM J PATHOL, V102, P396; Gresser I, 1982, Interferon, V4, P95; GRESSER I, 1987, AM J PATHOL, V128, P13; HANDMAN E, 1983, PARASITE IMMUNOL, V5, P109, DOI 10.1111/j.1365-3024.1983.tb00728.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HERTZOG PJ, 1991, CLIN IMMUNOL IMMUNOP, V58, P18, DOI 10.1016/0090-1229(91)90145-Z; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ITO S, 1999, BLOOD, V93, P1; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIU ZQ, 1995, INFECT IMMUN, V63, P2790, DOI 10.1128/IAI.63.7.2790-2792.1995; Lu BF, 1998, P NATL ACAD SCI USA, V95, P8233, DOI 10.1073/pnas.95.14.8233; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Massa PT, 1996, J IMMUNOL, V157, P5139; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MATTHYS P, 1995, INFECT IMMUN, V63, P1158, DOI 10.1128/IAI.63.4.1158-1164.1995; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PAUL WE, 1991, BLOOD, V77, P1859; PROUDFOOT L, 1995, BIOCHEM J, V15, P45; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TATAKE RJ, 1993, P SOC EXP BIOL MED, V203, P405; Thomas HE, 1998, J CLIN INVEST, V102, P1249, DOI 10.1172/JCI2899; TOYONAGA T, 1994, P NATL ACAD SCI USA, V91, P614, DOI 10.1073/pnas.91.2.614; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	66	624	649	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					597	608		10.1016/S0092-8674(00)80047-1	http://dx.doi.org/10.1016/S0092-8674(00)80047-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490099	Bronze			2022-12-24	WOS:000082433500007
J	Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN				Marine, JC; McKay, C; Wang, DM; Topham, DJ; Parganas, E; Nakajima, H; Pendeville, H; Yasukawa, H; Sasaki, A; Yoshimura, A; Ihle, JN			SOCS3 is essential in the regulation of fetal liver erythropoiesis	CELL			English	Article							EMBRYONIC STEM-CELLS; TRANSGENIC MICE; DEFICIENT MICE; RECEPTORS; JAK2; HEMATOPOIESIS; EXPRESSION; PROTEIN; BCL-2; DEATH	SOCS3 (CIS3/JAB2) is an SH2-containing protein that binds to the activation loop of Janus kinases, inhibiting kinase activity, and thereby suppressing cytokine signaling. During embryonic development, SOCS3 is highly expressed in erythroid lineage cells and is Epo independent. Transgene-mediated expression blocks fetal erythropoiesis, resulting in embryonic lethality. SOCS3 deletion results in an embryonic lethality at 12-16 days associated with marked erythrocytosis. Moreover, the in vitro proliferative capacity of progenitors is greatly increased. SOCS3-deficient fetal liver stem cells can reconstitute hematopoiesis in lethally irradiated adults, indicating that its absence does not disturb bone marrow erythropoiesis. Reconstitution of lymphoid lineages in JAK3-deficient mice also occurs normally. The results demonstrate that SOCS3 is critical in negatively regulating fetal liver hematopoiesis.	St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Tennessee, Sch Med, Memphis, TN USA; Kurume Univ, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Howard Hughes Medical Institute; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Kurume University	Ihle, JN (corresponding author), St Jude Childrens Res Hosp, Howard Hughes Med Inst, 332 N Lauderdale St, Memphis, TN 38105 USA.	jamesihle@stjude.org	Yoshimura, Akihiko/K-5515-2013; Wang, Demin/AAX-4449-2020; Marine, Jean-Christophe/K-3292-2016; Marine, Jean Christophe/J-2237-2015	Wang, Demin/0000-0001-5549-3795; Marine, Jean-Christophe/0000-0003-2433-9837; Sasaki, Atsuo/0000-0003-2963-4501	NCI NIH HHS [CA21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Andrews N C, 1994, Curr Opin Hematol, V1, P119; ANGERER LM, 1991, METHOD CELL BIOL, V35, P37; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Auernhammer CJ, 1999, ENDOCRINOLOGY, V140, P1559, DOI 10.1210/en.140.4.1559; Bentley DJ, 1996, NAT GENET, V13, P489, DOI 10.1038/ng0896-489; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Orkin SH, 1997, ANNU REV GENET, V31, P33, DOI 10.1146/annurev.genet.31.1.33; Orkin SH, 1998, INT J DEV BIOL, V42, P927; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; SASAKI A, 1999, IN PRESS GENES CELLS; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	41	299	306	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					617	627		10.1016/S0092-8674(00)80049-5	http://dx.doi.org/10.1016/S0092-8674(00)80049-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490101	Bronze			2022-12-24	WOS:000082433500009
J	Sharp, D				Sharp, D			An Ideal Husband in the wild(e)?	LANCET			English	Editorial Material									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, London WC1B 3SL, England.							CONNOR S, 1999, INDEPENDENT     0819, P5; Young LJ, 1999, NATURE, V400, P766, DOI 10.1038/23475	2	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					700	700		10.1016/S0140-6736(99)00287-1	http://dx.doi.org/10.1016/S0140-6736(99)00287-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475179				2022-12-24	WOS:000082233000007
J	Lipkin, DP				Lipkin, DP			Sleep-disordered breathing in chronic stable heart failure	LANCET			English	Editorial Material							CHEYNE-STOKES RESPIRATION; SYMPATHETIC ACTIVITY; APNEA		Royal Free Hosp, Dept Cardiol, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Lipkin, DP (corresponding author), Royal Free Hosp, Dept Cardiol, London NW3 2PF, England.							ANCOLIISRAEL S, 1994, CHEST, V106, P780, DOI 10.1378/chest.106.3.780; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; Cheyne J, 1818, DUBLIN HOSP REP, V12, p[216, 317]; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; JAHAVERI S, 1995, ANN INTERN MED, V122, P487; KAVERI S, 1995, ANN INTERN MED, V122, P487; Lanfranchi PA, 1999, CIRCULATION, V99, P1435, DOI 10.1161/01.CIR.99.11.1435; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; Staniforth AD, 1998, EUR HEART J, V19, P922, DOI 10.1053/euhj.1997.0861; Staniforth AD, 1998, HEART, V79, P394, DOI 10.1136/hrt.79.4.394; STOKES W, 1854, DIS HEART AORTA, P302; Tkacova R, 1997, J AM COLL CARDIOL, V30, P739, DOI 10.1016/S0735-1097(97)00199-X	13	13	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					531	532		10.1016/S0140-6736(99)00138-5	http://dx.doi.org/10.1016/S0140-6736(99)00138-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470694				2022-12-24	WOS:000081991000007
J	Youn, HD; Sun, L; Prywes, R; Liu, JO				Youn, HD; Sun, L; Prywes, R; Liu, JO			Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2	SCIENCE			English	Article							ORPHAN STEROID-RECEPTOR; NUR77; GENE; CALCINEURIN; LYMPHOCYTES; PROTEINS; DEATH	T cell receptor (TCR)-induced apoptosis of thymocytes is media ted by calcium-dependent expression of the steroid receptors Nur77 and Nor1, Nur77 expression is controlled by the transcription factor myocyte enhancer factor 2 (MEF2), but how MEF2 is activated by calcium signaling is still obscure. Cabin1, a calcineurin inhibitor, was found to regulate MEF2. MEF2 was normally sequestered by Cabin1 in a transcriptionally inactive state. TCR engagement led to an increase in intracellular calcium concentration and the dissociation of MEF2 from Cabin1, as a result of competitive binding of activated calmodulin to Cabin1. The interplay between Cabin1, MEF2, and calmodulin defines a distinct signaling pathway from the TCR to the Nur77 promoter during T cell apoptosis.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Columbia University	Liu, JO (corresponding author), MIT, Ctr Canc Res, Cambridge, MA 02139 USA.		Youn, Hong-Duk/J-2774-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055783] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55783] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; Wong B, 1997, CURR OPIN IMMUNOL, V9, P358, DOI 10.1016/S0952-7915(97)80082-9; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YOUN HD, UNPUB DATA; YOUN HW, UNPUB; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	21	225	234	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					790	793		10.1126/science.286.5440.790	http://dx.doi.org/10.1126/science.286.5440.790			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531067				2022-12-24	WOS:000083303200059
J	Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE				Chen, CS; Patterson, MC; Wheatley, CL; O'Brien, JF; Pagano, RE			Broad screening test for sphingolipid-storage diseases	LANCET			English	Article							PLASMA-MEMBRANE; GOLGI-APPARATUS; SPECTRAL PROPERTIES; SKIN FIBROBLASTS; ACCUMULATION; TRANSPORT; ANALOG; CELLS; MUCOLIPIDOSIS; DISORDERS	Background Lipid-storage diseases are collectively important because they cause substantial morbidity and mortality, and because they may present as dementia, major psychiatric illness, developmental delay, or cerebral palsy. At present, no single assay can be used as an initial general screen for lipid-storage diseases. Methods We used a fluorescent analogue of lactosylceramide, called N-{5-(5,7-dimethylborondipyrromethenedifluoride)-1-pentanoyl}-D-lactosylsphingosine (BODIPY-LacCer), the emission of which changes from green to red wavelengths with increasing concentrations in membranes, to examine the intracellular distribution of the lipid within living cells. Findings During a brief pulse-chase experiment, the fluorescent lipid accumulated in the lysosomes of fibroblasts from patients with Fabry's disease, GM(1) gangliosidosis, GM(2) gangliosidosis (Tay-Sachs and Sandhoff forms), metachromatic leucodystrophy, mucolipidosis type IV, Niemann-Pick disease (types A, B, and C), and sphingolipid-activator-protein-precursor (prosaposin) deficiency. In control cells, the lipid was mainly confined to the Golgi complex. In a masked study, replicate samples of 25 of 26 unique cell lines representing ten different lipid-storage diseases, and 18 of 20 unique cell lines representing controls were correctly identified; the sensitivity was 96.2% (95% CI 80.4-99.9) and the specificity 90.0% (68.3-98.8). Interpretation This method may be useful as an initial general screen for lipid-storage diseases, and, with modification, could be used for large-scale automated screening of drugs to abrogate lysosomal storage in various lipidoses. The unexpected accumulation of BODIPY-LacCer in several biochemically distinct diseases raises important questions about common mechanisms of cellular dysfunction in these disorders.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Neurol, Div Child & Adolescent Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Lab Genet, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Thorac Dis Res Unit, Guggenheim 621-C,200 1st St SW, Rochester, MN 55905 USA.		Patterson, Marc C./H-5331-2019; Patterson, Marc/AAI-5056-2020	Patterson, Marc/0000-0002-1116-126X	NIGMS NIH HHS [GM-22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022942, R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGMON V, 1993, CLIN CHIM ACTA, V218, P139; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; BACH G, 1977, AM J HUM GENET, V29, P610; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burkhardt JK, 1997, EUR J CELL BIOL, V73, P10; Chen CS, 1997, BIOPHYS J, V72, P37, DOI 10.1016/S0006-3495(97)78645-4; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; GALJAARD H, 1980, GENETIC METABOLIC DI; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; Hua CT, 1998, CLIN CHEM, V44, P2094; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Kopitz J, 1996, AM J MED GENET, V63, P198; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Meikle PJ, 1997, CLIN CHEM, V43, P1325; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, IN PRESS METHODS ENZ; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625	22	108	108	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					901	905		10.1016/S0140-6736(98)10034-X	http://dx.doi.org/10.1016/S0140-6736(98)10034-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489949				2022-12-24	WOS:000082511800012
J	Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P				Ghebreyesus, TA; Haile, M; Witten, KH; Getachew, A; Yohannes, AM; Yohannes, M; Teklehaimanot, HD; Lindsay, SW; Byass, P			Incidence of malaria among children living near dams in northern Ethiopia: community based incidence survey	BRITISH MEDICAL JOURNAL			English	Article							EPIDEMIOLOGY	Objective To assess the impact of construction of microdams on the incidence of malaria in nearby communities in terms of possibly increasing peak incidence and prolonging transmission. Design Four quarterly cycles of malaria incidence surveys, each taking 30 days, undertaken in eight at risk communities close to dams paired with eight control villages at similar altitudes but beyond flight range of mosquitoes. Setting Tigray region in northern Ethiopia at altitudes of 1800 to 2225 m. Subjects About 7000 children under 10 years living in villages within 3 km of microdams and in control villages 8-10 km distant. Main outcome measures Incidence of malaria in both communities. Results Overall incidence of malaria for the villages close to dams was 14.0 episodes/1000 child months at risk compared with 1.9 in the control villages-a sevenfold ratio. Incidence was significantly higher in both communities at altitudes below 1900 m. Conclusions There is a need for attention to be given to health issues in the implementation of ecological and environmental development programmes, specifically for appropriate malaria control measures to counteract the increased risks near these dams.	Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia; Mekelle Univ Coll, Mekelle, Ethiopia; Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Univ Nottingham, Sch Community Hlth Sci, Nottingham NG13 8FD, England	Mekelle University; Durham University; University of Nottingham	Ghebreyesus, TA (corresponding author), Tigray Reg Hlth Bur, Dept Malaria Control, Mekelle, Ethiopia.			Byass, Peter/0000-0001-5474-4361				Alemayehu T., 1998, Parassitologia (Rome), V40, P259; [Anonymous], 1993, PARASITIC DIS WATER; BOUMA MJ, 1994, LANCET, V343, P302, DOI 10.1016/S0140-6736(94)91152-5; BRADLEY DJ, 1998, VECTOR BORNE DIS CON, P29; COOSEMANS M, 1984, ANN SOC BELG MED TR, V64, P135; DEMEILLON B, 1947, PUBLICATIONS S AFRIC, V10, P190; ELGADDAL AA, 1985, J TROP MED HYG, V88, P153; Ghebreyesus TA, 1996, ACTA TROP, V61, P145, DOI 10.1016/0001-706X(95)00107-P; Ghebreyesus TA, 1998, J PUBLIC HEALTH MED, V20, P238, DOI 10.1093/oxfordjournals.pubmed.a024754; Gillies M. T., 1988, Malaria: principles and practice of malariology. Volume 1., P453; Gratz N. G., 1988, Vector-borne disease control in humans through rice agroecosystem management. Proceedings of the Workshop on Research and Training Needs in the Field of Integrated Vector-borne Disease Control in Riceland Agroecosystems of Developing Countries, 9-14 March 1987., P7; KIRKWOOD B, 1988, ESSENTIALS MED STAT, P129; RAMASAMY R, 1992, AM J TROP MED HYG, V47, P547, DOI 10.4269/ajtmh.1992.47.547; STEPHENS J, 1989, METHOD INFORM MED, V28, P155; TEKLEHAIMANOT A, 1986, LANCET, V2, P127	15	143	147	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					663	666		10.1136/bmj.319.7211.663	http://dx.doi.org/10.1136/bmj.319.7211.663			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10480820	Green Published, Bronze			2022-12-24	WOS:000082636800019
J	Roizen, R; Kerr, WC; Fillmore, KM				Roizen, R; Kerr, WC; Fillmore, KM			Cirrhosis mortality and per capita consumption of distilled spirits, United States, 1949-94: trend analysis	BRITISH MEDICAL JOURNAL			English	Article							ALCOHOL; WINE; CONSEQUENCES; IMPACT; RISK; BEER	Objective To describe, evaluate, and suggest interpretations for an observed aggregate level relation between trends in mortality from cirrhosis and per capita consumption of distilled spirits in the United States. Design Trend analysis using data on US cirrhosis mortality and per capita alcohol consumption. Results There is a consistent long term trend relation between mortality from cirrhosis and per capita consumption of distilled spirits in the United States from 1949 to 1994. Two instances of comparatively sharp drops in the consumption of spirits earlier in the 1940s generated mixed results in predicting changes in cirrhosis mortality. Conclusions An aggregate level relation between trends in long term cirrhosis mortality and the consumption of spirits falls considerably short of establishing a direct causal link between the two for individuals. Moreover, two sharp drops in the consumption of spirits generated only mixed results with respect to the short term trend in cirrhosis. Nevertheless, the observed relation between the consumption of spirits and cirrhosis mortality merits further investigation.	Univ Calif San Francisco, Dept Social & Behav Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Roizen, R (corresponding author), Univ Calif San Francisco, Dept Social & Behav Sci, Box 0612, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007034, R01AA009623] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09623, KO1 AA00073, R01 AA07034] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BOX EP, 1976, TIME SERIES ANAL FOR; Derr RF, 1996, BIOCHEM ARCH, V12, P277; Edwards G., 1994, ALCOHOL POLICY PUBLI; GODFREY LG, 1988, SPECIFICATION TESTS; GOTTMAN J. M., 1981, TIME SERIES ANAL COM; GRANT BF, 1985, US ALCOHOL EPIDEMIOL; GRUENEWALD PJ, 1995, J STUD ALCOHOL, V56, P635, DOI 10.15288/jsa.1995.56.635; HARFORD TC, 1979, INT J ADDICT, V14, P197, DOI 10.3109/10826087909060365; HERD D, 1992, ADDICTION, V87, P1113; HILTON ME, 1991, ALCOHOL AM DRINKING, P121; Holder HD, 1997, ADDICTION, V92, P5, DOI 10.1111/j.1360-0443.1997.tb03632.x; HYMAN MM, 1981, J STUD ALCOHOL, V42, P336, DOI 10.15288/jsa.1981.42.336; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; Kling W, 1991, J Stud Alcohol, V52, P503; KLING W, 1989, J STUD ALCOHOL, V50, P456, DOI 10.15288/jsa.1989.50.456; LELBACH WK, 1975, MED CONSEQUENCES ALC, V252; LINGEMAN RR, 1970, DONT YOU KNOW THERES, P247; LJUNG GM, 1979, BIOMETRIKA, V66, P265, DOI 10.1093/biomet/66.2.265; LONGNECKER MP, 1981, J STUD ALCOHOL, V42, P791, DOI 10.15288/jsa.1981.42.791; NORSTROM T, 1987, BRIT J ADDICT, V82, P67; PHILLIPS PCB, 1988, BIOMETRIKA, V75, P335, DOI 10.1093/biomet/75.2.335; Pindyck R.S., 1998, ECONOMETRIC MODELS E, V4th edition; *QUANT MICR SOFTW, 1994, E VIEWS US GUID; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; SAADATMAND R, 1997, 45 US DEP HLTH HUM S; SCHMIDT DN, 1991, INT J PANCREATOL, V8, P45; SELZER MI, 1977, J STUD ALCOHOL, V38, P1204; SKOG OJ, 1980, BRIT J ADDICT, V75, P227; SKOG OJ, 1988, ALCOHOL ALCOHOLISM, V22, P193; Smart RG, 1996, J STUD ALCOHOL, V57, P77, DOI 10.15288/jsa.1996.57.77; SMART RG, 1993, ADDICTION, V88, P193, DOI 10.1111/j.1360-0443.1993.tb00802.x; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TURRELL V, 1946, ALCOHOL POLICIES WAR; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; WILLIAMS GD, 1996, APPARENT CAPITA ALCO	36	55	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 11	1999	319	7211					666	670A		10.1136/bmj.319.7211.666	http://dx.doi.org/10.1136/bmj.319.7211.666			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	237CH	10480821	Green Published, Bronze			2022-12-24	WOS:000082636800020
J	Cubas, P; Vincent, C; Coen, E				Cubas, P; Vincent, C; Coen, E			An epigenetic mutation responsible for natural variation in floral symmetry	NATURE			English	Article							FLOWER DEVELOPMENT; ANTIRRHINUM-MAJUS; METHYLATION; MERISTEM	Although there have been many molecular studies of morphological mutants generated in the laboratory, it is unclear how these are related to mutants in natural populations, where the constraints of natural selection and breeding structure are quite different. sere we characterize a naturally occurring mutant of Linaria vulgaris, originally described more than 250 years ago by Linnaeus(1-3), in which the fundamental symmetry of the newer is changed from bilateral to radial. We show that the mutant carries a defect in Lcyc, a homologue of the cycloidea gene which controls dorsoventral asymmetry in Antirrhinum(4). The Lcyc gene is extensively methylated and transcriptionally silent in the mutant. This modification is heritable and co-segregates with the mutant phenotype. Occasionally the mutant reverts phenotypically during, somatic development, correlating with demethylation of Lcyc and restoration of gene expression. It is surprising that the first natural morphological mutant to be characterized should trace to methylation, given the rarity of this mutational mechanism in the laboratory. This indicates that epigenetic mutations may play a more significant role in evolution than has hitherto been suspected.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Cubas, Pilar/ABE-8670-2020; Cubas, Pilar/M-2268-2015	Cubas, Pilar/0000-0003-4679-2173; Cubas, Pilar/0000-0003-4679-2173				Almeida J, 1997, DEVELOPMENT, V124, P1387; Bradley D, 1996, NATURE, V379, P791, DOI 10.1038/379791a0; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; BRIEGER F. G., 1935, GENETICA, V17, P385, DOI 10.1007/BF01508186; CAMBARERI EB, 1989, SCIENCE, V244, P1571, DOI 10.1126/science.2544994; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COUNTS JL, 1995, CELL, V83, P13, DOI 10.1016/0092-8674(95)90228-7; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DAS OP, 1994, GENETICS, V136, P1121; DEVRIES H, 1904, SPECIES VARIETIES TH, P459; DOCHERTY Z, 1982, HEREDITY, V49, P349, DOI 10.1038/hdy.1982.108; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GUBLER U, 1988, NUCLEIC ACIDS RES, V16, P2726, DOI 10.1093/nar/16.6.2726; GUSTAFSSON A, 1979, THEOR APPL GENET, V54, P241, DOI 10.1007/BF00281206; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JABLONKA E, 1989, J THEOR BIOL, V139, P69, DOI 10.1016/S0022-5193(89)80058-X; Jablonka E, 1998, J EVOLUTION BIOL, V11, P159, DOI 10.1007/s000360050073; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; LINNAEUS C, 1749, THESIS UPPSALA; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; SHERMAN M, 1939, Z INDUKT ABSTAMMUNGS, V77, P1; WILLIAMS MH, 1988, PROTOPLASMA, V147, P77, DOI 10.1007/BF01403879	24	849	914	7	247	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					157	161		10.1038/43657	http://dx.doi.org/10.1038/43657			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490023				2022-12-24	WOS:000082458800052
J	Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF				Schwarze, SR; Ho, A; Vocero-Akbani, A; Dowdy, SF			In vivo protein transduction: Delivery of a biologically active protein into the mouse	SCIENCE			English	Article							CELLS; DRUGS; BRAIN	Delivery of therapeutic proteins into tissues and across the blood-brain barrier is severely limited by the size and biochemical properties of the proteins. Here it is shown that intraperitoneal injection of the 120-kilodalton beta-galactosidase protein, fused to the protein transduction domain from the human immunodeficiency virus TAT protein, results in-delivery of the biologically active fusion protein to all tissues in mice, including the brain. These results open new possibilities for direct delivery of proteins into patients in the context of protein therapy, as well as for epigenetic experimentation with model organisms.	Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Dowdy, SF (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA.							Anderson WF, 1998, NATURE, V392, P25; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8; Elefanty AG, 1998, P NATL ACAD SCI USA, V95, P11897, DOI 10.1073/pnas.95.20.11897; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Gius DR, 1999, CANCER RES, V59, P2577; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HO AF, UNPUB, P42707; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; KRALL WJ, 1992, NEW BIOL, V4, P581; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; RAPOPORT SI, 1972, SCIENCE, V170, P1243; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHELD WM, 1989, REV INFECT DIS S, V7, P1669; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; SCHWARZE S, UNPUB; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710	22	2084	2474	2	220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1569	1572		10.1126/science.285.5433.1569	http://dx.doi.org/10.1126/science.285.5433.1569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477521				2022-12-24	WOS:000082359500066
J	Muller, JR; Metha, AB; Krauskopf, J; Lennie, P				Muller, JR; Metha, AB; Krauskopf, J; Lennie, P			Rapid adaptation in visual cortex to the structure of images	SCIENCE			English	Article							CONTRAST GAIN-CONTROL; CAT STRIATE CORTEX; SYNAPTIC DEPRESSION; RECEPTIVE-FIELDS; CORTICAL-NEURONS; SINGLE UNITS; MACAQUE; CELLS; NORMALIZATION; SELECTIVITY	Complex cells in striate cortex of macaque showed a rapid pattern-specific adaptation. Adaptation made cells more sensitive to orientation change near the adapting orientation. It reduced correlations among the responses of populations of cells, thereby increasing the information transmitted by each action potential. These changes were brought about by brief exposures to stationary patterns, on the time scale of a single fixation. Thus, if successive fixations expose neurons' receptive fields to images with similar but not identical structure, adaptation will remove correlations and improve discriminability.	Univ Rochester, Ctr Visual Sci, Rochester, NY 14627 USA; Univ Rochester, Dept Brain & Cognit Sci, Rochester, NY 14627 USA; NYU, Ctr Neural Sci, New York, NY 10003 USA	University of Rochester; University of Rochester; New York University	Muller, JR (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Fairchild D209, Stanford, CA 94305 USA.		; Metha, Andrew/H-2401-2015	Lennie, Peter/0000-0002-2561-6368; Metha, Andrew/0000-0003-2997-4362	NEI NIH HHS [EY01319, EY06638, EY04440] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY004440, P30EY001319, R01EY004440] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ALBRECHT DG, 1984, J PHYSIOL-LONDON, V347, P713, DOI 10.1113/jphysiol.1984.sp015092; BAHILL AT, 1975, INVEST OPHTH VISUAL, V14, P468; BARLOW HB, 1976, VISION RES, V16, P1043, DOI 10.1016/0042-6989(76)90241-8; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; Blakemore C., 2010, VISION CODING EFFICI, P363, DOI 10.1017/cbo9780511626197.034; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; Carandini M, 1997, SCIENCE, V276, P949, DOI 10.1126/science.276.5314.949; Carandini M, 1997, PHILOS T R SOC B, V352, P1149, DOI 10.1098/rstb.1997.0098; Carandini M, 1997, J NEUROSCI, V17, P8621; CARANDINI M, COMMUNICATION; Chance FS, 1998, J NEUROSCI, V18, P4785; DEANGELIS GC, 1992, J NEUROPHYSIOL, V68, P144, DOI 10.1152/jn.1992.68.1.144; DEANGELIS GC, 1994, J NEUROPHYSIOL, V71, P347, DOI 10.1152/jn.1994.71.1.347; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; GILBERT CD, 1990, VISION RES, V30, P1689, DOI 10.1016/0042-6989(90)90153-C; GREENLEE MW, 1988, VISION RES, V28, P791, DOI 10.1016/0042-6989(88)90026-0; Hawken MJ, 1996, VISUAL NEUROSCI, V13, P477, DOI 10.1017/S0952523800008154; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; Land MF, 1997, PHILOS T ROY SOC B, V352, P1231, DOI 10.1098/rstb.1997.0105; Lankheet MJM, 1998, VISUAL NEUROSCI, V15, P37, DOI 10.1017/S0952523898151027; LENNIE P, 1990, J NEUROSCI, V10, P649; LENNIE P, 1994, INVEST OPHTH VIS SCI, V35, P1662; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; REGAN D, 1985, J OPT SOC AM A, V2, P147, DOI 10.1364/JOSAA.2.000147; SAUL AB, 1989, VISUAL NEUROSCI, V2, P593, DOI 10.1017/S0952523800003527; SAUL AB, 1989, VISUAL NEUROSCI, V2, P609, DOI 10.1017/S0952523800003539; SCLAR G, 1989, VISION RES, V29, P747, DOI 10.1016/0042-6989(89)90087-4; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SIMONCELLI EP, 1999, ADV NEURAL INFORMATI, V11; TOLHURST DJ, 1980, EXP BRAIN RES, V38, P431; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7	38	343	345	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1405	1408		10.1126/science.285.5432.1405	http://dx.doi.org/10.1126/science.285.5432.1405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464100				2022-12-24	WOS:000082233500044
J	Scott, J				Scott, J			Heart disease - Good cholesterol news	NATURE			English	Editorial Material							ABC		Univ London Imperial Coll Sci Technol & Med, Sch Med, London W12 0NN, England; Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England	Imperial College London; Imperial College London	Scott, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Du Cane Rd, London W12 0NN, England.							Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; LUCIANI MF, 1994, GENOMICS, V21, P150, DOI 10.1006/geno.1994.1237; MARCIL M, IN PRESS LANCET; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408	11	7	7	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					816	+		10.1038/23584	http://dx.doi.org/10.1038/23584			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476954				2022-12-24	WOS:000082233200019
J	Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH				Psaty, BM; Weiss, NS; Furberg, CD; Koepsell, TD; Siscovick, DS; Rosendaal, FR; Smith, NL; Heckbert, SR; Kaplan, RC; Lin, DY; Fleming, TR; Wagner, EH			Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY PULMONARY-HYPERTENSION; DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; CHOLESTEROL REDUCTION; PRIMARY PREVENTION; CLINICAL-TRIALS; EVENTS; COMPLICATIONS; DEXFENFLURAMINE; FENFLURAMINE		Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Med, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA; Univ Washington, Dept Biostat, Seattle, WA 98101 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Group Health Cooperative	Psaty, BM (corresponding author), Univ Washington, Cardiovasc Hlth Res Unit, Suite 1360,1730 Minor Ave, Seattle, WA 98101 USA.		Kaplan, Robert/A-2526-2011; Rosendaal, Frits/Q-3842-2017	Rosendaal, Frits/0000-0003-2558-7496	NHLBI NIH HHS [HL40628, HL60739, HL43201] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL040628, R01HL043201, R01HL040628, R01HL060739] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Abraira C, 1997, ARCH INTERN MED, V157, P181, DOI 10.1001/archinte.157.2.181; [Anonymous], 1991, JAMA, V265, P3255; BarrettConnor E, 1997, DIABETES CARE, V20, P1620, DOI 10.2337/diacare.20.10.1620; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Curfman GD, 1997, NEW ENGL J MED, V337, P629, DOI 10.1056/NEJM199708283370909; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; *FDA, 1999, EV US DRUG LAW; Ferner RE, 1996, BRIT MED J, V313, P1157, DOI 10.1136/bmj.313.7066.1157; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GUYGRAND B, 1989, LANCET, V2, P1142; Imura H, 1998, NEW ENGL J MED, V338, P908, DOI 10.1056/NEJM199803263381311; LIPICKY RJ, 1993, AM J CARDIOL, V22, pA179; Manson JE, 1996, NEW ENGL J MED, V335, P659, DOI 10.1056/NEJM199608293350910; Massy ZA, 1996, LANCET, V347, P102, DOI 10.1016/S0140-6736(96)90217-2; McCann UD, 1997, JAMA-J AM MED ASSOC, V278, P666, DOI 10.1001/jama.278.8.666; MEINERT CL, 1970, DIABETES, V19, P789; Mitchell P, 1997, LANCET, V350, P1685, DOI 10.1016/S0140-6736(05)64289-4; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sobel BE, 1997, CIRCULATION, V95, P1661; Tatti P, 1998, DIABETES CARE, V21, P597, DOI 10.2337/diacare.21.4.597; Temple Robert J., 1995, P3; Turner R, 1996, ANN INTERN MED, V124, P136, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00011; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vaughan CJ, 1996, LANCET, V348, P1079, DOI 10.1016/S0140-6736(96)05190-2	41	122	123	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					786	790		10.1001/jama.282.8.786	http://dx.doi.org/10.1001/jama.282.8.786			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463718	Green Published			2022-12-24	WOS:000082118800034
J	Temple, R				Temple, R			Are surrogate markers adequate to assess cardiovascular disease drugs?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; RANDOMIZED TRIALS; CLINICAL-TRIALS; BLOOD-PRESSURE; HYPERTENSION; MORTALITY; FAILURE; MORBIDITY; THERAPIES		US FDA, Ctr Drug Evaluat & Res Policy, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Temple, R (corresponding author), US FDA, Ctr Drug Evaluat & Res Policy, 5600 Fishers Ln,HFD 101, Rockville, MD 20857 USA.	Temple@CDER.fda.gov						Alderman M, 1997, J HYPERTENS, V15, P105; [Anonymous], 1992, Fed Regist, V57, P58942; Califf RM, 1998, CIRCULATION, V97, P1529, DOI 10.1161/01.CIR.97.16.1529; Cohn JN, 1998, NEW ENGL J MED, V339, P1810, DOI 10.1056/NEJM199812173392503; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; Effects of treatment on morbidity in hypertension, 1970, JAMA-J AM MED ASSOC, V213, P1143, DOI DOI 10.1001/JAMA.213.7.1143; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; Forker AD, 1996, J CLIN PHARMACOL, V36, P973, DOI 10.1177/009127009603601101; FREIS ED, 1990, HYPERTENSION, V16, P472, DOI 10.1161/01.HYP.16.4.472; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PACKER M, 1993, CIRCULATION S1, V88, P1; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Sobel BE, 1997, CIRCULATION, V95, P1661; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TEMPLE R, 1990, DEV CARDIOVASC MED, P139; TEMPLE R, 1988, P179; TEMPLE R, 1987, CONGESTIVE HEART FAI, P155; Temple Robert J., 1995, P3; US Government Printing Office, 1992, FED REGISTER, V57, P13234; *VET ADM COOP STUD, 1967, JAMA-J AM MED ASSOC, V202, P1228; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	30	220	222	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					790	795		10.1001/jama.282.8.790	http://dx.doi.org/10.1001/jama.282.8.790			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463719				2022-12-24	WOS:000082118800035
J	Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC				Dye, C; Scheele, S; Dolin, P; Pathania, V; Raviglione, RC		WHO Global Surveillance Monitoring Project	Global burden of tuberculosis - Estimated incidence, prevalence, and mortality by country	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTION; TRANSMISSION; SURVIVAL; ISSUES	Objective To estimate the risk and prevalence of Mycobacterium tuberculosis (MTB) infection and tuberculosis (TB) incidence, prevalence, and mortality, including disease attributable to human immunodeficiency virus (HIV), for 212 countries in 1997. Participants A panel of 86 TB experts and epidemiologists from more than 40 countries was chosen by the World Health Organization (WHO), with final agreement being reached between country experts and WHO staff. Evidence Incidence of TB and mortality in each country was determined by (1) case notification to the WHO, (2) annual risk of infection data from tuberculin surveys, and (3) data on prevalence of smear-positive pulmonary disease from prevalence surveys, Estimates derived from relatively poor data were strongly influenced by panel member opinion. Objective estimates were derived from high-quality data collected recently by approved procedures, Consensus Process Agreement was reached by (1) participants reviewing methods and data and making provisional estimates in dosed workshops held at WHO's 6 regional offices, (2) principal authors refining estimates using standard methods and all available data, and (3) country experts reviewing and adjusting these estimates and reaching final agreement with WHO staff. Conclusions In 1997, new cases of TB totaled an estimated 7.96 million (range, 6.3 million-11.1 million), including 3.52 million (2.8 million-4.9 million) cases (44%) of infectious pulmonary disease (smear-positive), and there were 16.2 million (12.1 million-22.5 million) existing cases of disease. An estimated 1.87 million (1.4 million-2.8 million) people died of TB and the global case fatality rate was 23% but exceeded 50% in some African countries with high HIV rates, Global prevalence of MTB infection was 32% (1.86 billion people). Eighty percent of all incident TB cases were found in 22 countries, with more than half the cases occurring in 5 Southeast Asian countries, Nine of 10 countries with the highest incidence rates per capita were in Africa. Prevalence of MTB/HIV coinfection worldwide was 0.18% and 640 000 incident TB cases (8%) had HIV infection. The global burden of tuberculosis remains enormous, mainly because of poor control in Southeast Asia, sub-Saharan Africa, and eastern Europe, and because of high rates of M tuberculosis and HIV coinfection in some African countries.	WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland	World Health Organization	Dye, C (corresponding author), WHO, Communicable Dis Prevent & Control, CH-1211 Geneva 27, Switzerland.		Dye, Christopher/AIC-4659-2022	RAVIGLIONE, Mario/0000-0002-9331-2067; Dye, Christopher/0000-0002-2957-1793				BARNETT G D, 1977, Bulletin of the International Union Against Tuberculosis, V52, P5; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CAUTHEN G, 1988, WHO PUBL; Cauthen GM, 1996, AM J EPIDEMIOL, V144, P69, DOI 10.1093/oxfordjournals.aje.a008856; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P585; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; DATTA M, 1993, TUBERCLE LUNG DIS, V74, P180, DOI 10.1016/0962-8479(93)90008-L; DeCock KM, 1996, JAMA-J AM MED ASSOC, V276, P1502, DOI 10.1001/jama.276.18.1502; *DEP HLTH TUB CONT, 1997, NAT TUB PREV SURV 19; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Espinal MA, 1996, J ACQ IMMUN DEF SYND, V13, P155, DOI 10.1097/00042560-199610010-00006; GITHUI W, 1992, TUBERCLE LUNG DIS, V73, P203, DOI 10.1016/0962-8479(92)90087-Z; Hilleboe HE, 1941, PUBLIC HEALTH REP, V56, P895, DOI 10.2307/4583713; KREBS W, 1930, AARGAULSCHEN HEILSTA, P345; MURRAY C, 1993, DIS CONTROL PRIORITI; MURRAY CJL, 1996, GLOBAL HLTH STAT, V2; OHMORI M, 1995, STAGNATION DECLINE T; Raviglione M C, 1997, AIDS, V11 Suppl B, pS115; RIEDER HL, 1995, TUBERCLE LUNG DIS, V76, P114, DOI 10.1016/0962-8479(95)90552-9; Shafer RW, 1996, CLIN INFECT DIS, V22, P683, DOI 10.1093/clinids/22.4.683; STYBLO K, 1978, Bulletin of the International Union Against Tuberculosis, V53, P141; Styblo K., 1985, B INT UNION TUBERC, V60, P117; STYBLO K, 1997, EXPECTED DECREASE TU; Styblo K, 1991, EPIDEMIOLOGY TUBERCU; SUDRE P, 1992, B WORLD HEALTH ORGAN, V70, P149; *UNAIDS WHO, 1998, REP GLOB HIV AIDS EP; *US BUR BENS, 1997, HIV AIDS SURV DAT JA; van den Broek J, 1998, INT J TUBERC LUNG D, V2, P547; Whalen C, 1996, AM J RESP CRIT CARE, V153, P1977, DOI 10.1164/ajrccm.153.6.8665064; *WHO, 1999, GLOB TUB CONR WHO RE; *WHO, 1998, 1996 WHO STAT ANN; *WHO, 1994, WHO PUBL; *WHO, 1996, DEM DAT HLTH SIT ASS; *WORLD BANK, 1993, WORLD DEV REP; World Health Organization, 1998, GLOB TUB CONTR WHO R	37	2361	2523	7	193	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					677	686		10.1001/jama.282.7.677	http://dx.doi.org/10.1001/jama.282.7.677			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517722				2022-12-24	WOS:000082033700028
J	Westendorp, RGJ; Hottenga, JJ; Slagboom, PE				Westendorp, RGJ; Hottenga, JJ; Slagboom, PE			Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock	LANCET			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; INTRAVASCULAR COAGULATION; ENDOTOXIN; SEPSIS; POLYMORPHISM; DIAGNOSIS; MORTALITY; PROMOTER; INCREASE; DISEASE	Background Some patients infected with Neisseria meningitidis develop septic shock accompanied by fibrin deposition and microthrombus formation in various organs, whereas others develop bacteraemia or meningitis without septic shock. We investigated whether genetic differences in the fibrinolytic system influence the development of meningococcal septic shock. Methods We investigated 50 patients who survived meningococcal infection, and 131 controls from the same geographical region. Because we had no information on genotypes of patients who died, we also genotyped 183 first-degree relatives of a consecutive series of patients with meningococcal infection for the 4G/5G deletion/insertion polymorphism in the promoter region of the plasminogen-activator-inhibitor-1 gene (PAI-1), The 4G allele is associated with increased gene transcription in cell lines in vitro and with increased PAI-1 concentrations in carriers in vivo. Findings The allele frequencies of 4G and 5G were similar between patients and controls. However, the 4G/4G genotype was present in only 9% of relatives of patients with meningitis compared with 36% of relatives of patients with septic shock. The 5G/5G genotype was more common among relatives of patients with meningitis (31 vs 11%, p=0.001). Patients whose relatives were carriers of the 4G/4G genotype had a six-fold higher risk of developing septic shock than meningitis (odds ratio 5.9 [95% CI 1.9-18.0]) compared with all other genotypes, Interpretation Variation in the PAI-1 gene does not affect the probability of contracting meningococcal infection, but does influence the development of septic shock.	Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; TNO, Gaubius Lab, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research	Westendorp, RGJ (corresponding author), Leiden Univ, Med Ctr, Dept Gen Internal Med, CO-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Slagboom, P. Eline/R-4790-2016	Slagboom, P. Eline/0000-0002-2875-4723				ANDERSEN BM, 1987, SCAND J INFECT DIS, V19, P409, DOI 10.3109/00365548709021673; BOHM N, 1982, PATHOL RES PRACT, V174, P92; BRANDTZAEG P, 1990, THROMB RES, V57, P271, DOI 10.1016/0049-3848(90)90326-8; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; MANSFIELD MW, 1995, THROMB HAEMOSTASIS, V74, P1032; Mesters RM, 1996, THROMB HAEMOSTASIS, V75, P902; Mohanty D, 1997, AM J HEMATOL, V54, P23, DOI 10.1002/(SICI)1096-8652(199701)54:1&lt;23::AID-AJH4&gt;3.0.CO;2-6; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Paloma MJ, 1995, THROMB HAEMOSTASIS, V74, P1578; PARAMO JA, 1990, THROMB HAEMOSTASIS, V64, P3; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; VANDEUREN M, 1993, BMJ-BRIT MED J, V306, P1229, DOI 10.1136/bmj.306.6887.1229; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; WESTENDORP RGJ, 1992, AM J MED, V92, P577, DOI 10.1016/0002-9343(92)90761-Y; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1996, THROMB HAEMOSTASIS, V75, P899; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	23	147	152	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					561	563		10.1016/S0140-6736(98)09376-3	http://dx.doi.org/10.1016/S0140-6736(98)09376-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470701				2022-12-24	WOS:000081991000014
J	Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW				Raaymakers, TWM; Rinkel, GJE; van Gijn, J; Greebe, P; Algra, A; Buskens, E; Buys, PC; Ramos, LMP; Witkamp, TD; Mali, WPTM; Tulleken, CAF; Limburg, M; Gorissen, A; Vonk, CM; Bossuyt, PMM; Bonsel, GJ; Verbeeten, B; Hulsmans, FJ; Albrecht, KW		Magnetic Resonance Angiography Rel	Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNRUPTURED CEREBRAL ANEURYSMS; SACCULAR ANEURYSMS; NATURAL-HISTORY; MR-ANGIOGRAPHY; RUPTURE; SURGERY	Background The first-degree relatives of patients who have subarachnoid hemorrhage from ruptured intracranial aneurysms are themselves at risk for subarachnoid hemorrhage. We studied the benefits and risks of screening for aneurysms in the first-degree relatives of patients with sporadic subarachnoid hemorrhage. Methods We screened 626 first-degree relatives (parents, siblings, or children) of 160 patients with sporadic subarachnoid hemorrhage, from a prospective series of 193 consecutive index patients. Magnetic resonance angiography was the screening tool, and conventional angiography was used as the reference test in subjects thought to have aneurysms. Six months after elective operation, outcome was assessed by means of the modified Rankin scale of neurologic function. This observational study design was combined with a decision-analysis model to estimate the effectiveness of screening. The efficiency of screening was defined by the number of relatives who needed to be screened in order to prevent one subarachnoid hemorrhage. Results Aneurysms were found in 25 of 626 first-degree relatives (4.0 percent; 95 percent confidence interval, 2.6 to 5.8 percent). Eighteen underwent surgery, which resulted in a decrease in function in 11 (disabling in 1). Five had medium-sized aneurysms that were 5 to 11 mm in diameter, 11 had small aneurysms that were less than 5 mm, and 2 had both small and medium-sized aneurysms. On average, surgery increased estimated life expectancy by 2.5 years for these 18 subjects (or by 0.9 month per person screened), at the expense of 19 years of decreased function per person. The number of relatives who would need to be screened in order to prevent 1 subarachnoid hemorrhage on a lifetime basis was 149, and 298 would have to be screened in order to prevent 1 fatal subarachnoid hemorrhage. Conclusions Implementation of a screening program for the first-degree relatives of patients with sporadic subarachnoid hemorrhage does not seem warranted at this time, since the resulting slight increase in life expectancy does not offset the risk of postoperative sequelae. (N Engl J Med 1999;341:1344-50.) (C) 1999, Massachusetts Medical Society.	Univ Utrecht Hosp, Dept Neurol, NL-3584 CX Utrecht, Netherlands; Julius Ctr Patient Oriented Res, Utrecht, Netherlands; Acad Med Ctr, Dept Neurosurg, Amsterdam, Netherlands; Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; Acad Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Raaymakers, TWM (corresponding author), Univ Utrecht Hosp, Dept Neurol, H2-128,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Mali, Willem PThM/I-1123-2014; van Gijn, Jan/A-9444-2008; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Mali, Willem PThM/0000-0003-4391-0904; Bossuyt, Patrick M/0000-0003-4427-0128				ASARI S, 1993, CLIN NEUROL NEUROSUR, V95, P205, DOI 10.1016/0303-8467(93)90125-Z; Atlas SW, 1997, RADIOLOGY, V203, P807, DOI 10.1148/radiology.203.3.9169709; Auger R G, 1991, J Stroke Cerebrovasc Dis, V1, P174, DOI 10.1016/S1052-3057(10)80014-X; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BROMBERG JEC, 1995, BRIT MED J, V311, P288, DOI 10.1136/bmj.311.7000.288; Caplan LR, 1998, NEW ENGL J MED, V339, P1774, DOI 10.1056/NEJM199812103392409; CHANG HS, 1995, J NEUROSURG, V83, P413, DOI 10.3171/jns.1995.83.3.0413; Crawley F, 1999, STROKE, V30, P312, DOI 10.1161/01.STR.30.2.312; Eskesen V, 1987, Br J Neurosurg, V1, P47, DOI 10.3109/02688698709034340; Eskesen V, 1988, Br J Neurosurg, V2, P379, DOI 10.3109/02688698809001009; HABBEMA JDF, 1990, STAT MED, V9, P1229, DOI 10.1002/sim.4780091104; HEISERMAN JE, 1994, AM J NEURORADIOL, V15, P1401; Hop JW, 1997, STROKE, V28, P660, DOI 10.1161/01.STR.28.3.660; INAGAWA T, 1992, SURG NEUROL, V38, P364, DOI 10.1016/0090-3019(92)90023-G; Inomiya K, 1995, Medinfo, V8 Pt 2, P889; JUVELA S, 1993, J NEUROSURG, V79, P174, DOI 10.3171/jns.1993.79.2.0174; Kojima M, 1998, NEUROSURGERY, V43, P776, DOI 10.1097/00006123-199810000-00026; KOROGI Y, 1994, RADIOLOGY, V193, P181, DOI 10.1148/radiology.193.1.8090889; LEBLANC R, 1994, NEUROSURGERY, V35, P9, DOI 10.1227/00006123-199407000-00002; LOCKSLEY HB, 1966, J NEUROSURG, V25, P321, DOI 10.3171/jns.1966.25.3.0321; MCCORMICK WF, 1970, J NEUROSURG, V33, P422, DOI 10.3171/jns.1970.33.4.0422; Mizoi K, 1995, SURG NEUROL, V44, P114, DOI 10.1016/0090-3019(95)00035-6; OBUCHOWSKI NA, 1995, J NEUROSURG, V83, P42, DOI 10.3171/jns.1995.83.1.0042; PRZELOMSKI MM, 1986, NEUROLOGY, V36, P584, DOI 10.1212/WNL.36.4.584; Raaymakers TWM, 1998, NEUROLOGY, V51, P1125, DOI 10.1212/WNL.51.4.1125; Raaymakers TWM, 1998, STROKE, V29, P1531, DOI 10.1161/01.STR.29.8.1531; RANKIN J, 1957, Scott Med J, V2, P200; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; Rinkel GJE, 1998, STROKE, V29, P251, DOI 10.1161/01.STR.29.1.251; RONKAINEN A, 1995, RADIOLOGY, V195, P35, DOI 10.1148/radiology.195.1.7892491; Ronkainen A, 1998, STROKE, V29, P359, DOI 10.1161/01.STR.29.2.359; Ronkainen A, 1997, LANCET, V349, P380, DOI 10.1016/S0140-6736(97)80009-8; SCHIEVINK WI, 1995, J NEUROSURG, V83, P426, DOI 10.3171/jns.1995.83.3.0426; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Tas R F, 1998, Maandstat Bevolking, V46, P8; Wiebers D, 1999, NEW ENGL J MED, V340, P744; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401; WIEBERS DO, 1987, J NEUROSURG, V66, P23, DOI 10.3171/jns.1987.66.1.0023; WILMS G, 1996, NEURORADIOLOGY, V38, P20; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; ZACKS DJ, 1980, ARCH NEUROL-CHICAGO, V37, P39, DOI 10.1001/archneur.1980.00500500069010	41	92	95	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1344	1350						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536126				2022-12-24	WOS:000083357800003
J	Mulligan, J; Voss, LD				Mulligan, J; Voss, LD			Identifying very fat and very thin children: test of criterion standards for screening test	BRITISH MEDICAL JOURNAL			English	Article							BODY-MASS INDEX		Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	University of Southampton	Mulligan, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.							FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; Hulse J A, 1995, J Med Screen, V2, P168; Power C, 1997, AM J CLIN NUTR, V66, P1094, DOI 10.1093/ajcn/66.5.1094; Prentice AM, 1998, BRIT MED J, V317, P1401, DOI 10.1136/bmj.317.7170.1401; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1103	1104		10.1136/bmj.319.7217.1103	http://dx.doi.org/10.1136/bmj.319.7217.1103			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531099	Bronze, Green Published			2022-12-24	WOS:000083419500022
J	Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL				Naren, AP; Cormet-Boyaka, E; Fu, J; Villain, M; Blalock, JE; Quick, MW; Kirk, KL			CFPR chloride channel regulation by an interdomain interaction	SCIENCE			English	Article							CYSTIC-FIBROSIS; CFTR; SYNTAXIN; DOMAIN	The cystic fibrosis gene encodes a chloride channel, CFTR (cystic fibrosis transmembrane conductance regulator), that regulates salt and water transport across epithelial tissues. Phosphorylation of the cytoplasmic regulatory (R) domain by protein kinase A activates CFTR by an unknown mechanism. The amino-terminal cytoplasmic tail of CFTR was found to control protein kinase A-dependent channel gating through a physical interaction with the R domain. This regulatory activity mapped to a cluster of acidic residues in the NH2-terminal tail; mutating these residues proportionately inhibited R domain binding and CFTR channel function. CFTR activity appears to be governed by an interdomain interaction involving the amino-terminal tail, which is a potential target for physiologic and pharmacologic modulators of this ion channel.	Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Naren, AP (corresponding author), Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Res Ctr, Dept Physiol & Biophys, Birmingham, AL 35294 USA.	kirk@phybio.bhs.uab.edu	Cormet-Boyaka, Estelle/H-5624-2011	Blalock, J. Edwin/0000-0001-5303-8123	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA010509, R01DA010509] Funding Source: NIH RePORTER; NIDA NIH HHS [DA10509] Funding Source: Medline; NIDDK NIH HHS [DK51868, DK50830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1989, CELL, V66, P1066; FU J, UNPUB; GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148; Ma JJ, 1997, J BIOL CHEM, V272, P28133, DOI 10.1074/jbc.272.44.28133; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; NAREN AP, UNPUB; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; QUICK MW, UNPUB; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514	17	108	108	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					544	548		10.1126/science.286.5439.544	http://dx.doi.org/10.1126/science.286.5439.544			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521352				2022-12-24	WOS:000083121200064
J	Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE				Burzlaff, NI; Rutledge, PJ; Clifton, IJ; Hensgens, CMH; Pickford, M; Adlington, RM; Roach, PL; Baldwin, JE			The reaction cycle of isopenicillin N synthase observed by X-ray diffraction	NATURE			English	Article							PENICILLIN BIOSYNTHESIS; LACTAM FORMATION; CRYSTALLOGRAPHY; PROGRAM; SULFUR	Isopenicillin N synthase (IPNS), a non-haem iron-dependent oxidase, catalyses the biosynthesis of isopenicillin N (IPN), the precursor of all penicillins and cephalosporins'. The key steps in this reaction are the two iron-dioxygen-mediated ring closures of the tripeptide delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valin (ACV). It has been proposed that the four-membered beta-lactam ring forms initially, associated with a highly oxidized iron(rv)-oxo (ferryl) moiety, which subsequently mediates closure of the five-membered thiazolidine ring(2). Here we describe observation of the IPNS reaction in crystals by X-ray crystallography. IPNS.Fe2+.substrate crystals were grown anaerobically(3,4), exposed to high pressures of oxygen to promote reaction and frozen, and their structures were elucidated by X-ray diffraction. Using the natural substrate ACV, this resulted in the IPNS.Fe2+.IPN product complex. With the substrate analogue, delta-(L-alpha-aminoadipoyl)-L-cysteinyl-L-S-methyl-cysteine (ACmC) in the crystal, the reaction cycle was interrupted at the monocyclic stage. These mono- and bicyclic structures support our hypothesis of a two-stage reaction sequence leading to penicillin. Furthermore, the formation of a monocyclic sulphoxide product from ACmC is most simply explained by the interception of a high-valency iron-ore species.	Univ Oxford, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Univ Oxford, Lab Mol Biophys, Oxford OX1 3QY, England	University of Oxford; University of Oxford; University of Oxford	Baldwin, JE (corresponding author), Univ Oxford, Dyson Perrins Lab, S Parks Rd, Oxford OX1 3QY, England.	jack.baldwin@chem.oz.ac.uk	Roach, Peter/AAW-7071-2021; Roach, Peter/C-6248-2013; Rutledge, Peter J/D-6253-2012	Rutledge, Peter/0000-0002-0767-5196				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN JE, 1984, J CHEM SOC CHEM COMM, P984, DOI 10.1039/c39840000984; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1128, DOI 10.1039/c39880001128; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BALDWIN JE, 1988, J CHEM SOC CHEM COMM, P1125, DOI 10.1039/c39880001125; BALDWIN JE, 1986, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39860000110; Berendzen J, 1998, BIOPHYS J, V74, pA250; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRIAUCIUNAS A, 1991, J BIOL CHEM, V266, P11779; LEE SK, 1993, J BIOL CHEM, V268, P21569; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RIGAU JJ, 1970, J ORG CHEM, V35, P3655, DOI 10.1021/jo00836a013; Roach PL, 1996, EUR J BIOCHEM, V242, P736, DOI 10.1111/j.1432-1033.1996.0736r.x; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; SCHLICHTING I, 1997, FASEB J, V1, pP2; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6	21	162	163	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					721	724		10.1038/44400	http://dx.doi.org/10.1038/44400			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537113				2022-12-24	WOS:000083207400062
J	Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H				Uchida, J; Yasui, T; Takaoka-Shichijo, Y; Muraoka, M; Kulwichit, W; Raab-Traub, N; Kikutani, H			Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses	SCIENCE			English	Article							NF-KAPPA-B; GERMINAL CENTER FORMATION; NECROSIS-FACTOR RECEPTOR; ACUTE INFECTIOUS-MONONUCLEOSIS; CELLS IN-VIVO; AFFINITY MATURATION; DEFICIENT MICE; CD40-DEFICIENT MICE; CYTOPLASMIC DOMAIN; IMMUNE-RESPONSES	The effect of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on the activation and differentiation of normal B cells was investigated. B cells of transgenic mice expressing LMP1 under the control of immunoglobulin promoter/enhancer displayed enhanced expression of activation antigens and spontaneously proliferated and produced antibody. Humoral immune responses of LMP1 transgenic mice in CD40-deficient or normal backgrounds revealed that LMP1 mimics CD40 signals to induce extrafollicular 13 cell differentiation but, unlike CD40, blocks germinal center formation. Thus, these specific properties of LMP1 may determine the site of primary B cell infection and the state of infection in the natural course of EBV infection, whereas subsequent loss of LMP1 expression may affect the site of persistent latent infection.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Osaka 5650871, Japan; Univ N Carolina, Dept Microbiol & Immunol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Osaka University; University of North Carolina; University of North Carolina Chapel Hill	Uchida, J (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, 3-1 Yamada Oka, Osaka 5650871, Japan.	kikutani@ragtime.biken.osaka-u.ac.jp	Kikutani, Hitoshi/C-9525-2009	Muraoka, Masaaki/0000-0002-2926-5374	NCI NIH HHS [CA19014] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA019014] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAN P, 1986, CURR TOP MICROBIOL, V132, P266; ANAGNOSTOPOULOS I, 1995, BLOOD, V85, P744, DOI 10.1182/blood.V85.3.744.bloodjournal853744; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CATTORETTI G, 1997, BLOOD, V90, P175; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; COHEN JI, 1991, J VIROL, V65, P2545, DOI 10.1128/JVI.65.5.2545-2554.1991; CUMANO A, 1985, EUR J IMMUNOL, V15, P512, DOI 10.1002/eji.1830150517; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; GAUCHAT JF, 1992, J IMMUNOL, V148, P2291; GRAY D, 1988, IMMUNOLOGY, V65, P73; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; HURLEY EA, 1988, J EXP MED, V168, P2059, DOI 10.1084/jem.168.6.2059; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; IZURNI KM, 1997, P NATL ACAD SCI USA, V94, P12592; JABARA HH, 1990, J IMMUNOL, V145, P3468; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; Kato J, 1998, J IMMUNOL, V160, P4788; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LIEBOWITZ D, 1992, J VIROL, V66, P4612, DOI 10.1128/JVI.66.7.4612-4616.1992; MACLENNAN ICM, 1988, CURR TOP MICROBIOL, V141, P138; MARTIN J, 1991, CELL GROWTH DIFFER, V2, P653; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; MIYASHITA EM, 1995, CELL, V80, P593, DOI 10.1016/0092-8674(95)90513-8; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDOBITEK G, 1992, BLOOD, V79, P2520; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROBINSON JE, 1981, J EXP MED, V153, P235, DOI 10.1084/jem.153.2.235; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; UCHIDA J, UNPUB; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	52	299	312	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					300	303		10.1126/science.286.5438.300	http://dx.doi.org/10.1126/science.286.5438.300			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514374				2022-12-24	WOS:000083024400046
J	Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S				Buchwitz, BJ; Ahmad, K; Moore, LL; Roth, MB; Henikoff, S			Cell division - A histone-H3-like protein in C-elegans	NATURE			English	Article							CENP-A; CAENORHABDITIS-ELEGANS; CENTROMERE; HISTONE		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Mol & Cellular Biol Program, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buchwitz, BJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.			Henikoff, Steven/0000-0002-7621-8685				ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; PALMER DK, 1991, P NATL ACAD SCI USA, V88, P3734, DOI 10.1073/pnas.88.9.3734; Riddle D. L, 1997, C ELEGANS, P47; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	11	203	209	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					547	548		10.1038/44062	http://dx.doi.org/10.1038/44062			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524621				2022-12-24	WOS:000083054900038
J	Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R				Zuniga, A; Haramis, APG; McMahon, AP; Zeller, R			Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds	NATURE			English	Article							APICAL ECTODERMAL RIDGE; DEVELOPING CHICK LIMB; SONIC HEDGEHOG; DEFORMITY GENE; PATTERN-FORMATION; PROTEINS; GROWTH; FGF-4; EXPRESSION; INDUCTION	Outgrowth and patterning of the vertebrate limb are controlled by reciprocal interactions between the posterior mesenchyme (polarizing region) and a specialized ectodermal structure, the apical ectodermal ridge (AER)(1). Sonic hedgehog (SHH) signalling by the polarizing region modulates fibroblast growth factor (FGF)4 signalling by the posterior AER, which in turn maintains the polarizing region (SHH/FGF4 feedback loop)(2,3). Here we report that the secreted bone-morphogenetic-protein (BMP) antagonist Gremlin(4) relays the SHH signal from the polarizing region to the AER. Mesenchymal Gremlin expression is lost in limb buds of mouse embryos homozygous for the limb deformity (Id) mutation, which disrupts establishment of the SHH/FGF4 feedback loop(5-7). Grafting Gremlin-expressing cells into Id mutant limb buds rescues Fgf4 expression and restores the SHH/FGF4 feedback loop. Analysis of Shh-null mutant embryos(8,9) reveals that SHH signalling is required for maintenance of Gremlin and Formin (the gene disrupted by the ld mutations)(10,11). In contrast, Formin, Gremlin and Fgf4 activation are independent of SHH signalling. This study uncovers the cascade by which the SHH signal is relayed from the posterior mesenchyme to the AER and establishes that Formin-dependent activation of the BMP antagonist Gremlin is sufficient to induce Fgf4 and establish the SHH/FGF4 feedback loop.	Univ Utrecht, Fac Biol, Dept Dev Biol, NL-3584 CH Utrecht, Netherlands; European Mol Biol Lab, D-69117 Heidelberg, Germany; Harvard Univ, Cambridge, MA 02138 USA	Utrecht University; European Molecular Biology Laboratory (EMBL); Harvard University	Zeller, R (corresponding author), Univ Utrecht, Fac Biol, Dept Dev Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	R.Zeller@bio.uu.nl	Zuniga, Aimée/AAG-7335-2020; Zuniga, Aimée/Q-2692-2018; Zeller, Rolf/C-2610-2013; McMahon, Andrew P/ABE-7520-2020	Zuniga, Aimée/0000-0002-9953-3637; Zuniga, Aimée/0000-0002-9953-3637; Zeller, Rolf/0000-0002-3186-7403; 				Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cho KWY, 1998, CURR OPIN GENET DEV, V8, P443, DOI 10.1016/S0959-437X(98)80116-0; Duprez D, 1998, DEVELOPMENT, V125, P495; Duprez DM, 1996, DEVELOPMENT, V122, P1821; Fraidenraich D, 1998, DEV BIOL, V204, P197, DOI 10.1006/dbio.1998.9053; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Haramis AG, 1995, DEVELOPMENT, V121, P4237; Hofmann C, 1996, DEV GENET, V19, P43, DOI 10.1002/(SICI)1520-6408(1996)19:1&lt;43::AID-DVG5&gt;3.0.CO;2-0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kuhlman J, 1997, DEVELOPMENT, V124, P133; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LUSSIER M, 1993, INT J DEV BIOL, V37, P555; MAAS RL, 1990, NATURE, V346, P853, DOI 10.1038/346853a0; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; Marigo V, 1996, DEVELOPMENT, V122, P1225; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; Pizette S, 1999, DEVELOPMENT, V126, P883; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; Zuniga A, 1999, DEVELOPMENT, V126, P13	30	364	368	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					598	602		10.1038/44157	http://dx.doi.org/10.1038/44157			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524628				2022-12-24	WOS:000083054900053
J	Young, LS				Young, LS			Epstein-Barr-virus infection and persistence: a B-cell marriage in sickness and in health	LANCET			English	Editorial Material							EBV PERSISTENCE; TUMORS		Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England	University of Birmingham	Young, LS (corresponding author), Univ Birmingham, Sch Med, CRC, Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.		Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				ALLDAY MJ, 1988, LANCET, V1, P855; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376; Faulkner GC, 1999, J VIROL, V73, P1555, DOI 10.1128/JVI.73.2.1555-1564.1999; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Sugawara Y, 1999, VIROLOGY, V256, P196, DOI 10.1006/viro.1999.9619	9	8	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	1999	354	9185					1141	1142		10.1016/S0140-6736(99)00237-8	http://dx.doi.org/10.1016/S0140-6736(99)00237-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	242QX	10513704				2022-12-24	WOS:000082954100006
J	Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M				Forster, R; Schubel, A; Breitfeld, D; Kremmer, E; Renner-Muller, I; Wolf, E; Lipp, M			CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs	CELL			English	Article							DENDRITIC CELL MATURATION; CHEMOKINE RECEPTOR; T-CELLS; MOLECULAR-CLONING; TISSUE CHEMOKINE; B-CELLS; LYMPHOCYTES; EXPRESSION; MEMORY; LIGAND	The proper function of immune surveillance requires well-coordinated mechanisms in order to guide the patrolling immune cells through peripheral tissues and into secondary lymphoid organs. Analyzing gene-targeted mice, we identified the chemokine receptor CCR7 as an important organizer of the primary immune response. CCR7-deficient mice show severely delayed kinetics regarding the antibody response and lack contact sensitivity and delayed type hypersensitivity reactions. Due to the impaired migration of lymphocytes, these animals reveal profound morphological alterations in all secondary lymphoid organs. Upon activation, mature skin dendritic cells fail to migrate into the draining lymph nodes. Thus, in order to bring together lymphocytes and dendritic cells to form the characteristic microarchitecture of secondary lymphoid organs, CCR7 is required to rapidly initiate an adoptive immune response.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; GSF, Res Ctr Environm & Hlth, Inst Mol Immunol, D-81377 Munich, Germany; Univ Munich, Inst Mol Anim Breeding, Gene Ctr, D-81377 Munich, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Forster, R (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.		Lipp, Martin/G-2235-2010; Förster, Reinhold/D-6770-2011	Wolf, Eckhard/0000-0002-0430-9510; Lipp, Martin/0000-0002-0087-2672; Forster, Reinhold/0000-0001-6190-7923				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799, DOI 10.1038/35876; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HILL S, 1990, IMMUNOLOGY, V71, P277; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Liu YJ, 1997, J EXP MED, V186, P625, DOI 10.1084/jem.186.5.625; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Nakano H, 1998, BLOOD, V91, P2886, DOI 10.1182/blood.V91.8.2886.2886_2886_2895; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553; Sozzani S, 1998, J IMMUNOL, V161, P1083; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; Tanabe S, 1997, J IMMUNOL, V159, P5671; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	34	1806	1878	3	55	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					23	33		10.1016/S0092-8674(00)80059-8	http://dx.doi.org/10.1016/S0092-8674(00)80059-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520991	Bronze			2022-12-24	WOS:000082981600005
J	Takahashi, JS				Takahashi, JS			Perspectives: Neurobiology - Narcolepsy genes wake up the sleep field	SCIENCE			English	Editorial Material							DEPRIVATION; NEURONS		Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, Evanston, IL 60208 USA	Howard Hughes Medical Institute; Northwestern University	Takahashi, JS (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Howard Hughes Med Inst, 2153 N Campus Dr, Evanston, IL 60208 USA.	J-takahashi@nwu.edu	Takahashi, Joseph S./Y-2781-2019; Takahashi, Joseph S/E-8482-2012	Takahashi, Joseph S./0000-0003-0384-8878; Takahashi, Joseph S/0000-0003-0384-8878				Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; DEMENT WC, 1994, PRINCIPLES PRACTICES, P309; KUSHIDA CA, 1989, SLEEP, V12, P22, DOI 10.1093/sleep/12.1.22; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; Peyron C, 1998, J NEUROSCI, V18, P9996; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Siegel JM, 1999, CELL, V98, P409, DOI 10.1016/S0092-8674(00)81969-8; van den Pol AN, 1998, J NEUROSCI, V18, P7962; van den Pol AN, 1999, J NEUROSCI, V19, P3171	18	11	11	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2076	2077		10.1126/science.285.5436.2076	http://dx.doi.org/10.1126/science.285.5436.2076			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10523205				2022-12-24	WOS:000082734300028
J	Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF				Huang, CC; Liu, CC; Chang, YC; Chen, CY; Wang, ST; Yeh, TF			Neurologic complications in children with enterovirus 71 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BRAIN-STEM ENCEPHALITIS; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; POLIOMYELITIS; MRI; PARALYSIS; OUTBREAK; HAND; FOOT	Background Enterovirus 71 infection causes hand-foot-and-mouth disease in young children, which is characterized by several days of fever and vomiting, ulcerative lesions in the oral mucosa, and vesicles on the backs of the hands and feet. The initial illness resolves bur is sometimes followed by aseptic meningitis, encephalomyelitis, or even acute flaccid paralysis similar to paralytic poliomyelitis. Methods We describe the neurologic complications associated with the enterovirus 71 epidemic that occurred in Taiwan in 1998. At three major hospitals we identified 41 children with culture-confirmed entero; virus 71 infection and acute neurologic manifestations. Magnetic resonance imaging (MRI) was performed in 4 patients with acute flaccid paralysis and 24 with rhombencephalitis. Results The mean age of the patients was 2.5 years (range, 3 months to 8.2 years). Twenty-eight patients had hand-foot-and-mouth disease (68 percent), and six had herpangina (15 percent). The other seven patients had no skin or mucosal lesions. Three neurologic syndromes were identified: aseptic meningitis tin 3 patients); brain-stem encephalitis, or rhombencephalitis (in 37); and acute flaccid paralysis (in 4), which followed rhombencephalitis in 3 patients. In 20 patients with rhombencephalitis, the syndrome was characterized by myoclonic jerks and tremor, ataxia, or both (grade I disease). Ten patients had myoclonus and cranial-nerve involvement (grade II disease). In seven patients the brain-stem infection produced transient myoclonus followed by the rapid onset of respiratory distress, cyanosis, poor peripheral perfusion, shock, coma, loss of the doll's eye reflex, and apnea (grade III disease); five of these patients died within 12 hours after admission. In 17 of the 24 patients with rhombencephalitis who underwent MRI, T-2-weighted scans showed high-intensity lesions in the brain stem, most commonly in the pontine tegmentum. At follow-up, two of the patients with acute flaccid paralysis had residual limb weakness, and five of the patients with rhombencephalitis had persistent neurologic deficits, including myoclonus tin one child), cranial-nerve deficits (in two), and ventilator-dependent apnea (in two). Conclusions In the 1998 enterovirus 71 epidemic in Taiwan, the chief neurologic complication was rhombencephalitis, which had a fatality rare of 14 percent. The most common initial symptoms were myoclonic jerks, and MRI usually showed evidence of brainstem involvement. (N Engl J Med 1999;341:936-42.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 704, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan; Triserv Gen Hosp & Natl Def Med Ctr, Dept Radiol, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital; National Defense Medical Center	Huang, CC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Chen, Cheng-Yu/0000-0003-0428-4373; Huang, Chao-Ching/0000-0003-2799-7181				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; ARMSTRONG RW, 1993, CLIN INFECT DIS, V16, P689, DOI 10.1093/clind/16.5.689; BICKERSTAFF ER, 1951, BMJ-BRIT MED J, V2, P77, DOI 10.1136/bmj.2.4723.77; BLOMBERG J, 1974, LANCET, V2, P112; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHONMAITREE T, 1981, PEDIATRICS, V67, P489; GELLER TJ, 1987, ANN NEUROL, V21, P602, DOI 10.1002/ana.410210614; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; Hall W A, 1993, Neurosurg Clin N Am, V4, P543; HATTORI T, 1988, J NEUROL NEUROSUR PS, V51, P1572, DOI 10.1136/jnnp.51.12.1572; Hauw J J, 1986, Adv Neurol, V43, P201; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; HSIUNG GD, 1994, HSIUNGS DIAGNOSTIC V, P119; HURST DL, 1988, PEDIATR NEUROL, V4, P122, DOI 10.1016/0887-8994(88)90054-9; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; James D., 1998, TXB PEDIAT INFECT DI, P1787; Kornreich L, 1996, NEURORADIOLOGY, V38, P371; Lai YY, 1997, BRAIN RES, V745, P257, DOI 10.1016/S0006-8993(96)01177-8; Lam SK, 1998, EMERG INFECT DIS, V4, P145, DOI 10.3201/eid0402.980201; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MALZBERG MS, 1993, AM J ROENTGENOL, V161, P863, DOI 10.2214/ajr.161.4.8372775; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; PROTHEROE SM, 1991, ARCH DIS CHILD, V66, P702, DOI 10.1136/adc.66.6.702; Sakakibara R, 1998, J NEUROL NEUROSUR PS, V64, P269, DOI 10.1136/jnnp.64.2.269; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHIAN WJ, 1994, PEDIATR RADIOL, V24, P596, DOI 10.1007/BF02012744; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SVED AF, 1999, FUNDAMENTAL NEUROSCI, P1051; Takimoto S, 1998, T ROY SOC TROP MED H, V92, P25, DOI 10.1016/S0035-9203(98)90939-7; Tartaglino LM, 1996, RADIOLOGY, V201, P661, DOI 10.1148/radiology.201.3.8939212; WAKAMOTO H, 1992, PEDIATR RADIOL, V22, P533, DOI 10.1007/BF02013004; 1998, MMWR MORB MORTAL WKL, V47, P718	34	512	609	0	50	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					936	942		10.1056/NEJM199909233411302	http://dx.doi.org/10.1056/NEJM199909233411302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498488	Bronze			2022-12-24	WOS:000082658100002
J	Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P				Johnston, LA; Prober, DA; Edgar, BA; Eisenman, RN; Gallant, P			Drosophila myc regulates cellular growth during development	CELL			English	Article							C-MYC; N-MYC; CYCLE PROGRESSION; DISC DEVELOPMENT; IN-VIVO; GENE; PROTEIN; TRANSCRIPTION; TARGET; CELLS	Transcription factors of the Myc proto-oncogene family promote cell division, but how they do this is poorly understood. Here we address the functions of Drosophila Myc (dMyc) during development. Using mosaic analysis in the fly wing, we show that loss of dMyc retards cellular growth (accumulation of cell mass) and reduces cell size, whereas dMyc overproduction increases growth rates and cell size, dMyc-induced growth promotes G1/S progression but fails to accelerate cell division because G2/M progression is independently controlled by Cdc25/String. We also show that the secreted signal Wingless patterns growth in the wing primordium by modulating dMyc expression. Our results indicate that dMyc links patterning signals to cell division by regulating primary targets involved in cellular growth and metabolism.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.		Johnston, Laura A/ABC-1945-2021	JOHNSTON, LAURA A/0000-0001-9477-7897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051186, F32GM017373] Funding Source: NIH RePORTER; NIGMS NIH HHS [F32 GM017373-04, F32 GM017373-03, F32 GM017373, R01 GM051186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; Ashburner M., 1989, DROSOPHILA LAB HDB; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KESSLER DJ, 1992, J EXP MED, V176, P787, DOI 10.1084/jem.176.3.787; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Lehman DA, 1999, DEVELOPMENT, V126, P1793; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McCabe J, 1997, GENET RES, V69, P61, DOI 10.1017/S0016672397002620; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Milan M, 1996, P NATL ACAD SCI USA, V93, P11687, DOI 10.1073/pnas.93.21.11687; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; OBROCHTA DA, 1985, NATURE, V313, P138, DOI 10.1038/313138a0; PHILLIPS RG, 1993, DEVELOPMENT, V118, P427; Pignoni F, 1997, DEVELOPMENT, V124, P271; Polymenis M, 1999, CURR OPIN GENET DEV, V9, P76, DOI 10.1016/S0959-437X(99)80011-2; Raff MC, 1996, CELL, V86, P173, DOI 10.1016/S0092-8674(00)80087-2; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SAWAI S, 1993, DEVELOPMENT, V117, P1445; SchreiberAgus N, 1997, P NATL ACAD SCI USA, V94, P1235, DOI 10.1073/pnas.94.4.1235; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; Stern DL, 1999, DEVELOPMENT, V126, P1091; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K; XU T, 1993, DEVELOPMENT, V117, P1223; Zaffran S, 1998, DEVELOPMENT, V125, P3571; Zornig M, 1996, CURR BIOL, V6, P1553, DOI 10.1016/S0960-9822(02)70769-0	57	508	517	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					779	790		10.1016/S0092-8674(00)81512-3	http://dx.doi.org/10.1016/S0092-8674(00)81512-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499795	Green Accepted, Bronze			2022-12-24	WOS:000082679200005
J	Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB				Korschen, HG; Beyermann, M; Muller, F; Heck, M; Vantler, M; Koch, KW; Kellner, R; Wolfrum, U; Bode, C; Hofmann, KP; Kaupp, UB			Interaction of glutamic-acid-rich proteins with the cGMP signalling pathway in rod photoreceptors	NATURE			English	Article							GATED CHANNEL; OUTER SEGMENTS; BETA-SUBUNIT; LOCALIZATION; CALMODULIN; CELLS; PHOTOTRANSDUCTION; MEMBRANE; DOMAIN; LIGHT	The assembly of signalling molecules into macromolecular complexes (transducisomes) provides specificity, sensitivity and speed in intracellular signalling pathways(1,2). Rod photoreceptors in the eye contain an unusual set of glutamic-acid-rich proteins (GARPs) of unknown function(3-7). GARPs exist as two soluble forms, GARP1 and GARP2, and as a large cytoplasmic domain (GARP' part) of the beta-subunit of the cyclic GMP-gated channel(3-7). Here we identify GARPs as multivalent proteins that interact with the key players of cGMP signalling, phosphodiesterase and guanylate cyclase, and with a retina-specific ATP-binding cassette transporter (ABCR)(8,9), through four, short, repetitive sequences. In electron micrographs, GARPs are restricted to the rim region and incisures of discs in dose proximity to the guanylate cyclase and ABCR, whereas the phosphodiesterase is randomly distributed. GARP2, the most abundant splice form, associates more strongly with light-activated than with inactive phosphodiesterase, and GARP2 potently inhibits phosphodiesterase activity. Thus, the GARPs organize a dynamic protein complex near the disc rim that may control cGMP turnover and possibly other light-dependent processes. Because there are no similar GARPs in cones, we propose that GARPs may prevent unnecessary cGMP turnover during daylight, when rods are held in saturation by the relatively high light levels.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung, D-52425 Julich, Germany; Forschungsinst Mol Pharmakol, D-10315 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10998 Berlin, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Karlsruhe, Inst Zool, D-76128 Karlsruhe, Germany	Helmholtz Association; Research Center Julich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Johannes Gutenberg University of Mainz; Helmholtz Association; Karlsruhe Institute of Technology	Kaupp, UB (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung, Postfach 1913, D-52425 Julich, Germany.	A.eckert@fz-juelich.de	Mueller, Frank/I-7196-2013; Koch, Karl-Wilhelm/C-9551-2015	Mueller, Frank/0000-0001-7264-1227; Koch, Karl-Wilhelm/0000-0003-1501-0044				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; Colville CA, 1996, J BIOL CHEM, V271, P32968, DOI 10.1074/jbc.271.51.32968; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; Eckmiller MS, 1998, ACTA ANAT, V162, P133; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KOCH KW, 1992, SIGNAL TRANSDUCTION, P259; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAMBRECHT HG, 1991, EMBO J, V10, P793, DOI 10.1002/j.1460-2075.1991.tb08011.x; LIU XR, 1994, EXP EYE RES, V59, P761, DOI 10.1006/exer.1994.1162; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; PEDLER CMH, 1967, VISION RES, V7, P829, DOI 10.1016/0042-6989(67)90003-X; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; Schrem A, 1999, J BIOL CHEM, V274, P6244, DOI 10.1074/jbc.274.10.6244; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wolfrum U, 1998, CELL MOTIL CYTOSKEL, V40, P261, DOI 10.1002/(SICI)1097-0169(1998)40:3<261::AID-CM5>3.3.CO;2-#; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Zoche M, 1996, BIOCHEMISTRY-US, V35, P8742, DOI 10.1021/bi960445t; Zuker CS, 1999, SCIENCE, V283, P650, DOI 10.1126/science.283.5402.650	29	105	108	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1999	400	6746					761	766		10.1038/23468	http://dx.doi.org/10.1038/23468			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466724				2022-12-24	WOS:000082131100049
J	Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR				Young, LJ; Nilsen, R; Waymire, KG; MacGregor, GR; Insel, TR			Increased affiliative response to vasopressin in mice expressing the V-1a receptor from a monogamous vole	NATURE			English	Article							MICROTUS-OCHROGASTER; PRAIRIE VOLES; SPECIES-DIFFERENCES; PATERNAL BEHAVIOR; COHABITATION; INNERVATION; HAMSTERS; BRAIN; GENE	Arginine vasopressin influences male reproductive and social behaviours in several vertebrate taxa(1) through its actions at the V-1a receptor in the brain, The neuroanatomical distribution of vasopressin V-1a receptors varies greatly between species with different forms of social organization(2,3). Here we show that centrally administered arginine vasopressin increases affiliative behaviour in the highly social, monogamous prairie vole, but not in the relatively asocial, promiscuous montana vole. Molecular analyses indicate that gene duplication and/or changes in promoter structure of the prairie vole receptor gene may contribute to the species differences in vasopressin-receptor expression. We further show that mice that are transgenic for the prairie vole receptor gene have a neuroanatomical pattern of receptor binding that is similar to that of the prairie vole, and exhibit increased affiliative behaviour after injection with arginine vasopressin. These data indicate that the pattern of V-1a-receptor gene expression in the brain may be functionally associated with species-typical social behaviours in male vertebrates.	Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; Emory Univ, Ctr Mol Med, Atlanta, GA 30322 USA	Emory University; Emory University	Young, LJ (corresponding author), Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.		Young, Larry/HGE-5031-2022					BAMSHAD M, 1994, PHYSIOL BEHAV, V56, P751, DOI 10.1016/0031-9384(94)90238-0; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Barberis C, 1996, CRIT REV NEUROBIOL, V10, P119; BESTERMEREDITH JK, IN PRESS HORM BEHAV; Choong CS, 1996, MOL ENDOCRINOL, V10, P1527, DOI 10.1210/me.10.12.1527; FERRIS CF, 1988, PHYSIOL BEHAV, V44, P235, DOI 10.1016/0031-9384(88)90144-8; Ferris CF, 1997, J NEUROSCI, V17, P4331; INSEL TR, 1994, J NEUROSCI, V14, P5381; Klesert TR, 1997, NAT GENET, V16, P402, DOI 10.1038/ng0897-402; Meloni R, 1998, HUM MOL GENET, V7, P423, DOI 10.1093/hmg/7.3.423; MOORE FL, 1983, PEPTIDES, V4, P97, DOI 10.1016/0196-9781(83)90173-0; RITTERS LV, 1997, ANN NY ACAD SCI, V807, P478; SHAPIRO LE, 1990, J COMP PSYCHOL, V104, P268, DOI 10.1037/0735-7036.104.3.268; WANG ZX, 1994, BRAIN RES, V650, P212, DOI 10.1016/0006-8993(94)91784-1; WANG ZX, 1994, P NATL ACAD SCI USA, V91, P400, DOI 10.1073/pnas.91.1.400; WINSLOW JT, 1993, NATURE, V365, P545, DOI 10.1038/365545a0; Young LJ, 1998, TRENDS NEUROSCI, V21, P71, DOI 10.1016/S0166-2236(97)01167-3; Young LJ, 1997, BEHAV NEUROSCI, V111, P599, DOI 10.1037/0735-7044.111.3.599	18	363	378	0	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					766	768		10.1038/23475	http://dx.doi.org/10.1038/23475			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466725				2022-12-24	WOS:000082131100050
J	Stephenson, J				Stephenson, J			Shingles vaccine trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-24	WOS:000082033700008
J	GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH				GOLOUBINOFF, P; CHRISTELLER, JT; GATENBY, AA; LORIMER, GH			RECONSTITUTION OF ACTIVE DIMERIC RIBULOSE BISPHOSPHATE CARBOXYLASE FROM AN UNFOLDED STATE DEPENDS ON 2 CHAPERONIN PROTEINS AND MG-ATP	NATURE			English	Article									DUPONT CO,DEPT CENT RES & DEV,DIV MOLEC BIOL,EXPTL STN,WILMINGTON,DE 19880	DuPont			Christeller, John T/E-6904-2010	Goloubinoff, Pierre/0000-0002-4802-0807				ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; BARRACLOUGH R, 1980, BIOCHIM BIOPHYS ACTA, V608, P19, DOI 10.1016/0005-2787(80)90129-X; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BOCHKAREVA ES, 1988, NATURE, V336, P254, DOI 10.1038/336254a0; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; CHORY J, 1985, J BACTERIOL, V161, P307, DOI 10.1128/JB.161.1.307-313.1985; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ELLIS RJ, 1988, PHOTOSYNTH RES, V16, P101, DOI 10.1007/BF00039488; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLIS RJ, 1989, BIOCHEM SOC SYMP, V55, P145; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GATENBY AA, 1988, EMBO J, V7, P1307, DOI 10.1002/j.1460-2075.1988.tb02945.x; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; LANDRY SJ, 1989, J BIOL CHEM, V264, P9090; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; MCMULLIN TW, 1988, MOL CELL BIOL, V8, P371, DOI 10.1128/MCB.8.1.371; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MUSGROVE JE, 1986, PHILOS T ROY SOC B, V313, P419, DOI 10.1098/rstb.1986.0048; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PICKETTS DJ, 1989, J BIOL CHEM, V264, P12001; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PIERCE J, 1986, ARCH BIOCHEM BIOPHYS, V245, P483, DOI 10.1016/0003-9861(86)90241-9; PUSHKIN AV, 1982, BIOCHIM BIOPHYS ACTA, V704, P379, DOI 10.1016/0167-4838(82)90169-8; READING DS, 1989, NATURE, V337, P655, DOI 10.1038/337655a0; ROY H, 1982, J CELL BIOL, V94, P20, DOI 10.1083/jcb.94.1.20; ROY H, 1988, BIOCHIM BIOPHYS ACTA, V957, P323, DOI 10.1016/0167-4838(88)90221-X; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; STERNBERG N, 1973, J MOL BIOL, V76, P25, DOI 10.1016/0022-2836(73)90079-X; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; TORRESRUIZ JA, 1988, ARCH BIOCHEM BIOPHYS, V261, P196, DOI 10.1016/0003-9861(88)90118-X; VODKIN MH, 1988, J BACTERIOL, V170, P1227, DOI 10.1128/jb.170.3.1227-1234.1988	42	646	660	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 21	1989	342	6252					884	889		10.1038/342884a0	http://dx.doi.org/10.1038/342884a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CF637	10532860				2022-12-24	WOS:A1989CF63700049
J	Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P				Cremona, O; Di Paolo, G; Wenk, MR; Luthi, A; Kim, WT; Takei, K; Daniell, L; Nemoto, Y; Shears, SB; Flavell, RA; McCormick, DA; De Camilli, P			Essential role of phosphoinositide metabolism in synaptic vesicle recycling	CELL			English	Article							NERVE-TERMINALS; INOSITOL PHOSPHOLIPIDS; NONUNIFORM PROBABILITY; MEDIATED ENDOCYTOSIS; TRANSFER PROTEIN; YEAST GOLGI; BINDING; MEMBRANE; DYNAMIN; SYNAPTOJANIN	Growing evidence suggests that phosphoinositides play an important role in membrane traffic. A polyphosphoinositide phosphatase, synaptojanin 1, was identified as a major presynaptic protein associated with endocytic coated intermediates. We report here that synaptojanin 1-deficient mice exhibit neurological defects and die shortly after birth. In neurons of mutant animals, PI(4,5)beta(2) levels are increased, and clathrin-coated vesicles accumulate in the cytomatrix-rich area that surrounds the synaptic vesicle cluster in nerve endings. In cell-free assays, reduced phosphoinositide phosphatase activity correlated with increased association of clathrin coats with liposomes. Intracellular recording in hippocampal slices revealed enhanced synaptic depression during prolonged high-frequency stimulation followed by delayed recovery. These results provide genetic evidence far a crucial role of phosphoinositide metabolism in synaptic vesicle recycling.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Neurobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Univ Piemonte Orientale A Avogadro, Dipartimento Sci Med, I-28100 Novara, Italy; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University; University of Eastern Piedmont Amedeo Avogadro; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Luthi, Anita/ABE-1411-2021; McCormick, David A/J-2649-2015; Kobelt, Liza/F-5926-2011; Shears, Stephen B/C-6335-2019; Cremona, Ottavio/AAB-8793-2019; Wenk, Markus Rene/D-1441-2014	McCormick, David A/0000-0002-9803-8335; Shears, Stephen B/0000-0001-7309-8916; Cremona, Ottavio/0000-0001-9462-1040; Luthi, Anita/0000-0002-4954-4143; Takei, Kohji/0000-0002-6555-9425	NINDS NIH HHS [NS26143, NS46128, NS36251] Funding Source: Medline; Telethon [D.111, D.061] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS036251, R37NS026143, R01NS036251, R01NS026143, R29NS026143] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Achiriloaie M, 1999, MOL CELL BIOL, V19, P1410; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Auger K. R., 1990, METHODS INOSITIDE RE, P159; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Banker G., 1991, CULTURING NERVE CELL; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Gaidarov I, 1999, J CELL BIOL, V146, P755, DOI 10.1083/jcb.146.4.755; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; GUSTAFSSON J, 1998, NEUROSCI SOC ABSTR, V327, P19; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HARRIS KM, 1995, NEUROPHARMACOLOGY, V34, P1387, DOI 10.1016/0028-3908(95)00142-S; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; HAWTHORNE JN, 1979, J NEUROCHEM, V32, P5, DOI 10.1111/j.1471-4159.1979.tb04503.x; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HOKIN MR, 1953, J BIOL CHEM, V203, P967; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Jost M, 1998, CURR BIOL, V8, P1399, DOI 10.1016/S0960-9822(98)00022-0; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kirk CJ., 1990, PEPTIDE HORMONE ACTI, P151; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; Lee A, 1999, CURR BIOL, V9, P261, DOI 10.1016/S0960-9822(99)80115-8; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mikoshiba K, 1999, CHEM PHYS LIPIDS, V98, P59, DOI 10.1016/S0009-3084(99)00018-3; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Singer-Kruger B, 1998, J CELL SCI, V111, P3347; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; VERHAGE M, 1997, NEUR SOC ABSTR, V23, P1168; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Woscholski R, 1997, J BIOL CHEM, V272, P9625; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	59	611	628	4	31	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					179	188		10.1016/S0092-8674(00)81649-9	http://dx.doi.org/10.1016/S0092-8674(00)81649-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535736	hybrid			2022-12-24	WOS:000083159700008
J	Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I				Folsch, H; Ohno, H; Bonifacino, JS; Mellman, I			A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells	CELL			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; DARBY CANINE KIDNEY; MDCK CELLS; SORTING SIGNALS; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; STRUCTURAL REQUIREMENTS; GOLGI-COMPLEX; FC-RECEPTORS	Although polarized epithelial cells are well known to maintain distinct apical and basolateral plasma membrane domains, the mechanisms responsible for targeting membrane proteins to the apical or basolateral surfaces have remained elusive. We have identified a novel form of the AP-1 clathrin adaptor complex that contains as one of its subunits mu 1B, an epithelial cell-specific homolog of the ubiquitously expressed mu 1A. LLC-PK1 kidney epithelial cells do not express mu 1B and missort many basolateral proteins to the apical surface. Stable expression of mu 1B selectively restored basolateral targeting, improved the overall organization of LLC-PK1 monolayers, and had no effect on apical targeting. We conclude that basolateral sorting is mediated by an epithelial cell-specific version of the AP-1 complex containing mu 1B.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, New Haven, CT 06520 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan	Yale University; Ludwig Institute for Cancer Research; Yale University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Kanazawa University	Mellman, I (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.		Ohno, Hiroshi/L-7899-2014; Mellman, Ira/ABG-5896-2020	Ohno, Hiroshi/0000-0001-8776-9661; Bonifacino, Juan S./0000-0002-5673-6370; Folsch, Heike/0000-0003-0897-0311	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029765] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29765] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirst J, 1999, MOL BIOL CELL, V10, P2787, DOI 10.1091/mbc.10.8.2787; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Keller P, 1997, J CELL SCI, V110, P3001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; Wilton JC, 1996, BIOESSAYS, V18, P229, DOI 10.1002/bies.950180310; Winckler B, 1999, NEURON, V23, P637, DOI 10.1016/S0896-6273(01)80021-0; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73; YOKODE M, 1992, J CELL BIOL, V117, P39, DOI 10.1083/jcb.117.1.39; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	46	420	422	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					189	198		10.1016/S0092-8674(00)81650-5	http://dx.doi.org/10.1016/S0092-8674(00)81650-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535737	hybrid			2022-12-24	WOS:000083159700009
J	Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA				Ketting, RF; Haverkamp, THA; van Luenen, HGAM; Plasterk, RHA			mut-7 of C-elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; DE-NOVO METHYLATION; M HYBRID DYSGENESIS; DNA-BINDING DOMAIN; TC3 TRANSPOSASE; MUTATOR ACTIVITY; MOLECULAR-BASIS; IN-VITRO; EXCISION; ELEMENTS	While all known natural isolates of C. elegans contain multiple copies of the Tc1 transposon, which are active in the soma, Tc1 transposition is fully silenced in the germline of many strains. We mutagenized one such silenced strain and isolated mutants in which Tct had been activated in the germline ("mutators"). Interestingly, many other transposons of unrelated sequence had also become active. Most of these mutants are resistant to RNA interference (RNAi). We found one of the mutated genes, mut-7, to encode a protein with homology to RNaseD. This provides support for the notion that RNAi works by dsRNA-directed, enzymatic RNA degradation. We propose a model in which MUT-7, guided by transposon-derived dsRNA, represses transposition by degrading transposon-specific messengers, thus preventing transposase production and transposition.	Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Plasterk, RHA (corresponding author), Netherlands Canc Inst, Div Mol Biol, Ctr Biomed Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	rplas@nki.nl	Haverkamp, Thomas H.A./H-2783-2019; Haverkamp, Thomas/B-3479-2008	Haverkamp, Thomas H.A./0000-0002-3070-9745; Ketting, Rene/0000-0001-6161-5621; van Luenen, Henri/0000-0002-5584-7968				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; BABITY JM, 1990, MOL GEN GENET, V222, P65, DOI 10.1007/BF00283024; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; BRYAN GJ, 1988, SCIENCE, V240, P215, DOI 10.1126/science.2832948; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; COLLINS J, 1989, GENETICS, V121, P47; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; COLLINS JJ, 1994, GENETICS, V137, P771; COLLOMS SD, 1994, NUCLEIC ACIDS RES, V22, P5548, DOI 10.1093/nar/22.25.5548; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; EIDE D, 1985, P NATL ACAD SCI USA, V82, P1756, DOI 10.1073/pnas.82.6.1756; EMMONS SW, 1984, CELL, V36, P599, DOI 10.1016/0092-8674(84)90339-8; EMMONS SW, 1983, CELL, V32, P55, DOI 10.1016/0092-8674(83)90496-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Grant SR, 1999, CELL, V96, P303, DOI 10.1016/S0092-8674(00)80541-3; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; Jones AL, 1998, EMBO J, V17, P6385, DOI 10.1093/emboj/17.21.6385; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; Kelly WG, 1997, GENETICS, V146, P227; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; MOERMAN DG, 1984, GENETICS, V108, P859; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; MORI I, 1990, MOL GEN GENET, V220, P251, DOI 10.1007/BF00260490; MORI I, 1988, GENETICS, V120, P397; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PEREIRA A, 1986, EMBO J, V5, P835, DOI 10.1002/j.1460-2075.1986.tb04292.x; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RUBIN GM, 1982, CELL, V29, P987, DOI 10.1016/0092-8674(82)90462-7; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Smyth DR, 1997, CURR BIOL, V7, pR793, DOI 10.1016/S0960-9822(06)00407-6; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VANLUENEN HGAM, 1993, EMBO J, V12, P2513, DOI 10.1002/j.1460-2075.1993.tb05906.x; vanPouderoyen G, 1997, EMBO J, V16, P6044, DOI 10.1093/emboj/16.19.6044; VOS JC, 1993, GENE DEV, V7, P1244, DOI 10.1101/gad.7.7a.1244; Vos JC, 1996, GENE DEV, V10, P755, DOI 10.1101/gad.10.6.755; VOS JC, 1994, EMBO J, V13, P6125, DOI 10.1002/j.1460-2075.1994.tb06959.x; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959	45	573	647	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					133	141		10.1016/S0092-8674(00)81645-1	http://dx.doi.org/10.1016/S0092-8674(00)81645-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535732	Bronze			2022-12-24	WOS:000083159700004
J	Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR				Graef, IA; Mermelstein, PG; Stankunas, K; Neilson, JR; Deisseroth, K; Tsien, RW; Crabtree, GR			L-type calcium channels and GSK-3 regulate the activity of NF-ATc4 in hippocampal neurons	NATURE			English	Article							LONG-TERM DEPRESSION; GLYCOGEN-SYNTHASE KINASE-3; LYMPHOCYTE-T ACTIVATION; CREB PHOSPHORYLATION; GENE-EXPRESSION; CYCLOSPORINE-A; NF-ATC; CALCINEURIN; INDUCTION; TRANSCRIPTION	The molecular basis of learning and memory has been the object of several recent advances, which have focused attention on calcium-regulated pathways controlling transcription. One of the molecules implicated by pharmacological, biochemical and genetic approaches is the calcium/calmodulin-regulated phosphatase, calcineurin(1-5). In lymphocytes, calcineurin responds to specific calcium signals and regulates expression of several immediate early genes by controlling the nuclear import of the NF-ATc family of transcription factors(6-9). Here we show that NF-ATc4/NF-AT3 (ref. 10) in hippocampal neurons can rapidly translocate from cytoplasm to nucleus and activate NF-AT-dependent transcription in response to electrical activity or potassium depolarization. The calcineurin-mediated translocation is critically dependent on calcium entry through L-type voltage-gated calcium channels. GSK-3 can phosphorylate NF-ATc4, promoting its export from the nucleus and antagonizing NF-ATc4-dependent transcription. Furthermore, we show that induction of the inositol 1,4,5-trisphosphate receptor type 1 is controlled by the calcium/calcineurin/NF-ATc pathway. This provides a new perspective on the function of calcineurin in the central nervous system and indicates that NF-AT-mediated gene expression may be involved in the induction of hippocampal synaptic plasticity and memory formation.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Beckman Ctr Mol & Genet Med, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.							Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEXNER LB, 1967, SCIENCE, V155, P1377, DOI 10.1126/science.155.3768.1377; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KASONO K, 1995, NEUROREPORT, V6, P569, DOI 10.1097/00001756-199502000-00040; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Reyes M, 1996, J NEUROSCI, V16, P5951; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	30	404	417	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					703	708		10.1038/44378	http://dx.doi.org/10.1038/44378			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537109				2022-12-24	WOS:000083207400058
J	Lee, JT; Lu, NF				Lee, JT; Lu, NF			Targeted mutagenesis of Tsix leads to nonrandom X inactivation	CELL			English	Article							CHROMOSOME INACTIVATION; XIST GENE; MOUSE EMBRYOS; INSITU HYBRIDIZATION; LINKED GENES; RNA; DIFFERENTIATION; STABILIZATION; EXPRESSION; INTERPHASE	During X inactivation, mammalian female cells make the selection of one active and one inactive X chromosome. X chromosome choice occurs randomly and results in Xist upregulation on the inactive X. We have hypothesized that the antisense gene, Tsix, controls Xist expression. Here, we create a targeted deletion of Tsix in female and male mouse cells. Despite a deficiency of Tsix RNA, X chromosome counting remains intact: female cells still inactivate one X, while male cells block X inactivation. However, heterozygous female cells show skewed Xist expression and primary nonrandom inactivation of the mutant X. The ability of the mutant X to block Xist accumulation is compromised. We conclude that Tsix regulates Xist in cis and determines X chromosome choice without affecting silencing. Therefore, counting, choice, and silencing are genetically separable. Contrasting effects in XX and XY cells argue that negative and positive factors are involved in choosing active and inactive Xs.	Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Lee, JT (corresponding author), Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058839] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM58839A01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avner P, 1998, GENET RES, V72, P217, DOI 10.1017/S0016672398003516; Brockdorff N, 1998, CURR OPIN GENET DEV, V8, P328, DOI 10.1016/S0959-437X(98)80090-7; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carrel L, 1996, HUM MOL GENET, V5, P1361, DOI 10.1093/hmg/5.9.1361; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Cattanach BM, 1994, MOUSE GENOME, V92, P114; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; COOPER DW, 1971, NATURE-NEW BIOL, V230, P155, DOI 10.1038/newbio230155a0; COURTIER B, 1995, P NATL ACAD SCI USA, V92, P3531, DOI 10.1073/pnas.92.8.3531; DREWS U, 1974, CELL, V1, P3, DOI 10.1016/0092-8674(74)90148-2; EICHER EM, 1970, ADV GENET, V15, P175, DOI 10.1016/S0065-2660(08)60074-7; EPSTEIN CJ, 1978, NATURE, V274, P500, DOI 10.1038/274500a0; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; KRATZER PG, 1978, NATURE, V274, P503, DOI 10.1038/274503a0; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Lee JT, 1999, P NATL ACAD SCI USA, V96, P3836, DOI 10.1073/pnas.96.7.3836; Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lyon MF, 1996, NATURE, V379, P116, DOI 10.1038/379116a0; LYON MF, 1971, NATURE-NEW BIOL, V232, P229, DOI 10.1038/newbio232229a0; LYON MF, 1972, BIOL REV, V47, P1; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V74, P207; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; OHNO S, 1969, ANNU REV GENET, V3, P495, DOI 10.1146/annurev.ge.03.120169.002431; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Papaioannou V., 1993, Gene targeting: a practical approach., P107; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; Torres RM, 1997, LAB PROTOCOLS CONDIT; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; Wurst W., 1993, Gene targeting: a practical approach., P33	47	400	419	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 1	1999	99	1					47	57		10.1016/S0092-8674(00)80061-6	http://dx.doi.org/10.1016/S0092-8674(00)80061-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520993	Bronze			2022-12-24	WOS:000082981600007
J	Pal-Bhadra, M; Bhadra, U; Birchler, JA				Pal-Bhadra, M; Bhadra, U; Birchler, JA			Cosuppression of nonhomologous transgenes in Drosophila involves mutually related endogenous sequences	CELL			English	Article							POLYCOMB RESPONSE ELEMENT; ADH PROMOTER SWITCH; GENE-EXPRESSION; ALCOHOL-DEHYDROGENASE; DNA-METHYLATION; VIRUS-RESISTANCE; BITHORAX COMPLEX; MELANOGASTER; PLANTS; WHITE	Cosuppression refers to the phenomenon in which silencing among dispersed homologous genes occurs. Here we demonstrate that two nonhomologous reciprocal fusion genes, white-Alcohol dehydrogenase (w-Adh) and Adh-w, exhibit cosuppression using the endogenous Adh sequence as an intermediary. Deletion of the endogenous Adh gene eliminates the interaction, while reintroduction of an 8.6 kb Adh fragment restores the silencing. Using truncated Adh constructs, a nontranscribed segment in the Adh regulatory region was found to be one of the sequences required for homology recognition. The silencing interaction is initiated during early development. The silenced transgenes are associated with the Polycomb group complex of chromatin proteins.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Birchler, JA (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	birchlerj@missouri.edu						Bahramian MB, 1999, MOL CELL BIOL, V19, P274; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BENYAJATI C, 1982, NUCLEIC ACIDS RES, V10, P7261, DOI 10.1093/nar/10.22.7261; BIRCHLER JA, 1990, GENETICS, V124, P677; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Chaboissier MC, 1998, P NATL ACAD SCI USA, V95, P11781, DOI 10.1073/pnas.95.20.11781; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Colot V, 1996, CELL, V86, P855, DOI 10.1016/S0092-8674(00)80161-0; CORBIN V, 1989, GENE DEV, V3, P2191, DOI 10.1101/gad.3.12b.2191; CORBIN V, 1989, NATURE, V337, P279, DOI 10.1038/337279a0; Csink AK, 1996, NATURE, V381, P529, DOI 10.1038/381529a0; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gubb D, 1997, GENETICS, V146, P919; Hagstrom K, 1997, GENETICS, V146, P1365; HIEBERT JC, 1994, GENETICS, V136, P913; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Jensen S, 1999, NAT GENET, V21, P209, DOI 10.1038/5997; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KASSIS JA, 1991, GENETICS, V128, P751; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LAURIEAHLBERG CC, 1987, GENETICS, V115, P129; Mallin DR, 1998, GENETICS, V148, P331; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; MEYER P, 1993, PLANT J, V4, P89, DOI 10.1046/j.1365-313X.1993.04010089.x; Mihaly J, 1998, MOL CELL, V1, P1065, DOI 10.1016/S1097-2765(00)80107-0; Montgomery MK, 1998, P NATL ACAD SCI USA, V95, P15502, DOI 10.1073/pnas.95.26.15502; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Paro R., 1996, EPIGENETIC MECH GENE, P507; RABINOW L, 1991, GENETICS, V129, P463; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; ROBERTSON HM, 1988, GENETICS, V118, P461; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; SCHMIDT ER, 1988, CHROMOSOMA, V96, P353, DOI 10.1007/BF00330701; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Sigrist CJA, 1997, GENETICS, V147, P209; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; Vaucheret H, 1998, PLANT J, V16, P651, DOI 10.1046/j.1365-313x.1998.00337.x; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; ZACHAR Z, 1982, CELL, V30, P529, DOI 10.1016/0092-8674(82)90250-1	55	67	75	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					35	46		10.1016/S0092-8674(00)80060-4	http://dx.doi.org/10.1016/S0092-8674(00)80060-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520992	Bronze			2022-12-24	WOS:000082981600006
J	Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL				Emanuel, EJ; Fairclough, DL; Slutsman, J; Alpert, H; Baldwin, D; Emanuel, LL			Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITALIZED ADULTS; ALZHEIMERS-DISEASE; MENTAL-HEALTH; BURDEN; CANCER; NEEDS	Background In addition to medical care, dying patients often need many types of assistance, including help with transportation, nursing care, homemaking services, and personal care. We interviewed terminally ill adults and their care givers in six randomly selected areas of the United States (five metropolitan areas and one rural county) to determine how their needs for assistance were met and the frequency with which they received such assistance from family members and paid and volunteer care givers. Methods The patients, whose physicians estimated them to have less than six months to live and who had clinically significant illness other than human immunodeficiency virus infection or the acquired immunodeficiency syndrome, were referred to the study by their physicians. Of the 1131 eligible patients, 988 (87.4 percent) consented to a detailed in-person interview conducted in English, as did 893 of the 915 eligible primary care givers (97.6 percent). Results Of the 988 terminally ill patients, 59.4 percent: were over the age of 65 years, and 51.5 percent were women; The most frequent terminal illness was cancer (in 51.8 percent of the patients), followed by heart disease (18.0 percent) and chronic obstructive pulmonary disease (10.9 percent). Four percent of the patients were in an institution, such as a nursing home, residential hospice, or hospital; the rest were living in a private residence. A need for assistance was reported by 86.8 percent of the patients; they required help with transportation (reported by 62.0 percent), homemaking services (55.2 percent), nursing care (28.7 percent), and personal care (26.0 percent). Of the care givers, 72.1 percent were women. Primary care givers were family members in 96.0 percent of cases; only 4.0 percent were unrelated. Most patients relied completely on family members and friends for assistance. A total of 15.5 percent of patients relied only on paid assistance for more than half of the types of care that they needed. Volunteers (that is, unpaid helpers who were not family members or friends) provided less than 3 percent of all care. Conclusions In our survey of terminally ill patients, family members, usually women, provided the majority of assistance with nonmedical care. Although many people received assistance from paid care givers, very few had assistance from volunteers; (N Engl J Med 1999;341:956-63.) (C) 1999, Massachusetts Medical Society.	NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Amer Med Ctr, Canc Res Ctr, Ctr Res Methodol & Biometr, Denver, CO USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Vital Sci & Hlth, Newtonville, MA USA; Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	National Institutes of Health (NIH) - USA; Johns Hopkins University; American Medical Association	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA.							BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ., 1997, APPROACHING DEATH IM, P50; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; GREER DS, 1986, J CHRON DIS, V39, P9, DOI 10.1016/0021-9681(86)90103-7; HEINRICH RL, 1984, J CLIN PSYCHOL, V40, P972, DOI 10.1002/1097-4679(198407)40:4<972::AID-JCLP2270400417>3.0.CO;2-W; HOUTS PS, 1988, CANCER, V62, P627, DOI 10.1002/1097-0142(19880801)62:3<627::AID-CNCR2820620331>3.0.CO;2-1; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KISSANE DW, 1994, PSYCHO-ONCOLOGY, V3, P47, DOI DOI 10.1002/P0N.2960030109; Kleinbaum D, 1988, APPL REGRESSION ANAL; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MAX W, 1995, J AGING HEALTH, V7, P179, DOI 10.1177/089826439500700202; Meyer H, 1997, HOSP HEALTH NETWORK, V71, P26; MOR V, 1987, Journal of Psychosocial Oncology, V5, P1, DOI 10.1300/J077v05n01_01; PRUCHNO RA, 1989, J AM GERIATR SOC, V37, P697, DOI 10.1111/j.1532-5415.1989.tb02230.x; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; SIEGEL K, 1991, CANCER, V68, P1131, DOI 10.1002/1097-0142(19910901)68:5<1131::AID-CNCR2820680541>3.0.CO;2-N; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; TAYLOR RJ, 1991, J GERONTOL, V46, pS210, DOI 10.1093/geronj/46.4.S210; US Bureau of the Census, 1998, STAT ABSTR US 1998; WACHTER RM, 1989, ANN INTERN MED, V111, P525, DOI 10.7326/0003-4819-111-6-525; Ware J., 1993, SF 36 HLTH SURVEY MA; Zubrod C.G., 1960, J CHRON DIS, V11, P7; 1998, WASHINGTON POST 0304, pA13; [No title captured]	30	240	246	1	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					956	963		10.1056/NEJM199909233411306	http://dx.doi.org/10.1056/NEJM199909233411306			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498492				2022-12-24	WOS:000082658100006
J	Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR				Ho, MT; Chen, ER; Hsu, KH; Twu, SJ; Chen, KT; Tsai, SF; Wang, JR; Shih, SR		Taiwan Enterovirus Epidemic Working Grp	An epidemic of enterovirus 71 infection in Taiwan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEUROGENIC PULMONARY-EDEMA; CENTRAL NERVOUS-SYSTEM; MOUTH-DISEASE; ENCEPHALOMYELITIS; HAND; FOOT	Background Enteroviruses can cause outbreaks of hand-foot-and-mouth disease (characterized by vesicular lesions on the hands, feet, and oral mucosa) or herpangina, usually without life-threatening manifestations. In 1998 an epidemic of enterovirus 71 infection caused hand-foot-and-mouth disease and herpangina in thousands of people in Taiwan, some of whom died. Methods We assessed the epidemiologic aspects of this outbreak. Cases of hand-foot-and-mouth disease or herpangina in ambulatory patients were reported to the Taiwan Department of Health by a mean of 818 sentinel physicians. Severe cases in hospitalized patients were reported by 40 medical centers and regional hospitals. Viruses were isolated by 10 hospital laboratories and the department of health. Results The sentinel physicians reported 129,106 cases of hand-foot-and-mouth disease or herpangina in two waves of the epidemic, which probably represents less than 10 percent of the estimated total number of cases. There were 405 patients with severe disease, most of whom were five years old or younger; severe disease was seen in all regions of the island. Complications included encephalitis, aseptic meningitis, pulmonary edema or hemorrhage, acute flaccid paralysis, and myocarditis. Seventy-eight patients died, 71 of whom (91 percent) were five years of age or younger. Of the patients who died, 65 (83 percent) had pulmonary edema or pulmonary hemorrhage. Among patients from whom a virus was isolated, enterovirus 71 was present in 48.7 percent of outpatients with uncomplicated hand-foot-and-mouth disease or herpangina, 75 percent of hospitalized patients who survived, and 92 percent of patients who died. Conclusions Although several enteroviruses were circulating in Taiwan during the 1998 epidemic, enterovirus 71 infection was associated with most of the serious clinical manifestations and with nearly all the deaths. Most of those who died were young, and the majority died of pulmonary edema and pulmonary hemorrhage. (N Engl J Med 1999;341:929-35.) (C) 1999. Massachusetts Medical Society.	Natl Hlth Res Inst, Div Clin Res, Taipei 115, Taiwan; Natl Dept Hlth, Taipei, Taiwan; Natl Cheng Kung Univ, Med Ctr, Virus Lab, Tainan 70101, Taiwan; Chang Gung Med Ctr, Virus Lab, Lin Ko, Taiwan	National Health Research Institutes - Taiwan; National Cheng Kung University; Chang Gung Memorial Hospital	Ho, MT (corresponding author), Natl Hlth Res Inst, Div Clin Res, 128 Yen Chiu Yuan Rd,Sect 2, Taipei 115, Taiwan.		Wang, Jen-Ren/F-5254-2011; Shih, Shin-Ru/M-9711-2016	Chen, Kow-Tong/0000-0001-9129-7054; Shih, Shin-Ru/0000-0003-4874-401X; Wang, Jen-Ren/0000-0002-4127-4046				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P629; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; *DEP ENV, 1995, POL GUID COAST, P65; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; Landry ML, 1995, PEDIATR INFECT DIS J, V14, P1095, DOI 10.1097/00006454-199512000-00013; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; MODLIN JF, 1995, PRINCIPLES PRACTICE, P1621; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321; 1998, MMWR MORB MORTAL WKL, V47, P718	17	941	1106	2	123	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					929	935		10.1056/NEJM199909233411301	http://dx.doi.org/10.1056/NEJM199909233411301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498487				2022-12-24	WOS:000082658100001
J	Fairley, CK; Sinclair, MI; Rizak, S				Fairley, CK; Sinclair, MI; Rizak, S			Monitoring not the answer to cryptosporidium in water	LANCET			English	Editorial Material									Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Fairley, CK (corresponding author), Monash Univ, Alfred Hosp, Monash Med Sch, Cooperat Res Ctr Water Qual & Treatment, Prahran, Vic 3181, Australia.			Sinclair, Martha/0000-0002-5900-487X; Christopher, Fairley/0000-0001-9081-1664				*AUSTR DRINK WAT G, 1996, AGR RES MAN COUNC AU; BOUCHIER I, 1998, CRYPTOSPOIRIDIUM WAT; CHAPPELL CH, 1998, CRYPTOSPORIDIUM WATE, P11; *DEP ENV TRANSP RE, 1998, PUBL HLTH DRINK WAT; EPA, 1998, FED REGISTER, V2040, P69389; *FED PROV SUBC DRI, 1997, PROT DRINK WAT DOC P; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; MCCLELLAN P, 1998, SYDNEY WATER INQUIRY; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; *PUBL HLTH LAB SER, 1999, FACTS FIG CRYPT; Sinclair MI, 1998, MED J AUSTRALIA, V169, P296, DOI 10.5694/j.1326-5377.1998.tb140278.x; VANINEVELD BM, 1993, EUR J CANCER, V29A, P1663, DOI 10.1016/0959-8049(93)90100-T; VESEY G, 1997, INT S WAT CRYPT MARC; Wheeler JG, 1999, BMJ-BRIT MED J, V318, P1046, DOI 10.1136/bmj.318.7190.1046; 1999, WATER SUPPLY WATER Q	15	8	8	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					967	969		10.1016/S0140-6736(99)90065-X	http://dx.doi.org/10.1016/S0140-6736(99)90065-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501354				2022-12-24	WOS:000082596000005
J	Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD				Poglitsch, CL; Meredith, GD; Gnatt, AL; Jensen, GJ; Chang, WH; Fu, JH; Kornberg, RD			Electron crystal structure of an RNA polymerase II transcription elongation complex	CELL			English	Article							3-DIMENSIONAL STRUCTURE; 2-DIMENSIONAL CRYSTALS; ESCHERICHIA-COLI; DNA; CRYSTALLOGRAPHY; MICROSCOPY; CRYSTALLIZATION; BINDING; SITE; CONFORMATIONS	The structure of an actively transcribing complex, containing yeast RNA polymerase II with associated template DNA and product RNA, was determined by electron crystallography. Nucleic acid, in all likelihood the "transcription bubble" at the active center of the enzyme, occupies a previously noted 25 Angstrom channel in the protein structure. Details are indicative of a roughly 90 degrees bend of the DNA between upstream and downstream regions. The DNA apparently lies entirely on one face of the polymerase, rather than passing through a hole to the opposite side, as previously suggested.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.		Chang, Wei-Hau/F-1965-2015	Chang, Wei-Hau/0000-0002-2612-850X	NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM07365, 2T32GM082494] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; Asturias FJ, 1998, ULTRAMICROSCOPY, V70, P133, DOI 10.1016/S0304-3991(97)00108-3; Asturias FJ, 1997, J MOL BIOL, V272, P536, DOI 10.1006/jmbi.1997.1273; ASTURIAS FJ, 1995, J STRUCT BIOL, V114, P60, DOI 10.1006/jsbi.1995.1005; Asturias FJ, 1999, J BIOL CHEM, V274, P6813, DOI 10.1074/jbc.274.11.6813; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DARST SA, 1991, J MOL BIOL, V221, P347, DOI 10.1016/0022-2836(91)80223-H; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fu JH, 1998, J MOL BIOL, V280, P317, DOI 10.1006/jmbi.1998.1557; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Hessler D, 1992, Neuroimage, V1, P55, DOI 10.1016/1053-8119(92)90007-A; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; Rippe K, 1997, J MOL BIOL, V270, P125, DOI 10.1006/jmbi.1997.1079; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	42	56	56	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					791	798		10.1016/S0092-8674(00)81513-5	http://dx.doi.org/10.1016/S0092-8674(00)81513-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499796	Bronze			2022-12-24	WOS:000082679200006
J	Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F				Zengler, K; Richnow, HH; Rossello-Mora, R; Michaelis, W; Widdel, F			Methane formation from long-chain alkanes by anaerobic microorganisms	NATURE			English	Article							MICROBIAL PROCESSES; HYDROCARBONS; DEGRADATION; ENRICHMENT; SEDIMENTS	Biological formation of methane is the terminal process of biomass degradation in aquatic habitats where oxygen, nitrate, ferric iron and sulphate have been depleted as electron accepters. The pathway leading from dead biomass to methane through the metabolism of anaerobic bacteria and archaea is well understood for easily degradable biomolecules such as carbohydrates, proteins and lipids(1,2). However, little is known about the organic compounds that lead to methane in old anoxic sediments where easily degradable biomolecules are no longer available. One class of naturally formed long-lived compounds in such sediments is the saturated hydrocarbons (alkanes)(3-5). Alkanes are usually considered to be inert in the absence of oxygen, nitrate or sulphate(6), and the analysis of alkane patterns is often used for biogeochemical characterization of sediments(7,8), However, alkanes might be consumed in anoxic sediments below the zone of sulphate reduction(9,10), but the underlying process has not been elucidated. Here we used enrichment cultures to show that the biological conversion of long-chain alkanes to the simplest hydrocarbon, methane, is possible under strictly anoxic conditions.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; Univ Hamburg, Inst Biogeochem & Marine Chem, D-20146 Hamburg, Germany	Max Planck Society; University of Hamburg	Widdel, F (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	fwiddel@mpi-bremen.de	Rossello-Mora, Ramon/L-4650-2014; Richnow, Hans H./H-8523-2017; Richnow, Hans/AAD-9016-2022	Rossello-Mora, Ramon/0000-0001-8253-3107; Richnow, Hans H./0000-0002-6144-4129; Richnow, Hans/0000-0002-6144-4129; Zengler, Karsten/0000-0002-8062-3296				Albert DB, 1997, MAR CHEM, V56, P27, DOI 10.1016/S0304-4203(96)00083-7; BEIER JA, 1991, NATURE, V351, P642, DOI 10.1038/351642a0; Birch L., 1988, BIOTECHNOLOGY B, V6b, P71; BLUMER M, 1971, MAR BIOL, V8, P183, DOI 10.1007/BF00355214; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Dojka MA, 1998, APPL ENVIRON MICROB, V64, P3869; EGLINTON G, 1968, ADV ORG GEOCHEM, V31, P1; GIGER W, 1980, GEOCHIM COSMOCHIM AC, V44, P119, DOI 10.1016/0016-7037(80)90182-9; HARDER J, IN PRESS GEOMICROBIO; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Heider J, 1998, FEMS MICROBIOL REV, V22, P459, DOI 10.1111/j.1574-6976.1998.tb00381.x; LIDE DR, 1998, HDB CHEM PHYSICS; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Martini AM, 1996, NATURE, V383, P155, DOI 10.1038/383155a0; MULLER FM, 1957, ANTON LEEUW INT J G, V23, P269; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Rowe D, 1999, NATURE, V398, P61, DOI 10.1038/18007; Rozanova EP, 1997, MICROBIOLOGY+, V66, P718; Schink B, 1997, MICROBIOL MOL BIOL R, V61, P262, DOI 10.1128/.61.2.262-280.1997; SCHINK B, 1985, FEMS MICROBIOL ECOL, V31, P69, DOI 10.1111/j.1574-6968.1985.tb01133.x; SCOTT AR, 1994, AAPG BULL, V78, P1186; Seiler W., 1980, ATMOS TECHNOL, V12, P40; SIMONEIT BRT, 1986, MAR GEOL, V70, P9, DOI 10.1016/0025-3227(86)90087-3; Tissot B.P., 1984, PETROLEUM FORMATION, DOI 10.1007/978-3-642-96446-6; WERSIN P, 1991, CHEM GEOL, V90, P233, DOI 10.1016/0009-2541(91)90102-W; Widdel F., 1992, PROKARYOTES, DOI 10.1007/978-1-4757-2191-1_2	28	454	490	2	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					266	269		10.1038/45777	http://dx.doi.org/10.1038/45777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499582				2022-12-24	WOS:000082678400050
J	Farrell, AM				Farrell, AM			Staphylococcal scalded-skin syndrome	LANCET			English	Editorial Material							EXFOLIATIVE TOXIN; EPIDERMOLYTIC TOXIN; SERINE-PROTEASE; AUREUS		John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England	University of Oxford	Farrell, AM (corresponding author), John Radcliffe Hosp, Dept Dermatol, Oxford OX3 7LJ, England.							Acland KM, 1999, BRIT J DERMATOL, V140, P518; CRIBIER B, 1994, J AM ACAD DERMATOL, V30, P319, DOI 10.1016/S0190-9622(94)70032-X; DANCER SJ, 1990, FEBS LETT, V268, P129, DOI 10.1016/0014-5793(90)80990-Z; ELSNER P, 1988, ZBL BAKT-INT J MED M, V268, P534; Farrell AM, 1996, BRIT J DERMATOL, V134, P962, DOI 10.1111/j.1365-2133.1996.tb06337.x; Kawabata A, 1997, J CLIN MICROBIOL, V35, P1984, DOI 10.1128/JCM.35.8.1984-1987.1997; Lina G, 1997, CLIN INFECT DIS, V25, P1369, DOI 10.1086/516129; Melish M.E., 1981, ZBL BAKT S, V10, P287; MELISH ME, 1972, J INFECT DIS, V125, P129, DOI 10.1093/infdis/125.2.129; Qasim W, 1998, ARCH DIS CHILD, V79, P290, DOI 10.1136/adc.79.3.290a; REDPATH MB, 1991, FEMS MICROBIOL LETT, V81, P151; SMITH TP, 1987, HISTOCHEM J, V19, P137, DOI 10.1007/BF01695138; Vath GM, 1997, BIOCHEMISTRY-US, V36, P1559, DOI 10.1021/bi962614f; WILEY BB, 1974, INFECT IMMUN, V9, P636, DOI 10.1128/IAI.9.4.636-640.1974	14	24	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					880	881		10.1016/S0140-6736(99)90120-4	http://dx.doi.org/10.1016/S0140-6736(99)90120-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489941				2022-12-24	WOS:000082511800004
J	Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W				Yeung, K; Seitz, T; Li, SF; Janosch, P; McFerran, B; Kaiser, C; Fee, F; Katsanakis, KD; Rose, DW; Mischak, H; Sedivy, JM; Kolch, W			Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP	NATURE			English	Article							CELL-CYCLE ARREST; DNA-SYNTHESIS; C-FOS; ACTIVATION; INHIBITION; BINDING; TRANSFORMATION; EXPRESSION; CASCADE; PURIFICATION	Raf-1 phosphorylates and activates MEK-1, a kinase that activates the extracellular signal regulated kinases (ERK), This kinase cascade controls the proliferation and differentiation of different cell types(1,2). Here we describe a Raf-1-interacting protein, isolated using a yeast two-hybrid screen. This protein inhibits the phosphorylation and activation of MEK by Raf-1 and is designated RKIP (Raf kinase inhibitor protein). In vitro, RKIP binds to Raf-1, MEK and ERK, but not to pas, RKIP co-immunoprecipitates with Raf-1 and MEK from cell lysates and colocalizes with Raf-1 when examined by confocal microscopy, RKIP is not a substrate for Raf-1 or MEK, but competitively disrupts the interaction between these kinases, RKIP overexpression interferes with the activation of MEK and ERK, induction of AP-1-dependent reporter genes and transformation elicited by an oncogenically activated Raf-1 kinase, Downregulation of endogenous RKIP by expression of antisense RNA or antibody microinjection induces the activation of MEK-, ERK- and AP-1-dependent transcription. RKIP represents a new class of protein-kinase-inhibitor protein that regulates the activity of the Raf/MEK/ERK module.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Richmond, RI 02912 USA; GSF Munich, Res Ctr Hlth & Environm, Inst Clin Mol Biol, D-81377 Munich, Germany; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Whittier Diabet Program, La Jolla, CA 92093 USA; Franz Volhard Klinikum, Max Delbruck Ctr, D-13122 Berlin, Germany	Beatson Institute; Brown University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of California System; University of California San Diego; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kolch, W (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	john_sedivy@brown.edu; wkolch@beatson.gla.ac.uk	Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Mischak, Harald/E-8685-2011	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Ferrell JE, 1996, CURR TOP DEV BIOL, V33, P1, DOI 10.1016/S0070-2153(08)60336-1; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Kolch W, 1996, ONCOGENE, V13, P1305; KOLCH W, 1993, ONCOGENE, V8, P361; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RAPP UR, 1994, ONCOGENE, V9, P3493; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Tombes RM, 1998, BIOCHEM J, V330, P1451; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598	26	678	743	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					173	177		10.1038/43686	http://dx.doi.org/10.1038/43686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490027	Green Accepted			2022-12-24	WOS:000082458800056
J	Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA				Lee, CK; Klopp, RG; Weindruch, R; Prolla, TA			Gene expression profile of aging and its retardation by caloric restriction	SCIENCE			English	Article							MESSENGER-RNA EXPRESSION; CAENORHABDITIS-ELEGANS; LIFE-SPAN; TRANSCRIPTION FACTOR; PROTEIN; MUSCLE; STRESS; LONGEVITY; EXTENSION; DAF-16	The gene expression profile of the aging process was analyzed in skeletal muscle of mice. Use of high-density oligonucleotide arrays representing 6347 genes revealed that aging resulted in a differential gene expression pattern indicative of a marked stress response and Lower expression of metabolic and biosynthetic genes. Most alterations were either completely or partially prevented by caloric restriction, the only intervention known to retard aging in mammals. Transcriptional patterns of calorie-restricted animals suggest that caloric restriction retards the aging process by causing a metabolic shift toward increased protein turnover and decreased macromolecular damage.	VA Hosp, Dept Med, GRECC 4D, Madison, WI 53705 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Inst Aging, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Weindruch, R (corresponding author), VA Hosp, Dept Med, GRECC 4D, 2500 Overlook Terrace, Madison, WI 53705 USA.	rhweindr@facstaff.wisc.edu; taprolla@facstaff.wisc.edu	Lee, Cheol-Koo/F-2103-2013	Lee, Cheol-Koo/0000-0003-3927-9195	NATIONAL CANCER INSTITUTE [R01CA078723] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA78723] Funding Source: Medline; NIA NIH HHS [P01 AG11915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Copray JCVM, 1997, NEUROSCI LETT, V236, P41, DOI 10.1016/S0304-3940(97)00747-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dutta C, 1997, MUSCLE NERVE, V5, P55; Goyns MH, 1998, MECH AGEING DEV, V101, P73, DOI 10.1016/S0047-6374(97)00166-8; HOEK JB, 1988, BIOCHEM J, V254, P1; JACKMAN J, 1994, CANCER RES, V54, P5656; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LARSSON L, 1995, J GERONTOL A-BIOL, V50, P91; Lexell J, 1997, J NUTR, V127, pS1011, DOI 10.1093/jn/127.5.1011S; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LISOWSKY T, 1994, CURR GENET, V26, P15, DOI 10.1007/BF00326299; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; LUDATSCHER R, 1983, EXP GERONTOL, V18, P113, DOI 10.1016/0531-5565(83)90004-9; MARAZZI G, 1993, DEV DYNAM, V197, P115, DOI 10.1002/aja.1001970205; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Murakami S, 1996, GENETICS, V143, P1207; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Peterson CA, 1997, J NUTR, V127, pS1007; Pugh TD, 1999, CANCER RES, V59, P1642; Schwartz AL, 1999, ANNU REV MED, V50, P57; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Tissenbaum HA, 1998, GENETICS, V148, P703; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Wang S, 1996, MECH AGEING DEV, V92, P121, DOI 10.1016/S0047-6374(96)01814-3; Weindruch R., 1988, RETARDATION AGING DI; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	40	1188	1252	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 27	1999	285	5432					1390	1393		10.1126/science.285.5432.1390	http://dx.doi.org/10.1126/science.285.5432.1390			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464095				2022-12-24	WOS:000082233500039
J	Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A				Rustin, P; von Kleist-Retzow, JC; Chantrel-Groussard, K; Sidi, D; Munnich, A; Rotig, A			Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study	LANCET			English	Article							MITOCHONDRIAL-FUNCTION; IRON ACCUMULATION; OXIDATIVE STRESS; FRATAXIN; HOMOLOG; DEFICIENCY; ACONITASE; CHAIN; GENE	Background Friedreich's ataxia is caused by a deficiency of frataxin, a protein involved in regulation of mitochondrial iron content. We have reported a combined deficiency of a Krebs-cycle enzyme, aconitase, and three mitochondrial respiratory-chain complexes in endomyocardial biopsy samples from patients with this disorder. All four enzymes share iron-sulphur cluster-containing proteins that are damaged by iron overload through generation of oxygen free radicals. We used an in-vitro system to elucidate the mechanism of iron-induced injury and to test the protective effects of various substances. On the basis of these results, we assessed the effect of idebenone (a free-radical scavenger) in three patients with Friedreich's ataxia. Methods Heart homogenates from patients with valvular stenosis were tested for respiratory-chain complex II activity, lipoperoxidation, and aconitase activity by spectrophotometric assays, in the presence of reduced iron (Fe2+), oxidised iron (Fe3+), desferrioxamine, ascorbic acid, and idebenone. The Friedreich's ataxia patients (aged 11 years, 19 years, and 21 years) underwent ultrasonographic heart measurements at baseline and after 4-9 months of idebenone (5 mg/kg daily). Findings Fe2+ (but not Fe3+) decreased complex II activity and increased lipoperoxidation in heart homogenate. Addition of ascorbate or desferrioxamine increased some of the iron-induced adverse effects. Idebenone protected against these effects. In the three patients, left-ventricular mass index decreased from baseline to 4-9 months of idebenone treatment (patient 1, 145 g to 114 g; patient 2, 215 g to 151 g; patient 3, 408 g to 279 g). Interpretation Our in-vitro data suggest that both iron chelators and antioxidant drugs that may reduce iron are potentially harmful in patients with Friedreich's ataxia. Conversely, our preliminary findings in patients suggest that idebenone protects heart muscle from iron-induced injury.	Hop Necker Enfants Malad, INSERM, U393,, F-75743 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Munnich, A (corresponding author), Hop Necker Enfants Malad, INSERM, U393,, Tour Lavoisler,149 Rue Sevres, F-75743 Paris, France.		Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHAMBERLAIN S, 1989, AM J HUM GENET, V44, P518; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GEOFFROY G, 1976, Canadian Journal of Neurological Sciences, V3, P279; GILLIS JC, 1994, DRUG AGING, V5, P133, DOI 10.2165/00002512-199405020-00007; HARDING AE, 1981, BRAIN, V104, P598; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; NIENHUIS AW, 1981, NEW ENGL J MED, V304, P170, DOI 10.1056/NEJM198101153040311; NZNAGY I, 1990, ARCH GERONTOL GERIAT, V11, P177; Priller J, 1997, ANN NEUROL, V42, P265, DOI 10.1002/ana.410420222; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; SANCHEZCASIS G, 1977, CAN J NEUROL SCI, V3, P349; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	18	284	301	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 7	1999	354	9177					477	479		10.1016/S0140-6736(99)01341-0	http://dx.doi.org/10.1016/S0140-6736(99)01341-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224KB	10465173				2022-12-24	WOS:000081896100013
J	Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ				Yang, D; Chertov, O; Bykovskaia, N; Chen, Q; Buffo, MJ; Shogan, J; Anderson, M; Schroder, JM; Wang, JM; Howard, OMZ; Oppenheim, JJ			beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6	SCIENCE			English	Article							CHEMOKINE RECEPTOR; CYSTIC-FIBROSIS; PROTEIN; PEPTIDE; HIV-1; IDENTIFICATION; INTERACTS; MIGRATION; RANTES; PLASMA	Defensins contribute to host defense by disrupting the cytoplasmic membrane of microorganisms. This report shows that human beta-defensins are also chemotactic for immature dendritic cells and memory T cells. Human beta-defensin was selectively chemotactic for cells stably transfected to express human CCR6, a chemokine receptor preferentially expressed by immature dendritic cells and memory T cells. The beta-defensin-induced chemotaxis was sensitive to pertussis toxin and inhibited by antibodies to CCR6. The binding of iodinated LARC, the chemokine Ligand for CCR6, to CCR6-transfected cells was competitively displaced by beta-defensin. Thus, beta-defensins may promote adaptive immune responses by recruiting dendritic and T cells to the site of microbial invasion through interaction with CCR6.	NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Allegheny Univ Hlth Sci, Pittsburgh, PA 15212 USA; Magainin Res Inst, Plymouth Meeting, PA 19642 USA; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Kiel	Oppenheim, JJ (corresponding author), NCI, Mol Immunoregulat Lab, Div Basic Sci, SAIC Frederick,Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.	oppenhei@mail.ncifcrf.gov	Schroeder, Jens M/B-3994-2009; Howard, O M Zack/B-6117-2012	Howard, O M Zack/0000-0002-0505-7052; Chertov, Oleg/0000-0002-0426-2521	NATIONAL CANCER INSTITUTE [Z01BC009369] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI [10.1104/pp.108.4.1353, 10.1016/j.chiabu.2021.105188]; Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; Lillard JW, 1999, P NATL ACAD SCI USA, V96, P651, DOI 10.1073/pnas.96.2.651; Prohaszka Z, 1997, MOL IMMUNOL, V34, P809, DOI 10.1016/S0161-5890(97)00097-7; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; Yang D., UNPUB	26	1417	1552	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					525	528		10.1126/science.286.5439.525	http://dx.doi.org/10.1126/science.286.5439.525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521347				2022-12-24	WOS:000083121200059
J	Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ				Hamburger, ZA; Brown, MS; Isberg, RR; Bjorkman, PJ			Crystal structure of invasin: A bacterial integrin-binding protein	SCIENCE			English	Article							CELL-ADHESION MOLECULE-1; YERSINIA-PSEUDOTUBERCULOSIS; MAMMALIAN-CELLS; LIGAND INTERACTION; RECEPTOR; IDENTIFICATION; DOMAINS; INTERNALIZATION; FIBRONECTIN; LOOP	The Yersinia pseudotuberculosis invasin protein promotes bacterial entry by binding to host cell integrins with higher affinity than natural substrates such as fibronectin, The 2.3 angstrom crystal structure of the invasin extracellular region reveals five domains that form a 180 angstrom rod with structural similarities to tandem fibronectin type III domains. The integrin-binding surfaces of invasin and fibronectin include similarly Located key residues, but in the context of different folds and surface shapes. The structures of invasin and fibronectin provide an example of convergent evolution, in which invasin presents an optimized surface for integrin binding, in comparison with host substrates.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Tufts University	Bjorkman, PJ (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.	bjorkman@cco.caltech.edu						Abagyan RA, 1997, J MOL BIOL, V273, P355, DOI 10.1006/jmbi.1997.1287; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Boyington JC, 1999, IMMUNITY, V10, P75, DOI 10.1016/S1074-7613(00)80008-4; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dersch P, 1999, EMBO J, V18, P1199, DOI 10.1093/emboj/18.5.1199; Diederichs K, 1998, PROTEIN SCI, V7, P2413, DOI 10.1002/pro.5560071119; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isberg Ralph R., 1994, Trends in Microbiology, V2, P10, DOI 10.1016/0966-842X(94)90338-7; ISBERG RR, 1993, J BIOL CHEM, V268, P15840; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Jap BK, 1996, PHYSIOL REV, V76, P1073, DOI 10.1152/physrev.1996.76.4.1073; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krukonis ES, 1998, J BIOL CHEM, V273, P31837, DOI 10.1074/jbc.273.48.31837; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; LEONG JM, 1993, J BIOL CHEM, V268, P20524; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LEONG JM, 1995, EMBO J, V14, P422, DOI 10.1002/j.1460-2075.1995.tb07018.x; Liu H, 1999, INFECT IMMUN, V67, P2045; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Marra A, 1997, INFECT IMMUN, V65, P3412, DOI 10.1128/IAI.65.8.3412-3421.1997; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEPE JC, 1993, INFECT AGENT DIS, V2, P236; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Saltman LH, 1996, J BIOL CHEM, V271, P23438, DOI 10.1074/jbc.271.38.23438; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; Tao YZ, 1997, STRUCTURE, V5, P789, DOI 10.1016/S0969-2126(97)00233-5; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VanNhieu GT, 1996, J BIOL CHEM, V271, P7665, DOI 10.1074/jbc.271.13.7665; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Worley MJ, 1998, MOL MICROBIOL, V29, P1471, DOI 10.1046/j.1365-2958.1998.01030.x; YU J, 1992, MOL MICROBIOL, V6, P411, DOI 10.1111/j.1365-2958.1992.tb01484.x	62	224	230	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					291	295		10.1126/science.286.5438.291	http://dx.doi.org/10.1126/science.286.5438.291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514372				2022-12-24	WOS:000083024400044
J	Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G				Steinmann, T; Geldner, N; Grebe, M; Mangold, S; Jackson, CL; Paris, S; Galweiler, L; Palme, K; Jurgens, G			Coordinated polar localization of auxin efflux carrier PIN1 by GNOM ARF GEF	SCIENCE			English	Article							ARABIDOPSIS GENE MONOPTEROS; PATTERN-FORMATION; BREFELDIN-A; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; NUCLEOTIDE EXCHANGE; PROTEIN; EMBRYO; CELLS; REDISTRIBUTION	The plant hormone auxin is transported in a polar manner along the shoot-root axis, which requires efflux carriers such as PIN1. Asymmetric localization-of PIN1 develops from a random distribution in Arabidopsis early embryogenesis. Coordinated polar localization of PIN1 is defective in gnom embryos. GNOM is a membrane-associated guanine-nucleotide exchange factor on ADP-ribosylation factor G protein (ARF GEF). Thus, GNOM-dependent vesicle trafficking may establish cell polarity, resulting in polar auxin transport.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany	Eberhard Karls University of Tubingen; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Max Planck Society	Jurgens, G (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 1, D-72076 Tubingen, Germany.		Jackson, Catherine/A-3421-2013; Jackson, Catherine/T-5688-2019; Geldner, Niko/Y-2481-2019; Palme, Klaus/A-9524-2013	Jackson, Catherine/0000-0002-0843-145X; Palme, Klaus/0000-0002-2728-3835; Grebe, Markus/0000-0001-7571-0670; Geldner, Niko/0000-0002-2300-9644				BERLETH T, 1993, DEVELOPMENT, V118, P575; Busch M, 1996, MOL GEN GENET, V250, P681, DOI 10.1007/BF02172979; Delbarre A, 1998, PLANT PHYSIOL, V116, P833, DOI 10.1104/pp.116.2.833; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAYER U, 1993, DEVELOPMENT, V117, P149; Morris DA, 1998, PLANTA, V205, P606, DOI 10.1007/s004250050363; Park JM, 1997, PLANT PHYSIOL, V115, P763, DOI 10.1104/pp.115.2.763; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; SACHS T, 1991, DEVELOPMENT S, V1, P83; SATIATJEUNEMAITRE B, 1992, J CELL SCI, V103, P1153; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Vroemen CW, 1996, PLANT CELL, V8, P783, DOI 10.1105/tpc.8.5.783; WENT FW, 1929, REC TRAV BOT NEERL, V25, P1	22	565	598	4	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					316	318		10.1126/science.286.5438.316	http://dx.doi.org/10.1126/science.286.5438.316			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514379				2022-12-24	WOS:000083024400051
J	Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN				Heron, E; Lozinguez, O; Emmerich, J; Laurian, C; Fiessinger, JN			Long-term sequelae of spontaneous axillary-subclavian venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; UPPER-EXTREMITY; PAIN	Background: The frequency and severity of post-thrombotic sequelae after spontaneous axillary-subclavian venous thrombosis remain poorly known. Objective: To determine the late sequelae of conventionally treated spontaneous axillary-subclavian venous thrombosis. Design: Cross-sectional study. Setting: University department of vascular medicine. Patients: 54 patients seen during an 18-year period (mean follow-up, 5 years). Measurements: Scores for the severity of post-thrombotic symptoms were graded on a numerical rating scale ranging from 0 to 10 and on a 6-point verbal rating scale. Ultrasonographic sequelae were classified as grade 0, normal flow; grade 1, moderate obstruction; or grade 2, severe obstruction or occlusion. Results: Verbal scores were "nil/negligible" in 47% of patients and "severe/intolerable" in 13%; numerical scores were 0 to 3 in 78% of patients and 7 to 10 in 9%. Grade 2 ultrasonographic sequelae were found in 22% of cases. No relation was seen between ultrasonographic sequelae and symptom severity scores. Conclusion: The overall clinical outcome of spontaneous axillary-subclavian venous thrombosis is good, and there is no relation between the severity of late symptoms and ultrasonographic sequelae.	Hop Broussais, Serv Med Vasc, F-75674 Paris 14, France; Hop Broussais, Ctr Blaude Bernard Rech Malad Vasc Peripher, F-75674 Paris 14, France; Hop St Joseph, Serv Chirurg Vasc, F-75674 Paris 14, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite	Fiessinger, JN (corresponding author), Hop Broussais, Serv Med Vasc, 96 Rue Didot, F-75674 Paris 14, France.							ADAMS JT, 1965, ARCH SURG-CHICAGO, V91, P29; AMELI FM, 1987, CAN J SURG, V30, P167; BECKER DM, 1991, ARCH INTERN MED, V151, P1934, DOI 10.1001/archinte.151.10.1934; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Elliott G, 1997, LANCET, V349, P1188, DOI 10.1016/S0140-6736(05)62408-7; GLOVICZKI P, 1986, J VASC SURG, V4, P333, DOI 10.1067/mva.1986.avs0040333; GRASSI CJ, 1990, RADIOLOGY, V175, P651, DOI 10.1148/radiology.175.3.2188295; HAIRE WD, 1995, CLIN CHEST MED, V16, P341; HOUDE RW, 1982, ACTA ANAESTH SCAND, V26, P25, DOI 10.1111/j.1399-6576.1982.tb01840.x; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JENSEN MP, 1994, PAIN, V58, P387, DOI 10.1016/0304-3959(94)90133-3; Lindblad B, 1988, Eur J Vasc Surg, V2, P161, DOI 10.1016/S0950-821X(88)80069-0; MACHLEDER HI, 1993, J VASC SURG, V17, P305, DOI 10.1016/0741-5214(93)90416-J; Meier GH, 1996, J VASC SURG, V24, P974, DOI 10.1016/S0741-5214(96)70043-5; MOLINA JE, 1995, J AM COLL SURGEONS, V181, P414; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; RICHARD HM, 1992, RADIOGRAPHICS, V12, P527, DOI 10.1148/radiographics.12.3.1609143; TILNEY NL, 1970, ARCH SURG-CHICAGO, V101, P792	18	49	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					510	513		10.7326/0003-4819-131-7-199910050-00006	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507960				2022-12-24	WOS:000083018800005
J	Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G				Montagne, J; Stewart, MJ; Stocker, H; Hafen, E; Kozma, SC; Thomas, G			Drosophila S6 kinase: A regulator of cell size	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; WING DEVELOPMENT; GROWTH; MELANOGASTER; COORDINATION; ACTIVATION; DIVISION; PROTEIN; CYCLE; DISKS	Cell proliferation requires cell growth; that is. cells only divide after they reach a critical size. However, the mechanisms by which cells grow and maintain their appropriate size have remained elusive. Drosophila deficient in the S6 kinase gene (dS6K) exhibited an extreme delay in development and a severe reduction in body size. These flies had smaller cells rather than fewer cells. The effect was cell-autonomous, displayed throughout Larval development, and distinct from that of ribosomal protein mutants (Minutes). Thus, the dS6K gene product regulates cell size in a cell-autonomous manner without impinging on cell number.	Friedrich Miescher Inst, CH-4056 Basel, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	Friedrich Miescher Institute for Biomedical Research; University of Zurich	Thomas, G (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4056 Basel, Switzerland.		Thomas, George/K-9235-2014; Stoecker, Horst/F-8382-2012	Thomas, George/0000-0003-3518-8149; Stoecker, Horst/0000-0002-3282-3664	NIGMS NIH HHS [F32 GM15926] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015926] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BRAND AH, 1993, DEVELOPMENT, V118, P401; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CONSORTIUM TF, 1994, NUCLEIC ACIDS RES, V22, P3456; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FAIN MJ, 1982, DEV BIOL, V92, P247, DOI 10.1016/0012-1606(82)90169-5; FRISTROM D, 1993, DEVELOPMENT, V117, P509; GARCIABELLIDO A, 1994, P NATL ACAD SCI USA, V91, P10222, DOI 10.1073/pnas.91.21.10222; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GLOOR GB, 1993, GENETICS, V135, P81; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; GRAVES BJ, 1982, DEV BIOL, V93, P104, DOI 10.1016/0012-1606(82)90243-3; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KARPEN GH, 1992, GENETICS, V132, P737; Lambert A, 1998, REPROD NUTR DEV, V38, P69, DOI 10.1051/rnd:19980106; Laser M, 1998, J BIOL CHEM, V273, P24610, DOI 10.1074/jbc.273.38.24610; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MITCHISON JM, 1971, BIOL CELL CYCLE; Nasmyth K, 1996, NATURE, V382, P28, DOI 10.1038/382028a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Nurse P., 1985, P185; PIRROTTA V, 1986, DROSOPHILA PRACTICAL, P82; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHUBIGER M, 1987, DEV BIOL, V123, P145, DOI 10.1016/0012-1606(87)90436-2; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stewart MJ, 1996, P NATL ACAD SCI USA, V93, P10791, DOI 10.1073/pnas.93.20.10791; STEWART MJ, 1993, MOL CELL BIOL, V13, P2524, DOI 10.1128/MCB.13.4.2524; Su TT, 1998, CURR BIOL, V8, pR687, DOI 10.1016/S0960-9822(98)70436-1; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TUCKER JB, 1986, EUR J CELL BIOL, V41, P279; XU T, 1993, DEVELOPMENT, V117, P1223	41	598	616	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2126	2129		10.1126/science.285.5436.2126	http://dx.doi.org/10.1126/science.285.5436.2126			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497130				2022-12-24	WOS:000082734300042
J	Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A				Lindsay, EA; Botta, A; Jurecic, V; Carattini-Rivera, S; Cheah, YC; Rosenblatt, HM; Bradley, A; Baldini, A			Congenital heart disease in mice deficient for the DiGeorge syndrome region	NATURE			English	Article							22Q11 DELETIONS; MOUSE; GENE; PAX3	The heterozygous chromosome deletion within the band 22q11 (del22q11) is an important cause of congenital cardiovascular defects(1), It is the genetic basis of DiGeorge syndrome and causes the most common deletion syndrome in humans(2). Because the deleted region is largely conserved in the mouse, we were able to engineer a chromosome deletion (Df1) spanning a segment of the murine region homologous to the human deleted region. Here we describe heterozygously deleted (Df1/+) mice with cardiovascular abnormalities of the same type as those associated with del22q11; we have traced the embryological origin of these abnormalities to defective development of the fourth pharyngeal arch arteries. Genetic complementation of the deletion using a chromosome duplicated for the Df1 DNA segment corrects the heart defects, indicating that they are caused by reduced dosage of genes located within Df1. The Df1/+ mouse model reveals the pathogenic basis of the most clinically severe aspect of DiGeorge syndrome and uncovers a new mechanism leading to aortic arch abnormalities. These mutants represent a mouse model of a human deletion syndrome generated by chromosome engineering.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat Allergy & Immunol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Baldini, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.		genes, anthony/F-2541-2012; botta, annalisa/AAB-8680-2019; BOTTA, ANNALISA/AAD-1581-2022; Baldini, Antonio/M-2355-2015	BOTTA, ANNALISA/0000-0003-4031-5624; Baldini, Antonio/0000-0002-5330-0256; Bradley, Allan/0000-0002-2349-8839				BALDINI A, 1994, IN SITU HYBRIDIZATIO, P75; Botta A, 1997, MAMM GENOME, V8, P890, DOI 10.1007/s003359900606; Conway SJ, 1997, DEVELOPMENT, V124, P505; Farrell MJ, 1999, CIRC RES, V84, P127, DOI 10.1161/01.RES.84.2.127; Galili N, 1997, GENOME RES, V7, P17, DOI 10.1101/gr.7.1.17; Iida K, 1997, DEVELOPMENT, V124, P4627; Kaufman M.H., 1992, ATLAS MOUSE DEV; Kidd PG, 1997, MANUAL CLIN LAB IMMU, V5th, P229; Kirby M. L., 1999, HEART DEV, P179; KRUISBECK AM, 1991, CURRENT PROTOCOLS IM; KRUISBECK AM, 1993, CURRENT PROTOCOLS IM; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lindsay EA, 1998, HUM MOL GENET, V7, P629, DOI 10.1093/hmg/7.4.629; Lindsay EA, 1998, MOL MED TODAY, V4, P350, DOI 10.1016/S1357-4310(98)01302-1; Liu PT, 1998, GENETICS, V150, P1155; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Pizzuti A, 1997, HUM MOL GENET, V6, P259, DOI 10.1093/hmg/6.2.259; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sutherland HF, 1998, GENOMICS, V52, P37, DOI 10.1006/geno.1998.5414; WILSON DI, 1994, AM J HUM GENET S, V55, pA975; Yamagishi H, 1999, SCIENCE, V283, P1158, DOI 10.1126/science.283.5405.1158; Yanagisawa H, 1998, J CLIN INVEST, V102, P22, DOI 10.1172/JCI2698	26	309	313	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					379	383		10.1038/43900	http://dx.doi.org/10.1038/43900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517636				2022-12-24	WOS:000082822600052
J	Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L				Yerly, S; Kaiser, L; Race, E; Bru, JP; Clavel, F; Perrin, L			Transmission of antiretroviral-drug-resistant HIV-1 variants	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITORS; IN-VIVO; ZIDOVUDINE; NEVIRAPINE; THERAPY; SWITZERLAND; PREVALENCE; LAMIVUDINE; INFECTION	Background Resistance of HIV-1 to antiretroviral drugs is the main cause of antiretroviral-treatment failure. We assessed the transmission of drug-resistant variants among individuals with primary HIV-1 infection. Methods Population-based sequencing of the viral reverse transcriptase and protease genes derived from plasma viral RNA was done in 82 consecutive individuals with documented primary HIV-1 infection from January, 1996, to July, 1998. Phenotypic resistance to protease inhibitors was assessed by recombinant virus assay in individuals with two or more mutations associated with resistance to protease inhibitors. Findings Zidovudine-resistance mutations were detected in seven (9%) of 82 individuals. Mutations associated with resistance to other reverse-transcriptase inhibitors (RTls) were detected in two individuals. Primary-resistance mutations associated with protease inhibitors (V82A, L90M) were detected in three (4%) of 70 individuals; two of these had also RTI-resistance mutations. Decreased sensitivity to three or four protease inhibitors was seen in three individuals, one of whom was infected with HIV-1 variants that harboured 12 mutations associated with resistance to multiple RTI and protease inhibitors. Interpretation To introduce the best antiretroviral treatment, resistance testing should be done in recently HIV-1-infected individuals.	Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Infect Dis, AIDS Unit, Geneva, Switzerland; Hop Xavier Bichat, INSERM, Antiviral Res Lab, Paris, France; Annecy Hosp Ctr, Div Infect Dis, Annecy, France	University of Geneva; University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Annecy Genevois	Perrin, L (corresponding author), Univ Hosp Geneva, Div Infect Dis, Virol Lab, CH-1211 Geneva 14, Switzerland.	luc.perrin@hcuge.ch		Kaiser, Laurent/0000-0002-0857-2252				Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; Eron J, 1998, AIDS, V12, pS13; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; GRANT RM, 1998, ANTIVIR THER S, V3, P108; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1996, J VIROL, V70, P7894, DOI 10.1128/JVI.70.11.7894-7899.1996; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Imrie A, 1997, J INFECT DIS, V175, P1502, DOI 10.1086/516487; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; LOES SKD, 1993, CLIN INFECT DIS, V17, P59, DOI 10.1093/clinids/17.1.59; Lorenzi P, 1999, AIDS, V13, pF17, DOI 10.1097/00002030-199902040-00001; MAYERS DL, 1995, AIDS RES HUM RETROV, V11, pS162; Miller V, 1998, J INFECT DIS, V177, P1521, DOI 10.1086/515304; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; PERRIN L, 1998, 12 WORLD AIDS C GEN; Roberts NA, 1998, AIDS, V12, P453, DOI 10.1097/00002030-199805000-00005; Schinazi R. F., 1997, International Antiviral News, V5, P129; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; Yerly S, 1996, SCHWEIZ MED WSCHR, V126, P1845; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998	26	332	342	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 28	1999	354	9180					729	733		10.1016/S0140-6736(98)12262-6	http://dx.doi.org/10.1016/S0140-6736(98)12262-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475184				2022-12-24	WOS:000082233000012
J	Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ				Mayer, TU; Kapoor, TM; Haggarty, SJ; King, RW; Schreiber, SL; Mitchison, TJ			Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen	SCIENCE			English	Article							MICROTUBULE MOTOR; KINESIN MOTORS; PROTEINS; CELLS	Small molecules that perturb specific protein functions are valuable tools for dissecting complex processes in mammalian cells. A combination of two phenotype-based screens, one based on a specific posttranslational modification, the other visualizing microtubules and chromatin, was used to identify compounds that affect mitosis. One compound, here named monastrol, arrested mammalian cells in mitosis with monopolar spindles. In vitro, monastrol specifically inhibited the motility of the mitotic kinesin Eg5, a motor protein required for spindle bipolarity. All previously known small molecules that specifically affect the mitotic machinery target tubulin. Monastrol will therefore be a particularly useful tool for studying mitotic mechanisms.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Howard Hughes Med Inst, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute; Harvard University	Mayer, TU (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Haggarty, Stephen J/M-9495-2016	Haggarty, Stephen J/0000-0002-7872-168X; Mayer, Thomas/0000-0001-6954-2287	NCI NIH HHS [CA78048] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078048] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGGARTY SJ, UNPUB; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kapoor TM, 1999, P NATL ACAD SCI USA, V96, P9106, DOI 10.1073/pnas.96.16.9106; Lewandowski K, 1999, J COMB CHEM, V1, P105, DOI 10.1021/cc980014p; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Sakowicz R, 1998, SCIENCE, V280, P292, DOI 10.1126/science.280.5361.292; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; SAXTON WM, 1994, METHOD CELL BIOL, V44, P279, DOI 10.1016/S0091-679X(08)60919-X; Schreiber SL, 1998, BIOORGAN MED CHEM, V6, P1127, DOI 10.1016/S0968-0896(98)00126-6; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3	20	1533	1655	3	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					971	974		10.1126/science.286.5441.971	http://dx.doi.org/10.1126/science.286.5441.971			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542155	Green Submitted			2022-12-24	WOS:000083368500050
J	Johnston, K; Brown, J				Johnston, K; Brown, J			Two view mammography at incident screens: cost effectiveness analysis of policy options	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the cost effectiveness of two view mammography at incident screens. Design Incremental cost effectiveness analyses recognising differences in current reading policy, based on effectiveness data from an observational study. Setting Breast screening programmes in England and Wales. Main outcome measures Health service costs, cancers detected, incremental cost effectiveness ratios per cancer detected, whole time equivalent staff. Results For programmes currently using one view with some form of double reading, the incremental cost effectiveness ratio of two view mammography art incident screens ranged between pound 6589 and pound 6716, depending on the reading policy. For programmes currently using one view with single reading, two policy options were found to be more efficient than two view single reading: one view with double reading (arbitration; incremental cost effectiveness ratio of pound 210) and two view double reading (arbitration). Tf programmes using one view with single reading changed to double reading (arbitration) and then subsequently to two views double reading (arbitration), additional cancers could be detected with an incremental cost effectiveness ratio of pound 7983. The implementation cost of two view mammography at incident screens in programmes in England and Wales would be pound 2.9 million and would require 13.4 whole time equivalent radiologists. Conclusions The cost effectiveness of two view mammography at incident screens depends on the film reading policy. A policy of two view mammography at incident screens in England and Wales would be efficient only if programmes using single reading moved to double reading. Given limited resources, priority should be given to introducing double reading in the subset of programmes currently using single reading as this requires fewer additional radiologists and is more cost effective.	Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England; Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England	University of Oxford; Brunel University	Johnston, K (corresponding author), Univ Oxford, Inst Hlth Sci, Hlth Econ Res Ctr, Oxford OX3 7LF, England.							Blanks R G, 1996, J Med Screen, V3, P79; Blanks RG, 1998, J MED SCREEN, V5, P195, DOI 10.1136/jms.5.4.195; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Brown J, 1996, BRIT MED J, V312, P809; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; Forrest APM, 1986, BREAST CANC SCREENIN; JOHNSTON K, 1996, NHS COSTS BREAST SCR; Karlsson G, 1996, PHARMACOECONOMICS, V9, P113, DOI 10.2165/00019053-199609020-00003; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; *NHS, 1995, QUAL NAT HLTH SERV B; WALD NJ, 1995, BRIT MED J, V311, P1189, DOI 10.1136/bmj.311.7014.1189; WARREN RML, 1995, BRIT J RADIOL, V68, P958, DOI 10.1259/0007-1285-68-813-958	12	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1097	1102		10.1136/bmj.319.7217.1097	http://dx.doi.org/10.1136/bmj.319.7217.1097			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531098	Green Published, Bronze			2022-12-24	WOS:000083419500021
J	Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB				Watts, DM; Porter, KR; Putvatana, P; Vasquez, B; Calampa, C; Hayes, CG; Halstead, SB			Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever	LANCET			English	Article							HEMORRHAGIC-FEVER; SHOCK SYNDROME; MOLECULAR EVOLUTION; TYPE-2 VIRUS; RISK-FACTORS; IDENTIFICATION; NUCLEOTIDE; ANTIBODIES; EPIDEMIC; THAILAND	Background Population-based epidemiological studies have shown that infection with dengue type 2 (DEN-2) virus in individuals previously infected with a different serotype of the virus is a major risk factor for dengue haemorrhagic fever and dengue shock syndrome. However, the western hemisphere was spared epidemics of these two syndromes, until the introduction of a southeast Asian DEN-2 genotype. Possibly American DEN-2 genotype strains lacked properties necessary to cause severe disease. We report on a major epidemic of DEN-2 in Peru in 1995, about 5 years after an epidemic of DEN-1 in the same population. Methods In Iquitos, a city of 344 686 inhabitants in Peru, cases of dengue fever were studied prospectively from 1990. Acute phase of illness serum samples from patients were tested for virus in C6/36 cells, and virus isolates were identified by immunofluorescence. Isolates of dengue 2 virus obtained from patients during an outbreak of mild febrile illness in 1995 were sequenced to determine the genotype. Serological analysis of paired samples from the patients was done with an IgM capture ELISA and an indirect IgG ELISA. In addition, serum samples collected annually between 1993 and 1996 from a large cohort of students were tested for dengue IgG antibody by an ELISA. Serum samples from a random sample of 129 students from this cohort were tested for dengue neutralising antibodies to quantify the serotype specific infection rates. Findings Among the 129 students (aged 7-20 years in 1993) who had serum samples available before and after the epidemic, 78 (60.5%) had a secondary DEN-2 virus infection. By extrapolation, 49 266 of the 81 479 children (aged 5-14 years) in Iquitos would have experienced such infections. From previous studies, between 887 and 10 247 cases of dengue haemorrhagic fever and dengue shock syndrome would have been expected. No cases were found. DEN-2 isolates were of the American genotype. Interpretation This prospective study shows that secondary infection by the American DEN-2 genotype did not cause dengue haemorrhagic fever and dengue shock syndrome.	USN, Med Res Ctr Detachment, AMEMB NAMRID, Unit 3800, Bethesda, MD USA; Peruvian Navy, Ctr Med Naval, Bellavista, Callao, Peru; Loreto Reg Minist Hlth, Iquitos, Loreto, Peru; Off Naval Res, Arlington, VA 22217 USA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy	Watts, DM (corresponding author), USN, Med Res Ctr, Detachment AMEMB NAMRID, Unit 3800, APO, AA 34031 USA.	Watts@namrid.sld.pe	Porter, Kevin/A-8027-2011					BURKE DS, 1988, AM J TROP MED HYG, V38, P172, DOI 10.4269/ajtmh.1988.38.172; CHUNGUE E, 1993, J GEN VIROL, V74, P2765, DOI 10.1099/0022-1317-74-12-2765; DEUBEL V, 1988, VIROLOGY, V165, P234, DOI 10.1016/0042-6822(88)90677-0; Duangchanda Sumlee, 1994, Southeast Asian Journal of Tropical Medicine and Public Health, V25, P243; Graham RR, 1999, AM J TROP MED HYG, V61, P412, DOI 10.4269/ajtmh.1999.61.412; GUZMAN MG, 1995, AM J TROP MED HYG, V52, P241, DOI 10.4269/ajtmh.1995.52.241; GUZMAN MG, 1990, AM J TROP MED HYG, V42, P179, DOI 10.4269/ajtmh.1990.42.179; Halstead S.B., 1980, TOGAVIRUSES BIOL STR, p107e173; HALSTEAD SB, 1967, JPN J MED SCI BIOL, VS 20, P96; Halstead Scott B., 1997, P23; Hayes CG, 1996, AM J TROP MED HYG, V55, P459, DOI 10.4269/ajtmh.1996.55.459; HENCHAL EA, 1983, AM J TROP MED HYG, V32, P164, DOI 10.4269/ajtmh.1983.32.164; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411, DOI 10.4269/ajtmh.1988.38.411; KLIKS SC, 1989, AM J TROP MED HYG, V40, P444, DOI 10.4269/ajtmh.1989.40.444; KOURI G, 1988, B PAN AM HLTH ORG, V20, P24; Kyaw-Zin-Thant, 1995, Southeast Asian J Trop Med Public Health, V26, P664; Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999; Mangada MNM, 1998, VIROLOGY, V244, P458, DOI 10.1006/viro.1998.9093; MORENS DM, 1985, J CLIN MICROBIOL, V22, P250, DOI 10.1128/JCM.22.2.250-254.1985; NEFF JM, 1967, AM J EPIDEMIOL, V86, P162, DOI 10.1093/oxfordjournals.aje.a120722; Phillips I, 1992, Bull Pan Am Health Organ, V26, P201; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; Rico-Hesse R, 1998, AM J TROP MED HYG, V58, P96, DOI 10.4269/ajtmh.1998.58.96; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; ROSEN L, 1977, AM J TROP MED HYG, V26, P337, DOI 10.4269/ajtmh.1977.26.337; RUSSELL PK, 1968, AM J TROP MED HYG, V17, P600, DOI 10.4269/ajtmh.1968.17.600; SANGKAWIBHA N, 1984, AM J EPIDEMIOL, V120, P653, DOI 10.1093/oxfordjournals.aje.a113932; SRIVASTAVA VK, 1990, ANN TROP PAEDIATR, V10, P329, DOI 10.1080/02724936.1990.11747453; TESH RB, 1979, AM J TROP MED HYG, V28, P1053, DOI 10.4269/ajtmh.1979.28.1053; Thein S, 1997, AM J TROP MED HYG, V56, P566, DOI 10.4269/ajtmh.1997.56.566; Watts DM, 1998, AM J TROP MED HYG, V58, P35, DOI 10.4269/ajtmh.1998.58.35; 1994, PAHO SCI PUB, V548, P98; 1993, EPIDEMIOL B PAN AM H, V14, P1	34	218	231	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1431	1434		10.1016/S0140-6736(99)04015-5	http://dx.doi.org/10.1016/S0140-6736(99)04015-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543670				2022-12-24	WOS:000083277400013
J	Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW				Calle, EE; Thun, MJ; Petrelli, JM; Rodriguez, C; Heath, CW			Body-mass index and mortality in a prospective cohort of US adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; ISCHEMIC-HEART-DISEASE; RISK-FACTORS; FOLLOW-UP; NATIONAL-HEALTH; RELATIVE WEIGHT; OLDER PERSONS; EVANS COUNTY; 26-YEAR RISK; WHITE WOMEN	Background Body-mass index (the weight in kilograms divided by the square of the height in meters) is known to be associated with overall mortality. We investigated the effects of age, race, sex, smoking status, and history of disease on the relation between body-mass index and mortality. Methods In a prospective study of more than 1 million adults in the United States (457,785 men and 588,369 women), 201,622 deaths occurred during 14 years of follow-up. We examined the relation between body-mass index and the risk of death from all causes in four subgroups categorized according to smoking status and history of disease. In healthy people who had never smoked, we further examined whether the relation varied according to race, cause of death, or age. The relative risk was used to assess the relation between mortality and body-mass index. Results The association between body-mass index and the risk of death was substantially modified by smoking status and the presence of disease. In healthy people who had never smoked, the nadir of the curve for body-mass index and mortality was found at a body-mass index of 23.5 to 24.9 in men and 22.0 to 23.4 in women. Among subjects with the highest body-mass indexes, white men and women had a relative risk of death of 2.58 and 2.00, respectively, as compared with those with a body-mass index of 23.5 to 24.9. Black men and women with the highest body-mass indexes had much lower risks of death (1.35 and 1.21), which did not differ significantly from 1.00. A high body-mass index was most predictive of death from cardiovascular disease, especially in men (relative risk, 2.90; 95 percent confidence interval, 2.37 to 3.56). Heavier men and women in all age groups had an increased risk of death. Conclusions The risk of death from all causes, cardiovascular disease, cancer, or other diseases increases throughout the range of moderate and severe overweight for both men and women in all age groups. The risk associated with a high body-mass index is greater for whites than for blacks. (N Engl J Med 1999;341:1097-105.) (C)1999, Massachusetts Medical Society.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA	American Cancer Society	Calle, EE (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.							Allison DB, 1997, INT J OBESITY, V21, P424, DOI 10.1038/sj.ijo.0800423; BORKAN GA, 1983, J GERONTOL, V38, P673, DOI 10.1093/geronj/38.6.673; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; COX DR, 1972, J R STAT SOC B, V34, P187; *DEP AGR, 1995, HOM GARD B, V232; *DEP AGR, 1990, HOM GARD B, V232; Diehr P, 1998, AM J PUBLIC HEALTH, V88, P623, DOI 10.2105/AJPH.88.4.623; Dunn SE, 1997, CANCER RES, V57, P4667; DurazoArvizu R, 1997, ANN EPIDEMIOL, V7, P383, DOI 10.1016/S1047-2797(97)00044-6; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P1254; FREEDMAN DS, 1995, AM J EPIDEMIOL, V142, P53, DOI 10.1093/oxfordjournals.aje.a117545; GARFINKEL L, 1986, CANCER-AM CANCER SOC, V58, P1826, DOI 10.1002/1097-0142(19861015)58:8+<1826::AID-CNCR2820581407>3.0.CO;2-6; Garfinkel L, 1985, Natl Cancer Inst Monogr, V67, P49; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kuczmarski RJ, 1997, OBES RES, V5, P542, DOI 10.1002/j.1550-8528.1997.tb00575.x; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LINDSTED K, 1991, INT J OBESITY, V15, P397; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; LOSONCZY KG, 1995, AM J EPIDEMIOL, V141, P312, DOI 10.1093/aje/141.4.312; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rothman K, 1986, MODERN EPIDEMIOLOGY; Singh PN, 1998, EPIDEMIOLOGY, V9, P246, DOI 10.1097/00001648-199805000-00007; STEVENS J, 1993, J GERONTOL, V48, pM249, DOI 10.1093/geronj/48.6.M249; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; Stevens J, 1998, OBES RES, V6, P268, DOI 10.1002/j.1550-8528.1998.tb00349.x; STEVENS J, 1992, ARCH INTERN MED, V152, P1257, DOI 10.1001/archinte.152.6.1257; THUN MJ, 1992, JNCI-J NATL CANCER I, V84, P1491, DOI 10.1093/jnci/84.19.1491; Troiano RP, 1996, INT J OBESITY, V20, P63; TYROLER HA, 1984, AM HEART J, V108, P738, DOI 10.1016/0002-8703(84)90667-7; WHO, 1977, MAN INT STAT CLASS D, V1; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; World Health Organization, 1995, TECHNICAL REPORT SER, V854, DOI DOI 10.1002/(sici)1520-6300(1996)8:6<786::aid-ajhb11>3.0.co;2-i	40	2678	2768	3	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1097	1105		10.1056/NEJM199910073411501	http://dx.doi.org/10.1056/NEJM199910073411501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511607				2022-12-24	WOS:000083087200001
J	Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W				Dodt, HU; Eder, M; Frick, A; Zieglgansberger, W			Precisely localized LTD in the neocortex revealed by infrared-guided laser stimulation	SCIENCE			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC ACTIVATION; DENDRITIC SPINES; RAT HIPPOCAMPUS; AMPA RECEPTORS; VISUAL-CORTEX; DEPRESSION; NMDA; PHOTOSTIMULATION; ENHANCEMENT	In a direct approach to elucidate the origin of long-term depression (LTD), glutamate was applied onto dendrites of neurons in rat neocortical slices. An infrared-guided laser stimulation was used to release glutamate from caged glutamate in the focal spot df an ultraviolet laser. A burst of light flashes caused an LTD-like depression of glutamate receptor responses, which was highly confined to the region of "tetanic" stimulation (<10 micrometers). A similar depression of glutamate receptor responses was observed during LTD of synaptic transmission. A spatially highly specific postsynaptic mechanism tan account for the LTD induced by glutamate release.	Max Planck Inst Psychiat, D-80804 Munich, Germany	Max Planck Society	Dodt, HU (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2, D-80804 Munich, Germany.			Eder, Matthias/0000-0002-2579-2628				ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BAUDE A, 1995, NEUROSCIENCE, V69, P1031, DOI 10.1016/0306-4522(95)00350-R; Benke TA, 1998, NATURE, V393, P793, DOI 10.1038/31709; BLISS TVP, 1996, CORTICAL PLASTICITY, P61; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BROCHER S, 1992, P NATL ACAD SCI USA, V89, P123, DOI 10.1073/pnas.89.1.123; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; DAVIES SN, 1989, NATURE, V338, P500, DOI 10.1038/338500a0; Dodt HU, 1998, EUR J NEUROSCI, V10, P3351, DOI 10.1046/j.1460-9568.1998.00338.x; Kandler K, 1998, NAT NEUROSCI, V1, P119, DOI 10.1038/368; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; KUNG G, 1972, Z MIKROSK ANAT FORSC, V3, P396; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; LYNCH GS, 1976, NATURE, V263, P151, DOI 10.1038/263151a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; PETIT DL, 1997, NEURON, V19, P465; Schiller J, 1998, NAT NEUROSCI, V1, P114, DOI 10.1038/363; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; SWARTZWELDER HS, 1989, NEUROPHARMACOLOGY, V28, P441, DOI 10.1016/0028-3908(89)90076-2; TSIEN RW, 1990, COLD SH Q B, V55, P147; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	68	90	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					110	113		10.1126/science.286.5437.110	http://dx.doi.org/10.1126/science.286.5437.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506556				2022-12-24	WOS:000082907400046
J	Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C				Onichtchouk, D; Chen, YG; Dosch, R; Gawantka, V; Dellus, H; Massague, J; Niehrs, C			Silencing of TGF-beta signalling by the pseudoreceptor BAMBI	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; VENTRALIZING FACTOR; XENOPUS-EMBRYOS; RECEPTOR; GENE; ORGANIZER; IDENTIFICATION; TRANSDUCTION; EXPRESSION; ACTIVATION	Members of the transforming growth factor-beta (TGF-beta) superfamily, including TGF-beta, bone morphogenetic proteins (BMPs), activins and nodals, are vital for regulating growth and differentiation(1). These growth factors transduce their signals through pairs of transmembrane type I and type II receptor kinases(2-4). Here, we have cloned a transmembrane protein, BAMBI, which is related to TGP-beta-family type I receptors but lacks an intracellular kinase domain. We show that BAMBI is co-expressed with the ventralizing morphogen BMP4 (refs 5, 6) during Xenopus embryogenesis and that it requires BMP signalling for its expression. The protein stably associates with TGF-beta-family receptors and inhibits BMP and activin as well as TGF-beta signalling. Finally, we provide evidence that BAMBI's inhibitory effects are mediated by its intracellular domain, which resembles the homodimerization interface of a type I receptor and prevents the formation of receptor complexes. The results indicate that BAMBI negatively regulates TGF-beta-family signalling by a regulatory mechanism involving the interaction of signalling receptors with a pseudoreceptor.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumor Virol, D-69120 Heidelberg, Germany; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Onichtchouk, Daria/E-1741-2012; Dosch, Roland/H-9633-2019	Onichtchouk, Daria/0000-0001-6497-1445; Dosch, Roland/0000-0001-9247-8586; Massague, Joan/0000-0001-9324-8408				CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Candia AF, 1997, DEVELOPMENT, V124, P4467; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen YG, 1999, J BIOL CHEM, V274, P3672, DOI 10.1074/jbc.274.6.3672; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; DALE L, 1992, DEVELOPMENT, V115, P573; Degen WGJ, 1996, INT J CANCER, V65, P460, DOI 10.1002/(SICI)1097-0215(19960208)65:4<460::AID-IJC12>3.3.CO;2-B; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Howell M, 1997, EMBO J, V16, P7411, DOI 10.1093/emboj/16.24.7411; HUANG HC, 1995, EMBO J, V14, P5965, DOI 10.1002/j.1460-2075.1995.tb00285.x; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JONES CM, 1992, DEVELOPMENT, V115, P639; KAUFMANN E, 1996, EMBO J, V15, P6379; Luo KX, 1996, EMBO J, V15, P4485, DOI 10.1002/j.1460-2075.1996.tb00826.x; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; WeisGarcia F, 1996, EMBO J, V15, P276, DOI 10.1002/j.1460-2075.1996.tb00358.x; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	30	548	585	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					480	485		10.1038/46794	http://dx.doi.org/10.1038/46794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519551				2022-12-24	WOS:000082981200057
J	van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N				van Wilpe, S; Ryan, MT; Hill, K; Maarse, AC; Meisinger, C; Brix, J; Dekker, PJT; Moczko, M; Wagner, R; Meijer, M; Guiard, B; Honlinger, A; Pfanner, N			Tom22 is a multifunctional organizer of the mitochondrial preprotein translocase	NATURE			English	Article							OUTER-MEMBRANE PROTEIN; GENERAL IMPORT PORE; RECEPTOR COMPLEX; YEAST MITOCHONDRIA; NEUROSPORA-CRASSA; CELL VIABILITY; CHANNEL; COMPONENT; DOMAINS; MOM22	Mitochondrial preproteins are imported by a multisubunit translocase of the outer membrane (TOM), including receptor proteins and a general import pore(1-5). The central receptor Tom22 binds preproteins through both its cytosolic domain and its intermembrane space domain(6-10) and is stably associated with the channel protein Tom40 (refs 11-13). Here we report the unexpected observation that a yeast strain can survive without Tom22, although it is strongly reduced in growth and the import of mitochondrial proteins. Tom22 is a multifunctional protein that is required for the higher-level organization of the TOM machinery. In the absence of Tom22, the translocase dissociates into core complexes, representing the basic import units, but lacks a tight control of channel gating. The single membrane anchor of Tom22 is required for a stable interaction between the core complexes, whereas its cytosolic domain, serves as docking point for the peripheral receptors Tom20 and Tom70. Thus a preprotein translocase can combine receptor functions with distinct organizing roles in a multidomain protein.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Biocentrum Amsterdam, Inst Mol Cell Biol, NL-1098 SM Amsterdam, Netherlands; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Paris 06, Ctr Genet Mol, CNRS, F-91190 Gif Sur Yvette, France	University of Freiburg; University of Amsterdam; University Osnabruck; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.		Ryan, Michael/X-2152-2019; Ryan, Michael T/C-6673-2011; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Ryan, Michael/0000-0003-2586-8829; Ryan, Michael T/0000-0003-2586-8829; Meisinger, Chris/0000-0002-8326-3548; Dekker, Peter/0000-0002-8197-8822				ALCONADA A, 1995, MOL CELL BIOL, V15, P6196; Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Guthrie C, 1991, METHOD ENZYMOL, P194; Haucke V, 1996, EMBO J, V15, P1231, DOI 10.1002/j.1460-2075.1996.tb00464.x; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Honlinger A, 1996, EMBO J, V15, P2125, DOI 10.1002/j.1460-2075.1996.tb00566.x; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; MAYER A, 1995, EMBO J, V14, P4205; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0	26	231	236	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					485	489		10.1038/46802	http://dx.doi.org/10.1038/46802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519552				2022-12-24	WOS:000082981200058
J	Balen, A				Balen, A			Pathogenesis of polycystic ovary syndrome - the enigma unravels?	LANCET			English	Editorial Material							INSULIN-RESISTANCE; PREGNANCY; MECHANISM		Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England	Leeds General Infirmary	Balen, A (corresponding author), Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England.							BALEN AH, 1993, BRIT J OBSTET GYNAEC, V100, P1082, DOI 10.1111/j.1471-0528.1993.tb15170.x; Balen AH, 1995, HUM REPROD, V10, P2705; CLARK AM, 1995, HUM REPROD, V10, P2705, DOI 10.1093/oxfordjournals.humrep.a135772; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Franks S, 1997, HUM REPROD, V12, P2641, DOI 10.1093/humrep/12.12.2641; Homburg R, 1996, HUM REPROD, V11, P29; Jacobs HS, 1999, HUM REPROD UPDATE, V5, P166, DOI 10.1093/humupd/5.2.166; Lockwood GM, 1998, J CLIN ENDOCR METAB, V83, P1730, DOI 10.1210/jc.83.5.1730; MICHELMORE KF, IN PRESS CLIN ENDOCR; Nestler JE, 1999, NEW ENGL J MED, V340, P1314, DOI 10.1056/NEJM199904293401703; Ong KKL, 1999, NAT GENET, V21, P262, DOI 10.1038/6775; POLSON DW, 1988, LANCET, V1, P870; Tapanainen JS, 1999, J CLIN ENDOCR METAB, V84, P1711, DOI 10.1210/jc.84.5.1711; VELAZQUEZ EM, 1994, METABOLISM, V43, P647, DOI 10.1016/0026-0495(94)90209-7; Waterworth DM, 1997, LANCET, V349, P986, DOI 10.1016/S0140-6736(96)08368-7	15	77	78	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					966	967		10.1016/S0140-6736(99)00218-4	http://dx.doi.org/10.1016/S0140-6736(99)00218-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501353				2022-12-24	WOS:000082596000004
J	Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM				Levashina, EA; Langley, E; Green, C; Gubb, D; Ashburner, M; Hoffmann, JA; Reichhart, JM			Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila	SCIENCE			English	Article							DORSAL-VENTRAL PATTERN; SIGNALING PATHWAY; GENE; PROTEIN; PEPTIDE; METCHNIKOWIN; EXPRESSION; POLARITY; EMBRYO	The antifungal defense of Drosophila is controlled by the spaetzle/Toll/cactus gene cassette, Here, a Loss-of-function mutation in the gene encoding a blood serine protease inhibitor, Spn43Ac, was shown to Lead to constitutive expression of the antifungal peptide drosomycin, and this effect was mediated by the spaetzle and Toll gene products. Spaetzle was cleaved by proteolytic enzymes to its active Ligand form shortly after immune challenge, and cleaved Spaetzle was constitutively present in Spn4Ac-deficient flies. Hence, Spn43Ac negatively regulates the Toll signaling pathway, and Toll does not function as a pattern recognition receptor in the Drosophila host defense.	Inst Biol Mol & Cellulaire, CNRS, UPR 9022, F-67084 Strasbourg, France; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Cambridge	Reichhart, JM (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9022, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	reichhart@ibmc.u-strasbg.fr	Gubb, David/F-9793-2011	Levashina, Elena/0000-0003-4605-906X				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Boswell D. R., 1986, REC ADV CLIN IMMUNOL, V4, P1; BRAND AH, 1993, DEVELOPMENT, V118, P401; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Gerard C, 1998, NATURE, V395, P217, DOI 10.1038/26104; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giebel B, 1997, MECH DEVELOP, V63, P75, DOI 10.1016/S0925-4773(97)00029-4; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEITZLER P, 1993, GENETICS, V135, P105; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Iwanaga S, 1998, J BIOCHEM, V123, P1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239	23	358	374	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1917	1919		10.1126/science.285.5435.1917	http://dx.doi.org/10.1126/science.285.5435.1917			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489372				2022-12-24	WOS:000082638300052
J	Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV				Komarov, PG; Komarova, EA; Kondratov, RV; Christov-Tselkov, K; Coon, JS; Chernov, MV; Gudkov, AV			A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy	SCIENCE			English	Article							HEMATOPOIETIC GROWTH-FACTORS; TUMOR-SUPPRESSOR GENE; IN-VIVO; P53-DEFICIENT MICE; APOPTOSIS; RADIATION; TUMORIGENESIS; IRRADIATION; ACTIVATION; RESISTANCE	Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy. Because these effects are in part determined by p53-mediated apoptosis, temporary suppression of p53 has been suggested as a therapeutic strategy to prevent damage of normal tissues during treatment of p53-deficient tumors. To test this possibility, a small molecule was isolated for its ability to reversibly block p53-dependent transcriptional activation and apoptosis. This compound, pifithrin-alpha, protected mice from the Lethal genotoxic stress associated with anticancer treatment without promoting the formation of tumors. Thus, inhibitors of p53 may be useful dregs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Cleveland Clin Fdn, Res Inst, Cleveland, OH 44195 USA; Quark Biotech, Pleasanton, CA 94566 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cleveland Clinic Foundation	Komarov, PG (corresponding author), Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Kondratov, Roman/0000-0003-3449-745X	NCI NIH HHS [CA60730, CA75179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRONCHUD M, 1993, ANTI-CANCER DRUG, V4, P127, DOI 10.1097/00001813-199304000-00002; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Deichman GI, 1998, INT J CANCER, V75, P277, DOI 10.1002/(SICI)1097-0215(19980119)75:2<277::AID-IJC17>3.0.CO;2-A; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hasegawa M, 1998, RADIAT RES, V149, P263, DOI 10.2307/3579959; Hendry JH, 1996, INT J RADIAT BIOL, V70, P677, DOI 10.1080/095530096144563; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Johnston EM, 1998, SEMIN ONCOL, V25, P552; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KOMAROVA EA, UNPUB; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; Steele RJC, 1998, BRIT J SURG, V85, P1460; Tron VA, 1998, AM J PATHOL, V153, P579, DOI 10.1016/S0002-9440(10)65600-3; Westphal CH, 1998, CANCER RES, V58, P5637; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	31	1074	1135	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1733	1737		10.1126/science.285.5434.1733	http://dx.doi.org/10.1126/science.285.5434.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481009				2022-12-24	WOS:000082472600035
J	De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G				De Stefano, V; Martinelli, I; Mannucci, PM; Paciaroni, K; Chiusolo, P; Casorelli, I; Rossi, E; Leone, G			The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACTIVATED PROTEIN-C; INHERITED THROMBOPHILIA; 20210A ALLELE; GLN MUTATION; GENE; THROMBOEMBOLISM; RESISTANCE; PREVALENCE; ARG-506; VARIANT	Background Point mutations in the factor V gene (factor V Leiden) and the prothrombin gene (the substitution of A for G at position 20210) are the most common causes of inherited thrombophilia. Whether or not factor V Leiden increases the risk of recurrent deep venous thrombosis is controversial, and there is no information on the risk of recurrence among carriers of both mutations. Methods We studied a retrospective cohort of 624 patients who were referred for a first episode of deep venous thrombosis. After excluding 212 patients with other inherited or acquired causes of thrombophilia, we compared 112 patients who were heterozygous carriers of factor V Leiden with 17 patients who were heterozygous for both factor V Leiden and the prothrombin mutation and 283 patients who had neither mutation. The relative risk of recurrent deep venous thrombosis was calculated with use of a proportional-hazards model. Results Patients who were heterozygous for factor V Leiden alone had a risk of recurrent deep venous thrombosis that was similar to that among patients who had neither mutation (relative risk, 1.1; 95 percent confidence interval, 0.7 to 1.6; P = 0.76). In contrast, patients who were heterozygous for both factor V Leiden and the prothrombin mutation had a higher risk of recurrent thrombosis than did carriers of factor V Leiden alone (relative risk, 2.6; 95 percent confidence interval, 1.3 to 5.1; P = 0.002). When the analysis was restricted to patients with spontaneous recurrences (i.e., ones that occurred in the absence of transient risk factors for venous thrombosis), the risk among carriers of both mutations, as compared with carriers of factor V Leiden alone, remained high (relative risk, 3.7; 95 percent confidence interval, 1.7 to 7.7; P<0.001), particularly if the first event had also been spontaneous (relative risk, 5.4; 95 percent confidence interval, 2.0 to 14.1; P<0.001). In contrast, the risk of recurrence in the presence of transient risk factors was similar among carriers of both mutations and carriers of factor V Leiden alone. Conclusions The risk of recurrent deep venous thrombosis is similar among carriers of factor V Leiden and patients without this mutation. Carriers of both factor V Leiden and the G20210A prothrombin mutation have an increased risk of recurrent deep venous thrombosis after a first episode and are candidates for lifelong anticoagulation. (N Engl J Med 1999;341:801-6.) (C)1999, Massachusetts Medical Society.	Univ Cattolica, Ist Semeiot Med, Dept Hematol, I-00168 Rome, Italy; Univ Milan, Osped Maggiore, Ist Ricovero & Cura Carattere Sci, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	De Stefano, V (corresponding author), Univ Cattolica, Ist Semeiot Med, Dept Hematol, Largo Gemelli 8, I-00168 Rome, Italy.		De Stefano, Valerio/J-3650-2018; Giuseppe Leone, Full Professor/I-9166-2019; Martinelli, ida/J-2287-2015; CHIUSOLO, PATRIZIA/J-3003-2018	De Stefano, Valerio/0000-0002-5178-5827; Giuseppe Leone, Full Professor/0000-0002-7812-5300; Martinelli, ida/0000-0001-9218-3622; CHIUSOLO, PATRIZIA/0000-0002-1355-1587				[Anonymous], 1998, BR J HAEMATOL, V101, P374; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; De Stefano V, 1998, SEMIN THROMB HEMOST, V24, P367, DOI 10.1055/s-2007-996025; De Stefano V, 1998, THROMB HAEMOSTASIS, V80, P342; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; Ehrenforth S, 1998, BLOOD, V91, P2209, DOI 10.1182/blood.V91.6.2209; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P824; Lane DA, 1997, THROMB HAEMOSTASIS, V77, P1047; Leroyer C, 1998, THROMB HAEMOSTASIS, V80, P49; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Makris M, 1997, THROMB HAEMOSTASIS, V78, P1426; Margaglione M, 1998, ANN INTERN MED, V129, P89, DOI 10.7326/0003-4819-129-2-199807150-00003; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; Ridker PM, 1997, CIRCULATION, V95, P1777; Rintelen C, 1996, THROMB HAEMOSTASIS, V75, P229; Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; Zoller B, 1998, BLOOD, V91, P2210, DOI 10.1182/blood.V91.6.2210	28	327	341	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1999	341	11					801	806		10.1056/NEJM199909093411104	http://dx.doi.org/10.1056/NEJM199909093411104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	235GM	10477778				2022-12-24	WOS:000082534000004
J	Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP				Finnin, MS; Donigian, JR; Cohen, A; Richon, VM; Rifkind, RA; Marks, PA; Breslow, R; Pavletich, NP			Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors	NATURE			English	Article							TRANSFORMED-CELL DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; PROTEINS; INDUCERS	Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression(1). HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers(2,3). HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell. growth(4-6), induce terminal differentiation(4,5) and prevent the formation of tumours in mice models(7,8), and they are effective in the treatment of promyelocytic leukemia(3). Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolieus, that shares 35.2% identity with human HDACl over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Columbia Univ, Dept Chem, New York, NY 10027 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Columbia University	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.	nikola@xray2.mskcc.org		Finnin, Michael/0000-0003-2794-2703				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003; Cohen L. A., 1998, Proceedings of the American Association for Cancer Research Annual Meeting, V39, P108; Davie JR, 1998, J CELL BIOCHEM, P203; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DESAI D, 1999, P AM ASSOC CANC RES, V40, P2396; Fenrick R, 1998, J CELL BIOCHEM, P194; FERSHT AR, 1973, J MOL BIOL, V74, P137, DOI 10.1016/0022-2836(73)90103-4; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GRAMS F, 1995, BIOCHEMISTRY-US, V34, P14012, DOI 10.1021/bi00043a007; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HOLMES MA, 1981, BIOCHEMISTRY-US, V20, P6912, DOI 10.1021/bi00527a026; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leipe DD, 1997, NUCLEIC ACIDS RES, V25, P3693, DOI 10.1093/nar/25.18.3693; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; SHUTE RE, 1987, J MED CHEM, V30, P71, DOI 10.1021/jm00384a013; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; YOSHIDA T, 1993, CHEM EXPRESS, V8, P17	30	1420	1580	3	215	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					188	193		10.1038/43710	http://dx.doi.org/10.1038/43710			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490031				2022-12-24	WOS:000082458800060
J	Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR				Tokars, JI; Cookson, ST; McArthur, MA; Boyer, CL; McGeer, AJ; Jarvis, WR			Prospective evaluation of risk factors for bloodstream infection in patients receiving home infusion therapy	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-STREAM INFECTIONS; INSERTED CENTRAL CATHETERS; NOSOCOMIAL INFECTIONS; ACCESS DEVICES; VENOUS ACCESS; RECIPIENTS; POPULATION; PREVENTION; SYSTEM; CANCER	Background: Intravenous therapy in the outpatient and home settings is commonplace for many diseases and nutritional disorders. Few data are available on the rate of and risk factors for bloodstream infection among patients receiving such therapy. Objective: To determine rates of and risk factors for bloodstream infection among patients receiving home infusion therapy. Design: Prospective, observational cohort study. Setting: Cleveland, Ohio, and Toronto, Ontario, Canada. Patients: Patients receiving home infusion therapy through a central or midline catheter. Measurements: Primary laboratory-confirmed bloodstream infection. Results: Among 827 patients (988 catheters), the most common diagnoses were infections other than HIV (67%), cancer (24%), nutritional and digestive disease (17%), heart disease (14%), receipt of bone marrow or solid organ transplants (11%), and HIV infection (7%). Sixty-nine bloodstream infections occurred during 69 532 catheter-days (0.99 infections per 1000 days). In a Cox regression model with time-dependent covariates, independent risk factors for bloodstream infection were recent receipt of a bone marrow transplant (hazard ratio, 5.8 [95% CI, 3.0 to 11.3]), receipt of total parenteral nutrition (hazard ratio, 4.1 [CI, 2.3 to 7.2]), receipt of therapy outside the home (for example, in an outpatient clinic or physician's office) (hazard ratio, 3.6 [CI, 2.2 to 5.9]), use of a multilumen catheter (hazard ratio, 2.8 [CI, 1.7 to 4.7]), and previous bloodstream infection (hazard ratio, 2.5 [CI, 1.5 to 4.2]). Rates of bloodstream infection per 1000 catheter-days varied from 0.16 for patients with none of these 5 risk factors to 6.77 for patients with 3 or more risk factors. Centrally inserted venous catheters were associated with a higher risk than implanted ports were, but the difference was not statistically significant. Conclusion: Bloodstream infections seem to be infrequent among outpatients receiving infusions through central and midline catheters. However, the rate of infection increases with bone marrow transplantation, parenteral nutrition, infusion therapy in a hospital clinic or physician's office, and use of multilumen catheters. Compared with implanted ports or peripherally inserted catheters, centrally inserted venous catheters may confer greater risk for bloodstream infection.	Ctr Dis Control & Prevent, Hosp Infect Program, Atlanta, GA 30333 USA; Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Centers for Disease Control & Prevention - USA; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Cleveland Clinic Foundation	Tokars, JI (corresponding author), Ctr Dis Control & Prevent, Hosp Infect Program, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA.		mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				CAMPION E, 1998, NEW ENGL J MED, V333, P1213; Cookson ST, 1998, INFECT CONT HOSP EP, V19, P23; DANZIG LE, 1995, JAMA-J AM MED ASSOC, V273, P1862, DOI 10.1001/jama.273.23.1862; Do AN, 1999, J INFECT DIS, V179, P442, DOI 10.1086/314592; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; Engelhard D, 1996, TRANSPLANTATION, V61, P430, DOI 10.1097/00007890-199602150-00020; FARKAS JC, 1992, AM J MED, V93, P277, DOI 10.1016/0002-9343(92)90233-2; GROEGER JS, 1993, ANN INTERN MED, V119, P1168, DOI 10.7326/0003-4819-119-12-199312150-00003; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; HOWELL PB, 1995, CANCER, V75, P1367, DOI 10.1002/1097-0142(19950315)75:6<1367::AID-CNCR2820750620>3.0.CO;2-Z; Jarvis WR, 1997, AM J INFECT CONTROL, V25, P477; Kellerman S, 1996, J PEDIATR-US, V129, P711, DOI 10.1016/S0022-3476(96)70154-3; LAM S, 1994, ARCH INTERN MED, V154, P1833, DOI 10.1001/archinte.154.16.1833; McDonald LC, 1998, INFECT CONT HOSP EP, V19, P772; Ng PK, 1997, MAYO CLIN PROC, V72, P225, DOI 10.4065/72.3.225; PARKER JW, 1995, J BONE JOINT SURG AM, V77A, P572, DOI 10.2106/00004623-199504000-00010; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pittet D, 1997, CLIN INFECT DIS, V24, P1068, DOI 10.1086/513640; RAAD I, 1993, ARCH INTERN MED, V153, P1791, DOI 10.1001/archinte.153.15.1791; RAVIGLIONE MC, 1989, AM J MED, V86, P780, DOI 10.1016/0002-9343(89)90473-7; *SAS I INC, 1992, P229 SAS I INC STAT, P434; Serody JS, 1997, INFECT DIS CLIN N AM, V11, P459, DOI 10.1016/S0891-5520(05)70365-2; Stroud L, 1997, INFECT CONT HOSP EP, V18, P479; VLADECK BC, 1994, JAMA-J AM MED ASSOC, V271, P1566	24	107	110	3	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					340	+		10.7326/0003-4819-131-5-199909070-00004	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475886				2022-12-24	WOS:000082458500003
J	Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E				Dominici, P; Bellentani, S; Di Biase, AR; Saccoccio, G; Le Rose, A; Masutti, F; Viola, L; Balli, F; Tiribelli, C; Grilli, R; Fusillo, M; Grossi, E			Familial clustering of Helicobacter pylori infection: population based study	BRITISH MEDICAL JOURNAL			English	Article							UPPER GASTROINTESTINAL SYMPTOMS; CAMPYLOBACTER-PYLORI; DUODENAL-ULCER; HEALTHY-INDIVIDUALS; IMMUNE-RESPONSE; CHILDREN; GASTRITIS; PREVALENCE; CHILDHOOD; IDENTIFICATION	Objectives To assess the rate of intrafamilial transmission of Helicobacter pylori infection in the general population and the role of a family's social background. Design Population survey. Setting Campogalliano, a town in northern Italy with about 5000 residents. Participants 3289 residents, accounting for 416 families. Main outcome measures Prevalence of H pylori infection assessed by presence of IgG antibodies to H pylori. Results The overall prevalence of H pylori infection was 58%. Children belonging to families with both parents infected had a significantly higher prevalence of H pylori infection (44%) than children from families with only one (30%) or no parents (21%) infected (P < 0.001). Multivariate analyses confirmed that children with both parents positive had double the risk of being infected by H pylori than those from families in which both parents were negative. Family social status was independently related to infection in children, with those from blue collar or farming families showing an increased risk of infection compared with children of white collars workers (odds ratio 2.02, 95% confidence interval 1.16 to 3.49). Conclusions H pylori infection clusters within families belonging to the same population. Social status may also be a risk factor. This suggests either a person to person transmission or a common source of exposure for H pylori infection.	Bracco SpA, Dept Med, I-20134 Milan, Italy; Fondo Studio Malattie Fegato ONLUS, I-34121 Trieste, Italy; Univ Modena & Reggio Emilia, Dept Gynaecol Obstet & Paediat Sci, I-41100 Modena, Italy	Bracco; Universita di Modena e Reggio Emilia	Bellentani, S (corresponding author), Fondo Studi Fegato, Sez Modena, I-41100 Ferrara, Italy.		Grossi, Enzo/AAF-7765-2020; Grilli, Roberto/K-1444-2016; Bellentani, Stefano/L-3600-2019; Grilli, Roberto/AAN-9249-2021; Tiribelli, Claudio/A-4716-2014	Grilli, Roberto/0000-0001-9425-7170; Grilli, Roberto/0000-0001-9425-7170; Tiribelli, Claudio/0000-0001-6596-7595; Bellentani, Stefano/0000-0003-2836-8870				ALFONSO V, 1995, REV ESP ENFERM DIG, V87, P109; ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; BEST LM, 1994, J CLIN MICROBIOL, V32, P1193, DOI 10.1128/JCM.32.5.1193-1196.1994; Bonamico M, 1996, ITAL J GASTROENTEROL, V28, P512; CARRICK J, 1989, GUT, V30, P790, DOI 10.1136/gut.30.6.790; CONTINIBALI S, 1988, RIV ITAL PED S1, V14, P87; DASKALOPOULOS G, 1987, GASTROENTEROLOGY, V92, P1363; DEGIACOMA C, 1991, J PEDIATR-US, V119, P205, DOI 10.1016/S0022-3476(05)80728-0; DEGIACOMO C, 1995, ACTA GASTROENTEROL S, P87; DOOLEY CP, 1993, GASTROENTEROL CLIN N, V22, P1; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1526; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIEDOREK SC, 1991, PEDIATRICS, V88, P578; FOX JG, 1989, AM J GASTROENTEROL, V84, P775; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GRAHAM DY, 1991, DIGEST DIS SCI, V36, P1084, DOI 10.1007/BF01297451; HOSMER DW, 1983, APPL LOGISTIC REGRES; JOHNSTON BJ, 1986, GUT, V27, P11532; JONES DM, 1987, BRIT MED J, V294, P615, DOI 10.1136/bmj.294.6572.615-a; KATELARIS PH, 1991, ITALIAN J GASTROE S2, V23, P12; LANGENBERG ML, 1984, LANCET, V1, P1348; LIN SK, 1991, ITAL J GASTROENTE S2, V23, P10; MALATY HM, 1991, SCAND J GASTROENTERO, V26, P927, DOI 10.3109/00365529108996244; MALATY HM, 1992, GASTROENTEROLOGY, V103, P813, DOI 10.1016/0016-5085(92)90011-M; MALATY HM, 1994, GUT, V35, P742, DOI 10.1136/gut.35.6.742; MAPSTONE NP, 1993, J CLIN PATHOL, V46, P540, DOI 10.1136/jcp.46.6.540; Mendall M A, 1997, Semin Gastrointest Dis, V8, P113; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MITCHELL HM, 1992, J INFECT DIS, V166, P149, DOI 10.1093/infdis/166.1.149; MITCHELL HM, 1987, LANCET, V2, P681; MITCHELL JD, 1992, AM J GASTROENTEROL, V87, P382; NWOKOLO CU, 1992, GUT, V33, P1323, DOI 10.1136/gut.33.10.1323; ODERDA G, 1991, DIGEST DIS SCI, V36, P572, DOI 10.1007/BF01297021; Palli D, 1997, ALIMENT PHARM THERAP, V11, P719, DOI 10.1046/j.1365-2036.1997.00215.x; TALLEY NJ, 1991, J CLIN MICROBIOL, V29, P1635, DOI 10.1128/JCM.29.8.1635-1639.1991; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1	38	79	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1999	319	7209					537	540		10.1136/bmj.319.7209.537	http://dx.doi.org/10.1136/bmj.319.7209.537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232CB	10463891	Green Published, Bronze			2022-12-24	WOS:000082347200017
J	Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L				Ursini, F; Heim, S; Kiess, M; Maiorino, M; Roveri, A; Wissing, J; Flohe, L			Dual function of the selenoprotein PHGPx during sperm maturation	SCIENCE			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; RAT SPERM; MITOCHONDRIAL CAPSULES; SELENIUM DEFICIENCY; PROTEIN; EXPRESSION; SELENOCYSTEINE; ENZYME; CELLS; CDNA	The selenoprotein phospholipid hydroperoxide glutathione peroxidase (PHGPx) changes its physical characteristics and biological functions during sperm maturation. PHGPx exists as a Soluble peroxidase in spermatids but persists in mature spermatozoa as an enzymatically inactive, oxidatively cross-linked, insoluble protein. in the midpiece of mature spermatozoa, PHGPx protein represents at least 50 percent of the capsule material that embeds the helix of mitochondria. The role of PHGPx as a structural protein may explain the mechanical instability of the mitochondrial midpiece that is observed in selenium deficiency.	Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Natl Res Ctr Biotechnol, D-38124 Braunschweig, Germany	Braunschweig University of Technology; University of Padua	Flohe, L (corresponding author), Tech Univ Braunschweig, Dept Biochem, Mascheroder Weg 1, D-38124 Braunschweig, Germany.		Roveri, Antonella/AAF-3669-2019	Roveri, Antonella/0000-0002-3252-0559				Adham IM, 1996, DNA CELL BIOL, V15, P159, DOI 10.1089/dna.1996.15.159; ANDREESE.JR, 1973, J BACTERIOL, V116, P867, DOI 10.1128/JB.116.2.867-873.1973; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; BAUCHE F, 1994, FEBS LETT, V349, P392, DOI 10.1016/0014-5793(94)00709-8; Behne D, 1996, J REPROD FERTIL, V106, P291, DOI 10.1530/jrf.0.1060291; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BROWN DG, 1973, J NUTR, V103, P102, DOI 10.1093/jn/103.1.102; CALVIN HI, 1981, GAMETE RES, V4, P139, DOI 10.1002/mrd.1120040208; Cataldo L, 1996, MOL REPROD DEV, V45, P320, DOI 10.1002/(SICI)1098-2795(199611)45:3&lt;320::AID-MRD9&gt;3.0.CO;2-U; Fisher HM, 1997, J EXP ZOOL, V277, P390, DOI 10.1002/(SICI)1097-010X(19970401)277:5&lt;390::AID-JEZ5&gt;3.0.CO;2-K; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; Flohe Leopold, 1997, P415; Giannattasio A, 1997, J ENDOCRINOL INVEST, V20, P439, DOI 10.1007/BF03347999; Gobom J, 1997, INT J MASS SPECTROM, V169, P153, DOI 10.1016/S0168-1176(97)00216-4; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MEISTRICH ML, 1981, BIOL REPROD, V25, P1065, DOI 10.1095/biolreprod25.5.1065; Nam Sang-Yoon, 1997, Journal of Reproduction and Development, V43, P227, DOI 10.1262/jrd.43.227; National Research Council (US) Subcommittee on Selenium: 7, 1983, SELENIUM NUTR REVISE; PALLINI V, 1979, J SUBMICR CYTOL PATH, V11, P165; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; ROVERI A, 1992, J BIOL CHEM, V267, P6142; Sandstrom PA, 1998, FREE RADICAL BIO MED, V24, P1485, DOI 10.1016/S0891-5849(98)00023-9; SCHUCKELT R, 1991, FREE RADICAL RES COM, V14, P343, DOI 10.3109/10715769109093424; SELIGMAN J, 1992, BIOL REPROD, V46, P301, DOI 10.1095/biolreprod46.2.301; SHALGI R, 1989, BIOL REPROD, V40, P1037, DOI 10.1095/biolreprod40.5.1037; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; TURNER DC, 1973, ARCH BIOCHEM BIOPHYS, V154, P366, DOI 10.1016/0003-9861(73)90069-6; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Wallace E, 1987, SELENIUM BIOL MED A, P181; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; WU ASH, 1979, BIOL REPROD, V20, P793, DOI 10.1095/biolreprod20.4.793	39	636	680	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1393	1396		10.1126/science.285.5432.1393	http://dx.doi.org/10.1126/science.285.5432.1393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464096				2022-12-24	WOS:000082233500040
J	Bengtsson, BA				Bengtsson, BA			Rethink about growth-hormone therapy for critically ill patients	LANCET			English	Editorial Material							PROLONGED CRITICAL ILLNESS; ADULTS; GH		Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Bengtsson, BA (corresponding author), Sahlgrenska Univ Hosp, Res Ctr Endocrinol & Metab, SE-41345 Gothenburg, Sweden.							BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Johannsson G, 1997, CLIN ENDOCRINOL, V47, P571, DOI 10.1046/j.1365-2265.1997.3271123.x; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; Van den Berghe G, 1999, J CLIN ENDOCR METAB, V84, P1311, DOI 10.1210/jc.84.4.1311; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P309, DOI 10.1210/jc.83.2.309	7	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1403	1404		10.1016/S0140-6736(99)00330-X	http://dx.doi.org/10.1016/S0140-6736(99)00330-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543662				2022-12-24	WOS:000083277400005
J	Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP				Hawker, JI; Bakhshi, SS; Ali, S; Farrington, CP			Ecological analysis of ethnic differences in relation between tuberculosis and poverty	BRITISH MEDICAL JOURNAL			English	Article							SOCIOECONOMIC DEPRIVATION; IMMIGRATION; ENGLAND	Objective To examine the effect of ethnicity on the relation between tuberculosis and deprivation. Design Retrospective ecological study comparing incidence of tuberculosis in white and south Asian residents of the 39 electoral wards in Birmingham with ethnic specific indices of deprivation. Setting Birmingham, 1989-93. Subjects 1516 notified cases of tuberculosis. Main outcome measures Rates of tuberculosis and measures of deprivation. Results Univariate analysis showed significant associations of tuberculosis rates for the whole population with several indices of deprivation (P < 0.01) and with the proportion of the population of south Asian origin (P < 0.01). All deprivation covariates were positively associated with each other but on multiple regression, higher level of overcrowding was independently associated with tuberculosis rates. For the white population, overcrowding was associated with tuberculosis rates independently of ether variables (P = 0.0036). No relation with deprivation was found for the south Asian population in either single or multivariable analyses. Conclusions Poverty is significantly associated with tuberculosis in the white population, but no such relation exists far those of Asian ethnicity. These findings suggest that causal factors, and therefore potential interventions, will also differ by ethnic group.	Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Birmingham B9 5SS, W Midlands, England; Birmingham Hlth Author, Birmingham B16 9RG, W Midlands, England; Open Univ, Dept Stat, Milton Keynes MK7 6AA, Bucks, England	Heart of England NHS Foundation Trust; University of Birmingham; Open University - UK	Hawker, JI (corresponding author), Birmingham Heartlands Hosp, Publ Hlth Lab Serv, Communicable Dis Surveillance Ctr W Midlands, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.			Farrington, Conor Patrick/0000-0002-7148-2612				Bakhshi S S, 1997, Ethn Health, V2, P147; BAKHSHI SS, 1995, J PUBLIC HEALTH MED, V17, P343; BHATTI N, 1995, BRIT MED J, V310, P967, DOI 10.1136/bmj.310.6985.967; Borgdorff MW, 1998, AM J EPIDEMIOL, V147, P187; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; *BRIT TUB ASS, 1966, TUBERCLE, V47, P145; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DOHERTY MJ, 1995, BRIT MED J, V311, P187, DOI 10.1136/bmj.311.6998.187b; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; KEARNEY MT, 1993, BRIT MED J, V307, P1143, DOI 10.1136/bmj.307.6912.1143; MANGTANI P, 1995, BRIT MED J, V310, P963, DOI 10.1136/bmj.310.6985.963; MCCARTHY OR, 1984, BRIT J DIS CHEST, V78, P248, DOI 10.1016/S0007-0971(84)80118-7; MEREDITH SK, 1992, THORAX, V47, P770; Ormerod P, 1996, BRIT J HOSP MED, V56, P209; PACKE GE, 1988, ARCH DIS CHILD, V63, P277, DOI 10.1136/adc.63.3.277; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; Springett V H, 1991, CDR (Lond Engl Rev), V1, pR149; *STAT SCI, 1997, S PLUS WIND US MAN V; Tocque K, 1998, INT J TUBERC LUNG D, V2, P213; Townsend PP., 1988, HLTH DEPRIVATION INE; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; WEBER HW, 1899, TUBERCULOSIS, V1, P101; *WHO, 1995, STOP TB SOURC REP TU	23	52	56	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1031	1034		10.1136/bmj.319.7216.1031	http://dx.doi.org/10.1136/bmj.319.7216.1031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521193	Green Published, Green Accepted, Bronze			2022-12-24	WOS:000083210100024
J	Pop, VJ; van Baar, AL; Vulsma, T				Pop, VJ; van Baar, AL; Vulsma, T			Should all pregnant women be screened for hypothyroidism?	LANCET			English	Editorial Material									Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands; Emmas Children Hosp, Dept Neonatal, Amsterdam, Netherlands; Emmas Children Hosp, Dept Paediat Endocrinol, Amsterdam, Netherlands	Tilburg University; Emma Children's Hospital; Emma Children's Hospital	Pop, VJ (corresponding author), Tilburg Univ, Dept Clin Hlth Psychol, NL-5000 LE Tilburg, Netherlands.		van Baar, Anneloes/L-8236-2013	van Baar, Anneloes/0000-0002-3498-9019				BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Cohen J., 1988, STAT POWER ANAL BEHA; De Santiago J., 1999, J ENDOCRINOL INVES S, V22, P68; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; Kester MHA, 1999, J CLIN ENDOCR METAB, V84, P2577, DOI 10.1210/jc.84.7.2577; Lazarus JH, 1999, THYROID, V9, P659, DOI 10.1089/thy.1999.9.659; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; Rovet J, 1996, J CHILD PSYCHOL PSYC, V37, P579, DOI 10.1111/j.1469-7610.1996.tb01444.x; Utiger RD, 1999, NEW ENGL J MED, V341, P601, DOI 10.1056/NEJM199908193410809	9	16	16	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 9	1999	354	9186					1224	1225						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520627				2022-12-24	WOS:000083010400004
J	Rozov, A; Burnashev, N				Rozov, A; Burnashev, N			Polyamine-dependent facilitation of postsynaptic AMPA receptors counteracts paired-pulse depression	NATURE			English	Article							TERM SYNAPTIC PLASTICITY; RAT HIPPOCAMPAL SLICES; CALCIUM-PERMEABLE AMPA; GLUTAMATE RECEPTORS; KAINATE RECEPTORS; RECTIFICATION; INTERNEURONS; NEURONS; BLOCK; BRAIN	At many glutamatergic synapses in the brain, calcium-permeable alpha - amino - 3 - hydro - 5 - methyl - 4 - isoxazolepropionate receptor (AMPAR) channels mediate fast excitatory transmission(1-6). These channels are blocked by endogenous intracellular polyamines(7-9), which are found in virtually every type of cell(10,11). In excised patches, use-dependent relief of polyamine block enhances glutamate-evoked currents through recombinant and native calcium-permeable, polyamine-sensitive AMPAR channels(12). The contribution of polyamine unblock to synaptic currents during high-frequency stimulation may be to facilitate currents and maintain current amplitudes in the face of a slow recovery from desensitization or presynaptic depression(12,13). Here we show, on pairs and triples of synaptically connected neurons in slices, that this mechanism contributes to short-term plasticity in local circuits formed by presynaptic pyramidal neurons and postsynaptic multipolar interneurons in layer 2/3 of rat neocortex, Activity-dependent relief from polyamine block of postsynaptic calcium-permeable AMPARs in the interneurons either reduces the rate of paired-pulse depression in a frequency-dependent manner or, at a given stimulation frequency, induces facilitation of a synaptic response that would otherwise depress. This mechanism for the enhancement of synaptic gain appears to be entirely postsynaptic.	Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, D-69120 Heidelberg, Germany	Max Planck Society	Burnashev, N (corresponding author), Max Planck Inst Med Forsch, Abt Zellphysiol Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.		Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013					BarnesDavies M, 1996, J PHYSIOL-LONDON, V495P, pP44; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; Fisher SA, 1997, TRENDS NEUROSCI, V20, P170, DOI 10.1016/S0166-2236(96)01001-6; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; Isa T, 1996, J PHYSIOL-LONDON, V491, P719, DOI 10.1113/jphysiol.1996.sp021252; JONES HC, 1988, J PHYSIOL-LONDON, V402, P579, DOI 10.1113/jphysiol.1988.sp017223; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; KOH DS, 1995, J PHYSIOL-LONDON, V486, P305, DOI 10.1113/jphysiol.1995.sp020813; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McBain CJ, 1998, J PHYSIOL-LONDON, V511, P331, DOI 10.1111/j.1469-7793.1998.331bh.x; OTIS TS, 1995, J PHYSIOL-LONDON, V482, P309, DOI 10.1113/jphysiol.1995.sp020519; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; SHAW GG, 1979, BIOCHEM PHARMACOL, V28, P1, DOI 10.1016/0006-2952(79)90261-2; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Thomson AM, 1997, J PHYSIOL-LONDON, V502, P131, DOI 10.1111/j.1469-7793.1997.131bl.x; WATANABE S, 1991, J BIOL CHEM, V266, P20803; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1994, NETH J ZOOL, V44, P495	23	151	153	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					594	598		10.1038/44151	http://dx.doi.org/10.1038/44151			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524627				2022-12-24	WOS:000083054900052
J	Epstein, N				Epstein, N			To dream	ANNALS OF INTERNAL MEDICINE			English	Article											Epstein, N (corresponding author), 2820 E 4th St, Tucson, AZ 85716 USA.	Nempe@aol.com							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					540	541		10.7326/0003-4819-131-7-199910050-00013	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507966				2022-12-24	WOS:000083018800010
J	Chelala, C; Beyrer, C				Chelala, C; Beyrer, C			Drug use and HIV/AIDS in Burma	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Chelala, C (corresponding author), 390 W Broadway, New York, NY 10012 USA.							UNICEF, 2021, LEVELS TRENDS CHILD	1	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1119	1119		10.1016/S0140-6736(05)76908-7	http://dx.doi.org/10.1016/S0140-6736(05)76908-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509520				2022-12-24	WOS:000082777500047
J	Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R				Perucchini, D; Fischer, U; Spinas, GA; Huch, R; Huch, A; Lehmann, R			Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: prospective population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; TOLERANCE; TESTS; CRITERIA; INSULIN; DISEASE; BIRTH; WOMEN	Objective To evaluate whether measuring fasting Plasma glucose concentration is an easier screening procedure for gestational diabetes mellitus than the 1 hour 50 g glucose challenge test. Design Prospective population based study. Setting Outpatient clinic in a university hospital. Participants 520 pregnant women (328 (63%) white, 99 (19%) Asian, 31 (6%) African, 62 (12%) others) with mean age 28.4 (SD 0.2; range 17-45) years. All underwent a glucose challenge test between the 24th and 28th gestational week, followed by a diagnostic 3 hour 100 g or al glucose tolerance test within one week. This was done irrespective of the result of the challenge lest. Main outcome measure Receiver operating curves were used to determine the best cut off values for screening with fasting plasma glucose concentrations, Results Fasting plasma glucose concentration at a threshold value of 4.5 mmol/l and the glucose challenge test with a threshold value of 7.8 mmol/l. yielded sensitivities of 81%, and 59% respectively and specificities of 76%, and 91% respectively Measuring fasting plasma glucose concentration as a screening procedure required a diagnostic test in 30%, compared with 14% when the challenge test was used. Conclusions Measuring fasting plasma glucose concentrations using a cut off value of greater than or equal to 4.8 mmol/l is an easier screening procedure for gestational diabetes than the 50 g glucose challenge test and allows 70% of women to avoid the challenge test.	Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland; Univ Zurich Hosp, Dept Obstet, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Gynaecol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Lehmann, R (corresponding author), Univ Zurich Hosp, Dept Internal Med, Div Endocrinol & Diabet, Zurich, Switzerland.	Roger.Lehmann@dim.usz.ch	Lehmann, Roger/B-9120-2015	Lehmann, Roger/0000-0002-3681-4431				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P958; BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BORTHEIRY AL, 1994, DIABETES CARE, V17, P1269, DOI 10.2337/diacare.17.11.1269; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; COUSTAN DR, 1993, DIABETES CARE, V16, P8, DOI 10.2337/diacare.16.3.8; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; ENGELGAU MM, 1995, DIABETES CARE, V18, P1606, DOI 10.2337/diacare.18.12.1606; Eriksson UJ, 1996, DIABETOLOGIA, V39, P1123; Gavin JR, 1997, DIABETES CARE, V20, P1183; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LEWIS GF, 1993, DIABETES CARE, V16, P1551, DOI 10.2337/diacare.16.12.1551; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MESTMAN JH, 1972, OBSTET GYNECOL, V39, P421; Metzger BE, 1998, DIABETES CARE, V21, pB161; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MORTENSEN HB, 1985, DIABETES METAB, V11, P249; Purdy LP, 1996, DIABETOLOGIA, V39, P1126; Reichelt AJ, 1998, DIABETES CARE, V21, P1246, DOI 10.2337/diacare.21.8.1246; SACKS DA, 1992, J REPROD MED, V37, P907; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; Weiss PAM, 1998, GYNAKOLOGE, V31, P12, DOI 10.1007/s001290050219; *WHO EXP COMM DIAB, 1985, DIAB MELL REP WHO ST	26	75	78	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 25	1999	319	7213					812	815		10.1136/bmj.319.7213.812	http://dx.doi.org/10.1136/bmj.319.7213.812			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496823	Bronze, Green Published			2022-12-24	WOS:000082865200021
J	Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA				Davis, RL; Shrimpton, AE; Holohan, PD; Bradshaw, C; Feiglin, D; Collins, GH; Sonderegger, P; Kinter, J; Becker, LM; Lacbawan, F; Krasnewich, D; Muenke, M; Lawrence, DA; Yerby, MS; Shaw, CM; Gooptu, B; Elliott, PR; Finch, JT; Carrell, RW; Lomas, DA			Familial dementia caused by polymlerization of mutant neurosergin	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; INHIBITOR; MUTATION; DISEASE; LOOP; POLYMERIZATION; SERPINS; LIVER	Aberrant protein processing with tissue deposition is associated with many common neurodegenerative disorders(1,2); however, the complex interplay of genetic and environmental factors has made it difficult to decipher the sequence of events linking protein aggregation with clinical disease(3). Substantial progress has been made toward understanding the pathophysiology of prototypical conformational diseases and protein polymerization in the super-family of serine proteinase inhibitors (serpins)(4,5). Here we describe a new disease, familial encephalopathy with neuroserpin inclusion bodies, characterized clinically as an autosomal dominantly inherited dementia, histologically by unique neuronal inclusion bodies and biochemically by polymers of the neuron-specific serpin, neuroserpin(6,7). We report the cosegregation of point mutations in the neuroserpin gene (PI12) with the disease in two families. The significance of one mutation, S49P, is evident from its homology to a previously described serpin mutation(8), whereas that of the other, S52R, is predicted by modelling of the serpin template. Our findings provide a molecular mechanism for a familial dementia and imply that inhibitors of protein polymerization may be effective therapies for this disorder and perhaps for other more common neurodegenerative diseases.	SUNY Hlth Sci Ctr, Dept Clin Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Radiol, Syracuse, NY 13210 USA; Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA; Amer Red Cross, Holland Labs, Rockville, MD 20855 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Publ Hlth, Portland, OR 97210 USA; Oregon Hlth Sci Univ, Dept Obstet Gynecol, Portland, OR 97210 USA; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England; MRC Ctr, Mol Biol Lab, Cambridge CB2 2XY, England	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Zurich; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); American Red Cross; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Cambridge; University of Cambridge; MRC Laboratory Molecular Biology	Shrimpton, AE (corresponding author), SUNY Hlth Sci Ctr, Dept Clin Pathol, 750 E Adams St, Syracuse, NY 13210 USA.		Kinter, Jochen/C-4515-2008	Gooptu, Bibek/0000-0002-5223-1121; Muenke, Maximilian/0000-0002-7719-6545; Lawrence, Daniel/0000-0003-3126-1935	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AULAK KS, 1993, J BIOL CHEM, V268, P18088; Beauchamp NJ, 1998, BLOOD, V92, P2696, DOI 10.1182/blood.V92.8.2696.420a43_2696_2706; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; CERVOSNAVARRO, 1995, METABOLIC DEGENERATI; ELDERING E, 1995, J BIOL CHEM, V270, P2579, DOI 10.1074/jbc.270.6.2579; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 1998, THORAX, V53, P1022, DOI 10.1136/thx.53.12.1022; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PRUSINER SB, 1994, J R COLL PHYSICIAN S, V28, P1; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Shrimpton AE, 1997, HUM MUTAT, V10, P436, DOI 10.1002/(SICI)1098-1004(1997)10:6<436::AID-HUMU4>3.0.CO;2-B; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; WALLACE AJ, 1993, J MED GENET, V30, P346; Yankner BA, 1996, NAT MED, V2, P850, DOI 10.1038/nm0896-850; YERBY MS, 1986, NEUROLOGY, V36, P68, DOI 10.1212/WNL.36.1.68	26	286	299	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					376	379		10.1038/43897	http://dx.doi.org/10.1038/43897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517635	Bronze			2022-12-24	WOS:000082822600051
J	Herrington, DM				Herrington, DM			The HERS trial results: Paradigms lost?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; MYOCARDIAL-INFARCTION; RISK; ESTROGEN; DISEASE; USERS; PREVENTION; PROGESTIN	The Heart and Estrogen/progestin Replacement Study (HERS) found no overall effect of 4.1 years of therapy with estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. However, within the overall null effect, a 50% increase in cardiovascular events was seen in the first year, followed by fewer events after 2 years of treatment in the hormone therapy group than in the placebo group. Understanding the cause of th is pattern of early increase and late reduction in risk is key to interpreting the HERS results and reconciling them with the large number of observational and other studies of the cardiovascular effects of estrogen. There are two possibilities. One is that the HERS regimen of estrogen plus progestin has no effect on risk for heart disease, and the pattern of changing risk over time is simply the result of chance or confounding. The other is that the pattern of early increase and late reduction in risk is due to real but opposing effects of this regimen. Several lines of evidence support each possibility. Attrition of a susceptible cohort of women uniquely at risk for a cardiovascular complication from hormone therapy coupled with a gradually progressive beneficial effect due to lipid lowering and other factors is a promising potential explanation. The HERS results remind us of the need for clinical trials to evaluate both the benefits and risks of new therapies. They also illustrate how much more we need to know about the cardiovascular effects of hormone replacement therapy.	Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Winston Salem, NC 27157 USA	Wake Forest University	Herrington, DM (corresponding author), Wake Forest Univ, Sch Med, Dept Internal Med Cardiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dherring@wfubmc.edu						Adams MR, 1997, ARTERIOSCL THROM VAS, V17, P217, DOI 10.1161/01.ATV.17.1.217; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Grundy SM, 1997, CIRCULATION, V95, P2329, DOI 10.1161/01.CIR.95.9.2329; Hulley S, 1999, JAMA-J AM MED ASSOC, V281, P796; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1329; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sidney S, 1997, ANN INTERN MED, V127, P501, DOI 10.7326/0003-4819-127-7-199710010-00001; SMITH SC, 1995, CIRCULATION, V92, P2; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; WILLIAMS JK, 1994, J AM COLL CARDIOL, V24, P1757, DOI 10.1016/0735-1097(94)90184-8	16	84	88	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					463	466		10.7326/0003-4819-131-6-199909210-00012	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498564				2022-12-24	WOS:000082641100010
J	Calverley, PMA				Calverley, PMA			Blood pressure, breathing, and the carotid body	LANCET			English	Editorial Material							OBSTRUCTIVE SLEEP-APNEA; SYMPATHETIC ACTIVITY; HYPERTENSION		Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England		Calverley, PMA (corresponding author), Univ Hosp Aintree, Dept Med Pulm & Rehabil, Liverpool L9 7AL, Merseyside, England.							Brooks D, 1997, J CLIN INVEST, V99, P106, DOI 10.1172/JCI119120; DOUGLAS NJ, 1994, LANCET, V344, P653, DOI 10.1016/S0140-6736(94)92088-5; Engleman HM, 1996, SLEEP, V19, P378, DOI 10.1093/sleep/19.5.378; HEDNER J, 1995, EUR RESPIR J, V8, P222, DOI 10.1183/09031936.95.08020222; LEUENBERGER U, 1995, J APPL PHYSIOL, V79, P581, DOI 10.1152/jappl.1995.79.2.581; Narkiewicz K, 1999, CIRCULATION, V99, P1183, DOI 10.1161/01.CIR.99.9.1183; Narkiewicz K, 1998, CIRCULATION, V98, P772, DOI 10.1161/01.CIR.98.8.772; Narkiewicz K, 1997, J HYPERTENS, V15, P1613, DOI 10.1097/00004872-199715120-00062; Narkiewicz K, 1998, CIRCULATION, V97, P943; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Osanai S, 1999, EUR RESPIR J, V13, P418, DOI 10.1183/09031936.99.13241899; REES K, 1995, AM J RESP CRIT CARE, V152, P1016, DOI 10.1164/ajrccm.152.3.7663777; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; Wright J, 1997, BRIT MED J, V314, P851; Young T, 1997, ARCH INTERN MED, V157, P1746, DOI 10.1001/archinte.157.15.1746; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	16	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					969	970		10.1016/S0140-6736(99)90135-6	http://dx.doi.org/10.1016/S0140-6736(99)90135-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501355				2022-12-24	WOS:000082596000006
J	Heppenstall, B; Tan, V				Heppenstall, B; Tan, V			Well-leg compartment syndrome	LANCET			English	Editorial Material							LITHOTOMY POSITION		Hosp Univ Penn, Dept Orthopaed Surg, Philadelphia, PA 19104 USA	University of Pennsylvania	Tan, V (corresponding author), Hosp Univ Penn, Dept Orthopaed Surg, 3400 Spruce St, Philadelphia, PA 19104 USA.							Adler LM., 1997, TECH ORTHOP, V12, P133, DOI [10.1097/00013611-199706010-00007, DOI 10.1097/00013611-199706010-00007]; Halliwill JR, 1998, ANESTHESIOLOGY, V89, P1373, DOI 10.1097/00000542-199812000-00014; MATSEN FA, 1983, PRACTICAL APPROACH C, P88; MOSES TA, 1994, UROLOGY, V43, P746, DOI 10.1016/0090-4295(94)90204-6; Mulhall J P, 1993, Conn Med, V57, P129; SLATER RR, 1994, ORTHOPEDICS, V17, P954; TAN V, 1998, ORTH TRAUM ASS 14 AN; TAN V, IN PRESS J ORTHOPAED; Wiger P, 1998, J ORTHOP TRAUMA, V12, P343, DOI 10.1097/00005131-199806000-00008	9	37	37	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					970	970		10.1016/S0140-6736(98)00409-7	http://dx.doi.org/10.1016/S0140-6736(98)00409-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501356				2022-12-24	WOS:000082596000007
J	Rollmann, SM; Houck, LD; Feldhoff, RC				Rollmann, SM; Houck, LD; Feldhoff, RC			Proteinaceous pheromone affecting female receptivity in a terrestrial salamander	SCIENCE			English	Article								A 22-kilodalton protein was isolated from the submandibular (mental) gland of the male terrestrial salamander, Plethodon jordani (family: Plethodontidae). This proteinaceous pheromone, termed plethodontid receptivity factor (PRF), was experimentally delivered to the female during courtship and shown to increase female receptivity, In most plethodontid salamanders, ovulation occurs weeks or months after insemination, so the pheromone-induced change in receptivity is the only known function of PRF, The messenger RNAs corresponding to isoforms of PRF were transcribed into complementary DNA, cloned, sequenced, and shown to have homology with cytokines of the interleukin-6 family. Pheromone activity would represent a previously unrecognized function for cytokines.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA; Univ Louisville, Sch Med, Dept Biochem, Louisville, KY 40292 USA	University of Chicago; Oregon State University; University of Louisville	Rollmann, SM (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57 St, Chicago, IL 60637 USA.	smrollma@midway.uchicago.edu						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARNOLD SJ, 1976, Z TIERPSYCHOL, V42, P247; Arnold SJ., 1982, BIOCH ASP EVOL BIOL, P173; ARNOLD SJ, 1972, THESIS U MICHIGAN AN; DUELLMAN WE, 1986, BIOL AMPHIBIANS, pCH2; DULKA JG, 1987, NATURE, V325, P251, DOI 10.1038/325251a0; Feldhoff Richard C., 1999, P117; Houck LD, 1998, COPEIA, P214; HOUCK LD, 1990, ANIM BEHAV, V39, P729, DOI 10.1016/S0003-3472(05)80384-7; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; Meager T., 1998, MOL BIOL CYTOKINES; MELROSE DR, 1971, BRIT VET J, V127, P497, DOI 10.1016/S0007-1935(17)37337-2; NICOLA NN, 1994, GUIDEBOOK CYTOKINES, P57; SIGNORET JP, 1961, 4 INT C AN REPR ART, P171; SINGER AG, 1986, J BIOL CHEM, V261, P3323	16	157	159	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1907	1909		10.1126/science.285.5435.1907	http://dx.doi.org/10.1126/science.285.5435.1907			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489368				2022-12-24	WOS:000082638300048
J	Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P				Antson, AA; Dodson, EJ; Dodson, G; Greaves, RB; Chen, XP; Gollnick, P			Structure of the trp RNA-binding attenuation protein, TRAP, bound to RNA	NATURE			English	Article							BACILLUS-SUBTILIS BINDS; CRYSTAL-STRUCTURE; LEADER RNA; TRANSCRIPTION ATTENUATION; OPERON; COMPLEX; SYNTHETASE; EXPRESSION; REPEATS; DOMAIN	The frp RNA-binding attenuation protein (TRAP) regulates expression of the tryptophan biosynthetic genes of several bacilli by binding single-stranded RNA. The binding sequence is composed of eleven triplet repeats, predominantly GAG, separated by two or three non-conserved nucleotides, Here we present the crystal structure of a complex of TRAP and a 53-base single-stranded RNA containing eleven GAG triplets, revealing that each triplet is accommodated in a binding pocket formed by beta-strands. In the complex, the RNA has an extended structure without any base-pairing and binds to the protein mostly by specific protein-base interactions. Eleven binding pockets on the circular TRAP Il-mer form a belt with a diameter of about 80 Angstrom. This simple but elegant mechanism of arresting the RNA segment by encircling it around a protein disk is applicable to both transcription, when TRAP binds the nascent RNA, and to translation, when TRAP binds the same sequence within a non-coding leader region of the messenger RNA.	Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	University of York - UK; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Antson, AA (corresponding author), Univ York, Dept Chem, York Struct Biol Lab, York Y010 5DD, N Yorkshire, England.	fred@yorvic.york.ac.uk	Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816				Allemand JF, 1998, P NATL ACAD SCI USA, V95, P14152, DOI 10.1073/pnas.95.24.14152; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRZOZOWSKI AM, 1993, ACTA CRYSTALLOGR D, V49, P352, DOI 10.1107/S0907444993000952; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; ELLIOTT MB, IN PRESS RNA; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; OLDFIELD TJ, 1994, P CCP4 STUD WEEK; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAULING L, 1953, P NATL ACAD SCI USA, V39, P84, DOI 10.1073/pnas.39.2.84; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; Schneider B, 1997, BIOPOLYMERS, V42, P113, DOI 10.1002/(SICI)1097-0282(199707)42:1<113::AID-BIP10>3.0.CO;2-O; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; Tomchick DR, 1998, STRUCTURE, V6, P337, DOI 10.1016/S0969-2126(98)00036-7; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; Ziehler WA, 1996, BIOTECHNIQUES, V20, P622	50	203	209	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					235	242		10.1038/45730	http://dx.doi.org/10.1038/45730			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499579				2022-12-24	WOS:000082678400043
J	Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF				Lu, MF; Pressman, C; Dyer, R; Johnson, RL; Martin, JF			Function of Rieger syndrome gene in left-right asymmetry and craniofacial development	NATURE			English	Article							SIGNALING PATHWAY; PITX2; REGULATOR; SEQUENCE; TISSUES; FAMILY	Rieger syndrome, an autosomal dominant disorder, includes ocular, craniofacial and umbilical abnormalities, The pitx2 homeobox gene, which is mutated in Rieger syndrome(1,2), has been proposed to be the effector molecule interpreting left-right axial information from the early embryonic trunk to each organ(3-7). Here we have used gene targeting in mice to generate a loss-of-function allele that would be predicted to result in organ randomization or isomerization. Although pitx2(-/-) embryos had abnormal cardiac morphogenesis, mutant hearts looped in the normal direction. Pitx2(-/-) embryos had correctly oriented, but arrested, embryonic rotation and right pulmonary isomerism. They also had defective development of the mandibular and maxillary facial prominences, regression of the stomodeum and arrested tooth development. Fgf8 expression was absent, and Bmp4 expression was expanded in the branchial-arch ectoderm. These data reveal a critical role for pitx2 in left-right asymmetry but indicate that pitx2 may function at an intermediate step in cardiac morphogenesis and embryonic rotation.	Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Martin, JF (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Ctr Canc Biol & Nutr, Alkek Inst Biosci & Technol, 2121 Holcombe Blvd, Houston, TX 77030 USA.							Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Campione M, 1999, DEVELOPMENT, V126, P1225; Flomen RH, 1998, GENOMICS, V47, P409, DOI 10.1006/geno.1997.5127; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; JOHNSTON MC, 1979, EXP EYE RES, V29, P27, DOI 10.1016/0014-4835(79)90164-7; Kaufman M.H., 1992, ATLAS MOUSE DEV; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lu MF, 1999, DEVELOPMENT, V126, P495; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; MIKKILA SP, 1994, AM J MED GENET, V49, P435, DOI 10.1002/ajmg.1320490417; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	20	404	406	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					276	278		10.1038/45797	http://dx.doi.org/10.1038/45797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499585				2022-12-24	WOS:000082678400053
J	Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M				Gong, JP; Xu, J; Bezanilla, M; van Huizen, R; Derin, R; Li, M			Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2	SCIENCE			English	Article							ION CHANNELS; TYROSINE KINASE; PROTEIN-KINASES; K+ CHANNELS; MODULATION; SUBUNIT; BINDING; DOMAIN; ALPHA; LOCALIZATION	Targeting of protein modification enzymes is a key biochemical step to achieve specific and effective posttranslational modifications, Two alternatively spliced ZIP1 and ZIP2 proteins are described, which bind to both Kv beta 2 subunits of potassium channel and protein kinase C (PKC) zeta, thereby acting as a physical link in the assembly of PKC zeta-ZIP-potassium channel complexes. ZIP1 and ZIP2 differentially stimulate phosphorylation of Kv beta 2 by PKC zeta. They also interact to form heteromultimers, which allows for a hybrid stimulatory activity to PKC zeta. Finally, ZIP1 and ZIP2 coexist in the same cell type and are elevated differentially by neurotrophic factors. These results provide a mechanism for specificity and regulation of PKC zeta-targeted phosphorylation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	minli@jhmi.edu			NINDS NIH HHS [NS33324] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R55NS033324, R01NS033324] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIELEFELDT K, 1994, BIOPHYS J, V66, P1904, DOI 10.1016/S0006-3495(94)80984-1; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GONG JP, UNPUB; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hille B., 1991, IONIC CHANNELS EXCIT; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P11, DOI 10.1016/S0968-0004(06)80020-4; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; REINHART PH, 1995, J NEUROSCI, V15, P4572; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Xu J, 1998, TRENDS CARDIOVAS MED, V8, P229, DOI 10.1016/S1050-1738(98)00011-5; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Xu J, 1998, METHOD ENZYMOL, V293, P3; Xu J, 1998, P NATL ACAD SCI USA, V95, P1846, DOI 10.1073/pnas.95.4.1846; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	35	111	116	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1565	1569		10.1126/science.285.5433.1565	http://dx.doi.org/10.1126/science.285.5433.1565			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477520				2022-12-24	WOS:000082359500065
J	Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E				Nordmann, A; Frach, B; Walker, T; Martina, B; Battegay, E			Reliability of patients measuring blood pressure at home: prospective observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland	University of Basel	Battegay, E (corresponding author), Univ Basel Hosp, Dept Internal Med, Med Outpatient Div, CH-4031 Basel, Switzerland.	battegay@ubaclu.unibas.ch						[Anonymous], 1997, ARCH INTERN MED, V157, P2413; AUDET AM, 1993, ANN INTERN MED, V118, P889, DOI 10.7326/0003-4819-118-11-199306010-00010; CAMPBELL NRC, 1995, CAN J CARDIOL SH, P18; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; Ohkubo T, 1998, J HYPERTENS, V16, P971, DOI 10.1097/00004872-199816070-00010	5	53	55	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	1999	319	7218					1172	1172		10.1136/bmj.319.7218.1172	http://dx.doi.org/10.1136/bmj.319.7218.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541509	Bronze, Green Published			2022-12-24	WOS:000083536200024
J	Draper, ES; Manktelow, B; Field, DJ; James, D				Draper, ES; Manktelow, B; Field, DJ; James, D			Prediction of survival for preterm births by weight and gestational age: restrospective population based study	BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; INFANTS; ORIGIN	Objective To produce current data on survival of preterm infants. Design Retrospective population based study. Setting Trent health region. Subjects All European and Asian live births, stillbirths, and late fetal losses from 22 to 32 weeks' gestation, excluding those with major congenital malformations, in women resident in the Trent health region between 1 January 1994 and 31 December 1997. Main outcome measures Birth weight and gestational age specific survival for both European and Asian infants (a) known to be alive at the onset of labour and (b) admitted for neonatal care. Results 738 deaths occurred in 3760 infants born between 22 and 32 weeks' gestation during the study period, giving an overall survival rate of 80.4%. The survival rate for the 3489 (92.8%) infants admitted for neonatal care was 86.6%. For European infants known to be alive at the onset of labour, significant variations in gestation specific survival by birth weight emerged from 24 weeks' gestation: survival ranged from 9% (95% confidence interval 7% to 13%) for infants of birth weight 250-499 g to 21% (16% to 28%) for those of 1000-1249 g. At 27 weeks' gestation, survival ranged from 55% (49% to 61%) for infants of birth weight 500-749 g (below the 10th centile) to 80% (76%, to 85%) for those of 1250-1499 g. Infants who were large for dates (greater than or equal to 27 weeks' gestation) had a slightly reduced, but not significant, predicted survival. Similar survival rates were observed for Asian infants. The odds ratio for the survival of infants from a multiple birth compared with singleton infants was 1.4 (1.1 to 1.8). Survival graphs for infants admitted for neonatal care are presented by sex. Conclusion Easy to use birth weight and gestational age specific predicted survival graphs for preterm infants facilitate decision making for clinicians and parents. It is important that these graphs are representative, are produced for a geographically defined population, and are not biased towards the outcomes of particular centres. Such graphs, produced in two stages, allow for the changing pattern of survival of infants from the start of the intrapartum period to immediately after admission for neonatal care.	Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England; Leicester Royal Infirm, Dept Child Hlth, Leicester LE2 7LX, Leics, England; Univ Nottingham, Queens Med Ctr, Dept Obstet & Gynaecol, Nottingham NG7 2UH, England	University of Leicester; University of Leicester; University of Nottingham	Draper, ES (corresponding author), Univ Leicester, Sch Med, Dept Epidemiol & Publ Hlth, Leicester LE1 6TP, Leics, England.		Draper, Elizabeth/S-6874-2019; Draper, Elizabeth S/I-6304-2018; Manktelow, Bradley N/G-2794-2011	Draper, Elizabeth/0000-0001-9340-8176; Draper, Elizabeth S/0000-0001-9340-8176; Manktelow, Bradley N/0000-0002-3264-0323				BURTON P, 1995, J EPIDEMIOL PUBLIC H, V48, P617; Cartlidge PHT, 1997, ACTA PAEDIATR, V86, P105, DOI 10.1111/j.1651-2227.1997.tb08842.x; CLARKE M, 1996, CONFIDENTIAL ENQUIRY; Cooper TR, 1998, PEDIATRICS, V101, P975, DOI 10.1542/peds.101.6.975; COPPER RL, 1993, AM J OBSTET GYNECOL, V168, P78, DOI 10.1016/S0002-9378(12)90889-3; FIELD D, 1987, PEDIAT PULMONOL, V8, P231; FIELD DJ, 1989, BRIT MED J, V299, P1305, DOI 10.1136/bmj.299.6711.1305; FIELD DJ, 1985, BMJ-BRIT MED J, V290, P1539, DOI 10.1136/bmj.290.6481.1539; FuentesAfflick E, 1997, AM J EPIDEMIOL, V145, P148, DOI 10.1093/oxfordjournals.aje.a009085; GREENBERG DN, 1993, PEDIATRICS, V91, P572; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Rennie JM, 1996, ARCH DIS CHILD-FETAL, V74, pF214, DOI 10.1136/fn.74.3.F214; Tin W, 1997, BMJ-BRIT MED J, V314, P107, DOI 10.1136/bmj.314.7074.107; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; WOLF EJ, 1992, OBSTET GYNECOL, V80, P436; YUKSEL B, 1995, THORAX, V50, P773, DOI 10.1136/thx.50.7.773	16	157	167	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1093	1097		10.1136/bmj.319.7217.1093	http://dx.doi.org/10.1136/bmj.319.7217.1093			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	250ZE	10531097	Green Published, Bronze			2022-12-24	WOS:000083419500020
J	Glossop, NRJ; Lyons, LC; Hardin, PE				Glossop, NRJ; Lyons, LC; Hardin, PE			Interlocked feedback loops within the Drosophila circadian oscillator	SCIENCE			English	Article							PERIOD PROTEIN; CLOCK GENE; BEHAVIORAL RHYTHMS; DOUBLE-TIME; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION; HOMOLOG; SYSTEM; BRAIN	Drosophila Clock (dClk) is rhythmically expressed, with peaks in mRNA and protein (dCLK) abundance early in the morning. dClk mRNA cycling is shown here to be regulated by PERIOD-TIMELESS (PER-TIM)-mediated release of dCLK- and CYCLE (CYC)-dependent repression. Lack of both PER-TIM derepression and dCLK-CYC repression results in high levels of dClk mRNA, which implies that a separate dClk activator is present. These results demonstrate that the Drosophila circadian feedback loop is composed of two interlocked negative feedback Loops: a per-tim loop, which is activated by dCLK-CYC and repressed by PER-TIM, and a dClk Loop, which is repressed by dCLK-CYC and derepressed by PER-TIM.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Hardin, PE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.			Hardin, Paul/0000-0002-3370-9011	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031214, R29NS031214] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-31214] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; Helfrich-Forster C, 1998, J COMP PHYSIOL A, V182, P435, DOI 10.1007/s003590050192; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 1999, MOL CELL BIOL, V19, P5316; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; MEESE DA, 1994, 941 CRREL REPORT; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SO VW, 1997, EMBO J, V16, P7146; ZERR DM, 1990, J NEUROSCI, V10, P2749	25	302	311	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					766	768		10.1126/science.286.5440.766	http://dx.doi.org/10.1126/science.286.5440.766			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531060				2022-12-24	WOS:000083303200052
J	McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL				McAlister, FA; Laupacis, A; Wells, GA; Sackett, DL		Evidence-Based Med Working Grp	Users' Guides to the Medical Literature - XIX. Applying clinical trial results - B. Guidelines for determining whether a drug is exerting (more than) a class effect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AVERAGE CHOLESTEROL LEVELS; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; RANDOMIZED TRIALS; DOUBLE-BLIND; RISK; PRAVASTATIN; HYPERCHOLESTEROLEMIA; TECHNOLOGY		John Radcliffe Hosp, Natl Hlth Serv Res & Dev Ctr Evidence Based Med, Oxford OX3 9DU, England; Ottawa Hosp, Div Gen Internal Med, Ottawa, ON, Canada; Loeb Hlth Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada	University of Oxford; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	McAlister, FA (corresponding author), McMaster Univ, Hlth Sci Ctr, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Wells, George A/M-4549-2017; McAlister, Finlay/C-4151-2013	Wells, George A/0000-0002-2289-9139; McAlister, Finlay/0000-0001-7435-3341				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Bucher HC, 1999, JAMA-J AM MED ASSOC, V282, P771, DOI 10.1001/jama.282.8.771; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOK RJ, 1995, PLANT PHYSIOL, V108, P4; Dans AL, 1998, JAMA-J AM MED ASSOC, V279, P545, DOI 10.1001/jama.279.7.545; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; Fager G, 1997, ARTERIOSCL THROM VAS, V17, P3527, DOI 10.1161/01.ATV.17.12.3527; Furberg CD, 1996, AM J HYPERTENS, V9, P122, DOI 10.1016/0895-7061(96)00014-3; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; Gotto AM, 1997, CIRCULATION, V96, P4424; Grover SA, 1998, ARCH INTERN MED, V158, P655, DOI 10.1001/archinte.158.6.655; Grover SA, 1998, ARCH INTERN MED, V158, P1228; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HUNT D, 1992, LANCET, V339, P753; Jones P, 1998, AM J CARDIOL, V81, P582, DOI 10.1016/S0002-9149(97)00965-X; Korttila K, 1997, ACTA ANAESTH SCAND, V41, P914, DOI 10.1111/j.1399-6576.1997.tb04809.x; Lacour A, 1998, CAN J CARDIOL, V14, P355; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Marshall WJS, 1998, CAN MED ASSOC J, V158, P489; McAlister FA, 1997, DRUGS, V54, P235, DOI 10.2165/00003495-199754020-00003; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; NAYLOR CD, 1993, CAN MED ASSOC J, V148, P921; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; Psaty BM, 1996, AM J HYPERTENS, V9, P178, DOI 10.1016/0895-7061(96)00015-5; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; ROTHWELL PM, 1995, LANCET, V345, P1616, DOI 10.1016/S0140-6736(95)90120-5; SACKETT DL, 1980, MONITORING DRUG SAFE, P427; SACKS FM, 1995, AM J CARDIOL, V76, pC78, DOI 10.1016/S0002-9149(99)80475-5; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V280, P683, DOI 10.1001/jama.280.8.683; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, BRIT MED J, V306, P1648; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tu JV, 1998, CAN J CARDIOL, V14, P349; Waldo AL, 1996, LANCET, V348, P7, DOI 10.1016/S0140-6736(96)02149-6; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	53	131	133	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	1999	282	14					1371	1377		10.1001/jama.282.14.1371	http://dx.doi.org/10.1001/jama.282.14.1371			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243MB	10527185				2022-12-24	WOS:000083000800033
J	Cassell, EJ				Cassell, EJ			Diagnosing suffering: A perspective	ANNALS OF INTERNAL MEDICINE			English	Article									Cornell Univ, Weill Med Coll, New York, NY USA	Cornell University	Cassell, EJ (corresponding author), 28 Old Fulton St, Brooklyn, NY 11201 USA.		COZZA, DEBORA/AAH-2572-2021; De Carlo, Esterina/Q-1309-2016	COZZA, DEBORA/0000-0002-1730-089X; De Carlo, Esterina/0000-0001-7883-1283				CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1991, NATURE SUFFERING GOA, P30; CASSELL EJ, 1997, DOCTORING NATURE PRI, P121; DAVIDOFF F, 1996, WHO HAS SEEN BLOOD S, P141; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Field MJ, 1997, APPROACHING DEATH IM; FOLEY KM, 1995, PAIN FORUM, V4, P163; HUNTER KM, 1991, DOCTORS STORIES NARR, P121; LAUER Q, 1978, TRIUMPH SUBJECTIVITY, P70; LOCKE J, 1995, ESSAY HUMAN UNDERSTA, P433; Lynn J, 1997, J AM GERIATR SOC, V45, P526; PLATT FW, 1994, J GEN INTERN MED, V9, P222, DOI 10.1007/BF02600129; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	14	184	186	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					531	534		10.7326/0003-4819-131-7-199910050-00009	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507963				2022-12-24	WOS:000083018800007
J	Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R				Benedetti, LR; Nguyen, JH; Caldwell, WA; Liu, HJ; Kruger, M; Jeanloz, R			Dissociation of CH4 at high pressures and temperatures: Diamond formation in giant planet interiors?	SCIENCE			English	Article							CHEMICAL-VAPOR-DEPOSITION; X-RAY-DIFFRACTION; METHANE; URANUS; HYDROCARBONS; NEPTUNE; FILMS; MBAR; GPA	Experiments using Laser-heated diamond anvil cells show that methane (CH4) breaks down to form diamond at pressures between 10 and 50 gigapascals and temperatures of about 2000 to 3000 kelvin. Infrared absorption and Raman spectroscopy, along with x-ray diffraction, indicate the presence of polymeric hydrocarbons in addition to the diamond, which is in agreement with theoretical predictions, Dissociation of CH4 at high pressures and temperatures can influence the energy budgets of planets containing substantial amounts of CH4, water, and ammonia, such as Uranus and Neptune.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Geol & Geophys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Univ Calif Berkeley, Miller Inst Basic Res Sci, Berkeley, CA 94720 USA; Univ Calif Lawrence Livermore Natl Lab, Phys Directorate, Div H, Livermore, CA 94551 USA; Univ Missouri, Dept Phys, Kansas City, MO 64110 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of Missouri System; University of Missouri Kansas City	Benedetti, LR (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.							Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ANGUS JC, 1993, PHILOS T ROY SOC A, V342, P195, DOI 10.1098/rsta.1993.0014; ATOU T, 1995, J SOLID STATE CHEM, V118, P299, DOI 10.1006/jssc.1995.1348; BADDING JV, 1991, SCIENCE, V253, P412; BENEDETTI LR, UNPUB; Bini R, 1997, PHYS REV B, V55, P14800, DOI 10.1103/PhysRevB.55.14800; BLOCK S, 1970, SCIENCE, V169, P586, DOI 10.1126/science.169.3945.586; Bloss FD., 1961, INTRO METHODS OPTICA, V116, P485, DOI 10.1524/zkri.1961.116.3-6.485; BUTLER RN, UNPUB; HUBBARD WB, 1991, SCIENCE, V253, P648, DOI 10.1126/science.253.5020.648; Jeanloz R, 1996, PHILOS T R SOC A, V354, P1279, DOI 10.1098/rsta.1996.0049; Kavner A, 1998, J APPL PHYS, V83, P7553, DOI 10.1063/1.367520; KLAGES CP, 1993, APPL PHYS A-MATER, V56, P513, DOI 10.1007/BF00331401; Liebert J, 1999, NATURE, V400, P316, DOI 10.1038/22430; Loubeyre P, 1996, NATURE, V383, P702, DOI 10.1038/383702a0; MAO HK, 1979, REV SCI INSTRUM, V50, P1002, DOI 10.1063/1.1135966; MAO HK, 1978, J APPL PHYS, V49, P3276, DOI 10.1063/1.325277; Michler J, 1998, J APPL PHYS, V83, P187, DOI 10.1063/1.366672; NELLIS WJ, 1981, J CHEM PHYS, V75, P3055, DOI 10.1063/1.442401; NGUYEN JH, 1993, REV SCI INSTRUM, V64, P3456, DOI 10.1063/1.1144267; Oppenheimer BR, 1998, ASTROPHYS J, V502, P932, DOI 10.1086/305928; RADOUSKY HB, 1990, J CHEM PHYS, V93, P8235, DOI 10.1063/1.459302; REE FH, 1979, J CHEM PHYS, V70, P974, DOI 10.1063/1.437487; ROSS M, 1981, NATURE, V292, P435, DOI 10.1038/292435a0; WENTORF RH, 1965, J PHYS CHEM-US, V69, P3063, DOI 10.1021/j100893a041; WU YH, 1995, J RAMAN SPECTROSC, V26, P963, DOI 10.1002/jrs.1250261007; Yoshimoto M, 1999, NATURE, V399, P340, DOI 10.1038/20653	27	143	147	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					100	102		10.1126/science.286.5437.100	http://dx.doi.org/10.1126/science.286.5437.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506552				2022-12-24	WOS:000082907400042
J	de Medina, EOR; Algra, A				de Medina, EOR; Algra, A			Digoxin in the treatment of paroxysmal atrial fibrillation	LANCET			English	Editorial Material							SINUS RHYTHM; PLACEBO		Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Neurol, Utrecht, Netherlands; Univ Med Ctr, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Utrecht University; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	de Medina, EOR (corresponding author), Univ Utrecht, Med Ctr, Heart Lung Inst, Dept Cardiol, NL-3508 GA Utrecht, Netherlands.							ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; BEASLEY R, 1985, BRIT MED J, V290, P9, DOI 10.1136/bmj.290.6461.9; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; Jordaens L, 1997, EUR HEART J, V18, P643; Karki K, 1997, EUR HEART J, V18, P649; Levy S, 1998, EUR HEART J, V19, P1294, DOI 10.1053/euhj.1998.1050; Murgatroyd FD, 1999, CIRCULATION, V99, P2765, DOI 10.1161/01.CIR.99.21.2765; PETERSEN P, 1986, STROKE, V17, P622, DOI 10.1161/01.STR.17.4.622	10	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					882	883						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489943				2022-12-24	WOS:000082511800006
J	Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH				Liebl, U; Lipowski, G; Negrerie, M; Lambry, JC; Martin, JL; Vos, MH			Coherent reaction dynamics in a bacterial cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; REACTION CENTERS; VIBRATIONAL COHERENCE; ELECTRON-TRANSFER; HEME-PROTEINS; PRIMARY EVENT; SPECTROSCOPY; ACTIVATION; ABSORPTION; PROGRAM	Biological reactions in protein complexes involve structural dynamics spanning many orders of magnitude in time. In standard descriptions of catalysis by enzymes, the transition state between reactant and product is reached by thermal, stochastic motion. In the ultrashort time domain, however, the protein moiety and cofactor motions leading to altered conformations can be coherent rather than stochastic in nature(1-4). Such coherent motions may play a key role in controlling the accessibility of the transition state and explain the high efficiency of the reaction. Here we present evidence for coherent population transfer to the product state during an ultrafast reaction catalysed by a key enzyme in aerobic organisms. Using the enzyme cytochrome c oxidase aa(3) from the bacterium Paracoccus denitrificans, we have studied haem dynamics during the photo-initiated ultrafast transfer of carbon monoxide from haem a(3) to CuB by femtosecond spectroscopy. The ground state of the unliganded a(3) species is populated in a stepwise manner in time, indicating that the reaction is mainly governed by coherent vibrations (47 cm(-1)). The reaction coordinate involves conformational relaxation of the haem group and we suggest that ligand transfer also contributes.	Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Polytechnique de Paris	Vos, MH (corresponding author), Ecole Polytech, ENSTA, Lab Opt Appl, INSERM,U451, F-91761 Palaiseau, France.		Negrerie, Michel/L-2283-2018	Negrerie, Michel/0000-0001-9918-031X; Lambry, Jean-Christophe/0000-0001-8264-0391; Vos, Marten/0000-0003-0493-4831				Asher S, 1981, Methods Enzymol, V76, P371; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BAGCHI B, 1990, J PHYS CHEM-US, V94, P9, DOI 10.1021/j100364a004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHAMPION PM, 1998, P 16 INT C RAM SPECT, P73; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; FRANZEN S, 1994, NAT STRUCT BIOL, V1, P230, DOI 10.1038/nsb0494-230; GEORGIADIS KE, 1994, BIOCHEMISTRY-US, V33, P9245, DOI 10.1021/bi00197a028; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEMON DD, 1993, BIOCHEMISTRY-US, V32, P11953, DOI 10.1021/bi00096a002; LI XY, 1992, CHEM PHYS LETT, V188, P16, DOI 10.1016/0009-2614(92)85081-K; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; Martin J. L., 1984, ULTRAFAST PHENOMENA, VIV, P447; MARTIN JL, 1994, METHOD ENZYMOL, V232, P416; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Rischel C, 1997, NATURE, V390, P490, DOI 10.1038/37317; Rischel C, 1998, P NATL ACAD SCI USA, V95, P12306, DOI 10.1073/pnas.95.21.12306; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; STOUTLAND PO, 1991, J PHYS CHEM-US, V95, P6406, DOI 10.1021/j100170a004; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VOS MH, 1991, P NATL ACAD SCI USA, V88, P8885, DOI 10.1073/pnas.88.20.8885; VOS MH, 1993, NATURE, V363, P320, DOI 10.1038/363320a0; Vos MH, 1998, CHEM PHYS, V233, P179, DOI 10.1016/S0301-0104(97)00355-8; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; ZHU LY, 1994, SCIENCE, V266, P629, DOI 10.1126/science.7939716	30	92	93	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					181	184		10.1038/43699	http://dx.doi.org/10.1038/43699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490029				2022-12-24	WOS:000082458800058
J	Brearley, AJ				Brearley, AJ			Origin of graphitic carbon and pentlandite in matrix olivines in the Allende meteorite	SCIENCE			English	Article							DARK INCLUSIONS; SOLAR NEBULA; AQUEOUS ALTERATION; FAYALITIC OLIVINE; CHONDRITES; PHYLLOSILICATES; RIMS	Matrix olivines in the Allende carbonaceous chondrite are believed to have formed by condensation processes in the primitive solar nebula. However, transmission electron microscope observations of numerous matrix olivines show that they contain abundant, previously unrecognized, nanometer-sized inclusions of pentlandite and poorly graphitized carbon. Neither of these phases would have been stable at the high-temperature conditions required to condense iron-rich olivine in the solar nebula. The presence of these inclusions is consistent with formation of the olivines by parent body processes that involved overgrowth of fine-grained organic materials and sulfides in the precursor matrix materials.	Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA	University of New Mexico	Brearley, AJ (corresponding author), Univ New Mexico, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA.			Brearley, Adrian/0000-0002-7364-8815				AKAI J, 1988, GEOCHIM COSMOCHIM AC, V52, P1593, DOI 10.1016/0016-7037(88)90228-1; AKAI J, 1994, ANTARCT METEORITES, V7, P94; ASH RD, 1999, LUNAR PLANET SCI, V30; ASHWORTH JR, 1975, EARTH PLANET SC LETT, V27, P43, DOI 10.1016/0012-821X(75)90158-2; Brearley A.J., 1996, CHONDRULES PROTOPLAN, P137; Brearley AJ, 1997, SCIENCE, V276, P1103, DOI 10.1126/science.276.5315.1103; BREARLEY AJ, 1990, GEOCHIM COSMOCHIM AC, V54, P831, DOI 10.1016/0016-7037(90)90377-W; BUNCH TE, 1980, GEOCHIM COSMOCHIM AC, V44, P1543, DOI 10.1016/0016-7037(80)90118-0; BUSECK PR, 1988, ORG GEOCHEM, V12, P221, DOI 10.1016/0146-6380(88)90260-4; Cassen P., 1996, CHONDRULES PROTOPLAN, P21; CLAYTON RN, 1997, WORKSH PAR BOD NEB 1, P10; Cronin J.R., 1988, METEORITES EARLY SOL, P819; DURAND B, 1980, KEROGENS; Fischbach D. B., 1971, CHEM PHYS CARBON, V7, P1; FRANKLIN RE, 1951, ACTA CRYSTALLOGR, V4, P253, DOI 10.1107/S0365110X51000842; GREEN HW, 1971, SCIENCE, V172, P936, DOI 10.1126/science.172.3986.936; HYATSU R, 1980, SCIENCE, V208, P1515; Jarosewich E., 1987, SMITHSONIAN CONTRIB, V27, P1; KOJIMA T, 1995, METEORITICS, V30, P529; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; Krot AN, 1997, METEORIT PLANET SCI, V32, P31, DOI 10.1111/j.1945-5100.1997.tb01238.x; Kullerud G., 1963, CARNEGIE I ANN REPOR, V62, P175; LARIMER JW, 1967, GEOCHIM COSMOCHIM AC, V31, P1239, DOI 10.1016/S0016-7037(67)80014-0; Lauretta DS, 1998, METEORIT PLANET SCI, V33, P821, DOI 10.1111/j.1945-5100.1998.tb01689.x; MACPHERSON GJ, 1985, GEOCHIM COSMOCHIM AC, V49, P2267, DOI 10.1016/0016-7037(85)90227-3; PALME H, 1990, EARTH PLANET SC LETT, V101, P180, DOI 10.1016/0012-821X(90)90152-N; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; SMITH PPK, 1981, SCIENCE, V212, P322, DOI 10.1126/science.11536554; SWART PK, 1982, J GEOPHYS RES, V87, pA283, DOI 10.1029/JB087iS01p0A283; TORIUMI M, 1989, EARTH PLANET SC LETT, V92, P265, DOI 10.1016/0012-821X(89)90051-4; Weisberg MK, 1998, METEORIT PLANET SCI, V33, P1087, DOI 10.1111/j.1945-5100.1998.tb01714.x; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452	32	77	77	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1380	1382		10.1126/science.285.5432.1380	http://dx.doi.org/10.1126/science.285.5432.1380			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464092				2022-12-24	WOS:000082233500036
J	Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T				Minowa, O; Ikeda, K; Sugitani, Y; Oshima, T; Nakai, S; Katori, Y; Suzuki, M; Furukawa, M; Kawase, T; Zheng, Y; Ogura, M; Asada, Y; Watanabe, K; Yamanaka, H; Gotoh, S; Nishi-Takeshima, M; Sugimoto, T; Kikuchi, T; Takasaka, T; Noda, T			Altered cochlear fibrocytes in a mouse model of DFN3 nonsyndromic deafness	SCIENCE			English	Article							FACTOR BRN-2; DIFFERENTIATION; HYPOTHALAMUS; MUTATIONS; SURVIVAL	DFN3, an X chromosome-linked nonsyndromic mixed deafness, is caused by mutations in the BRN-4 gene, which encodes a POU transcription factor. Brn-4-deficient mice were created and found to exhibit profound deafness, No gross morphological changes were observed in the conductive ossicles or cochlea, although there was a dramatic reduction in endocochlear potential. Electron microscopy revealed severe ultrastructural alterations in cochlear spiral Ligament fibrocytes. The findings suggest that these fibrocytes, which are mesenchymal in origin and for which a role in potassium ion homeostasis has been postulated, may play a critical role in auditory function.	Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, Tokyo 1708455, Japan; Tohoku Univ, Sch Med, Dept Otorhinolaryngol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Fac Med, Dept Pharmacol, Bunkyo Ku, Tokyo 1138655, Japan; Kansai Med Univ, Dept Anat, Moriguchi, Osaka 5708506, Japan	Japanese Foundation for Cancer Research; Tohoku University; Japan Science & Technology Agency (JST); Tohoku University; University of Tokyo; Kansai Medical University	Noda, T (corresponding author), Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.		Minowa, Osamu/AAM-1238-2020; Noda, Tetsuo/B-1667-2016	Watanabe, Kenichi/0000-0002-5269-146X				Avraham KB, 1998, NAT MED, V4, P1238, DOI 10.1038/3215; Bermingham JR, 1996, GENE DEV, V10, P1751, DOI 10.1101/gad.10.14.1751; DAVIS H, 1965, COLD SPRING HARB SYM, V30, P181, DOI 10.1101/SQB.1965.030.01.020; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; HONRUBIA V, 1969, J ACOUST SOC AM, V46, P388, DOI 10.1121/1.1911701; Katori Y, 1996, CELL TISSUE RES, V284, P473, DOI 10.1007/s004410050608; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; McEvilly RJ, 1996, NATURE, V384, P574, DOI 10.1038/384574a0; Nakai S, 1995, GENE DEV, V9, P3109, DOI 10.1101/gad.9.24.3109; NANCE W E, 1971, Birth Defects Original Article Series, V7, P64; Phippard D, 1998, HEARING RES, V120, P77, DOI 10.1016/S0378-5955(98)00059-8; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHULTE BA, 1989, J HISTOCHEM CYTOCHEM, V37, P127, DOI 10.1177/37.2.2536055; Spicer SS, 1996, HEARING RES, V100, P80, DOI 10.1016/0378-5955(96)00106-2; SPICER SS, 1991, HEARING RES, V56, P53, DOI 10.1016/0378-5955(91)90153-Z; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693	18	159	164	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1408	1411		10.1126/science.285.5432.1408	http://dx.doi.org/10.1126/science.285.5432.1408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464101				2022-12-24	WOS:000082233500045
J	Shellens, T				Shellens, T			The legal position	BRITISH MEDICAL JOURNAL			English	Article									Bevam Ashford Solicitors, Cardiff CF240BA, S Glam, Wales		Shellens, T (corresponding author), Bevam Ashford Solicitors, Waterloo House,Fitzalan Court, Cardiff CF240BA, S Glam, Wales.							Caldicott Committee Department of Health, 1997, REP REV PAT ID INF; *DEP HLTH WELSH OF, 1996, GUID PROT US PAT INF	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	374						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490323				2022-12-24	WOS:000082001700031
J	Motchoulski, A; Liscum, E				Motchoulski, A; Liscum, E			Arabidopsis NPH3: A NPH1 photoreceptor-interacting protein essential for phototropism	SCIENCE			English	Article							COILED COILS; LINKAGE MAP; PHOSPHORYLATION; FLAVOPROTEIN; ELONGATION; MUTATIONS; RESPONSES; DOMAIN; KINASE	Phototropism of Arabidopsis thaliana seedlings in response to a blue Light source is initiated by nonphototropic hypocotyl 1 (NPH1), a Light-activated serine-threonine protein kinase. Mutations in three Loci [NPH2, root phototropism 2 (RPT2), and NPH3] disrupt early signaling occurring downstream of the NPH1 photoreceptor, The NPH3 gene, now cloned, encodes a NPH1-interacting protein. NPH3 is a member of a large protein family, apparently specific to higher plants, and may function as an adapter or scaffold protein to bring together the enzymatic components of a NPH1-activated phosphorelay.	Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Liscum, E (corresponding author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.	liscumm@missouri.edu		Liscum, Emmanuel/0000-0002-8672-9315				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; CHOI S, 1995, WEEDS WORLD, V2, P17; Christie JM, 1999, P NATL ACAD SCI USA, V96, P8779, DOI 10.1073/pnas.96.15.8779; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Fankhauser C, 1999, CURR BIOL, V9, pR123, DOI 10.1016/S0960-9822(99)80078-5; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fields Stanley, 1993, Methods (Orlando), V5, P116, DOI 10.1006/meth.1993.1016; Huala E, 1997, SCIENCE, V278, P2120, DOI 10.1126/science.278.5346.2120; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; MOTCHOULSKI A, UNPUB; NAGAO M, 1992, J BIOL CHEM, V267, P17925; Nakamura Y, 1997, DNA Res, V4, P401, DOI 10.1093/dnares/4.6.401; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; Ni M, 1998, CELL, V95, P657, DOI 10.1016/S0092-8674(00)81636-0; Okada K., 1994, ARABIDOPSIS, P665; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Quail PH, 1997, PLANT CELL ENVIRON, V20, P657, DOI 10.1046/j.1365-3040.1997.d01-108.x; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Sambrook JFE, 1989, MOL CLONING LAB MANU; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHORT TW, 1993, PLANT PHYSIOL, V101, P647, DOI 10.1104/pp.101.2.647; Stowe-Evans EL, 1998, PLANT PHYSIOL, V118, P1265, DOI 10.1104/pp.118.4.1265	34	235	265	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 29	1999	286	5441					961	964		10.1126/science.286.5441.961	http://dx.doi.org/10.1126/science.286.5441.961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10542152				2022-12-24	WOS:000083368500047
J	Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP				Netzer, NC; Stoohs, RA; Netzer, CM; Clark, K; Strohl, KP			Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome	ANNALS OF INTERNAL MEDICINE			English	Article						sleep apnea syndromes; questionnaires; hypertension; obesity; snoring	PREVALENCE; POPULATION; ADULTS; PREDICTION; COMMUNITY; ACCIDENTS; HEALTH; SAMPLE; MEN	Background: Although sleep apnea is common, it often goes undiagnosed in primary care encounters. Objective: To test the Berlin Questionnaire as a means of identifying patients with sleep apnea. Design: Survey followed by portable, unattended sleep studies in a subset of patients. Setting: Five primary care sites in Cleveland, Ohio. Patients: 744 adults (of 1008 surveyed [74%]), of whom 100 underwent sleep studies. Measurements: Survey items addressed the presence and frequency of snoring behavior, waketime sleepiness or fatigue, and history of obesity or hypertension. Patients with persistent and frequent symptoms in any two of these three domains were considered to be at high risk for sleep apnea. Portable sleep monitoring was conducted to measure the number of respiratory events per hour in bed (respiratory disturbance index [RDI]). Results: Questions about symptoms demonstrated internal consistency (Cronbach correlations, 0.86 to 0.92). Of the 744 respondents, 279 (37.5%) were in a high-risk group that was defined a priori. For the 100 patients who underwent sleep studies, risk grouping was useful in prediction of the RDI. For example, being in the high-risk group predicted an RDI greater than 5 with a sensitivity of 0.86, a specificity of 0.77, a positive predictive value of 0.89, and a likelihood ratio of 3.79. Conclusion: The Berlin Questionnaire provides a means of identifying patients who are likely to have sleep apnea.	Case Western Reserve Univ, Ctr Sleep Educ & Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sleep Disorders Res Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Strohl, KP (corresponding author), Case Western Reserve Univ, Ctr Sleep Educ & Res, 10701 E Blvd, Cleveland, OH 44106 USA.			Netzer, Nikolaus/0000-0001-7534-3575	NHLBI NIH HHS [HL-42215, HL-03650] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042215, K07HL003650] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ball EM, 1997, ARCH INTERN MED, V157, P419, DOI 10.1001/archinte.157.4.419; Bradley TD, 1998, AM J RESP CRIT CARE, V157, P335; Briones B, 1996, SLEEP, V19, P583, DOI 10.1093/sleep/19.7.583; CIRIGNOTTA F, 1989, ACTA NEUROL SCAND, V79, P366, DOI 10.1111/j.1600-0404.1989.tb03802.x; Flemons WW, 1996, SLEEP, V19, pS243; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FLEMONS WW, 1994, AM J RESP CRIT CARE, V150, P1279, DOI 10.1164/ajrccm.150.5.7952553; Haponik EF, 1996, J GEN INTERN MED, V11, P759, DOI 10.1007/BF02598994; KAPUNIAI LE, 1988, SLEEP, V11, P430, DOI 10.1093/sleep/11.5.430; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUMP K, 1994, AM J RESP CRIT CARE, V150, P735, DOI 10.1164/ajrccm.150.3.8087345; LOGUE E, 1995, J FAM PRACTICE, V41, P357; Lyznicki JM, 1998, JAMA-J AM MED ASSOC, V279, P1908, DOI 10.1001/jama.279.23.1908; MAISLIN G, 1995, SLEEP, V18, P158, DOI 10.1093/sleep/18.3.158; Marin JM, 1997, INT J EPIDEMIOL, V26, P381, DOI 10.1093/ije/26.2.381; Ohayon MM, 1997, BRIT MED J, V314, P860; OLSON LG, 1995, AM J RESP CRIT CARE, V152, P711, DOI 10.1164/ajrccm.152.2.7633731; Redline S, 1998, CLIN CHEST MED, V19, P1, DOI 10.1016/S0272-5231(05)70428-7; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Stoohs R A, 1997, Sleep Breath, V2, P11; Wu H, 1996, NEUROLOGY, V46, P1254, DOI 10.1212/WNL.46.5.1254; Young T, 1997, SLEEP, V20, P608, DOI 10.1093/sleep/20.8.608; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705	24	1828	1900	0	56	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					485	+		10.7326/0003-4819-131-7-199910050-00002	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507956				2022-12-24	WOS:000083018800001
J	Carlson, RW; Johnson, RE; Anderson, MS				Carlson, RW; Johnson, RE; Anderson, MS			Sulfuric acid on Europa and the radiolytic sulfur cycle	SCIENCE			English	Article							MAGNETOSPHERIC ION-BOMBARDMENT; ICY GALILEAN SATELLITES; IRRADIATION EXPERIMENTS; REFLECTANCE SPECTRA; SURFACE-COMPOSITION; SPECTROSCOPY; OXYGEN; SYSTEM	A comparison of laboratory spectra with Galileo data indicates that hydrated sulfuric acid is present and is a major component of Europa's surface. In addition, this moon's visually dark surface material, which spatially correlates with the sulfuric acid concentration, is identified as radiolytically altered sulfur polymers. Radiolysis of the surface: by magnetospheric plasma bombardment continuously cycles sulfur between three forms: sulfuric acid, sulfur dioxide, and sulfur polymers, with sulfuric acid being about 50 times as abundant as the other forms. Enhanced sulfuric acid concentrations are found in Europa's geologically young terrains, suggesting that low-temperature, liquid sulfuric acid may influence geological processes.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Virginia, Sch Engn & Appl Sci, Charlottesville, VA 22903 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Virginia	Carlson, RW (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.	rcarlson@lively.jpl.nasa.gov						Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; CALVIN WM, 1995, J GEOPHYS RES-PLANET, V100, P19041, DOI 10.1029/94JE03349; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; CARLSON RW, 1998, HIGHLIGHTS ASTRONO B, V11, P1078; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CLARK RN, 1990, J GEOPHYS RES-SOLID, V95, P12653, DOI 10.1029/JB095iB08p12653; COOPER JR, UNPUB; DONALDSON GW, 1968, J PHYS CHEM-US, V72, P3552, DOI 10.1021/j100856a033; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; HOCHANADEL CJ, 1955, J AM CHEM SOC, V77, P3215, DOI 10.1021/ja01617a017; HOGENBOOM DL, 1995, ICARUS, V115, P258, DOI 10.1006/icar.1995.1096; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jayne JT, 1997, J PHYS CHEM A, V101, P10000, DOI 10.1021/jp972549z; JOHNSON ER, 1952, J AM CHEM SOC, V74, P4147, DOI 10.1021/ja01136a056; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1998, GEOPHYS RES LETT, V25, P3257, DOI 10.1029/98GL02565; JOHNSON RE, 1988, ICARUS, V75, P423, DOI 10.1016/0019-1035(88)90155-8; JOHNSON TV, 1983, J GEOPHYS RES, V88, P5789, DOI 10.1029/JB088iB07p05789; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; LANE AL, 1981, NATURE, V292, P38, DOI 10.1038/292038a0; LEBOFSKY LA, 1976, ICARUS, V28, P379, DOI 10.1016/0019-1035(76)90151-2; Martin ST, 1997, J PHYS CHEM B, V101, P5307, DOI 10.1021/jp970607a; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; Moore M., COMMUNICATION; MOORE MH, 1984, ICARUS, V59, P114, DOI 10.1016/0019-1035(84)90059-9; MOOTZ D, 1987, Z NATURFORSCH B, V42, P1231, DOI 10.1515/znb-1987-1004; NANOBASHVILI EM, 1957, P 1 ALL UN C RAD CHE, P69; NANOBASHVILI EM, 1964, P 2 ALL UN C RAD CHE, P159; NASH DB, 1977, ICARUS, V31, P40, DOI 10.1016/0019-1035(77)90070-7; NELSON ML, 1986, ICARUS, V65, P129, DOI 10.1016/0019-1035(86)90068-0; NOLL KS, 1995, J GEOPHYS RES-PLANET, V100, P19057, DOI 10.1029/94JE03294; OSHAUGHNESSY DJ, 1988, NATURE, V333, P240, DOI 10.1038/333240a0; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; POSPIESZALSKA MK, 1989, ICARUS, V78, P1, DOI 10.1016/0019-1035(89)90065-1; SACK NJ, 1992, ICARUS, V100, P534, DOI 10.1016/0019-1035(92)90116-O; SASAKI T, 1978, J CHEM PHYS, V68, P2718, DOI 10.1063/1.436109; SPENCER JR, 1995, J GEOPHYS RES-PLANET, V100, P19049, DOI 10.1029/95JE01503; STRAZZULLA G, 1993, ADV SPACE RES, V13, P189; THOMPSON BA, 1963, J GEOPHYS RES, V68, P6431, DOI 10.1029/JZ068i024p06431; YAROSLAVTSEV AB, 1983, ZH NEORG KHIM+, V28, P2746; ZELEZNIK FJ, 1991, J PHYS CHEM REF DATA, V20, P1157, DOI 10.1063/1.555899	42	258	260	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 1	1999	286	5437					97	99		10.1126/science.286.5437.97	http://dx.doi.org/10.1126/science.286.5437.97			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506568				2022-12-24	WOS:000082907400041
J	Perrotta, AT; Shih, IH; Been, MD				Perrotta, AT; Shih, IH; Been, MD			Imidazole rescue of a cytosine mutation in a self-cleaving ribozyme	SCIENCE			English	Article							HEPATITIS-DELTA-VIRUS; RNA; CLEAVAGE; CATALYSIS; SEQUENCES; MUTANT; BASES; CORE	Ribozymes use a number of the same catalytic strategies as protein enzymes. However, general base catalysis by a ribozyme has not been demonstrated. In the hepatitis delta virus antigenomic ribozyme, imidazole buffer rescued activity of a mutant with a cytosine-76 (C76) to uracil substitution. In addition, a C76 to adenine substitution reduced the apparent pK(a) (where K-a is the acid constant) of the self-cleavage reaction by an amount consistent with differences in the pK(a) values of these two side chains. These results suggest that, in the wild-type ribozyme, C76 acts as a general base. This finding has implications for potential catalytic functions of conserved cytosines and adenines in other ribozymes and in ribonuclear proteins with enzymatic activity.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Been, MD (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.				NIGMS NIH HHS [GM47322] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSLYN E, 1989, J AM CHEM SOC, V111, P4473, DOI 10.1021/ja00194a050; Bravo C, 1996, NUCLEIC ACIDS RES, V24, P1351, DOI 10.1093/nar/24.7.1351; Cech TR, 1999, RNA WORLD, P321; CONNELL GJ, 1994, SCIENCE, V264, P1137, DOI 10.1126/science.7513905; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Huang SQ, 1997, BIOCHEMISTRY-US, V36, P14609, DOI 10.1021/bi9722554; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LEGAULT P, 1994, J AM CHEM SOC, V116, P8390, DOI 10.1021/ja00097a066; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; Narlikar GJ, 1997, ANNU REV BIOCHEM, V66, P19, DOI 10.1146/annurev.biochem.66.1.19; Newmyer SL, 1996, J BIOL CHEM, V271, P14891, DOI 10.1074/jbc.271.25.14891; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1998, RNA, V4, P1332, DOI 10.1017/S1355838298980979; Perrin D. D., 2012, BUFFERS PH METAL ION; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; Perrotta AT, 1998, J MOL BIOL, V279, P361, DOI 10.1006/jmbi.1998.1798; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027; Saenger W., 1984, SPRINGER ADV TEXTS C; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; Wadkins TS, 1999, RNA, V5, P720, DOI 10.1017/S1355838299990209; WADKINS TS, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	28	249	256	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					123	126		10.1126/science.286.5437.123	http://dx.doi.org/10.1126/science.286.5437.123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506560				2022-12-24	WOS:000082907400050
J	De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C				De Maria, R; Zeuner, A; Eramo, A; Domenichelli, C; Bonci, D; Grignani, F; Srinivasula, SM; Alnemri, ES; Testa, U; Peschle, C			Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1	NATURE			English	Article							TRANSCRIPTION FACTOR GATA-1; TNF RECEPTORS; APOPTOSIS; ANEMIA; GENE; DIFFERENTIATION; HEMATOPOIESIS; EXPRESSION; PROTEASE; DISEASE	The production of red blood cells follows the sequential formation of proerythroblasts and basophilic, polychromatophilic and orthochromatic erythroblasts, and is promoted by the hormone erythropoietin (Epo) in response to tissue hypoxia(1). However, little is known about the negative regulation of this process(2). Death receptors are a family of surface molecules that trigger caspase activation and apoptosis in a variety of cell types(3-5). Here we show that immature erythroid cells express several death receptors whose ligands are produced by mature erythroblasts. Exposure of erythroid progenitors to mature erythroblasts or death-receptor ligands resulted in caspase-mediated degradation of the transcription factor GATA-1, which is associated with impaired erythroblast development. Expression of a caspase-resistant GATA-1 mutant, but not of the wild-type gene, completely restored erythroid expansion and differentiation following the triggering of death receptors, indicating that there is regulatory feedback between mature and immature erythroblasts through caspase-mediated cleavage of GATA-1. Similarly, erythropoiesis blockade following Epo deprivation was largely prevented by the expression of caspase-inhibitory proteins or caspase-resistant GATA-1 in erythroid progenitors. Caspase-mediated cleavage of GATA-1 may therefore represent an important negative control mechanism in erythropoiesis.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Catania, Ist Patol Gen, I-95124 Catania, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06122 Perugia, Italy	Jefferson University; University of Catania; Istituto Superiore di Sanita (ISS); University of Perugia	De Maria, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.	rdemaria@lac.jci.tju.edu	De Maria, Ruggero/S-6385-2019; Zeuner, Ann/K-8607-2016; Testa, Ugo/J-6472-2016; Grignani, Francesco/AAC-2565-2022; Bonci, Desiree/K-6488-2016; Alnemri, Emad S/B-4526-2010; Eramo, Adriana/K-6694-2016; Zeuner, Ann/A-8529-2010	De Maria, Ruggero/0000-0003-2255-0583; Testa, Ugo/0000-0001-7900-8942; Bonci, Desiree/0000-0002-2472-5140; Eramo, Adriana/0000-0002-0814-6683; Zeuner, Ann/0000-0002-8295-3715				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis D, 1997, BRIT J RHEUMATOL, V36, P950; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grignani F, 1998, CANCER RES, V58, P14; Gupta P, 1999, LEUKEMIA, V13, P44, DOI 10.1038/sj.leu.2401233; Hasegawa D, 1998, BLOOD, V91, P2793, DOI 10.1182/blood.V91.8.2793.2793_2793_2799; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Krammer P H, 1999, Adv Immunol, V71, P163; KRANTZ SB, 1991, BLOOD, V77, P419; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RUSTEN LS, 1995, BLOOD, V85, P989, DOI 10.1182/blood.V85.4.989.bloodjournal854989; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vyas P, 1999, BLOOD, V93, P2867; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1995, P NATL ACAD SCI USA, V92, P9623, DOI 10.1073/pnas.92.21.9623; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	28	324	332	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					489	493		10.1038/46809	http://dx.doi.org/10.1038/46809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519553				2022-12-24	WOS:000082981200059
J	Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH				Kotagal, UR; Atherton, HD; Eshett, R; Schoettker, PJ; Perlstein, PH			Safety of early discharge for Medicaid newborns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL READMISSION; STAY	Context Neonates are being discharged from the hospital more rapidly, but the risks associated with this practice, especially for low-income populations, are unclear. Objective To determine the impact of decreasing postnatal length of stay on rehospitalization rates in the immediate postdischarge period for Medicaid neonates. Design and Setting Retrospective, population-based cohort study using Ohio Medicaid claims data linked to vital statistics files from July 1, 1991, to June 15, 1995. Participants A total of 102 678 full-term neonates born to mothers receiving Medicaid for at least 30 days after birth. Main Outcome Measures Rehospitalization rates within 7 and 14 days of discharge, postdischarge health care use, and regional variations in length of stay and rehospitalization. Results The proportion of neonates who were discharged following a short stay (less than 1 day after vaginal delivery, less than 2 days after cesarean birth) increased 185%, from 21 % to 59.8% (P<.001) and the mean (SD) length of stay decreased 27%, from 2.2 (1.0) to 1.6 (0.9) days (P<.001), over the course of the study, The proportion of neonates who received a primary care visit within 14 days of birth increased 117% (P = .001). Rehospitalization rates within 7 and 14 days of discharge decreased by 23 %, from 1.3 % to 1.0% (P = .01), and by 19%, from 2.1% to 1.7% (P = .03), respectively. Short stay across the 6 regions of the state varied significantly over time (P<.001), Factors significantly associated with increased likelihood of rehospitalization within both 7 and 14 days of discharge were white race, shorter gestation, primiparity, earlier year of birth, lower 5-minute Apgar score, vaginal delivery, married mother, and region of the state. Conclusion Our data suggest that reductions in length of stay for full-term Medicaid newborns in Ohio have not resulted in an increase in rehospitalization rates in the immediate postnatal period.	Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Neonatol, Div Hlth Policy & Clin Effectiveness, Cincinnati, OH 45229 USA; Univ Cincinnati, Inst Hlth Policy & Hlth Serv Res, Cincinnati, OH USA; Ohio Dept Human Serv, Bur Medicaid Policy, Columbus, OH USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Kotagal, UR (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Hlth Policy & Clin Effectiveness, 3333 Burnet Ave, Cincinnati, OH 45229 USA.							ADEBONOJO FO, 1973, CLIN PEDIATR, V12, P644, DOI 10.1177/000992287301201107; Bragg EJ, 1997, OBSTET GYNECOL, V89, P930, DOI 10.1016/S0029-7844(97)85764-X; BRAVEMAN P, 1995, PEDIATRICS, V96, P716; BRITTON JR, 1994, PEDIATRICS, V94, P291; CATZ C, 1995, PEDIATRICS, V96, P743; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; COOPER WO, 1995, PEDIATRICS, V96, P957; COTTRELL DG, 1983, J AM OSTEOPATH ASSOC, V83, P216; Czarnecki M T, 1996, J Nurs Care Qual, V10, P1; Edmonson MB, 1997, JAMA-J AM MED ASSOC, V278, P299, DOI 10.1001/jama.278.4.299; Fox M H, 1995, Am J Med Qual, V10, P206, DOI 10.1177/0885713X9501000407; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; Kotagal UR, 1996, J PEDIATR GASTR NUTR, V22, P402, DOI 10.1097/00005176-199605000-00012; KRAMER MS, 1991, PEDIATRICS, V87, P399; LEE KS, 1995, J PEDIATR-US, V127, P758, DOI 10.1016/S0022-3476(95)70170-2; Liu LL, 1997, JAMA-J AM MED ASSOC, V278, P293, DOI 10.1001/jama.278.4.293; Maisels MJ, 1998, PEDIATRICS, V101, P995, DOI 10.1542/peds.101.6.995; *NAT CTR HLTH STAT, 1995, HLTH PEOPL 2000 REV; Norr K F, 1989, J Obstet Gynecol Neonatal Nurs, V18, P133, DOI 10.1111/j.1552-6909.1989.tb00476.x; *OH DEP HLTH, 1977, STAT PER GUID; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PITTARD WB, 1988, J PEDIATR-US, V112, P257, DOI 10.1016/S0022-3476(88)80066-0; Pruett S H, 1996, Am J Med Qual, V11, pS39; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; RYAN AS, 1991, PEDIATRICS, V88, P719; Smith R D, 1988, Pediatr Emerg Care, V4, P107, DOI 10.1097/00006565-198806000-00005; SPONG FW, 1997, INPATIENT CARE MOTHE	27	59	59	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1150	1156		10.1001/jama.282.12.1150	http://dx.doi.org/10.1001/jama.282.12.1150			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501118				2022-12-24	WOS:000082596200030
J	Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R				Valverde, MA; Rojas, P; Amigo, J; Cosmelli, D; Orio, P; Bahamonde, MI; Mann, GE; Vergara, C; Latorre, R			Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit	SCIENCE			English	Article							VASCULAR SMOOTH-MUSCLE; POTASSIUM CHANNELS; CA2+ CURRENTS; CELL-LINE; ESTROGEN; MEMBRANE; 17-BETA-ESTRADIOL; RECEPTOR; INHIBITION; RELAXATION	Maxi-K channels consist of a pore-forming alpha subunit and a regulatory beta subunit, which confers the channel with a higher Ca2+ sensitivity. Estradiol bound to the beta subunit and activated the Maxi-K channel (hSlo) only when both a and beta subunits were present. This activation was independent of the generation of intracellular signals and could be triggered by estradiol conjugated to a membrane-impenetrable carrier protein. This study documents the direct interaction of a hormone with a voltage-gated channel subunit and provides the molecular mechanism for the modulation of vascular smooth muscle Maxi-K channels by estrogens.	Univ Pompeu Fabra, Dept Ciencias Expt & Salut, Barcelona 08003, Spain; Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Ctr Estudios Cient, Valdivia 9, Chile; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Kings Coll London, Sch Biomed Sci, Ctr Cardiovasc Biol & Med, London SE1 9RT, England	Pompeu Fabra University; Universidad de Chile; University of California System; University of California Los Angeles; University of London; King's College London	Valverde, MA (corresponding author), Univ Pompeu Fabra, Dept Ciencias Expt & Salut, C-Doctor Aiguader 80, Barcelona 08003, Spain.	miguel.valverde@cexs.upf.es	Vergara, Cecilia/H-6964-2014; Orio, Patricio/F-6207-2010	Vergara, Cecilia/0000-0002-4015-7438; Orio, Patricio/0000-0003-0332-8098; Valverde, Miguel A./0000-0002-6961-3361; ROZALI, ZALNIATI FONNA/0000-0003-2242-5125	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADELMAN JP, 1992, NEURON, V9, P209, DOI 10.1016/0896-6273(92)90160-F; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Clark AG, 1999, J PHYSIOL-LONDON, V516, P45, DOI 10.1111/j.1469-7793.1999.045aa.x; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Farhat MY, 1996, FASEB J, V10, P615, DOI 10.1096/fasebj.10.5.8621060; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDY SP, 1994, FASEB J, V8, P760, DOI 10.1096/fasebj.8.10.8050676; JIANG C, 1994, BRIT J PHARMACOL, V104, P1033; Jiang Z, 1999, GENOMICS, V55, P57, DOI 10.1006/geno.1998.5627; Kitazawa T, 1997, J PHYSIOL-LONDON, V499, P497, DOI 10.1113/jphysiol.1997.sp021944; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Moats RK, 1998, BIOL REPROD, V58, P531, DOI 10.1095/biolreprod58.2.531; MOCZYDLOWSKI EG, 1983, BIOCHIM BIOPHYS ACTA, V732, P412, DOI 10.1016/0005-2736(83)90058-5; Nadal A, 1998, FASEB J, V12, P1341, DOI 10.1096/fasebj.12.13.1341; Nakajima T, 1995, EUR J PHARMACOL, V294, P625, DOI 10.1016/0014-2999(95)00602-8; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; Ogata R, 1996, BRIT J PHARMACOL, V117, P351, DOI 10.1111/j.1476-5381.1996.tb15198.x; PAPPAS TC, 1995, FASEB J, V9, P404, DOI 10.1096/fasebj.9.5.7896011; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Ruehlmann DO, 1998, FASEB J, V12, P613, DOI 10.1096/fasebj.12.7.613; Russell KS, 1997, CIRCULATION, V96, P256; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; TAGLIALATELA M, 1993, P NATL ACAD SCI USA, V90, P4758, DOI 10.1073/pnas.90.10.4758; Toro L, 1998, NEWS PHYSIOL SCI, V13, P112; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; Wetzel CHR, 1998, MOL ENDOCRINOL, V12, P1441, DOI 10.1210/me.12.9.1441; WHITE RE, 1995, CIRC RES, V77, P936, DOI 10.1161/01.RES.77.5.936; ZHANG F, 1994, AM J PHYSIOL, V266, pC975, DOI 10.1152/ajpcell.1994.266.4.C975	38	429	447	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1999	285	5435					1929	1931		10.1126/science.285.5435.1929	http://dx.doi.org/10.1126/science.285.5435.1929			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489376				2022-12-24	WOS:000082638300056
J	Larkin, M				Larkin, M			US online pharmacies strive for respectability	LANCET			English	Editorial Material																		1999, LANCET, V354, P138	1	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 28	1999	354	9180					782	782		10.1016/S0140-6736(05)76034-7	http://dx.doi.org/10.1016/S0140-6736(05)76034-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230BY	10475233				2022-12-24	WOS:000082233000077
J	Schwaiger, M; Melin, J				Schwaiger, M; Melin, J			Cardiological applications of nuclear medicine	LANCET			English	Article							CORONARY-ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; ISCHEMIC-HEART-DISEASE; MYOCARDIAL BLOOD-FLOW; PROGNOSTIC VALUE; VENTRICULAR DYSFUNCTION; VIABILITY ASSESSMENT; TL-201; REVASCULARIZATION; CARDIOMYOPATHY	Cardiovascular mortality is falling in most industrialised nations. Primarily responsible for this encouraging trend are preventive measures such as risk-factor modification but improved medical and surgical management have helped too. Clinical decision making in the patient with coronary heart disease demands techniques that not only describe coronary anatomy but also provide functional indices for early detection and to monitor the severity and extent of disease. Nuclear medicine methods can characterise non-invasively myocardial function, perfusion, and metabolism. Novel radiopharmaceuticals, improvements in imaging equipment, and extensive validation have contributed to the growing clinical acceptance of these techniques and to their cost-effective integration in the workup of patients with cardiovascular disease.	Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, D-81675 Munich, Germany; Catholic Univ Louvain, Clin Univ St Luc, Dept Internal Med, Div Nucl Med, Brussels, Belgium	Technical University of Munich; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwaiger, M (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, Ismaninger Str 22, D-81675 Munich, Germany.	M.Schwaiger@lrz.tu-muenchen.de		schwaiger, markus/0000-0002-2305-7144				Bax JJ, 1997, J AM COLL CARDIOL, V30, P1451, DOI 10.1016/S0735-1097(97)00352-5; Beller GA, 1998, J AM COLL CARDIOL, V31, P1286; BERGMANN SR, 1989, J AM COLL CARDIOL, V14, P639, DOI 10.1016/0735-1097(89)90105-8; Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BROWN KA, 1993, AM J CARDIOL, V71, P865, DOI 10.1016/0002-9149(93)90840-9; Campisi R, 1999, CIRCULATION, V99, P491, DOI 10.1161/01.CIR.99.4.491; Carrio I, 1998, J NUCL CARDIOL, V5, P551, DOI 10.1016/S1071-3581(98)90108-8; DICARLI MF, 1995, CIRCULATION, V92, P3436, DOI 10.1161/01.CIR.92.12.3436; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; EITZMAN D, 1992, J AM COLL CARDIOL, V20, P559, DOI 10.1016/0735-1097(92)90008-B; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOULD KL, 1978, AM J CARDIOL, V41, P267, DOI 10.1016/0002-9149(78)90165-0; Guethlin M, 1999, CIRCULATION, V99, P475, DOI 10.1161/01.CIR.99.4.475; Haas F, 1997, J AM COLL CARDIOL, V30, P1693, DOI 10.1016/S0735-1097(97)00375-6; Hachamovitch R, 1998, CIRCULATION, V97, P535; Iskander S, 1998, J AM COLL CARDIOL, V32, P57, DOI 10.1016/S0735-1097(98)00177-6; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; Kontos MC, 1999, CIRCULATION, V99, P2073, DOI 10.1161/01.CIR.99.16.2073; Laine M, 1998, J CLIN INVEST, V101, P1156, DOI 10.1172/JCI1065; MACHECOURT J, 1994, J AM COLL CARDIOL, V23, P1096, DOI 10.1016/0735-1097(94)90597-5; MAISEY MN, 1990, EUR J NUCL MED, V16, P869, DOI 10.1007/BF01280254; MELIN JA, 1986, J NUCL MED, V27, P641; OHTANI H, 1990, AM J CARDIOL, V66, P394, DOI 10.1016/0002-9149(90)90692-T; Pagley PR, 1997, CIRCULATION, V96, P793; Pennell DJ, 1998, HEART, V80, P296, DOI 10.1136/hrt.80.3.296; POHOST GM, 1977, CIRCULATION, V55, P294, DOI 10.1161/01.CIR.55.2.294; PORT SC, 1995, J NUCL CARDIOL, V2, P551, DOI 10.1016/S1071-3581(05)80049-2; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Shaw LJ, 1999, J AM COLL CARDIOL, V33, P661, DOI 10.1016/S0735-1097(98)00606-8; SILSIZIAN V, 1996, J AM COLL CARDIOL, V27, P910; Stollfuss JC, 1998, EUR J NUCL MED, V25, P522, DOI 10.1007/s002590050253; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; UDELSON JE, 1994, CIRCULATION, V89, P2552, DOI 10.1161/01.CIR.89.6.2552; Underwood SR, 1999, EUR HEART J, V20, P157, DOI 10.1053/euhj.1998.1196; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; Wijns W, 1998, NEW ENGL J MED, V339, P173, DOI 10.1056/NEJM199807163390307; ZARET BL, 1973, NEW ENGL J MED, V288, P809, DOI 10.1056/NEJM197304192881602; ZARET BL, 1995, CIRCULATION, V91, P313, DOI 10.1161/01.CIR.91.2.313	43	59	61	2	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					661	666		10.1016/S0140-6736(99)06057-2	http://dx.doi.org/10.1016/S0140-6736(99)06057-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466685				2022-12-24	WOS:000082214500045
J	Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R				Danesh, J; Youngman, L; Clark, S; Parish, S; Peto, R; Collins, R		Int Studies Infarct Survival ISIS	Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; RISK; AGE	Objectives To examine the association between coronary heart disease and chronic Helicobacter pylori infection. Design Case-control study of myocardial infarction at young ages and study of sibling pairs with one member affected and the other not. Setting United Kingdom. Participants 1122 survivors of suspected acute myocardial infarction at ages 30-49 (mean age 44 years) and 1122 age and sex matched controls with no history of coronary heart disease; 510 age and sex matched pairs of siblings (mean age 59 years) in which one sibling had survived myocardial infarction and one had no history of coronary heart disease. Main outcome measures Serological evidence of chronic infection with H pylori. Results 472 (42%) of the 1122 cases with early onset myocardial infarction were seropositive for H pylori antibodies compared with 272 (24%) of the 1122 age and sex matched controls, giving an odds ratio of 2.28 (99% confidence interval 1.80 to 2.90). This odds ratio fell to 1.87 (1.42 to 2.47; P < 0.0001) after smoking and indicators of socioeconomic status were adjusted for and to 1.75 (1.29 to 2.36) after additional adjustment for blood lipid concentrations and obesity. Only 158 of the 510 pairs of siblings were discordant for H pylori status; among these, 91 cases and 6'7 controls were seropositive (odds ratio 1.33 (0.86 to 2.05)). No strong correlations were observed between H pylori seropositivity and measurements of other risk factors for coronary heart disease (plasma lipids, fibrinogen, C reactive protein, albumin, etc). Conclusion In the context of results from other relevant studies, these two studies suggest a moderate association between coronary hear: disease and H pylori seropositivity that cannot be fully accounted for by other risk factors. But even if this association is causal and largely reversible by eradication of chronic infection, very large randomised trials would be needed to show this.	Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England; Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Epidemiol Studies Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford; Radcliffe Infirmary; University of Oxford	Danesh, J (corresponding author), Univ Oxford, Radcliffe Infirm, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford OX2 6HE, England.							BLASER MJ, 1995, CANCER RES, V55, P562; Collins R, 1996, OXFORD TXB MED, V1, P21; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Danesh J, 1998, Expert Opin Investig Drugs, V7, P691, DOI 10.1517/13543784.7.5.691; Danesh J, 1998, BRIT MED J, V316, P1130, DOI 10.1136/bmj.316.7138.1130; Danesh J, 1999, BRIT MED J, V318, P843, DOI 10.1136/bmj.318.7187.843; FELDMAN RA, 1995, ALIMENT PHARM THER, V9, P21; GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; HUNT D, 1992, LANCET, V339, P753; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; Pasceri V, 1998, CIRCULATION, V97, P1675, DOI 10.1161/01.CIR.97.17.1675; Qizilbash N, 1995, LANCET, V346, P1647; SITAS F, 1991, GUT, V32, P25, DOI 10.1136/gut.32.1.25; Sonke GS, 1996, BRIT MED J, V313, P853; YARNELL JWG, 1992, EUR HEART J, V13, P1602, DOI 10.1093/oxfordjournals.eurheartj.a060111	19	122	127	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1157	1162		10.1136/bmj.319.7218.1157	http://dx.doi.org/10.1136/bmj.319.7218.1157			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541503	Green Published, Bronze			2022-12-24	WOS:000083536200019
J	Wilton, LV; Stephens, MDB; Mann, RD				Wilton, LV; Stephens, MDB; Mann, RD			Visual field defect associated with vigabatrin: observational cohort study	BRITISH MEDICAL JOURNAL			English	Article							CONSTRICTION		Drug Safety Res Unit, Southampton SO31 1AA, Hants, England		Wilton, LV (corresponding author), Drug Safety Res Unit, Southampton SO31 1AA, Hants, England.							*COMM ADV TROP MED, 1998, CAN COMMUN DIS REP, V24, P1; Eke T, 1997, BRIT MED J, V314, P180, DOI 10.1136/bmj.314.7075.180; Mackenzie R, 1998, BRIT MED J, V316, P233; Mann RD, 1998, BRIT J CLIN PHARMACO, V46, P195, DOI 10.1046/j.1365-2125.1998.00774.x	4	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1165	1166		10.1136/bmj.319.7218.1165	http://dx.doi.org/10.1136/bmj.319.7218.1165			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541505	Bronze, Green Published			2022-12-24	WOS:000083536200021
J	Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW				Parker, L; Pearce, MS; Dickinson, HO; Aitkin, M; Craft, AW			Stillbirths among offspring of male radiation workers at Sellafield nuclear reprocessing plant	LANCET			English	Article							CONGENITAL-MALFORMATIONS; IONIZING-RADIATION; TUMOR-INDUCTION; WEST CUMBRIA; MALE-MICE; INSTALLATION; IRRADIATION; LEUKEMIA; EXPOSURE; ENGLAND	Background Ionising radiation is a known mutagen, but few studies have examined transgenerational effects of paternal exposure in human beings. The workforce at the Sellafield nuclear reprocessing plant in the county of Cumbria, UK, is the most highly exposed workforce in western Europe and North America. This study, which is part of a larger programme of work investigating the health of the children of the Sellafield workforce, set out to find whether there was evidence of an association between stillbirth risk and paternal exposure to ionising radiation. Methods We collected details from birth registration documents for all singleton 248 097 livebirths and 3715 stillbirths in the county of Cumbria 1950-89. Within this cohort the 130 stillbirths and 9078 livebirths to partners of male radiation workers employed at Sellafield were identified. Logistic regression was' used to analyse the relation between stillbirth risk and father's preconceptional radiation exposure, with adjustment for social class, year of birth, father's age, and birth order. Findings A significant positive association was found between the risk of a baby being stillborn and the father's total exposure to external ionising radiation before conception (adjusted odds ratio per 100 mSv 1.24 [95% CI 1.04-1.45], p=0.009); The risk was higher for stillbirths with congenital anomaly and was highest for the nine stillbirths with neural-tube defects. The statistical models predicted that, were the association to be interpreted as causal, between 0 and 31.9 of the 130 stillbirths to the workforce may be attributable to father's radiation exposure. Interpretation The findings of an increased risk of stillbirth with increasing paternal occupational exposure to external radiation are qualitatively consistent with those from animal models, though the risk estimate is higher. Although we cannot exclude the possibility of an unmeasured risk factor for stillbirth, confounded with paternal preconceptional irradiation, extensive checks confirmed that the statistical models were a good fit to the data and there was not statistical evidence of unmeasured factors.	Newcastle Univ, Dept Child Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Newcastle Univ, Dept Stat, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Parker, L (corresponding author), Royal Victoria Infirm, Sir James Spence Inst, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	Louise.Parker@ncl.ac.uk		PARKER, LOUISE/0000-0002-5188-8113; Pearce, Mark/0000-0002-0583-3779				Aitkin M, 1999, BIOMETRICS, V55, P117, DOI 10.1111/j.0006-341X.1999.00117.x; Aitkin M, 1996, STAT COMPUT, V6, P251, DOI 10.1007/BF00140869; ALBERMAN E, 1994, ARCH DIS CHILD, V70, P403, DOI 10.1136/adc.70.5.403; BOBROW M, 1988, 2 COMARE; BRENDER JD, 1990, AM J EPIDEMIOL, V131, P517, DOI 10.1093/oxfordjournals.aje.a115526; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRIDGES BA, 1996, 4 COMARE; CARDIS E, 1994, LANCET, V344, P1039; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; Copp AJ, 1998, CURR OPIN NEUROL, V11, P97, DOI 10.1097/00019052-199804000-00003; Daher A, 1998, CARCINOGENESIS, V19, P1553, DOI 10.1093/carcin/19.9.1553; Denniston C, 1998, MUTAT RES-FUND MOL M, V405, P57, DOI 10.1016/S0027-5107(98)00146-8; Dickinson HO, 1996, J EPIDEMIOL COMMUN H, V50, P645, DOI 10.1136/jech.50.6.645; DOLL R, 1994, NATURE, V367, P678, DOI 10.1038/367678a0; Draper GJ, 1997, BRIT MED J, V315, P1181, DOI 10.1136/bmj.315.7117.1181; Dummer TJB, 1998, INT J EPIDEMIOL, V27, P74, DOI 10.1093/ije/27.1.74; Dummer TJB, 1999, PAEDIATR PERINAT EP, V13, P131; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; *INT COMM RAD PROT, 1988, ICRP PUB, V54; KIRK KM, 1984, MUTAT RES, V125, P75, DOI 10.1016/0027-5107(84)90034-4; Kite AV, 1996, RADIAT PROT DOSIM, V67, P23, DOI 10.1093/oxfordjournals.rpd.a031792; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; MCCULLAGH P., 1991, GEN LINEAR MODELS; National Council on Radiation Protection and Measurements, 1997, 126 NCRP; Neel J V, 1991, CHILDREN ATOMIC BOMB; *OFF POP CENS SURV, 1974, BIRT STAT FM1; *OFF POP CENS SURV, 1974, MORT SER; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V3; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V1; Office of Population Censuses and Surveys, 1990, STAND OCC CLASS, V2; PARKER L, 1993, BRIT MED J, V307, P966, DOI 10.1136/bmj.307.6910.966; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Russell WL, 1998, GENETICS, V148, P1567; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226, DOI 10.1093/oxfordjournals.aje.a114799; *UN, 1994, SCI COMM EFF AT RAD; *UN, 1993, SCI COMM EFF AT RAD; Wakeford R., 1994, Journal of Radiological Protection, V14, P3, DOI 10.1088/0952-4746/14/1/001; [No title captured]	40	81	88	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 23	1999	354	9188					1407	1414		10.1016/S0140-6736(99)04138-0	http://dx.doi.org/10.1016/S0140-6736(99)04138-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543666				2022-12-24	WOS:000083277400009
J	Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW				Akaaboune, M; Culican, SM; Turney, SG; Lichtman, JW			Rapid and reversible effects of activity on acetylcholine receptor density at the neuromuscular junction in vivo	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT DIAPHRAGM; POSTSYNAPTIC CHANGES; PROLONGED PARALYSIS; ALPHA-BUNGAROTOXIN; VERTEBRATE MUSCLE; TURNOVER RATE; DEGRADATION; SYNAPSE; STABILIZATION	Quantitative fluorescence imaging was used to study the regulation of acetylcholine receptor (AChR) number and density at neuromuscular junctions in Living adult mice. At fully functional synapses, AChRs have a half-life of about 14 days. However, 2 hours after neurotransmission was blocked, the half-life of the AChRs was now Less than a day; the rate was 25 times faster than before. Most of the Lost receptors were not quickly replaced. Direct muscle stimulation or restoration of synaptic transmission inhibited this process. AChRs that were removed from nonfunctional synapses resided for hours in the perijunctional membrane before being Locally internalized. Dispersed AChRs could also reaggregate at the junction once neurotransmission was restored. The rapid and reversible alterations in AChR density at the neuromuscular junction in vivo parallel changes thought to occur in the central nervous system at synapses undergoing potentiation and depression.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Akaaboune, M (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.		Culican, Susan/F-4279-2019	Culican, Susan/0000-0002-0273-4310				ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BRETT RS, 1982, BRAIN RES, V233, P133, DOI 10.1016/0006-8993(82)90935-0; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; CULICAN SM, UNPUB; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; DENNIS MJ, 1974, J PHYSIOL-LONDON, V237, P431, DOI 10.1113/jphysiol.1974.sp010490; FAMBROUGH DM, 1972, SCIENCE, V176, P189, DOI 10.1126/science.176.4031.189; FERTUCK H C, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1376, DOI 10.1073/pnas.71.4.1376; FERTUCK HC, 1976, J CELL BIOL, V69, P144, DOI 10.1083/jcb.69.1.144; FU DX, 1994, J BIOL CHEM, V269, P26152; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; HARTZELL HC, 1972, J GEN PHYSIOL, V60, P248, DOI 10.1085/jgp.60.3.248; Kurt TL, 1996, J TOXICOL-CLIN TOXIC, V34, P253, DOI 10.3109/15563659609013783; LEVITT TA, 1980, SCIENCE, V210, P550, DOI 10.1126/science.7423205; LINGLE CJ, 1988, INT ANESTHESIOL CLIN, V26, P288, DOI 10.1097/00004311-198802640-00007; Lissin DV, 1999, J NEUROSCI, V19, P1263; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MCMANAMAN JL, 1981, J NEUROSCI, V1, P771, DOI 10.1523/JNEUROSCI.01-07-00771.1981; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; RAMSAY DA, 1992, BRAIN RES, V581, P198, DOI 10.1016/0006-8993(92)90709-I; RAVDIN P, 1977, ANAL BIOCHEM, V80, P585, DOI 10.1016/0003-2697(77)90682-0; RICH MM, 1989, J NEUROSCI, V9, P1781, DOI 10.1523/jneurosci.09-05-01781.1989; ROTZLER S, 1991, NATURE, V349, P337, DOI 10.1038/349337a0; SALPETER MM, 1983, J CELL BIOL, V96, P1781, DOI 10.1083/jcb.96.6.1781; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHYNG SL, 1989, J CELL BIOL, V108, P647, DOI 10.1083/jcb.108.2.647; STANLEY EF, 1983, SCIENCE, V222, P67, DOI 10.1126/science.6623057; STYA M, 1984, J NEUROSCI, V4, P70; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2	35	189	189	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					503	507		10.1126/science.286.5439.503	http://dx.doi.org/10.1126/science.286.5439.503			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521340				2022-12-24	WOS:000083121200052
J	Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER				Casadio, A; Martin, KC; Giustetto, M; Zhu, HX; Chen, M; Bartsch, D; Bailey, CH; Kandel, ER			A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis	CELL			English	Article							APLYSIA SENSORY NEURONS; CAMP-RESPONSIVE ELEMENT; SYNAPTIC FACILITATION; STRUCTURAL-CHANGES; TRANSLATION INITIATION; MEMORY STORAGE; SEROTONIN; SENSITIZATION; VARICOSITIES; POTENTIATION	In a culture system where a bifurcated Aplysia sensory neuron makes synapses with two motor neurons, repeated application of serotonin (5-HT) to one synapse produces a CREB-mediated, synapse-specific, longterm facilitation, which can be captured at the opposite synapse by a single pulse of 5-HT. Repeated pulses of 5-HT applied to the cell body of the sensory neuron produce a CREB-dependent, cell-wide facilitation, which, unlike synapse-specific facilitation, is not associated with growth and does not persist beyond 48 hr. Persistent facilitation and synapse-specific growth can be induced by a single pulse of 5-HT applied to a peripheral synapse. Thus, the short-term process initiated by a single pulse of 5-HT serves not only to produce transient facilitation, but also to mark and stabilize any synapse of the neuron for long-term facilitation by means of a covalent mark and rapamycin-sensitive local protein synthesis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA.	erk5@columbia.edu	giustetto, maurizio/D-6606-2011	giustetto, maurizio/0000-0003-1323-4060	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 37134] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bartsch D, 1998, CELL, V95, P211, DOI 10.1016/S0092-8674(00)81752-3; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; Frey U, 1998, NEUROPHARMACOLOGY, V37, P545, DOI 10.1016/S0028-3908(98)00040-9; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GOLDBERG DJ, 1980, J PHYSIOL-LONDON, V307, P259, DOI 10.1113/jphysiol.1980.sp013434; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P389; KISTLER HB, 1985, J NEUROSCI, V5, P72; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Sun ZY, 1998, J NEUROSCI, V18, P3991; Yanow SK, 1998, J NEUROCHEM, V70, P572; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG ZS, 1991, J COMP NEUROL, V311, P259, DOI 10.1002/cne.903110207	36	400	410	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 15	1999	99	2					221	237		10.1016/S0092-8674(00)81653-0	http://dx.doi.org/10.1016/S0092-8674(00)81653-0			17	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535740	hybrid			2022-12-24	WOS:000083159700012
J	Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S				Jaeger, JJ; Thein, T; Benammi, M; Chaimanee, Y; Soe, AN; Lwin, T; Tun, T; Wai, S; Ducrocq, S			A new primate from the Middle Eocene of Myanmar and the Asian early origin of anthropoids	SCIENCE			English	Article							THAILAND; CHINA	A new genus and species of anthropoid primate, Bahinia pondaungensis gen. et sp. nov., is described from the Yashe Kyitchaung Locality in the Late Middle Eocene Pondaung Formation (Myanmar). it is related to Eosimias, but it is represented by more complete remains. including upper dentition with associated lower jaw fragment. it is interpreted as a new representative of the family Eosimiidae, which corresponds to the sister group of the Amphipithecidae and of all other anthropoids. Eosimiidae are now recorded from three distinct Middle Eocene Localities in Asia, giving support to the hypothesis of an Asian origin of anthropoids.	Univ Montpellier 2, Inst Sci Evolut, F-34095 Montpellier 5, France; Univ Pathein, Dept Geol, Pathein, Myanmar; Dept Mineral Resources, Geol Survey Div, Paleontol Sect, Bangkok 10400, Thailand; Univ Yangon, Dept Geol, Yangon, Myanmar; Minist Def, Off Strateg Studies, Yangon, Myanmar	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Department of Mineral Resources - Thailand; University of Yangon	Ducrocq, S (corresponding author), Univ Montpellier 2, Inst Sci Evolut, Case 064, F-34095 Montpellier 5, France.			chaimanee, yaowalak/0000-0002-8432-3880				Beard K. Christopher, 1998, Bulletin of Carnegie Museum of Natural History, V34, P260; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BEARD KC, 1994, NATURE, V368, P604, DOI 10.1038/368604a0; Chaimanee Y, 1997, NATURE, V385, P429, DOI 10.1038/385429a0; CHOW M, 1961, VERTEBRAT PALASIATIC, V1, P1; DUCROCQ S, 1995, J HUM EVOL, V28, P477, DOI 10.1006/jhev.1995.1035; GINGERICH PD, 1980, AM J PHYS ANTHROPOL, V52, P231; Gingerich Philip D., 1994, P163; GODINOT M, 1992, NATURE, V357, P324, DOI 10.1038/357324a0; Godinot Marc, 1994, P235; JAEGER JA, UNPUB; Jaeger JJ, 1998, CR ACAD SCI III-VIE, V321, P953, DOI 10.1016/S0764-4469(99)80010-9; Kay Richard F., 1994, P361; Legendre S., 1989, Muenchner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V16, P1; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Rose Kenneth D., 1994, P1; Rossow KD, 1998, VET PATHOL, V35, P1, DOI 10.1177/030098589803500101; RUSSELL DE, 1980, CR ACAD SCI D NAT, V291, P621; RUSSELL DE, 1987, CR ACAD SCI II, V304, P209; SIGE B, 1990, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V214, P31; SIMONS EL, 1985, NATURE, V313, P475, DOI 10.1038/313475a0; SIMONS EL, 1995, SCIENCE, V268, P1885, DOI 10.1126/science.7604261; Simons Elwyn L., 1994, P179; Szalay F.S., 1979, EVOLUTIONARY HIST PR, DOI [10.1002/ajpa.1330600122, DOI 10.1002/AJPA.1330600122]; TONG YS, 1997, PALEONTOLOGICA SIN C, V26, P189	25	104	111	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					528	530		10.1126/science.286.5439.528	http://dx.doi.org/10.1126/science.286.5439.528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521348				2022-12-24	WOS:000083121200060
J	O'Hanlan, KA				O'Hanlan, KA			Domestic partnership benefits at medical universities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Stanford Med Ctr, Palo Alto, CA 94305 USA	Stanford University	O'Hanlan, KA (corresponding author), Stanford Med Ctr, Palo Alto, CA 94305 USA.		O'Hanlan, Katherine/A-4073-2017	O'Hanlan, Katherine/0000-0002-7577-4188				*AM MED WOM ASS, 1993, J AM MED WOMEN ASSOC, V49, P86; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P538; BERSOFF DN, 1991, AM PSYCHOL, V46, P950, DOI 10.1037/0003-066X.46.9.950; BUSH CN, 1991, STANFORD U CAMPUS RE, P1; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; FRIED B, 1992, REPORT SUBCOMMITTEE, P37; KOHN S, 1999, DOMESTIC PARTNER ORG, P120; OHANLAN KA, 1991, FAC SEN STANF U OCT; 1992, TOT COMP NEWS    DEC, P1	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1289	+		10.1001/jama.282.13.1289	http://dx.doi.org/10.1001/jama.282.13.1289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517436	hybrid			2022-12-24	WOS:000082901100041
J	Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y				Borg, LE; Connelly, JN; Nyquist, LE; Shih, CY; Wiesmann, H; Reese, Y			The age of the carbonates in martian meteorite ALH84001	SCIENCE			English	Article							PETROLOGIC EVIDENCE; SM-ND; MARS; ORIGIN; DIFFERENTIATION; TEMPERATURE; CHRONOLOGY; RB; SR	The age of secondary carbonate mineralization in the martian meteorite ALH84001 was determined to be 3.90 +/- 0.04 billion years by rubidium-strontium (Rb-Sr) dating and 4.04 +/- 0.10 billion years by Lead-Lead (Pb-Pb) dating. The Rb-Sr and Pb-Pb isochrons are defined by Leachates of a mixture of high-graded carbonate (visually estimated as similar to 5 percent). whitlockite (trace), and orthopyroxene (similar to 95 percent). The carbonate formation age is contemporaneous with a period in martian history when the surface is thought to have had flowing water, but also was undergoing heavy bombardment by meteorites. Therefore, this age does not distinguish between aqueous and impact origins for the carbonates.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Univ Texas, Dept Geol Sci, Austin, TX 78713 USA; Lockheed Engn & Sci Co, Houston, TX 77258 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; University of Texas System; University of Texas Austin; Lockheed Martin	Borg, LE (corresponding author), Univ New Mexico, Inst Meteorit, Albuquerque, NM 87131 USA.		Connelly, James/O-7996-2015					BENOTHMAN D, 1989, EARTH PLANET SC LETT, V94, P1, DOI 10.1016/0012-821X(89)90079-4; Bogard DD, 1999, METEORIT PLANET SCI, V34, P451, DOI 10.1111/j.1945-5100.1999.tb01353.x; Borg LE, 1997, GEOCHIM COSMOCHIM AC, V61, P4915, DOI 10.1016/S0016-7037(97)00276-7; CARR MH, 1983, ICARUS, V56, P476, DOI 10.1016/0019-1035(83)90168-9; CARR MH, 1996, WATER MARS, V20, P229; FANNALE FP, 1992, MARS, P1135; Gilmour JD, 1997, METEORIT PLANET SCI, V32, pA48; Gleason JD, 1997, GEOCHIM COSMOCHIM AC, V61, P3503, DOI 10.1016/S0016-7037(97)00173-7; HARPER CL, 1995, SCIENCE, V267, P213, DOI 10.1126/science.7809625; Hartmann W.K., 1981, BASALTIC VOLCANISM T, P1049; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; JAGOUTZ E, 1994, METEORITICS, V29, P478; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; McSween HY, 1998, INT GEOL REV, V40, P774, DOI 10.1080/00206819809465238; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; NAKAMURA N, 1982, GEOCHIM COSMOCHIM AC, V46, P1555, DOI 10.1016/0016-7037(82)90314-3; NEUKUM G, 1976, SCIENCE, V194, P1381, DOI 10.1126/science.194.4272.1381; NYQUIST LE, 1995, LUNAR PLANET SCI, V26, P1065; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; Scott ERD, 1998, METEORIT PLANET SCI, V33, P709, DOI 10.1111/j.1945-5100.1998.tb01677.x; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SHIH CY, 1982, GEOCHIM COSMOCHIM AC, V46, P2323, DOI 10.1016/0016-7037(82)90205-8; TATSUMOTO M, 1973, SCIENCE, V180, P1279, DOI 10.1126/science.180.4092.1279; TRIEMAN AH, 1995, METEORITICS, V30, P294; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Wadhwa M, 1998, METEORIT PLANET SCI, V33, P685, DOI 10.1111/j.1945-5100.1998.tb01674.x; Wadhwa M., 1996, METEORIT PLANET SCI, V31, pA145; Warren PH, 1998, J GEOPHYS RES-PLANET, V103, P16759, DOI 10.1029/98JE01544; YORK D, 1966, CAN J PHYS, V44, P1079, DOI 10.1139/p66-090; [No title captured]; [No title captured]	32	130	134	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					90	94		10.1126/science.286.5437.90	http://dx.doi.org/10.1126/science.286.5437.90			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506566	Green Submitted			2022-12-24	WOS:000082907400039
J	Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S				Andreu, AL; Hanna, MG; Reichmann, H; Bruno, C; Penn, AS; Tanji, K; Pallotti, F; Iwata, S; Bonilla, E; Lach, B; Morgan-Hughes, J; DiMauro, S			Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLEX-III DEFICIENCY; C-OXIDASE DEFICIENCY; SKELETAL-MUSCLE; POINT MUTATION; MYOPATHY; MTDNA; PATIENT; DISEASE; GENOME	Background The mitochondrial myopathies typically affect many organ systems and are associated with mutations in mitochondrial DNA (mtDNA) that are maternally inherited. However, there is also a sporadic form of mitochondrial myopathy in which exercise intolerance is the predominant symptom. We studied the biochemical and molecular characteristics of this sporadic myopathy. Methods We sequenced the mtDNA cytochrome b gene in blood and muscle specimens from five patients with severe exercise intolerance, lactic acidosis in the resting state (in four patients), and biochemical evidence of complex III deficiency. We compared the clinical and molecular features of these patients with those previously described in four other patients with mutations in the cytochrome b gene. Results We found a total of three different nonsense mutations (G15084A, G15168A, and G15723A), one missense mutation (G14846A), and a 24-bp deletion (nucleotides 15498 to 15521) in the cytochrome b gene in the five patients. Each of these mutations impairs the enzymatic function of the cytochrome b protein. In these patients and those previously described, the clinical manifestations included progressive exercise intolerance, proximal limb weakness, and in some cases, attacks of myoglobinuria. There was no maternal inheritance and there were no mutations in tissues other than muscle. The absence of these findings suggests that the disorder is due to somatic mutations in myogenic stem cells after germ-layer differentiation. All the point mutations involved the substitution of adenine for guanine, but all were in different locations. Conclusions The sporadic form of mitochondrial myopathy is associated with somatic mutations in the cytochrome b gene of mtDNA. This myopathy is one cause of the common and often elusive syndrome of exercise intolerance. (N Engl J Med 1999; 341:1037-44.) (C)1999, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, H Houston Merritt Clin Res Ctr Muscular Dystrophy, Dept Neurol, New York, NY 10032 USA; Hosp Valle De Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona, Spain; UCL, Inst Neurol, London, England; Tech Univ Dresden, Klinikum Carl Gustav Carus, Neurol Klin, D-8027 Dresden, Germany; Univ Genoa, Ist Giannina Gaslini, Dept Pediat, Genoa, Italy; NINDS, NIH, Bethesda, MD 20892 USA; Uppsala Univ, Dept Biochem, Uppsala, Sweden; Ottawa Hosp, Dept Lab Med, Ottawa, ON, Canada	Columbia University; Hospital Universitari Vall d'Hebron; University of London; University College London; Technische Universitat Dresden; University of Genoa; IRCCS Istituto Giannina Gaslini; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Uppsala University; University of Ottawa; Ottawa Hospital Research Institute	DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.	sd12@columbia.edu	Hanna, Michael G/B-1995-2009; Bruno, Claudio/A-3148-2015	Bruno, Claudio/0000-0002-3426-2901; ANDREU, antonio luis/0000-0002-3936-3234; Hanna, Michael/0000-0003-0825-4075; Pallotti, Francesco/0000-0001-9946-8516	NICHD NIH HHS [P01HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD032062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, P01NS011766] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andreu AL, 1999, MOL GENET METAB, V67, P49, DOI 10.1006/mgme.1999.2843; Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444; Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599; Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DiMauro S, 1997, MOL GENETIC BASIS NE, P201; Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053; ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529; ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919; Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835; Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kennaway N. G., 1998, MOL GENET METAB, V63, P49; Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112; MARTIN GM, 1973, TISSUE CULTURE METHO, P39; MIRANDA AF, 1986, METHOD ENZYMOL, V119, P619; Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4; MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284; MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617; REICHMANN H, 1986, ARCH NEUROL-CHICAGO, V43, P957, DOI 10.1001/archneur.1986.00520090081024; Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2; SCIACCO M, 1994, HUM MOL GENET, V3, P687; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Weber K, 1997, AM J HUM GENET, V60, P373	28	313	321	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1037	1044		10.1056/NEJM199909303411404	http://dx.doi.org/10.1056/NEJM199909303411404			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502593				2022-12-24	WOS:000082880500004
J	Fauci, AS				Fauci, AS			The AIDS epidemic - Considerations for the 21st century	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTION; UNITED-STATES; TRANSMISSION; RESERVOIR; MORTALITY		NIAID, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Fauci, AS (corresponding author), NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1999, WORLD HLTH REPORT 19; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Coates TJ, 1998, SCI AM, V279, P96, DOI 10.1038/scientificamerican0798-96; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper DA, 1999, NAT MED, V5, P611, DOI 10.1038/9454; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dore GJ, 1998, AIDS, V12, P2354; Durant J, 1999, LANCET, V353, P2195, DOI 10.1016/S0140-6736(98)12291-2; Elias CJ, 1996, AIDS, V10, pS43; Evans TG, 1999, J INFECT DIS, V180, P290, DOI 10.1086/314895; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Folkers GK, 1998, NAT MED, V4, P491, DOI 10.1038/nm0598supp-491; Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; Hoyert D L, 1999, Natl Vital Stat Rep, V47, P1; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Kilbourne E.D., 1987, INFLUENZA, P3; Kramer Larry, 1994, REPORTS HOLOCAUST ST; Krause RM, 1998, BIOMED RES REP, P1; Mann JM, 1997, HASTINGS CENT REP, V27, P6, DOI 10.2307/3528660; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mofenson LM, 1999, LANCET, V353, P766, DOI 10.1016/S0140-6736(99)90028-4; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PHS TASK FORC, 1998, MMWR-MORBID MORTAL W, V47, P1; Pomerantz RJ, 1999, NEW ENGL J MED, V340, P1672, DOI 10.1056/NEJM199905273402110; Quinn TC, 1998, BIOMED RES REP, P327; ROSENBERG PS, 1994, NEW ENGL J MED, V330, P789, DOI 10.1056/NEJM199403173301114; ROSENBERG PS, 1995, SCIENCE, V270, P1372, DOI 10.1126/science.270.5240.1372; SABA J, 1999, RESULTS PETRA INTERV; SWEENEY PA, 1997, INT C ANT AG CHEM TO; *UN, 1999, DEM IMP HIV AIDS; Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623; Weiss RA, 1999, NATURE, V397, P385, DOI 10.1038/17008; *WHO, 1998, AIDS EP UPD DEC 1998; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; World Health Organization, 1999, REM OBST HLTH DEV; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; 1998, MMWR MORB MORTAL WKL, P47	48	188	195	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1999	341	14					1046	1050		10.1056/NEJM199909303411406	http://dx.doi.org/10.1056/NEJM199909303411406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241JX	10502595				2022-12-24	WOS:000082880500006
J	Rauskolb, C; Correla, T; Irvine, KD				Rauskolb, C; Correla, T; Irvine, KD			Fringe-dependent separation of dorsal and ventral cells in the Drosophila wing	NATURE			English	Article							IMAGINAL DISC; NOTCH; LIMB; COMPARTMENTALIZATION; EXPRESSION; ACTIVATION; BOUNDARY; RECEPTOR; PROTEIN; SERRATE	The separation of cells into populations that do not intermix, termed compartments, is a fundamental organizing principle during development(1-5). Dorsal-ventral compartmentalization of the Drosophila wing is regulated downstream of the apterous (np) gene, which encodes a transcription factor that specifies dorsal wing fate(6-8). fringe (fng) is normally expressed by dorsal cells downstream of ap(9); here we show that fng plays a key role in dorsal-ventral compartmentalization. Loss of fng function causes dorsal cells to violate the compartment boundary, and ectopic expression of the Fng protein causes ventral cells to violate the compartment boundary. Fng modulates signalling through the Notch receptor(10,11). Notch and its ligands are essential for formation of the dorsal-ventral compartment border, and repositioning the stripe of Notch activation that is normally established there appears to reposition the compartment border. However, activation of Notch does not itself confer either dorsal or ventral cell location, and fng can influence compartmentalization even within regions of ubiquitous Notch activation. Our results indicate that the primary mechanism by which fng establishes a compartment border is by positioning a stripe of Notch activation, but also that fng may exert additional influences on compartmentalization.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu						Altabef M, 1997, DEVELOPMENT, V124, P4547; BLAIR SS, 1993, DEVELOPMENT, V119, P339; BLAIR SS, 1994, DEVELOPMENT, V120, P1805; Blair SS, 1997, DEVELOPMENT, V124, P4053; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Irvine KD, 1999, CURR OPIN GENET DEV, V9, P434, DOI 10.1016/S0959-437X(99)80066-5; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Ito K, 1997, DEVELOPMENT, V124, P761; KIM J, 1995, CELL, V82, P795, DOI 10.1016/0092-8674(95)90476-X; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 1999, DEVELOPMENT, V126, P2441; LYMAN D, 1993, P NATL ACAD SCI USA, V90, P10395, DOI 10.1073/pnas.90.21.10395; Micchelli CA, 1997, DEVELOPMENT, V124, P1485; Michaud JL, 1997, DEVELOPMENT, V124, P1453; Panin VM, 1998, SEMIN CELL DEV BIOL, V9, P609, DOI 10.1006/scdb.1998.0263; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; RULIFSON EJ, 1995, DEVELOPMENT, V121, P2813; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; XU T, 1993, DEVELOPMENT, V117, P1223	29	90	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 30	1999	401	6752					476	480		10.1038/46786	http://dx.doi.org/10.1038/46786			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519550				2022-12-24	WOS:000082981200056
J	Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC				Gussoni, E; Soneoka, Y; Strickland, CD; Buzney, EA; Khan, MK; Flint, AF; Kunkel, LM; Mulligan, RC			Dystrophin expression in the mdx mouse restored by stem cell transplantation	NATURE			English	Article							GENE-THERAPY; ENDOTHELIAL-CELLS; NUCLEAR DOMAINS; SKELETAL-MUSCLE; FULL-LENGTH; MICE; MARROW; BONE; INJECTION; MYOBLASTS	The development of cell or gene therapies for diseases involving cells that are widely distributed throughout the body has been severely hampered by the inability to achieve the disseminated delivery of cells or genes to the affected tissues or organ(1). Here we report the results of bone marrow transplantation studies in the mdx mouse, an animal model of Duchenne's muscular dystrophy(2), which indicate that the intravenous injection of either normal haematopoietic stem cells or a novel population of muscle-derived stem cells into irradiated animals results in the reconstitution of the haematopoietic compartment of the transplanted recipients, the incorporation of donor-derived nuclei into muscle, and the partial restoration of dystrophin expression in the affected muscle. These results suggest that the transplantation of different stem cell populations, using the procedures of bone marrow transplantation, might provide an unanticipated avenue for treating muscular dystrophy as well as other diseases where the systemic delivery of therapeutic cells to sites throughout the body is critical. Our studies also suggest that the inherent developmental potential of stem cells isolated from diverse tissues or organs may be more similar than previously anticipated.	Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Boston, MA 02115 USA; Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Mulligan, RC (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA.	kunkel@rascal.med.harvard.edu; mulligan@rascal.med.harvard.edu	Ahmad Khan, Mohammad Kalim/AAA-2751-2022; Gussoni, Emanuela/AAL-6150-2021	Ahmad Khan, Mohammad Kalim/0000-0002-8004-1448; Gussoni, Emanuela/0000-0002-9915-3677				ACSADI G, 1991, NATURE, V352, P815, DOI 10.1038/352815a0; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baroffio A, 1995, DIFFERENTIATION, V59, P259, DOI 10.1046/j.1432-0436.1995.5940259.x; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1996, NAT BIOTECHNOL, V14, P1012, DOI 10.1038/nbt0896-1012; Gussoni E, 1997, NAT MED, V3, P970, DOI 10.1038/nm0997-970; HALL ZW, 1989, CELL, V59, P771, DOI 10.1016/0092-8674(89)90597-7; HOFFMAN EP, 1990, J NEUROL SCI, V99, P9, DOI 10.1016/0022-510X(90)90195-S; KARPATI G, 1989, AM J PATHOL, V135, P27; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1989, NATURE, V337, P176, DOI 10.1038/337176a0; PAVLATH GK, 1989, NATURE, V337, P570, DOI 10.1038/337570a0; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; PHELPS SF, 1995, HUM MOL GENET, V4, P1251, DOI 10.1093/hmg/4.8.1251; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; RAFAEL JA, 1994, HUM MOL GENET, V3, P1725, DOI 10.1093/hmg/3.10.1725; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; Saito T, 1995, Tissue Eng, V1, P327, DOI 10.1089/ten.1995.1.327; Shi Q, 1998, BLOOD, V92, P362, DOI 10.1182/blood.V92.2.362.414k38_362_367; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404	29	1441	1638	1	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					390	394		10.1038/43919	http://dx.doi.org/10.1038/43919			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517639				2022-12-24	WOS:000082822600055
J	Quinn, C				Quinn, C			The pirates	ANNALS OF INTERNAL MEDICINE			English	Article											Quinn, C (corresponding author), 49 Thomas Rd, Rockville Ctr, NY 11570 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					472	473		10.7326/0003-4819-131-6-199909210-00015	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00015			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498567				2022-12-24	WOS:000082641100013
J	Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC				Cardosa, MJ; Krishnan, S; Tio, PH; Perera, D; Wong, SC			Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak	LANCET			English	Article							NEUROGENIC PULMONARY-EDEMA; POLYMERASE CHAIN-REACTION; JAPANESE ENCEPHALITIS; ENZYME-IMMUNOASSAY; RAPID DIAGNOSIS; MYOCARDITIS; VIRUS; ENCEPHALOMYELITIS; IDENTIFICATION; SAMPLES	Background In mid-1997, several children died in Sarawak, Malaysia,during an epidemic of enterovirus-71 (EV71) hand, foot, and mouth disease. The children who died had a febrile illness that rapidly progressed to cardiopulmonary failure and the cause was not satisfactorily resolved. We describe the isolation and identification of a subgenus B adenovirus from the children who died. Methods We studied two groups of children presenting to Sibu Hospital from April 14 to Sept 30, 1997. For children who died, the inclusion criterion was death after febrile illness, and for those who did not die it was acute flaccid paralysis (AFP). Serum and cerebrospinal fluid samples were tested for IgM antibodies to Japanese encephalitis and dengue viruses. Viruses isolated were identified by immunofluorescence, reverse-transcriptase PCR, or PCR and DNA sequencing. Findings Enterovirus was isolated in three (19%) of 16 children who died and in none of the eight surviving children with AFP. However, an agent that was initially difficult to identify was found in ten (63%) children who died and five (63%) surviving children who had AFP. The agents isolated from ten (66.7%) of these 15 children were eventually identified as adenoviruses and were isolated mainly from clinically important sterile sites or tissues. All the enterovirus positive children who died had this second agent. Interpretation Our data raises doubts that EV71 was the only aetiological agent in these deaths.	Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia; Sibu Hosp, Sibu, Sarawak, Malaysia	University of Malaysia Sarawak	Cardosa, MJ (corresponding author), Univ Malaysia Sarawak, Inst Hlth & Community Med, Kota Samarahan 94300, Sarawak, Malaysia.	jcardosa@mailhost.unimas.my	Cardosa, Mary Jane/A-3611-2009					ALLARD A, 1990, J CLIN MICROBIOL, V28, P2659, DOI 10.1128/JCM.28.12.2659-2667.1990; [Anonymous], 1997, Wkly Epidemiol Rec, V72, P211; BOWLES NE, 1986, LANCET, V1, P1120; BRANDON F. B., 1962, ADVANCES VIRUS RES, V9, P157; CARDOSA MJ, 1995, CLIN DIAGN VIROL, V3, P343, DOI 10.1016/0928-0197(94)00049-Z; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; Kidd AH, 1996, J CLIN MICROBIOL, V34, P622, DOI 10.1128/JCM.34.3.622-627.1996; Libby P, 1997, CIRCULATION, V95, P551, DOI 10.1161/01.CIR.95.3.551; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MARTIN AB, 1994, CIRCULATION, V90, P330, DOI 10.1161/01.CIR.90.1.330; Romero Jose R., 1993, P401; Solomon T, 1998, J CLIN MICROBIOL, V36, P2030, DOI 10.1128/JCM.36.7.2030-2034.1998; Solomon T, 1998, LANCET, V351, P1094, DOI 10.1016/S0140-6736(97)07509-0; TANAKA M, 1993, J VIROL METHODS, V41, P311, DOI 10.1016/0166-0934(93)90020-R; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P184; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	18	106	116	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					987	991		10.1016/S0140-6736(98)11032-2	http://dx.doi.org/10.1016/S0140-6736(98)11032-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501361	Green Accepted			2022-12-24	WOS:000082596000012
J	Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA				Lee, SB; Huang, K; Palmer, R; Truong, VB; Herzlinger, D; Kolquist, KA; Wong, J; Paulding, C; Yoon, SK; Gerald, W; Oliner, JD; Haber, DA			The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MICE LACKING GDNF; GENE-PRODUCT; KIDNEY DEVELOPMENT; DNA-BINDING; EXPRESSION; PROTEIN; PROLIFERATION; RECEPTOR; SEQUENCE	WT1 encodes a zinc finger transcription factor implicated in kidney differentiation and tumorigenesis. In reporter assays, WT1 represses transcription from GC- and To-rich promoters, but its physiological targets remain uncertain. We used hybridization to high-density oligonucleotide arrays to search for native genes whose expression is altered following inducible expression of WT1. The major target of WT1 was amphiregulin, a member of the epidermal growth factor family. The WT1(-KTS) isoform binds directly to the amphiregulin promoter, resulting in potent transcriptional activation. The in vivo expression profile of amphiregulin during fetal kidney development mirrors the highly specific pattern of WT1 itself, and recombinant Amphiregulin stimulates epithelial branching in organ cultures of embryonic mouse kidney. These observations suggest a model for WT1 as a transcriptional regulator during kidney differentiation.	Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA; Harvard Med Sch, Charlestown, MA 02129 USA; Affymetrix, Santa Clara, CA 95051 USA; Cornell Univ, Dept Physiol & Biophys, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Affymetrix; Cornell University; Memorial Sloan Kettering Cancer Center	Haber, DA (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Genet Mol Lab, Charlestown, MA 02129 USA.			Wong, Jenise C./0000-0003-0573-6650; Lee, Sean/0000-0001-6211-3498	NCI NIH HHS [CA71167, CA58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071167, R01CA058596, R37CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; COLES HSR, 1993, DEVELOPMENT, V118, P777; Davies JA, 1996, ACTA ANAT, V156, P187; Donovan MJ, 1999, DEV GENET, V24, P252, DOI 10.1002/(SICI)1520-6408(1999)24:3/4<252::AID-DVG8>3.0.CO;2-K; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; FISHER DA, 1989, ANNU REV PHYSIOL, V51, P67, DOI 10.1146/annurev.ph.51.030189.000435; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kim J, 1999, MOL CELL BIOL, V19, P2289; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Maheswaran S, 1998, GENE DEV, V12, P1108, DOI 10.1101/gad.12.8.1108; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Pepicelli CV, 1997, DEV BIOL, V192, P193, DOI 10.1006/dbio.1997.8745; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Qiao JZ, 1999, DEVELOPMENT, V126, P547; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Saxen L., 1987, ORGANOGENESIS KIDNEY; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; Vainio S, 1997, CELL, V90, P975, DOI 10.1016/S0092-8674(00)80363-3; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	42	238	242	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					663	673		10.1016/S0092-8674(00)80053-7	http://dx.doi.org/10.1016/S0092-8674(00)80053-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490105	Bronze			2022-12-24	WOS:000082433500013
J	Laezza, F; Doherty, JJ; Dingledine, R				Laezza, F; Doherty, JJ; Dingledine, R			Long-term depression in hippocampal interneurons: Joint requirement for pre- and postsynaptic events	SCIENCE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; CA2+-PERMEABLE AMPA RECEPTORS; GYRUS IN-VITRO; RAT HIPPOCAMPUS; DENTATE GYRUS; POTENTIATION; EXPRESSION; CHANNELS; LOCALIZATION; SUBTYPES	Long-term depression (LTD) is a well-known form of synaptic plasticity of principal neurons in the mammalian brain. Whether such changes occur in interneurons is still controversial. CA3 hippocampal interneurons expressing Ca2+-permeable AMPA receptors exhibited LTD after tetanic stimulation of CA3 excitatory inputs. LTD was independent of NMDA receptors and required both Ca2+-influx through postsynaptic AMPA receptors and activation of presynaptic mGluR7-Like receptors. These results point to the capability of interneurons to undergo plastic changes of synaptic strength through joint activation of pre- and postsynaptic glutamate receptors.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Neurosci, Atlanta, GA 30322 USA	Emory University; Emory University	Dingledine, R (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA.		Laezza, Fernanda/L-6019-2016; dingledine, Ray/F-5173-2011; Laezza, Fernanda/X-4076-2019	Laezza, Fernanda/0000-0003-1141-1852; Laezza, Fernanda/0000-0003-1141-1852; Dingledine, Ray/0000-0001-7128-4520				Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Bleakman D, 1996, NEUROPHARMACOLOGY, V35, P1689, DOI 10.1016/S0028-3908(96)00156-6; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bradley SR, 1996, J NEUROSCI, V16, P2044; Carroll RC, 1999, NAT NEUROSCI, V2, P454, DOI 10.1038/8123; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONN PJ, COMMUNICATION; Doherty J, 1997, J NEUROPHYSIOL, V77, P393, DOI 10.1152/jn.1997.77.1.393; Gu JG, 1996, NATURE, V381, P793, DOI 10.1038/381793a0; HERLITZE S, 1993, NEURON, V10, P1131, DOI 10.1016/0896-6273(93)90061-U; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Huang LQ, 1997, NEUROREPORT, V8, P687, DOI 10.1097/00001756-199702100-00022; IINO M, 1994, NEUROSCI LETT, V173, P14, DOI 10.1016/0304-3940(94)90139-2; Isa T, 1996, NEUROREPORT, V7, P689, DOI 10.1097/00001756-199602290-00002; JACKSON H, 1988, TRENDS NEUROSCI, V11, P278, DOI 10.1016/0166-2236(88)90112-9; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Lissin DV, 1999, J NEUROSCI, V19, P1263; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; Maccaferri G, 1996, J NEUROSCI, V16, P5334; Maccaferri G, 1998, SCIENCE, V279, P1368, DOI 10.1126/science.279.5355.1368; MACCAFERRI G, 1995, NEURON, V15, P135; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; McMahon LL, 1997, NEURON, V18, P295, DOI 10.1016/S0896-6273(00)80269-X; OUARDOUZ M, 1995, J NEUROPHYSIOL, V73, P2; Phillips T, 1997, NEUROREPORT, V8, P3349, DOI 10.1097/00001756-199710200-00031; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Tzounopoulos T, 1998, NEURON, V21, P837, DOI 10.1016/S0896-6273(00)80599-1; Vida I, 1998, J PHYSIOL-LONDON, V506, P755, DOI 10.1111/j.1469-7793.1998.755bv.x; Wang Y, 1997, J NEUROPHYSIOL, V77, P812, DOI 10.1152/jn.1997.77.2.812; Washburn MS, 1997, J NEUROSCI, V17, P9393; Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180; YOKI M, 1996, SCIENCE, V273, P645; ZALUTSKY RA, 1990, SCIENCE, V248, P1619, DOI 10.1126/science.2114039	40	131	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1411	1414		10.1126/science.285.5432.1411	http://dx.doi.org/10.1126/science.285.5432.1411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464102				2022-12-24	WOS:000082233500046
J	Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC				Lawrence, CM; Ray, S; Babyonyshev, M; Galluser, R; Borhani, DW; Harrison, SC			Crystal structure of the ectodomain of human transferrin receptor	SCIENCE			English	Article							INTERMOLECULAR DISULFIDE BONDS; INDUCED CONFORMATIONAL CHANGE; LINKED GLYCOSYLATION SITE; X-RAY-DIFFRACTION; GLUTAMATE CARBOXYPEPTIDASE; SERUM TRANSFERRIN; LIGAND-BINDING; EXPRESSION; HEMOCHROMATOSIS; ASSOCIATION	The transferrin receptor (TfR) undergoes multiple rounds of clathrin-mediated endocytosis and reemergence at the cell surface, importing iron-loaded transferrin (Tf) and recycling apotransferrin after discharge of iron in the endosome. The crystal structure of the dimeric ectodomain of the human TfR, determined here to 3.2 angstroms resolution, reveals a three-domain subunit. One domain closely resembles carboxy- and aminopeptidases, and features of membrane glutamate carboxypeptidase can be deduced from the TfR structure. A model is proposed for Tf binding to the receptor.	Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Harrison, SC (corresponding author), Howard Hughes Med Inst, 320 Longwood Ave, Boston, MA 02115 USA.		Lawrence, C. Martin/AAH-3420-2020; Borhani, David/O-2692-2019	Lawrence, C. Martin/0000-0002-5398-466X; Borhani, David/0000-0002-8486-8792				ALVAREZ E, 1989, EMBO J, V8, P2231, DOI 10.1002/j.1460-2075.1989.tb08347.x; ANDERSON BF, 1990, NATURE, V344, P784, DOI 10.1038/344784a0; ANDERSON BF, 1989, J MOL BIOL, V209, P711, DOI 10.1016/0022-2836(89)90602-5; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; BALI PK, 1991, BIOCHEMISTRY-US, V30, P324, DOI 10.1021/bi00216a003; BORHANI DW, 1991, J MOL BIOL, V218, P685, DOI 10.1016/0022-2836(91)90255-5; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; Bzdega T, 1997, J NEUROCHEM, V69, P2270; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; HEMMAPLARDH D, 1976, BIOCHIM BIOPHYS ACTA, V426, P3852; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KORNFELD S, 1968, BIOCHEMISTRY-US, V7, P945, DOI 10.1021/bi00843a010; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MASON AB, 1993, BIOCHEMISTRY-US, V32, P5472, DOI 10.1021/bi00071a025; Mason AB, 1997, BIOCHEM J, V326, P77, DOI 10.1042/bj3260077; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; Richardson DR, 1997, BBA-REV BIOMEMBRANES, V1331, P1, DOI 10.1016/S0304-4157(96)00014-7; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; Roy CN, 1999, J BIOL CHEM, V274, P9022, DOI 10.1074/jbc.274.13.9022; RUTLEDGE EA, 1994, BLOOD, V83, P580; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SIPE DM, 1991, J BIOL CHEM, V266, P8002; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P16309; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; ZAK O, 1994, J BIOL CHEM, V269, P7110	40	240	255	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					779	782		10.1126/science.286.5440.779	http://dx.doi.org/10.1126/science.286.5440.779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531064				2022-12-24	WOS:000083303200056
J	Prut, Y; Fetz, EE				Prut, Y; Fetz, EE			Primate spinal interneurons show pre-movement instructed delay activity	NATURE			English	Article							PREMOTOR CORTEX; MOTOR CORTEX; CORTICOSPINAL PROJECTIONS; INTENDED DIRECTION; WRIST MOVEMENTS; REACHING TASK; FRONTAL-LOBE; MONKEY; AREAS; FOREPERIOD	Preparatory changes in neural activity before the execution of a movement have been documented in tasks that involve an instructed delay period (an interval between a transient instruction cue and a subsequently triggered movement). Such preparatory activity occurs in many motor centres in the brain, including the primary motor cortex(1-6), premotor cortex(7-9), supplementary motor area(6,10,11) and basal ganglia(6,12,13). Activity during the instructed delay period reflects movement planning, as it correlates with parameters of the cue and the subsequent movement (such as direction and extent(5,6,9)), although it occurs well before muscle activity. How such delay-period activity shapes the ensuring motor action remains unknown. Here we show that spinal interneurons also exhibit early pre-movement delay activity that often differs from their responses during the subsequent muscle activity. This delay activity resembles the set-related activity found in various supraspinal areas, indicating that movement preparation may occur simultaneously over widely distributed regions, including spinal levels. Our results also suggest that two processes occur in the spinal circuitry during this delay period: the motor network is primed with rate changes in the same direction as subsequent movement-related activity; and a superimposed global inhibition suppresses the expression of this activity in muscles.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Prut, Y (corresponding author), Univ Washington, Dept Physiol & Biophys, Box 357330, Seattle, WA 98195 USA.							ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1987, EXP BRAIN RES, V67, P623; Baumgartner C, 1996, NEUROLOGY, V46, P753, DOI 10.1212/WNL.46.3.753; BONNET M, 1991, ELECTROEN CLIN NEURO, V81, P135, DOI 10.1016/0168-5597(91)90007-K; BRUNIA CHM, 1982, PSYCHOPHYSIOLOGY, V19, P63, DOI 10.1111/j.1469-8986.1982.tb02600.x; BURKE D, 1980, J PHYSIOL-LONDON, V306, P337, DOI 10.1113/jphysiol.1980.sp013400; DUM RP, 1991, J NEUROSCI, V11, P667; GEORGOPOULOS AP, 1989, EXP BRAIN RES, V75, P183; GERILOVSKY L, 1983, ELECTROEN CLIN NEURO, V56, P487, DOI 10.1016/0013-4694(83)90233-X; HE SQ, 1993, J NEUROSCI, V13, P952; JAEGER D, 1993, EXP BRAIN RES, V95, P51; KOMIYAMA T, 1990, EXP BRAIN RES, V79, P357, DOI 10.1007/BF00608245; KUBOTA K, 1979, BRAIN RES, V168, P435, DOI 10.1016/0006-8993(79)90189-6; KURATA K, 1993, J NEUROPHYSIOL, V69, P187, DOI 10.1152/jn.1993.69.1.187; KURATA K, 1988, EXP BRAIN RES, V69, P327; KUYPERS HGJ, 1970, BRAIN RES, V24, P29, DOI 10.1016/0006-8993(70)90272-6; MOLL L, 1977, SCIENCE, V198, P317, DOI 10.1126/science.410103; MURRAY EA, 1981, J COMP NEUROL, V195, P339, DOI 10.1002/cne.901950212; Perlmutter SI, 1998, J NEUROPHYSIOL, V80, P2475, DOI 10.1152/jn.1998.80.5.2475; REQUIN J, 1977, ATTENTION PERFORM, V6, P139; RIEHLE A, 1995, BEHAV BRAIN RES, V70, P1, DOI 10.1016/0166-4328(94)00180-N; Sawaguchi T, 1996, J NEUROPHYSIOL, V75, P2150, DOI 10.1152/jn.1996.75.5.2150; TANJI J, 1976, J NEUROPHYSIOL, V39, P1062, DOI 10.1152/jn.1976.39.5.1062; TANJI J, 1980, J NEUROPHYSIOL, V43, P60, DOI 10.1152/jn.1980.43.1.60; TANJI J, 1985, J NEUROPHYSIOL, V53, P129, DOI 10.1152/jn.1985.53.1.129; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; TOYOSHIMA K, 1982, J HIRNFORSCH, V23, P257; WEINRICH M, 1982, J NEUROSCI, V2, P1329; WISE SP, 1986, PROG BRAIN RES, V64, P117	29	169	171	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					590	594		10.1038/44145	http://dx.doi.org/10.1038/44145			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524626				2022-12-24	WOS:000083054900051
J	Schneider, JS; Levin, S				Schneider, JS; Levin, S			Uneasy partners: The lesbian and gay health care community and the AMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NYU, Sch Med, New York, NY 10012 USA; Access Consulting Int Inc, Washington, DC USA	New York University	Schneider, JS (corresponding author), NYU, Sch Med, New York, NY 10012 USA.							*ACCR COUNC GRAD M, 1999, I REV REQ; *AM AC FAM PHYS, 1999, COMP AAFP POS SEL HL; *AM MED ASS, 1982, P AM MED ASS HOUS DE, V2, P579; *AM MED ASS, 1992, P AM MED ASS HOUS DE, V1, P151; *AM MED ASS, 1999, CULT COMP COMP; *AM MED ASS, 1989, DEL HDB; *AM MED ASS, 1999, POL COMP; *AM MED ASS, 1990, P AM MED ASS HOUS DE, V1, P276; *AM MED ASS, 1998, POLICY COMPENDIUM; *AM MED ASS, 1998, POL COMP; BEACH RK, 1993, PEDIATRICS, V92, P631; Davis RM, 1996, JAMA-J AM MED ASSOC, V275, P1354, DOI 10.1001/jama.1996.03530410068036; JONES RJ, 1982, JAMA-J AM MED ASSOC, V248, P736; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; MCCORMICK B, 1998, AM MED NEWS     1019, P24; Wallick M M, 1997, N C Med J, V58, P123; WALLICK MM, 1995, ACAD MED, V70, P2, DOI 10.1097/00001888-199501000-00003	18	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1287	1288		10.1001/jama.282.13.1287	http://dx.doi.org/10.1001/jama.282.13.1287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517435	hybrid			2022-12-24	WOS:000082901100040
J	Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H				Holmbeck, K; Bianco, P; Caterina, J; Yamada, S; Kromer, M; Kuznetsov, SA; Mankani, M; Robey, PG; Poole, AR; Pidoux, I; Ward, JM; Birkedal-Hansen, H			MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover	CELL			English	Article							TYPE-1 MATRIX METALLOPROTEINASE; PRO-GELATINASE-A; EXTRACELLULAR-MATRIX; OSTEOBLAST DIFFERENTIATION; HYPERTROPHIC CHONDROCYTES; INTERSTITIAL COLLAGENASE; RHEUMATOID-ARTHRITIS; MOUSE EMBRYOGENESIS; BONE-RESORPTION; IN-VIVO	MT1-MMP is a membrane-bound matrix metalloproteinase (MT-MMP) capable of mediating pericellular proteolysis of extracellular matrix components. MT1-MMP is therefore thought to be an important molecular tool for cellular remodeling of the surrounding matrix. To establish the biological role of this membrane proteinase we generated MT1-MMP-deficient mice by gene targeting. MT1-MMP deficiency causes craniofacial dysmorphism, arthritis, osteopenia, dwarfism, and fibrosis of soft tissues due to ablation of a collagenolytic activity that is essential for modeling of skeletal and extraskeletal connective tissues. Our findings demonstrate the pivotal function of MT1-MMP in connective tissue metabolism, and illustrate that modeling of the soft connective tissue matrix by resident cells is essential for the development and maintenance of the hard tissues of the skeleton.	Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA; Univ Roma La Sapienza, I-00161 Rome, Italy; Univ Aquila, I-67100 Laquila, Italy; McGill Univ, Shriners Hosp Children, Canadian Unit, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada; NCI, Vet & Tumor Pathol Sect, Anim Sci Branch, Div Basic Sci, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Sapienza University Rome; University of L'Aquila; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birkedal-Hansen, H (corresponding author), Natl Inst Dent & Craniofacial Res, MMP Unit, Bethesda, MD 20892 USA.	hbhansen@dir.nidcr.nih.gov	Robey, Pamela Gehron/H-1429-2011	Robey, Pamela Gehron/0000-0002-5316-5576; Holmbeck, Kenn/0000-0002-4472-3257	Telethon [E.1029] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000380, ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000380, Z01DE000676] Funding Source: NIH RePORTER	Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Apte SS, 1997, J BIOL CHEM, V272, P25511, DOI 10.1074/jbc.272.41.25511; BIANCO P, 1984, BASIC APPL HISTOCHEM, V28, P265; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Chen HX, 1998, DEV GENET, V22, P314, DOI 10.1002/(SICI)1520-6408(1998)22:4<314::AID-DVG2>3.0.CO;2-9; Chin JR, 1997, DEVELOPMENT, V124, P1519; COLE AA, 1985, AM J ANAT, V174, P119, DOI 10.1002/aja.1001740203; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; GAMERO P, 1998, J BIOL CHEM, V273, P32347; Gravallese EM, 1998, AM J PATHOL, V152, P943; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Kaufmann MH, 1998, ATLAS MOUSE DEV; KIDWELL JF, 1961, J HERED, V52, P145, DOI 10.1093/oxfordjournals.jhered.a107050; Kinoh H, 1996, J CELL SCI, V109, P953; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Kuettner K.E., 1983, SEFER RABIAH, V1, P281; Kuznetsov S, 1996, CALCIFIED TISSUE INT, V59, P265, DOI 10.1007/s002239900121; Lark MW, 1997, J CLIN INVEST, V100, P93, DOI 10.1172/JCI119526; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUFTI AM, 1970, J ANAT, V106, P135; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATTOT V, 1995, J CELL SCI, V108, P529; MELCHER AH, 1981, J ULTRA MOL STRUCT R, V77, P1, DOI 10.1016/S0022-5320(81)80064-0; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Mudgett JS, 1998, ARTHRITIS RHEUM-US, V41, P110, DOI 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.0.CO;2-G; Nagase H, 1998, Cell Res, V8, P179; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Okada A, 1997, J CELL BIOL, V137, P67, DOI 10.1083/jcb.137.1.67; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Puente XS, 1996, CANCER RES, V56, P944; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; StahleBackdahl M, 1997, LAB INVEST, V76, P717; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suzuki Y, 1998, J RHEUMATOL, V25, P1154; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANDERLUGT N, 1991, GENE, V105, P263, DOI 10.1016/0378-1119(91)90161-4; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Werb Z, 1996, KIDNEY INT, V49, pS68; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402	53	1041	1074	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 1	1999	99	1					81	92		10.1016/S0092-8674(00)80064-1	http://dx.doi.org/10.1016/S0092-8674(00)80064-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	243DK	10520996	Bronze			2022-12-24	WOS:000082981600010
J	Dawes, PT				Dawes, PT			MRI abnormalities in rheumatoid arthritis	LANCET			English	Editorial Material									N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England	University Hospital of North Staffordshire NHS Trust	Dawes, PT (corresponding author), N Staffordshire Hosp NHS Trust, Staffordshire Rheumatol Ctr, Stoke On Trent ST6 7AG, Staffs, England.							DAWES P T, 1988, British Journal of Rheumatology, V27, P21; Gaffney K, 1998, ANN RHEUM DIS, V57, P152, DOI 10.1136/ard.57.3.152; HASSELL AB, 1993, Q J MED, V86, P601; Klarlund M, 1999, RHEUMATOLOGY, V38, P66, DOI 10.1093/rheumatology/38.1.66; Mc Gonagle D, 1999, RHEUMATOLOGY, V38, P329, DOI 10.1093/rheumatology/38.4.329; McQueen FM, 1999, ANN RHEUM DIS, V58, P156, DOI 10.1136/ard.58.3.156; Molenaar ETH, 1999, J RHEUMATOL, V26, P749; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; WOLFE F, 1993, J RHEUMATOL, V20, P2005	9	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1051	1052		10.1016/S0140-6736(99)90121-6	http://dx.doi.org/10.1016/S0140-6736(99)90121-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509493				2022-12-24	WOS:000082777500007
J	Romelsjo, A; Leifman, A				Romelsjo, A; Leifman, A			Association between alcohol consumption and mortality, myocardial infarction, and stroke in 25 year follow up of 49 618 young Swedish men	BRITISH MEDICAL JOURNAL			English	Article									Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden; Karolinska Inst, Novum, Ctr Alcohol & Drug Prevent, S-14157 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet	Romelsjo, A (corresponding author), Karolinska Inst, Novum, Dept Publ Hlth Sci, S-14157 Huddinge, Sweden.							ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; Beaglehole R, 1992, Drug Alcohol Rev, V11, P275, DOI 10.1080/09595239200185811; Edwards G., 1994, ALCOHOL POLICY PUBLI; REHM J, 1998, ALCOHOLISM CLIN EX S, V22, P15; ROTHMAN K, 1998, MODERN EPIDEMIOLOGY, P430	5	47	47	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					821	822		10.1136/bmj.319.7213.821	http://dx.doi.org/10.1136/bmj.319.7213.821			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496826	Bronze, Green Published			2022-12-24	WOS:000082865200024
J	Kakei, S; Hoffman, DS; Strick, PL				Kakei, S; Hoffman, DS; Strick, PL			Muscle and movement representations in the primary motor cortex	SCIENCE			English	Article							STEP-TRACKING MOVEMENTS; FREE ARM MOVEMENTS; 3-DIMENSIONAL SPACE; CORTICOMOTONEURONAL CELLS; NEURAL REPRESENTATIONS; VISUAL TARGETS; REACHING TASK; DIRECTION; FORCE; DISCHARGE	What aspects of movement are represented in the primary motor cortex (M1): relatively low-level parameters like muscle force, or more abstract parameters like handpath? To examine this issue, the activity of neurons in M1 was recorded in a monkey trained to perform a task that dissociates three major variables of wrist movement: muscle activity, direction of movement at the wrist joint, and direction of movement in space. A substantial group of neurons in M1 (28 out of 88) displayed changes in activity that were muscle-like. Unexpectedly an even larger group of neurons in M1 (44 out of 88) displayed changes in activity that were related to the direction of wrist movement in space independent of the pattern of muscle activity that generated the movement. Thus, both "muscles" and "movements" appear to be strongly represented in M1.	Vet Affairs Med Ctr, Res Serv 151S, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosurg, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Dept Neurosci & Physiol, Syracuse, NY 13210 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Strick, PL (corresponding author), Vet Affairs Med Ctr, Res Serv 151S, 800 Irving Ave, Syracuse, NY 13210 USA.			Kakei, Shinji/0000-0001-5111-5789				ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P164, DOI 10.1152/jn.1990.64.1.164; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; Crammond DJ, 1996, EXP BRAIN RES, V108, P45; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1983, EXP BRAIN RES S, V7; HOFFMAN DS, 1986, J NEUROSCI, V6, P3309; HOFFMAN DS, 1995, J NEUROPHYSIOL, V73, P891, DOI 10.1152/jn.1995.73.2.891; Hoffman DS, 1999, J NEUROPHYSIOL, V81, P319, DOI 10.1152/jn.1999.81.1.319; HOLLERBACH JM, 1982, TRENDS NEUROSCI, V5, P189, DOI 10.1016/0166-2236(82)90111-4; Kakei S., 1998, Society for Neuroscience Abstracts, V24, P2108; Kakei S., 1997, Society for Neuroscience Abstracts, V23, P2096; KALASKA JF, 1989, J NEUROSCI, V9, P2080; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; Scott SH, 1997, J NEUROPHYSIOL, V77, P826, DOI 10.1152/jn.1997.77.2.826; Sergio LE, 1998, J NEUROPHYSIOL, V80, P1577, DOI 10.1152/jn.1998.80.3.1577; Shen LM, 1997, J NEUROPHYSIOL, V77, P1171, DOI 10.1152/jn.1997.77.3.1171; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654	29	515	520	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 24	1999	285	5436					2136	2139		10.1126/science.285.5436.2136	http://dx.doi.org/10.1126/science.285.5436.2136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497133	Green Submitted			2022-12-24	WOS:000082734300045
J	Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N				Gallardo, MH; Bickham, JW; Honeycutt, RL; Ojeda, RA; Kohler, N			Discovery of tetraploidy in a mammal	NATURE			English	Article									Univ Austral Chile, Inst Ecol & Evoluc, Valdivia, Chile; Texas A&M Univ, Dept Wildlife & Fisheries Sci, College Stn, TX 77843 USA; Inst Argentino Invest Zonas Aridas, Cricyt, RA-5500 Mendoza, Argentina	Universidad Austral de Chile; Texas A&M University System; Texas A&M University College Station; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Gallardo, MH (corresponding author), Univ Austral Chile, Inst Ecol & Evoluc, Casilla 567, Valdivia, Chile.			Ojeda, Ricardo/0000-0001-5246-0496				CONTRERAS LC, 1990, EXPERIENTIA, V46, P506, DOI 10.1007/BF01954248; Ferrari MR, 1998, ANDROLOGIA, V30, P85; Gallardo MH, 1997, CHROMOSOM T, V12, P347; Muller HJ, 1925, AM NAT, V59, P346, DOI 10.1086/280047; NIEBUHR E, 1974, HUMANGENETIK, V21, P103, DOI 10.1007/BF00281030; OHNO S., 1963, CYTO GENETICS [BASEL], V2, P42, DOI 10.1159/000129764; Ojeda RA, 1999, J ARID ENVIRON, V41, P443, DOI 10.1006/jare.1999.0496; ORR HA, 1990, AM NAT, V136, P759, DOI 10.1086/285130; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q	10	127	134	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					341	341		10.1038/43815	http://dx.doi.org/10.1038/43815			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517628	Bronze			2022-12-24	WOS:000082822600037
J	Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M				Rao, JK; Mihaliak, K; Kroenke, K; Bradley, J; Tierney, WM; Weinberger, M			Use of complementary therapies for arthritis among patients of rheumatologists	ANNALS OF INTERNAL MEDICINE			English	Article							ALTERNATIVE MEDICINE USE; UNCONVENTIONAL MEDICINE; RHEUMATOID-ARTHRITIS; UNITED-STATES; HEALTH-CARE; PREVALENCE; REMEDIES; OSTEOARTHRITIS; COMMUNITY; PRACTITIONERS	Background: Use of complementary and alternative medicine (CAM) is common among persons with chronic conditions. Objective: To identify correlates of and describe patients' perspective on use of CAM for rheumatologic conditions. Design: Telephone survey. Setting: Three university practices and three private rheumatology practices. Patients: 232 of 428 eligible consecutive patients (54%) with scheduled appointments. Measurements: Patients answered questions on CAM use, functional status, pain, provider satisfaction, and health services utilization. Chart reviews provided demographic information and rheumatologic diagnoses. Bivariate analyses identified correlates of four CAM outcomes (history, magnitude, and frequency of CAM use and communication about CAM use with a physician), and multiple logistic regression identified independent correlates of regular CAM use. Results: Approximately two thirds of the respondents (n = 146) had used CAM. Of these 146 respondents, 82 (56%) currently used CAM and 132 (90%) regularly used CAM or had done so in the past. Fifty-five respondents (24%) had used three or more types of CAM. In multivariate analyses, persons who used CAM regularly were more likely to have osteoarthritis (odds ratio, 5.6 [95% CI, 1.9 to 16.8]), severe pain (odds ratio, 2.5 [CI, 1.4 to 4.8]), and a college degree (odds ratio, 2.6 [CI, 1.3 to 5.4]) than patients who had never used CAM. Nearly half of the respondents discussed CAM use with their physicians. The most common reasons for not disclosing CAM use were that the physician had not asked about it and that the patient forgot to tell the physician; fear of disapproval was rarely cited. Discussions about CAM use between patient and physician occurred more frequently among patients with fibromyalgia and persons who regularly used CAM or used several types of CAM. Conclusions: Patients with rheumatologic conditions frequently use CAM. Severe pain and osteoarthritis predict regular use of CAM but do not predict a greater likelihood of discussing CAM use with physicians. Routine inquiry by physicians will probably detect CAM use.	Indiana Univ, Richard L Roudebush Vet Affairs Med Ctr, Sch Med, Indianapolis, IN 46202 USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Rao, JK (corresponding author), Vet Affairs Med Ctr, Hlth Serv Res & Dev 152, MHS, 508 Fulton St, Durham, NC 27705 USA.		anand, amit/A-7222-2009	Kroenke, Kurt/0000-0002-0114-4669				Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Arcury TA, 1996, ARTHRIT CARE RES, V9, P384, DOI 10.1002/1529-0131(199610)9:5<384::AID-ANR1790090507>3.0.CO;2-Y; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; BOISSET M, 1994, J RHEUMATOL, V21, P148; CAMPION EW, 1993, NEW ENGL J MED, V328, P282, DOI 10.1056/NEJM199301283280413; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; CORNELISSEN PGJ, 1988, ANN RHEUM DIS, V47, P150, DOI 10.1136/ard.47.2.150; Cronan T A, 1993, Arthritis Care Res, V6, P149, DOI 10.1002/art.1790060307; CRONAN TA, 1989, ARTHRITIS RHEUM, V32, P1604, DOI 10.1002/anr.1780321217; Dalen JE, 1998, ARCH INTERN MED, V158, P2179, DOI 10.1001/archinte.158.20.2179; Davidoff F, 1998, ANN INTERN MED, V129, P1068, DOI 10.7326/0003-4819-129-12-199812150-00014; DEVELLIS RF, 1993, J RHEUMATOL, V20, P866; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Fairfield KM, 1998, ARCH INTERN MED, V158, P2257, DOI 10.1001/archinte.158.20.2257; Fontanarosa PB, 1997, JAMA-J AM MED ASSOC, V278, P2111, DOI 10.1001/jama.1997.03550230087045; GRAY D, 1985, SOC SCI MED, V21, P507, DOI 10.1016/0277-9536(85)90034-6; GRAY D, 1983, MED ANTHROPOL, V7, P29; HIGHAM C, 1983, PRACTITIONER, V227, P1201; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1541, DOI 10.1002/art.1780381104; HOCHBERG MC, 1995, ARTHRITIS RHEUM, V38, P1535, DOI 10.1002/art.1780381103; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; KAZIS LE, 1990, J CLIN EPIDEMIOL, V43, P1243, DOI 10.1016/0895-4356(90)90025-K; KESTIN M, 1985, MED J AUSTRALIA, V143, P516, DOI 10.5694/j.1326-5377.1985.tb119916.x; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; KRONENFELD JJ, 1982, SOC SCI MED, V16, P1119, DOI 10.1016/0277-9536(82)90114-9; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MacLennan AH, 1996, LANCET, V347, P569, DOI 10.1016/S0140-6736(96)91271-4; MILLER IW, 1979, PSYCHOL BULL, V86, P93, DOI 10.1037/0033-2909.86.1.93; Nicassio PM, 1997, J RHEUMATOL, V24, P2008; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107; PioroBoisset M, 1996, ARTHRIT CARE RES, V9, P13, DOI 10.1002/art.1790090105; Rao JK, 1998, ARTHRIT CARE RES, V11, P253, DOI 10.1002/art.1790110406; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; STRUTHERS GR, 1983, RHEUMATOL INT, V3, P151, DOI 10.1007/BF00541593; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; VECCHIO PC, 1994, J RHEUMATOL, V21, P145; VISSER GJ, 1992, BRIT J RHEUMATOL, V31, P485; WASNER CK, 1991, RHEUM DIS CLIN N AM, V17, P197; Weisbord SD, 1997, NEW ENGL J MED, V337, P825, DOI 10.1056/NEJM199709183371205; WIENER CL, 1975, SOC SCI MED, V9, P97, DOI 10.1016/0037-7856(75)90101-8; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1124	46	283	287	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					409	416		10.7326/0003-4819-131-6-199909210-00003	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498556				2022-12-24	WOS:000082641100002
J	Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV				Makridakis, NM; Ross, RK; Pike, MC; Crocitto, LE; Kolonel, LN; Pearce, CL; Henderson, BE; Reichardt, JKV			Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA	LANCET			English	Article							STEROID 5-ALPHA-REDUCTASE; SUSCEPTIBILITY LOCUS; RISK; POLYMORPHISM; CHROMOSOME	Background Prostate cancer is a very common disease in more-developed countries, but its cause is largely unknown. It is an androgen-dependent cancer, and androgens have been proposed as having a substantial role in predisposition to the disease. Thus, variations in androgen metabolism genes may affect risk of this disease, Methods We screened 216 African-American and 172 Hispanic men with prostate cancer, and 261 African-American and 200 Hispanic healthy men (controls), from a large prospective cohort study (the Hawaii-Los Angeles Multiethnic Cohort Study) for a mis-sense substitution in the human prostatic (or type II) steroid 5 alpha-reductase (SRD5A2) gene, the product of which controls metabolic activation of testosterone to dihydrotestosterone. This mis-sense substitution results in an alanine residue at codon 49 being replaced with threonine (A49T). We also reconstructed this mutation in the SRD5A2 cDNA, and overexpressed the enzyme in mammalian tissue culture cells, Findings The A49T aminoacid substitution in the SRD5A2 gene increased the risk of clinically significant disease 7.2-fold in African-American men (95% CI=2.17-27.91; p=0.001) and 3.6-fold in Hispanic men (1.09-12.27; p=0.04). The mutant enzyme had a higher in-vitro V-max than the normal enzyme (9.9 vs 1.9 nmol min(-1) mg(-1)). Interpretation The A49T variant of the SRD5A2 gene may be a significant contributor to the incidence of prostate cancer in African-American and Hispanic men in Los Angeles. We estimate that the population attributable risk due to this aminoacid substitution for clinically significant disease is about 8% in both populations. Increased conversion of testosterone to dihydrotestosterone catalysed by this variant steroid 5 alpha-reductase enzyme may be the cause of the increased risk.	Univ So Calif, Sch Med, Inst Med Genet, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Biochem, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California; Cancer Research Center of Hawaii; University of Hawaii System	Reichardt, JKV (corresponding author), Univ So Calif, Sch Med, Inst Med Genet, 2250 Alcazar St,IGM 240, Los Angeles, CA 90033 USA.	reichard@hsc.usc.edu		Reichardt, Juergen/0000-0001-6458-2773	NATIONAL CANCER INSTITUTE [R01CA054281, R01CA063464, R37CA054281, R01CA068581, U01CA063464] Funding Source: NIH RePORTER; NCI NIH HHS [CA63464, CA54281, CA68581] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRIOLE GL, 1991, ANNU REV MED, V42, P9, DOI 10.1146/annurev.med.42.1.9; Berthon P, 1998, AM J HUM GENET, V62, P1416, DOI 10.1086/301879; Black RJ, 1997, EUR J CANCER, V33, P1075, DOI 10.1016/S0959-8049(96)00492-3; CARTER BS, 1992, P NATL ACAD SCI USA, V89, P3367, DOI 10.1073/pnas.89.8.3367; DAVIS DL, 1993, HUM MOL GENET, V2, P820, DOI 10.1093/hmg/2.6.820; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huggins C, 1941, CANCER RES, V1, P293; Kantoff PW, 1997, CANCER EPIDEM BIOMAR, V6, P189; KOLONEL LN, IN PRESS AM J EPIDEM; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Makridakis N, 1997, CANCER RES, V57, P1020; McIndoe RA, 1997, AM J HUM GENET, V61, P347, DOI 10.1086/514853; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MONTIE JE, 1992, SEMIN UROL, V11, P10; MONTIE JE, 1996, COMPREHENSIVE TXB GE, P712; Moore DD, 1995, GLOB MOB SURV; REICHARDT JKV, 1995, CANCER RES, V55, P3973; ROSS RK, 1992, LANCET, V339, P887, DOI 10.1016/0140-6736(92)90927-U; Ross RK, 1998, CANCER RES, V58, P4497; Smith JR, 1996, SCIENCE, V274, P1371, DOI 10.1126/science.274.5291.1371; Stoner E, 1996, PROSTATE, P82; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; WIGLEY WC, 1994, BIOCHEMISTRY-US, V33, P1265, DOI 10.1021/bi00171a029; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477	24	224	235	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	1999	354	9183					975	978		10.1016/S0140-6736(98)11282-5	http://dx.doi.org/10.1016/S0140-6736(98)11282-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501358				2022-12-24	WOS:000082596000009
J	Fu, YX; Galan, JE				Fu, YX; Galan, JE			A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion	NATURE			English	Article							RHO-GTPASES; PSEUDOMONAS-AERUGINOSA; NUCLEAR RESPONSES; EXOENZYME-S; TYPHIMURIUM; IDENTIFICATION; DISRUPTION; YERSINIA; GENE	An essential feature of the bacterial pathogen Salmonella spp. is its ability to enter cells that are normally non-phagocytic, such as those of the intestinal epithelium(1). The bacterium achieves entry by delivering effector proteins into the host-cell cytosol by means of a specialized protein-secretion system (termed type III), which causes reorganization of the cell's actin cytoskeleton and ruffling of its membrane(2-4). One of the bacterial effecters that stimulates these cellular responses is SopE, which acts as a guanyl-nucleotide-exchange factor on Rho GTPase proteins such as Cdc42 and Rac (ref. 5). As the actin-cytoskeleton reorganization induced by Salmonella is reversible and short-lived, infected cells regain their normal architecture after bacterial internalization(6,7). We show here that the S. Typhimurium effector protein SptP, which is delivered to the host-cell cytosol by the type-III secretion system, is directly responsible for the reversal of the actin cytoskeletal changes induced by the bacterium. SptP exerts this function by acting as a GTPase-activating protein (GAP) for Rac-1 and Cdc42.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA	Yale University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu						Chen LM, 1999, J EXP MED, V189, P1479, DOI 10.1084/jem.189.9.1479; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; FORSBERG A, 1990, J BACTERIOL, V172, P1547, DOI 10.1128/jb.172.3.1547-1555.1990; FrithzLindsten E, 1997, MOL MICROBIOL, V25, P1125, DOI 10.1046/j.1365-2958.1997.5411905.x; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; KULICH SM, 1994, J BIOL CHEM, V269, P10431; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; ROSQVIST R, 1991, INFECT IMMUN, V59, P4562, DOI 10.1128/IAI.59.12.4562-4569.1991; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Vallis AJ, 1999, INFECT IMMUN, V67, P2040; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	21	430	445	4	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					293	297		10.1038/45829	http://dx.doi.org/10.1038/45829			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499590				2022-12-24	WOS:000082678400058
J	Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A				Naidoo, N; Song, W; Hunter-Ensor, M; Sehgal, A			A role for the proteasome in the light response of the timeless clock protein	SCIENCE			English	Article							DROSOPHILA CLOCK; CIRCADIAN CLOCK; IN-VIVO; DEGRADATION; KINASE; PERIOD; PROTEOLYSIS; INHIBITORS; MECHANISM; GENE	The cyclic expression of the period (PER) and timeless (TIM) proteins is critical for the molecular circadian feedback Loop in Drosophila. The entrainment by Light of the circadian clock is mediated by a reduction in TIM Levels. To elucidate the mechanism of this process, the sensitivity of TIM regulation by Light was tested in an in vitro assay with inhibitors of candidate proteolytic pathways. The data suggested that TIM is degraded through a ubiquitin-proteasome mechanism. In addition, in cultures from third-instar Larvae, TIM degradation was blocked specifically by inhibitors of proteasome activity. Degradation appeared to be preceded by tyrosine phosphorylation. Finally, TIM was ubiquitinated in response to Light in cultured cells.	Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania	Sehgal, A (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Philadelphia, PA 19104 USA.			Naidoo, Navindhra/0000-0001-9142-3751; Song, Wei/0000-0001-6531-8317; Naidoo, Nirinjini/0000-0002-7463-2559				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHEN Y, 1998, CELL, V13, P364; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Davydov IV, 1998, ARCH BIOCHEM BIOPHYS, V357, P317, DOI 10.1006/abbi.1998.0829; Dembinska ME, 1997, J BIOL RHYTHM, V12, P157, DOI 10.1177/074873049701200207; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Emery IF, 1997, P NATL ACAD SCI USA, V94, P4092, DOI 10.1073/pnas.94.8.4092; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; HARDIN PE, 1999, HDB BEHAV STATE CONT, P61; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaneko M, 1997, J NEUROSCI, V17, P6745; KOBAYASHI E, 1989, J ANTIBIOT, V42, P1470, DOI 10.7164/antibiotics.42.1470; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; MYERS MP, 1996, SCIENCE, V271, P1740; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yang XM, 1998, J IRON STEEL RES INT, V5, P21; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	35	220	223	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1737	1741		10.1126/science.285.5434.1737	http://dx.doi.org/10.1126/science.285.5434.1737			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481010				2022-12-24	WOS:000082472600036
J	Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE				Ottemann, KM; Xiao, WZ; Shin, YK; Koshland, DE			A piston model for transmembrane signaling of the aspartate receptor	SCIENCE			English	Article							LIGAND-BINDING DOMAIN; SINGLE CYTOPLASMIC DOMAIN; DISULFIDE CROSS-LINKING; BACTERIAL CHEMOTAXIS; ESCHERICHIA-COLI; SENSORY RECEPTOR; SPIN LABELS; TRANSDUCTION; CHEMORECEPTOR; ADAPTATION	To characterize the mechanism by which receptors propagate conformational changes across membranes, nitroxide spin labels were attached at strategic positions in the bacterial aspartate receptor. By collecting the electron paramagnetic resonance spectra of these labeled receptors in the presence and absence of the Ligand aspartate, ligand binding was shown to generate an similar to 1 angstrom intrasubunit piston-type movement of one transmembrane helix downward relative to the other transmembrane helix. The receptor-associated phosphorylation cascade proteins CheA and CheW did not alter the ligand-induced movement. Because the piston movement is very small, the ability of receptors to produce Large outcomes in response to stimuli is caused by the ability of the receptor-coupled enzymes to detect small changes in the conformation of the receptor.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Shin, YK (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.			Ottemann, Karen/0000-0001-6265-7401; xiao, wenzhong/0000-0003-4944-6380	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009765, R37DK009765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051290, R29GM051290] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09765] Funding Source: Medline; NIGMS NIH HHS [GM51290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; CHEN X, 1997, BIOCHEM, V39, P11858; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Chi YI, 1997, FEBS LETT, V414, P327, DOI 10.1016/S0014-5793(97)01027-2; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DEFIZE LHK, 1986, EMBO J, V5, P1187, DOI 10.1002/j.1460-2075.1986.tb04345.x; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Gerstein M, 1998, NUCLEIC ACIDS RES, V26, P4280, DOI 10.1093/nar/26.18.4280; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; KESSLER C, 1990, GENE, V92, P1, DOI 10.1016/0378-1119(90)90486-B; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; Liu Y, 1997, EMBO J, V16, P7231, DOI 10.1093/emboj/16.24.7231; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; MACNAB RM, 1972, P NATL ACAD SCI USA, V69, P2509, DOI 10.1073/pnas.69.9.2509; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MOWBRAY SL, 1987, CELL, V50, P171, DOI 10.1016/0092-8674(87)90213-3; OGAWA S, 1967, P NATL ACAD SCI USA, V58, P719; Ottemann KM, 1998, BIOCHEMISTRY-US, V37, P7062, DOI 10.1021/bi980305e; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; REIDEL H, 1986, NATURE, V324, P68; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; STRYER L, 1967, P NATL ACAD SCI USA, V58, P719, DOI 10.1073/pnas.58.2.719; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; Thorgeirsson TE, 1997, J MOL BIOL, V273, P951, DOI 10.1006/jmbi.1997.1362; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507	46	228	229	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1751	1754		10.1126/science.285.5434.1751	http://dx.doi.org/10.1126/science.285.5434.1751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481014				2022-12-24	WOS:000082472600040
J	Thurman, D; Guerrero, J				Thurman, D; Guerrero, J			Trends in hospitalization associated with traumatic brain injury	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROSPECTIVE-PAYMENT SYSTEM; HEAD-INJURY; ACCURACY	Context Traumatic brain injury (TBI) is associated with more than 50 000 deaths in the United States each year, and recent observations suggest a substantial decline in TBI-related hospitalizations and deaths. Objective To analyze long-term trends in TBI-related hospitalization in the United States. Design, Setting, and Participants Analysis of existing data from 1980 through 1995 from the National Hospital Discharge Survey, an annual survey representing the US general population. The number of participating hospitals ranged from 400 to 494. Main Outcome Measures Annual rates of TBI-related hospitalization, stratified by age, sex, severity of injury, and outcome. Results The annual number of TBI cases identified from the sample during the study : period ranged from 1611 to 3129. Overall rates of hospitalization for TBI declined an estimated 51 %, from 199 to 98 per 100 000 per year. When analyzed by severity of injury, mild TBIs declined most during this period, from 130 to 51 hospitalizations per 100 000 per year (61 % decline; P<.001 compared with intermediate and severe TBI); The decline was greatest among those aged 5-14 years (-66%) and least among those. aged 65 years or older (-9%). The ratio of male to female rates showed little variation during the study period (ratio, 1.8; 95% confidence interval [CI], 1.6-2.0), as did the in-hospital mortality rate (mean, 5.3 per 100 000; 95% CI, 3.6-7.1). Conclusions Changes in hospital practices may be a major factor in the declining rates of TBI-related hospital admissions. These practices increasingly appear to exclude persons with less severe TBI from hospital admission and shift: their care to outpatient settings.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Thurman, D (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Mailstop F-41,4770 Buford Hwy NE, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062				ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Burt C W, 1998, Vital Health Stat 13, P1; *CDCP, 1997, DAT FIL DOC NAT HOSP; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; *CTR INJ RES POL J, 1997, ICDMAP90 SOTW; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; Graves E J, 1997, Vital Health Stat 13, P1; Gronwall D., 1989, MILD HEAD INJURY, P153; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; KISH L, 1965, SURVEY SAMPLING, P206; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; *NAT CTR HLTH STAT, 1997, DAT FIL DOC NAT HOSP; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Robinson JC, 1996, JAMA-J AM MED ASSOC, V276, P1060, DOI 10.1001/jama.276.13.1060; Ruff R. M., 1989, MILD HEAD INJURY, P176; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; THURMAN DJ, IN PRESS J HEAD TRAU; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DHHS, 1989, FED INT HEAD INJ TAS; *US DHHS, 1996, INT CLASS DIS	24	370	379	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					954	957		10.1001/jama.282.10.954	http://dx.doi.org/10.1001/jama.282.10.954			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485680				2022-12-24	WOS:000082335900033
J	Sugase, Y; Yamane, S; Ueno, S; Kawano, K				Sugase, Y; Yamane, S; Ueno, S; Kawano, K			Global and fine information coded by single neurons in the temporal visual cortex	NATURE			English	Article							INFEROTEMPORAL CORTEX; POLYSENSORY AREA; MACAQUE MONKEY; RHESUS-MONKEY; RESPONSES; SULCUS; FACE; CONNECTIONS; IDENTITY	When we see a person's face, we can easily recognize their species, individual identity and emotional state. How does the brain represent such complex information? A substantial number of neurons in the macaque temporal cortex respond to faces(1-12) However, the neuronal mechanisms underlying the processing of complex information are not yet clear. Here we recorded the activity of single neurons in the temporal cortex of macaque monkeys while presenting visual stimuli consisting of geometric shapes, and monkey and human faces with various expressions. Information theory was used to investigate how well the neuronal responses could categorize the stimuli. We found that single neurons conveyed two different scales of facial information in their firing patterns, starting at different latencies. Global information, categorizing stimuli as monkey faces, human faces or shapes, was conveyed in the earliest part of the responses. Fine information about identity or expression was conveyed later, beginning on average 51 ms after global information. We speculate that global information could be used as a 'header' to prepare destination areas for receiving more detailed information.	Electrotech Lab, Tsukuba, Ibaraki 3058568, Japan; Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Sugase, Y (corresponding author), Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 3058566, Japan.		sugase-miyamoto, yasuko/N-2769-2016	sugase-miyamoto, yasuko/0000-0003-3097-3789				AMARAL DG, 1984, J COMP NEUROL, V230, P465, DOI 10.1002/cne.902300402; AMARI SI, 1977, BIOL CYBERN, V26, P175, DOI 10.1007/BF00365229; BAYLIS GC, 1987, J NEUROSCI, V7, P330; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; Ellis HD, 1986, NEUROPSYCHOLOGY FACE, P1; Golomb D, 1997, NEURAL COMPUT, V9, P649, DOI 10.1162/neco.1997.9.3.649; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; HECAEN H, 1962, INTERHEMISPHER RELAT, P215; HELLER J, 1995, J COMPUT NEUROSCI, V2, P175, DOI 10.1007/BF00961433; Kitazawa S, 1998, NATURE, V392, P494, DOI 10.1038/33141; Lavenex P., 1998, Society for Neuroscience Abstracts, V24, P1905; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MIKAMI A, 1994, BEHAV BRAIN RES, V60, P1, DOI 10.1016/0166-4328(94)90057-4; NAKAMURA K, 1994, J NEUROPHYSIOL, V71, P1206, DOI 10.1152/jn.1994.71.3.1206; NAKAMURA K, 1992, J NEUROPHYSIOL, V67, P1447, DOI 10.1152/jn.1992.67.6.1447; ORAM MW, 1992, J NEUROPHYSIOL, V68, P70, DOI 10.1152/jn.1992.68.1.70; Oram MW, 1996, J NEUROPHYSIOL, V76, P109, DOI 10.1152/jn.1996.76.1.109; Panzeri S, 1996, NETWORK-COMP NEURAL, V7, P87, DOI [10.1088/0954-898X/7/1/006, 10.1080/0954898X.1996.11978656]; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Sugase Y., 1998, Society for Neuroscience Abstracts, V24, P899; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	28	553	563	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					869	873		10.1038/23703	http://dx.doi.org/10.1038/23703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476965				2022-12-24	WOS:000082233200045
J	Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ				Yin, XM; Wang, K; Gross, A; Zhao, YG; Zinkel, S; Klocke, B; Roth, KA; Korsmeyer, SJ			Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis	NATURE			English	Article							CYTOCHROME-C; CELL-DEATH; PROTEASE; PATHWAYS; ANTIBODY; FAMILY; REQUIREMENT; ACTIVATION; CASPASE-9; INDUCTION	The protein Bid is a participant in the pathway that leads to cell death (apoptosis), mediating the release of cytochrome c from mitochondria in response to signals from 'death' receptors known as TNFR1/Fas on the cell surface(1-7). It is a member of the pro-apoptotic Bcl-2 familys and is activated as a result of its cleavage by caspase 8, one of a family of proteolytic cell-death proteins. To investigate the role of Bid in vivo, we have generated mice deficient for Bid. We find that when these mice are injected with an antibody directed against Fas, they nearly all survive, whereas wild-type mice die from hepatocellular apoptosis and haemorrhagic necrosis. About half of the Bid-deficient animals had no apparent liver injury and showed no evidence of activation of the effector caspases 3 and 7, although the initiator caspase 8 had been activated. Other Bid-deficient mice survived with only moderate damage: all three caspases (8 and 37) were activated but their cell nuclei were intact and no mitochondrial cytochrome c was released. We also investigated the effects of Bid deficiency in cultured cells treated with anti-pas antibody (hepatocytes and thymocytes) or with TNF-alpha. (fibroblasts). In these Bid(-/-) cells, mitochondrial dysfunction was delayed, cytochrome c was not released, effector caspase activity was reduced and the cleavage of apoptosis substrates was altered. This loss-of-function model indicates that Bid is a critical substrate in vivo for signalling by death-receptor agonists, which mediates a mitochondrial amplification loop that is essential for the apoptosis of selected cells.	Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Korsmeyer, SJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, Howard Hughes Med Inst, St Louis, MO 63110 USA.			Roth, Kevin/0000-0002-0643-995X; zinkel, sandra/0000-0002-2818-9795				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 1999, MOL CELL BIOL, V19, P1381; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1996, CURR BIOL, V6, P1241, DOI 10.1016/S0960-9822(02)70706-9; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, GENOMICS, V53, P235, DOI 10.1006/geno.1998.5489; XUESONG L, 1997, CELL, V89, P175; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	30	831	858	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					886	891		10.1038/23730	http://dx.doi.org/10.1038/23730			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476969				2022-12-24	WOS:000082233200049
J	Cuckle, H				Cuckle, H			Maternal age-standardisation of prevalence of Down's syndrome	LANCET			English	Editorial Material									Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England	University of Leeds	Cuckle, H (corresponding author), Univ Leeds, Sch Med, Ctr Reprod Growth, Leeds LS2 9NZ, W Yorkshire, England.							Carothers AD, 1999, J MED GENET, V36, P386; Cuckle HS, 1999, PRENATAL DIAG, V19, P505, DOI 10.1002/(SICI)1097-0223(199906)19:6<505::AID-PD572>3.0.CO;2-6; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; HOOK EB, 1994, SCREENING DOWNS SYND, P1; James RS, 1998, EUR J HUM GENET, V6, P207, DOI 10.1038/sj.ejhg.5200178; Mutton D, 1998, BRIT MED J, V317, P922; *OFF POP CENS SURV, 1990, BIRTH STAT SER FM1, P17; Penrose LS, 1933, J GENET, V27, P219, DOI 10.1007/BF02984413	8	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 14	1999	354	9178					529	530		10.1016/S0140-6736(99)00174-9	http://dx.doi.org/10.1016/S0140-6736(99)00174-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470692				2022-12-24	WOS:000081991000005
J	Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX				Stroschein, SL; Wang, W; Zhou, SL; Zhou, Q; Luo, KX			Negative feedback regulation of TGF-beta signaling by the SnoN oncoprotein	SCIENCE			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR SMAD4; DNA-BINDING PROTEIN; MAD-RELATED PROTEIN; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; CDNA CLONES; N-COR; PROMOTER; SKI	Smad proteins mediate transforming growth factor-beta (TGF-beta) signaling to regulate cell growth and differentiation. The SnoN oncoprotein was found to interact with Smad2 and Smad4 and to repress their abilities to activate transcription through recruitment of the transcriptional corepressor N-CoR, Immediately after TGF-beta stimulation, SnoN is rapidly degraded by the nuclear accumulation of Smad3, allowing the activation of TGF-beta target genes. By 2 hours, TGF-beta induces a marked increase in SnoN expression, resulting in termination of Smad-mediated transactivation. Thus, SnoN maintains the repressed state of TGF-beta-responsive genes in the absence of ligand and participates in negative feedback regulation of TGF-beta signaling.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Luo, KX (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 229 Stanley Hall,Mail Code 3206, Berkeley, CA 94720 USA.							Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BOYER PL, 1993, ONCOGENE, V8, P457; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Cohen SB, 1998, ONCOGENE, V17, P2505, DOI 10.1038/sj.onc.1202177; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PEARSONWHITE S, 1993, NUCLEIC ACIDS RES, V21, P4632, DOI 10.1093/nar/21.19.4632; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STAVNEZER E, 1986, J VIROL, V57, P1073, DOI 10.1128/JVI.57.3.1073-1083.1986; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681	49	423	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					771	774		10.1126/science.286.5440.771	http://dx.doi.org/10.1126/science.286.5440.771			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531062	Green Submitted			2022-12-24	WOS:000083303200054
J	Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS				Strausberg, RL; Feingold, EA; Klausner, RD; Collins, FS			The mammalian gene collection	SCIENCE			English	Editorial Material							HUMAN-GENOME-PROJECT; EXPRESSION; SEQUENCE; CDNA	The Mammalian Cone Collection (MGC) project is a new effort by the NIH to generate full-length complementary DNA (cDNA) resources. This project will provide publicly accessible resources to the full research community. The MGC project entails the production of libraries, sequencing, and database and repository development, as well as the support of Library construction, sequencing, and analytic technologies dedicated to the goal of obtaining a full set of human and other mammalian full-length (open reading frame) sequences and clones of expressed genes.	NCI, NIH, Bethesda, MD 20892 USA; Natl Human Genome Res Inst, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, FS (corresponding author), NCI, NIH, Bethesda, MD 20892 USA.							ADAMS MD, 1995, NATURE, V377, P3; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; [Anonymous], COMMUNICATION; Bonaldo MDF, 1996, GENOME RES, V6, P791, DOI 10.1101/gr.6.9.791; Carninci P, 1997, DNA Res, V4, P61, DOI 10.1093/dnares/4.1.61; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; *COMM MAPP SEQ HUM, 1988, REP COMM MAPP SEQ HU; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; EDERY I, 1995, MOL CELL BIOL, V15, P3363; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Rubin GM, 1998, TRENDS GENET, V14, P340, DOI 10.1016/S0168-9525(98)01568-6; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; SOARES MA, UNPUB; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; Williamson AR, 1999, DRUG DISCOV TODAY, V4, P115, DOI 10.1016/S1359-6446(99)01303-3	16	210	229	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					455	457		10.1126/science.286.5439.455	http://dx.doi.org/10.1126/science.286.5439.455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521335				2022-12-24	WOS:000083121200046
J	Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y				Tomita, H; Ohbayashi, M; Nakahara, K; Hasegawa, I; Miyashita, Y			Top-down signal from prefrontal cortex in executive control of memory retrieval	NATURE			English	Article							INFERIOR TEMPORAL NEURONS; LONG-TERM-MEMORY; FRONTAL DISCONNECTION; COGNITIVE INTERACTION; WORKING-MEMORY; MONKEYS; TASK; ORGANIZATION; ACTIVATION	Knowledge or experience is voluntarily recalled from memory by reactivation of the neural representations in the cerebral association cortex(1-4). In inferior temporal cortex, which serves as the storehouse of visual long-term memory(5-8), activation of mnemonic engrams through electric stimulation results in imagery recall in humans(9), and neurons can be dynamically activated by the necessity for memory recall in monkeys(10,11). Neuropsychological studies(12) and previous split-brain experiments(13) predicted that prefrontal cortex exerts executive control upon inferior temporal cortex in memory retrieval; however, no neuronal correlate of this process has ever been detected. Here we show evidence of the top-down signal from prefrontal cortex. In the absence of bottom-up visual inputs, single inferior temporal neurons were activated by the top-down signal, which conveyed information on semantic categorization imposed by visual stimulus-stimulus association. Behavioural performance was severely impaired with loss of the top-down signal. Control experiments confirmed that the signal was transmitted not through a subcortical but through a frontotemporal cortical pathway. Thus, feedback projections from prefrontal cortex to the posterior association cortex(2,3,14) appear to serve the executive control of voluntary recall.	Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, ICORP, Mind Articulat Project, Bunkyo Ku, Tokyo 1130034, Japan; Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Tomita, H (corresponding author), Univ Tokyo, Sch Med, Dept Physiol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hyoe@m.u-tokyo.ac.jp; yasushi_miyashita@m.u-tokyo.ac.jp	Miyashita, Yasushi/B-7171-2019; Hasegawa, Isao/AAW-5682-2021; Ohbayashi, Machiko/A-6910-2018	Miyashita, Yasushi/0000-0003-3496-8637; Hasegawa, Isao/0000-0002-8633-2502; Ohbayashi, Machiko/0000-0003-2563-9049; Nakahara, Kiyoshi/0000-0001-6701-6216				Buckner RL, 1996, J NEUROSCI, V16, P6219; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; DOTY RW, 1988, BEHAV BRAIN RES, V29, P267, DOI 10.1016/0166-4328(88)90031-9; EACOTT MJ, 1992, EUR J NEUROSCI, V4, P1320, DOI 10.1111/j.1460-9568.1992.tb00157.x; EACOTT MJ, 1989, EXP BRAIN RES, V74, P348; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Fletcher PC, 1998, BRAIN, V121, P1249, DOI 10.1093/brain/121.7.1249; Fuster J. M., 1997, PREFRONTAL CORTEX; FUSTER JM, 1985, BRAIN RES, V330, P299, DOI 10.1016/0006-8993(85)90689-4; GAZZANIGA MS, 1995, NEURON, V14, P217, DOI 10.1016/0896-6273(95)90280-5; Goldman-Rakic P. S., 1987, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; GROSS CG, 1977, BRAIN RES, V131, P227, DOI 10.1016/0006-8993(77)90517-0; Gutnikov SA, 1997, EUR J NEUROSCI, V9, P1524, DOI 10.1111/j.1460-9568.1997.tb01507.x; Hasegawa I, 1998, SCIENCE, V281, P814, DOI 10.1126/science.281.5378.814; MACPHERSON JM, 1979, BRAIN RES, V175, P183, DOI 10.1016/0006-8993(79)90530-4; MISHKIN M, 1982, PHILOS T R SOC B, V298, P85, DOI 10.1098/rstb.1982.0074; MIYASHITA Y, 1993, ANNU REV NEUROSCI, V16, P245, DOI 10.1146/annurev.ne.16.030193.001333; MIYASHITA Y, IN PRESS COGNITIVE N; Naya Y, 1996, P NATL ACAD SCI USA, V93, P2664, DOI 10.1073/pnas.93.7.2664; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; Petrides M, 1994, HDB NEUROPSYCHOLOGY, V9, P59; Rainer G, 1999, J NEUROSCI, V19, P5493; RINGO JL, 1993, J NEUROPHYSIOL, V70, P2215, DOI 10.1152/jn.1993.70.6.2215; Rolls E T, 1991, Curr Opin Neurobiol, V1, P274, DOI 10.1016/0959-4388(91)90090-T; SAKAI K, 1991, NATURE, V354, P152, DOI 10.1038/354152a0; SARY G, 1993, SCIENCE, V260, P995, DOI 10.1126/science.8493538; SIDTIS JJ, 1981, SCIENCE, V212, P344, DOI 10.1126/science.6782673	29	448	458	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					699	703		10.1038/44372	http://dx.doi.org/10.1038/44372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537108				2022-12-24	WOS:000083207400057
J	Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR				Brodine, SK; Shaffer, RA; Starkey, MJ; Tasker, SA; Gilcrest, JL; Louder, MK; Barile, A; VanCott, TC; Vahey, MT; McCutchan, FE; Birx, DL; Richman, DD; Mascola, JR			Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion	ANNALS OF INTERNAL MEDICINE			English	Article						epidemiology, molecular; drug resistance, microbial; human immunodeficiency virus; human immunodeficiency virus infections; anti-HIV agents	TYPE-1 SUBTYPE; UNITED-STATES; VIRUS; SENSITIVITY; PREVALENCE; INFECTION; DIVERSITY; COMMUNITY; THERAPY; PLASMA	Background: Regular testing of military personnel identifies early HIV infection; this identification provides a sentinel cohort in which to describe the evolving molecular epidemiology of HIV-1 transmission. Objective: To describe the prevalence and epidemiologic correlates associated with the acquisition of non-subtype B and drug-resistant HIV infections. Design: Cross-sectional study. Setting: Military referral hospital. Patients: 95 military personnel with HIV-1 seroconversion. Measurements: Self-reported questionnaire, CD4 cell counts, plasma HIV-1 RNA levels, and nucleic acid sequence analysis for drug-resistant mutations and HIV-1 genetic subtype. Results: 95 patients were enrolled between February 1997 and February 1998. The likely geographic location of HIV-1 acquisition was overseas in 8% of patients, the United States in 68%, and either overseas or the United States in 24%. Seven patients (7.4%) had subtype E infection; the remainder had subtype B infection. Eight of 31 (26%) treatment-naive patients had mutations in the reverse transcriptase or protease gene associated with drug resistance. Conclusions: The percentage of HIV-1 non-subtype B infection and antiretroviral drug-resistant mutations was relatively high in U.S. military personnel with recently acquired HIV-1 infection.	San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, San Diego, CA 92182 USA; Naval Hlth Res Ctr, Div Clin Epidemiol, San Diego, CA 92186 USA; Naval Hlth Res Ctr, San Diego, CA 92152 USA; Naval Med Ctr, San Diego, CA 92134 USA; Henry M Jackson Fdn Advancement Mil Med, Rockville, MD USA; Walter Reed Army Inst Res, Div Retrovirol, Rockville, MD 20850 USA; Univ Calif San Diego, La Jolla, CA 92093 USA	California State University System; San Diego State University; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC); United States Department of Defense; United States Navy; Naval Medical Center San Diego; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University of California System; University of California San Diego	Brodine, SK (corresponding author), San Diego State Univ, Coll Hlth & Human Serv, Grad Sch Publ Hlth, 5500 Campanile Dr, San Diego, CA 92182 USA.		Mascola, John/AAI-7193-2021		NIAID NIH HHS [AI 38858, AI 27670, AI 36214] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027670, P30AI036214, U01AI038858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUERBACH JD, 1998, CURRENT OPINION INFE, P3; Brodine SK, 1997, INFECT MED, V14, P739; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Debyser Z, 1998, AIDS RES HUM RETROV, V14, P453, DOI 10.1089/aid.1998.14.453; Gaywee J, 1996, J ACQ IMMUN DEF SYND, V13, P392, DOI 10.1097/00042560-199612010-00014; Gomez-Cano M, 1998, AIDS, V12, P1015, DOI 10.1097/00002030-199809000-00007; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hawkes S, 1998, INFECT DIS CLIN N AM, V12, P413, DOI 10.1016/S0891-5520(05)70011-8; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210; Irwin KL, 1997, J INFECT DIS, V176, P1629, DOI 10.1086/517343; LEVIN LI, 1995, AM J PUBLIC HEALTH, V85, P1500, DOI 10.2105/AJPH.85.11.1500; Mayers DL, 1998, JAMA-J AM MED ASSOC, V279, P2000, DOI 10.1001/jama.279.24.2000; Nolte FS, 1998, J CLIN MICROBIOL, V36, P716, DOI 10.1128/JCM.36.3.716-720.1998; Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157; Pinkerton SD, 1998, AM J PUBLIC HEALTH, V88, P1239, DOI 10.2105/AJPH.88.8.1239; Rayfield MA, 1996, EMERG INFECT DIS, V2, P209, DOI 10.3201/eid0203.960307; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977	20	95	96	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 5	1999	131	7					502	+		10.7326/0003-4819-131-7-199910050-00004	http://dx.doi.org/10.7326/0003-4819-131-7-199910050-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243VU	10507958				2022-12-24	WOS:000083018800003
J	Sandham, JD				Sandham, JD			Complications of acute anaemia: caused by low packed-cell volume or by transfusion?	LANCET			English	Editorial Material							POSTOPERATIVE DELIRIUM		Univ Calgary, Reg Div Crit Care, Calgary, AB T2N 2T9, Canada	University of Calgary	Sandham, JD (corresponding author), Univ Calgary, Reg Div Crit Care, Foothills Hosp Site, Calgary, AB T2N 2T9, Canada.							Ely EW, 1999, NEW ENGL J MED, V340, P467, DOI 10.1056/NEJM199902113400610; FREDERICK AM, 1997, ARCH SURG-CHICAGO, V132, P620; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; Marcantonio ER, 1998, AM J MED, V105, P380, DOI 10.1016/S0002-9343(98)00292-7	6	1	1	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 11	1999	354	9182					883	884		10.1016/S0140-6736(99)90268-4	http://dx.doi.org/10.1016/S0140-6736(99)90268-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489944				2022-12-24	WOS:000082511800007
J	Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R				Klinke, R; Kral, A; Heid, S; Tillein, J; Hartmann, R			Recruitment of the auditory cortex in congenitally deaf cats by long-term cochlear electrostimulation	SCIENCE			English	Article							INTRACOCHLEAR ELECTRICAL-STIMULATION; NEURONAL RESPONSES; WHITE CAT; EVOKED-POTENTIALS; CEREBRAL-CORTEX; REPETITION RATE; BRAIN-STEM; PLASTICITY; IMPLANT; NUCLEUS	In congenitally deaf cats, the central auditory system is deprived of acoustic input because of degeneration of the organ of Corti before the onset of hearing. Primary auditory afferents survive and can be stimulated electrically. By means of an intracochlear implant and an accompanying sound processor, congenitally deaf kittens were exposed to sounds and conditioned to respond to tones. After months of exposure to meaningful stimuli, the cortical activity in chronically implanted cats produced field potentials of higher amplitudes, expanded in area, developed Long Latency responses indicative of intracortical information processing, and showed more synaptic efficacy than in naive, unstimulated deaf cats. The activity established by auditory experience resembles activity in hearing animals.	Physiol Inst 3, D-60590 Frankfurt, Germany		Klinke, R (corresponding author), Physiol Inst 3, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	klinke@em.uni-frankuft.de		Kral, Andrej/0000-0002-7762-4642				AITKIN L, 1990, AUDITORY CORTEX; BAKIN JS, 1990, BRAIN RES, V536, P271, DOI 10.1016/0006-8993(90)90035-A; BLAKEMORE C, 1978, HDB SENSORY PHYSL, V8, P392; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; BUSBY PA, 1993, J ACOUST SOC AM, V93, P1058, DOI 10.1121/1.405554; CHOUARD CH, 1983, ANN NY ACAD SCI, V405, P387, DOI 10.1111/j.1749-6632.1983.tb31653.x; FOX K, 1994, J NEUROSCI, V14, P7665; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; Hardie NA, 1999, HEARING RES, V128, P147, DOI 10.1016/S0378-5955(98)00209-3; HARTMANN R, 1984, HEARING RES, V13, P47, DOI 10.1016/0378-5955(84)90094-7; Hartmann R, 1997, HEARING RES, V112, P115, DOI 10.1016/S0378-5955(97)00114-7; Heid S, 1997, HEARING RES, V110, P191, DOI 10.1016/S0378-5955(97)00074-9; Heid S, 1998, HEARING RES, V115, P101, DOI 10.1016/S0378-5955(97)00182-2; HOCHMAIR ES, 1979, INT J ARTIF ORGANS, V2, P255; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; Kral A, 1999, NEUROREPORT, V10, P781, DOI 10.1097/00001756-199903170-00022; Kral A, 1998, HEARING RES, V121, P11, DOI 10.1016/S0378-5955(98)00061-6; KRAUS N, 1993, HEARING RES, V65, P118, DOI 10.1016/0378-5955(93)90206-G; LARSEN SA, 1992, EXP NEUROL, V115, P151, DOI 10.1016/0014-4886(92)90240-Q; LEAKE PA, 1988, HEARING RES, V33, P11, DOI 10.1016/0378-5955(88)90018-4; Mair I W, 1973, Acta Otolaryngol Suppl, V314, P1; MITANI A, 1985, J COMP NEUROL, V235, P430, DOI 10.1002/cne.902350403; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Popelar J, 1995, HEARING RES, V92, P63, DOI 10.1016/0378-5955(95)00199-9; PRIETO JJ, 1994, J COMP NEUROL, V344, P349, DOI 10.1002/cne.903440304; RAGGIO MW, 1994, J NEUROPHYSIOL, V72, P2334, DOI 10.1152/jn.1994.72.5.2334; Rajan R, 1998, AUDIOL NEURO-OTOL, V3, P123, DOI 10.1159/000013786; Rauschecker JP, 1999, TRENDS NEUROSCI, V22, P74, DOI 10.1016/S0166-2236(98)01303-4; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; REBILLARD G, 1980, BRAIN RES, V188, P252, DOI 10.1016/0006-8993(80)90572-7; ROMAND R, 1992, DEV AUDITORY VESTIBU, V2; Ryugo DK, 1998, J COMP NEUROL, V397, P532, DOI 10.1002/(SICI)1096-9861(19980810)397:4<532::AID-CNE6>3.0.CO;2-2; Schreiner CE, 1996, J NEUROPHYSIOL, V75, P1283, DOI 10.1152/jn.1996.75.3.1283; SCHWARTZ IR, 1982, ACTA OTO-LARYNGOL, V93, P9, DOI 10.3109/00016488209130847; Shepherd RK, 1997, ACTA OTO-LARYNGOL, P28; SKUSE SDH, 1993, LANGUAGE DEV EXCEPTI, P29; SNYDER RL, 1991, HEARING RES, V56, P246, DOI 10.1016/0378-5955(91)90175-9; SNYDER RL, 1990, HEARING RES, V50, P7, DOI 10.1016/0378-5955(90)90030-S; VANDENHONERT C, 1984, HEARING RES, V14, P225, DOI 10.1016/0378-5955(84)90052-2; Weinberger NM, 1998, TRENDS COGN SCI, V2, P271, DOI 10.1016/S1364-6613(98)01200-5; WURTH N, 1999, GOTTINGEN NEUROBIO R, V27, P318	41	148	154	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1729	1733		10.1126/science.285.5434.1729	http://dx.doi.org/10.1126/science.285.5434.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481008				2022-12-24	WOS:000082472600034
J	Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL				Millett, S; Campbell, K; Epstein, DJ; Losos, K; Harris, E; Joyner, AL			A role for Gbx2 in repression of Otx2 and positioning the mid/hindbrain organizer	NATURE			English	Article							EXPRESSION; GENE; SPECIFICATION; FOREBRAIN; BRAIN; NEUROECTODERM; INFORMATION; CEREBELLUM; INDUCTION; HINDBRAIN	The mid/hindbrain (MHB) junction can act as an organizer to direct the development of the midbrain and anterior hindbrain(1,2) In mice, Otx2 is expressed in the forebrain and midbrain and Gbx2 is expressed in the anterior hindbrain, with a shared border at the level of the MHB organizer. Here we show that, in Gbx2(-/-) mutants, the earliest phenotype is a posterior expansion of the Otx2 domain during early somite stages. Furthermore, organizer genes are expressed at the shifted Otx2 border, but not in a normal spatial relationship. To test whether Gbx2 is sufficient to position the MHB organizer, we transiently expressed Gbx2 in the caudal Otx2 domain and found that the Otx2 caudal border was indeed shifted rostrally and a normal appearing organizer formed at this new Otx2 border. Transgenic embryos then showed an expanded hindbrain and a reduced midbrain at embryonic day 9.5-10. We propose that formation of a normal MHB organizer depends on a sharp Otx2 caudal border and that Gbx2 is required to position and sharpen this border.	NYU, Sch Med, Dev Genet Program, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol & Physiol & Neurosci, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University; New York University	Joyner, AL (corresponding author), NYU, Sch Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.		Campbell, Kenneth/ABC-3570-2021					ACAMPORA D, 1995, DEVELOPMENT, V121, P3279; Acampora D, 1997, DEVELOPMENT, V124, P3639; Acampora D, 1996, NAT GENET, V14, P218, DOI 10.1038/ng1096-218; ALVARADOMALLART RM, 1993, J NEUROBIOL, V24, P1341, DOI 10.1002/neu.480241007; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; Hogan B, 1994, MANIPULATING MOUSE E; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MATSUO I, 1995, GENE DEV, V9, P2646, DOI 10.1101/gad.9.21.2646; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; Millen KJ, 1995, DEVELOPMENT, V121, P3935; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; Rhinn M, 1998, DEVELOPMENT, V125, P845; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Toresson H, 1999, DEVELOPMENT, V126, P1317; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassef M, 1997, PERSPECT DEV NEUROBI, V5, P3; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	19	236	236	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					161	164		10.1038/43664	http://dx.doi.org/10.1038/43664			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490024				2022-12-24	WOS:000082458800053
J	Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR				Seto, AG; Zaug, AJ; Sobel, SG; Wolin, SL; Cech, TR			Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle	NATURE			English	Article							REVERSE-TRANSCRIPTASE; YEAST; PROTEIN; RNA; BINDING; CELLS; IDENTIFICATION; COMPONENTS; SNRNA	Activation of the chromosome end-replicating enzyme telomerase can greatly extend the lifespan of normal human cells' and is associated with most human cancers(2). In all eukaryotes examined, telomerase has an RNA subunit(3), a conserved reverse transcriptase subunit(4) and additional proteins(5,6) but little is known about the assembly of these components. Here we show that the Saccharomyces cerevisiae telomerase RNA(7) has a 5'-2,2,7-trimethyl-guanosine (TMG) cap and a binding site for the Sm proteins, both hallmarks of small nuclear ribonucleoprotein particles (snRNPs) that are involved in nuclear messenger RNA splicing(8,9). Immunoprecipitation of telomerase from yeast extracts shows that Sm proteins are assembled on the RNA and that most or all of the telomerase activity is associated with the Sm-containing complex These data support a model in which telomerase RNA is transcribed by RNA polymerase II (ref. 10) and 7-methylguanosine-capped, binds the seven Sm proteins, becomes TMG-capped and picks up the other protein subunits, We conclude that the functions of snRNPs assembled by this pathway are not restricted to RNA processing, but also include chromosome telomere replication.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; Yale University; Howard Hughes Medical Institute; Yale University	Cech, TR (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Wolin, Sandra/H-2333-2016	Wolin, Sandra/0000-0001-6730-0399	NIGMS NIH HHS [R01 GM048410] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048410] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chapon C, 1997, RNA, V3, P1337; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; Elela SA, 1998, EMBO J, V17, P3738, DOI 10.1093/emboj/17.13.3738; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; JONES MH, 1990, EMBO J, V9, P2555, DOI 10.1002/j.1460-2075.1990.tb07436.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; ROY J, 1995, MOL CELL BIOL, V15, P445, DOI 10.1128/MCB.15.1.445; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Seipelt RL, 1999, NUCLEIC ACIDS RES, V27, P587, DOI 10.1093/nar/27.2.587; SINGH D, 1994, INDIAN J CHEM TECHN, V1, P266; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; Yu YT, 1999, RNA WORLD, P487; [No title captured]	27	230	237	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					177	180		10.1038/43694	http://dx.doi.org/10.1038/43694			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490028				2022-12-24	WOS:000082458800057
J	Berger, A				Berger, A			What is allodynia?	BRITISH MEDICAL JOURNAL			English	Editorial Material																		BERDE C, 1995, PAIN, V62, P1, DOI 10.1016/0304-3959(95)00035-Q; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Gardmark M, 1998, J PHARM SCI, V87, P813, DOI 10.1021/js980056f; 1998, CURRENT OPINION ANAE, V11, P436	4	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 4	1999	319	7210					629	629						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AJ	10523091				2022-12-24	WOS:000082460300030
J	Xu, QA; Buckley, D; Guan, CD; Guo, HC				Xu, QA; Buckley, D; Guan, CD; Guo, HC			Structural insights into the mechanism of intramolecular proteolysis	CELL			English	Article							N-TERMINAL NUCLEOPHILE; CRYSTAL-STRUCTURE; 20S PROTEASOME; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; FLAVOBACTERIUM-MENINGOSEPTICUM; HISTIDINE-DECARBOXYLASE; BETA-SUBUNITS; GLYCOSYLASPARAGINASE; RESOLUTION; HEDGEHOG	A variety of proteins, including glycosylasparaginase, have recently been found to activate functions by self-catalyzed peptide bond rearrangements from single-chain precursors. Here we present the 1.9 Angstrom crystal structures of glycosylasparaginase precursors that are able to autoproteolyze via an N --> O acyl shift. Several conserved residues are aligned around the scissile peptide bond that is in a highly strained trans peptide bond configuration. The structure illustrates how a nucleophilic side chain may attack the scissile peptide bond at the immediate upstream backbone carbonyl and provides an understanding of the structural basis for peptide bond cleavage via an N --> O or N --> S acyl shift that is used by various groups of intramolecular autoprocessing proteins.	Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Boston University	Guo, HC (corresponding author), Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA.	hcguo@bu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053893] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53893] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert A, 1998, NAT STRUCT BIOL, V5, P289, DOI 10.1038/nsb0498-289; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALASUBR.R, 1972, INT J PEPT PROT RES, V4, P91; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; CUI T, 1999, IN PRESS ACTA CRYS D; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Ditzel L, 1998, J MOL BIOL, V279, P1187, DOI 10.1006/jmbi.1998.1818; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fisher AJ, 1996, J BIOL CHEM, V271, P21956, DOI 10.1074/jbc.271.36.21956; GALLAGHER T, 1993, J MOL BIOL, V230, P516, DOI 10.1006/jmbi.1993.1168; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan C, 1998, J BIOL CHEM, V273, P9695, DOI 10.1074/jbc.273.16.9695; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; Guo HC, 1998, J BIOL CHEM, V273, P20205, DOI 10.1074/jbc.273.32.20205; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; Khan AR, 1998, PROTEIN SCI, V7, P815; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Kleywegt GJ, 1999, J MOL BIOL, V285, P1887, DOI 10.1006/jmbi.1998.2393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; Perler FB, 1998, NAT STRUCT BIOL, V5, P249, DOI 10.1038/nsb0498-249; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; RECSEI PA, 1983, P NATL ACAD SCI-BIOL, V80, P973, DOI 10.1073/pnas.80.4.973; Saarela J, 1998, J BIOL CHEM, V273, P25320, DOI 10.1074/jbc.273.39.25320; Sakon J, 1996, BIOCHEMISTRY-US, V35, P10648, DOI 10.1021/bi9604439; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xuan JC, 1998, PROTEIN SCI, V7, P774, DOI 10.1002/pro.5560070327; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	62	115	116	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 3	1999	98	5					651	661		10.1016/S0092-8674(00)80052-5	http://dx.doi.org/10.1016/S0092-8674(00)80052-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490104	hybrid			2022-12-24	WOS:000082433500012
J	Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA				Ban, N; Nissen, P; Hansen, J; Capel, M; Moore, PB; Steitz, TA			Placement of protein and RNA structures into a 5 angstrom-resolution map of the 50S ribosomal subunit	NATURE			English	Article							ELONGATION-FACTOR-G; ESCHERICHIA-COLI RIBOSOME; CRYSTAL-STRUCTURE; CROSS-LINKING; 23S RNA; EF-TU; DOMAIN; LOOP; VISUALIZATION; ARRANGEMENT	We have calculated at 5.0 Angstrom resolution an electron-density map of the large 50S ribosomal subunit from the bacterium Haloarcula marismortui by using phases derived from four heavy-atom derivatives, intercrystal density averaging and density-modification procedures. More than 300 base pairs of A-form RNA duplex have been fitted into this map, as have regions of non-A-form duplex, single-stranded segments and tetraloops. The long rods of RNA crisscrossing the subunit arise from the stacking of short, separate double helices, not all of which are A-form, and in many places proteins crosslink two or more of these rods. The polypeptide exit channel was marked by tungsten cluster compounds bound in one heavy-atom-derivatized crystal. We have determined the structure of the translation-factor-binding centre by fitting the crystal structures of the ribosomal proteins L6, L11 and L14, the sarcin-ricin loop RNA, and the RNA sequence that binds L11 into the electron density. We can position either elongation factor a or elongation factor Tu complexed with an aminoacylated transfer RNA and GTP onto the factor-binding centre in a manner that is consistent with results from biochemical and electron microscopy studies.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; United States Department of Energy (DOE); Brookhaven National Laboratory	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009; Nissen, Poul/D-5774-2014	Nissen, Poul/0000-0003-0948-6628				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Davies C, 1996, STRUCTURE, V4, P55, DOI 10.1016/S0969-2126(96)00009-3; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GOLDEN BL, 1993, EMBO J, V12, P4901, DOI 10.1002/j.1460-2075.1993.tb06184.x; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; Jucker FM, 1996, J MOL BIOL, V264, P968, DOI 10.1006/jmbi.1996.0690; Kleywegt GJ, 1997, ACTA CRYSTALLOGR D, V53, P179, DOI 10.1107/S0907444996012279; LEFFERS H, 1988, J MOL BIOL, V204, P507, DOI 10.1016/0022-2836(88)90351-8; LEFFERS H, 1987, J MOL BIOL, V195, P43, DOI 10.1016/0022-2836(87)90326-3; LILJAS A, 1990, RIBOSOME, P309; MAY RP, 1992, EMBO J, V11, P373, DOI 10.1002/j.1460-2075.1992.tb05060.x; MILLER KD, 1993, J AM HIST, V80, P319, DOI 10.2307/2079816; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Nakagawa A, 1999, EMBO J, V18, P1459, DOI 10.1093/emboj/18.6.1459; NEVSKAYA N, IN PRESS J MOL BIOL; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; OAKES M, 1986, STRUCTURE FUNCTION G, P47; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P52; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SKOLD SE, 1982, EUR J BIOCHEM, V127, P225, DOI 10.1111/j.1432-1033.1982.tb06859.x; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STOEFFLER G, 1986, STRUCTURE FUNCTION G, P28; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; Uchiumi T, 1999, J BIOL CHEM, V274, P681, DOI 10.1074/jbc.274.2.681; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VONBOHLEN K, 1991, J MOL BIOL, V222, P11, DOI 10.1016/0022-2836(91)90730-T; WALLECZEK J, 1988, EMBO J, V7, P3571, DOI 10.1002/j.1460-2075.1988.tb03234.x; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3	50	341	368	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					841	847		10.1038/23641	http://dx.doi.org/10.1038/23641			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476961				2022-12-24	WOS:000082233200036
J	Griffin, EA; Staknis, D; Weitz, CJ				Griffin, EA; Staknis, D; Weitz, CJ			Light-independent role of CRY1 and CRY2 in the mammalian circadian clock	SCIENCE			English	Article							DROSOPHILA PERIOD GENE; TRANSCRIPTION; PHOTORECEPTOR; CRYPTOCHROME; EXPRESSION; TIMELESS; ORTHOLOG; HOMOLOGS; PROTEIN; MPER1	Cryptochrome (CRY), a photoreceptor for the circadian clock in Drosophila, binds to the clock component TIM in a light-dependent fashion and blocks its function. In mammals, genetic evidence suggests a role for CRYs within the clock, distinct from hypothetical photoreceptor functions. Mammalian CRY1 and CRY2 are here shown to act as light-independent inhibitors of CLOCK-BMAL1, the activator driving Per1 transcription. CRY1 or CRY2 (or both) showed Light-independent interactions with CLOCK and BMAL1, as well as with PER1, PER2, and TIM. Thus, mammalian CRYs act as light-independent components of the circadian clock and probably regulate Per1 transcriptional cycling by contacting both the activator and its feedback inhibitors.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.	cweitz@hms.harvard.edu		Griffin, Edmund/0000-0001-7291-6091	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059943] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-59943] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; GRIFFIN EA, UNPUB; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lucas RJ, 1999, CURR BIOL, V9, pR214, DOI 10.1016/S0960-9822(99)80132-8; Lucas RJ, 1999, J BIOL RHYTHM, V14, P4, DOI 10.1177/074873099129000380; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; VITATERNA MH, IN PRESS P NATL ACAD; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	27	493	506	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					768	771		10.1126/science.286.5440.768	http://dx.doi.org/10.1126/science.286.5440.768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10531061				2022-12-24	WOS:000083303200053
J	Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME				Tang, YQ; Yuan, J; Osapay, G; Osapay, K; Tran, D; Miller, CJ; Ouellette, AJ; Selsted, ME			A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins	SCIENCE			English	Article							INHIBITORY MACROCYCLIC PEPTIDES; HUMAN BETA-DEFENSIN-1; ANTIBIOTIC AS-48; AIRWAY EPITHELIA; CYSTIC-FIBROSIS; BETA-DEFENSINS; HOST-DEFENSE; CIRCULIN-A; PURIFICATION; LUNG	Analysis of rhesus macaque leukocytes disclosed the presence of an 18-residue macrocyclic, tridisulfide antibiotic peptide in granules of neutrophils and monocytes. The peptide, termed rhesus theta defensin-1 (RTD-1), is microbicidal for bacteria and fungi at Low micromolar concentrations. Antibacterial activity of the cyclic peptide was threefold greater than that of an open-chain analog, and the cyclic conformation was required for antimicrobial activity in the presence of 150 millimolar sodium chloride. Biosynthesis of RTD-1 involves the head-to-tail ligation of two alpha-defensin-related nonapeptides, requiring the formation of two new peptide bonds. Thus, host defense cells possess mechanisms for synthesis and granular packaging of macrocyclic antibiotic peptides that are components of the phagocyte antimicrobial armamentarium.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Davis, Sch Vet Med, Calif Reg Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Ctr Comparat Med, Davis, CA 95616 USA	University of California System; University of California Irvine; University of California System; University of California Davis; University of California System; University of California Davis	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.		Abrams, William R/A-5782-2008		NIAID NIH HHS [AI22931] Funding Source: Medline; NIDDK NIH HHS [DK44632, DK33506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022931, R37AI022931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506, R55DK044632, R01DK044632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bals R, 1998, INFECT IMMUN, V66, P1225, DOI 10.1128/IAI.66.3.1225-1232.1998; Blond A, 1999, EUR J BIOCHEM, V259, P747, DOI 10.1046/j.1432-1327.1999.00085.x; Boman HG, 1998, IMMUNOLOGIST, V6, P234; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; Derua R, 1996, BIOCHEM BIOPH RES CO, V228, P632, DOI 10.1006/bbrc.1996.1708; Diamond G, 1998, CLIN IMMUNOL IMMUNOP, V88, P221, DOI 10.1006/clin.1998.4587; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GALVEZ A, 1989, ANTIMICROB AGENTS CH, V33, P437, DOI 10.1128/AAC.33.4.437; Ganz T, 1997, Curr Opin Hematol, V4, P53; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; MARTINEZBUENO M, 1994, J BACTERIOL, V176, P6334, DOI 10.1128/jb.176.20.6334-6339.1994; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; Selsted M E, 1993, Genet Eng (N Y), V15, P131; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; TANG YQ, 1993, J BIOL CHEM, V268, P6649; TANG YQ, IN PRESS INFECT IMMU; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; WHITE SH, 1995, CURR OPIN STRUC BIOL, V5, P521, DOI 10.1016/0959-440X(95)80038-7; YOUNT NY, 1995, J IMMUNOL, V155, P4476; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHAO CQ, 1995, FEBS LETT, V368, P197, DOI 10.1016/0014-5793(95)00633-K	34	593	659	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					498	502		10.1126/science.286.5439.498	http://dx.doi.org/10.1126/science.286.5439.498			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521339	Green Submitted			2022-12-24	WOS:000083121200051
J	Bull, C				Bull, C		British Paediat Cardiac Assoc	Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK	LANCET			English	Article							PRENATAL-DIAGNOSIS; ECHOCARDIOGRAPHY; FETUS	Background Assessment of the effect of fetal diagnosis on the prevalence of congenital heart disease at term requires national ascertainment because referral patterns are not rigorously structured. Methods Between 1993 and 1995, all 17 paediatric cardiac centres in the UK submitted to a database lists of all fetuses diagnosed, and all infants needing surgery or interventional catheterisation or dying in the first year of life because of structural heart disease: details included the postal area of residence. Findings There were 4799 affected pregnancies, 4165 babies born alive, 1124 fetal diagnoses, and 567 terminations of pregnancy because the fetus had structural heart disease. Thus, a fetal diagnosis was made in 23.4% of affected pregnancies (11.7% of all affected livebirths) with geographical variability in diagnostic rates. babies born alive. Interpretation Fetal cardiac screening has an effect on the prevalence and types of congenital heart disease seen at term because many affected pregnancies are terminated. If detection rates of affected fetuses rose nationally to those seen in the 15 postal areas where detection rates were significantly higher than the national average in 1993-95, we would expect about 218 fewer affected individuals to be born annually.	Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Bull, C (corresponding author), Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, Great Ormond St, London WC1N 3JH, England.							ABUHARB M, 1995, BRIT HEART J, V74, P192; ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; ALLAN LD, 1980, BRIT HEART J, V44, P444; BONNETT D, 1988, FETAL DIAGN THER S1, V13, P148; Breslow NE., 1987, STAT METHODS CANC RE, P81; *CENTR STAT OFF, 1996, SOC TRENDS, V26, P62; CHANG AC, 1991, J THORAC CARDIOV SUR, V102, P841, DOI 10.1016/S0022-5223(19)33933-9; Copel JA, 1997, ULTRASOUND OBST GYN, V10, P237, DOI 10.1046/j.1469-0705.1997.10040237.x; CULLEN S, 1992, ARCH DIS CHILD-FETAL, V67, P775, DOI 10.1136/adc.67.7_Spec_No.775; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; GEMBRUCH U, 1993, ULTRASOUND OBST GYN, V3, P310, DOI 10.1046/j.1469-0705.1993.03050310.x; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; Hyett J, 1999, BRIT MED J, V318, P81, DOI 10.1136/bmj.318.7176.81; LANGE LW, 1980, CIRCULATION, V62, P799, DOI 10.1161/01.CIR.62.4.799; LUCK CA, 1992, BRIT MED J, V304, P1474, DOI 10.1136/bmj.304.6840.1474; Marteau TM, 1995, PRENATAL DIAG, V15, P1215, DOI 10.1002/pd.1970151304; *OFF NAT STAT, 1995, AB STAT, V22, P13; *OFF NAT STAT, 1997, REG TRENDS, V32, P37; SADIQ M, 1995, BRIT HEART J, V73, P173; SHARLAND GK, 1992, BRIT J OBSTET GYNAEC, V99, P220, DOI 10.1111/j.1471-0528.1992.tb14503.x; Stumpflen I, 1996, LANCET, V348, P854, DOI 10.1016/S0140-6736(96)04069-X; THORNTON JG, 1995, BMJ-BRIT MED J, V311, P1127, DOI 10.1136/bmj.311.7013.1127; WYLLIE J, 1994, BRIT HEART J, V71, P20	23	255	261	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 9	1999	354	9186					1242	1247		10.1016/S0140-6736(99)01167-8	http://dx.doi.org/10.1016/S0140-6736(99)01167-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243RE	10520632				2022-12-24	WOS:000083010400009
J	Henney, JE				Henney, JE			Quick test for pneumonia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-24	WOS:000082901100008
J	McNamara, JM; Gasson, CE; Houston, AI				McNamara, JM; Gasson, CE; Houston, AI			Incorporating rules for responding into evolutionary games	NATURE			English	Article							VIGILANCE; PREDATION; RISK	Evolutionary game theory(1,2) is concerned with the evolutionarily stable outcomes of the process of natural selection. The theory is especially relevant when the fitness of an organism depends on the behaviour of other members of its population. Here we focus on the interaction between two organisms that have a conflict of interest. The standard approach to such two-player games is to assume that each player chooses a single action and that the evolutionarily stable action of each player is the best given the action of its opponent. We argue that, instead, most two-player games should be modelled as involving a series of interactions in which opponents negotiate the final outcome, Thus we should be concerned with evolutionarily stable negotiation rules rather than evolutionarily stable actions. The evolutionarily stable negotiation rule of each player is the best rule given the rule of its opponent. As we show, the action chosen as a result of the negotiation is not the best action given the action of the opponent. This conclusion necessitates a fundamental change in the way that evolutionary games are modelled.	Univ Bristol, Sch Math, Bristol BS8 1TW, Avon, England; Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England	University of Bristol; University of Bristol	McNamara, JM (corresponding author), Univ Bristol, Sch Math, Univ Walk, Bristol BS8 1TW, Avon, England.	john.mcnamara@bristol.ac.uk						Clutton-Brock T., 1991, P234; Dugatkin L.A., 1997, COOPERATION ANIMALS; GODFRAY HCJ, 1991, NATURE, V352, P328, DOI 10.1038/352328a0; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HATCHWELL BJ, 1990, BEHAV ECOL SOCIOBIOL, V27, P199; Houston A.I., 1985, P471; JOHNSTONE RA, 1994, P ROY SOC B-BIOL SCI, V256, P169, DOI 10.1098/rspb.1994.0066; LIMA SL, 1987, J THEOR BIOL, V124, P303, DOI 10.1016/S0022-5193(87)80118-2; MARKMAN S, 1995, ANIM BEHAV, V50, P655, DOI 10.1016/0003-3472(95)80127-8; Maynard Smith J., 1982, pi; MCNAMARA JM, 1992, ANIM BEHAV, V43, P641, DOI 10.1016/0003-3472(92)90086-O; Mock D. W., 1997, EVOLUTION SIBLING RI; PARKER GA, 1990, NATURE, V348, P27, DOI 10.1038/348027a0; Parker GA, 1997, P ROY SOC B-BIOL SCI, V264, P1239, DOI 10.1098/rspb.1997.0171; PULLIAM HR, 1982, J THEOR BIOL, V95, P89, DOI 10.1016/0022-5193(82)90289-2; SMITH JM, 1991, ANIM BEHAV, V42, P1034, DOI 10.1016/S0003-3472(05)80161-7; Wright J, 1990, BEHAV ECOL, V1, P116, DOI 10.1093/beheco/1.2.116	17	300	302	0	95	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					368	371		10.1038/43869	http://dx.doi.org/10.1038/43869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517633	Bronze			2022-12-24	WOS:000082822600049
J	Zhen, M; Jin, YS				Zhen, M; Jin, YS			The liprin protein SYD-2 regulates the differentiation of presynaptic termini in C-elegans	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; SYNAPTIC VESICLES; TYROSINE-PHOSPHATASE; NERVE-TERMINALS; ACTIVE ZONE; SYNAPTOTAGMIN; ORGANIZATION; MUTANTS; SYSTEM	At synaptic junctions, specialized subcellular structures occur in both pre- and postsynaptic cells. Most presynaptic termini contain electron-dense membrane structures(1), often referred to as active zones, which function in vesicle docking and release(2). The components of those active zones and how they are formed are largely unknown. We report here that a mutation in the Caenorhabditis elegans syd-2 (for synapse-defective) gene causes a diffused localization of several presynaptic proteins and of a synaptic-vesicle membrane associated green fluorescent protein (GFP) marker(3,4). Ultrastructural analysis revealed that the active zones of syd-2 mutants were significantly lengthened, whereas the total number of vesicles per synapse and the number of vesicles at the prominent active zones were comparable to those in wild-type animals. Synaptic transmission is partially impaired in syn-2 mutants. syd-2 encodes a member of the liprin (for LAR-interacting protein) family of proteins which interact with LAR-type (for leukocyte common antigen related) receptor proteins with tyrosine phosphatase activity (RPTPs)(5,6). SYD-2 protein is localized at presynaptic termini independently of the presence of vesicles, and functions cell autonomously. We propose that SYD-2 regulates the differentiation of presynaptic termini in particular the formation of the active zone, by acting as an intracellular anchor for RPTP signalling at synaptic junctions.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Jin, YS (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.		Zhen, Mei/A-4967-2012	Zhen, Mei/0000-0003-0086-9622; Jin, Yishi/0000-0002-9371-9860	NINDS NIH HHS [NS35546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BRENNER S, 1974, GENETICS, V77, P71; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hallam SJ, 1998, NATURE, V395, P78, DOI 10.1038/25757; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Jin YS, 1999, J NEUROSCI, V19, P539; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; KRASZEWSKI K, 1995, J NEUROSCI, V15, P4328; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nonet ML, 1997, J NEUROSCI, V17, P8061; Nonet ML, 1999, J NEUROSCI METH, V89, P33, DOI 10.1016/S0165-0270(99)00031-X; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; TRENT C, 1983, GENETICS, V104, P619; WANG YQ, 1993, J MATER RES, V8, P388, DOI 10.1557/JMR.1993.0388; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Yochem J, 1998, GENETICS, V149, P1323	28	278	296	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					371	375		10.1038/43889	http://dx.doi.org/10.1038/43889			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517634	Bronze			2022-12-24	WOS:000082822600050
J	Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA				Zhang, GY; Campbell, EA; Minakhin, L; Richter, C; Severinov, K; Darst, SA			Crystal structure of Thermus aquaticus core RNA polymerase at 3.3 angstrom resolution	CELL			English	Article							TRANSCRIPTION ELONGATION COMPLEX; COLI RPOB GENE; ESCHERICHIA-COLI; ACTIVE-CENTER; BETA-SUBUNIT; 3-DIMENSIONAL STRUCTURE; ALPHA-SUBUNIT; BINDING; DETERMINANTS; ORGANIZATION	The X-ray crystal structure of Thermus aquaticus core RNA polymerase reveals a "crab claw"-shaped molecule with a 27 Angstrom wide internal channel. Located on the back wall of the channel is a Mg2+ ion required for catalytic activity, which is chelated by an absolutely conserved motif from all bacterial and eukaryotic cellular RNA polymerases. The structure places key functional sites, defined by mutational and cross-linking analysis, on the inner walls of the channel in close proximity to the active center Mg2+. Further out from the catalytic center, structural features are found that may be involved in maintaining the melted transcription bubble, clamping onto the RNA product and/or DNA template to assure processivity, and delivering nucleotide substrates to the active center.	Rockefeller Univ, New York, NY 10021 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rockefeller University; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Severinov, Konstantin/C-8545-2016	Campbell, Elizabeth/0000-0002-1332-128X	NIGMS NIH HHS [GM19441-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; Darst SA, 1998, COLD SPRING HARB SYM, V63, P269, DOI 10.1101/sqb.1998.63.269; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; de La Fortelle E., 1997, CRYSTALLOGRAPHIC COM, P1; DEGRYSE E, 1978, ARCH MICROBIOL, V117, P189, DOI 10.1007/BF00402307; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GENTRY DR, 1993, BIOCHEMISTRY-US, V32, P11224, DOI 10.1021/bi00092a036; Gnatt A, 1997, J BIOL CHEM, V272, P30799, DOI 10.1074/jbc.272.49.30799; Gross CA, 1996, PHILOS T R SOC B, V351, P475, DOI 10.1098/rstb.1996.0045; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HUANG RC, 1960, BIOCHEM BIOPH RES CO, V3, P689, DOI 10.1016/0006-291X(60)90088-7; HURWITZ J, 1960, BIOCHEM BIOPH RES CO, V3, P15, DOI 10.1016/0006-291X(60)90094-2; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JOKERST RS, 1989, MOL GEN GENET, V215, P266, DOI 10.1007/BF00339727; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARKOV D, 1999, IN PRESS GENES DEV; Markovtsov V, 1996, P NATL ACAD SCI USA, V93, P3221, DOI 10.1073/pnas.93.8.3221; MECSAS J, 1991, J MOL BIOL, V220, P585, DOI 10.1016/0022-2836(91)90102-C; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; Mukherjee K, 1997, EUR J BIOCHEM, V247, P884, DOI 10.1111/j.1432-1033.1997.00884.x; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; Mustaev A, 1997, P NATL ACAD SCI USA, V94, P6641, DOI 10.1073/pnas.94.13.6641; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; REES WA, 1993, SCIENCE, V260, P1646, DOI 10.1126/science.8503010; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; Sentenac A., 1992, YEAST RNA POLYM SUBU, P27; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; STEVENS A, 1960, BIOCHEM BIOPH RES CO, V3, P92, DOI 10.1016/0006-291X(60)90110-8; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; WEISS SB, 1959, J AM CHEM SOC, V81, P4118, DOI 10.1021/ja01524a087; Zakharova N, 1999, J BACTERIOL, V181, P3857, DOI 10.1128/JB.181.12.3857-3859.1999; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang GY, 1998, SCIENCE, V281, P262, DOI 10.1126/science.281.5374.262	61	635	665	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					811	824		10.1016/S0092-8674(00)81515-9	http://dx.doi.org/10.1016/S0092-8674(00)81515-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499798	Bronze			2022-12-24	WOS:000082679200008
J	Davies, EK; Peters, AD; Keightley, PD				Davies, EK; Peters, AD; Keightley, PD			High frequency of cryptic deleterious mutations in Caenorhabditis elegans	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; AMBER SUPPRESSORS; SELECTION; RATES; RISK	Deleterious mutations with very small phenotypic effects could be important for several evolutionary phenomena, but the extent of their contribution has been unknown. Fitness effects of induced mutations in Lines of Caenorhabditis elegans were measured using a system for which the number of deleterious point mutations in the DNA can be estimated. In fitness assays, only about 4 percent of the deleterious mutations fixed in each Line were detectable. The remaining 96 percent, though cryptic, are significant for mutation Load and, potentially, for the evolution of sex.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of Edinburgh	Keightley, PD (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	p.keightley@ed.ac.uk						ANDERSON P, 1995, CAENORHABDITIS ELEGA, P31; BARNES TM, 1995, GENETICS, V141, P159; BEJSOVEC A, 1990, CELL, V60, P133, DOI 10.1016/0092-8674(90)90723-R; BEJSOVEC A, 1988, GENE DEV, V2, P1307, DOI 10.1101/gad.2.10.1307; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Crow J.F., 1983, Genetics and Biology of Drosophila, V3c, P1; Crow JF, 1997, P NATL ACAD SCI USA, V94, P8380, DOI 10.1073/pnas.94.16.8380; EIDE D, 1985, GENETICS, V109, P67; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Fry JD, 1999, P NATL ACAD SCI USA, V96, P574, DOI 10.1073/pnas.96.2.574; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; HODGKIN J, 1985, GENETICS, V111, P287; Keightley PD, 1997, P NATL ACAD SCI USA, V94, P3823, DOI 10.1073/pnas.94.8.3823; Keightley PD, 1998, CURR BIOL, V8, pR235, DOI 10.1016/S0960-9822(98)70148-4; Keightley PD, 1996, GENETICS, V144, P1993; Keightley PD, 1998, GENETICS, V148, P753; KONDO K, 1990, J MOL BIOL, V215, P7, DOI 10.1016/S0022-2836(05)80090-7; KONDRASHOV AS, 1995, J THEOR BIOL, V175, P583, DOI 10.1006/jtbi.1995.0167; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, P ROY SOC B-BIOL SCI, V258, P221, DOI 10.1098/rspb.1994.0166; KONDRASHOV AS, 1993, HUM MUTAT, V2, P229, DOI 10.1002/humu.1380020312; LANDE R, 1994, EVOLUTION, V48, P1460, DOI [10.2307/2410240, 10.1111/j.1558-5646.1994.tb02188.x]; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P292, DOI 10.1093/nar/27.1.292; ROSENBLUTH RE, 1983, MUTAT RES, V110, P39, DOI 10.1016/0027-5107(83)90016-7; Shabalina SA, 1997, P NATL ACAD SCI USA, V94, P13034, DOI 10.1073/pnas.94.24.13034; SHABALINA SA, IN PRESS GENET RES; STENICO M, 1994, NUCLEIC ACIDS RES, V22, P2437, DOI 10.1093/nar/22.13.2437; Sulston J, 1988, NEMATODE CAENORHABDI, P587; Vassilieva LL, 1999, GENETICS, V151, P119; WATERSTON RH, 1981, GENETICS, V97, P307	30	110	112	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1748	1751		10.1126/science.285.5434.1748	http://dx.doi.org/10.1126/science.285.5434.1748			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481013				2022-12-24	WOS:000082472600039
J	Broccoli, V; Boncinelli, E; Wurst, W				Broccoli, V; Boncinelli, E; Wurst, W			The caudal limit of Otx2 expression positions the isthmic organizer	NATURE			English	Article							MIDBRAIN-HINDBRAIN BOUNDARY; NERVOUS-SYSTEM; ROSTRAL BRAIN; MOUSE; GENES; PHENOTYPE; FGF8; ENGRAILED-1; RHOMBOMERES; INDUCTION	The homeobox gene Otx2 is expressed in the anterior neural tube with a sharp limit at the midbrain/hindbrain junction (the isthmic organizer)(1). Otx2 inactivation experiments have shown that this gene is essential for the development of its expression domain(2). Here we investigate whether the caudal limit of Otx2 expression is instrumental in positioning the isthmic organizer and in specifying midbrain versus hindbrain fate, by ectopically expressing Otx2 in the presumptive anterior hindbrain using a knock-in strategy into the En1 locus. Transgenic offspring display a cerebellar ataxia. Morphological and histological studies of adult transgenic brains reveal that most of the anterior cerebellar vermis is missing whereas the inferior colliculus is complementarily enlarged. During early neural pattern formation expression of the midbrain markers Wnt1 and Ephrin-A5, the isthmic organizer markers Pax2 and Fgf-8 and the hindbrain marker Gbx2 are shifted caudally in the presumptive hindbrain territory. These findings show that the caudal limit of Otx2 expression is sufficient for positioning the isthmic organizer and encoding caudal midbrain fate within the mid/hindbrain domain.	GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Hosp San Raffaele, DIBIT, I-20132 Milan, Italy	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Wurst, W (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Mammalian Genet, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Broccoli, Vania/K-3464-2016	Broccoli, Vania/0000-0003-4050-0926; Wurst, Wolfgang/0000-0003-4422-7410				Acampora D, 1999, TRENDS NEUROSCI, V22, P116, DOI 10.1016/S0166-2236(98)01387-3; Acampora D, 1997, DEVELOPMENT, V124, P3639; ANG SL, 1994, DEVELOPMENT, V120, P2979; BALLYCUIF L, 1995, CURR OPIN GENET DEV, V5, P450, DOI 10.1016/0959-437X(95)90048-L; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Danielian PS, 1996, NATURE, V383, P332, DOI 10.1038/383332a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; Flenniken AM, 1996, DEV BIOL, V179, P382, DOI 10.1006/dbio.1996.0269; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Joyner AL, 1996, TRENDS GENET, V12, P15, DOI 10.1016/0168-9525(96)81383-7; Lee SMK, 1997, DEVELOPMENT, V124, P959; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lun K, 1998, DEVELOPMENT, V125, P3049; Mallamaci A, 1996, MECH DEVELOP, V58, P165, DOI 10.1016/S0925-4773(96)00571-0; MARIN F, 1995, EUR J NEUROSCI, V7, P1714, DOI 10.1111/j.1460-9568.1995.tb00693.x; Martinez S, 1999, DEVELOPMENT, V126, P1189; MARTINEZ S, 1991, NEURON, V6, P971, DOI 10.1016/0896-6273(91)90237-T; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; Millet S, 1996, DEVELOPMENT, V122, P3785; Reifers F, 1998, DEVELOPMENT, V125, P2381; Schwarz M, 1997, P NATL ACAD SCI USA, V94, P14518, DOI 10.1073/pnas.94.26.14518; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Suda Y, 1997, MECH DEVELOP, V69, P125, DOI 10.1016/S0925-4773(97)00161-5; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; Wassilew S, 1997, ANTIVIR CHEM CHEMOTH, V8, P3, DOI 10.1177/09563202970080S602; WURST W, 1994, DEVELOPMENT, V120, P2065	30	245	245	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 9	1999	401	6749					164	168		10.1038/43670	http://dx.doi.org/10.1038/43670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490025				2022-12-24	WOS:000082458800054
J	Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ				Yokouchi, Y; Vogan, KJ; Pearse, RV; Tabin, CJ			Antagonistic signaling by Caronte, a novel Cerberus-related gene, establishes left-right asymmetric gene expression	CELL			English	Article							SONIC-HEDGEHOG; NEURALIZING ACTIVITY; CHICK EMBRYOGENESIS; SECRETED FACTOR; PATHWAY; LIMB; CONSERVATION; INDUCTION; ENDODERM; HOMOLOG	Left-right asymmetry is initiated during chick embryogenesis in small domains near Hensen's node. Subsequently, broad asymmetric gene expression domains are established in the lateral plate mesoderm, ultimately determining the directionality of morphogenetic events. The transfer of asymmetric information from the node to the lateral plate is mediated by Caronte (Car), a navel member of the Cerberus/Dan gene family, which induces targets by antagonizing symmetrically expressed BMP signals. In addition, BMP antagonism by Car induces asymmetric expression of Lefty in the midline, preventing spread of left-sided signals to the contralateral side.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Nagoya Univ, Sch Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan	Harvard University; Harvard Medical School; Nagoya University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.			Vogan, Kyle/0000-0001-9565-9665; Pearse, Richard/0000-0003-3972-1457				Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Capdevila J, 1998, DEV BIOL, V197, P205, DOI 10.1006/dbio.1997.8824; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; Levin M, 1996, NATURE, V384, P321, DOI 10.1038/384321a0; Levin M, 1997, DEV BIOL, V189, P57, DOI 10.1006/dbio.1997.8662; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LEVIN M, 1996, MOL BASIS LEFT RIGHT; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; LOHR JL, 1997, DEVELOPMENT, V124, P1467; Marigo V, 1996, DEVELOPMENT, V122, P1225; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pearce JJH, 1999, DEV BIOL, V209, P98, DOI 10.1006/dbio.1999.9240; Perrimon N, 1999, CELL, V97, P13, DOI 10.1016/S0092-8674(00)80710-2; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; RAMSDELL AF, 1999, IN PRESS DEVELOPMENT; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RODRIGUEZESTEBA.C, 1999, IN PRESS NATURE; Tabin CJ, 1997, TRENDS CELL BIOL, V7, P442, DOI 10.1016/S0962-8924(97)01159-8; Thomas P, 1997, COLD SPRING HARB SYM, V62, P115; THOMSEN HS, 1997, TRENDS GENET, V13, P209; Vogan KJ, 1999, NATURE, V397, P295, DOI 10.1038/16796; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; ZHU L, 1999, IN PRESS CURR BIOL	36	143	150	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					573	583		10.1016/S0092-8674(00)80045-8	http://dx.doi.org/10.1016/S0092-8674(00)80045-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490097	Bronze			2022-12-24	WOS:000082433500005
J	Donelly, PD				Donelly, PD			Potential problems for tenants	BRITISH MEDICAL JOURNAL			English	Article									Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales		Donelly, PD (corresponding author), Iechyd Morgannwg Hlth, Swansea SA1 1LT, W Glam, Wales.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					373	373						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490322				2022-12-24	WOS:000082001700029
J	Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA				Dundas, S; Murphy, J; Soutar, RL; Jones, GA; Hutchinson, SJ; Todd, WTA			Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157 : H7 outbreak	LANCET			English	Article							HEMOLYTIC-UREMIC SYNDROME; THROMBOTIC THROMBOCYTOPENIC PURPURA; HEMORRHAGIC COLITIS	Background The haemolytic uraemic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP) during an Escherichia coli O157 outbreak occurred in 1996 in central Scotland. Adults who develop HUS/TTP induced by E coli O157 tend to be elderly and have a historical mortality rate of almost 90% when treated conservatively, Therefore the decision was made to treat adults who developed HUS/TTP during this outbreak with therapeutic plasma exchange (TPE). We report our outcome with this controversial treatment. largest number of adult cases of uraemic syndrome (HUS)/thrombotic Methods A case definition for HUS/TTP was developed at the beginning of the outbreak. All cases meeting this definition were considered for TPE. Information on demographics, clinical features, treatment and outcome of patients was obtained by retrospective case note review. Findings 22 adults developed HUS/TTP. They had a mean age of 71 years. 16 cases received TPE. Six cases had contraindications to TPE or died before the procedure could be done. Ten of the 22 (45%) adults with HUS/TTP died. Five of the 16 (31%) TPE treated cases died, four of eight aged over 70 years compared with one of eight aged less than 70 years. Premorbid illness, neurological features, treatment with ciprofloxacin or prostacyclin, and the laboratory severity of HUS/TTP were not associated with death; the number of cases, however, was too small to allow statistical conclusion. Interpretation The mortality rate is high in adults who develop HUS/TTP induced by E coli O157. TPE appears to be a promising treatment that was well tolerated in our elderly patients. A national register of adult cases of HUS/TTP induced by E coli O157 should be established.	Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland; Monklands Hosp, Dept Haematol, Airdrie ML6 0JS, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries, Scotland; Scottish Ctr Infect & Environm Hlth, Glasgow, Lanark, Scotland	Monklands Hospital; Monklands Hospital	Todd, WTA (corresponding author), Monklands Hosp, Dept Infect Dis, Airdrie ML6 0JS, Lanark, Scotland.	andrew@todds.demon.co.uk						Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; Begue RE, 1998, SOUTHERN MED J, V91, P798, DOI 10.1097/00007611-199809000-00001; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; CIMOLAI N, 1990, J PEDIATR-US, V116, P589, DOI 10.1016/S0022-3476(05)81609-9; DELAHUNT MN, 1991, BRIT J SURG, V78, P1469, DOI 10.1002/bjs.1800781220; DRUMMOND KN, 1985, NEW ENGL J MED, V312, P116, DOI 10.1056/NEJM198501103120211; Duncan L., 1986, ONTARIO DIS SURVEILL, V7, P604; DUNDAS S, 1996, IN PRESS CENTRAL SCO; GRIFFIN PM, 1990, GASTROENTEROLOGY, V99, P142, DOI 10.1016/0016-5085(90)91241-W; HUGHES DA, 1991, SCOT MED J, V36, P9, DOI 10.1177/003693309103600105; Karch H, 1996, J CLIN MICROBIOL, V34, P516, DOI 10.1128/JCM.34.3.516-519.1996; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; LOUSI CB, 1991, INFECT IMMUN, V59, P4173; MCBRIEN AD, 1983, LANCET, V1, P702; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; MOAKE JL, 1989, AM J MED, V87, P3; PETITT RM, 1980, SEMIN THROMB HEMOST, V6, P350, DOI 10.1055/s-2007-1005108; REILLY WJ, 1997, SCIEH WKLY REP, V97, P4; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; Rock G, 1996, BRIT J HAEMATOL, V94, P383, DOI 10.1046/j.1365-2141.1996.d01-1800.x; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; RUGGENENTI P, 1997, KIDNEY INT S, V58, pS97; TESH VL, 1991, MOL MICROBIOL, V5, P1817, DOI 10.1111/j.1365-2958.1991.tb00805.x; WALTERS MDS, 1989, PEDIATR NEPHROL, V3, P130, DOI 10.1007/BF00852893; 1986, MMWR MORB MORTAL WKL, V35, P549	25	116	122	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	1999	354	9187					1327	1330		10.1016/S0140-6736(99)01251-9	http://dx.doi.org/10.1016/S0140-6736(99)01251-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533860				2022-12-24	WOS:000083149900009
J	Neri, P; Parker, AJ; Blakemore, C				Neri, P; Parker, AJ; Blakemore, C			Probing the human stereoscopic system with reverse correlation	NATURE			English	Article							BINOCULAR DISPARITY; DEPTH-PERCEPTION; NEURONS; CORTEX	Our two eyes obtain slightly different views of the world. The resulting differences in the two retinal images, called binocular disparities, provide us with a stereoscopic sense of depth(1). The primary visual cortex (V1) contains neurons that are selective for the disparity(2-4) of individual elements in an image, but this information must be further analysed to complete the stereoscopic process(5,6). Here we apply the psychophysical technique of reverse correlation(7) to investigate disparity processing in human vision. Observers viewed binocular random-dot patterns, with 'signal' dots in a specific depth plane plus 'noise' dots with randomly assigned disparities. By examining the correlation between the observers' ability to detect the plane and the particular sample of 'noise' disparities presented on each trial, we revealed detection 'filters: whose disparity selectivity was remarkably similar to that of individual neurons in monkey V1. Moreover, if the noise dots were of opposite contrast in the two eyes, the tuning inverted, just like the response patterns of V1 neurons(5,6). Reverse correlation appears to probe disparity processing at the earliest stages of binocular combination, prior to the generation of a full stereoscopic depth percept.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	University of Oxford	Neri, P (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.		Parker, Andrew J/I-7867-2013; Neri, Peter/G-1066-2012	Parker, Andrew J/0000-0001-5800-0407; Blakemore, Colin/0000-0003-2659-7899; Neri, Peter/0000-0003-1981-5309	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Beard BL, 1998, P SOC PHOTO-OPT INS, V3299, P79, DOI 10.1117/12.320099; COGAN AI, 1995, PERCEPTION, V24, P33, DOI 10.1068/p240033; COGAN AI, 1993, VISION RES, V33, P1959, DOI 10.1016/0042-6989(93)90021-N; CORMACK LK, 1993, VISUAL NEUROSCI, V10, P585, DOI 10.1017/S0952523800005290; Cumming BG, 1997, NATURE, V389, P280, DOI 10.1038/38487; Cumming BG, 1998, PERCEPTION, V27, P1367, DOI 10.1068/p271367; Efron Bradley., 1994, INTRO BOOTSTRAP; Fleet DJ, 1996, VISION RES, V36, P1839, DOI 10.1016/0042-6989(95)00313-4; GREEN DM, 1966, SIGNAL DETECTION THE; Julesz B., 1971, FDN CYCLOPEAN PERCEP; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; Masson GS, 1997, NATURE, V389, P283, DOI 10.1038/38496; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; SCHOR C, 1984, VISION RES, V24, P661, DOI 10.1016/0042-6989(84)90207-4; STEVENSON SB, 1992, VISION RES, V32, P1685, DOI 10.1016/0042-6989(92)90161-B; WATSON AB, 1983, PERCEPT PSYCHOPHYS, V33, P113, DOI 10.3758/BF03202828; Wheatstone C., 1838, PHILOS T ROY SOC LON, V128, P371, DOI DOI 10.1098/RSTL.1838.0019	20	94	95	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					695	698		10.1038/44409	http://dx.doi.org/10.1038/44409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537107				2022-12-24	WOS:000083207400056
J	Macklin, R				Macklin, R			The ethical problems with sham surgery in clinical research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DEVELOPING-COUNTRIES; PLACEBO ORTHODOXY; TRIALS; MYTHS		Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Macklin, R (corresponding author), Yeshiva Univ Albert Einstein Coll Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							Advisory Committee on Human Radiation Experiments, 1996, FIN REP ADV COMM HUM; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; APPELBAUM PS, 1982, INT J LAW PSYCHIAT, V5, P319, DOI 10.1016/0160-2527(82)90026-7; CLARK PI, 1994, ANNU REV PUBL HEALTH, V15, P19; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; Cohen Peter J, 1998, IRB, V20, P6, DOI 10.2307/3563555; Freedman B, 1996, J LAW MED ETHICS, V24, P243, DOI 10.1111/j.1748-720X.1996.tb01859.x; Freedman B, 1996, J LAW MED ETHICS, V24, P252, DOI 10.1111/j.1748-720X.1996.tb01860.x; Freedman Benjamin, 1990, IRB, V12, P1, DOI 10.2307/3564541; JOHANNES L, 1998, WALL STREET J   1211, pA8; Johannes Laura, 1998, Wall St J (East Ed), pA1; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; KING NMP, 1995, HASTINGS CENT REP, V25, P6, DOI 10.2307/3562155; Levit K R, 1985, Health Care Financ Rev, V7, P1; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Martin Douglas K, 1995, IRB, V17, P8, DOI 10.2307/3563530; Meslin Eric M, 1990, IRB, V12, P7, DOI 10.2307/3563683; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1978, BELM REP ETH PRINC G; Orr RD, 1996, PSYCHIATR SERV, V47, P1262; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Stolberg Sheryl Gay, 1999, N Y Times Web, pF2; Stolberg Sheryl Gay, 1999, N Y Times Web, P3; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; Williams Peter C, 1984, IRB, V6, P1, DOI 10.2307/3563870	25	197	200	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					992	996		10.1056/NEJM199909233411312	http://dx.doi.org/10.1056/NEJM199909233411312			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498498				2022-12-24	WOS:000082658100012
J	Leggatt, V; Mackay, J; Yates, JRW				Leggatt, V; Mackay, J; Yates, JRW			Evaluation of questionnaire on cancer family history in identifying patients at increased genetic risk in general practice	BRITISH MEDICAL JOURNAL			English	Article							COLORECTAL-CANCER		E Barnwell Hlth Ctr, Cambridge CB5 8SP, England; Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge; Addenbrooke's Hospital; University of Cambridge	Leggatt, V (corresponding author), E Barnwell Hlth Ctr, Cambridge CB5 8SP, England.							Dunlop MG, 1997, BMJ-BRIT MED J, V314, P1882, DOI 10.1136/bmj.314.7098.1882; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Lalloo F, 1998, EUR J CANCER, V34, P937, DOI 10.1016/S0959-8049(98)00005-7; Mackay James, 1997, Cancer Treatment Reviews, V23, pS13, DOI 10.1016/S0305-7372(97)90003-7; Pharoah PDP, 1998, BRIT MED BULL, V54, P823	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					757	758		10.1136/bmj.319.7212.757	http://dx.doi.org/10.1136/bmj.319.7212.757			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10488003	Bronze, Green Published			2022-12-24	WOS:000082701500022
J	Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC				Harbour, JW; Luo, RX; Santi, AD; Postigo, AA; Dean, DC			Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1	CELL			English	Article							TRANSCRIPTIONAL REPRESSOR MOTIF; CYCLIN-DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; PRB PHOSPHORYLATION; PHASE-TRANSITION; E2F; FAMILY; BINDING; POCKET	We present evidence that phosphorylation of the C-terminal region of Rb by Cdk4/6 initiates successive intramolecular interactions between the C-terminal region and the central pocket. The initial interaction displaces histone deacetylase from the pocket, blocking active transcriptional repression by Rb. This facilitates a second interaction that leads to phosphorylation of the pocket by Cdk2 and disruption of pocket structure. These intramolecular interactions provide a molecular basis for sequential phosphorylation of Rb by Cdk4/6 and Cdk2. Cdk4/6 is activated early in G1, blocking active repression by Rb. However, it is not until near the end of G1, when cyclin E is expressed and Cdk2 is activated, that Rb is prevented from binding and inactivating E2F.	Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA.	ddean@im.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809; Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Adams PD, 1999, MOL CELL BIOL, V19, P1068; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 1996, ONCOGENE, V12, P1173; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; KATO J, 1993, GENE DEV, V7, P331; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	49	790	819	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 17	1999	98	6					859	869		10.1016/S0092-8674(00)81519-6	http://dx.doi.org/10.1016/S0092-8674(00)81519-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499802	Bronze			2022-12-24	WOS:000082679200012
J	Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA				Ames, RS; Sarau, HM; Chambers, JK; Willette, RN; Alyar, NV; Romanic, AM; Louden, CS; Foley, JJ; Sauermelch, CF; Coatney, RW; Ao, ZH; Disa, J; Holmes, SD; Stadel, JM; Martin, JD; Liu, WS; Glover, GI; Wilson, S; McNulty, DE; Ellis, CE; Elshourbagy, NA; Shabon, U; Trill, JJ; Hay, DWP; Ohlstein, EH; Bergsma, DJ; Douglas, SA			Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14	NATURE			English	Article							CLONING; PEPTIDE; GENES; RATS	Urotensin-II (U-II) is a vasoactive 'somatostatin-like' cyclic peptide which was originally isolated from fish spinal cords(1,2), and which has recently been cloned from man(3). Here we describe the identification of an orphan human G-protein-coupled receptor homologous to rat GPR14 (refs 4, 5) and expressed predominantly in cardiovascular tissue, which functions as a U-II receptor. Goby and human U-II bind to recombinant human GPR14 with high affinity, and the binding is functionally coupled to calcium mobilization. Human U-II is found within both vascular and cardiac tissue (including coronary atheroma) and effectively constricts isolated arteries from non-human primates. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far. In vivo, human U-II markedly increases total peripheral resistance in anaesthetized non-human primates, a response associated with profound cardiac contractile dysfunction. Furthermore, as U-II immunoreactivity is also found within central nervous system and endocrine tissues, it may have additional activities.	SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm & Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Funct Gene Anal, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pathol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Lab Anim Sci, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; USA & So Way, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Ames, RS (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Biol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Conlon JM, 1996, J EXP ZOOL, V275, P226, DOI 10.1002/(SICI)1097-010X(19960601/15)275:2/3<226::AID-JEZ14>3.3.CO;2-Y; Coulouarn Y, 1998, P NATL ACAD SCI USA, V95, P15803, DOI 10.1073/pnas.95.26.15803; DOUGLAS SA, 1991, BRIT J PHARMACOL, V104, P311, DOI 10.1111/j.1476-5381.1991.tb12428.x; Elshourbagy NA, 1998, ENDOCRINOLOGY, V139, P1678, DOI 10.1210/en.139.4.1678; GIBSON A, 1986, GEN COMP ENDOCR, V64, P435, DOI 10.1016/0016-6480(86)90080-8; HASEGAWA K, 1992, NEUROENDOCRINOL LETT, V14, P357; ITOH H, 1988, EUR J PHARMACOL, V149, P61, DOI 10.1016/0014-2999(88)90042-8; KING DS, 1990, INT J PEPT PROT RES, V36, P255; Libert F, 1991, CURR OPIN CELL BIOL, V3, P218, DOI 10.1016/0955-0674(91)90142-L; MARCHESE A, 1995, GENOMICS, V29, P335, DOI 10.1006/geno.1995.9996; ODOWD BF, 1995, GENOMICS, V28, P84, DOI 10.1006/geno.1995.1109; OHSAKO S, 1986, J NEUROSCI, V6, P2730; PEARSON D, 1980, P NATL ACAD SCI-BIOL, V77, P5021, DOI 10.1073/pnas.77.8.5021; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAL M, 1995, BIOCHEM BIOPH RES CO, V209, P752, DOI 10.1006/bbrc.1995.1563; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	19	713	865	3	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					282	286		10.1038/45809	http://dx.doi.org/10.1038/45809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499587				2022-12-24	WOS:000082678400055
J	Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL				Selhub, J; Jacques, PF; Rosenberg, IH; Rogers, G; Bowman, BA; Gunter, EW; Wright, JD; Johnson, CL			Serum total homocysteine concentrations in the third national health and nutrition examination survey (1991-1994): Population reference ranges and contribution of vitamin status to high serum concentrations	ANNALS OF INTERNAL MEDICINE			English	Article							PLASMA TOTAL HOMOCYSTEINE; FOLIC-ACID; COBALAMIN DEFICIENCY; REFERENCE INTERVALS; METHYLMALONIC ACID; ELDERLY POPULATION; VASCULAR-DISEASE; BRITISH MEN; RISK; HYPERHOMOCYSTEINEMIA	Background: The concentration of circulating total homocysteine is a sensitive marker of inadequate folate and vitamin B-12 status. Elevated homocysteine concentrations are associated with an increased risk for vascular disease. Objective: To identify reference ranges for serum total homocysteine concentration in U.S. residents and quantify the contribution of circulating vitamin concentrations to high homocysteine concentrations. Design: Cross-sectional prevalence study. Setting: United States. Patients: A nationally representative sample of 3563 male participants and 4523 female participants 12 years of age or older who participated in the third National Health and Nutrition Examination Survey. Measurements: Reference ranges (5th and 95th percentiles) for the total homocysteine concentration were defined among participants who were folate- and vitamin B-12-replete and had normal creatinine concentrations. A high total homocysteine concentration was defined as one that exceeded the sex-specific 95th percentile for the reference sample (participants 20 to 39 years of age). The population attributable risk percentage was calculated to determine the contribution of low folate (<11 nmol/L) and vitamin B-12 (<185 pmol/L) concentrations to a high homocysteine concentration. Results: Reference ranges for serum total homocysteine concentration increased with age; these ranges were 4.3 to 9.9 mu mol/L for male participants and 3.3 to 7.2 mu mol/L for female participants 12 to 19 years of age and from 5.9 to 15.3 mu mol/L for men and 4.9 to 11.6 mu mol/L for women 60 years of age or older. A high homocysteine concentration was defined as at least 11.4 mu mol/L for male participants and at least 10.4 mu mol/L for female participants. Approximately two thirds of the cases of high homocysteine concentrations were associated with low vitamin concentrations. Conclusions: Upper reference limits for the serum total homocysteine concentration increased with age and were higher for male participants than for female participants at all ages. In most cases, high homocysteine concentrations were associated with low serum vitamin concentrations.	Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Ctr Dis Control & Prevent, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Environm Hlth Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Tufts University; United States Department of Agriculture (USDA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Selhub, J (corresponding author), Tufts Univ, USDA, Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052630] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL52630] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Bates CJ, 1997, EUR J CLIN NUTR, V51, P691, DOI 10.1038/sj.ejcn.1600468; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; Chambers J. M., 1983, GRAPHICAL METHODS DA, DOI DOI 10.1201/9781351072304; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gunter EW, 1996, LAB PROCEDURES USED; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; Herbert V, 1999, MODERN NUTR HLTH DIS, P433; Jacques PF, 1999, AM J CLIN NUTR, V69, P482; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Joosten E, 1996, EUR J HAEMATOL, V57, P222; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; LINDENBAUM J, 1994, AM J CLIN NUTR, V60, P2, DOI 10.1093/ajcn/60.1.2; MALINOW MR, 1993, CIRCULATION, V87, P1107, DOI 10.1161/01.CIR.87.4.1107; Mijatovic V, 1998, OBSTET GYNECOL, V91, P432, DOI 10.1016/S0029-7844(97)00704-7; Nygard O, 1998, AM J CLIN NUTR, V67, P263, DOI 10.1093/ajcn/67.2.263; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Rasmussen K, 1996, CLIN CHEM, V42, P630; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBERG IH, 1992, AM J CLIN NUTR, V55, P1237; *SAS I INC, 1996, SAS SYST WIND VERS 6; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Selhub J., 1996, PRESENT KNOWLEDGE NU, P206; Shah BV, 1996, SUDAAN USERS MANUAL; *SPSS INC, 1997, SYSTAT 7 0 WIND; *THREE NAT HLTH NU, 1996, REF MAN REP WEIGHT E; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; UBBINK JB, 1995, CLIN CHEM, V41, P1033; *US DEP HHS, 1994, DHHS PUBL PHS; Weir D. G., 1999, MODERN NUTR HLTH DIS, P447; WILCKEN DEL, 1988, METABOLISM, V37, P697, DOI 10.1016/0026-0495(88)90093-5; Wright J.D., 1998, VITAL HLTH STAT, V11, P1; 1997, MMWR MORB MORTAL WKL, V46, P721	41	302	320	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					331	+		10.7326/0003-4819-131-5-199909070-00003	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475885				2022-12-24	WOS:000082458500002
J	Ferry, LH; Grissino, LM; Runfola, PS				Ferry, LH; Grissino, LM; Runfola, PS			Tobacco dependence curricula in US undergraduate medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; UNITED-STATES; STUDENTS; PHYSICIANS; QUIT	Context Tobacco use is the leading preventable cause of death in the United States. And yet only 21% of practicing physicians claim they received adequate training to help their patients stop smoking. Objective To assess the content and extent of tobacco education and intervention skills in US medical schools' curricula. Design A survey with 13 multiple-response items on tobacco education, Survey questions were based on the recommendations of the Agency for Health Care Policy and Research and the National Cancer Institute Expert Panel, The Liaison Committee on Medical Education included 4 of these items in a modified form on the 1997 annual questionnaire. Setting One hundred twenty-six US medical schools. Participants Surveys were obtained from 122 associate deans for medical education (98.6%), Main Outcome Measures Curriculum content in basic science and clinical science, elective or required clinical experience, hours of instruction, and resource materials, Results Inclusion of all 6 tobacco curricula content areas recommended by the National Cancer Institute and the Agency for Health Care Policy and Research was higher in basic science (63/115 [54.8%]) than in clinical science (5/115 [4.4%]). Most medical schools (83/120 [69.2%]) did not require clinical training in smoking cessation techniques, while 23.5% (27/115) offered additional experience as an elective course, Thirty-one percent (32/102) of schools averaged less than 1 hour of instruction per year in smoking cessation techniques during the 4 years of medical school. A minority of schools reported 3 or more hours of clinical smoking cessation instruction in the third (14.7%) and fourth (4.9%) years. Conclusions A majority of US medical school graduates are not adequately trained to treat nicotine dependence. The major deficit is the lack of smoking cessation instruction and evaluation in the clinical years. A model core tobacco curricula that meets national recommendations should be developed and implemented in all US medical schools.	Loma Linda Univ, Sch Med, Dept Prevent Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Publ Hlth, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University	Ferry, LH (corresponding author), Loma Linda Univ, Sch Med, Dept Prevent Med, Nichol Hall,Room 1516, Loma Linda, CA 92350 USA.							ALLEN SS, 1990, AM J PREV MED, V6, P28, DOI 10.1016/S0749-3797(18)31041-9; *AM AC FAM PHYS, 1987, STOP SMOK KIT; CANTOR JC, 1993, JAMA-J AM MED ASSOC, V270, P1035, DOI 10.1001/jama.270.9.1035; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P854; COULTAS DB, 1994, ACAD MED, V69, pS48, DOI 10.1097/00001888-199410000-00039; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P624, DOI 10.1001/jama.271.8.624; GLYNN TJ, 1993, NIH PUBLICATION; GOLDSTEIN MG, 1989, PROJECT ADEPT CURRIC; HORTON J, 1986, CANCER DETECT PREV, V9, P417; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Richmond R, 1997, ED MED STUDENTS TOBA, P281; Richmond RL, 1998, TOB CONTROL, V7, P247, DOI 10.1136/tc.7.3.247; U. S. Department of Health and Human Services, 1998, HLTH PEOPL 2010 OBJ; [U.S. Department of Health and Human Services Public Health Service Agency], 1996, AHCPR PUBL; U. S. Department of Health and Human Services Public Health Service Office of Disease Prevention and Health Promotion., 1994, CLIN HDB PREV SERV P; *US DEP HHS, 1995, HLTH PEOPL 2000 MIDC; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VARNER KF, 1996, DIRECTORY AM MED ED	19	154	157	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					825	829		10.1001/jama.282.9.825	http://dx.doi.org/10.1001/jama.282.9.825			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478687	Bronze			2022-12-24	WOS:000082272200006
J	Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H				Zolensky, ME; Bodnar, RJ; Gibson, EK; Nyquist, LE; Reese, Y; Shih, CY; Wiesmann, H			Asteroidal water within fluid inclusion-bearing halite in an H5 chondrite, Monahans (1998)	SCIENCE			English	Article							CARBONACEOUS CHONDRITES; AQUEOUS ALTERATION; CONSTRAINTS; MINERALOGY; AGE	Crystals of halite and sylvite within the Monahans (1998) H5 chondrite contain aqueous fluid inclusions. The fluids are dominantly sodium chloride-potassium chloride brines. but they also contain divalent cations such as iron, magnesium, or calcium. Two possible origins for the brines are indigenous fluids flowing within the asteroid and exogenous fluids delivered into the asteroid surface from a salt-containing icy object.	NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA; Virginia Tech, Dept Geol Sci, Blacksburg, VA 24061 USA; Lockheed Martin Space Operat Co, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER; Virginia Polytechnic Institute & State University; Lockheed Martin	Zolensky, ME (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mail Code SN2, Houston, TX 77058 USA.		Bodnar, Robert J/A-1916-2009	Zolensky, Michael/0000-0002-3181-1303				BARBER DJ, 1981, GEOCHIM COSMOCHIM AC, V45, P945, DOI 10.1016/0016-7037(81)90120-4; BERKLEY JL, 1978, GEOPHYS RES LETT, V5, P1075, DOI 10.1029/GL005i012p01075; BRIDGES JC, 1998, LUNAR PLANET SCI, V29; Browning L, 1998, METEORIT PLANET SCI, V33, P1213, DOI 10.1111/j.1945-5100.1998.tb01306.x; Chang L, 1996, ROCK FORMING MINER B, V5, P369; DAVIS DW, 1990, GEOCHIM COSMOCHIM AC, V54, P591, DOI 10.1016/0016-7037(90)90355-O; DUFRESNE ER, 1962, GEOCHIM COSMOCHIM AC, V26, P1085, DOI 10.1016/0016-7037(62)90047-9; Fieni C., 1978, METEORITICS, V13, P460; Garner E.L., 1975, LUNAR SCI C P, V6, P1845; GOODING JL, 1991, METEORITICS, V26, P135, DOI 10.1111/j.1945-5100.1991.tb01029.x; KROT AN, 1995, METEORITICS, V30, P748, DOI 10.1111/j.1945-5100.1995.tb01173.x; LANGENAUER M, 1993, EARTH PLANET SC LETT, V120, P431, DOI 10.1016/0012-821X(93)90255-8; LAWLER JP, 1983, ECON GEOL, V78, P527, DOI 10.2113/gsecongeo.78.3.527; McSween H.Y., 1988, METEORITES EARLY SOL, P102; MCSWEEN HY, 1987, GEOCHIM COSMOCHIM AC, V51, P2469, DOI 10.1016/0016-7037(87)90298-5; MERNAGH TP, 1989, GEOCHIM COSMOCHIM AC, V53, P765, DOI 10.1016/0016-7037(89)90022-7; MINSTER JF, 1982, NATURE, V300, P414, DOI 10.1038/300414a0; NASSAU K, 1983, PHYSICS CHEM COLOR; NYQUIST LE, 1990, GEOCHIM COSMOCHIM AC, V54, P2195, DOI 10.1016/0016-7037(90)90045-M; NYQUIST LE, 1994, METEORITICS, V29, P872, DOI 10.1111/j.1945-5100.1994.tb01102.x; Roedder E., 1984, FLUID INCLUSIONS; ROEDDER E, 1968, FLUID INCLUSION RES; RUDNICK RL, 1985, J GEOPHYS RES, V90, pC669, DOI 10.1029/JB090iS02p0C669; STOFFLER D, 1991, GEOCHIM COSMOCHIM AC, V55, P3845, DOI 10.1016/0016-7037(91)90078-J; TARTER JG, 1981, THESIS ARIZONA STATE; WARNER JL, 1983, J GEOPHYS RES, V88, pA731, DOI DOI 10.1029/JB088IS02P0A731); Zolensky M., 1988, METEORITES EARLY SOL, P114; ZOLENSKY ME, 1989, ICARUS, V78, P411, DOI 10.1016/0019-1035(89)90188-7; ZOLENSKY ME, 1999, LUNAR PLANET SCI, V30	29	158	164	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1377	1379		10.1126/science.285.5432.1377	http://dx.doi.org/10.1126/science.285.5432.1377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464091				2022-12-24	WOS:000082233500035
J	Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY				Yao, Y; Ferrer-Montiel, AV; Montal, M; Tsien, RY			Activation of store-operated Ca2+ current in Xenopus oocytes requires SNAP-25 but not a diffusible messenger	CELL			English	Article							CAPACITATIVE CALCIUM-ENTRY; 3T3-L1 ADIPOCYTES; SNARE-COMPLEX; INOSITOL TRISPHOSPHATE; LAEVIS OOCYTES; RHO-GTPASES; G-PROTEIN; INFLUX; MEMBRANE; CELLS	Depletion of Ca2+ stores in Xenopos oocytes activated entry of Ca2+ across the plasma membrane, which was measured as a current I-soc in subsequently formed cell-attached patches. I-soc survived excision into inside-out configuration. If cell-attached patches were formed before store depletion, I-soc was activated outside but not inside the patches. I-soc was potentiated by microinjection of Clostridium C3 transferase, which inhibits Rho GTPase, whereas I-soc was inhibited by expression of wild-type or constitutively active Rho. Activation of I-soc was also inhibited by botulinum neurotoxin A and dominant-negative mutants of SNAP-25 but was unaffected by brefeldin A. These results suggest that oocyte I-soc is dependent not on aqueous diffusible messengers but on SNAP-25, probably via exocytosis of membrane channels or regulatory molecules.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.		Ferrer-Montiel, Antonio/C-3072-2015	Ferrer-Montiel, Antonio/0000-0002-2973-6607	NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; Calakos N, 1996, PHYSIOL REV, V76, P1; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Favre CJ, 1996, J LAB CLIN MED, V128, P19, DOI 10.1016/S0022-2143(96)90110-9; Ferrer-Montiel AV, 1998, FEBS LETT, V435, P84, DOI 10.1016/S0014-5793(98)01012-6; FerrerMontiel AV, 1996, J BIOL CHEM, V271, P18322, DOI 10.1074/jbc.271.31.18322; Fomina AF, 1999, J NEUROSCI, V19, P3711; Gregory RB, 1996, BIOCHEM J, V319, P755, DOI 10.1042/bj3190755; GUTIERREZ LM, 1995, FEBS LETT, V372, P39, DOI 10.1016/0014-5793(95)00944-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hilgemann Donald W., 1995, P307; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Holda JR, 1998, NEWS PHYSIOL SCI, V13, P157; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; KRAMER RH, 1990, NEURON, V4, P335, DOI 10.1016/0896-6273(90)90046-I; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARKER I, 1993, J PHYSIOL-LONDON, V461, P133, DOI 10.1113/jphysiol.1993.sp019506; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Putney JW, 1999, BIOESSAYS, V21, P38; QUICK MW, 1992, BIOTECHNIQUES, V13, P357; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROSSETTO O, 1994, NATURE, V372, P415, DOI 10.1038/372415a0; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; Shurety W, 1998, MOL BIOL CELL, V9, P957, DOI 10.1091/mbc.9.4.957; SOKABE M, 1990, J CELL BIOL, V111, P599, DOI 10.1083/jcb.111.2.599; Solsona C, 1998, BIOPHYS J, V74, P1061, DOI 10.1016/S0006-3495(98)74030-5; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; vandenBerghe N, 1996, BIOCHEM BIOPH RES CO, V229, P430, DOI 10.1006/bbrc.1996.1821; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507	57	225	230	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					475	485		10.1016/S0092-8674(00)81976-5	http://dx.doi.org/10.1016/S0092-8674(00)81976-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481912	Bronze			2022-12-24	WOS:000082174900008
J	Mulholland, K				Mulholland, K			Magnitude of the problem of childhood pneumonia	LANCET			English	Editorial Material							RESPIRATORY-TRACT INFECTIONS; UPPER RIVER DIVISION; GAMBIAN CHILDREN; LOBAR PNEUMONIA; RURAL AREA; ETIOLOGY; MORTALITY; INFANT; BANGLADESH; PATTERN		WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Mulholland, K (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	mulhollande@who.ch						ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; BILLEWICZ WZ, 1981, J BIOSOC SCI, V13, P219, DOI 10.1017/S0021932000013390; CHEN LC, 1980, INT J EPIDEMIOL, V9, P25, DOI 10.1093/ije/9.1.25; DEFRANCISCO A, 1993, ANN TROP PAEDIATR, V13, P345, DOI 10.1080/02724936.1993.11747669; EVANS JR, 1981, NEW ENGL J MED, V305, P1117, DOI 10.1056/NEJM198111053051904; Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P42, DOI 10.1097/00006454-199101000-00009; FORGIE IM, 1992, PEDIATR INFECT DIS J, V11, P466, DOI 10.1097/00006454-199206000-00009; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; GRANT JP, 1996, STATE WORLDS CHILDRE; GRANT P, 1980, STATE WORLDS CHILDRE; GREENWOOD B, 1992, J INFECT DIS, V165, pS26, DOI 10.1093/infdis/165-Supplement_1-S26; GWATKIN DR, 1980, AM J PUBLIC HEALTH, V70, P1286, DOI 10.2105/AJPH.70.12.1286; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; KABIR M, 1995, J BIOSOC SCI, V27, P179, DOI 10.1017/S0021932000022689; Leowski J, 1986, World Health Stat Q, V39, P138; Lewis F L, 1944, Arch Dis Child, V19, P122; Mulholland K, 1997, LANCET, V349, P1191, DOI 10.1016/S0140-6736(96)09267-7; Murray CJL, 1996, GLOBAL HLTH STAT; ORUBULOYE IO, 1975, POP STUD-J DEMOG, V29, P259, DOI 10.2307/2173511; PRESTON SH, 1976, MORTALITY PATTERNS N, P89; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; WALL RA, 1986, B WORLD HEALTH ORGAN, V64, P553; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; WARREN KS, 1988, SOC SCI MED, V26, P891, DOI 10.1016/0277-9536(88)90407-8; WHO (World Health Organization), 1978, PRIM HLTH CAR JOINT; World Bank, 1993, INV HLTH WORLD DEV R	29	74	80	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 14	1999	354	9178					590	592		10.1016/S0140-6736(98)10238-6	http://dx.doi.org/10.1016/S0140-6736(98)10238-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225XJ	10470718				2022-12-24	WOS:000081991000048
J	de Abajo, FJ; Rodriguez, LAG; Montero, D				de Abajo, FJ; Rodriguez, LAG; Montero, D			Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FLUOXETINE; PERFORATION; DISORDER; THERAPY; RISK	Objective To examine the association between selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Design Population based case-control study. Setting General practices included in the UK general practice research database. Subjects 1651 incident cases of upper gastrointestinal bleeding and 248 cases of ulcer perforation among patients aged 40 to 79 years between April 1993 and September 1997, and 10 000 controls matched for age, sex, and year that the case was identified. Interventions Review of computer profiles for all potential cases, and an internal validation study to confirm the accuracy of the diagnosis on the basis of the computerised information. Main outcome measures Current use of selective serotonin reuptake inhibitors or other antidepressants within 30 days before the index date. Results Current exposure to selective serotonin reuptake inhibitors was identified in 3.1% (52 of 1651) of patients with upper gastrointestinal bleeding but only 1.0% (95 of 10 000) of controls, giving an adjusted rate ratio of 3.0 (95% confidence interval 2.1 to 4.4). This effect measure was not modified by sex, age, dose, or treatment duration. A crude incidence of 1 case per 8000 prescriptions was estimated. A small association was found with non-selective serotonin reuptake inhibitors (relative risk 1.4, 1.1 to 1.9) but not with antidepressants lacking this inhibitory effect None of the groups of antidepressants was associated with ulcer perforation. The concurrent use of select-ive serotonin reuptake inhibitors with non-steroidal anti-inflammatory drugs increased the risk of upper gastrointestinal bleeding beyond the sum of their independent effects (15.6, 6.6 to 36.6). A smaller interaction was also found between selective serotonin reuptake inhibitors and low dose-aspirin (7.2, 3.1 to 17.1). Conclusions Selective serotonin reuptake inhibitors increase the risk of upper gastrointestinal bleeding The absolute effect is, however, moderate and about equivalent to low dose ibuprofen. The concurrent use of non-steroidal anti-inflammatory drugs or aspirin with selective serotonin reuptake inhibitors greatly increases the risk of upper gastrointestinal bleeding.	Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain; Agencia Espanola Medicamento, Div Parmacoepidemiol & Farmacovigilancia, Safety Evaluat Unit, Madrid 28220, Spain; Ctr Espanol Invest Farmacoepidemiol, Madrid, Spain		de Abajo, FJ (corresponding author), Agencia Espanola Medicamento, Div Farmacoepidemiol, Madrid 28220, Spain.		rodriguez, luis a garcia/B-1980-2010; de Abajo, Fancisco/Z-1711-2019	de Abajo, Fancisco/0000-0001-9119-8646				ALDERMAN CP, 1992, ANN PHARMACOTHER, V26, P1517, DOI 10.1177/106002809202601205; [Anonymous], [No title captured]; Baldessarini RJ, 1996, GOODMAN GILMANS PHAR, P431; EVANS TG, 1991, NEW ENGL J MED, V324, P1671; Gutthann SP, 1997, EPIDEMIOLOGY, V8, P18, DOI 10.1097/00001648-199701000-00003; ISHIKAWA K, 1986, EUR J PHARMACOL, V120, P63, DOI 10.1016/0014-2999(86)90640-0; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; LANCASTER SG, 1989, DRUGS, V38, P123, DOI 10.2165/00003495-198938010-00005; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Li N, 1997, BLOOD COAGUL FIBRIN, V8, P517, DOI 10.1097/00001721-199711000-00006; MAREK GJ, 1992, PSYCHOPHARMACOLOGY, V109, P2, DOI 10.1007/BF02245475; MONTERO DR, 1996, 4 ANN M EUR SOC PHAR; OTTERVANGER JD, 1994, AM J PSYCHIAT, V151, P781; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; ROSS SB, 1980, PSYCHOPHARMACOLOGY, V67, P1, DOI 10.1007/BF00427588; ROTHMAN KJ, 1986, MODER EPIDEMIOLOGY; Skop BP, 1996, PSYCHOSOMATICS, V37, P12, DOI 10.1016/S0033-3182(96)71592-X; TIELENS JAE, 1997, AM J PSYCHIAT, V153, P883; WAGNER A, 1990, J AFFECT DISORDERS, V20, P101, DOI 10.1016/0165-0327(90)90123-P; YARYURATOBIAS JA, 1991, AM J PSYCHIAT, V148, P949; 1998, WHO ADR NEWSLETTER, V3, P1	24	285	288	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1106	1109		10.1136/bmj.319.7217.1106	http://dx.doi.org/10.1136/bmj.319.7217.1106			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531103	Bronze, Green Published			2022-12-24	WOS:000083419500025
J	Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ				Shay, DK; Holman, RC; Newman, RD; Liu, LL; Stout, JW; Anderson, LJ			Bronchiolitis-associated hospitalizations among US children, 1980-1996	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; GROUP-A; GROUP-B; UNITED-STATES; INFECTION; EPIDEMIOLOGY; CARE; WASHINGTON; EMERGENCY; ILLNESS	Context Respiratory syncytial virus (RSV) causes more lower respiratory tract infections, often manifested as bronchiolitis, among young children than any other pathogen. Few national estimates exist of the hospitalizations attributable to RSV, and recent advances in prophylaxis warrant an update of these estimates. Objectives To describe rates of bronchiolitis-associated hospitalizations and to estimate current hospitalizations associated with RSV infection. Design and Setting Descriptive analysis of US National Hospital Discharge Survey data from 1980 through 1996. Participants Children younger than 5 years who were hospitalized in short-stay, nonfederal hospitals for bronchiolitis. Main Outcome Measure Bronchiolitis-associated hospitalization rates by age and year. Results During the 17-year study period, an estimated 1.65 million hospitalizations for bronchiolitis occurred among children younger than 5 years, accounting for 7.0 million inpatient days. Fifty-seven percent of these hospitalizations occurred among children younger than 6 months and 81 % among those younger than 1 year. Among children younger than 1 year, annual bronchiolitis hospitalization rates increased 2.4-fold, from 12.9 per 1000 in 1980 to 31.2 per 1000 in 1996. During 1988-1995, infant hospitalization rates for bronchiolitis increased significantly (P for trend <.001), while hospitalization rates for lower respiratory tract diseases excluding bronchiolitis did not vary significantly (P for trend = .20). The proportion of hospitalizations for lower respiratory tract illnesses among children younger than 1 year associated with bronchiolitis increased from 2.2% in 1980 to 47.4% in 1996; among total hospitalizations, this proportion increased from 5.4% to 16.4%, Averaging bronchiolitis hospitalizations during 1994-1996 and assuming that RSV was the etiologic agent in 50% to 80% of November through April hospitalizations, an estimated 51 240 to 81 985 annual bronchiolitis hospitalizations among children younger than 1 year were related to RSV infection. Conclusions During 1980-1996, rates of hospitalization of infants with bronchiolitis increased substantially, as did the proportion of total and lower respiratory tract hospitalizations associated with bronchiolitis. Annual bronchiolitis hospitalizations associated with RSV infection among infants may be greater than previous estimates for RSV bronchiolitis and pneumonia hospitalizations combined.	Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Off Director, Atlanta, GA USA; Univ Washington, Sch Med, Dept Pediat, Div Gen Pediat, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shay, DK (corresponding author), Ctr Dis Control & Prevent, Resp & Enter Viruses Branch, 1600 Clifton Rd NE,MS A-34, Atlanta, GA 30333 USA.	dks4@cdc.gov		Shay, David/0000-0001-9619-4820				ANDERSON LJ, 1988, PEDIATRICS, V82, P300; ANDERSON LJ, 1985, J INFECT DIS, V151, P626, DOI 10.1093/infdis/151.4.626; ANDERSON LJ, 1991, J INFECT DIS, V163, P687, DOI 10.1093/infdis/163.4.687; [Anonymous], 1998, Pediatrics, V102, P1211; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; BREESE C, 1975, NEW ENGL J MED, V293, P1343, DOI 10.1056/NEJM197512252932604; CAUL EO, 1976, J HYG-CAMBRIDGE, V77, P383, DOI 10.1017/S0022172400055765; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1163; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893, DOI 10.1001/archpedi.1995.02170210067012; DAGAN R, 1993, PEDIATR INFECT DIS J, V12, P381, DOI 10.1097/00006454-199305000-00006; FOY HM, 1973, AM J EPIDEMIOL, V97, P80, DOI 10.1093/oxfordjournals.aje.a121492; GARDNER PS, 1973, BMJ-BRIT MED J, V2, P571, DOI 10.1136/bmj.2.5866.571; GILCHRIST S, 1994, J INFECT DIS, V170, P986, DOI 10.1093/infdis/170.4.986; Gillum B S, 1996, Vital Health Stat 13, P1; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1987, PEDIAT VIROL, V2, P1; GRAVES EJ, 1999, VITAL HLTH STAT, V13, P1; HALL CB, 1975, J INFECT DIS, V131, P1, DOI 10.1093/infdis/131.1.1; HALL CB, 1994, SCIENCE, V265, P1393, DOI 10.1126/science.7915433; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HALL CB, 1998, TXB PEDIAT INFECT DI, P2087; HAUPT BJ, 1992, VITAL HLTH STAT, V13, P1; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Hofferth SL, 1996, FUTURE CHILD, V6, P41, DOI 10.2307/1602418; *I MED, 1986, NEW VACC DEV EST PRI, V2, P299; Institute of Medicine, 1986, NEW VACC DEV EST PRI, V1, P397; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; KIM HW, 1973, AM J EPIDEMIOL, V98, P216, DOI 10.1093/oxfordjournals.aje.a121550; Kozak L J, 1995, Adv Data, P1; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; MANEKER AJ, 1995, ANN EMERG MED, V25, P36, DOI 10.1016/S0196-0644(95)70352-7; MCCONNOCHLE KM, 1990, J PEDIAT, V162, P1283; MCINTOSH EDG, 1993, PEDIATR INFECT DIS J, V12, P815, DOI 10.1097/00006454-199310000-00004; MONTO AS, 1971, AM J EPIDEMIOL, V94, P290, DOI 10.1093/oxfordjournals.aje.a121322; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; *NAT CTR HLTH STAT, 1998, NAT HOSP DISCH SURV; Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289, DOI 10.1093/oxfordjournals.aje.a121558; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; *RES COUNC SUBC RE, 1978, BRIT MED J, V2, P796; Saijo Masayuki, 1993, Acta Paediatrica Japonica, V35, P233; Shah BV, 1996, SUDAAN USERS MANUAL; SIMS DG, 1976, BRIT MED J, V2, P1095, DOI 10.1136/bmj.2.6044.1095; SINGLETON RJ, 1995, PEDIATR INFECT DIS J, V14, P26, DOI 10.1097/00006454-199501000-00005; SIRKEN MG, 1992, MANUAL STANDARDS PRO; *US BUR CENS, 1998, INT EST POP AG SEX R; *US DHHS, 1998, DET DAT 1979 96 PUBL; *US PHS HLTH CAR F, 1998, INT CLASS DIS; Walsh EE, 1997, J INFECT DIS, V175, P814, DOI 10.1086/513976; YAMAMOTO LG, 1993, AM J EMERG MED, V11, P109, DOI 10.1016/0735-6757(93)90101-G; Yun BY, 1995, PEDIATR INFECT DIS J, V14, P1054, DOI 10.1097/00006454-199512000-00005	53	1029	1106	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1440	1446		10.1001/jama.282.15.1440	http://dx.doi.org/10.1001/jama.282.15.1440			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535434	Bronze			2022-12-24	WOS:000083111000029
J	Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD				Van Rie, A; Warren, R; Richardson, M; Victor, TC; Gie, RP; Enarson, DA; Beyers, N; van Helden, PD			Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS	Background For decades it has been assumed that postprimary tuberculosis is usually caused by reactivation of endogenous infection rather than by a new, exogenous infection. Methods We performed DNA fingerprinting with restriction-fragment-length polymorphism analysis on pairs of isolates of Mycobacterium tuberculosis from 16 compliant patients who had a relapse of pulmonary tuberculosis after curative treatment of post-primary tuberculosis. The patients lived in areas of South Africa where tuberculosis is endemic. Medical records were reviewed for clinical data. Results For 12 of the 16 patients, the restriction-fragment-length polymorphism banding patterns for the isolates obtained after the relapse were different from those for the isolates from the initial tuberculous disease. This finding indicates that reinfection was the cause of the recurrence of tuberculosis after curative treatment. Two patients had reinfections with a multidrug-resistant strain. All 15 patients who were tested for the human immunodeficiency virus were seronegative. Conclusions Exogenous reinfection appears to be a major cause of postprimary tuberculosis after a previous cure in an area with a high incidence of this disease. This finding emphasizes the importance of achieving cures and of preventing anyone with infectious tuberculosis from exposing others to the disease. (N Engl J Med 1999;341:1174-9.) (C)1999, Massachusetts Medical Society.	Univ Stellenbosch, Dept Pediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, MRC, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Katholieke Univ Leuven, Dept Pediat, Louvain, Belgium	Stellenbosch University; Stellenbosch University; Stellenbosch University; KU Leuven	van Helden, PD (corresponding author), Univ Stellenbosch, Dept Biochem Med, POB 19063, ZA-7505 Tygerberg, South Africa.		Van Rie, Annelies/C-2082-2017	Van Rie, Annelies/0000-0001-7666-3263; Warren, Robin/0000-0001-5741-7358				ALLAN WGL, 1982, TUBERCLE, V63, P89; ALLAN WGL, 1977, AM REV RESPIR DIS, V115, P727; Beyers N, 1996, S AFR MED J, V86, P40; BRITISH THORACIC ASSOCIATION, 1982, American Review of Respiratory Disease, V126, P460; CANETTI G, 1972, Bulletin of the International Union Against Tuberculosis, V47, P116; DAS S, 1993, TUBERCLE LUNG DIS, V74, P48; KATZ HL, 1958, VETERANS ADM ARMED F, P214; MCKINNEY JD, 1997, PERSISTING PROBLEMS, P69; MITCHISON DA, 1980, TUBERCLE, V61, P135, DOI 10.1016/0041-3879(80)90002-1; SAHADEVAN R, 1995, J CLIN MICROBIOL, V33, P3037, DOI 10.1128/JCM.33.11.3037-3039.1995; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STYBLO K, 1991, P TUBERC RES COUNC, V24, P62; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Vynnycky E, 1997, EPIDEMIOL INFECT, V119, P183, DOI 10.1017/S0950268897007917; Warren R, 1996, J CLIN MICROBIOL, V34, P2219, DOI 10.1128/JCM.34.9.2219-2224.1996	15	471	483	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1999	341	16					1174	1179		10.1056/NEJM199910143411602	http://dx.doi.org/10.1056/NEJM199910143411602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BY	10519895				2022-12-24	WOS:000083087400002
J	Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA				Brogan, DJ; Frank, E; Elon, L; Sivanesan, SP; O'Hanlan, KA			Harassment of lesbians as medical students and physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN PHYSICIANS		Emory Univ, Atlanta, GA 30322 USA; Stanford Med Ctr, Stanford, CA USA	Emory University; Stanford University	Frank, E (corresponding author), Emory Univ, Atlanta, GA 30322 USA.		; O'Hanlan, Katherine/A-4073-2017	Frank, Erica/0000-0001-7159-5417; O'Hanlan, Katherine/0000-0002-7577-4188				Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1998, ARCH INTERN MED, V158, P342, DOI 10.1001/archinte.158.4.342; Frank E, 1998, ARCH INTERN MED, V158, P352, DOI 10.1001/archinte.158.4.352; MATHEWS WC, 1986, WESTERN J MED, V144, P106; ORIEL KA, 1996, FAM MED, V28, P7205; Schatz B, 1994, ANTIGAY DISCRIMINATI; STEVENS PE, 1991, INT J HEALTH SERV, V21, P291, DOI 10.2190/R2AW-MTCR-U0Q7-XMMY	7	31	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1290	+		10.1001/jama.282.13.1290	http://dx.doi.org/10.1001/jama.282.13.1290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10532853	hybrid			2022-12-24	WOS:000082901100042
J	Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP				Wabnitz, PA; Bowie, JH; Tyler, MJ; Wallace, JC; Smith, BP			Animal behaviour - Aquatic sex pheromone from a male tree frog	NATURE			English	Article							SKIN; PEPTIDE; LITORIA		Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Environm Biol, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide; University of Adelaide	Wabnitz, PA (corresponding author), Univ Adelaide, Dept Chem, Adelaide, SA 5005, Australia.		Smith, Ben PC/GXZ-8778-2022; , John/AAP-5150-2020	Wabnitz, Paul/0000-0002-0820-9509; Smith, Benjamin/0000-0003-0651-9420				AGOSTA WC, 1994, J CHEM EDUC, V71, P242, DOI 10.1021/ed071p242; BIRCH MC, 1974, PHEROMONES, V32, P1; BUTENANDT A, 1984, TECHNIQUES PHEROMONE, P4; Erspamer V., 1993, AMPHIBIAN BIOL, P178; Houck LD, 1998, AM ZOOL, V38, P108; JOHNSTONE RE, 1983, PHEROMONES REPROD MA, P8; KIKUYAMA S, 1995, SCIENCE, V267, P1643, DOI 10.1126/science.7886452; LAZARUS LH, 1993, PROG NEUROBIOL, V41, P473, DOI 10.1016/0301-0082(93)90027-P; Steinborner ST, 1998, J PEPT RES, V51, P121; TYLER MJ, 1992, J PHARMACOL TOXICOL, V28, P199, DOI 10.1016/1056-8719(92)90004-K; Wabnitz PA, 1998, J PEPT RES, V52, P477; Wong H, 1997, EUR J BIOCHEM, V247, P545, DOI 10.1111/j.1432-1033.1997.00545.x	12	106	111	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					444	445		10.1038/46724	http://dx.doi.org/10.1038/46724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519546				2022-12-24	WOS:000082981200043
J	Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH				Mellemkjaer, L; Sorensen, HT; Dreyer, L; Olsen, J; Olsen, JH			Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; ORAL-CONTRACEPTIVES; RISK		Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark; Aarhus Univ Hosp, Dept Med 5, DK-8000 Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark	Danish Cancer Society; Aarhus University; Aarhus University	Mellemkjaer, L (corresponding author), Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark.		Sorensen, Henrik Toft/Z-6181-2019	Sorensen, Henrik Toft/0000-0003-4299-7040; Olsen, Jorgen Helge/0000-0001-9633-5662				JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; POULTER NR, 1995, LANCET, V346, P1575; Spitzer WO, 1996, BRIT MED J, V312, P83; Thomas SHL, 1996, LANCET, V348, P402, DOI 10.1016/S0140-6736(05)65016-7; Vandenbroucke JP, 1996, LANCET, V348, P401, DOI 10.1016/S0140-6736(96)24032-2	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					820	821		10.1136/bmj.319.7213.820	http://dx.doi.org/10.1136/bmj.319.7213.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496825	Bronze, Green Published			2022-12-24	WOS:000082865200023
J	Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C				Fynes, M; Donnelly, V; Behan, M; O'Connell, PR; O'Herlihy, C			Effect of second vaginal delivery on anorectal physiology and faecal continence: a prospective study	LANCET			English	Article							ANAL-SPHINCTER INJURY; FECAL INCONTINENCE; PELVIC FLOOR; CHILDBIRTH; DAMAGE; WOMEN	Background Because obstetric injury to the anal sphincters may be occult, and because the mechanism of injury differs between first and subsequent deliveries, we prospectively assessed the effects of first and second vaginal deliveries on anal physiology and continence. Methods We undertook a prospective observational study of 59 previously nulliparous women through two successive vaginal deliveries by means of a bower-function questionnaire, and an anorectal-physiology assessment, both antepartum and 6-12 weeks post parium. Findings 13 (22%) women reported altered faecal continence after their first vaginal delivery: eight had persistent symptoms during their second pregnancy, of whom seven deteriorated after the second delivery; five regained continence before their second pregnancy, but two became incontinent again after the second delivery. Five women developed incontinence for the first time after their second vaginal delivery, of whom three had occult primiparous sphincter injury. 20 (34%) women, seven of whom had no symptoms, had anal-sphincter injury as a result of their first delivery, but only two new injuries occurred after the second vaginal delivery (p=0.013). Although pudendal neuropathy was no more common after the second than after the first vaginal delivery (15 vs 19%, p=0.8), pudendal-nerve latency was longer after the second delivery (p=0.02). Interpretation Primiparous women with persistent symptoms of altered faecal continence experience deterioration after a second vaginal delivery. Women with transient faecal incontinence or occult anal-sphincter injury after their first vaginal delivery are at high risk of faecal incontinence after a second vaginal delivery. The risk of mechanical anal sphincter injury is greatest after the first delivery.	Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Dublin 2, Ireland; Mater Misericordiae Hosp, Dept Radiol, Dublin, Ireland; Mater Misericordiae Hosp, Dept Surg, Dublin, Ireland	National Maternity Hospital, Dublin; University College Dublin; Mater Misericordiae University Hospital; University College Dublin; Mater Misericordiae University Hospital; University College Dublin	O'Herlihy, C (corresponding author), Univ Coll Dublin, Natl Matern Hosp, Dept Obstet & Gynaecol, Holles St, Dublin 2, Ireland.		O'Connell, Patrick Ronan/H-6583-2019	O'Connell, Patrick Ronan/0000-0002-1846-5629				ALLEN RE, 1990, BRIT J OBSTET GYNAEC, V97, P770, DOI 10.1111/j.1471-0528.1990.tb02570.x; AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; BEK KM, 1992, BRIT J OBSTET GYNAEC, V99, P724, DOI 10.1111/j.1471-0528.1992.tb13870.x; BOYLAN P, ANN CLIN REPORTS 199; Campbell DM, 1996, CLIN RADIOL, V51, P559, DOI 10.1016/S0009-9260(96)80135-8; CHERRY DA, 1988, SURG CLIN N AM, V68, P1217; Donnelly V, 1998, OBSTET GYNECOL, V92, P955, DOI 10.1016/S0029-7844(98)00255-5; Donnelly V, 1997, BRIT J OBSTET GYNAEC, V104, P311, DOI 10.1111/j.1471-0528.1997.tb11459.x; Donnelly VS, 1998, DIS COLON RECTUM, V41, P586, DOI 10.1007/BF02235263; Fynes M, 1998, OBSTET GYNECOL, V92, P496, DOI 10.1016/S0029-7844(98)00256-7; Fynes MM, 1999, DIS COLON RECTUM, V42, P753, DOI 10.1007/BF02236930; LAW PJ, 1991, BRIT J SURG, V78, P312, DOI 10.1002/bjs.1800780315; LEIGH RJ, 1982, LANCET, V1, P1349; MacArthur C, 1997, BRIT J OBSTET GYNAEC, V104, P46, DOI 10.1111/j.1471-0528.1997.tb10648.x; ODRISCOLL MD, 1986, ACTIVE MANAGEMENT LA; PERRY RE, 1990, AM J SURG, V159, P112, DOI 10.1016/S0002-9610(05)80615-4; PESCATORI M, 1992, DIS COLON RECTUM, V35, P482, DOI 10.1007/BF02049407; SNOOKS JJ, 1985, COLOPROCTOLOGY PELVI, P112; SNOOKS SJ, 1990, BRIT J SURG, V77, P1358, DOI 10.1002/bjs.1800771213; SNOOKS SJ, 1984, LANCET, V2, P546; Sultan AH, 1996, BRIT J OBSTET GYNAEC, V103, P731, DOI 10.1111/j.1471-0528.1996.tb09864.x; SULTAN AH, 1993, NEW ENGL J MED, V329, P1905, DOI 10.1056/NEJM199312233292601; SWASH M, 1993, BRIT MED J, V307, P636, DOI 10.1136/bmj.307.6905.636	23	149	151	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 18	1999	354	9183					983	986		10.1016/S0140-6736(98)11205-9	http://dx.doi.org/10.1016/S0140-6736(98)11205-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JG	10501360				2022-12-24	WOS:000082596000011
J	Carrell, RW				Carrell, RW			Biochemistry - How serpins are shaping up	SCIENCE			English	Editorial Material							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANTITHROMBIN; ADHESION		Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Cambridge CB2 2XY, England	University of Cambridge	Carrell, RW (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge CB2 2XY, England.							Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BANDA M, 1998, J BIOL CHEM, V263, P4481; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; Chang WSW, 1997, THROMB HAEMOSTASIS, V77, P323; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Preissner KT, 1997, THROMB HAEMOSTASIS, V78, P88; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; ZHOU A, IN PRESS BLOOD; 1999, P 2 INT S STRUCT BIO	12	23	25	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1861	+		10.1126/science.285.5435.1861	http://dx.doi.org/10.1126/science.285.5435.1861			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515791				2022-12-24	WOS:000082638300033
J	Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE				Orth, K; Palmer, LE; Bao, ZQ; Stewart, S; Rudolph, AE; Bliska, JB; Dixon, JE			Inhibition of the mitogen-activated protein kinase kinase superfamily by a Yersinia effector	SCIENCE			English	Article							NF-KAPPA-B; ALPHA PRODUCTION; CELL-DEATH; BETA; MACROPHAGES; APOPTOSIS; YOPJ; PHOSPHORYLATION; SUPPRESSION; RESISTANCE	The bacterial pathogen Yersinia uses a type III secretion system to inject several virulence factors into target cells. One of the Yersinia virulence factors, YopJ, was shown to bind directly to the superfamily of MAPK (mitogen-activated protein kinase) kinases (MKKs) blocking both phosphorylation and subsequent activation of the MKKs. These results explain the diverse activities of YopJ in inhibiting the extracellular signal-regulated kinase, c-Jun amino-terminal kinase, p38, and nuclear factor kappa B signaling pathways, preventing cytokine synthesis and promoting apoptosis. YopJ-related proteins that are found in a number of bacterial pathogens of animals and plants may function to block MKKs so that host signaling responses can be modulated upon infection.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Sch Med, Ctr Infect Dis, Stony Brook, NY 11794 USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dixon, JE (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035175] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35175] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; Brubaker R R, 1972, Curr Top Microbiol Immunol, V57, P111; Ciesiolka LD, 1999, MOL PLANT MICROBE IN, V12, P35, DOI 10.1094/MPMI.1999.12.1.35; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Freiberg C, 1997, NATURE, V387, P394, DOI 10.1038/387394a0; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; ORTH K, UNPUB; Palmer L. C., UNPUB; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Stewart S, 1999, MOL CELL BIOL, V19, P5523; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHALEN MC, 1988, P NATL ACAD SCI USA, V85, P6743, DOI 10.1073/pnas.85.18.6743; WHALEN MC, 1993, MOL PLANT MICROBE IN, V6, P616, DOI 10.1094/MPMI-6-616; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	43	327	338	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1920	1923		10.1126/science.285.5435.1920	http://dx.doi.org/10.1126/science.285.5435.1920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489373				2022-12-24	WOS:000082638300053
J	Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG				Lin, CR; Kioussi, C; O'Connell, S; Briata, P; Szeto, D; Liu, F; Izpisua-Belmonte, JC; Rosenfeld, MG			Pitx2 regulates lung asymmetry, cardiac positioning and pituitary and tooth morphogenesis	NATURE			English	Article							SIGNALING PATHWAY; NODAL EXPRESSION; HOMEOBOX GENE; ORGANOGENESIS; FAMILY; EHAND; MOUSE	Pitx1 (refs 1-3) and Pitx2 (refs 4, 5) are highly homologous, bicoid-related transcription factors. Pitx2 was initially identified as the gene responsible for the human Rieger syndrome(4), an autosomal dominant condition that causes developmental abnormalities. Pitx2 is asymmetrically expressed in the left lateral-plate mesoderm(5-11), and mutant mice with laterality defects show altered patterns of Pitx2 expression that correlate with changes in the visceral symmetry (situs). Ectopic expression of Pitx2 in the right lateral-plate mesoderm alters looping of the heart and gut and reverses body rotation in chick and Xenopus embryose(6-11). Here we describe the phenotype of Pitx2 gene-deleted mice, characterized by defective body-wall closure, right pulmonary isomerism, altered cardiac position, arrest in turning and, subsequently a block in the determination and proliferation events of anterior pituitary gland and tooth organogenesis. Thus, Pitx2 is a transcription factor that encodes 'leftness' of the lung.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Sch Med, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Salk Institute	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	mrosenfeld@ucsd.edu	Briata, Paola/AAC-6039-2020	Briata, Paola/0000-0003-3470-0454				Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Ericson J, 1998, DEVELOPMENT, V125, P1005; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Martinez S, 1999, DEVELOPMENT, V126, P1189; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Mucchielli ML, 1997, DEV BIOL, V189, P275, DOI 10.1006/dbio.1997.8672; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Peters H, 1999, TRENDS GENET, V15, P59, DOI 10.1016/S0168-9525(98)01662-X; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Semina EV, 1997, HUM MOL GENET, V6, P2109, DOI 10.1093/hmg/6.12.2109; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Thomas T, 1998, DEV BIOL, V196, P228, DOI 10.1006/dbio.1998.8849; Treier M, 1998, GENE DEV, V12, P1691, DOI 10.1101/gad.12.11.1691; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	26	452	464	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					279	282		10.1038/45803	http://dx.doi.org/10.1038/45803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499586				2022-12-24	WOS:000082678400054
J	Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR				Bailey, JE; Van Brunt, DL; Mirvis, DM; McDaniel, S; Spears, CR; Chang, CF; Schaberg, DR			Academic managed care organizations and adverse selection under Medicaid managed care in Tennessee	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-ADJUSTMENT; RAPID CHANGES; CENTERS; TENNCARE; SYSTEM; PAYMENTS	Context Health plans competing in a managed care system may face serious financial consequences if they are disproportionately selected by enrollees with expensive health conditions. Academic medical centers (AMCs) have traditionally provided medical care for the sickest patients and may be at particularly high risk for adverse selection, but whether this occurs is not known. Objective To determine whether managed care organizations (MCOs) representing AMCs are adversely selected by Medicaid managed care (MMC) enrollees with expensive chronic health conditions. Design and Setting Observational study using state Medicaid claims data from all of 1994 and January to August 1995 for Tennessee's statewide MMC program (TennCare). Participants All 12 capitated MCOs in Tennessee, which collectively provided services for 1.2 million Medicaid enrollees from January 1994 through August 1995 following the initiation of TennCare. Main Outcome Measures Prevalence of 6 state-specified high-cost chronic conditions-acquired immunodeficiency syndrome (AIDS), coagulation defects, cystic fibrosis, pregnancy, prematurity, and organ transplantation-and 27 additional high-cost conditions compared by academic, statewide, and regional MCOs, Results The prevalence of state-specified high-cost chronic conditions was generally higher for academic MCOs compared with other MCOs, Specifically, prevalence of AIDS was 14.1 times higher in academic MCOs than in statewide MCOs; coagulation defects, 6.4 times higher; transplantations, 4.4; pregnancy, 3.3; cystic fibrosis, 2.4; and prevalence of prematurity was equivalent. Prevalence was higher for academic than for statewide MCOs for 22 of the additional 27 high-cost conditions considered and similar for the remaining 5 conditions, Conclusions Our results suggest that academic MCOs in an MMC system are selected by a large percentage of the sickest patients. Adverse selection may present serious financial risks for AMCs participating in managed care.	Univ Tennessee, Dept Med, Div Gen Internal Med, Memphis, TN 38103 USA; Univ Tennessee, Dept Prevent Med, Memphis, TN 38103 USA; Univ Memphis, Memphis Managed Care Corp, Memphis, TN 38103 USA; Univ Memphis, Dept Econ, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis	Bailey, JE (corresponding author), Univ Tennessee, Dept Med, Div Gen Internal Med, 842 Jefferson Ave,Room A607, Memphis, TN 38103 USA.	jebailey@utmem.edu						CLARK DO, 1995, MED CARE, V33, P783, DOI 10.1097/00005650-199508000-00004; Culbertson RA, 1997, J HEALTH POLIT POLIC, V22, P1359; DIEHR P, 1993, MED CARE, V31, P1093, DOI 10.1097/00005650-199312000-00003; Eggers P, 1980, Health Care Financ Rev, V1, P91; Ellis RP, 1996, HEALTH CARE FINANC R, V17, P101; EPSTEIN AM, 1995, JAMA-J AM MED ASSOC, V273, P1203, DOI 10.1001/jama.273.15.1203; Fowles JB, 1996, JAMA-J AM MED ASSOC, V276, P1316, DOI 10.1001/jama.276.16.1316; FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; GOLDMAN L, 1995, JAMA-J AM MED ASSOC, V273, P1549, DOI 10.1001/jama.273.19.1549; Hellinger F J, 1987, Health Care Financ Rev, V9, P55; HILLMAN AL, 1991, ACAD MED, V66, P134, DOI 10.1097/00001888-199103000-00003; Holahan J, 1999, HEALTH AFFAIR, V18, P217, DOI 10.1377/hlthaff.18.3.217; HUGHES R, 1995, PUBLICATION GAO HEHS; HUNT S, 1999, ACTUARIAL REV CAPITA; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; IGLEHART JK, 1995, NEW ENGL J MED, V332, P407, DOI 10.1056/NEJM199502093320624; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; Kilbreth EH, 1998, INQUIRY-J HEALTH CAR, V35, P250; KRONICK R, 1997, CHALLENGE RISK ADJUS, P1; Ku LT, 1998, INQUIRY-J HEALTH CAR, V35, P332; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; NEWHOUSE JP, 1997, HLTH AFF MILLWOOD, V15, P27; REUTER JA, 1999, PATTERNS SPECIALITY; ROBINSON JC, 1995, MED CARE, V33, P1161, DOI 10.1097/00005650-199512000-00001; Rogal DL, 1998, INQUIRY-J HEALTH CAR, V35, P115; Smith N S, 1994, Manag Care Q, V2, P21; Summitt RL, 1998, JAMA-J AM MED ASSOC, V279, P767, DOI 10.1001/jama.279.10.767; Wilensky G R, 1986, Health Aff (Millwood), V5, P66, DOI 10.1377/hlthaff.5.1.66	29	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1067	1072		10.1001/jama.282.11.1067	http://dx.doi.org/10.1001/jama.282.11.1067			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493206				2022-12-24	WOS:000082512300031
J	Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB				Collins, MW; Grindel, SH; Lovell, MR; Dede, DE; Moser, DJ; Phalin, BR; Nogle, S; Wasik, M; Cordry, D; Daugherty, MK; Sears, SF; Nicolette, G; Indelicato, P; McKeag, DB			Relationship between concussion and neuropsychological performance in college football players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINOR HEAD-INJURY	Context Despite the high prevalence and potentially serious outcomes associated with concussion in athletes, there is little systematic research examining risk factors and short- and long-term outcomes. Objectives To assess the relationship between concussion history and learning disability (LD) and the association of these variables with neuropsychological performance and to evaluate postconcussion recovery in a sample of college football players. Design, Setting, and Participants A total of 393 athletes from 4 university football programs across the United States received preseason baseline evaluations between May 1997 and February 1999. Subjects who had subsequent football-related acute concussions (n = 16) underwent neuropsychological comparison with matched control athletes from within the sample (n = 10). Main Outcome Measures Clinical interview, 8 neuropsychological measures, and concussion symptom scale ratings at baseline and after concussion. Results Of the 393 players, 129 (34%) had experienced 1 previous concussion and 79 (20%) had experienced 2 or more concussions. Multivariate analysis of variance yielded significant main effects for both LD (P<.001) and concussion history (P = .009), resulting in lowered baseline neuropsychological performance. A significant interaction was found between LD and history of multiple concussions and LD on 2 neurol psychological measures (Trail-Making Test, Form B [P = .007] and Symbol Digit Modalities Test [P = .009]), indicating poorer performance for the group with LD and multiple concussions compared with other groups. A discriminant function analysis using neuropsychological testing of athletes 24 hours after acute in-season concussion compared with controls resulted in an overall 89.5% correct classification rate. Conclusions Our study suggests that neuropsychological assessment is a useful indicator of cognitive functioning in athletes and that bath history of multiple concussions and LD are associated with reduced cognitive performance. These variables may be detrimentally synergistic and should receive further study.	Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, Detroit, MI 48202 USA; Univ Pittsburgh, Dept Family Practice, Pittsburgh, PA USA; Univ Pittsburgh, Dept Family Med Sports Med, Pittsburgh, PA USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Coll Med, Dept Orthoped & Rehabil, Gainesville, FL USA; Univ Florida, Dept Community & Family Hlth, Gainesville, FL USA; Univ Florida, Dept Sports Hlth, Gainesville, FL USA; Michigan State Univ, Dept Athlet Training, E Lansing, MI 48824 USA; Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA; St Vincents Med Ctr, Dept Sports Med, Erie, PA USA	Henry Ford Health System; Henry Ford Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University; Michigan State University	Collins, MW (corresponding author), Henry Ford Hlth Syst, Div Neuropsychol, Dept Behav Hlth, 1 Ford Pl 1E, Detroit, MI 48202 USA.			sears, samuel/0000-0002-7863-3591; Moser, David/0000-0003-4102-5266				Barth J.T., 1989, MILD HEAD INJURY, P257; BEARS SR, 1995, J LEARN DISABIL, V27, P315; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donders J, 1997, Pediatr Rehabil, V1, P179; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HENDERSON C, 1994, COLL FRESHMEN DISABI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; HURBERT RT, 1994, COMPREHENDING BEHAV; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; JORDAN BD, 1994, MILD BRAIN INJURY SP; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; LOVELL MR, 1999, SPORTS RELATED CONCU; Nicolson RI, 1999, LANCET, V353, P1662, DOI 10.1016/S0140-6736(98)09165-X; Powell JW, 1999, SPORTS-RELATED CONCUSSION, P75; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O, 1995, DEV NEUROPSYCHOLOGY; *STATS, 1995, STAT WIND COMP PROGR; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Torg JS, 1982, ATHLETIC INJURIES HE; [No title captured]	29	585	598	3	82	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					964	970		10.1001/jama.282.10.964	http://dx.doi.org/10.1001/jama.282.10.964			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485682				2022-12-24	WOS:000082335900035
J	Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA				Bostom, AG; Rosenberg, IH; Silbershatz, H; Jacques, PF; Selhub, J; D'Agostino, RB; Wilson, PWF; Wolf, PA			Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study	ANNALS OF INTERNAL MEDICINE			English	Article							VASCULAR-DISEASE; NATURAL-HISTORY; RISK FACTOR; HYPERHOMOCYSTEINEMIA; SERUM; HOMOCYSTINURIA; ADULTS	Background: Total homocysteine levels are associated with arteriosclerotic outcomes. Objective: To determine whether total homocysteine levels predict incident stroke in elderly persons. Design: Prospective population-based cohort study with 9.9 years of follow-up. Setting: Framingham, Massachusetts. Patients: 1947 Framingham Study participants (1158 women and 789 men; mean age +/- SD, 70 +/- 7 years). Measurements: Baseline total homocysteine levels and 9.9-year stroke incidence. Results: The quartiles of nonfasting total homocysteine levels were as follows: quartile 1, 4.13 to 9.25 mu mol/L; quartile 2, 9.26 to 11.43 mu mol/L; quartite 3, 11.44 to 14.23 mu mol/L; quartile 4, 14.24 to 219.84 mu mol/L. During follow-up, 165 incident strokes occurred. In proportional hazards models adjusted for age, sex, systolic blood pressure, diabetes, smoking, and history of atrial fibrillation and coronary heart disease, relative risk (RR) estimates comparing quartile 1 with the other three quartiles were as follows: quartile 2 compared with quartile 1-RR, 1.32 (95% CI, 0.81 to 2.14); quartile 3 compared with quartile 1-RR, 1.44 (CI, 0.89 to 2.34); quartile 4 compared with quartile 1-RR, 1.82 (CI, 1.14 to 2.91). The linear trend across the quartiles was significant (P < 0.001). Conclusion: Nonfasting total homocysteine levels are an independent risk factor for incident stroke in elderly persons.	Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Brown Univ, Mem Hosp Rhode Isl, Providence, RI 02912 USA; NHLBI, Framingham Study, Framingham, MA 01701 USA	Tufts Medical Center; Tufts University; United States Department of Agriculture (USDA); Boston University; Brown University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rosenberg, IH (corresponding author), Tufts Univ, New England Med Ctr, Jean Mayer USDA Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.	rosenberg@hnrc.tufts.edu	Wilson, Peter W.F./J-2455-2016	Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [R01-HL-40423-05, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-RO1-NS-17950-17] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Bellamy MF, 1998, CIRCULATION, V98, P1848, DOI 10.1161/01.CIR.98.18.1848; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; KANNEL WB, 1987, FRAMINGHAM STUDY EPI, P1; Lentz SR, 1996, J CLIN INVEST, V98, P24, DOI 10.1172/JCI118771; Manolio TA, 1996, STROKE, V27, P1479, DOI 10.1161/01.STR.27.9.1479; MUDD SH, 1985, AM J HUM GENET, V37, P1; Omenn GS, 1998, CIRCULATION, V97, P421; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Petri M, 1996, LANCET, V348, P1120, DOI 10.1016/S0140-6736(96)03032-2; Robins M., 1981, STROKE, V12, pI45; ROLLAND PH, 1995, CIRCULATION, V91, P1161, DOI 10.1161/01.CIR.91.4.1161; UELAND PM, 1993, CLIN CHEM, V39, P1764; VERHOEF P, 1994, STROKE, V25, P1924, DOI 10.1161/01.STR.25.10.1924; Wilcken DEL, 1997, J INHERIT METAB DIS, V20, P295, DOI 10.1023/A:1005373209964; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	20	327	341	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					352	355		10.7326/0003-4819-131-5-199909070-00006	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475888				2022-12-24	WOS:000082458500005
J	Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH				Kark, JD; Selhub, J; Adler, B; Gofin, J; Abramson, JH; Friedman, G; Rosenberg, IH			Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem	ANNALS OF INTERNAL MEDICINE			English	Article							SERUM TOTAL HOMOCYSTEINE; REDUCTASE GENE MUTATION; CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; RISK FACTOR; HEALTH; HYPERHOMOCYSTEINEMIA; PHYSICIANS; VITAMINS	Background: Elevated plasma total homocysteine level has been associated with cardiovascular disease in many studies, mostly in Europe and North America. Data on persons from other areas and on associations with overall mortality are sparse. Objective: To determine the relation of plasma homocysteine level to all-cause and cause-specific mortality. Design: Prospective observational study with 9- to 11-year follow-up. Setting: A free-living, multiethnic Jewish population in western Jerusalem, Israel. Participants: 1788 residents of Jerusalem (808 men and 980 women) who were at least 50 years of age and were examined between 1985 and 1987 as part of the Kiryat Yovel Community Health Study. Measurements: Nonfasting plasma homocysteine level was determined in frozen stored samples. Deaths during follow-up were identified by linkage with the national population registry. Results: Plasma homocysteine levels exceeded 14 mu mol/L in 28% of men and 20% of women. During the study period, 405 deaths occurred. In multivariate Cox models that controlled for possible confounders, a nonmonotonic increase in mortality hazard ratios was associated with ascending quintile of homocysteine level: 1.0, 1.4, 1.3, 1.5, and 2.0 (P < 0.001 for trend), The relation was similar for cardiovascular and noncardiovascular causes of death (excluding cancer). The association was weaker when deaths that occurred during the first 5 years of follow-up were excluded; corresponding hazard ratios for ascending quintile of homocysteine level were 1.0, 1.0, 1.2, 1.1, and 1.6 (P = 0.063 for trend). Age- and sex-adjusted percentages of deaths "attributable" to elevated plasma homocysteine level(greater than or equal to 14 mu mol/L) were 12.5% (95% CI, 6.7% to 18.8%)for all deaths, 16.0% (CI, 7.2% to 25.6%) for deaths during the first 5 years of follow-up, and 8.3% (CI, 1.5% to 16.1%) for later deaths. Conclusions: A mildly to moderately elevated nonfasting plasma homocysteine level is a substantial risk marker for death from all causes. The association seems to be stronger during the first 5 years of follow-up.	Hadassah Univ Hosp, Dept Social Med, IL-91120 Ein Kerem, Israel; Hebrew Univ Jerusalem, Hadassah Sch Publ Hlth & Community Med, Ein Kerem, Israel; Tufts Univ, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Hadassah Univ Hosp, Geriatr Unit, IL-91120 Ein Kerem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Tufts University; United States Department of Agriculture (USDA); Hebrew University of Jerusalem	Kark, JD (corresponding author), Hadassah Univ Hosp, Dept Social Med, POB 12000, IL-91120 Ein Kerem, Israel.	jeremyl@vms.huji.ac.il						ABRAMSON JH, 1992, J CLIN EPIDEMIOL, V45, P651, DOI 10.1016/0895-4356(92)90137-C; ABRAMSON JH, 1994, INT J EPIDEMIOL, V23, P98, DOI 10.1093/ije/23.1.98; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; Arnadottir M, 1996, SCAND J CLIN LAB INV, V56, P41, DOI 10.3109/00365519609088586; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOSTOM A, 1995, ATHEROSCLEROSIS, V116, P59, DOI 10.1016/0021-9150(95)05522-X; Bostom AG, 1997, KIDNEY INT, V52, P10, DOI 10.1038/ki.1997.298; Bostom AG, 1999, ARCH INTERN MED, V159, P1077, DOI 10.1001/archinte.159.10.1077; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Brattstrom L, 1998, ATHEROSCLEROSIS, V141, P315, DOI 10.1016/S0021-9150(98)00154-3; BRATTSTROM L, 1994, J INTERN MED, V236, P633, DOI 10.1111/j.1365-2796.1994.tb00856.x; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAngelo A, 1997, BLOOD, V90, P1; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; Gofin J, 1996, INT J OBESITY, V20, P260; Gofin J, 1995, EUR HEART J, V16, P1988, DOI 10.1093/oxfordjournals.eurheartj.a060858; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Guttormsen AB, 1997, KIDNEY INT, V52, P495, DOI 10.1038/ki.1997.359; IDLER EL, 1990, AM J PUBLIC HEALTH, V80, P446, DOI 10.2105/AJPH.80.4.446; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; KAPLAN G, 1988, J GERONTOL, V43, pS114, DOI 10.1093/geronj/43.4.S114; KAPLAN GA, 1983, AM J EPIDEMIOL, V117, P292, DOI 10.1093/oxfordjournals.aje.a113541; Kuller LH, 1998, CIRCULATION, V98, P196, DOI 10.1161/01.CIR.98.3.196; LARUE A, 1979, J GERONTOL, V34, P687, DOI 10.1093/geronj/34.5.687; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; MCCULLY KS, 1969, AM J PATHOL, V56, P111; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Peterson JC, 1998, LANCET, V351, P263, DOI 10.1016/S0140-6736(05)78275-1; Rose G, 1982, CARDIOVASCULAR SURVE; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; *WHO REG OFF EUR, 1996, HIGHL HLTH ISR, P21; Wollesen F, 1999, KIDNEY INT, V55, P1028, DOI 10.1046/j.1523-1755.1999.0550031028.x	43	113	116	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					321	+		10.7326/0003-4819-131-5-199909070-00002	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234AC	10475884				2022-12-24	WOS:000082458500001
J	Reirden, DH				Reirden, DH			Lessons outside the lecture hall	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA; Connecticut Childrens Med Ctr, Farmington, CT USA	University of Connecticut; Connecticut Children's Medical Center	Reirden, DH (corresponding author), Univ Connecticut, Ctr Hlth, Farmington, CT 06032 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1999	282	9					820	821		10.1001/jama.282.9.820	http://dx.doi.org/10.1001/jama.282.9.820			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	230VK	10478685	hybrid			2022-12-24	WOS:000082272200004
J	Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H				Apelqvist, A; Li, H; Sommer, L; Beatus, P; Anderson, DJ; Honjo, T; de Angelis, MH; Lendahl, U; Edlund, H			Notch signalling controls pancreatic cell differentiation	NATURE			English	Article							LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR; INSULIN GENE; EXPRESSION; PROGENITOR; NEURONS; NEUROGENESIS; ORIGIN; MICE	The pancreas contains both exocrine and endocrine cells, but the molecular mechanisms controlling the differentiation of these cell types are largely unknown. Despite their endodermal origin, pancreatic endocrine cells share several molecular characteristics with neurons(1-5), and, like neurons in the central nervous system(6,7) differentiating endocrine cells in the pancreas appear in a scattered fashion within a field of progenitor coils(8,9). This indicates that they may be generated by lateral specification through Notch signalling(6,7). Here, to test this idea, we analysed pancreas development in mice genetically altered at several steps in the Notch signalling pathway, Mice deficient for Delta-like gene 1 (Dll1)(10) or the intracellular mediator RBP-JK(11) showed accelerated differentiation of pancreatic endocrine cells. A similar phenotype was observed in mice over-expressing neurogenin 3 (ngn 3)(12) or the intracellular form of Notch3 (ref. 13) (a repressor of Notch signalling). These data provide evidence that ngn3 acts as pro-endocrine gene and that Notch signalling is critical for the decision between the endocrine and progenitor/exocrine fates in the developing pancreas.	Umea Univ, Dept Microbiol, S-90187 Umea, Sweden; ETH Honggerberg, Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; Kyoto Univ, Fac Med, Dept Med Chem, Sakyo Ku, Kyoto 6068501, Japan; GSF, Inst Mammalian Genet, D-85764 Neuherberg, Germany; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Umea University; Swiss Federal Institutes of Technology Domain; ETH Zurich; California Institute of Technology; Kyoto University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Karolinska Institutet	Edlund, H (corresponding author), Umea Univ, Dept Microbiol, S-90187 Umea, Sweden.		de Angelis, Martin Hrabe/F-5531-2012; Honjo, Tasuku/N-4470-2016	de Angelis, Martin Hrabe/0000-0002-7898-2353; Edlund, Helena/0000-0002-3553-7348; Sommer, Lukas/0000-0002-1143-7908; Lendahl, Urban/0000-0001-9543-8141				Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Beatus P, 1998, J NEUROSCI RES, V54, P125, DOI 10.1002/(SICI)1097-4547(19981015)54:2<125::AID-JNR1>3.3.CO;2-C; Beatus P, 1999, DEVELOPMENT, V126, P3925; deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Fode C, 1998, NEURON, V20, P483, DOI 10.1016/S0896-6273(00)80989-7; FONTAINE J, 1977, J EMBRYOL EXP MORPH, V41, P209; Hogan B, 1994, MANIPULATING MOUSE E; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lewis J, 1996, CURR OPIN NEUROBIOL, V6, P3, DOI 10.1016/S0959-4388(96)80002-X; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; MISHIBASHI M, 1995, GENE DEV, V15, P3136; Mitsiadis TA, 1998, DEV BIOL, V204, P420, DOI 10.1006/dbio.1998.9092; Mitsiadis TA, 1997, DEVELOPMENT, V124, P1473; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OKA C, 1995, DEVELOPMENT, V121, P3291; Pictet R., 1972, HDB PHYSL, P25; PICTET RL, 1976, SCIENCE, V191, P191, DOI 10.1126/science.1108195; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Sommer L, 1996, MOL CELL NEUROSCI, V8, P221, DOI 10.1006/mcne.1996.0060; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245	30	912	949	0	63	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					877	881		10.1038/23716	http://dx.doi.org/10.1038/23716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476967				2022-12-24	WOS:000082233200047
J	Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER				Littleton, JT; Serano, TL; Rubin, GM; Ganetzky, B; Chapman, ER			Synaptic function modulated by changes in the ratio of synaptotagmin I and IV	NATURE			English	Article							NEUROTRANSMITTER RELEASE; MUTATIONAL ANALYSIS; BINDING; DOMAIN; DROSOPHILA; VESICLES; PROTEINS; SENSOR; REGION; SNARE	Communication within the nervous system is mediated by Ca2+-triggered fusion of synaptic vesicles with the presynaptic plasma membrane. Genetic and biochemical evidence indicates that synaptotagmin I may function as a Ca2+ sensor in neuronal exocytosis because it can bind Ca2+ and penetrate into lipid bilayers(1-4). Chronic depolarization or seizure activity results in the upregulation of a distinct and unusual isoform of the synaptotagmin family, synaptotagmin IV (ref. 5). We have identified a Drosophila homologue of synaptotagmin IV that is enriched on synaptic vesicles and contains an evolutionarily conserved substitution of aspartate to serine that abolishes its ability to bind membranes in response to Ca2+ influx. Synaptotagmin IV forms hetero-oligomers with synaptotagmin I, resulting in synaptotagmin clusters that cannot effectively penetrate lipid bilayers and are less efficient at coupling Ca2+ to secretion in vivo: upregulation of synaptotagmin IV, but not synaptotagmin I, decreases evoked neurotransmission. These findings indicate that modulating the expression of synaptotagmins with different Ca2+-binding affinities can lead to heteromultimers that can regulate the efficiency of excitation-secretion coupling in vivo and represent a new molecular mechanism for synaptic plasticity.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Littleton, JT (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.			Rubin, Gerald/0000-0001-8762-8703; Chapman, Edwin/0000-0001-9787-8140; Littleton, J. Troy/0000-0001-5576-2887				BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Ferguson GD, 1999, J NEUROCHEM, V72, P1821, DOI 10.1046/j.1471-4159.1999.0721821.x; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Osborne SL, 1999, J BIOL CHEM, V274, P59, DOI 10.1074/jbc.274.1.59; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	20	135	139	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					757	760		10.1038/23462	http://dx.doi.org/10.1038/23462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466723				2022-12-24	WOS:000082131100048
J	Liu, L; Wolf, R; Ernst, R; Heisenberg, M				Liu, L; Wolf, R; Ernst, R; Heisenberg, M			Context generalization in Drosophila visual learning requires the mushroom bodies	NATURE			English	Article							FLIGHT ORIENTATION; MELANOGASTER; BRAIN; EXPRESSION; GENE	The world is permanently changing, Laboratory experiments on learning and memory normally minimize this feature of reality, keeping all conditions except the conditioned and unconditioned stimuli as constant as possible(1). In the real world, however, animals need to extract from the universe of sensory signals the actual predictors of salient events by separating them from nonpredictive stimuli (context(2)), In principle, this can be achieved if only those sensory inputs that resemble the reinforcer in their temporal structure are taken as predictors. Here we study visual learning in the fly Drosophila melanogaster, using a flight simulator(3,4), and show that memory retrieval is, indeed, partially context-independent. Moreover, we show that the mushroom bodies, which are required for olfactory(5-7) but not visual or tactile learning(8), effectively support context generalization. In visual learning in Drosophila, it appears that a facilitating effect of context cues for memory retrieval is the default state, whereas making recall context-independent requires additional processing.	Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany	University of Wurzburg	Heisenberg, M (corresponding author), Biozentrum, Lehrstuhl Genet, D-97074 Wurzburg, Germany.							ASHBURNER M, 1989, LAB MANUAL PROTOCOLL, P254; Barth M, 1997, LEARN MEMORY, V4, P219, DOI 10.1101/lm.4.2.219; BICKEL WK, 1985, J EXP ANAL BEHAV, V44, P245, DOI 10.1901/jeab.1985.44-245; BOUTON ME, 1993, PSYCHOL BULL, V114, P80, DOI 10.1037/0033-2909.114.1.80; BUCHNER E, 1988, CELL TISSUE RES, V253, P357, DOI 10.1007/BF00222292; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Crittenden JR, 1998, LEARN MEMORY, V5, P38; deBelle JS, 1996, P NATL ACAD SCI USA, V93, P9875, DOI 10.1073/pnas.93.18.9875; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; ERBRE J, 1987, ANTHR BRAIN ITS EVOL; ERNST R, IN PRESS VIS RES; Guo A, 1996, LEARN MEMORY, V3, P49, DOI 10.1101/lm.3.1.49; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HEISENBERG M, 1988, J COMP PHYSIOL A, V163, P373, DOI 10.1007/BF00604013; Heisenberg M., 1984, STUDIES BRAIN FUNCTI, V12; Ito K, 1998, LEARN MEMORY, V5, P52; Li YS, 1997, J COMP NEUROL, V387, P631; MARTIN JR, 1998, DROSOPHILA MELANOGAS, V5, P179; Pavlov I.P., 1927, CONDITIONED REFLEXES; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Rybak J, 1998, LEARN MEMORY, V5, P133; SCHILDBERGER K, 1984, J COMP PHYSIOL, V154, P71, DOI 10.1007/BF00605392; SCHURMANN FW, 1974, EXP BRAIN RES, V19, P406, DOI 10.1007/BF00234464; Strausfeld NJ, 1998, LEARN MEMORY, V5, P11; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; Tarpy R.M., 1997, CONT LEARNING THEORY; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; Wolf R, 1998, LEARN MEMORY, V5, P166; WOLF R, 1991, J COMP PHYSIOL A, V169, P699	29	221	224	2	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					753	756		10.1038/23456	http://dx.doi.org/10.1038/23456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	228HM	10466722				2022-12-24	WOS:000082131100047
J	Druss, BG; Rosenheck, RA				Druss, BG; Rosenheck, RA			Association between use of unconventional therapies and conventional medical services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; ALTERNATIVE MEDICINE; UNITED-STATES; COSTS; DEPRESSION; CARE; PATTERNS	Context The terms alternative and complementary medicine suggest 2 contradictory possibilities. Whether individuals use unconventional therapies as a substitute for or as an "add on" to conventional medical treatments is uncertain. Objective To determine the association between use of unconventional therapies and conventional medical care in a national sample. Design, Setting, and Participants The 1996 Medical Expenditure Panel Survey was distributed to a probability sample of the noninstitutionalized civilian US population. Of 24 676 individuals responding (77.7% response rate), 16 068 adults 18 years or older were included in the analysis. Main Outcome Measures Visits to practitioners for unconventional therapies and conventional medical services, including number of inpatient, outpatient, and emergency department visits and use of 8 types of preventive medical services (blood pressure, cholesterol level, physical examination, influenza vaccination, prostate examination, breast examination, mammography, and Papanicolaou test). Results During 1996, an estimated 6.5% of the US population had visits for both unconventional therapies and conventional medical care; 1.8% used only unconventional services; 59.5% used only conventional care; and 32.2% used neither. Compared with those with only conventional visits, those who used both types of care had significantly more outpatient physician visits (7.9 vs 5.4; P<.001), and used more of all types of preventive services except mammography. These groups did not differ significantly in inpatient care, prescription drug use, or number of emergency department visits. Individuals in the top quartile of number of physician visits were more than twice as likely as those in the bottom quartile to have used unconventional therapies in the past year (14.5% vs 6.4%; P<.001). The association between unconventional treatments and physician visits remained after adjusting for potential confounders and across different types of unconventional treatment. Conclusions In this sample, use of unconventional therapies was substantially lower than has been reported in previous national surveys, but was associated with increased use of physician services. From a health services perspective, practitioner-based unconventional therapies appear to serve more as a complement than an alternative to conventional medicine.	Yale Univ, Dept Psychiat, West Haven, CT USA; Yale Univ, Dept Publ Hlth, West Haven, CT USA	Yale University; Yale University	Druss, BG (corresponding author), 950 Campbell Ave,116A, West Haven, CT 06516 USA.	benjamin.druss@yale.edu	Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213	NATIONAL INSTITUTE OF MENTAL HEALTH [K08MH001556] Funding Source: NIH RePORTER; NIMH NIH HHS [K08 MH01556] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; CAIRNS J, 1995, BRIT MED J, V311, P1520, DOI 10.1136/bmj.311.7019.1520; COHEN J, 1997, AHCPR PUBL; COHEN S, 1997, AHCPR PUBL; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P263; DADY PJ, 1987, NEW ZEAL MED J, V100, P110; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Eskinazi DP, 1998, JAMA-J AM MED ASSOC, V280, P1621, DOI 10.1001/jama.280.18.1621; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Gundling KE, 1998, ARCH INTERN MED, V158, P2185, DOI 10.1001/archinte.158.20.2185; HASKELL W, 1998, STANF CTR RES DIS PR; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; Jonas W, 1998, JAMA, V279, P708; Jonas WB, 1998, JAMA-J AM MED ASSOC, V280, P1616, DOI 10.1001/jama.280.18.1616; KOLATA G, 1998, N Y TIMES       0604, P4; Marwick C, 1998, JAMA-J AM MED ASSOC, V280, P1553, DOI 10.1001/jama.280.18.1553; MCFARLAND BH, 1985, MED CARE, V23, P1221, DOI 10.1097/00005650-198511000-00001; *MED EXP PAN SURV, 1997, AHCPR PUBL; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; SPIGELBLATT L, 1994, PEDIATRICS, V94, P811; Von Korff M, 1998, PSYCHOSOM MED, V60, P143, DOI 10.1097/00006842-199803000-00005; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	25	292	292	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					651	656		10.1001/jama.282.7.651	http://dx.doi.org/10.1001/jama.282.7.651			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10517718	Bronze			2022-12-24	WOS:000082033700024
J	Ives, AR; Gross, K; Klug, JL				Ives, AR; Gross, K; Klug, JL			Stability and variability in competitive communities	SCIENCE			English	Article							STATISTICAL INEVITABILITY; DIVERSITY; ECOLOGY; BIODIVERSITY; ECOSYSTEM	Long-term variability in the abundance of populations depends on the sensitivity of species to environmental fluctuations and the amplification of environmental fluctuations by interactions among species. Although competitive interactions and species number may have diverse effects on variability measured at the individual species level, a combination of theoretical analyses shows that these factors have no effect on variability measured at the community level. Therefore, biodiversity may increase community stability by promoting diversity among species in their responses to environmental fluctuations, but increasing the number and strength of competitive interactions has little effect.	Univ Wisconsin, Dept Zool, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Ives, AR (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	arives@facstaff.wisc.edu	Ives, Anthony/A-5698-2008	Ives, Anthony/0000-0001-9375-9523				Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; ELTON CS, 1958, ECOLOGY INVASIONS PL; FROST TM, 1994, LINKING SPECIES ECOS, P224; Ives AR, 1998, ECOLOGY, V79, P1039, DOI 10.1890/0012-9658(1998)079[1039:CDISTM]2.0.CO;2; IVES AR, 1995, ECOL MONOGR, V65, P217, DOI 10.2307/2937138; LAWTON JH, 1993, BIODIVERSITY ECOSYST, V80, P255; MACARTHUR R, 1955, ECOLOGY, V36, P533, DOI 10.2307/1929601; MARGALEF R, 1969, BROOKHAVEN SYM BIOL, P25; May R.M., 1974, STABILITY COMPLEXITY; MAY RM, 1972, NATURE, V238, P413, DOI 10.1038/238413a0; MCNAUGHTON SJ, 1985, ECOL MONOGR, V55, P259, DOI 10.2307/1942578; MCNAUGHTON SJ, 1977, AM NAT, V111, P515, DOI 10.1086/283181; Pimm S.L., 1991, BALANCE NATURE; PIMM SL, 1984, NATURE, V307, P321, DOI 10.1038/307321a0; Tilman D, 1998, AM NAT, V151, P277, DOI 10.1086/286118; Tilman D, 1999, ECOLOGY, V80, P1455, DOI 10.1890/0012-9658(1999)080[1455:TECOCI]2.0.CO;2; Tilman D, 1996, ECOLOGY, V77, P350, DOI 10.2307/2265614; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0	18	225	242	2	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					542	544		10.1126/science.286.5439.542	http://dx.doi.org/10.1126/science.286.5439.542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	245RD	10521351				2022-12-24	WOS:000083121200063
J	Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW				Jenney, FE; Verhagen, MFJM; Cui, XY; Adams, MWW			Anaerobic microbes: Oxygen detoxification without superoxide dismutase	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ALKYL HYDROPEROXIDE REDUCTASE; AMINO-ACID-SEQUENCE; RBO GENE-PRODUCT; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; DESULFOVIBRIO-GIGAS; REDOX PROTEINS; RESOLUTION	Superoxide reductase from the hyperthermophilic anaerobe Pyrococcus furiosus uses electrons from reduced nicotinamide adenine dinucleotide phosphate, by way of rubredoxin and an oxidoreductase, to reduce superoxide to hydrogen peroxide, which is then reduced to water by peroxidases. Unlike superoxide dismutase, the enzyme that protects aerobes from the toxic effects of oxygen, SOR does not catalyze the production of oxygen from superoxide and therefore confers a selective advantage on anaerobes. Superoxide reductase and associated proteins are catalytically active 80 degrees C below the optimum growth temperature (100 degrees C) of P. furiosus, conditions under which the organism is likely to be exposed to oxygen.	Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Adams, MWW (corresponding author), Univ Georgia, Ctr Metalloenzyme Studies, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	adams@bmb.uga.edu						Adams MWW, 1996, ADV PROTEIN CHEM, V48, P101; ADAMS MWW, 1992, ADV INORG CHEM, V38, P341, DOI 10.1016/S0898-8838(08)60068-9; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alban PS, 1998, J APPL MICROBIOL, V85, P875, DOI 10.1046/j.1365-2672.1998.00602.x; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Bau R, 1998, J BIOL INORG CHEM, V3, P484, DOI 10.1007/s007750050258; BEAUCHAMP C, 1970, J BIOL CHEM, V245, P4641; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bonomi F, 1996, J BIOL INORG CHEM, V1, P67, DOI 10.1007/s007750050024; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN L, 1993, EUR J BIOCHEM, V216, P443, DOI 10.1111/j.1432-1033.1993.tb18162.x; CHEN LA, 1994, EUR J BIOCHEM, V226, P613, DOI 10.1111/j.1432-1033.1994.tb20087.x; Choudhury SB, 1999, BIOCHEMISTRY-US, V38, P3744, DOI 10.1021/bi982537j; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; CYPIONKA H, 1985, FEMS MICROBIOL ECOL, V31, P39, DOI 10.1016/0378-1097(85)90045-X; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Flohe L, 1988, CRC HDB FREE RADICAL, V3, P287; FOUQUET Y, 1993, ECON GEOL BULL SOC, V88, P2018, DOI 10.2113/gsecongeo.88.8.2018; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Fridovich I, 1998, J EXP BIOL, V201, P1203; HUBER R, 1990, NATURE, V345, P179, DOI 10.1038/345179a0; JENNEY FE, UNPUB; Johnson MS, 1997, J BACTERIOL, V179, P5598, DOI 10.1128/jb.179.17.5598-5601.1997; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KITAMURA M, 1998, AB020341 GENBANK; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Kurtz DM, 1997, J BIOL INORG CHEM, V2, P159, DOI 10.1007/s007750050120; LAI KN, 1992, M96560 GENBANK; LEE TH, 1998, AAD03716 GANBANK; Lehmann Y, 1996, J BACTERIOL, V178, P7152, DOI 10.1128/jb.178.24.7152-7158.1996; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LUDWIG ML, 1991, J MOL BIOL, V219, P335, DOI 10.1016/0022-2836(91)90569-R; Ma K, 1999, J BACTERIOL, V181, P5530, DOI 10.1128/JB.181.17.5530-5533.1999; Mallett TC, 1998, BIOCHEMISTRY-US, V37, P8790, DOI 10.1021/bi9803630; Marklund, 1985, HDB METHODS OXYGEN R, V243, P247; MARVINSIKKEMA FD, 1993, ARCH MICROBIOL, V160, P388; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P328; NAKAYAMA K, 1994, J BACTERIOL, V176, P1939, DOI 10.1128/jb.176.7.1939-1943.1994; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Pianzzola MJ, 1996, J BACTERIOL, V178, P6736, DOI 10.1128/jb.178.23.6736-6742.1996; Poole LB, 1996, BIOCHEMISTRY-US, V35, P56, DOI 10.1021/bi951887s; PRIEUR D, 1999, GENOSCOPE; ROBERTON AM, 1970, J BACTERIOL, V102, P43, DOI 10.1128/JB.102.1.43-51.1970; Rocha ER, 1996, J BACTERIOL, V178, P6895, DOI 10.1128/jb.178.23.6895-6903.1996; Romao CV, 1999, EUR J BIOCHEM, V261, P438, DOI 10.1046/j.1432-1327.1999.00278.x; ROSS RP, 1992, J MOL BIOL, V227, P658, DOI 10.1016/0022-2836(92)90215-6; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; SEARCY DG, 1995, ARCH BIOCHEM BIOPHYS, V318, P251, DOI 10.1006/abbi.1995.1228; SHENVI NV, 1997, AF034841 GENBANK; SHENVI NV, 1997, AF034965 GENBANK; Silva G, 1999, EUR J BIOCHEM, V259, P235, DOI 10.1046/j.1432-1327.1999.00025.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; STEHLE T, 1991, J MOL BIOL, V221, P1325, DOI 10.1016/0022-2836(91)90936-Z; STODDARD BL, 1990, BIOCHEMISTRY-US, V29, P8885, DOI 10.1021/bi00490a002; Summit M, 1998, DEEP-SEA RES PT II, V45, P2751, DOI 10.1016/S0967-0645(98)00092-7; TAINER JA, 1983, NATURE, V306, P284, DOI 10.1038/306284a0; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; TIVEY MK, 1995, SEAFLOOR HYDROTHERMA, P158; Valentine JS, 1998, CURR OPIN CHEM BIOL, V2, P253, DOI 10.1016/S1367-5931(98)80067-7; van Niel EWJ, 1998, APPL ENVIRON MICROB, V64, P1034	67	317	324	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					306	309		10.1126/science.286.5438.306	http://dx.doi.org/10.1126/science.286.5438.306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514376				2022-12-24	WOS:000083024400048
J	Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC				Joazeiro, CAP; Wing, SS; Huang, HK; Leverson, JD; Hunter, T; Liu, YC			The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; IDENTIFICATION; PRODUCT; CONJUGATION; DEGRADATION; ONCOGENE; COMPLEX; SYSTEM; YEAST	Ubiquitination of receptor protein-tyrosine kinases (RPTKs) terminates signaling by marking active receptors for degradation. c-Cbl, an adapter protein for RPTKs, positively regulates RPTK ubiquitination in a manner dependent on its variant SRC homology 2 (SH2) and RING finger domains. Ubiquitin-protein Ligases (or E3s) are the components of ubiquitination pathways that recognize target substrates and promote their Ligation to ubiquitin. The c-Cbl protein acted as an E3 that can recognize tyrosine-phosphorylated substrates, such as the activated platelet-derived growth factor receptor, through its SH2 domain and that recruits and allosterically activates an E2 ubiquitin-conjugating enzyme through its RING domain. These results reveal an SH2-containing protein that functions as a ubiquitin-protein Ligase and thus provide a distinct mechanism for substrate targeting in the ubiquitin system.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Salk Institute; McGill University; La Jolla Institute for Immunology	Hunter, T (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA.	hunter@salk.edu		LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL CANCER INSTITUTE [R35CA039780, T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER; NCI NIH HHS [CA39780, T32CA09523] Funding Source: Medline; NIDDK NIH HHS [R01 DK56558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Haas AL, 1997, FASEB J, V11, P1257; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; JOAZEIRO CAP, UNPUB; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mori S, 1997, EUR J BIOCHEM, V247, P1190, DOI 10.1111/j.1432-1033.1997.01190.x; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; OU F, COMMUNICATION; Oughtred R, 1998, J BIOL CHEM, V273, P18435, DOI 10.1074/jbc.273.29.18435; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Rajapurohitam V, 1999, DEV BIOL, V212, P217, DOI 10.1006/dbio.1999.9342; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shimizu A, 1998, GENES CELLS, V3, P125, DOI 10.1046/j.1365-2443.1998.00174.x; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THILEN CB, 1998, IMMUNOL CELL BIOL, V76, P473; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	32	877	904	2	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 8	1999	286	5438					309	312		10.1126/science.286.5438.309	http://dx.doi.org/10.1126/science.286.5438.309			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10514377				2022-12-24	WOS:000083024400049
J	Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M				Rolink, AG; Nutt, SL; Melchers, F; Busslinger, M			Long-term in vivo reconstitution of T-cell development by Pax5-deficient B-cell progenitors	NATURE			English	Article							RECEPTOR-ALPHA-GENE; BONE-MARROW; REARRANGEMENT; MICE; IDENTIFICATION; EXPRESSION; CHAIN; DIFFERENTIATION; THYMOCYTES; THYMUS	The mechanisms controlling the commitment of haematopoietic progenitors to the B-lymphoid lineage are poorly understood. The observations that mice deficient in E2A(1,2) and EBF3 lack B-lineage cells have implicated these two transcription factors in the commitment process. Moreover, the expression of genes encoding components of the rearrangement machinery (RAG1, RAG2, TdT) or pre-B-cell receptor (lambda 5, VpreB, Ig alpha, Ig beta) has been considered to indicate B-lineage commitment(4). All these genes including E2A and EBF are expressed in pro-B cells lacking the transcription factor Pax5 (refs 5-7). Here we show that cloned Pax5-deficient pro-B cells transferred into RAG2-deficient mice provide longterm reconstitution of the thymus and give rise to mature T cells expressing alpha/beta-T-cell receptors. The bone marrow of these mice contains a population of cells of Pax5(-/-) origin with the same phenotype as the donor pro-B cells. When transferred into secondary recipients, these pro-B cells again home to the bone marrow and reconstitute the thymus. Hence, B-Lineage commitment is determined neither by immunoglobulin DJ rearrangement nor by the expression of E2A, EBF, lambda 5, VpreB, Ig alpha and Ig beta. Instead, our data implicate Pax5 in the control of B-lineage commitment.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Rolink, AG (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Busslinger, Meinrad J./J-1249-2016; Nutt, Stephen L/C-9256-2013	Busslinger, Meinrad J./0000-0002-9111-9351; Nutt, Stephen L/0000-0002-0020-6637				Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BORN W, 1988, J IMMUNOL, V140, P3228; BRUNO L, 1995, EUR J IMMUNOL, V25, P1877, DOI 10.1002/eji.1830250713; CEREDIG R, 1984, THYMUS, V6, P15; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Melchers F, 1999, FUNDAMENTAL IMMUNOLO, V4th, P183; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Reininger L, 1996, J EXP MED, V184, P853, DOI 10.1084/jem.184.3.853; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLLINK A, 1991, EMBO J, V10, P327; ROLLINK A, 1994, INT IMMUNOL, V6, P1257; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Wang H, 1998, P NATL ACAD SCI USA, V95, P6831, DOI 10.1073/pnas.95.12.6831; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	26	293	300	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					603	606		10.1038/44164	http://dx.doi.org/10.1038/44164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524629				2022-12-24	WOS:000083054900054
J	Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE				Sheehan, KM; Sheahan, K; O'Donoghue, DP; MacSweeney, F; Conroy, RM; Fitzgerald, DJ; Murray, FE			The relationship between cyclooxygenase-2 expression and colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN COLON-CANCER; NONSTEROIDAL ANTIINFLAMMATORY DRUG; SPONTANEOUS INTESTINAL ADENOMAS; MIN MOUSE MODEL; PLASMINOGEN-ACTIVATOR; DEPENDENT INCREASE; REDUCED RISK; ASPIRIN USE; SULINDAC	Context Epidemiological studies have implicated the inducible form of cyclooxygenase (COX-2) in the pathogenesis of colorectal cancer; however, its role is not fully understood. Objective To examine the relationship between the expression of COX-2 in human colorectal cancer and patient survival. Design Patients diagnosed as having colorectal cancer were evaluated and followed up for up to 9.4 years (median follow-up, 2.7 years). Tumor sections were stained for COX-2 using a rabbit polyclonal antibody raised against human COX-2, The extent of COX-2 staining was graded by 2 observers blinded to outcome, Preabsorption of the anti-COX-2 antibody with a COX-2 peptide abolished the staining, demonstrating the specificity of the assay. Setting Gastrointestinal unit of a large general teaching hospital in Dublin, Ireland. Participants Seventy-six patients (median age, 66.5 years) with colorectal cancer (Dukes tumor stage A, n = 9; Dukes B, n = 30; Dukes C, n = 25; Dukes D, n = 12) whose diagnosis was made between 1988 and 1991, Fourteen normal colon biopsies were stained for COX-2 as controls. Main Outcome Measures Survival in years following diagnosis compared by extent of COX-2 epithelial staining (grade 1, <1%; grade 2, 1%-19%; grade 3, 20%-49%; grade 4, greater than or equal to 50%), Dukes stage, tumor size, and lymph mode metastasis. Results COX-2 was found in tumor epithelial cells, inflammatory cells, vascular endothelium, and/or fibroblasts. The extent of epithelial staining was heterogeneous, varying markedly among different tumors. Normal tissue adjacent to the tumors also stained weakly for COX-2, No COX-2 was detected in control tissue samples, The Kaplan-Meier survival estimate was 68% in patients who had grade 1 tumor epithelial staining compared with 35% in those with higher grades combined (log-rank chi(2) = 5.7; P =.02). Greater expression of COX-2 correlated with more advanced Dukes stage (Kendall tau-b, 0.22; P=.03) and larger tumor size (Kendall tau-b, 0.21; P=.02) and was particularly evident in tumors with lymph node involvement (Kendall tau-b, 0.26; P=.02). Conclusions Our data indicate that COX-2 expression in colorectal cancer may be related to survival. These data add to the growing epidemiological and experimental evidence that COX-2 may play a role in colorectal tumorigenesis.	Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland; Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin 2, Ireland; St Vincents Hosp, Dept Pathol, Dublin 4, Ireland; St Vincents Hosp, Dept Gastroenterol, Dublin 4, Ireland; Beaumont Hosp, Dept Gastroenterol, Dublin 9, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland; University College Dublin; University College Dublin	Sheehan, KM (corresponding author), Royal Coll Surgeons Ireland, Dept Clin Pharmacol, 123 St Stephens Green, Dublin 2, Ireland.	ksheehan@rcsi.ie	Conroy, Ronan/C-6416-2008	Conroy, Ronan/0000-0001-5983-8682; Sheehan, Katherine/0000-0002-8969-3610				Barnes CJ, 1998, GASTROENTEROLOGY, V114, P873, DOI 10.1016/S0016-5085(98)70305-1; CHAPUIS PH, 1985, BRIT J SURG, V72, P698, DOI 10.1002/bjs.1800720909; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; Dukes CE, 1932, J PATHOL BACTERIOL, V35, P323, DOI 10.1002/path.1700350303; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fujita T, 1998, CANCER RES, V58, P4823; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRAHAM DM, 1990, MODERN PATHOL, V3, P332; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Jacoby RF, 1996, CANCER RES, V56, P710; JASS JR, 1987, J CLIN PATHOL, V40, P1016, DOI 10.1136/jcp.40.9.1016; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; MOORGHEN M, 1988, J PATHOL, V156, P341, DOI 10.1002/path.1711560411; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; Mulcahy HE, 1997, DIS COLON RECTUM, V40, P326, DOI 10.1007/BF02050424; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PASRICHA PJ, 1995, GASTROENTEROLOGY, V109, P994, DOI 10.1016/0016-5085(95)90411-5; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Sandler RS, 1998, GASTROENTEROLOGY, V114, P441, DOI 10.1016/S0016-5085(98)70526-8; SANO H, 1995, CANCER RES, V55, P3785; SHEPHERD NA, 1989, HISTOPATHOLOGY, V14, P613, DOI 10.1111/j.1365-2559.1989.tb02202.x; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Skelly MM, 1997, CLIN CANCER RES, V3, P1837; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Troisi RJ, 1999, CANCER, V85, P1670, DOI 10.1002/(SICI)1097-0142(19990415)85:8<1670::AID-CNCR5>3.0.CO;2-M; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Yang VW, 1998, CANCER RES, V58, P1750	33	356	382	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1254	1257		10.1001/jama.282.13.1254	http://dx.doi.org/10.1001/jama.282.13.1254			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517428	Bronze			2022-12-24	WOS:000082901100033
J	Carvalho, AB; Clark, AG				Carvalho, AB; Clark, AG			Genetic recombination - Intron size and natural selection	NATURE			English	Article							SMALL DROSOPHILA INTRON; MELANOGASTER; SEQUENCES		Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; Penn State Univ, Inst Mol Evolutionary Genet, Mueller Lab 208, University Pk, PA 16802 USA	Universidade Federal do Rio de Janeiro; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Carvalho, AB (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil.		Carvalho, Antonio/D-5402-2013	Carvalho, Antonio/0000-0001-8959-6469; Clark, Andrew/0000-0001-7159-8511				Comeron JM, 1999, GENETICS, V151, P239; GUO M, 1995, J MOL BIOL, V253, P426, DOI 10.1006/jmbi.1995.0564; HILL WG, 1966, GENET RES, V8, P269, DOI 10.1017/S0016672300010156; HUGHES AL, 1995, NATURE, V377, P391, DOI 10.1038/377391a0; Kennedy CF, 1997, MOL CELL BIOL, V17, P2774, DOI 10.1128/MCB.17.5.2774; KLIMAN RM, 1993, MOL BIOL EVOL, V10, P1239; Moriyama EN, 1998, MOL BIOL EVOL, V15, P770, DOI 10.1093/oxfordjournals.molbev.a025980; MORONI G, 1993, ATLAS DROSOPHILA GEN, P319; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; Ogata H, 1996, FEBS LETT, V390, P99, DOI 10.1016/0014-5793(96)00636-9; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEPHAN W, 1994, GENETICS, V138, P135, DOI 10.1093/genetics/138.1.135	13	105	107	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 23	1999	401	6751					344	344		10.1038/43827	http://dx.doi.org/10.1038/43827			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517631				2022-12-24	WOS:000082822600041
J	Peters, JM; McKay, RM; McKay, JP; Graff, JM				Peters, JM; McKay, RM; McKay, JP; Graff, JM			Casein kinase I transduces Wnt signals	NATURE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; EARLY XENOPUS-EMBRYOS; C-ELEGANS EMBRYOS; BETA-CATENIN; CAENORHABDITIS-ELEGANS; SPEMANN ORGANIZER; AXIS FORMATION; BUDDING YEAST; PROTEIN; TRANSCRIPTION	The Wnt signalling cascade is essential for the development of both invertebrates and vertebrates, and is altered during tumorigenesis. Although a general framework for Wnt signalling has been elucidated, not all of the components have been identified. Here we describe a serine kinase, casein kinase I (CKI), which was isolated by expression cloning in Xenopus embryos. CKI reproduces several properties of Wnt signals, including generation of complete dorsal axes, stabilization of beta-catenin and induction of genes that are direct targets of Wnt signals. Dominant-negative forms of CKI and a pharmacological blocker of CKI inhibited Wnt signals in Xenopus, Inhibiting CKI in Caenorhabditis elegans generated worms with a mom phenotype, indicative of a loss of Wnt signals. In addition, CKI bound to and increased the phosphorylation of dishevelled, a known component of the Wnt pathway. These data indicate that CKI may be a conserved component of the Wnt pathway.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Graff, JM (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Mol Biol, 5323 Harry Hines Blvd,NB 5-208, Dallas, TX 75235 USA.	graff02@utsw.swmed.edu						Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Camac G., 1996, DEVELOPMENT, V122, P3055; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DEMAGGIO AJ, 1992, P NATL ACAD SCI USA, V89, P7008, DOI 10.1073/pnas.89.15.7008; EPSTEIN HF, 1995, METHODS CELL BIOL; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LeSuer JA, 1999, DEVELOPMENT, V126, P137; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xu QH, 1998, DEVELOPMENT, V125, P4767; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	50	374	390	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					345	350		10.1038/43830	http://dx.doi.org/10.1038/43830			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517632				2022-12-24	WOS:000082822600042
J	Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K				Tanaka, TU; Cosma, MP; Wirth, K; Nasmyth, K			Identification of cohesin association sites at centromeres and along chromosome arms	CELL			English	Article							SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; REPLICATION ORIGINS; DNA-REPLICATION; BUDDING YEAST; MCM PROTEIN; MEIOSIS; COMPLEX; NONDISJUNCTION; RECOMBINATION	A multisubunit cohesin complex holds sister chromatids together after DNA replication. Using chromatin immunoprecipitation, we detected cohesin association with centromeres and with discrete sites along chromosome arms from S phase until metaphase in S. cerevisiae, Short DNA sequences (130-280 bp) are sufficient to confer cohesin association. Cohesin association with a centromere depends on Mif2p, the centromere binding factor CBF3, and a centromere-specific histone variant, Cse4p. Because only active centromeres confer cohesin association with centromeric DNA, we suggest that cohesin is recruited by the same chromatin structure that confers the attachment of microtubules. Propagation of this structure might be partly epigenetic. Finally, cohesion associated with "minimal" centromeres is insufficient to resist the splitting force exerted by microtubules and appears to be reinforced by cohesion provided by their flanking DNA sequences.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Tanaka, Tomoyuki U/A-4775-2008; Cosma, Maria Pia/E-8731-2015	Cosma, Maria Pia/0000-0003-4207-5097; Tanaka, Tomoyuki/0000-0002-9886-5947; Nasmyth, Kim/0000-0001-7030-4403				Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Choo KHA., 1997, CENTROMERE; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hartwell LW, 1982, RECENT ADV YEAST MOL, V1, P28; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HILL A, 1989, MOL CELL BIOL, V9, P1368, DOI 10.1128/MCB.9.3.1368; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; JEHN B, 1991, MOL CELL BIOL, V11, P5212, DOI 10.1128/MCB.11.10.5212; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; SEARS DD, 1995, GENETICS, V139, P1159; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Tanaka TU, 1998, EMBO J, V17, P5182, DOI 10.1093/emboj/17.17.5182; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460	36	249	253	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 17	1999	98	6					847	858		10.1016/S0092-8674(00)81518-4	http://dx.doi.org/10.1016/S0092-8674(00)81518-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	237WH	10499801	Bronze			2022-12-24	WOS:000082679200011
J	Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ				Kelz, MB; Chen, JS; Carlezon, WA; Whisler, K; Gilden, L; Beckmann, AM; Steffen, C; Zhang, YJ; Marotti, L; Self, DW; Tkatch, T; Baranauskas, G; Surmeier, DJ; Neve, RL; Duman, RS; Picciotto, MR; Nestler, EJ			Expression of the transcription factor Delta FosB in the brain controls sensitivity to cocaine	NATURE			English	Article							NUCLEUS-ACCUMBENS NEURONS; DOPAMINE-RECEPTORS; GENE-EXPRESSION; SENSITIZATION; INDUCTION; ADDICTION; PROTEINS; MICE; RAT; PSYCHOMOTOR	Acute exposure to cocaine transiently induces several Fos family transcription factors in the nucleus accumbens(1), a region of the brain that is important for addiction(2,3). In contrast, chronic exposure to cocaine does not induce these proteins, but instead causes the persistent expression of highly stable isoforms of Delta FosB(4-6). Delta FoSB is also induced in the nucleus accumbens by repeated exposure to other drugs of abuse, including amphetamine, morphine, nicotine and phencyclidine(7-10). The sustained accumulation of Delta FosB in the nucleus accumbens indicates that this transcription factor may mediate some of the persistent neural and behavioural plasticity that accompanies chronic drug exposure(1). Using transgenic mice in which Delta FosB can be induced in adults in the subset of nucleus accumbens neurons in which cocaine induces the protein,we show that Delta FosB expression increases the responsiveness of an animal to the rewarding and locomotor-activating effects of cocaine. These effects of Delta FosB appear to be mediated partly by induction of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole) glutamate receptor subunit GluR2 in the nucleus accumbens. These results support a model in which Delta FosB, by altering gene expression, enhances sensitivity to cocaine and may thereby contribute to cocaine addiction.	Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA; Yale Univ, Sch Med, Yale Ctr Genes & Behav, New Haven, CT 06508 USA; Connecticut Mental Hlth Ctr, New Haven, CT 06508 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Psychiat, Belmont, MA 02178 USA; Harvard Univ, McLean Hosp, Sch Med, Dept Genet, Belmont, MA 02178 USA; Northwestern Univ, Inst Neurosci, Chicago, IL 60611 USA	Yale University; Yale University; Harvard University; McLean Hospital; Harvard University; McLean Hospital; Northwestern University	Nestler, EJ (corresponding author), Yale Univ, Sch Med, Lab Mol Psychiat, New Haven, CT 06508 USA.		Picciotto, Marina R./F-8747-2012; Kelz, Max/E-4054-2010	Picciotto, Marina R./0000-0002-4404-1280; Kelz, Max/0000-0002-2803-6078; /0000-0002-4162-3947; Tkatch, Tatiana/0000-0001-6626-7435				Atkins JB, 1999, SYNAPSE, V33, P118, DOI 10.1002/(SICI)1098-2396(199908)33:2<118::AID-SYN2>3.0.CO;2-L; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Brene S., 1997, Society for Neuroscience Abstracts, V23, P923; Carlezon WA, 1998, SCIENCE, V282, P2272, DOI 10.1126/science.282.5397.2272; Carlezon WA, 1997, SCIENCE, V277, P812, DOI 10.1126/science.277.5327.812; Chen JS, 1998, MOL PHARMACOL, V54, P495, DOI 10.1124/mol.54.3.495; Chen JS, 1997, J NEUROSCI, V17, P4933; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GERFEN CR, 1991, J NEUROSCI, V11, P1016; Hiroi N, 1998, J NEUROSCI, V18, P6952; Hiroi N, 1997, P NATL ACAD SCI USA, V94, P10397, DOI 10.1073/pnas.94.19.10397; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Kalivas PW, 1998, J PSYCHOPHARMACOL, V12, P49, DOI 10.1177/026988119801200107; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Moratalla R, 1996, NEUROREPORT, V8, P1, DOI 10.1097/00001756-199612200-00001; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nye HE, 1995, J PHARMACOL EXP THER, V275, P1671; Nye HE, 1996, MOL PHARMACOL, V49, P636; PENNARTZ CMA, 1994, PROG NEUROBIOL, V42, P719, DOI 10.1016/0301-0082(94)90025-6; Peoples LL, 1998, NEUROSCIENCE, V86, P13, DOI 10.1016/S0306-4522(98)00116-X; Pich EM, 1997, SCIENCE, V275, P83; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Rocha BA, 1998, NATURE, V393, P175, DOI 10.1038/30259; Seeburg PH, 1998, BRAIN RES REV, V26, P217, DOI 10.1016/S0165-0173(97)00062-3; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; White F J, 1998, Adv Pharmacol, V42, P1006; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7	30	490	508	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					272	276		10.1038/45790	http://dx.doi.org/10.1038/45790			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499584				2022-12-24	WOS:000082678400052
J	Yoshizawa, S; Fourmy, D; Puglisi, JD				Yoshizawa, S; Fourmy, D; Puglisi, JD			Recognition of the codon-anticodon helix by ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DEACYLATED TRANSFER-RNA; A-SITE; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; CATALYTIC CORE; MESSENGER-RNA; BINDING-SITES; TRANSLATION; COMPLEX	Translational fidelity is established by ribosomal recognition of the codon-anticodon interaction within the aminoacyl-transfer RNA (tRNA) site (A site) of the ribosome. Experiments are presented that reveal possible contacts between 16S ribosomal RNA and the codon-anticodon complex. Nf methylation of adenine at position 1492 (A1492) and A1493 interfered with A-site tRNA binding. Mutation of A1492 and A1493 to guanine or cytosine also impaired A-site tRNA binding. The deleterious effects of A1492G or A1493G (or both) mutations were compensated by 2' fluorine substitutions in the mRNA codon. The results suggest that the ribosome recognizes the codon-anticodon complex by adenine contacts to the messenger RNA backbone and provide a mechanism for molecular discrimination of correct versus incorrect codon-anticodon pairs.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	puglisi@stanford.edu	Yoshizawa, Satoko/T-8302-2018; fourmy, dominique/J-4766-2014	Yoshizawa, Satoko/0000-0002-9333-8961; fourmy, dominique/0000-0002-2170-3536	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AURUP H, 1994, NUCLEIC ACIDS RES, V22, P4963, DOI 10.1093/nar/22.23.4963; Blanchard SC, 1998, BIOCHEMISTRY-US, V37, P7716, DOI 10.1021/bi973125y; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7600, DOI 10.1021/bi00485a009; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; DAVIES J, 1964, P NATL ACAD SCI USA, V51, P883, DOI 10.1073/pnas.51.5.883; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN HJ, 1978, P NATL ACAD SCI USA, V75, P610, DOI 10.1073/pnas.75.2.610; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; KARIMI R, 1994, EUR J BIOCHEM, V226, P355, DOI 10.1111/j.1432-1033.1994.tb20059.x; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUTLAND CG, 1992, ANNU REV GENET, V26, P29; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; LILL R, 1984, BIOCHEMISTRY-US, V23, P6710, DOI 10.1021/bi00321a066; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; MCCARTHY BJ, 1965, P NATL ACAD SCI USA, V54, P880, DOI 10.1073/pnas.54.3.880; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Narlikar GJ, 1998, BIOCHEMISTRY-US, V37, P9902, DOI 10.1021/bi980495t; Pape T, 1998, EMBO J, V17, P7490, DOI 10.1093/emboj/17.24.7490; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; POTAPOV AP, 1995, J BIOL CHEM, V270, P17680, DOI 10.1074/jbc.270.30.17680; POWERS T, 1994, TRENDS GENET, V10, P27, DOI 10.1016/0168-9525(94)90016-7; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; Recht MI, 1999, J MOL BIOL, V286, P33, DOI 10.1006/jmbi.1998.2446; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; Rodnina MV, 1996, J BIOL CHEM, V271, P646, DOI 10.1074/jbc.271.2.646; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; Szewczak AA, 1998, NAT STRUCT BIOL, V5, P1037, DOI 10.1038/4146; TAKAHASHI LH, 1989, J AM CHEM SOC, V111, P3368, DOI 10.1021/ja00191a039; VanLoock MS, 1999, J MOL BIOL, V285, P2069, DOI 10.1006/jmbi.1998.2442; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATANABE S, 1972, J MOL BIOL, V67, P443, DOI 10.1016/0022-2836(72)90462-7; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437; YOSHIZAWA S, UNPUB	39	196	206	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1722	1725		10.1126/science.285.5434.1722	http://dx.doi.org/10.1126/science.285.5434.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481006				2022-12-24	WOS:000082472600032
J	Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J				Matser, EJT; Kessels, AG; Lezak, MD; Jordan, BD; Troost, J			Neuropsychological impairment in amateur soccer players	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BRAIN INJURY	Context Soccer players incur concussions during matches and training sessions, as well as numerous subconcussive blows to the head from impacts with the soccer ball (headers). The combination of soccer-related concussions and the number of headers may be a risk for chronic traumatic brain injury (CTBI). Objective To determine whether amateur soccer players have evidence of CTBI. Design, Setting, and Participants Cross-sectional study of 33 amateur soccer players and 27 amateur athletes involved in swimming and track (controls) in the Netherlands who underwent interviews and neuropsychological testing. Main Outcome Measures Performance of soccer players vs controls on 16 neuropsychological tests having 27 outcomes. Results Compared with control athletes, amateur soccer players exhibited impaired performance on tests of planning (39% vs 13%; P = .001) and memory (27% vs 7%; P = .004). Among soccer players, 9 (27%) had incurred 1 soccer-related concussion and 7 (23%) had had 2 to 5 concussions during their career. The number of concussions incurred in soccer was inversely related to the neuropsychological performance on 6 of the neuropsychological tests. Conclusions Our results indicate that participation in amateur soccer in general and concussion specifically is associated with impaired performance in memory and planning functions. Due to the worldwide popularity of soccer, these observations may have important public health implications.	St Anna Hosp, Det Neuropsychol & Sports Neurol, NL-5560 AB Geldrop, Netherlands; Erasmus Univ, Fac Med & Hlth Sci, Dept Anat, NL-3000 DR Rotterdam, Netherlands; Univ Hosp Maastricht, Res Unit Patient Care, Maastricht, Netherlands; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Burke Rehabil Hosp, Traumat Brain Injury Program, White Plains, NY USA	Erasmus University Rotterdam; Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Oregon Health & Science University	Matser, EJT (corresponding author), St Anna Hosp, Det Neuropsychol & Sports Neurol, POB 90, NL-5560 AB Geldrop, Netherlands.							[Anonymous], 1981, WAIS R MANUAL; Army Individual Test Battery, 1944, ARM COMB FITN TEST; Benton A.L., 1994, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; CORSELLIS JA, 1976, LANCET, V1, P401; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Deelman B.G., 1980, NEUROPSYCHOLOGIE NED; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Luteyn, 1966, DUTCH J PSYCHOL, V2, P675; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATSER JT, 1996, GENEESKUNDE SPORT, V29, P66; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Osterrieth P., 1944, ARCH PSYCHOL-GENEVE, V30, P206; Raven J.C., 1960, GUIDE STANDARD PROGR; ROBBERTS AH, 1969, BRAIN DAMAGE BOXERS; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van De Loo L., 1956, TIJIKSCHRIFT PSYCHOL, V2, P33; VANDERVLUGT H, 1979, LATERALISATIES HERSE; Wechsler D, 1974, WECHSLER MEMORY SCAL; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	28	272	275	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					971	973		10.1001/jama.282.10.971	http://dx.doi.org/10.1001/jama.282.10.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485683	Bronze			2022-12-24	WOS:000082335900036
J	Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB				Ozes, ON; Mayo, LD; Gustin, JA; Pfeffer, SR; Pfeffer, LM; Donner, DB			NF-kappa B activation by tumour necrosis factor requires the Akt serine-threonine kinase	NATURE			English	Article							SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; IKK-ALPHA; TNF; COMPLEX; PHOSPHORYLATION; 3-KINASE; BETA	Activation of the nuclear transcription factor NF-kappa B by inflammatory cytokines requires the successive action of NF-kappa B-inducing kinase (NIK) and an I kappa B-kinase (IKK) complex composed of IKK alpha and IKK beta(1-5). Here we show that the Akt serine-threonine kinase(6) is involved in the activation of NF-kappa B by tumour necrosis factor (TNF). TNF activates phosphatidylinositol-3-OH kinase (PI(3)K) and its downstream target Akt (protein kinase B). Wortmannin (a PI(3)K inhibitor), dominant-negative PI(3)K or kinase-dead Akt inhibits TNF-mediated NF-kappa B activation. Constitutively active Akt induces NF-kappa B activity and this effect is blocked by dominant-negative NIK. Conversely, NIK activates NF-KB and this is blocked by kinase-dead Akt. Thus, both Akt and NIK are necessary for TNF activation of NF-kappa B. Akt mediates IKKa phosphorylation at threonine 23. Mutation of this amino acid blocks phosphorylation by Akt or TNF and activation of NF-kappa B. These findings indicate that Akt is part of a signalling pathway that is necessary for inducing key immune and inflammatory responses.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Oncol Ctr, Indianapolis, IN 46202 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pathol, Memphis, TN 38163 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center	Donner, DB (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA.			Pfeffer, Lawrence/0000-0003-2809-1234				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Bauerle PA, 1996, CELL, V87, P13; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	20	1829	1884	1	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					82	85						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485710				2022-12-24	WOS:000082374400046
J	Bahcall, DO; Kowler, E				Bahcall, DO; Kowler, E			Illusory shifts in visual direction accompany adaptation of saccadic eye movements	NATURE			English	Article							DISPLACEMENT; TARGETS; REPRESENTATION; LOCALIZATION; PERCEPTION	A central problem in human vision is to explain how the visual world remains stable despite the continual displacements of the retinal image produced by rapid saccadic movements of the eyes. Perceived stability has been attributed to 'efferent-copy' signals, representing the saccadic motor commands, that cancel the effects of saccade-related retinal displacements(1-6). Here we show by means of a perceptual illusion, that traditional cancellation theories cannot explain stability. The perceptual illusion was produced by first inducing adaptive changes in saccadic gain (ratio of saccade size to target eccentricity). Following adaptation, subjects experienced an illusory mislocalization in which widely separated targets flashed before and after saccades appeared to be in the same place. The illusion shows that the perceptual system did not take the adaptive changes into account, Perceptual localization is based on signals representing the size of the initially-intended saccade, not the size of the saccade that is ultimately executed, Signals representing intended saccades initiate a visual comparison process used to maintain perceptual stability across saccades and to generate the oculomotor error signals that ensure saccadic accuracy.	Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Kowler, E (corresponding author), Rutgers State Univ, Dept Psychol, Piscataway, NJ 08854 USA.	kowler@rci.rutgers.edu						ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; CARPENTER RHS, 1992, MOVEMENTS EYES; CORNSWEET TN, 1962, AM J PSYCHOL, V75, P485, DOI 10.2307/1419876; CRANE HD, 1978, APPL OPTICS, V17, P691, DOI 10.1364/AO.17.000691; DASSONVILLE P, 1992, VISUAL NEUROSCI, V9, P261, DOI 10.1017/S0952523800010671; Desmurget M, 1998, NAT NEUROSCI, V1, P524, DOI 10.1038/2241; Deubel H, 1996, VISION RES, V36, P985, DOI 10.1016/0042-6989(95)00203-0; DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157; Frens MA, 1997, BRAIN RES BULL, V43, P473, DOI 10.1016/S0361-9230(97)80001-9; GOLDBERG ME, 1993, INT CONGR SER, V1024, P203; GOODALE MA, 1986, NATURE, V320, P748, DOI 10.1038/320748a0; KOWLER E, 1995, VISION RES, V35, P1741, DOI 10.1016/0042-6989(94)00255-K; LEIGH RJ, 1991, NEUROBIOLOGY EYE MOV, P82; LENNIE P, 1978, NATURE, V275, P766, DOI 10.1038/275766a0; LUDVIGH E, 1952, AMA ARCH OPHTHALMOL, V48, P442; MACKAY DM, 1973, HDB SENSORY PHYSIOLO, V7, P307; MATIN L, 1965, SCIENCE, V148, P1485, DOI 10.1126/science.148.3676.1485; MATIN L, 1972, HDB SENSORY PHYSIOLO, V7, P331; McGowan JW, 1998, VISION RES, V38, P895, DOI 10.1016/S0042-6989(97)00232-0; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; MILLER JM, 1981, J EXP PSYCHOL HUMAN, V7, P356, DOI 10.1037/0096-1523.7.2.356; OPTICAN LM, 1985, ADAPTIVE MECH GAZE C, P71; POLA J, 1976, EYE MOVEMENTS PSYCHO, P245; Skavenski A. A., 1990, EYE MOVEMENTS THEIR, P263; SKAVENSKI AA, 1972, PERCEPT PSYCHOPHYS, V11, P287, DOI 10.3758/BF03210380; Sperling G., 1990, EYE MOVEMENTS THEIR, P307; VONHELMHOLTZ H, 1963, TREATISE PHYSL OPTIC, V3; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	30	81	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					864	866		10.1038/23693	http://dx.doi.org/10.1038/23693			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476963				2022-12-24	WOS:000082233200043
J	Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP				Coral-Vazquez, R; Cohn, RD; Moore, SA; Hill, JA; Weiss, RM; Davisson, RL; Straub, V; Barresi, R; Bansal, D; Hrstka, RF; Williamson, R; Campbell, KP			Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy	CELL			English	Article							GLYCOPROTEIN COMPLEX; DILATED CARDIOMYOPATHY; GAMMA-SARCOGLYCAN; DEFICIENT MICE; HEART-FAILURE; MUTATIONS; GENE; NICORANDIL; LGMD2F; ACTIN	To investigate mechanisms in the pathogenesis of cardiomyopathy associated with mutations of the dystrophin-glycoprotein complex, we analyzed genetically engineered mice deficient for either alpha-sarcoglycan (Sgca) or delta-sarcoglycan (Sgcd). We found that only Sgcd null mice developed cardiomyopathy with focal areas of necrosis as the histological hallmark in cardiac and skeletal muscle. Absence of the sarcoglycan-sarcospan (SG-SSPN) complex in skeletal and cardiac membranes was observed in both animal models. Loss of vascular smooth muscle SG-SSPN complex was only detected in Sgcd null mice and associated with irregularities of the coronary vasculature. Administration of a vascular smooth muscle relaxant prevented onset of myocardial necrosis. Our data indicate that disruption of the SG-SSPN complex in vascular smooth muscle perturbs vascular function, which initiates cardiomyopathy and exacerbates muscular dystrophy.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Neurol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pathol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Dept Vet Affairs, Iowa City, IA 52242 USA; Univ Iowa, Dept Anat & Cell Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Iowa	Campbell, KP (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	kevin-campbell@uiowa.edu	Cohn, Ronald/AAC-5835-2021; Barresi, Rita/AAB-9569-2022; Pillay, Nischalan/F-9536-2012	Barresi, Rita/0000-0001-7351-959X; Campbell, Kevin/0000-0003-2066-5889; Coral, Ramon/0000-0001-6126-2002; Moore, Steven/0000-0002-6353-7900; Straub, Volker/0000-0001-9046-3540	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295] Funding Source: Medline; Telethon [305/B] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Badorff C, 1999, NAT MED, V5, P320, DOI 10.1038/6543; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Crosbie RH, 1999, J CELL BIOL, V145, P153, DOI 10.1083/jcb.145.1.153; Crosbie RH, 1997, J BIOL CHEM, V272, P31221, DOI 10.1074/jbc.272.50.31221; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Fewell JG, 1997, AM J PHYSIOL-HEART C, V273, pH1595, DOI 10.1152/ajpheart.1997.273.3.H1595; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; KASKI JC, 1995, CARDIOVASC DRUG THER, V9, P221, DOI 10.1007/BF00878469; KUKOVETZ WR, 1992, J CARDIOVASC PHARM, V20, pS1, DOI 10.1097/00005344-199206203-00002; Lim LE, 1998, CURR OPIN NEUROL, V11, P443, DOI 10.1097/00019052-199810000-00006; Melacini P, 1999, MUSCLE NERVE, V22, P473, DOI 10.1002/(SICI)1097-4598(199904)22:4<473::AID-MUS8>3.0.CO;2-5; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; Moreira ES, 1998, J MED GENET, V35, P951, DOI 10.1136/jmg.35.11.951; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; Sakamoto A, 1999, FEBS LETT, V447, P124, DOI 10.1016/S0014-5793(99)00267-7; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; STRAUB V, 1999, IN PRESS J BIOL CHEM; Towbin JA, 1998, CURR OPIN CELL BIOL, V10, P131, DOI 10.1016/S0955-0674(98)80096-3	25	300	310	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	1999	98	4					465	474		10.1016/S0092-8674(00)81975-3	http://dx.doi.org/10.1016/S0092-8674(00)81975-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481911	Bronze			2022-12-24	WOS:000082174900007
J	Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC				Campbell, JJ; Haraldsen, G; Pan, J; Rottman, J; Qin, S; Ponath, P; Andrew, DP; Warnke, R; Ruffing, N; Kassam, N; Wu, L; Butcher, EC			The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells	NATURE			English	Article							LYMPHOCYTE-ASSOCIATED ANTIGEN; ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; HOMING RECEPTOR; E-SELECTIN; EXPRESSION; PHENOTYPE; SUBSETS; INTERLEUKIN-8; RECRUITMENT	Lymphocytes that are responsible for regional (tissue-specific) immunity home from the blood to the intestines, inflamed skin or other sites through a multistep process involving recognition of vascular endothelial cells and extravasation(1). Chemoattractant cytokine molecules known as chemokines(2) regulate this lymphocyte traffic, in part by triggering arrest (stopping) of lymphocytes rolling on endothelium(3-5). Here we shaw that many systemic memory T cells in blood carry the chemokine receptor CCR4 (ref. 6) and therefore respond to its ligands, the chemokines TARC and MDC. These cells include essentially all skin-homing cells expressing the cutaneous lymphocyte antigen and a subset of other systemic memory lymphocytes; however, intestinal (alpha 4 beta 7(+)) memory and naive T cells respond poorly. Immunohistochemistry reveals anti-TARC reactivity of venules and infiltration of many CCR4(+) lymphocytes in chronically inflamed skin, but not in the gastrointestinal lamina propria. Moreover, TARC induces integrin-dependent adhesion of skin (but not intestinal) memory T cells to the cell-adhesion molecule ICAM-1, and causes their rapid arrest under physiological now. Our results suggest that CCR4 and TARC are important in the recognition of skin vasculature by circulating T cells and in directing lymphocytes that are involved in systemic as opposed to intestinal immunity to their target tissues.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; LeukoSite Inc, Cambridge, MA 02142 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Haraldsen, Guttorm/W-4359-2019; Haraldsen, Guttorm/I-2680-2013	Campbell, James/0000-0003-4252-5182; Haraldsen, Guttorm/0000-0002-0064-9665				Anderson A O, 1993, Semin Immunol, V5, P271, DOI 10.1006/smim.1993.1031; Andrew DP, 1998, J IMMUNOL, V161, P5027; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Baekkevold ES, 1999, LAB INVEST, V79, P327; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Mackay CR, 1996, EUR J IMMUNOL, V26, P2433, DOI 10.1002/eji.1830261025; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Qin SX, 1996, EUR J IMMUNOL, V26, P640, DOI 10.1002/eji.1830260320; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SILBER A, 1994, J CLIN INVEST, V93, P1554, DOI 10.1172/JCI117134; Teraki Y, 1997, J IMMUNOL, V159, P6018; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Williams MB, 1997, J IMMUNOL, V159, P1746; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	30	674	698	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					776	780		10.1038/23495	http://dx.doi.org/10.1038/23495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466728				2022-12-24	WOS:000082131100053
J	Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL				Humphries, DE; Wong, GW; Friend, DS; Gurish, MF; Qiu, WT; Huang, CF; Sharpe, AH; Stevens, RL			Heparin is essential for the storage of specific granule proteases in mast cells	NATURE			English	Article							DIPEPTIDYL PEPTIDASE-I; MOLECULAR-CLONING; SERINE PROTEASES; MESSENGER-RNA; MOUSE; GENE; TRANSCRIPTION; EXPRESSION; SUBCLASS; SULFOTRANSFERASE	All mammals produce heparin, a negatively charged glycosaminoglycan that is a major constituent of the secretory granules of mast cells which are found in the peritoneal cavity and most connective tissues. Although heparin is one of the most studied molecules in the body, its physiological function has yet to be determined. Here we describe transgenic mice, generated by disrupting the N-deacetylase/N-sulphotransferase-2 gene(1,2), that cannot express fully sulphated heparin, The mast cells in the skeletal muscle that normally contain heparin lacked metachromatic granules and failed to store appreciable amounts of mouse mast-cell protease (mMCP)-4, mMCP-5 and carboxypeptidase A (mMC-CPA), even though they contained substantial amounts of mMCP-7, We developed mast cells from the bone marrow of the transgenic mice. Although these cultured cells contained high levels of various protease transcripts and had substantial amounts of mMCP-6 protein in their granules, they also failed to express mMCP-5 and mMC-CPA, Our data show that heparin controls, through a post-translational mechanism, the levels of specific cassettes of positively charged proteases inside mast cells.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02130 USA; VA Med Ctr, Boston, MA 02130 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Boston University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Stevens, RL (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.			Wong, G. William/0000-0002-5286-6506				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; ERIKSSON I, 1994, J BIOL CHEM, V269, P10439; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Gurish MF, 1997, BLOOD, V90, P382; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P16744; Huang CF, 1998, J IMMUNOL, V160, P1910; Humphries DE, 1997, BIOCHEM J, V325, P351, DOI 10.1042/bj3250351; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; LEVISCHAFFER F, 1986, P NATL ACAD SCI USA, V83, P6485, DOI 10.1073/pnas.83.17.6485; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, BIOSYNTHESIS HEPARIN, P159; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P1022, DOI 10.1002/(SICI)1521-4141(199803)28:03<1022::AID-IMMU1022>3.0.CO;2-1; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; RAZIN E, 1982, J BIOL CHEM, V257, P7229; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; SAITO H, 1968, J BIOL CHEM, V243, P1536; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; STEVENS RL, 1982, J BIOL CHEM, V257, P253; STEVENS RL, 1986, J IMMUNOL, V137, P291; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054	30	341	348	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 19	1999	400	6746					769	772		10.1038/23481	http://dx.doi.org/10.1038/23481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HM	10466726				2022-12-24	WOS:000082131100051
J	Evans, D				Evans, D			Ethical viewpoint	BRITISH MEDICAL JOURNAL			English	Article									Univ Otago, Dunedin Sch Med, Ctr Bioeth, Dunedin, New Zealand	University of Otago	Evans, D (corresponding author), Univ Otago, Dunedin Sch Med, Ctr Bioeth, POB 913, Dunedin, New Zealand.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					374	375						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10490324				2022-12-24	WOS:000082001700030
J	Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA				Stratakis, CA; Sarlis, N; Kirschner, LS; Carney, JA; Doppman, JL; Nieman, LK; Chrousos, GP; Papanicolaou, DA			Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease	ANNALS OF INTERNAL MEDICINE			English	Article						dexamethasone; adrenocortical disorder, primary, pigmented; adrenocortical disorder, macronodular; Carney complex; Cushing syndrome	GASTRIC-INHIBITORY POLYPEPTIDE; FAMILIAL CUSHINGS-SYNDROME; CARNEY COMPLEX; ADRENAL-CELLS; FREE CORTISOL; RARE CAUSE; DYSPLASIA; MYXOMAS; SUBTYPE; CT	Background: Primary pigmented nodular adrenocortical disease causes the Cushing syndrome in children and young adults and is most frequently associated with the Carney complex. Objective: To evaluate diagnostic tests for primary pigmented nodular adrenocortical disease. Design: Retrospective cohort study. Setting: Tertiary care center. Patients: 21 patients with primary pigmented nodular adrenocortical disease. The control groups consisted of 9 patients with macronodular adrenocortical disease and 15 patients with primary unilateral adrenocortical disease (single adenomas). Measurements: Clinical characteristics, radiologic imaging, and a 6-day Liddle test with determination of urinary free cortisol and 17-hydroxycorticosteroid excretion. Results: Adrenal imaging and other tests were of limited value for the diagnosis of primary pigmented nodular adrenocortical disease. The Liddle test, however, distinguished patients with this disorder from those with other primary adrenocortical lesions. An increase of 50% or more in urinary free cortisol levels on day 6 of the Liddle test identified 9 of 13 patients (69.2% [95% Cl, 46.6% to 91.8%]) with primary pigmented nodular adrenocortical disease, excluded all patients with macronodular adrenocortical disease, and was present in only 3 of the 15 patients with single adrenocortical adenomas (20% [Cl, 0% to 40.2%]). An increase in urinary free cortisol excretion of 100% or more on day 6 of the Liddle test identified only patients with primary pigmented nodular adrenocortical disease. Conclusions: Patients with primary pigmented nodular adrenocortical disease responded to dexamethasone with a paradoxical increase in glucocorticoid excretion during the Liddle test. This feature distinguishes such patients from those who have the Cushing syndrome caused by other primary adrenal disorders and may lead to timely detection of the Carney complex (a potentially fatal disorder) in asymptomatic patients.	NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	National Institutes of Health (NIH) - USA; Mayo Clinic	Stratakis, CA (corresponding author), NIH, Bldg 10,Room 10N262,10 Ctr Dr,MSC 1862, Bethesda, MD 20892 USA.	stratakc@cc1.nichd.nih.gov	Stratakis, Constantine/AAP-4745-2020; Sarlis, Nicholas/AAN-9444-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000638] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000638, ZIAHD000642, Z01HD000642, Z01HD000615] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARCHAMBEAUDMOUV.F, 1996, 10 INT C END SAN FRA, P899; Basson CT, 1997, AM J CARDIOL, V79, P994, DOI 10.1016/S0002-9149(97)00033-7; BOHM N, 1983, ACTA ENDOCRINOL-COP, V102, P428, DOI 10.1530/acta.0.1020428; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BROOKS RV, 1966, J ENDOCRINOL, V36, P53, DOI 10.1677/joe.0.0360053; Carney JA., 1992, ENDOCRINOLOGIST, V2, P6, DOI DOI 10.1097/00019616-199201000-00003; Casey M, 1998, CIRCULATION, V98, P2560, DOI 10.1161/01.CIR.98.23.2560; CATICHA O, 1993, J CLIN ENDOCR METAB, V77, P494, DOI 10.1210/jc.77.2.494; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; DEMOOR P, 1965, J CLIN ENDOCR METAB, V25, P612, DOI 10.1210/jcem-25-5-612; DOPPMAN JL, 1989, RADIOLOGY, V172, P415, DOI 10.1148/radiology.172.2.2748822; Doppman JL, 1997, ENDOCRIN METAB CLIN, V26, P973, DOI 10.1016/S0889-8529(05)70290-5; DOPPMAN JL, 1991, J COMPUT ASSIST TOMO, V15, P773, DOI 10.1097/00004728-199109000-00009; ELIAS LL, 1999, ENDOCINE SOC, P582; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; GarciaMayor RV, 1997, J CLIN ENDOCR METAB, V82, P3517; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; KIRSCHNER MA, 1964, J CLIN ENDOCR METAB, V24, P947, DOI 10.1210/jcem-24-10-947; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V70, P192, DOI 10.1210/jcem-70-1-192; LARSEN JL, 1986, AM J MED, V80, P976, DOI 10.1016/0002-9343(86)90648-0; LEVIN ME, 1966, AM J MED, V40, P318, DOI 10.1016/0002-9343(66)90112-4; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; LIEBERMAN SA, 1994, EUR J ENDOCRINOL, V131, P67, DOI 10.1530/eje.0.1310067; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; OELKERS W, 1986, ACTA ENDOCRINOL-COP, V113, P370, DOI 10.1530/acta.0.1130370; Papanicolaou DA, 1998, J CLIN ENDOCR METAB, V83, P1163, DOI 10.1210/jc.83.4.1163; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; RUDER HJ, 1974, J CLIN ENDOCR METAB, V39, P1138, DOI 10.1210/jcem-39-6-1138; Sarlis NJ, 1997, J CLIN ENDOCR METAB, V82, P1274, DOI 10.1210/jc.82.4.1274; SHENOY BV, 1984, AM J SURG PATHOL, V8, P335, DOI 10.1097/00000478-198405000-00002; SILVERMAN SR, 1963, J CLIN ENDOCR METAB, V23, P167, DOI 10.1210/jcem-23-2-167; Stratakis CA, 1996, J CLIN INVEST, V97, P699, DOI 10.1172/JCI118467; Stratakis CA, 1999, J CLIN ENDOCR METAB, V84, P1122, DOI 10.1210/jc.84.3.1122; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Stratakis CA, 1996, J CLIN ENDOCR METAB, V81, P3607, DOI 10.1210/jc.81.10.3607; WULFFRAAT NM, 1988, J CLIN ENDOCR METAB, V66, P301, DOI 10.1210/jcem-66-2-301; YOTSUMOTO S, 1979, J CLIN ENDOCR METAB, V48, P660, DOI 10.1210/jcem-48-4-660; YOUNG WF, 1989, NEW ENGL J MED, V321, P1659, DOI 10.1056/NEJM198912143212407; ZEIGER MA, 1991, SURGERY, V110, P1106	41	155	166	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					585	+		10.7326/0003-4819-131-8-199910190-00006	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523219				2022-12-24	WOS:000083196600005
J	Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B				Helweg-Larsen, J; Benfield, TL; Eugen-Olsen, J; Lundgren, JD; Lundgren, B			Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P carinii pneumonia	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SULFONAMIDE RESISTANCE; PROGNOSTIC FACTORS; ESCHERICHIA-COLI; INFECTION; CORTICOSTEROIDS; PROPHYLAXIS; THERAPY; PCR	Background Sulpha drugs are widely used for the treatment and long-term prophylaxis of Pneumocystis carinii pneumonia (PCP) in HIV-1-infected individuals. Sulpha resistance in many microorganisms Is caused by point mutations in dihydropteroate synthase (DHPS), an enzyme that Is essential for folate biosynthesis. We assessed whether mutations in the DHPS gene of P carinii were associated with exposure to sulpha drugs and influenced outcome from PCP. Methods We studied bronchoalveolar samples collected in 1989-99 from prospective cohort of HIV-1-infected patients who had PCP. In 144 patients with 152 episodes of PCP, we analysed portions of DHPS using PCR and direct sequencing. The relation between survival, P carinii DHPS mutations, and other predictors of treatment failure was assessed by Kaplan-Meier and multivariate Cox regression analysis. Findings P carinii DHPS mutations were found in 31 (20.4%) of 152 PCP episodes. 3-month survival was significantly lower in patients infected with mutant P carinii DHPS strains than in those with wild-type strains (p=0.002). After adjustment for other prognostic variables, presence of DHPS mutations remained the most important predictor of mortality (hazard ratio 3.1 [95% CI 1.2-8.1]). DHPS mutations were significantly more common in patients who had previous exposure to sulpha drugs (18 of 29 [62%]) than in those who had no exposure (13 of 123 [10.5%]; p<0.0001). A significant increase with time in the rate of DHPS mutations (p=0.01 for trend) was closely correlated with the rate of previous or current use of sulpha drugs as chemoprophylaxis. Interpretation Mutations in DHPS are associated with impaired prognosis in PCP, and may develop as a result of exposure to sulpha drugs.	Univ Copenhagen, Hvidovre Hosp, Dept Infect Dis, Copenhagen, Denmark; Univ Copenhagen, Hvidovre Hosp, Climat Res Unit, Copenhagen, Denmark; State Serum Inst, Dept Mycobacteriol, Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; Statens Serum Institut	Helweg-Larsen, J (corresponding author), Hvidovre Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark.		Lundgren, Jens/AAE-6876-2019	Lundgren, Jens/0000-0001-8901-7850; Benfield, Thomas/0000-0003-0698-9385; Helweg-Larsen, Jannik/0000-0001-7192-0144; Eugen-Olsen, Jesper/0000-0002-4630-4275				Balslev U, 1997, SCAND J INFECT DIS, V29, P337, DOI 10.3109/00365549709011827; BENFIELD TL, 1995, AM J RESP CRIT CARE, V151, P1058; BOZZETTE SA, 1990, J INFECT DIS, V162, P1365, DOI 10.1093/infdis/162.6.1365; BRENNER M, 1987, AM REV RESPIR DIS, V136, P1199, DOI 10.1164/ajrccm/136.5.1199; DALLAS WS, 1992, J BACTERIOL, V174, P5961, DOI 10.1128/jb.174.18.5961-5970.1992; FERNANDEZ P, 1995, THORAX, V50, P668, DOI 10.1136/thx.50.6.668; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P1309, DOI 10.1128/AAC.42.6.1309; Fishman JA, 1998, ANTIMICROB AGENTS CH, V42, P995, DOI 10.1128/AAC.42.5.995; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Helweg-Larsen J, 1998, J CLIN MICROBIOL, V36, P2068, DOI 10.1128/JCM.36.7.2068-2072.1998; Helweg-Larsen J, 1998, QJM-INT J MED, V91, P813, DOI 10.1093/qjmed/91.12.813; HelwegLarsen J, 1997, LANCET, V350, P1363, DOI 10.1016/S0140-6736(97)24045-6; Kazanjian P, 1998, AIDS, V12, P873, DOI 10.1097/00002030-199808000-00009; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Kumar SD, 1998, CHEST, V113, P430, DOI 10.1378/chest.113.2.430; Lane BR, 1997, J INFECT DIS, V175, P482, DOI 10.1093/infdis/175.2.482; LUNDGREN JD, 1996, CLIN PULM MED, V3, P304; MASON GR, 1989, AM REV RESPIR DIS, V139, P1336, DOI 10.1164/ajrccm/139.6.1336; Mei Q, 1998, LANCET, V351, P1631, DOI 10.1016/S0140-6736(05)77687-X; MONTANER JSG, 1990, ANN INTERN MED, V113, P14, DOI 10.7326/0003-4819-113-1-14; NIELSEN TL, 1992, J ACQ IMMUN DEF SYND, V5, P726; Stringer JR, 1996, AIDS, V10, P561, DOI 10.1097/00002030-199606000-00001; Swedberg G, 1998, ANTIMICROB AGENTS CH, V42, P1062, DOI 10.1128/AAC.42.5.1062; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; Vedantam G, 1998, ANTIMICROB AGENTS CH, V42, P88, DOI 10.1128/AAC.42.1.88; VOLPE F, 1993, EUR J BIOCHEM, V216, P449, DOI 10.1111/j.1432-1033.1993.tb18163.x; Wakefield AE, 1998, FEMS IMMUNOL MED MIC, V22, P59, DOI 10.1111/j.1574-695X.1998.tb01187.x; WALZER PD, 1992, ANTIMICROB AGENTS CH, V36, P1935, DOI 10.1128/AAC.36.9.1935; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0	29	198	202	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 16	1999	354	9187					1347	1351		10.1016/S0140-6736(99)03320-6	http://dx.doi.org/10.1016/S0140-6736(99)03320-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246DV	10533864				2022-12-24	WOS:000083149900013
J	Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A				Sallusto, F; Lenig, D; Forster, R; Lipp, M; Lanzavecchia, A			Two subsets of memory T lymphocytes with distinct homing potentials and effector functions	NATURE			English	Article							IMMUNOLOGICAL MEMORY; T-HELPER-2 CELLS; B-CELL; EXPRESSION; IMMUNITY; NAIVE; CHEMOKINES; ADHESION	Naive T lymphocytes travel to T-cell areas of secondary lymphoid organs in search of antigen presented by dendritic cells(1,2). Once activated, they proliferate vigorously, generating effector cells that can migrate to B-cell areas or to inflamed tissues(3-6). A fraction of primed T lymphocytes persists as circulating memory cells that can confer protection and give, upon secondary challenge, a qualitatively different and quantitatively enhanced response(7-9) The nature of the cells that mediate the different facets of immunological memory remains unresolved. Here we show that expression of CCR7, a chemokine receptor that controls homing to secondary lymphoid organs, divides human memory T cells into two functionally distinct subsets, CCR7(-) memory cells express receptors for migration to inflamed tissues and display immediate effector function. In contrast, CCR7(+) memory cells express lymph-node homing receptors and lack immediate effector function, but efficiently stimulate dendritic cells and differentiate into CCR7(-) effector cells upon secondary stimulation. The CCR7(+) and CCR7(-) T cells, which we have named central memory (T-CM) and effector memory (T-EM), differentiate in a step-wise fashion from naive T cells, persist for years after immunization and allow a division of labour in the memory response.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sallusto, F (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Förster, Reinhold/D-6770-2011; Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672; Forster, Reinhold/0000-0001-6190-7923				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Garside P, 1998, SCIENCE, V281, P96, DOI 10.1126/science.281.5373.96; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; MacLennan ICM, 1997, IMMUNOL REV, V156, P53, DOI 10.1111/j.1600-065X.1997.tb00958.x; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sprent J, 1997, IMMUNOL REV, V156, P79, DOI 10.1111/j.1600-065X.1997.tb00960.x; Tanchot C, 1998, IMMUNOL TODAY, V19, P575, DOI 10.1016/S0167-5699(98)01344-9; Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	29	4446	4577	6	230	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					708	712		10.1038/44385	http://dx.doi.org/10.1038/44385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537110				2022-12-24	WOS:000083207400059
J	Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C				Rodstrom, K; Bengtsson, C; Lissner, L; Bjorkelund, C			Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; LIPOPROTEINS; MENOPAUSE; MORTALITY; HEALTH	Objective To assess whether risk factor profiles for cardiovascular disease differed, before starting treatment, between women who would subsequently use hormone replacement therapy and those who would remain untreated. Design Prospective population study, initiated in 1968-9, with follow ups in 1974, 1980, and 1992. Setting Gothenburg, Sweden. Participants 1201 women born in 1918, 1922, and 1930, representative of women of the same age in the general population. Main outcome measures Hormone replacement therapy as a function of initial systolic and diastolic blood pressure, waist and hip circumference, waist to hip ratio, body mass index, serum concentrations of cholesterol and triglycerides, smoking status, education, leisure time activity, and socioeconomic group. Results 179 of the 1201 women (14.9%) used hormone replacement therapy sometime during the 24 year follow up period. Multivariate models indicated that these women had significantly lower blood pressure, had less obesity, and belonged to a higher social group before the start of treatment than women who would remain untreated. Conclusion Women who would subsequently use hormone replacement therapy were already at lower cardiovascular risk before the start of treatment than women who would remain untreated. Some of the claimed beneficial effects of treatment may thus be explained by women who would use hormone replacement therapy representing a healthier cohort than women who would remain untreated.	Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden; Univ Gothenburg, Sahlgrens Univ Hosp, Dept Internal Med, SE-41345 Gothenburg, Sweden	University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg	Rodstrom, K (corresponding author), Univ Gothenburg, Vasa Hosp, Dept Primary Hlth, SE-41133 Gothenburg, Sweden.	Kerstin.Rodstrom@allmed.gu.se						BarrettConnor E, 1996, MATURITAS, V23, P227, DOI 10.1016/0378-5122(95)00975-2; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; Bengtsson C, 1997, SCAND J PRIM HEALTH, V15, P214, DOI 10.3109/02813439709035031; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND S, V549; Carlsson G., 1958, SOCIAL MOBILITY CLAS; CHRISTIANSEN C, 1991, AM J MED, V90, P107; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GORDON T, 1978, ANN INTERN MED, V89, P157, DOI 10.7326/0003-4819-89-2-157; HALLING A, 1984, SWED DENT J, V8, P183; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Lissner L, 1996, AM J EPIDEMIOL, V143, P54; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; VANDERMAAREL SM, 1995, EUR J HUM GENET, V3, P207; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816	22	51	52	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 2	1999	319	7214					890	893		10.1136/bmj.319.7214.890	http://dx.doi.org/10.1136/bmj.319.7214.890			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	243AU	10506047	Green Published, Bronze			2022-12-24	WOS:000082975600026
J	Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS				Lee, AYY; Julian, JA; Levine, MN; Weitz, JI; Kearon, C; Wells, PS; Ginsberg, JS			Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							FIBRIN DEGRADATION PRODUCTS; VEIN THROMBOSIS; PULMONARY-EMBOLISM; DIAGNOSIS; THROMBOEMBOLISM; ULTRASONOGRAPHY; OUTPATIENTS; IMMUNOASSAY; HOME	Background: Although D-dimer assays have high negative predictive values for the diagnosis of deep venous thrombosis, their accuracy in patients with cancer is uncertain. Objective: To compare the clinical utility of a whole-blood D-dimer assay for the diagnosis of deep venous thrombosis in patients with and those without cancer. Design: Retrospective analysis of three prospective studies. Setting: Two tertiary care hospitals. Patients: 1068 consecutive outpatients with suspected deep venous thrombosis. Measurements: All patients underwent D-dimer testing and assessment with a priori diagnostic strategies that incorporated impedance plethysmography, compression ultrasonography, or contrast venography. Patients in whom deep venous thrombosis was not diagnosed initially were followed for 3 months for the development of thrombosis. Results of D-dimer testing were assessed according to the final diagnosis based on objective testing and clinical follow-up. Cancer status was identified at presentation. Results: The prevalence of deep venous thrombosis was 48.8% in 121 patients with cancer and 14.6% in 947 pa patients without cancer. Although the sensitivity of the D-dimer assay was similar in patients with and those without cancer (86.4% [95% CI, 75.0% to 94.0%] and 82.6% [CI, 75.2% to 88.5%], respectively), the specificity was significantly lower in patients with cancer (48.4% [CI, 35.5% to 61.4%] and 82.2% [CI, 79.4% to 84.8%]), as was the negative predictive value (78.9% [CI, 62.7% to 90.4%] and 96.5% [CI, 94.9% to 97.8%]). In contrast, the likelihood ratios of a negative test result (0.28 [CI, 0.14 to 0.56] and 0.21 [CI, 0.15 to 0.31]) did not differ significantly. Conclusions: A negative D-dimer test result in patients with cancer does not reliably exclude deep venous thrombosis because the negative predictive value of the test is significantly lower in these patients than in patients without cancer.	McMaster Univ, Hamilton, ON, Canada; Univ Ottawa, Ottawa, ON K1N 6N5, Canada	McMaster University; University of Ottawa	Lee, AYY (corresponding author), Hamilton Civ Hosp, Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	alee@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019; ginsberg, jeffrey s/ABC-1065-2020	Weitz, Jeffrey/0000-0002-1092-7550; 				AMBRUS JL, 1975, J MED, V6, P61; Becker DM, 1996, ARCH INTERN MED, V156, P939, DOI 10.1001/archinte.156.9.939; Birdwell BG, 1998, ANN INTERN MED, V128, P1, DOI 10.7326/0003-4819-128-1-199801010-00001; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BRENNER B, 1995, BLOOD COAGUL FIBRIN, V6, P219, DOI 10.1097/00001721-199505000-00004; CHAPMAN CS, 1990, CLIN LAB HAEMATOL, V12, P37; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; Falanga A, 1999, SEMIN THROMB HEMOST, V25, P173, DOI 10.1055/s-2007-994919; FALANGA A, 1993, THROMB HAEMOSTASIS, V70, P540; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GABAZZA EC, 1991, EUR J CANCER, V30, P1271; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kearon C, 1997, THROMB HAEMOSTASIS, V78, P553; KEEFE DL, 1994, ANGIOLOGY, V45, P771, DOI 10.1177/000331979404500904; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE M, 1990, SEMIN ONCOL, V17, P160; LUZZATTO G, 1990, SEMIN ONCOL, V17, P147; Mayer W, 1997, VASA-J VASCULAR DIS, V26, P97; NANNINGA PB, 1990, THROMB HAEMOSTASIS, V64, P361; Perrier A, 1996, ARCH INTERN MED, V156, P531, DOI 10.1001/archinte.156.5.531; PINI M, 1993, FIBRINOLYSIS, V7, P391, DOI 10.1016/0268-9499(93)90064-3; RAIMONDI P, 1993, THROMB RES, V69, P125, DOI 10.1016/0049-3848(93)90009-D; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCATES SM, 1992, SEMIN THROMB HEMOST, V18, P373, DOI 10.1055/s-2007-1002576; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Turkstra F, 1996, THROMB HAEMOSTASIS, V76, P9; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; WHEELER HB, 1994, ARCH INTERN MED, V154, P1921, DOI 10.1001/archinte.154.17.1921; WILDE JT, 1989, BRIT J HAEMATOL, V71, P65, DOI 10.1111/j.1365-2141.1989.tb06276.x; ZUFFA M, 1982, NEOPLASMA, V29, P241	35	98	103	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	1999	131	6					417	423		10.7326/0003-4819-131-6-199909210-00004	http://dx.doi.org/10.7326/0003-4819-131-6-199909210-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237DY	10498557				2022-12-24	WOS:000082641100003
J	Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH				Chin, J; Lee, SS; Lee, KJ; Park, S; Kim, DH			A metal complex that binds alpha-amino acids with high and predictable stereospecificity	NATURE			English	Article							COBALT(III) COMPLEXES; RECOGNITION; RECEPTORS; LIGANDS; ESTERS; RNA	Molecular recognition is the key step in a wide range of controlled separation and chemical transformation processes, with enzymes performing this task with an unsurpassed degree of selectivity. Enzymes contain only 20 simple amino acids, yet it remains difficult to rationalize or even predict these stereospecific recognition events. Nonetheless, the rational design of receptors able to recognize amino acids stereospecifically is attracting considerable interest because therapeutic drugs, that may be developed from chiral amino acid intermediates, are increasingly required in enantiomerically pure form(1). Early work(2-4) has stimulated the development of efficient receptors based on small molecules(5-8), but binding of amino acids with high and predictable stereospecificity remains difficult to achieve. Directed molecular evolution(9), on the other hand, does select for RNA sequences or antibodies that bind amino acids with high specificity(10-12), but typically without providing insights into the molecular recognition mechanisms involved. Here we show that a rationally designed metal complex formed from a trivalent cobalt ion and a tetradentate ligand binds natural amino acids, including the simple yet challenging amino acid alanine, with high and predictable regio- and stereospecificity. We expect that our approach will allow the binding as well as separation and stereospecific catalytic formation of its target amino acids.	McGill Univ, Dept Chem, Montreal, PQ H3A 2K6, Canada; Pohang Univ Sci & Technol, Ctr Biofunct Mol, Pohang 790784, South Korea	McGill University; Pohang University of Science & Technology (POSTECH)	Chin, J (corresponding author), McGill Univ, Dept Chem, 801 Sherbrooke St W, Montreal, PQ H3A 2K6, Canada.							BUCKINGHAM DA, 1967, J AM CHEM SOC, V89, P5133, DOI 10.1021/ja00996a009; CHIN J, 1991, ACCOUNTS CHEM RES, V24, P145, DOI 10.1021/ar00005a004; Collins A.N., 1997, CHIRALITY IND, VII; COLLINS AN, 1992, CHIRALITY IND, V1; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; DABROWIAK JC, 1975, INORG CHEM, V14, P1305, DOI 10.1021/ic50148a020; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Evans DA, 1997, J AM CHEM SOC, V119, P7893, DOI 10.1021/ja971521y; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FENTON RR, 1995, INORG CHIM ACTA, V236, P109, DOI 10.1016/0020-1693(95)04625-J; FUJII Y, 1981, B CHEM SOC JPN, V54, P2029, DOI 10.1246/bcsj.54.2029; GREENSTEIN JP, 1996, CHEM AMINO ACIDS, V1, P594; Hofstetter O, 1998, J AM CHEM SOC, V120, P3251, DOI 10.1021/ja973680n; JOB RC, 1974, J AM CHEM SOC, V96, P809, DOI 10.1021/ja00810a028; JOYCE GE, 1992, SCI AM, V12, P92; KURODA Y, 1995, J AM CHEM SOC, V117, P10950, DOI 10.1021/ja00149a018; LEHN JM, 1978, J CHEM SOC CHEM COMM, P949, DOI 10.1039/c39780000949; Li GG, 1996, ANGEW CHEM INT EDIT, V35, P451, DOI 10.1002/anie.199604511; SCRIMIN P, 1994, J ORG CHEM, V59, P4194, DOI 10.1021/jo00094a034; Sessler JL, 1998, CHEM-EUR J, V4, P159, DOI 10.1002/(SICI)1521-3765(199801)4:1<159::AID-CHEM159>3.0.CO;2-N; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; Tokunaga M, 1997, SCIENCE, V277, P936, DOI 10.1126/science.277.5328.936; YAMAGUCHI M, 1980, INORG CHEM, V19, P2010, DOI 10.1021/ic50209a035; Zelewsky A.V., 1996, STEREOCHEMISTRY COOR; Zhang XX, 1997, CHEM REV, V97, P3313, DOI 10.1021/cr960144p	25	155	158	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					254	257		10.1038/45751	http://dx.doi.org/10.1038/45751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499581				2022-12-24	WOS:000082678400046
J	Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA				Gilliver, MA; Bennett, M; Begon, M; Hazel, SM; Hart, CA			Enterobacteria - Antibiotic resistance found in wild rodents	NATURE			English	Article							BACTERIA; FITNESS		Univ Liverpool, Ctr Comp Infect Dis, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Gilliver, MA (corresponding author), Univ Liverpool, Ctr Comp Infect Dis, POB 147, Liverpool L69 3BX, Merseyside, England.		; Bennett, Malcolm/G-4004-2010	Begon, Mike/0000-0003-1715-5327; Bennett, Malcolm/0000-0003-0475-390X				Bjorkman J, 1998, P NATL ACAD SCI USA, V95, P3949, DOI 10.1073/pnas.95.7.3949; *BSAC, GUID SENS TEST METH, V35; Davies JE, 1997, CIBA F SYMP, V207, P15; HUGHES VM, 1983, NATURE, V302, P725, DOI 10.1038/302725a0; LENSKI RE, 1994, J BACTERIOL, V176, P3140, DOI 10.1128/jb.176.11.3140-3147.1994; LEVIN BR, 1997, CLIN INFECT DIS   S1, V24, P9; MEDEIROS AA, 1997, CLIN INFECT DIS   S1, V24, P19; Piddock LJV, 1996, J ANTIMICROB CHEMOTH, V38, P1, DOI 10.1093/jac/38.1.1; ROLLAND RM, 1985, APPL ENVIRON MICROB, V49, P791, DOI 10.1128/AEM.49.4.791-794.1985; Schrag SJ, 1996, NATURE, V381, P120, DOI 10.1038/381120b0; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Waters B, 1997, ANTIMICROB AGENTS CH, V41, P2766, DOI 10.1128/AAC.41.12.2766; Wiener P, 1998, MOL ECOL, V7, P1205, DOI 10.1046/j.1365-294x.1998.00450.x	13	192	198	4	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					233	234		10.1038/45724	http://dx.doi.org/10.1038/45724			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499578				2022-12-24	WOS:000082678400041
J	Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP				Scita, G; Nordstrom, J; Carbone, R; Tenca, P; Giardina, G; Gutkind, S; Bjarnegard, M; Betsholtz, C; Di Fiore, PP			EPS8 and E3B1 transduce signals from Ras to Rac	NATURE			English	Article							SH3 DOMAIN; BINDING-PROTEIN; RHO-GTPASES; GROWTH; KINASE; CDC42; AFFINITY; PATHWAYS	The small guanine nucleotide (GTP)-binding protein Rac regulates mitogen-induced cytoskeletal changes and c-Jun aminoterminal kinase (JNK), and its activity is required for Ras-mediated cell transformation(1). Epistatic analysis placed Rac as a key downstream target in pas signalling(2); however, the biochemical mechanism regulating the cross-talk among these small GTP-binding proteins remains to be elucidated. Eps8 (relative molecular mass 97,000) is a substrate of receptors with tyrosine kinase activity(3) which binds, through its SH3 domain, to a protein designated E3b1/Abi-1 (refs 4, 5). Here we show that Eps8 and E3b1/Abi-1 participate in the transduction of signals from pas to Rac, by regulating Rac-specific guanine nucleotide exchange factor (GEF) activities. We also show that Eps8, E3b1 and Sos-1 form a tri-complex in vivo that exhibits Rac-specific GEF activity in vitro. We propose a model in which Eps8 mediates the transfer of signals between Ras and pac, by forming a complex with E3b1 and Sos-1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Bari, Ist Microbiol, I-70124 Bari, Italy; NIH, Mol Signaling Unit, Cellular Dev & Oncol Lab, Bethesda, MD 20892 USA	IRCCS European Institute of Oncology (IEO); University of Gothenburg; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA	Di Fiore, PP (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	pdifiore@ieo.cilea.it	Gutkind, J. Silvio/A-1053-2009; Di Fiore, Pier Paolo/K-2130-2012; Scita, Giorgio/J-9670-2012; Gutkind, J. Silvio/J-1201-2016	Di Fiore, Pier Paolo/0000-0002-2252-0950; Gutkind, J. Silvio/0000-0002-5150-4482; Scita, Giorgio/0000-0001-7984-1889				Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1997, SCIENCE, V276, P185; Kishan KVR, 1997, NAT STRUCT BIOL, V4, P739; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANFRANCONE L, 1995, ONCOGENE, V11, P607; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Matoskova B, 1996, ONCOGENE, V12, P2679; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; SASTRY L, 1995, ONCOGENE, V11, P1107; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	23	278	289	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1999	401	6750					290	293		10.1038/45822	http://dx.doi.org/10.1038/45822			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499589				2022-12-24	WOS:000082678400057
J	Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG				Park, DH; Somers, DE; Kim, YS; Choy, YH; Lim, HK; Soh, MS; Kim, HJ; Kay, SA; Nam, HG			Control of circadian rhythms and photoperiodic flowering by the Arabidopsis GIGANTEA gene	SCIENCE			English	Article							CDNA CLONE; CLOCK; THALIANA; TRANSCRIPTION; PERIOD; DROSOPHILA; MUTANT; PLANTS; ENTRAINMENT; EXPRESSION	Photoperiodic responses in plants include flowering that is day-length-dependent. Mutations in the Arabidopsis thaliana GIGANTEA (GI) gene cause photoperiod-insensitive flowering and alteration of circadian rhythms. The GI gene encodes a protein containing six putative transmembrane domains. Circadian expression patterns of the GI gene and the clock-associated genes, LHY and CCA1, are altered in gi mutants, showing that GI is required for maintaining circadian amplitude and appropriate period length of these genes. The gi-1 mutation also affects Light signaling to the clock, which suggests that GI participates in a feedback loop of the plant circadian system.	Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92307 USA; Scripps Res Inst, Natl Sci Fdn, Ctr Biol Timing, La Jolla, CA 92307 USA	Pohang University of Science & Technology (POSTECH); Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute	Nam, HG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea.		Somers, David E/A-9209-2010; Kay, Steve A/F-6025-2011	Kay, Steve A/0000-0002-0402-2878; SOH, MOON-SOO/0000-0002-4430-516X	NIGMS NIH HHS [GM56006] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Amasino RM, 1996, CURR OPIN GENET DEV, V6, P480, DOI 10.1016/S0959-437X(96)80071-2; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Carre IA, 1996, SEMIN CELL DEV BIOL, V7, P775, DOI 10.1006/scdb.1996.0095; CHOI S, 1995, PLANT MOL BIOL REP, V13, P124, DOI 10.1007/BF02668782; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Fankhauser C, 1997, ANNU REV CELL DEV BI, V13, P203, DOI 10.1146/annurev.cellbio.13.1.203; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Green RM, 1999, P NATL ACAD SCI USA, V96, P4176, DOI 10.1073/pnas.96.7.4176; Hicks KA, 1996, SCIENCE, V274, P790, DOI 10.1126/science.274.5288.790; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; JOHNSON CH, 1995, SCIENCE, V269, P1863, DOI 10.1126/science.7569925; Kim YS, 1998, PLANT MOL BIOL, V37, P955, DOI 10.1023/A:1006030617502; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Kreps JA, 1997, PLANT CELL, V9, P1235, DOI 10.1105/tpc.9.7.1235; Kwak JM, 1997, PLANTA, V201, P245, DOI 10.1007/s004250050063; Lumsden P. J., 1998, BIOL RHYTHMS PHOTOPE; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Millar AJ, 1992, PLANT MOL BIOL REP, V10, P324, DOI 10.1007/BF02668909; Plautz JD, 1997, J BIOL RHYTHM, V12, P204, DOI 10.1177/074873049701200302; Redei G. P., 1974, STADLER S, V6, P135; Roenneberg T, 1997, PHOTOCHEM PHOTOBIOL, V66, P549, DOI 10.1111/j.1751-1097.1997.tb03188.x; Schaffer R, 1998, CELL, V93, P1219, DOI 10.1016/S0092-8674(00)81465-8; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Somers DE, 1998, DEVELOPMENT, V125, P485; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Thomas B., 1997, PHOTOPERIODISM PLANT; Wang ZY, 1998, CELL, V93, P1207, DOI 10.1016/S0092-8674(00)81464-6; WHITELAM GC, 1998, ARABIDOPSIS ANN PLAN, V1, P331; Wilsbacher LD, 1998, CURR OPIN GENET DEV, V8, P595, DOI 10.1016/S0959-437X(98)80017-8; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	36	452	480	5	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1579	1582		10.1126/science.285.5433.1579	http://dx.doi.org/10.1126/science.285.5433.1579			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477524				2022-12-24	WOS:000082359500069
J	Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW				Olynyk, JK; Cullen, DJ; Aquilia, S; Rossi, E; Summerville, L; Powell, LW			A population-based study of the clinical expression of the hemochromatosis gene	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEREDITARY HEMOCHROMATOSIS; MUTATION ANALYSIS; EARLY DIAGNOSIS; TRANSFERRIN; SATURATION; PREDICTION; PREVALENCE; FIBROSIS; HFE	Background and Methods Hereditary hemochromatosis is associated with homozygosity for the C282Y mutation in the hemochromatosis (HFE) gene on chromosome 6, elevated serum transferrin saturation, and excess iron deposits throughout the body. To assess the prevalence and clinical expression of the HFE gene, we conducted a population-based study in Busselton, Australia. In 1994, we obtained blood samples for the determination of serum transferrin saturation and ferritin levels and the presence or absence of the C282Y mutation and the H63D mutation (which may contribute to increased hepatic iron levels) in 3011 unrelated white adults. We evaluated all subjects who had persistently elevated transferrin-saturation values (45 percent or higher) or were homozygous for the C282Y mutation. We recommended liver biopsy for subjects with serum ferritin levels of 300 ng per milliliter or higher. The subjects were followed for up to four years. Results Sixteen of the subjects (0.5 percent) were homozygous for the C282Y mutation, and 424 (14.1 percent) were heterozygous. The serum transferrin saturation was 45 percent or higher in 15 of the 16 who were homozygous; in 1 subject it was 43 percent. Four of the homozygous subjects had previously been given a diagnosis of hemochromatosis, and 12 had not. Seven of these 12 patients had elevated serum ferritin levels in 1994; 6 of the 7 had further increases in 1998, and 1 had a decrease, although the value remained elevated. The serum ferritin levels in the four other homozygous patients remained in the normal range. Eleven of the 16 homozygous subjects underwent liver biopsy; 3 had hepatic fibrosis, and 1, who had a history of excessive alcohol consumption, had cirrhosis and mild microvesicular steatosis. Eight of the 16 homozygous subjects had clinical findings that were consistent with the presence of hereditary hemochromatosis, such as hepatomegaly, skin pigmentation, and arthritis. Conclusions In a population of white adults of northern European ancestry, 0.5 percent were homozygous for the C282Y mutation in the HFE gene. However, only half of those who were homozygous had clinical features of hemochromatosis, and one quarter had serum ferritin levels that remained normal over a four-year period. (N Engl J Med 1999;341:718-24.) (C)1999, Massachusetts Medical Society.	Univ Western Australia, Dept Med, Fremantle, WA 6959, Australia; Fremantle Hosp, Dept Gastroenterol, Fremantle, WA, Australia; Busselton Populat Med Res Fdn, Perth, WA, Australia; Queen Elizabeth II Med Ctr, Pathctr, Nedlands, WA, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; Univ Queensland, Brisbane, Qld, Australia	University of Western Australia; University of Western Australia; University of Western Australia; QIMR Berghofer Medical Research Institute; University of Queensland	Olynyk, JK (corresponding author), Univ Western Australia, Dept Med, POB 480, Fremantle, WA 6959, Australia.	jolynyk@cyllene.uwa.edu.au		Olynyk, John/0000-0003-0417-3411				Adams PC, 1998, GASTROENTEROLOGY, V114, P319, DOI 10.1016/S0016-5085(98)70483-4; Adams PC, 1997, HEPATOLOGY, V26, P986, DOI 10.1002/hep.510260428; Bacon BR, 1999, ANN INTERN MED, V130, P953, DOI 10.7326/0003-4819-130-12-199906150-00002; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; Barton JC, 1997, BLOOD CELL MOL DIS, V23, P135, DOI 10.1006/bcmd.1997.0129; BASSETT ML, 1988, ANN NY ACAD SCI, V526, P274, DOI 10.1111/j.1749-6632.1988.tb55512.x; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; BEILBY J, 1992, CLIN CHEM, V38, P2078; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; Borot N, 1997, IMMUNOGENETICS, V45, P320, DOI 10.1007/s002510050211; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Burt MJ, 1998, GUT, V43, P830, DOI 10.1136/gut.43.6.830; Cardoso EMP, 1998, J INTERN MED, V243, P203; Carella M, 1997, AM J HUM GENET, V60, P828; Crawford DHG, 1998, GASTROENTEROLOGY, V114, P1003, DOI 10.1016/S0016-5085(98)70320-8; Cullen LM, 1997, BLOOD, V90, P4236, DOI 10.1182/blood.V90.10.4236; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; JEFFREY GP, IN PRESS NAT GENET; Knuiman MW, 1997, J EPIDEMIOL COMMUN H, V51, P515, DOI 10.1136/jech.51.5.515; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; McLaren CE, 1998, GASTROENTEROLOGY, V114, P543, DOI 10.1016/S0016-5085(98)70538-4; Mendler MH, 1998, HEPATOLOGY, V28, p419A; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; Moirand R, 1999, GASTROENTEROLOGY, V116, P372, DOI 10.1016/S0016-5085(99)70134-4; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; OLYNYK JK, 1994, POSTGRAD MED, V96, P151, DOI 10.1080/00325481.1994.11945914; POWELL LW, 1990, GASTROENTEROLOGY, V98, P1625, DOI 10.1016/0016-5085(90)91100-K; Powell W.L., 1994, IRON METABOLISM HLTH; Robson KJH, 1997, GUT, V41, P841; Rossi E, 1999, J GASTROEN HEPATOL, V14, P427, DOI 10.1046/j.1440-1746.1999.01884.x; SEARLE J, 1994, PATHOLOGY LIVER, P224; SINGERSAM J, 1989, AMPL FOR PCR US; Snedecor G.W., 1967, STAT METHODS; Welborn T A, 1968, Med J Aust, V2, P778	36	565	577	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 2	1999	341	10					718	724		10.1056/NEJM199909023411002	http://dx.doi.org/10.1056/NEJM199909023411002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231DB	10471457	Green Published			2022-12-24	WOS:000082291900002
J	Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY				Harton, JA; Cressman, DE; Chin, KC; Der, CJ; Ting, JPY			GTP binding by class II transactivator: Role in nuclear import	SCIENCE			English	Article							BARE LYMPHOCYTE SYNDROME; NUCLEOTIDE-BINDING; RAS P21; PROTEIN; CIITA; EXPRESSION; GENES; MHC; ACTIVATION; DEFICIENCY	Class II transactivator (CIITA) is a global transcriptional coactivator of human Leukocyte antigen-D (HLA-D) genes. CIITA contains motifs similar to guanosine triphosphate (CTP)-binding proteins. This report shows that CIITA binds GTP, and mutations in these motifs decrease its GTP-binding and transactivation activity. Substitution of these motifs with analogous sequences from Ras restores CIITA function. CIITA exhibits little GTPase activity, yet mutations in CIITA that confer GTPase activity reduce transcriptional activity. GTP binding by CIITA correlates with nuclear import. Thus, unlike other GTP-binding proteins, CIITA is involved in transcriptional activation that uses GTP binding to facilitate its own nuclear import.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ting, JPY (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		Harton, Jonathan/F-2848-2010; Harton, Jonathan A/AAW-5283-2021	Harton, Jonathan/0000-0002-0350-1877; Harton, Jonathan A/0000-0002-0350-1877; Der, Channing/0000-0002-7751-2747	NIAID NIH HHS [AI41751, AI45580, AI29564] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045580, R01AI029564] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; COLLART FR, 1987, MOL CELL BIOL, V7, P3328, DOI 10.1128/MCB.7.9.3328; Crespo J. A., 1963, Revista del Museo arg Cienc nat Bernadino Rivadavia (Ecol), V1, P1; CRESSMAN DE, UNPUB; DAYTON JS, 1994, J IMMUNOL, V152, P984; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DOWNWARD J, 1995, METHOD ENZYMOL, V255, P110; Fontes JD, 1996, J EXP MED, V183, P2517, DOI 10.1084/jem.183.6.2517; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Foster R, 1996, MOL CELL BIOL, V16, P2689; Gu JJ, 1997, J BIOL CHEM, V272, P4458, DOI 10.1074/jbc.272.7.4458; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; HART PA, 1990, ONCOGENE, V5, P1099; HARTON JJ, UNPUB; Kjeldgaard M, 1996, FASEB J, V10, P1347, DOI 10.1096/fasebj.10.12.8903506; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Mahanta SK, 1997, P NATL ACAD SCI USA, V94, P6324, DOI 10.1073/pnas.94.12.6324; MONROE JG, 1983, J IMMUNOL, V130, P626; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Overmeyer JH, 1998, MOL BIOL CELL, V9, P223, DOI 10.1091/mbc.9.1.223; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Ramaswamy S, 1998, J BIOL CHEM, V273, P9243, DOI 10.1074/jbc.273.15.9243; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; Yu B, 1997, J BIOL CHEM, V272, P18015, DOI 10.1074/jbc.272.29.18015; ZHONG JM, 1995, J BIOL CHEM, V270, P10002, DOI 10.1074/jbc.270.17.10002; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9	48	85	87	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1999	285	5432					1402	1405		10.1126/science.285.5432.1402	http://dx.doi.org/10.1126/science.285.5432.1402			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CD	10464099				2022-12-24	WOS:000082233500043
J	Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M				Mochizuki, N; Ohba, Y; Kiyokawa, E; Kurata, T; Murakami, T; Ozaki, T; Kitabatake, A; Nagashima, K; Matsuda, M			Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with G alpha(i)	NATURE			English	Article							PROTEIN-KINASE ACTIVATION; RAS-DEPENDENT ACTIVATION; MAP KINASE; FIBROBLASTS; TRANSFORMATION; RECEPTORS; SUBUNITS; P21(RAS); GENE	Many receptors for neuropeptides and hormones are coupled with the heterotrimeric G(i) protein, which activates the p42/44 mitogen-activated protein kinase (ERK/MAPE;) cascade through both the alpha- and beta gamma-subunits of G(i) (refs 1-3). The beta gamma-subunit activates the ERK/MAPK cascade through tyrosine kinase(4-6). Constitutively active G alpha(i2) (gip2) isolated from adrenal and ovarian tumours(7,8) transforms Rat-1 fibroblasts and also activates the ERK/MAPK cascade by an unknown mechanism(9,10). The ERK/MAPK pathway is activated by Ras, and is inhibited when the low-molecular-mass GTP-binding protein Rap1 antagonizes pas function(11). Here we show that a novel isoform of Rap1 GTPase-activating protein, called rap1GAPII, binds specifically to the alpha-subunits of the G(i) family of heterotrimeric G-proteins. Stimulation of the G(i)-coupled m2-muscarinic receptor translocates rap1GAPII from the cytosol to the membrane and decreases the amount of GTP-bound Rap1. This decrease in GTP-bound Rap1 activates ERK/MAPK. Thus, the alpha-subunit of G(i) activates the Ras-ERK/MAPK mitogenic pathway by membrane recruitment of rap1GAPII and reduction of GTP-bound Rap1.	Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan; Hokkaido Univ, Sch Med, Dept Cardiovasc Med, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Sch Med, Dept Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Hokkaido University; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan.		Ohba, Yusuke/E-7944-2011	Matsuda, Michiyuki/0000-0002-5876-9969				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Ishimaru S, 1999, EMBO J, V18, P145, DOI 10.1093/emboj/18.1.145; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PIZON V, 1994, J CELL SCI, V107, P1661; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	25	193	197	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					891	894		10.1038/23738	http://dx.doi.org/10.1038/23738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476970				2022-12-24	WOS:000082233200050
J	Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS				Cole, CR; Blackstone, EH; Pashkow, FJ; Snader, CE; Lauer, MS			Heart-rate recovery immediately after exercise as a predictor of mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMISSION COMPUTED-TOMOGRAPHY; FOLLOW-UP; INFARCTION; STRESS; DEATH	Background The increase in heart rate that accompanies exercise is due in part to a reduction in vagal tone. Recovery of the heart rate immediately after exercise is a function of vagal reactivation. Because a generalized decrease in vagal activity is known to be a risk factor for death, we hypothesized that a delayed fall in the heart rate after exercise might be an important prognostic marker. Methods For six years we followed 2428 consecutive adults (mean [+/-SD] age, 57+/-12 years; 63 percent men) without a history of heart failure or coronary revascularization and without pacemakers. The patients were undergoing symptom-limited exercise testing and single-photon-emission computed tomography with thallium scintigraphy for diagnostic purposes. The value for the recovery of heart rate was defined as the decrease in the heart rate from peak exercise to one minute after the cessation of exercise. An abnormal value for the recovery of heart rate was defined as a reduction of 12 beats per minute or less from the heart rate at peak exercise. Results There were 213 deaths from all causes. A total of 639 patients (26 percent) had abnormal values for heart-rate recovery. In univariate analyses, a low value for the recovery of heart rate was strongly predictive of death (relative risk, 4.0; 95 percent confidence interval, 3.0 to 5.2; P<0.001). After adjustments were made for age, sex, the use or nonuse of medications, the presence or absence of myocardial perfusion defects on thallium scintigraphy, standard cardiac risk factors, the resting heart rate, the change in heart rate during exercise, and workload achieved, a low value for heart-rate recovery remained predictive of death (adjusted relative risk, 2.0; 95 percent confidence interval, 1.5 to 2.7; P<0.001). Conclusions A delayed decrease in the heart rate during the first minute after graded exercise, which may be a reflection of decreased vagal activity, is a powerful predictor of overall mortality, independent of workload, the presence or absence of myocardial perfusion defects, and changes in heart rate during exercise. (N Engl J Med 1999;341:1351-7.) (C) 1999, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Epidemiol & Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplantat Med, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013	Lauer, Michael S/0000-0002-9217-8177				ARAI Y, 1989, AM J PHYSIOL, V256, pH132, DOI 10.1152/ajpheart.1989.256.1.H132; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, AM J EPIDEMIOL, V121, P754, DOI 10.1093/aje/121.5.754; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; FLETCHER GF, 1995, CIRCULATION, V91, P580, DOI 10.1161/01.CIR.91.2.580; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1990, J NUCL MED, V31, P1899; Goldstein RE, 1999, JAMA-J AM MED ASSOC, V281, P565, DOI 10.1001/jama.281.6.565; Gottlieb SS, 1997, LANCET, V349, P662, DOI 10.1016/S0140-6736(97)22010-6; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; IMAI K, 1994, J AM COLL CARDIOL, V24, P1529, DOI 10.1016/0735-1097(94)90150-3; La Rovere MT, 1998, LANCET, V351, P478; Lauer MS, 1999, JAMA-J AM MED ASSOC, V281, P524, DOI 10.1001/jama.281.6.524; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; LAUER MS, 1996, CIRCULATION, V93, P150; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; NALLAMOTHU N, 1995, J AM COLL CARDIOL, V25, P830, DOI 10.1016/0735-1097(94)00471-2; SANDVIK L, 1995, CORONARY ARTERY DIS, V6, P667, DOI 10.1097/00019501-199508000-00012; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; Snader CE, 1997, J AM COLL CARDIOL, V30, P641, DOI 10.1016/S0735-1097(97)00217-9; Wilkoff Bruce L., 1992, Cardiology Clinics, V10, P705	22	1256	1323	0	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1351	1357		10.1056/NEJM199910283411804	http://dx.doi.org/10.1056/NEJM199910283411804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	249XE	10536127	Bronze			2022-12-24	WOS:000083357800004
J	Harris, AJ				Harris, AJ			Cortical origin of pathological pain	LANCET			English	Article							PRIMARY SOMATOSENSORY CORTEX; FOCAL HAND DYSTONIA; BRAILLE READERS; PHANTOM LIMBS; PLASTICITY; REPRESENTATION; REORGANIZATION; STIMULATION; AMPUTATION; MONKEYS	Pain without accompanying tissue pathology poses a classic puzzle, presented in extreme form by phantom pain in a non-existent amputated limb. A clue to the origin of such pain is given by the recent discovery of a region of cortex active in response to incongruence between motor intention, awareness of movement, and visual feedback. Phantom-limb sensation, and repetitive strain injuries or focal hand dystonias in writers, musicians, or keyboard operators, are accompanied by plastic changes in sensorimotor cortex and by pathological pain. Disorganised or inappropriate cortical representation of proprioception may falsely signal incongruence between motor intention and movement, which results in pathological pain in the same way that incongruence between vestibular and visual sensation results in motion sickness.	Univ Otago, Sch Med, Dev Biol Unit, Dunedin, New Zealand; Univ Otago, Sch Med, Dept Physiol, Dunedin, New Zealand	University of Otago; University of Otago	Harris, AJ (corresponding author), Univ Otago, Sch Med, Dev Biol Unit, POB 913, Dunedin, New Zealand.		Harris, Linda J/B-5030-2011	Harris, Linda J/0000-0002-1911-752X				Bara-Jimenez W, 1998, ANN NEUROL, V44, P828, DOI 10.1002/ana.410440520; BISIACH E, 1991, NEUROPSYCHOLOGIA, V29, P1029, DOI 10.1016/0028-3932(91)90066-H; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Byl N, 1996, J ORTHOP SPORT PHYS, V23, P234, DOI 10.2519/jospt.1996.23.4.234; Byl N N, 1997, J Hand Ther, V10, P160; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; Fink GR, 1999, BRAIN, V122, P497, DOI 10.1093/brain/122.3.497; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; Goodale MA, 1998, NOVART FDN SYMP, V218, P21; Hallett M, 1998, Adv Neurol, V78, P11; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1979, SCIENCE, V204, P521, DOI 10.1126/science.107591; Knecht S, 1998, BRAIN, V121, P717, DOI 10.1093/brain/121.4.717; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058; RAMACHANDRAN VS, 1995, CONSCIOUS COGN, V4, P22, DOI 10.1006/ccog.1995.1002; Ramachandran VS, 1998, BRAIN, V121, P1603, DOI 10.1093/brain/121.9.1603; SLLARD T, 1991, J COMP NEUROL, V311, P563; Sterr A, 1998, J NEUROSCI, V18, P4417; Topp KS, 1999, MOVEMENT DISORD, V14, P295, DOI 10.1002/1531-8257(199903)14:2<295::AID-MDS1015>3.0.CO;2-J; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	231	238	0	31	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 23	1999	354	9188					1464	1466		10.1016/S0140-6736(99)05003-5	http://dx.doi.org/10.1016/S0140-6736(99)05003-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	248LY	10543687				2022-12-24	WOS:000083277400041
J	Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A				Acharyya, SK; Chakraborty, P; Lahiri, S; Raymahashay, BC; Guha, S; Bhowmik, A			Arsenic poisoning in the Ganges delta	NATURE			English	Article							GROUNDWATER		Geol Survey India, Kolkata 700016, W Bengal, India; Indian Inst Technol, Dept Civil Engn, Kanpur 208016, Uttar Pradesh, India	Geological Survey India; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Kanpur	Acharyya, SK (corresponding author), Geol Survey India, Kolkata 700016, W Bengal, India.							Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; Bhattacharya P., 1997, INT J WATER RESOUR D, V13, P79, DOI DOI 10.1080/07900629749944; Hiller K., 1988, GEOL JB D, V90, P3; Joshi A, 1996, J ENVIRON ENG-ASCE, V122, P769, DOI 10.1061/(ASCE)0733-9372(1996)122:8(769); Mallick S, 1996, CURR SCI INDIA, V70, P956; MUKHERJEE A, 1997, INDIAN J GEOL, V69, P41; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; WONG PLN, 1995, CHIN I ENV ENG, V5, P241	8	316	342	7	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 7	1999	401	6753					545	545		10.1038/44052	http://dx.doi.org/10.1038/44052			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524619	Bronze			2022-12-24	WOS:000083054900036
J	Simon, HU; Plotz, SG; Dummer, R; Blaser, K				Simon, HU; Plotz, SG; Dummer, R; Blaser, K			Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOMA STUDY-GROUP; HYPEREOSINOPHILIC SYNDROME; INTERFERON-ALPHA; SEZARY-SYNDROME; APOPTOSIS; FAS; IDENTIFICATION; CLASSIFICATION; NEOPLASMS; EXPANSION	Background The cause of persistent eosinophilia and the hypereosinophilic syndrome is unknown. Recent work suggests that in some patients with the hypereosinophilic syndrome, a clone of abnormal T cells produces large amounts of interleukin-5, a cytokine required for the growth and differentiation of eosinophils. We examined T-cell surface markers, rearranged T-cell-receptor genes, and in vitro production of cytokines by T cells from patients with idiopathic eosinophilia. Methods The expression of surface molecules on T cells was measured by flow cytometry. Cytokine expression was measured by enzyme-linked immunosorbent assay, flow cytometry, and immunohistochemical analysis. To identify dominant (clonal) rearrangements of the T-cell receptor within the lymphocyte population, Southern blot analysis (beta chain) and the polymerase chain reaction (gamma chain) were performed according to standard protocols. Results Among 60 patients with idiopathic eosinophilia, 16 had circulating T cells with an aberrant immunophenotype. In each of these patients, the abnormal immunophenotype was unique. Evidence of clonal rearrangements of the T-cell receptor was obtained in 8 of the 16 patients. In most instances, the abnormal T cells expressed large amounts of surface proteins associated with T-cell activation (the a chain of the interleukin-2 receptor and the HLA-DR antigen). Moreover, the aberrant T cells produced large amounts of interleukin-5 in vitro. Conclusions Clonal populations of abnormal T cells producing interleukin-5 occur in some patients with idiopathic eosinophilia. (N Engl J Med 1999;341:1112-20.) (C)1999, Massachusetts Medical Society.	Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Tech Univ Munich, Res Ctr Environm & Hlth, D-8000 Munich, Germany; Univ Zurich, Dept Dermatol, Zurich, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich; Technical University of Munich; University of Zurich	Simon, HU (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	hus@siaf.unizh.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; Bogen SA, 1996, AM J CLIN PATHOL, V106, P739; BOURGUIN A, 1990, P NATL ACAD SCI USA, V87, P8536, DOI 10.1073/pnas.87.21.8536; Brugnoni D, 1996, BLOOD, V87, P1416, DOI 10.1182/blood.V87.4.1416.bloodjournal8741416; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; Dummer R, 1996, BLOOD, V88, P1383, DOI 10.1182/blood.V88.4.1383.bloodjournal8841383; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; HARRIS NL, 1994, BLOOD, V84, P1361; Kamarashev J, 1998, J CUTAN PATHOL, V25, P407, DOI 10.1111/j.1600-0560.1998.tb01766.x; Meyer JC, 1997, EXP DERMATOL, V6, P122, DOI 10.1111/j.1600-0625.1997.tb00158.x; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Selleri C, 1997, BLOOD, V89, P957, DOI 10.1182/blood.V89.3.957; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; Simon HU, 1997, J IMMUNOL, V158, P3902; WELLER PF, 1994, BLOOD, V83, P2759, DOI 10.1182/blood.V83.10.2759.2759; Willemze R, 1997, BLOOD, V90, P354; WOOD GS, 1991, AM J PATHOL, V138, P1503	22	380	395	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1999	341	15					1112	1120		10.1056/NEJM199910073411503	http://dx.doi.org/10.1056/NEJM199910073411503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245BW	10511609	Bronze			2022-12-24	WOS:000083087200003
J	Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF				Blanche, S; Tardieu, M; Rustin, P; Slama, A; Barret, B; Firtion, G; Ciraru-Vigneron, N; Lacroix, C; Rouzioux, C; Mandelbrot, L; Desguerre, I; Rotig, A; Mayaux, MJ; Delfraissy, JF			Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues	LANCET			English	Article; Proceedings Paper	6th Conference on Retroviruses and Opportunistic Infections	JAN 31-FEB 04, 1999	CHICAGO, IL				IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; RESPIRATORY-CHAIN; HIV TRANSMISSION; PREVENTION; TOXICITY; DNA; AZT	Background Zidovudine is commonly administered during pregnancy to prevent mother-to-child HIV-transmission. We investigated mitochondrial toxic effects in children exposed to zidovudine in utero and after birth. Methods We analysed observations of a trial of tolerance of combined zidovudine and lamivudine and preliminary results of a continuing retrospective analysis of clinical and biological symptoms of mitochondrial dysfunction in children born to HIV-1-infected women in France. Mitochondrial dysfunction was studied by spectrophotometry and polarography of respiratory-chain complexes in various tissues. Findings Fight children had mitochondrial dysfunction. Five, of whom two died, presented with delayed neurological symptoms and three were symptom-free but had severe biological or neurological abnormalities. Four of these children had been exposed to combined zidovudine and lamivudine, and four to zidovudine alone. No child was infected with HIV-1. All children had abnormally low absolute or relative activities of respiratory-chain complexes I, IV, or both months or years after the end of antiretroviral treatment. No mutation currently associated with constitutional disease was detected in any patient. Interpretation Our findings support the hypothesis of a link between mitochondrial dysfunction and the perinatal administration of prophylactic nucleoside analogues. Current recommendations for zidovudine monotherapy should however be maintained. Further assessment of the toxic effects of these drugs is required.	Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U429 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, INSERM, U393 Lab, F-75743 Paris, France; Hop Necker Enfants Malad, Virol Lab, F-75743 Paris, France; Hop Bicetre, Serv Neurol Pediat, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, U292 Lab, Le Kremlin Bicetre, France; Hop Bicetre, INSERM, CRI 9612 Lab, Le Kremlin Bicetre, France; Hop Bicetre, Biochim Lab, Le Kremlin Bicetre, France; Hop Bicetre, Serv Neuropathol, Le Kremlin Bicetre, France; Hop Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; Hop Cochin Port Royal, Paris, France; Hop Lariboisiere, F-75475 Paris, France; Hop St Vincent de Paul, Serv Neurol, F-75674 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Blanche, S (corresponding author), Hop Necker Enfants Malad, Unite Immunol Hematol Pediat, Serv Immunol Hematol Pediat, F-75743 Paris, France.	stephane.blanche@nck.ap-hop-paris.fr	Rötig, Agnès/G-9592-2017; Mandelbrot, Laurent/AAD-3554-2019	Rötig, Agnès/0000-0003-0589-0703; Mandelbrot, Laurent/0000-0002-5883-7597				Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; [Anonymous], 1994, LANCET, V344, P207; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004; CHRETIEN D, BIOCH J, V329, P249; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695; GERSCHENSON M, 1998, AM J HUM GENET, V63, pA164; Hall SM, 1998, CHILD CARE HLTH DEV, V24, P129; JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007; Kreuzer KA, 1997, ANN HEMATOL, V75, P179, DOI 10.1007/s002770050340; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Mayaux MJ, 1997, J PEDIATR-US, V131, P857, DOI 10.1016/S0022-3476(97)70033-7; Morris K, 1998, LANCET, V351, P651, DOI 10.1016/S0140-6736(05)78436-1; NEWELL ML, 1995, DRUG SAFETY, V12, P274, DOI 10.2165/00002018-199512040-00007; Olivero OA, 1997, J NATL CANCER I, V89, P1602, DOI 10.1093/jnci/89.21.1602; PONCHAUT S, 1995, EUR J PEDIATR, V154, P79, DOI 10.1007/BF01972980; Poulton J, 1998, Eur J Paediatr Neurol, V2, P99, DOI 10.1016/S1090-3798(98)80049-4; *PUBL HLTH SERV, 1998, MMWR-MORBID MORTAL W, V47, P688; ROUSE DJ, 1995, J ACQ IMMUN DEF SYND, V9, P401; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V; Scalfaro P, 1998, INTENS CARE MED, V24, P247, DOI 10.1007/s001340050558; Sperling RS, 1998, AIDS, V12, P1805, DOI 10.1097/00002030-199814000-00012	28	479	495	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 25	1999	354	9184					1084	1089		10.1016/S0140-6736(99)07219-0	http://dx.doi.org/10.1016/S0140-6736(99)07219-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	239PA	10509500				2022-12-24	WOS:000082777500014
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Protein interaction - Complex grabbing	SCIENCE			English	Editorial Material																		RIGAUT G, IN PRESS NATURE BIOT	1	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1868	1868						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515792				2022-12-24	WOS:000082638300036
J	Zeisel, SH				Zeisel, SH			Health - Regulation of "nutraceuticals"	SCIENCE			English	Editorial Material									Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zeisel, SH (corresponding author), Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27599 USA.							AARTS T, 1998, NUTR BUS J, V3, P1; Clydesdale FM, 1997, NUTR REV, V55, P413, DOI 10.1111/j.1753-4887.1997.tb01588.x; Klepser TB, 1999, AM J HEALTH-SYST PH, V56, P125, DOI 10.1093/ajhp/56.2.125; VOGEL MR, 1998, PHARM TODAY, V4, P14; Williamson BL, 1998, TOXICOL LETT, V99, P139, DOI 10.1016/S0378-4274(98)00223-9; 1997, FED REG         0604, V62, P30677; 1999, MORB MORTAL WKLY REP, V481, P37; 1997, FED REG         0206, V62, P5699	8	200	207	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1853	+		10.1126/science.285.5435.1853	http://dx.doi.org/10.1126/science.285.5435.1853			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10515789				2022-12-24	WOS:000082638300027
J	Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ				Kwok, JMF; Miller, TD; Christian, TF; Hodge, DO; Gibbons, RJ			Prognostic value of a treadmill exercise score in symptomatic patients with nonspecific ST-T abnormalities on resting ECG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; LEFT-VENTRICULAR FUNCTION; ASSOCIATION TASK-FORCE; SEGMENT DEPRESSION; ELECTROCARDIOGRAPHIC FINDINGS; ARTERY-DISEASE; DIAGNOSIS; PREVALENCE; GUIDELINES; MORTALITY	Context Exercise testing of patients with ST-T abnormalities on the resting electrocardiogram (ECG) is problematic because in the presence of pre-existing ST-T abnormalities, the exercise test is less specific for the diagnosis of coronary artery disease. The prognostic capability of the Duke treadmill score in patients with ST-T abnormalities vs those with normal findings on resting ECG has, to our knowledge, not been evaluated. Objective To compare the prognostic accuracy of the Duke treadmill score in patients with nonspecific ST-T abnormalities vs those with normal results on resting ECG. Design Inception cohort study with 7 years of follow-up. Setting Nuclear cardiology laboratory of a US referral center. Patients All symptomatic patients who underwent exercise thallium testing between 1989 and 1991, 939 of whom had nonspecific ST-T abnormalities and 1466 of whom had normal findings on resting ECG. Exclusion criteria included congenital, valvular, or cardiomyopathic heart disease; prior coronary artery revascularization; resting ECC with secondary ST-T abnormalities; or missing data. Main Outcome Measures Rates of overall mortality and cardiac death for subjects classified by Duke treadmill store risk group. Results For the end point cardiac death, 7-year survival in the study population in the low-, intermediate-, and high-risk groups was 97%, 92%, and 76%, respectively (P<.001), Compared with the control group, the study group had lower 7-year survival (94% vs 98%; P<.001), fewer low-risk patients (426 [45%] vs 811 [55%]; P<.001) with worse 7-year survival (97% vs 99%; P=.008), and more high-risk patients (49 [5%] vs 34 [2%];P<.001) with a nonsignificant trend toward worse 7-year survival (76% vs 93%; P =.36). Conclusions The Duke treadmill score can effectively risk-stratify patients with ST-T abnormalities on the resting EGG. In classified risk categories, patients with ST-T abnormalities have a worse prognosis than those with normal results on resting ECG.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biostat, Rochester, MN 55905 USA; Princess Margaret Hosp, Dept Med, Kowloon, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic	Miller, TD (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA.	miller.todd@mayo.edu						ARAVINDAKSHAN V, 1977, AM HEART J, V93, P706, DOI 10.1016/S0002-8703(77)80065-3; ARONOW WS, 1989, AM J CARDIOL, V64, P232, DOI 10.1016/0002-9149(89)90465-7; BERMAN JL, 1978, CIRCULATION, V58, P505, DOI 10.1161/01.CIR.58.3.505; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; Christian TF, 1997, AM J CARDIOL, V79, P1295, DOI 10.1016/S0002-9149(97)00108-2; CHRISTIAN TF, 1994, ANN INTERN MED, V121, P825, DOI 10.7326/0003-4819-121-11-199412010-00001; COHN K, 1979, CIRCULATION, V59, P286, DOI 10.1161/01.CIR.59.2.286; COHN PF, 1971, CIRCULATION, V43, P648, DOI 10.1161/01.CIR.43.5.648; CONNOLLY DC, 1984, MAYO CLIN PROC, V59, P247, DOI 10.1016/S0025-6196(12)61257-9; CULLEN K, 1982, BRIT HEART J, V47, P209; DETRANO R, 1989, J AM COLL CARDIOL, V14, P1501, DOI 10.1016/0735-1097(89)90388-4; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P474; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; GOLDSCHLAGER N, 1976, ANN INTERN MED, V85, P277, DOI 10.7326/0003-4819-85-3-277; HARRIS FJ, 1977, ADV CARDIOL, V22, P11; HOLLENBERG M, 1980, CIRCULATION, V61, P276, DOI 10.1161/01.CIR.61.2.276; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KANSAL S, 1976, CIRCULATION, V54, P636, DOI 10.1161/01.CIR.54.4.636; KREGER BE, 1987, AM HEART J, V113, P377, DOI 10.1016/0002-8703(87)90281-X; LADENHEIM ML, 1987, AM J CARDIOL, V59, P270, DOI 10.1016/0002-9149(87)90798-3; LINHART JW, 1974, CIRCULATION, V49, P667; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MEYERS DG, 1990, AM HEART J, V119, P272, DOI 10.1016/S0002-8703(05)80016-X; MIRANDA CP, 1991, AM HEART J, V122, P1617, DOI 10.1016/0002-8703(91)90279-Q; MIRVIS DM, 1990, AM J CARDIOL, V66, P699, DOI 10.1016/0002-9149(90)91133-Q; OKEEFE JH, 1989, AM J MED, V86, P658, DOI 10.1016/0002-9343(89)90439-7; OSTOR E, 1981, EUR HEART J, V2, P317; Pollock ML, 1990, EXERCISE HLTH DIS EV; REUNANEN A, 1977, ADV CARDIOL, V21, P310; ROMHILT DW, 1968, CIRCULATION, V37, P15, DOI 10.1161/01.CIR.37.1.15; ROSE G, 1978, BRIT HEART J, V40, P636; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; WEINER DA, 1983, AM HEART J, V105, P749, DOI 10.1016/0002-8703(83)90236-3	37	65	66	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1047	1053		10.1001/jama.282.11.1047	http://dx.doi.org/10.1001/jama.282.11.1047			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493203	Bronze			2022-12-24	WOS:000082512300028
J	Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF				Fattori, R; Nienaber, CA; Descovich, B; Ambrosetto, P; Reggiani, LB; Pepe, G; Kaufmann, U; Negrini, N; von Kodolitsch, Y; Gensini, GF			Importance of dural ectasia in phenotypic assessment of Marfan's syndrome	LANCET			English	Article							FIBRILLIN-1 FBN1; MUTATIONS	Background Early identification of Marfan's syndrome is fundamental in the prevention of aortic dilatation, but the wide phenotypic expression of the disorder makes the clinical diagnosis very difficult. Dural ectasia has been classified as a major diagnostic criterion; however, its prevalence is not known. We aimed to identify the true prevalence of dural ectasia in Marfan's syndrome, and to investigate its relation to aortic pathology. Methods A magnetic-resonance-imaging (MRI) study of the thoracic aorta and of the lumbosacral spine was done in an inclusive series of 83 patients with Marfan's syndrome to assess the presence and degree of dural ectasia and aortic involvement; 12 patients were younger than 18 years. 100 individuals who underwent MRI of the lumbar spine for routine clinical indications represented the control group; none of them had any potential causes for dural ectasia. Findings Dural ectasia was identified in 76 (92%) patients and none of the control group. The severity of dural ectasia was related to age; the mean (SD) age of patients with mild dural ectasia was 26 years (14) whereas that of those with severe disease (meningocele) was 36 years (9) (p=0.038). 11 of 12 patients younger than 18 years had dural ectasia. No association was found between aortic dilatation and dural ectasia. Interpretation Dural ectasia is a highly characteristic sign of Marian's syndrome, even at an early age.	Univ Hosp S Orsola, Inst Radiol, Bologna, Italy; Univ Hosp S Orsola, Neurol Inst, Bologna, Italy; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, Div Cardiol, D-20246 Hamburg, Germany; Univ Roma Tor Vergata, Dept Internal Med, Clin Biochem Sect, I-00173 Rome, Italy; Univ Hosp Careggi, Dept Internal Med & Cardiol, Florence, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University of Hamburg; University of Rome Tor Vergata; University of Florence; Azienda Ospedaliero Universitaria Careggi	Fattori, R (corresponding author), Osped S Orsola Malpighi, Ist Radiol Radiol 3, Via Massarenti 9, I-40100 Bologna, Italy.	ross@med.unibo.it	Pepe, Guglielmina/K-8013-2016; Fattori, Rossella/L-1017-2016; Bacchi Reggiani, Maria Letizia/O-2311-2014	Pepe, Guglielmina/0000-0001-9825-6618; Bacchi Reggiani, Maria Letizia/0000-0003-3985-1542				[Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; DePaepe A, 1996, AM J MED GENET, V62, P417, DOI 10.1002/(SICI)1096-8628(19960424)62:4<417::AID-AJMG15>3.3.CO;2-S; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DUNCAN RW, 1995, SPINE, V20, P1197, DOI 10.1097/00007632-199505150-00016; ELDADAH ZA, 1995, J CLIN INVEST, V95, P874, DOI 10.1172/JCI117737; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; Legget ME, 1996, HEART, V75, P389, DOI 10.1136/hrt.75.4.389; Milewicz DM, 1996, CIRCULATION, V94, P2708, DOI 10.1161/01.CIR.94.11.2708; MITCHELL GE, 1967, RADIOLOGY, V89, P67, DOI 10.1148/89.1.67; NELSON JD, 1958, BRIT J RADIOL, V31, P561, DOI 10.1259/0007-1285-31-370-561; PEPIN MG, 1992, AM J HUM GENET, V5, pA44; PYERITZ RE, 1988, AM J HUM GENET, V43, P726; PYERITZ RE, 1993, AM J MED GENET, V47, P127, DOI 10.1002/ajmg.1320470131; RAFTOPOULOS C, 1993, ACTA CHIR BELG, P1; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SILVERMAN DI, 1995, AM J CARDIOL, V75, P157, DOI 10.1016/S0002-9149(00)80066-1; SMITH MD, 1993, J BONE JOINT SURG AM, V75A, P1067, DOI 10.2106/00004623-199307000-00013; SONIER CB, 1993, J NEURORADIOLOGY, V20, P292; SOULEN RL, 1987, RADIOLOGY, V165, P697, DOI 10.1148/radiology.165.3.3685348; STERN WE, 1988, J NEUROSURG, V69, P221, DOI 10.3171/jns.1988.69.2.0221; ZANHKA KG, 1989, J AM COLL CARDIOL  S, V13, pA119	23	144	145	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 11	1999	354	9182					910	913		10.1016/S0140-6736(98)12448-0	http://dx.doi.org/10.1016/S0140-6736(98)12448-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YK	10489951				2022-12-24	WOS:000082511800014
J	Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD				Schmidt, A; Wolde, M; Thiele, C; Fest, W; Kratzin, H; Podtelejnikov, AV; Witke, W; Huttner, WB; Soling, HD			Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid	NATURE			English	Article							ACYL-COENZYME-A; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; PHOSPHOLIPID-METABOLISM; TRANSPORT VESICLES; BINDING PARTNERS; PROTEIN; DYNAMIN; ENDOCYTOSIS; DOMAIN	Endophilin I is a presynaptic protein of unknown function that binds to dynamin, a GTPase that is implicated in endocytosis and recycling of synaptic vesicles. Here we show that endophilin I is essential for the formation of synaptic-like microvesicles (SLMVs) from the plasma membrane. Endophilin I exhibits lysophosphatidic acid acyl transferase (LPAAT) activity, and endophilin-I-mediated SLMV formation requires the transfer of the unsaturated fatty acid arachidonate to lysophosphatidic acid, converting it to phosphatidic acid. A deletion mutant lacking the SH3 domain through which endophilin I interacts with dynamin still exhibits LPAAT activity but no longer mediates SLMV formation. These results indicate that endophilin I may induce negative membrane curvature by converting an inverted-cone-shaped lipid to a cone-shaped lipid in the cytoplasmic leaflet of the bilayer. We propose that, through this action, endophilin I works with dynamin to mediate synaptic vesicle invagination from the plasma membrane and fission.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Gottingen, Dept Clin Biochem, D-37077 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg; Max Planck Society; University of Gottingen; Max Planck Society; European Molecular Biology Laboratory (EMBL)	Huttner, WB (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 110, D-01307 Dresden, Germany.	whuttner@sun0.urz.uni-heidelberg.de; hsoelin@gwdg.de	Huttner, Wieland B./P-4080-2018; Podtelejnikov, Alexandre/B-6120-2017	Podtelejnikov, Alexandre/0000-0002-8124-6584; Schmidt, Anne/0000-0002-8326-0937				Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Chernomordik LV, 1997, J CELL BIOL, V136, P81, DOI 10.1083/jcb.136.1.81; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DESNOS C, 1995, J CELL BIOL, V130, P1041, DOI 10.1083/jcb.130.5.1041; DUZGUNES N, 1995, NATO ADV SCI INST SE, V91, P97; Eberhardt C, 1997, J BIOL CHEM, V272, P20299, DOI 10.1074/jbc.272.32.20299; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; JANMEY PA, 1991, METHOD ENZYMOL, V196, P92; Kates M., 1986, TECHNIQUES LIPIDOLOG; Kirchhausen T, 1999, NATURE, V398, P470, DOI 10.1038/18989; Kozlov MM, 1998, BIOPHYS J, V75, P1384, DOI 10.1016/S0006-3495(98)74056-1; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; LIPOWSKY R, 1993, BIOPHYS J, V64, P1133, DOI 10.1016/S0006-3495(93)81479-6; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Micheva KD, 1997, FEBS LETT, V414, P308, DOI 10.1016/S0014-5793(97)01016-8; MORRIS SA, 1995, CURR BIOL, V5, P113, DOI 10.1016/S0960-9822(95)00028-5; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schmidt A, 1998, METHODS, V16, P160, DOI 10.1006/meth.1998.0663; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SOLING HD, 1989, ADV ENZYME REGUL, V28, P35, DOI 10.1016/0065-2571(89)90062-9; SOLING HD, 1989, J BIOL CHEM, V264, P10643; SOLING HD, 1987, J BIOL CHEM, V262, P16786; Spang A, 1998, P NATL ACAD SCI USA, V95, P11199, DOI 10.1073/pnas.95.19.11199; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; SPECTOR AA, 1969, ANAL BIOCHEM, V32, P297, DOI 10.1016/0003-2697(69)90089-X; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tuscher O, 1997, FEBS LETT, V419, P271, DOI 10.1016/S0014-5793(97)01471-3; VALLEE RB, 1995, TRENDS CELL BIOL, V5, P43, DOI 10.1016/S0962-8924(00)88937-0; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107; West J, 1997, DNA CELL BIOL, V16, P691, DOI 10.1089/dna.1997.16.691; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	49	436	457	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1999	401	6749					133	141		10.1038/43613	http://dx.doi.org/10.1038/43613			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234AF	10490020				2022-12-24	WOS:000082458800045
J	Katan, MB				Katan, MB			Functional foods	LANCET			English	Editorial Material									Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands; Agr Univ Wageningen, Div Human Nutr & Epidemiol, NL-6703 HD Wageningen, Netherlands	Wageningen University & Research; Wageningen University & Research	Katan, MB (corresponding author), Agr Univ Wageningen, Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands.							Bellisle F, 1998, BRIT J NUTR, V80, pS173, DOI 10.1079/BJN19980109; Diplock AT, 1999, BRIT J NUTR, V81, pS1, DOI 10.1017/S0007114599000471; Levin A, 1999, ANN INTERN MED, V131, P161, DOI 10.7326/0003-4819-131-2-199907200-00101; MIETTINEN TA, 1995, NEW ENGL J MED, V333, P1308, DOI 10.1056/NEJM199511163332002; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; Weststrate JA, 1998, EUR J CLIN NUTR, V52, P334, DOI 10.1038/sj.ejcn.1600559	6	14	15	6	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	1999	354	9181					794	794						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	232ZH	10485719				2022-12-24	WOS:000082400700006
J	Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE				Fernandez, G; Effern, A; Grunwald, T; Pezer, N; Lehnertz, K; Dumpelmann, M; Van Roost, D; Elger, CE			Real-time tracking of memory formation in the human rhinal cortex and hippocampus	SCIENCE			English	Article							MEDIAL TEMPORAL-LOBE; EVENT-RELATED POTENTIALS; EPISODIC MEMORY; ANTIEPILEPTIC DRUGS; SEMANTIC MEMORY; BRAIN ACTIVITY; SYSTEM; WORDS; ORGANIZATION; RECOGNITION	A fundamental question about human memory is which brain structures are involved, and when, in transforming experiences into memories. This experiment sought to identify neural correlates of memory formation with the use of intracerebral electrodes implanted in the brains of patients with temporal Lobe epilepsy. Event-related potentials (ERPs) were recorded directly from the medial temporal Lobe (MTL) as the patients studied single words. ERPs elicited by words subsequently recalled in a memory test were contrasted with ERPs elicited by unrecalled words. Memory formation was associated with distinct but interrelated ERP differences within the rhinal cortex and the hippocampus, which arose after about 300 and 500 milliseconds, respectively. These findings suggest that declarative memory formation is dissociable into subprocesses and sequentially organized within the MTL.	Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany; Univ Bonn, Dept Radiat & Nucl Phys, D-53105 Bonn, Germany; Univ Bonn, Dept Neurosurg, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn	Fernandez, G (corresponding author), Univ Bonn, Dept Epileptol, D-53105 Bonn, Germany.		Duempelmann, Matthias/K-2583-2012; Fernandez, Guillen/B-3771-2009	Duempelmann, Matthias/0000-0002-1476-7777; Fernandez, Guillen/0000-0002-5522-0604; Lehnertz, Klaus/0000-0002-5529-8559				AGGLETON JP, IN PRESS BEHAV BRAIN; Akaho R, 1996, PSYCHIAT CLIN NEUROS, V50, P61, DOI 10.1111/j.1440-1819.1996.tb01665.x; Amaral DG, 1990, HUMAN NERVOUS SYSTEM, P711; Baayen R. H., 1993, CELEX LEXICAL DATABA; Brewer JB, 1998, SCIENCE, V281, P1185, DOI 10.1126/science.281.5380.1185; Chen YJ, 1996, EPILEPSIA, V37, P81, DOI 10.1111/j.1528-1157.1996.tb00516.x; Cohen NJ, 1993, MEMORY AMNESIA HIPPO; Dolan RJ, 1999, HIPPOCAMPUS, V9, P25, DOI 10.1002/(SICI)1098-1063(1999)9:1<25::AID-HIPO3>3.0.CO;2-4; EICHENBAUM H, 1994, BEHAV BRAIN SCI, V17, P449, DOI 10.1017/S0140525X00035391; Elger CE, 1997, NEUROPSYCHOLOGIA, V35, P657, DOI 10.1016/S0028-3932(96)00110-8; Fernandez G, 1998, PSYCHOPHYSIOLOGY, V35, P709, DOI 10.1017/S0048577298970500; Fernandez G, 1999, HIPPOCAMPUS, V9, P35, DOI 10.1002/(SICI)1098-1063(1999)9:1<35::AID-HIPO4>3.0.CO;2-Z; Fernandez G, 1998, J NEUROSCI, V18, P1841; Gleissner U, 1997, NEUROREPORT, V8, P2893, DOI 10.1097/00001756-199709080-00018; Gregg V., 1976, RECALL RECOGNITION, P183; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HALGREN E, 1994, J PHYSIOL-PARIS, V88, P1, DOI 10.1016/0928-4257(94)90092-2; HEIT G, 1988, NATURE, V333, P773, DOI 10.1038/333773a0; Henke K, 1999, P NATL ACAD SCI USA, V96, P5884, DOI 10.1073/pnas.96.10.5884; JACKSON GD, 1996, MRI NEUROANATOMY; JONESGOTMAN M, 1991, EPILEPSY SURG, P469; Kelley WM, 1998, NEURON, V20, P927, DOI 10.1016/S0896-6273(00)80474-2; KLEE M, 1977, J NEUROPHYSIOL, V40, P647, DOI 10.1152/jn.1977.40.3.647; KUTAS M, 1997, COGNITIVE NEUROSCIEN, P197; Lepage M, 1998, HIPPOCAMPUS, V8, P313, DOI 10.1002/(SICI)1098-1063(1998)8:4<313::AID-HIPO1>3.0.CO;2-I; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; Mishkin M, 1997, PHILOS T R SOC B, V352, P1461, DOI 10.1098/rstb.1997.0132; NEVILLE HJ, 1986, J MEM LANG, V25, P75, DOI 10.1016/0749-596X(86)90022-7; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; PALLER KA, 1987, ELECTROEN CLIN NEURO, V67, P360, DOI 10.1016/0013-4694(87)90124-6; PALLER KA, 1992, ELECTROEN CLIN NEURO, V84, P269, DOI 10.1016/0168-5597(92)90008-Y; PALLER KA, 1990, J EXP PSYCHOL LEARN, V16, P1021, DOI 10.1037/0278-7393.16.6.1021; Panagopoulos GR, 1997, ACTA NEUROL SCAND, V96, P62; Picton TW., 1995, HDB NEUROPHYSIOLOGY, P3; RINGO JL, 1995, J NEUROPHYSIOL, V73, P1712, DOI 10.1152/jn.1995.73.4.1712; RUGG MD, 1995, NEUROPSYCHOLOGIA, V33, P471, DOI 10.1016/0028-3932(94)00132-9; Rugg MD, 1998, HUM BRAIN MAPP, V6, P394, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<394::AID-HBM12>3.3.CO;2-G; Schacter DL, 1999, HIPPOCAMPUS, V9, P7, DOI 10.1002/(SICI)1098-1063(1999)9:1<7::AID-HIPO2>3.0.CO;2-K; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Squire LR, 1998, HIPPOCAMPUS, V8, P205, DOI 10.1002/(SICI)1098-1063(1998)8:3<205::AID-HIPO3>3.0.CO;2-I; SUZUKI WA, 1994, J NEUROSCI, V14, P1856, DOI 10.1523/JNEUROSCI.14-03-01856.1994; Tulving E., 1972, ORG MEMORY, DOI DOI 10.1017/S0140525X00047257; UNDERWOO.BJ, 1969, PSYCHOL REV, V76, P559, DOI 10.1037/h0028143; Van Roost D, 1998, NEUROSURGERY, V43, P819, DOI 10.1097/00006123-199810000-00058; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; Wagner AD, 1998, SCIENCE, V281, P1188, DOI 10.1126/science.281.5380.1188; ZOLAMORGAN S, 1994, HIPPOCAMPUS, V4, P483, DOI 10.1002/hipo.450040410; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	51	243	245	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1582	1585		10.1126/science.285.5433.1582	http://dx.doi.org/10.1126/science.285.5433.1582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477525				2022-12-24	WOS:000082359500070
J	Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD				Ma, WY; Korngreen, A; Uzlaner, N; Priel, Z; Silberberg, SD			Extracellular sodium regulates airway ciliary motility by inhibiting a P2X receptor	NATURE			English	Article							HYPERTONIC SALINE AEROSOL; CYSTIC-FIBROSIS; MUCOCILIARY CLEARANCE; SURFACE LIQUID; HUMAN LUNG; EPITHELIA; INHALATION; INCREASES; HEALTHY; FLUID	The mucociliary system is responsible for clearing inhaled particles and pathogens from the airways, This important task is performed by the beating of cilia and the consequent movement of mucus from the lungs to the upper airways(1,2). Because ciliary motility is enhanced by elevated intracellular calcium concentrations, inhibition of calcium influx could lead to disease by jeopardizing mucociliary clearance. Several hormones and neurotransmitters stimulate ciliary motility, one of the most potent of which is extracellular ATP (ATP(0))(1), which acts by releasing calcium ions from internal stores and by activating calcium influx(3-5). Here we show that, in airway ciliated cells, extracellular sodium ions (Na-0(+)) specifically and competitively inhibit an ATP. gated channel that is permeable to calcium ions, and thereby attenuate ATP(0)-induced ciliary motility, Our finding points to a physiological role for Na-0(+) in ciliary function, and indicates that mucociliary clearance might be improved in respiratory disorders such as chronic bronchitis and cystic fibrosis by decreasing the sodium concentration of the airway surface fluid in which the cilia are bathed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Chem, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University	Silberberg, SD (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.		Silberberg, Shai/ABA-2778-2020	Korngreen, Alon/0000-0002-2036-6160				Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Boitano S, 1997, AM J PHYSIOL-LUNG C, V272, pL1189, DOI 10.1152/ajplung.1997.272.6.L1189; Daviskas E, 1997, EUR RESPIR J, V10, P2449, DOI 10.1183/09031936.97.10112449; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; Eng PA, 1996, PEDIATR PULM, V21, P77, DOI 10.1002/(SICI)1099-0496(199602)21:2<77::AID-PPUL3>3.0.CO;2-M; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Hull J, 1998, AM J RESP CRIT CARE, V157, P10, DOI 10.1164/ajrccm.157.1.9703045; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; Korngreen A, 1996, J PHYSIOL-LONDON, V497, P53, DOI 10.1113/jphysiol.1996.sp021749; Korngreen A, 1998, J PHYSIOL-LONDON, V508, P703, DOI 10.1111/j.1469-7793.1998.703bp.x; Matsui H, 1998, J CLIN INVEST, V102, P1125, DOI 10.1172/JCI2687; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PAVIA D, 1978, AM REV RESPIR DIS, V117, P199; Robinson M, 1996, AM J RESP CRIT CARE, V153, P1503, DOI 10.1164/ajrccm.153.5.8630593; Robinson M, 1997, THORAX, V52, P900, DOI 10.1136/thx.52.10.900; SILBERBERG A, 1990, BIORHEOLOGY, V27, P295; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Uzlaner N, 1999, J PHYSIOL-LONDON, V516, P179, DOI 10.1111/j.1469-7793.1999.179aa.x; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wills PJ, 1997, J CLIN INVEST, V99, P9, DOI 10.1172/JCI119138; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	24	64	68	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					894	897		10.1038/23743	http://dx.doi.org/10.1038/23743			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476971				2022-12-24	WOS:000082233200051
J	Moreno, E; Morata, G				Moreno, E; Morata, G			Caudal is the Hox gene that specifies the most posterior Drosophile segment	NATURE			English	Article							PROXIMAL-DISTAL AXIS; BRACHYURY GENE; HOMEOBOX GENES; GENITAL DISC; PROTEIN; MELANOGASTER; HEDGEHOG; EXPRESSION; ENCODES; ORGANIZATION	The homeobox gene caudal (can) has a maternal embryonic function that establishes the antero-posterior body axis of Drosophila(1,2). It also has a conserved(2,4) late embryonic and imaginal function(1) related to the development of the posterior body region. Here we report the developmental role of can in adult Drosophila, It is required for the normal development of the analia structures, which derive from the most posterior body segment. In the absence of cad function, the analia develop like the immediately anterior segment (male genitalia), following the transformation rule of the canonical Hox genes(5), We also show that cad can induce ectopic analia development if expressed in the head or wing. We propose that cad is the Hox gene that determines the development of the fly's most posterior segment. cad acts in combination with the Hedgehog (Hh) pathway(6) to specify the different components of the analia: the activities of cad and of the Hh pathway induce Distal-less expression that, together with cad, promote external analia development. In the absence of the Hh pathway, cad induces internal analia development, probably by activating the brachyenteron and even-skipped genes.	UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Morata, G (corresponding author), UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain.		Moreno, Eduardo/D-7262-2011	Morata, Gines/0000-0003-3274-5173; moreno, eduardo/0000-0001-5040-452X				Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Casares F, 1997, DEV GENES EVOL, V207, P216, DOI 10.1007/s004270050110; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DiazBenjumea FJ, 1995, DEVELOPMENT, V121, P4215; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; EPPER F, 1983, ROUX ARCH DEV BIOL, V192, P270, DOI 10.1007/BF00848659; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; Gorfinkiel N, 1997, GENE DEV, V11, P2259, DOI 10.1101/gad.11.17.2259; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; KISPERT A, 1994, GENE DEV, V8, P2137, DOI 10.1101/gad.8.18.2137; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MILLER DJ, 1993, NATURE, V365, P215, DOI 10.1038/365215b0; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MURAKAMI R, 1995, ROUX ARCH DEV BIOL, V205, P89, DOI 10.1007/BF00188847; NOTHIGER R, 1977, ROUX ARCH DEV BIOL, V181, P367, DOI 10.1007/BF00848062; NUSSLEINVOLHARD C, 1985, COLD SPRING HARB SYM, V50, P145, DOI 10.1101/SQB.1985.050.01.020; Sanchez L, 1997, DEV GENES EVOL, V207, P229, DOI 10.1007/s004270050111; SANCHEZHERRERO E, 1985, NATURE, V313, P108, DOI 10.1038/313108a0; SINGER JB, 1996, DEVELOPMENT, V122, P3703; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wu LH, 1998, DEVELOPMENT, V125, P2433	28	111	114	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					873	877		10.1038/23709	http://dx.doi.org/10.1038/23709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476966				2022-12-24	WOS:000082233200046
J	Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA				Wang, SL; Hawkins, CJ; Yoo, SJ; Muller, HAJ; Hay, BA			The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by HID	CELL			English	Article							REAPER-INDUCED APOPTOSIS; BACULOVIRUS INHIBITOR; NURSE CELLS; DEATH; GENE; PROTEINS; GRIM; MELANOGASTER; EXPRESSION; PROTEASES	Drosophila Reaper (RPR), Head Involution Defective (HID), and GRIM induce caspase-dependent cell death and physically interact with the cell death inhibitor DIAP1. Here we show that HID blocks DIAP1's ability to inhibit caspase activity and provide evidence suggesting that RPR and GRIM can act similarly. Based on these results, we propose that RPR, HID, and GRIM promote apoptosis by disrupting productive IAP-caspase interactions and that DIAP1 is required to block apoptosis-inducing caspase activity. Supporting this hypothesis, we show that elimination of DIAP1 function results in global early embryonic cell death and a large increase in DIAP1-inhibitable caspase activity and that DIAP1 is still required for cell survival when expression of rpr, hid, and grim is eliminated.	CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA; Univ Dusseldorf, Genet Inst, D-40225 Dusseldorf, Germany	California Institute of Technology; Heinrich Heine University Dusseldorf	Muller, HAJ (corresponding author), CALTECH, Div Biol MC156 29, Pasadena, CA 91125 USA.		Müller, Hans-Arno/G-5753-2012; Muller, Hans-Arno/Q-2864-2019; Hawkins, Christine/B-8769-2011	Müller, Hans-Arno/0000-0002-7525-6874; Muller, Hans-Arno/0000-0002-7525-6874; Hawkins, Christine/0000-0001-8120-1071	NIGMS NIH HHS [GM057422-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Cavaliere V, 1998, DEV GENES EVOL, V208, P106, DOI 10.1007/s004270050160; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Foley K, 1998, DEVELOPMENT, V125, P1075; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thress K, 1998, EMBO J, V17, P6135, DOI 10.1093/emboj/17.21.6135; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhou L, 1997, P NATL ACAD SCI USA, V94, P5131, DOI 10.1073/pnas.94.10.5131	49	417	432	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 20	1999	98	4					453	463		10.1016/S0092-8674(00)81974-1	http://dx.doi.org/10.1016/S0092-8674(00)81974-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	229CA	10481910	Bronze			2022-12-24	WOS:000082174900006
J	Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C				Gabolde, M; Guilloud-Bataille, M; Feingold, J; Besmond, C			Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Hop Robert Debre, INSERM, U458, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Besmond, C (corresponding author), Hop Robert Debre, INSERM, U458, F-75019 Paris, France.		BESMOND, Claude/L-8451-2018	BESMOND, Claude/0000-0001-9073-8225				Gabolde M, 1999, HUM MUTAT, V14, P80, DOI 10.1002/(SICI)1098-1004(1999)14:1<80::AID-HUMU10>3.0.CO;2-J; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Hull J, 1998, THORAX, V53, P1018, DOI 10.1136/thx.53.12.1018; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8	5	79	79	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1999	319	7218					1166	1167		10.1136/bmj.319.7218.1166	http://dx.doi.org/10.1136/bmj.319.7218.1166			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	253BF	10541506	Green Published, Bronze			2022-12-24	WOS:000083536200022
J	Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F				Knight, BP; Pelosi, F; Michaud, GF; Strickberger, SA; Morady, F			Clinical consequences of electrocardiographic artifact mimicking ventricular tachycardia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-RISK		Univ Michigan, Med Ctr, Dept Internal Med, Div Cardiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Knight, BP (corresponding author), Univ Michigan Hlth Syst, 1500 E Med Ctr Dr,B1F245, Ann Arbor, MI 48109 USA.							Dyke DBS, 1997, J CARDIOVASC ELECTR, V8, P1327, DOI 10.1111/j.1540-8167.1997.tb01025.x; FALK RH, 1987, AM J CARDIOL, V59, P924, DOI 10.1016/0002-9149(87)91124-6; Gregoratos G, 1998, J AM COLL CARDIOL, V31, P1175; KANTOR HI, 1966, AM J OBSTET GYNECOL, V94, P287, DOI 10.1016/0002-9378(66)90484-4; KLEINMAN B, 1990, J CLIN MONITOR, V6, P258; KRASNOW AZ, 1976, AM HEART J, V91, P349, DOI 10.1016/S0002-8703(76)80220-7; LAMPERT BA, 1988, ANESTH ANALG, V67, P1096, DOI 10.1213/00000539-198867110-00014; LIN SL, 1991, JPN HEART J, V32, P847; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MURDOCK DK, 1986, HEART LUNG, V15, P150; PAULSEN AW, 1988, ANESTHESIOLOGY, V69, P803, DOI 10.1097/00000542-198811000-00043; SCHILLER EC, 1988, ANESTHESIOLOGY, V68, P477, DOI 10.1097/00000542-198803000-00043	13	143	147	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 21	1999	341	17					1270	1274		10.1056/NEJM199910213411704	http://dx.doi.org/10.1056/NEJM199910213411704			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247NF	10528037				2022-12-24	WOS:000083226300004
J	Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL				Friedberg, M; Saffran, B; Stinson, TJ; Nelson, W; Bennett, CL			Evaluation of conflict of interest in economic analyses of new drugs used in oncology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; COST-EFFECTIVENESS ANALYSIS; ADVANCED OVARIAN-CANCER; CELL LUNG-CANCER; PLACEBO-CONTROLLED TRIAL; BLOOD PROGENITOR CELLS; NON-HODGKINS-LYMPHOMA; FIRST-LINE THERAPY; FACTOR GM-CSF	Context Recent studies have found that when investigators have financial relationships with pharmaceutical or product manufacturers, they are less likely to criticize the safety or efficacy of these agents. The effects of health economics research on pharmaceutical company revenue make drug investigations potentially vulnerable to this bias. Objective To determine whether there is an association between pharmaceutical industry sponsorship and economic assessment of oncology drugs. Design MEDLINE and HealthSTAR databases (1988-1998) were searched for original English-language research articles of cost or cost-effectiveness analyses of 6 oncology drugs in 3 new drug categories (hematopoietic colony-stimulating factors, serotonin antagonist antiemetics, and taxanes), yielding 44 eligible articles. Two investigators independently abstracted each article based on specific criteria. Main Outcome Measure Relationships between funding source and (1) qualitative cost assessment (favorable, neutral, or unfavorable) and (2) qualitative conclusions that overstated quantitative results. Results Pharmaceutical company-sponsored studies were less likely than nonprofit-sponsored studies to report unfavorable qualitative conclusions (1/20 [5%] vs 9/24 [38%]; P = .04), whereas overstatements of quantitative results were not significantly different in pharmaceutical company-sponsored (6/20 [30%]) vs nonprofit-sponsored (3/24 [13%]) studies (P = .26). Conclusions Although we did riot identify bias in individual studies, these findings indicate that pharmaceutical company sponsorship of economic analyses is associated with reduced likelihood of reporting unfavorable results.	Lakeside Vet Adm Med Ctr, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Northwestern Univ, Div Hematol Oncol, Evanston, IL USA; Swarthmore Coll, Dept Econ, Swarthmore, PA USA	Northwestern University; Northwestern University; Swarthmore College	Bennett, CL (corresponding author), Lakeside Vet Adm Med Ctr, 400 E Ontario Ave, Chicago, IL 60611 USA.	cbenne@nwu.edu	Friedberg, Mark William/Y-2607-2019; Bennett, Charles L/C-2050-2008	Friedberg, Mark William/0000-0002-7907-8358; 				Azimi NA, 1998, J GEN INTERN MED, V13, P664, DOI 10.1046/j.1525-1497.1998.00201.x; BALLATORI E, 1994, PHARMACOECONOMICS, V5, P227, DOI 10.2165/00019053-199405030-00006; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; BENNETT CL, 1995, STEM CELLS, V13, P414, DOI 10.1002/stem.5530130412; Bennett CL, 1997, CANCER INVEST, V15, P227, DOI 10.3109/07357909709039720; BENNETT CL, 1995, J CLIN ONCOL, V13, P2457, DOI 10.1200/JCO.1995.13.9.2457; Bernini JC, 1996, J PEDIATR-US, V129, P551, DOI 10.1016/S0022-3476(96)70120-8; BLEIBERG H, 1994, SUPPORT CARE CANCER, V2, P145, DOI 10.1007/BF00417472; BRICE P, 1995, PHARMACOECONOMICS, V7, P238, DOI 10.2165/00019053-199507030-00007; BUXTON MJ, 1992, BRIT J CANCER, V66, pS64; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; CHAO NJ, 1993, BLOOD, V81, P2031; Chouaid C, 1998, J CLIN ONCOL, V16, P2700, DOI 10.1200/JCO.1998.16.8.2700; Cieslak GD, 1996, ANESTHESIOLOGY, V85, P1076, DOI 10.1097/00000542-199611000-00016; CLARK RE, 1994, LEUKEMIA LYMPHOMA, V16, P141, DOI 10.3109/10428199409114151; Covens A, 1996, CANCER, V77, P2086, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2086::AID-CNCR18>3.0.CO;2-R; CUNNINGHAM D, 1993, EUR J CANCER, V29A, P303, DOI 10.1016/0959-8049(93)90372-M; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; Dranitsaris G, 1997, PHARMACOECONOMICS, V11, P566, DOI 10.2165/00019053-199711060-00005; DRANITSARIS G, 1995, LEUKEMIA LYMPHOMA, V17, P139, DOI 10.3109/10428199509051714; DRUMMOND M, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199400061-00012; Duncan N, 1997, PHARMACOECONOMICS, V11, P169, DOI 10.2165/00019053-199711020-00006; DUNLOP DJ, 1994, BRIT J CANCER, V70, P943, DOI 10.1038/bjc.1994.425; Edwards G, 1998, BRIT MED J, V317, P336; Eichenwald Kurt, 1999, N Y Times Web, pA16; Eichenwald Kurt, 1999, N Y Times Web, P34; Elit LM, 1997, J CLIN ONCOL, V15, P632, DOI 10.1200/JCO.1997.15.2.632; ELKS ML, 1995, J LAB CLIN MED, V126, P19; FAUCHER C, 1994, BONE MARROW TRANSPL, V14, P895; GLASPY JA, 1993, EUR J CANCER, V29A, pS23, DOI 10.1016/0959-8049(93)90613-K; GULATI S, 1993, STEM CELLS, V11, P20, DOI 10.1002/stem.5530110105; GULATI S, 1993, ANTI-CANCER DRUG, V4, P13, DOI 10.1097/00001813-199305001-00003; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; GULATI SC, 1995, J CLIN ONCOL, V13, P2152, DOI 10.1200/JCO.1995.13.9.2152; HILLMAN AL, 1995, ANN INTERN MED, V123, P61; Jefferson T, 1998, JAMA-J AM MED ASSOC, V280, P275, DOI 10.1001/jama.280.3.275; Johnson N E, 1993, Pharmacoeconomics, V3, P471, DOI 10.2165/00019053-199303060-00007; Krimsky S, 1998, JAMA-J AM MED ASSOC, V280, P225, DOI 10.1001/jama.280.3.225; LUCE BR, 1994, PHARMACOECONOMICS, V6, P42, DOI 10.2165/00019053-199406010-00005; Lyman G H, 1995, Oncology (Williston Park), V9, P85; LYMAN GH, 1995, JNCI-J NATL CANCER I, V85, P488; Mapelli V, 1994, Pharmacoeconomics, V6 Suppl 2, P27; McGuire W, 1997, J CLIN ONCOL, V15, P640, DOI 10.1200/JCO.1997.15.2.640; McQuaker IG, 1997, J CLIN ONCOL, V15, P451, DOI 10.1200/JCO.1997.15.2.451; Messori A, 1996, CANCER, V78, P2366, DOI 10.1002/(SICI)1097-0142(19961201)78:11<2366::AID-CNCR15>3.3.CO;2-R; Messori A, 1996, J CLIN PHARM THER, V21, P57, DOI 10.1111/j.1365-2710.1996.tb00001.x; Mitchell PLR, 1997, J CLIN ONCOL, V15, P1163, DOI 10.1200/JCO.1997.15.3.1163; NICHOLS CR, 1994, J CLIN ONCOL, V12, P1245, DOI 10.1200/JCO.1994.12.6.1245; Ortega A, 1997, GYNECOL ONCOL, V66, P454, DOI 10.1006/gyno.1997.4786; PEROUTKA JA, 1995, FORMULARY, V30, P394; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; RIIKONEN P, 1995, STEM CELLS, V13, P289, DOI 10.1002/stem.5530130310; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; Rundall P, 1998, BRIT MED J, V317, P338; Smith R, 1998, BMJ-BRIT MED J, V317, P291, DOI 10.1136/bmj.317.7154.291; SMITH TJ, 1993, JNCI-J NATL CANCER I, V85, P1460, DOI 10.1093/jnci/85.18.1460; Sorell T, 1998, BRIT MED J, V317, P334; Souetre E, 1996, EUR J CANCER, V32A, P1162, DOI 10.1016/0959-8049(95)00655-9; Splinter WM, 1997, CAN J ANAESTH, V44, P825, DOI 10.1007/BF03013158; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; Tang J, 1996, ANESTH ANALG, V83, P304, DOI 10.1097/00000539-199608000-00018; TANNEBERGER S, 1992, J CHEMOTHERAPY, V4, P326; Teoh G. K. H., 1994, Annals Academy of Medicine Singapore, V23, P823; UYLDEGROOT CA, 1994, EUR J CANCER, V30A, P1631; Vellenga E, 1996, J CLIN ONCOL, V14, P619, DOI 10.1200/JCO.1996.14.2.619; WATCHA MF, 1994, J CLIN ANESTH, V6, P370, DOI 10.1016/S0952-8180(05)80006-6; ZAGONEL V, 1994, ANN ONCOL, V5, pS127, DOI 10.1093/annonc/5.suppl_2.S127; ZBROZEK AS, 1994, AM J HOSP PHARM, V51, P1555, DOI 10.1093/ajhp/51.12.1555	68	311	320	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	1999	282	15					1453	1457		10.1001/jama.282.15.1453	http://dx.doi.org/10.1001/jama.282.15.1453			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245LT	10535436	Bronze			2022-12-24	WOS:000083111000031
J	Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S				Takei, Y; Ikeda, S; Hashikura, Y; Ikegami, T; Kawasaki, S			Partial-liver transplantation to treat familial amyloid polyneuropathy: Follow-up of 11 patients	ANNALS OF INTERNAL MEDICINE			English	Article							TRANSTHYRETIN AMYLOIDOSIS; CLINICAL IMPROVEMENT; SWEDISH PATIENTS; NERVE	Background: Recently, liver transplantation has been used to treat patients with familial amyloid polyneuropathy (FAP). Objective: To describe the clinical course of patients with FAP who received partial-liver transplantation from living donors. Design: Case series. Setting: University hospital in Matsumoto, Japan. Patients: 11 patients with FAP who underwent partial-liver transplantation. The transthyretin gene abnormality in all 11 patients was the substitution of methionine for valine at position 30. Intervention: Partial liver transplantation from living donors. Measurements: Preoperative and follow-up (3 to 64 months) clinical data, including routine laboratory data, nerve conduction velocity tests, and sural nerve histology. Results: All 7 patients who had severe gastrointestinal autonomic disorders or polyneuropathy localized to the lower limbs for less than 4 years showed improvement. Three of 4 patients with polyneuropathy involving both the upper and lower limbs had adverse outcomes, including two deaths. The preoperative duration of their illness was more than 6 years. These 3 patients also had marked decreases in creatinine clearance and nerve conduction velocities and severe loss of myelinated fibers in sural nerves. Conclusion: Preoperative clinical severity and duration of illness are associated with outcomes after liver transplantation for FAP.	Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Surg, Matsumoto, Nagano 3908621, Japan	Shinshu University; Shinshu University	Ikeda, S (corresponding author), Shinshu Univ, Sch Med, Dept Med Neurol, Matsumoto, Nagano 3908621, Japan.	ikedasi@hsp.md.shinshu-u.ac.jp						Benson MD, 1996, AMYLOID, V3, P44, DOI 10.3109/13506129609014354; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; ERICZON BG, 1999, FAMILIAL AMYLOID POL; Glenner G.G, 1980, AMYLOID AMYLOIDOSIS, P88; HANYU N, 1989, ANN NEUROL, V25, P340, DOI 10.1002/ana.410250405; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; HOLMGREN G, 1991, CLIN GENET, V40, P242; Ikeda S, 1997, AMYLOID, V4, P18, DOI 10.3109/13506129708995264; IKEDA S, 1992, EUR NEUROL, V32, P308, DOI 10.1159/000116850; IKEDA SI, 1987, BRAIN, V110, P315, DOI 10.1093/brain/110.2.315; Kawasaki S, 1998, ANN SURG, V227, P269, DOI 10.1097/00000658-199802000-00017; KYLE RA, 1993, PERIPHERAL NEUROPATH, P1294; MAKUUCHI M, 1993, SURGERY, V113, P395; PARRILLA P, 1995, BRIT J SURG, V82, P825, DOI 10.1002/bjs.1800820634; SKINNER M, 1994, ANN INTERN MED, V120, P133, DOI 10.7326/0003-4819-120-2-199401150-00006; SOPRANO DR, 1985, J BIOL CHEM, V260, P1793; STEEN L, 1994, AMYLOID, V1, P138, DOI 10.3109/13506129409148636; SUHR OB, 1995, TRANSPLANTATION, V60, P933, DOI 10.1097/00007890-199511150-00009; THOMAS PK, 1974, BRAIN, V97, P395, DOI 10.1093/brain/97.1.395	19	44	45	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	1999	131	8					592	595		10.7326/0003-4819-131-8-199910190-00008	http://dx.doi.org/10.7326/0003-4819-131-8-199910190-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	246ZR	10523220				2022-12-24	WOS:000083196600006
J	Eshed, Y; Baum, SF; Bowman, JL				Eshed, Y; Baum, SF; Bowman, JL			Distinct mechanisms promote polarity establishment in carpels of Arabidopsis	CELL			English	Article							HISTONE DEACETYLASE; OVULE DEVELOPMENT; GENE; THALIANA; PROTEINS; FAMILY; AINTEGUMENTA; PLANTS; MEMBER	Lateral organs of plants display asymmetry with abaxial identity being specified by members of the Arabidopsis YABBY gene family. Mutations in CRABS CLAW, the founding family member, display ectopic formation of adaxial carpel tissues only when the functions of other genes, such as GYMNOS or KANADI, are also compromised. Mutations in these genes alone do not result in loss of polar differentiation, and therefore, they act redundantly with CRABS CLAW to establish polarity. As GYMNOS encodes a uniformly expressed homolog of the chromatin-remodeling protein, Mi2, we argue that the unique genetic interactions do not reflect a molecular redundancy. Rather, CRABS CLAW regulates transcription spatially, whereas GYMNOS regulates downstream targets temporally to ensure proper differentiation of the carpels.	Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis	Bowman, JL (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.	jlbowman@ucdavis.edu	Bowman, John P./ABF-5108-2020	Bowman, John P./0000-0002-4528-9333; Eshed, Yuval/0000-0001-8290-0018; Bowman, John/0000-0001-7347-3691				Alvarez J, 1999, DEVELOPMENT, V126, P2377; Baker SC, 1997, GENETICS, V145, P1109; Baum SF, 1996, PROTOPLASMA, V192, P178, DOI 10.1007/BF01273890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Bowman JL, 1999, CURR TOP DEV BIOL, V45, P155, DOI 10.1016/S0070-2153(08)60316-6; Bowman JL, 1999, DEVELOPMENT, V126, P2387; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Elliott RC, 1996, PLANT CELL, V8, P155, DOI 10.1105/tpc.8.2.155; ESTRUCH JJ, 1991, SCIENCE, V254, P1364, DOI 10.1126/science.254.5036.1364; Grossniklaus U, 1998, SCIENCE, V280, P446, DOI 10.1126/science.280.5362.446; HAKE S, 1995, PHILOS T R SOC B, V350, P45, DOI 10.1098/rstb.1995.0136; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Klucher KM, 1996, PLANT CELL, V8, P137, DOI 10.1105/tpc.8.2.137; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; McConnell JR, 1998, DEVELOPMENT, V125, P2935; Ogas J, 1997, SCIENCE, V277, P91, DOI 10.1126/science.277.5322.91; Ori N, 1999, PLANT CELL, V11, P1073, DOI 10.1105/tpc.11.6.1073; Pearse A.G.E., 1985, ANAL TECHNOLOGY, V2, P748; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Sessions A, 1999, GENE DEV, V13, P1051, DOI 10.1101/gad.13.9.1051; SESSIONS RA, 1995, DEVELOPMENT, V121, P1519; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; THOMAS JH, 1993, TRENDS GENET, V9, P395, DOI 10.1016/0168-9525(93)90140-D; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	31	286	301	2	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 15	1999	99	2					199	209		10.1016/S0092-8674(00)81651-7	http://dx.doi.org/10.1016/S0092-8674(00)81651-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	246JB	10535738	Bronze			2022-12-24	WOS:000083159700010
J	Henney, JE				Henney, JE			Warning on dietary supplements	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1218	1218		10.1001/jama.282.13.1218	http://dx.doi.org/10.1001/jama.282.13.1218			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241UM	10517411				2022-12-24	WOS:000082901100006
J	van Weel, C; van Grunsven, P				van Weel, C; van Grunsven, P			Resistance to prescribing and to antibiotics	LANCET			English	Editorial Material							DOXYCYCLINE; TRIAL		Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	van Weel, C (corresponding author), Univ Nijmegen, Dept Gen Practice & Social Med, NL-6500 HB Nijmegen, Netherlands.		van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Graham A, 1999, BRIT MED J, V319, P173, DOI 10.1136/bmj.319.7203.173; HAYNES RB, COMPLIANCE HLTH CARE; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Spach DH, 1998, ANN ALLERG ASTHMA IM, V81, P293, DOI 10.1016/S1081-1206(10)63121-3; Stalman W, 1997, BRIT J GEN PRACT, V47, P794; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; ZWART S, 1999, THESIS U UTRECHT UTR; 1990, LANCET, V335, P262	9	5	5	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 25	1999	354	9184					1052	1052		10.1016/S0140-6736(99)90107-1	http://dx.doi.org/10.1016/S0140-6736(99)90107-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	239PA	10509494				2022-12-24	WOS:000082777500008
J	Javaheri, S				Javaheri, S			A mechanism of central sleep apnea in patients with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; VENTILATORY RESPONSE; HYPOPNEA SYNDROME; HYPERCAPNIA; RESPONSIVENESS; PATHOGENESIS; THEOPHYLLINE; INSTABILITY; HYPOCAPNIA; DISEASE	Background Breathing is controlled by a negative-feedback system in which an increase in the partial pressure of arterial carbon dioxide stimulates breathing and a decrease inhibits it. Although enhanced sensitivity to carbon dioxide helps maintain the partial pressure of arterial carbon dioxide within a narrow range during waking hours, in some persons a large hyperventilatory response during sleep may lower the value below the apneic threshold, thereby resulting in central apnea. I tested the hypothesis that enhanced sensitivity to carbon dioxide contributes to the development of central sleep apnea in some patients with heart failure. Methods This prospective study included 20 men who had treated, stable heart failure with left ventricular systolic dysfunction. Ten had central sleep apnea, and 10 did not. The patients underwent polysomnography and studies of their ventilatory response to carbon dioxide. Results Patients who met the criteria for central sleep apnea had significantly more episodes of central apnea per hour than those without central sleep apnea (mean [+/-SD], 35+/-24 vs. 0.5+/-1.0 episodes per hour). Those with sleep apnea also had a significantly larger ventilatory response to carbon dioxide than those without central sleep apnea (5.1+/-3.1 vs. 2.1=/-1.0 liters per minute per millimeter of mercury, P=0.007), and there was a significant positive correlation between ventilatory response and the number of episodes of apnea and hypopnea per hour during sleep (r=0.6, P=0.01). Conclusions Enhanced sensitivity to carbon dioxide may predispose some patients with heart failure to the development of central sleep apnea. (N Engl J Med 1999;341:949-54.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Med Ctr, Pulm Serv, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), VA Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.	javaheri.shahrokh@cincinnati.va.gov						Andreas S, 1998, RESP MED, V92, P426, DOI 10.1016/S0954-6111(98)90286-4; [Anonymous], 1992, SLEEP, V15, P174; Bradley T D, 1996, J Card Fail, V2, P223, DOI 10.1016/S1071-9164(96)80045-5; CARSKADON MA, 1994, PRINCIPLES PRACTICE, P16; CHAPMAN KR, 1988, J APPL PHYSIOL, V64, P1000, DOI 10.1152/jappl.1988.64.3.1000; CHERNIACK NS, 1990, PROG CLIN BIOL RES, V345, P167; CHERNIACK NS, 1973, NEW ENGL J MED, V288, P952, DOI 10.1056/NEJM197305032881810; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; Dempsey JA, 1996, SLEEP, V19, P236; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; ESPINOZA H, 1991, AM REV RESPIR DIS, V144, P1121, DOI 10.1164/ajrccm/144.5.1121; GUYTON AC, 1956, AM J PHYSIOL, V187, P395, DOI 10.1152/ajplegacy.1956.187.2.395; Hall MJ, 1996, AM J RESP CRIT CARE, V154, P376, DOI 10.1164/ajrccm.154.2.8756809; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; Javaheri S, 1998, ANN INTERN MED, V128, P204, DOI 10.7326/0003-4819-128-3-199802010-00006; JAVAHERI S, 1995, ANN INTERN MED, V123, P77; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1990, THORAX, V45, P743, DOI 10.1136/thx.45.10.743; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; JAVAHERI S, 1992, AM REV RESPIR DIS, V145, P837, DOI 10.1164/ajrccm/145.4_Pt_1.837; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; KAWAKAMI Y, 1984, AM REV RESPIR DIS, V129, P703, DOI 10.1164/arrd.1984.129.5.703; KELLER CA, 1984, AM REV RESPIR DIS, V130, P606; KELSEN SG, 1984, CHRONIC OBSTRUCTIVE, P65; KHOO MCK, 1982, J APPL PHYSIOL, V53, P644, DOI 10.1152/jappl.1982.53.3.644; KHOO MCK, 1991, LUNG SCI FDN, V2, P1419; MOORE GC, 1976, NEW ENGL J MED, V295, P861, DOI 10.1056/NEJM197610142951604; MOUNTAIN R, 1978, NEW ENGL J MED, V298, P521, DOI 10.1056/NEJM197803092981001; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; SAUNDERS NA, 1976, AM REV RESPIR DIS, V113, P497; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; SMITH CA, 1995, J APPL PHYSIOL, V79, P689, DOI 10.1152/jappl.1995.79.3.689; Weil J, 1984, PULMONARY HYPERTENSI, P321; WHITE DP, 1983, AM REV RESPIR DIS, V128, P984; WHITE DP, 1994, PRINCIPLES PRACTICE, P630; Wilcox I, 1998, EUR RESPIR J, V11, P7, DOI 10.1183/09031936.98.11010007; XIE AL, 1995, AM J RESP CRIT CARE, V152, P1950, DOI 10.1164/ajrccm.152.6.8520761; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	43	331	366	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1999	341	13					949	954		10.1056/NEJM199909233411304	http://dx.doi.org/10.1056/NEJM199909233411304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237LP	10498490				2022-12-24	WOS:000082658100004
J	Liebelt, EL; DeAngelis, CD				Liebelt, EL; DeAngelis, CD			Evolving trends and treatment advances in pediatric poisoning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROL-CENTERS; EFFICACY; CHARCOAL; IPECAC; SAFETY; HOME		Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Liebelt, EL (corresponding author), Johns Hopkins Sch Med, Dept Pediat, 600 N Wolfe St,CMSC 144, Baltimore, MD 21287 USA.							*AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P711; *AM AC CLIN TOX EU, 1997, CLIN TOXICOL, V35, P699; American Academy of Clinical Toxicology European Association of Poison Centres and Clinical Toxicologists, 1997, CLIN TOXICOL, V35, P721; BOND GR, 1995, ANN EMERG MED, V25, P338, DOI 10.1016/S0196-0644(95)70291-1; BOND GR, 1993, ANN EMERG MED, V22, P1403, DOI 10.1016/S0196-0644(05)81986-9; BOYLE PJ, 1993, J CLIN ENDOCR METAB, V76, P752, DOI 10.1210/jc.76.3.752; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; KORNBERG AE, 1991, ANN EMERG MED, V20, P648, DOI 10.1016/S0196-0644(05)82385-6; LAMMINPAA A, 1993, HUM EXP TOXICOL, V12, P29, DOI 10.1177/096032719301200106; LITOVITZ T, 1992, PEDIATRICS, V89, P999; LOVEJOY FH, 1994, PEDIATRICS, V94, P220; Miller TR, 1997, ANN EMERG MED, V29, P239, DOI 10.1016/S0196-0644(97)70275-0; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; Rodgers GB, 1996, JAMA-J AM MED ASSOC, V275, P1661, DOI 10.1001/jama.275.21.1661; SCALZO AJ, 1990, AM J DIS CHILD, V144, P867, DOI 10.1001/archpedi.1990.02150320031020; Shannon M, 1997, J PEDIATR-US, V131, P582, DOI 10.1016/S0022-3476(97)70066-0; Shanon M, 1998, PEDIATR EMERG CARE, V14, P293, DOI 10.1097/00006565-199808000-00015; TENENBEIN M, 1987, J PEDIATR-US, V111, P142, DOI 10.1016/S0022-3476(87)80365-7; WOOLF AD, 1992, NEW ENGL J MED, V326, P1739, DOI 10.1056/NEJM199206253262604	19	40	44	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1999	282	12					1113	1115		10.1001/jama.282.12.1113	http://dx.doi.org/10.1001/jama.282.12.1113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	236JJ	10501099				2022-12-24	WOS:000082596200002
J	Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A				Hendrich, B; Hardeland, U; Ng, HH; Jiricny, J; Bird, A			The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites	NATURE			English	Article							CYTOSINE RESIDUES; DNA GLYCOSYLASES; ESCHERICHIA-COLI; ENDONUCLEASE; DINUCLEOTIDE; MUTATION; MISPAIRS; CLONING; URACIL; CANCER	In addition to its well-documented effects on gene silencing, cytosine methylation is a prominent cause of mutations. In humans, the mutation rate from 5-methylcytosine (m(5)C) to thymine (T) is 10-50-fold higher(1-4) than other transitions and the methylated sequence CpG is consequently under-represented(5). Over one-third of germline point mutations associated with human genetic disease(6) and many somatic mutations leading to cancer(7,8) involve loss of CpG. The primary cause of mutability appears to be hydrolytic deamination. Cytosine deamination produces mismatched uracil (U), which can be removed by uracil glycosylase(9,10), whereas m(5)C deamination generates a GT mispair that cannot be processed by this enzyme. Correction of m(5)CpG.TpG mismatches may instead be initiated by the thymine DNA glycosylase, TDG(11,12). Here we show that MBD4, an unrelated mammalian protein that contains a methyl-CpG binding domain(13,14), can also efficiently remove thymine or uracil from a mismatches CpG site in vitro. Furthermore, the methyl-CpG binding domain of MBD4 binds preferentially to m(5)CpG.TpG mismatches-the primary product of deamination at methyl-CpG. The combined specificities of binding and catalysis indicate that this enzyme may function to minimize mutation at methyl-CpG.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Inst Med Radiobiol, CH-8008 Zurich, Switzerland	University of Edinburgh	Bird, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.	A.Bird@ed.ac.uk	Ng, Huck Hui/A-1135-2009; Hendrich, Brian/AAG-5898-2020	Hendrich, Brian/0000-0002-0231-3073; Bird, Adrian/0000-0002-8600-0372	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P444; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BULMER M, 1986, MOL BIOL EVOL, V3, P322; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; DUNCAN BK, 1980, NATURE, V287, P560, DOI 10.1038/287560a0; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Horst JP, 1996, EMBO J, V15, P5459, DOI 10.1002/j.1460-2075.1996.tb00929.x; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Lindahl T, 1997, CURR OPIN GENET DEV, V7, P158, DOI 10.1016/S0959-437X(97)80124-4; MANIATIS T, 1982, MOL CLONING LABORATO, P196; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; Shiota S, 1997, P NATL ACAD SCI USA, V94, P593, DOI 10.1073/pnas.94.2.593; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; SVED J, 1990, P NATL ACAD SCI USA, V87, P4692, DOI 10.1073/pnas.87.12.4692; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	27	496	510	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 16	1999	401	6750					301	304		10.1038/45843	http://dx.doi.org/10.1038/45843			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237VZ	10499592				2022-12-24	WOS:000082678400060
J	Rossi, JJ				Rossi, JJ			Molecular biology - Ribozymes in the nucleolus	SCIENCE			English	Editorial Material							VIRAL-RNA; LOCALIZATION		City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Biol, Duarte, CA 91010 USA.	jrossi@coh.org						Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOND VC, 1993, MOL CELL BIOL, V13, P3221, DOI 10.1128/MCB.13.6.3221; Buonomo SBC, 1999, RNA, V5, P993, DOI 10.1017/S1355838299990064; CULLEN BR, 1988, J VIROL, V62, P2498, DOI 10.1128/JVI.62.7.2498-2501.1988; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lee NS, 1999, RNA, V5, P1200, DOI 10.1017/S1355838299990246; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Pyper JM, 1998, J VIROL, V72, P7697, DOI 10.1128/JVI.72.9.7697-7702.1998; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2	14	14	18	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1999	285	5434					1685	1685		10.1126/science.285.5434.1685	http://dx.doi.org/10.1126/science.285.5434.1685			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10523186				2022-12-24	WOS:000082472600022
J	Hussein, WI; Green, R; Jacobsen, DW; Faiman, C				Hussein, WI; Green, R; Jacobsen, DW; Faiman, C			Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Association-of-Clinical-Endocrinology	1998	ORLANDO, FL	Amer Assoc Clin Endocrinol			VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; HYPERTENSION	Background: Hyperhomocysteinemia is an independent risk factor for coronary, peripheral, and cerebrovascular disease. Elevated plasma homocysteine levels were described in a preliminary report on primary hypothyroidism. Objective: To determine whether restoration of euthyroidism by L-thyroxine replacement therapy would reduce or normalize plasma homocysteine levels. Design: Prospective cohort study. Setting: Outpatient endocrinology department of a tertiary center. Patients: 14 patients (10 women and 4 men; 25 to 77 years of age): 4 with newly diagnosed chronic (Hashimoto) hypothyroidism and 10 who had been rendered acutely hypothyroid (thyroid-stimulating hormone level > 25 mU/L) by total thyroidectomy for thyroid carcinoma. Measurements: Total plasma homocysteine levels were measured at baseline and 3 to 9 months later, after euthyroidism had been attained by L-thyroxine replacement therapy. Results: Median baseline plasma homocysteine levels in both sexes (women, 11.65 mu mol/L [range, 7.2 to 26.5 mu mol/ L]; men, 15.1 mu mol/L [range, 14.1 to 16.3 mu mol/L]) were higher (P = 0.002) than those in healthy female (n = 35) and male (n = 36) volunteers (women, 7.52 mu mol/L [range, 4.3 to 14.0 mu mol/L]; men, 8.72 mu mol/L [range, 5.94 to 14.98 mu mol/L]). Eight patients (57%) had baseline plasma homocysteine levels that exceeded the upper limit of sex-specific reference ranges. Upon attainment of euthyroidism, all patients had a diminution in plasma homocysteine levels. The median overall change of -5.5 mu mol/L (range, -15.4 to -1.8 mu mol/L) corresponds to a difference of -44% (range, -58% to -13%) (P < 0.001). Homocysteine levels returned to normal in 7 of the 8 patients with elevated pretreatment values. Conclusions: Hypothyroidism may be a treatable cause of hyperhomocysteinemia, and elevated plasma homocysteine levels may be an independent risk factor for the accelerated atherosclerosis seen in primary hypothyroidism.	Cleveland Clin Fdn, Dept Endocrinol, Cleveland, OH 44195 USA; Univ Calif Davis, Davis, CA 95616 USA	Cleveland Clinic Foundation; University of California System; University of California Davis	Faiman, C (corresponding author), Cleveland Clin Fdn, Dept Endocrinol, 9500 Euclid Ave,Desk A30, Cleveland, OH 44195 USA.	faimancl@cesmtp.ccf.org		Hussein, Wiam/0000-0002-7416-4521	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CAMP VM, 1983, CLIN CHEM, V29, P642; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; GREEN R, 1995, IRISH J MED SCI S15, V164, P27; GRYTTING G, 1957, ACTA MED SCAND, V157, P169; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; LINDENBAUM J, 1964, J CLIN PATHOL, V17, P666, DOI 10.1136/jcp.17.6.666; Mason RL, 1930, NEW ENGL J MED, V203, P1273, DOI 10.1056/NEJM193012252032601; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; NAIR CPP, 1994, METABOLISM, V43, P1575, DOI 10.1016/0026-0495(94)90019-1; Nedrebo BG, 1998, METABOLISM, V47, P89, DOI 10.1016/S0026-0495(98)90198-6; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; SAITO I, 1994, ENDOCRIN METAB CLIN, V23, P379, DOI 10.1016/S0889-8529(18)30103-8; STEINBERG AD, 1968, ANN INTERN MED, V68, P338, DOI 10.7326/0003-4819-68-2-338; STREETEN DHP, 1988, HYPERTENSION, V11, P78, DOI 10.1161/01.HYP.11.1.78; VANHAELST L, 1967, LANCET, V2, P800, DOI 10.1016/S0140-6736(67)92235-0; WILLIAMS GH, 1984, HEART DISEASE TXB CA, P1722	20	72	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 7	1999	131	5					348	351		10.7326/0003-4819-131-5-199909070-00005	http://dx.doi.org/10.7326/0003-4819-131-5-199909070-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	234AC	10475887				2022-12-24	WOS:000082458500004
J	Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG				Kinrade, SD; Del Nin, JW; Schach, AS; Sloan, TA; Wilson, KL; Knight, CTG			Stable five- and six-coordinated silicate anions in aqueous solution	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SI-29 NMR; PENTACOORDINATE; SILICON(IV); ALUMINUM(III); EQUILIBRIUM; COMPLEXES; SIO2; ACID	Addition of aliphatic polyols to aqueous silicate solutions is shown to yield high concentrations of stable polyolate complexes containing five- or six-coordinated silicon. Coordinating polyols require at Least four hydroxy groups, two of which must be in three configuration, and coordinate to silicon via hydroxy oxygens at chain positions on either side of the threo pair. The remarkable ease by which these simple sugar-like molecules react to form hypervalent silicon complexes in aqueous solution supports a long-standing supposition that such species play a significant role in the biological uptake and transport of silicon and in mineral diagenesis.	Lakehead Univ, Dept Chem, Thunder Bay, ON P7B 5E1, Canada; Univ Illinois, Sch Chem Sci, Urbana, IL 61801 USA	Lakehead University; University of Illinois System; University of Illinois Urbana-Champaign	Kinrade, SD (corresponding author), Lakehead Univ, Dept Chem, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.				NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR010444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042208] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01811, 1 S10 RR 10444-01] Funding Source: Medline; NIGMS NIH HHS [GM-42208] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRCHALL JD, 1995, CHEM SOC REV, V24, P351, DOI 10.1039/cs9952400351; BLOHOWIAK KY, 1994, CHEM MATER, V6, P2177, DOI 10.1021/cm00047a045; CHUIT C, 1993, CHEM REV, V93, P1371, DOI 10.1021/cr00020a003; EVANS DF, 1992, POLYHEDRON, V11, P567, DOI 10.1016/S0277-5387(00)83306-9; GAINSFORD GJ, 1995, ACTA CRYSTALLOGR C, V51, P8, DOI 10.1107/S010827019400702X; HERREROS B, 1994, SCIENCE, V263, P1585, DOI 10.1126/science.263.5153.1585; HOPPE ML, 1993, ANGEW CHEM INT EDIT, V32, P287, DOI 10.1002/anie.199302871; Iler R. K, 1979, CHEM SILICA; KEMMITT T, 1995, AUST J CHEM, V48, P93, DOI 10.1071/CH9950093; Kinrade SD, 1998, INORG CHEM, V37, P4278, DOI 10.1021/ic971630d; Kinrade SD, 1998, INORG CHEM, V37, P4272, DOI 10.1021/ic971629e; Kinrade SD, 1996, J PHYS CHEM-US, V100, P4760, DOI 10.1021/jp952683o; KINRADE SD, IN PRESS J CHEM S DA; KNIGHT CTG, 1989, ZEOLITES, V9, P448, DOI 10.1016/0144-2449(89)90103-6; LAINE RM, 1991, NATURE, V353, P642, DOI 10.1038/353642a0; Laine RM, 1996, J MATER CHEM, V6, P1441, DOI 10.1039/jm9960601441; Liebau F., 1985, STRUCTURAL CHEM SILI; MUNOZ A, 1991, CARBOHYD RES, V225, P113; Rosenheim A, 1931, Z ANORG ALLG CHEM, V196, P160, DOI 10.1002/zaac.19311960117; SEDEH IF, 1993, J INORG BIOCHEM, V50, P119, DOI 10.1016/0162-0134(93)80019-6; SEDEH IF, 1992, ACTA CHEM SCAND, V46, P933, DOI 10.3891/acta.chem.scand.46-0933; SJOBERG S, 1985, J INORG BIOCHEM, V24, P267, DOI 10.1016/0162-0134(85)85055-8; SMALL JH, 1995, ACS SYM SER, V585, P248; STEBBINS JF, 1993, J NON-CRYST SOLIDS, V160, P116, DOI 10.1016/0022-3093(93)90292-6; STEBBINS JF, 1989, AM MINERAL, V74, P965; SVENSSON IL, 1989, J CHEM SOC FARADAY T, V31, P4558; Weiss A., 1964, ANGEW CHEM, V76, P818; Williams R.J.P., 1991, BIOL CHEM ELEMENTS	28	156	168	3	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 3	1999	285	5433					1542	1545		10.1126/science.285.5433.1542	http://dx.doi.org/10.1126/science.285.5433.1542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477513				2022-12-24	WOS:000082359500058
J	Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T				Usui, T; Shima, Y; Shimada, Y; Hirano, S; Burgess, RW; Schwarz, TL; Takeichi, M; Uemura, T			Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of frizzled	CELL			English	Article							TISSUE POLARITY; DROSOPHILA-MELANOGASTER; MOLECULAR ANALYSIS; GENE-EXPRESSION; MORPHOGENESIS; PROTEIN; RECEPTOR; ADHESION; DOMAINS; ROLES	We identified a seven-pass transmembrane receptor of the cadherin superfamily, designated Flamingo (Fmi), localized at cell-cell boundaries in the Drosophila wing. In the absence of Fmi, planar polarity was distorted. Before morphological polarization of wing cells along the proximal-distal (P-D) axis, Fmi was redistributed predominantly to proximal and distal cell edges. This biased localization of Fmi appears to be driven by an imbalance of the activity of Frizzled (Fz) across the proximal/distal cell boundary. These results, together with phenotypes caused by ectopic expression of fz and fmi, suggest that cells acquire the P-D polarity by way of the Fz-dependent boundary localization of Fmi.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan; Kyoto Univ, Fac Sci, Dept Biophys, Kyoto 6068502, Japan; Japan Sci & Technol Corp, PRESTO, Osaka 5650082, Japan; Stanford Univ, Dept Mol Cellular Physiol, Sch Med, Stanford, CA 94305 USA	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Stanford University	Uemura, T (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Kyoto 6068502, Japan.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378; Burgess, Robert/0000-0002-9229-3407; Usui, Tadao/0000-0002-0507-1495; UEMURA, Tadashi/0000-0001-7204-3606				ADLER PN, 1994, MECH DEVELOP, V46, P101, DOI 10.1016/0925-4773(94)90079-5; ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; Adler PN, 1997, CURR BIOL, V7, P940, DOI 10.1016/S0960-9822(06)00413-1; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bolt MW, 1997, ANAL BIOCHEM, V247, P185, DOI 10.1006/abio.1997.2061; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cooper MTD, 1999, NATURE, V397, P526, DOI 10.1038/17395; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; Eaton S, 1997, CURR OPIN CELL BIOL, V9, P860, DOI 10.1016/S0955-0674(97)80089-0; Fanto M, 1999, NATURE, V397, P523, DOI 10.1038/17389; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; Gubb D, 1998, INT J DEV BIOL, V42, P369; Hadjantonakis AK, 1998, MECH DEVELOP, V78, P91, DOI 10.1016/S0925-4773(98)00153-1; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hough CD, 1997, GENE DEV, V11, P3242, DOI 10.1101/gad.11.23.3242; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Jones KH, 1996, GENETICS, V142, P205; Krasnow RE, 1995, DEVELOPMENT, V121, P4095; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Miller JR, 1997, DEV BIOL, V192, P323, DOI 10.1006/dbio.1997.8740; MITCHELL HK, 1983, DEV BIOL, V95, P387, DOI 10.1016/0012-1606(83)90040-4; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T., 1996, DNA RES, V3; Nakayama M, 1998, GENOMICS, V51, P27, DOI 10.1006/geno.1998.5341; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; PARK WJ, 1994, MECH DEVELOP, V45, P127, DOI 10.1016/0925-4773(94)90026-4; PARK WJ, 1994, DEV GENET, V15, P383, DOI 10.1002/dvg.1020150410; PERRIMON N, 1987, DEV BIOL, V119, P587, DOI 10.1016/0012-1606(87)90061-3; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Taylor J, 1998, GENETICS, V150, P199; Turner CM, 1998, MECH DEVELOP, V70, P181, DOI 10.1016/S0925-4773(97)00194-9; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; Wolff T, 1998, DEVELOPMENT, V125, P1149; WONG LL, 1993, J CELL BIOL, V123, P209, DOI 10.1083/jcb.123.1.209; XU T, 1993, DEVELOPMENT, V117, P1223; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719	51	561	569	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					585	595		10.1016/S0092-8674(00)80046-X	http://dx.doi.org/10.1016/S0092-8674(00)80046-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490098	Bronze			2022-12-24	WOS:000082433500006
J	Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C				Ziegler, BL; Valtieri, M; Porada, GA; De Maria, R; Muller, R; Masella, B; Gabbianelli, M; Casella, I; Pelosi, E; Bock, T; Zanjani, ED; Peschle, C			KDR receptor: A key marker defining hematopoietic stem cells	SCIENCE			English	Article							HUMAN BONE-MARROW; LONG-TERM CULTURE; GROWTH-FACTOR; IN-VIVO; REPOPULATING ACTIVITY; ENDOTHELIAL-CELLS; COMMON PRECURSOR; EXPRESSION; DIFFERENTIATION; IDENTIFICATION	Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR). Pluripotent HSCs were restricted to the CD34(+)KDR(+) cell fraction. Conversely, Lineage-committed HPCs were in the CD34(+)KDR(-) subset. On the basis of Limiting dilution analysis, the HSC frequency in the CD34(+)KDR(+) fraction was 20 percent in bone marrow (BM) by mouse xenograft assay and 25 to 42 percent in BM, peripheral blood, and cord blood by 12-week long-term culture (LTC) assay. The latter values rose to 53 to 63 percent in LTC supplemented with VEGF and to greater than 95 percent, for the cell subfraction resistant to growth factor starvation. Thus, KDR is a positive functional marker defining stem cells and distinguishing them from progenitors.	Univ Tubingen, Dept Hematol & Oncol, D-72076 Tubingen, Germany; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Ist Super Sanita, Dept Hematol & Oncol, I-00161 Rome, Italy; Univ Nevada, Dept Vet Affairs, Reno, NV 89520 USA	Eberhard Karls University of Tubingen; Jefferson University; Istituto Superiore di Sanita (ISS); Nevada System of Higher Education (NSHE); University of Nevada Reno	Peschle, C (corresponding author), Univ Tubingen, Dept Hematol & Oncol, Otfried Muller Str 10, D-72076 Tubingen, Germany.	cesare.peschle@mail.tju.edu	pelosi, elvira/J-7298-2016; valtieri, mauro/H-1044-2016; Gabbianelli, Marco/O-1210-2017; De Maria, Ruggero/S-6385-2019	pelosi, elvira/0000-0002-3043-6249; valtieri, mauro/0000-0002-9139-6754; Gabbianelli, Marco/0000-0002-7824-780X; De Maria, Ruggero/0000-0003-2255-0583; Casella, Ida/0000-0002-3358-4976				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bhatia M, 1998, NAT MED, V4, P1038, DOI 10.1038/2023; Bhatia M, 1997, P NATL ACAD SCI USA, V94, P5320, DOI 10.1073/pnas.94.10.5320; BRANDT J, 1990, J CLIN INVEST, V86, P932, DOI 10.1172/JCI114795; Broxmeyer HE, 1995, INT J HEMATOL, V62, P203; Care A, 1999, ONCOGENE, V18, P1993, DOI 10.1038/sj.onc.1202498; Choi K, 1998, DEVELOPMENT, V125, P725; Civin CI, 1996, BLOOD, V88, P4102, DOI 10.1182/blood.V88.11.4102.bloodjournal88114102; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Garcia-Ojeda ME, 1998, J EXP MED, V187, P1813, DOI 10.1084/jem.187.11.1813; Hao QL, 1996, BLOOD, V88, P3306, DOI 10.1182/blood.V88.9.3306.bloodjournal8893306; Kabrun N, 1997, DEVELOPMENT, V124, P2039; KATOH O, 1995, CANCER RES, V55, P5687; Kawashima I, 1996, BLOOD, V87, P4136, DOI 10.1182/blood.V87.10.4136.bloodjournal87104136; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Larochelle A, 1996, NAT MED, V2, P1329, DOI 10.1038/nm1296-1329; Nishikawa S, 1998, DEVELOPMENT, V125, P1747; OGAWA M, 1993, BLOOD, V81, P2844; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Sutherland DR, 1996, EXP HEMATOL, V24, P795; SUTHERLAND HJ, 1990, P NATL ACAD SCI USA, V87, P3584, DOI 10.1073/pnas.87.9.3584; TERMAN BI, 1991, ONCOGENE, V6, P1677; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; Uchida N, 1996, BLOOD, V88, P1297, DOI 10.1182/blood.V88.4.1297.bloodjournal8841297; VANDERLOO JCM, 1995, BLOOD, V85, P2598, DOI 10.1182/blood.V85.9.2598.bloodjournal8592598; Verstegen MMA, 1998, BLOOD, V91, P1966, DOI 10.1182/blood.V91.6.1966.1966_1966_1976; Wang JCY, 1997, BLOOD, V89, P3919, DOI 10.1182/blood.V89.11.3919; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; Zanjani ED, 1998, EXP HEMATOL, V26, P353	34	368	419	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1553	1558		10.1126/science.285.5433.1553	http://dx.doi.org/10.1126/science.285.5433.1553			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477517				2022-12-24	WOS:000082359500062
J	Slifka, MK; Rodriguez, F; Whitton, JL				Slifka, MK; Rodriguez, F; Whitton, JL			Rapid on/off cycling of cytokine production by virus-specific CD8(+) T cells	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; TUMOR-NECROSIS-FACTOR; VIRAL-INFECTION; MESSENGER-RNA; HOST-DEFENSE; MICE; PERFORIN; CYTOTOXICITY; ACTIVATION; CLEARANCE	CD8-positive T cells protect the body against viral pathogens by two important mechanisms: production of antiviral cytokines(1,2) and lysis of infected cells(3,4). Cytokine production can have both local and systemic consequences(5,6), whereas cytolytic activity is limited to infected cells that are in direct contact with T cells(7-9). Here we analyse activated CD8-positive T cells from mice infected with lymphocytic choriomeningitis virus and find that cytokines are not produced ex vivo in the absence of peptide stimulation, but that they are rapidly generated after T cells encounter viral peptides bound to the major histocompatibility complex. Remarkably, cytokine production ceases immediately upon dissociation of the T cells from their targets and resumes when antigenic contact is restored. In contrast to the 'on/off/on' cycling of cytokines, the pore-forming cytotoxic protein perforin is constitutively maintained. Our results indicate that there is differential expression of effector molecules according to whether the antiviral product is secreted (like cytokines) or stored inside the cell (like perforin). The ability to turn cytokines on and off while maintaining intracellular stores of perforin shows the versatility of the cellular immune response and provides a mechanism for maintaining effective immune surveillance while reducing systemic immunopathology.	Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Slifka, MK (corresponding author), Scripps Res Inst, Dept Neuropharmacol, CVN-9,10550 N torrey Pines Rd, La Jolla, CA 92037 USA.		Rodriguez, Fernando/C-3972-2011; Rodriguez, Fernando/GLN-3947-2022	Rodriguez, Fernando/0000-0001-7361-8408				AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; BYRNE JA, 1984, J VIROL, V51, P682, DOI 10.1128/JVI.51.3.682-686.1984; CAMPBELL IL, 1995, INT J DEV NEUROSCI, V13, P275, DOI 10.1016/0736-5748(94)00073-C; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Guidotti LG, 1996, CURR OPIN IMMUNOL, V8, P478, DOI 10.1016/S0952-7915(96)80034-3; HAHN K, 1994, VIROLOGY, V201, P330, DOI 10.1006/viro.1994.1298; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Masuda N, 1998, BRIT J CANCER, V78, P388, DOI 10.1038/bjc.1998.504; MOSKOPHIDIS D, 1987, J VIROL, V61, P1867, DOI 10.1128/JVI.61.6.1867-1874.1987; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; RAMSAY AJ, 1993, IMMUNOL TODAY, V14, P155, DOI 10.1016/0167-5699(93)90277-R; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHULZ M, 1989, EUR J IMMUNOL, V19, P1657, DOI 10.1002/eji.1830190921; Selin LK, 1998, J EXP MED, V188, P1705, DOI 10.1084/jem.188.9.1705; TRACEY KJ, 1992, P SOC EXP BIOL MED, V200, P233; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WALSH CM, 1994, P NATL ACAD SCI USA, V91, P10854, DOI 10.1073/pnas.91.23.10854; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WHITTON JL, 1990, SEMIN VIROL, V1, P257; WHITTON JL, 1996, FIELDS VIROLOGY, V3, P345; Yang Y, 1998, J EXP MED, V188, P247, DOI 10.1084/jem.188.2.247	26	216	220	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					76	79		10.1038/43454	http://dx.doi.org/10.1038/43454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485708				2022-12-24	WOS:000082374400044
J	Alter, DA; Naylor, CD; Austin, P; Tu, JV				Alter, DA; Naylor, CD; Austin, P; Tu, JV			Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; UNITED-STATES; SOCIAL-CLASS; CATHETERIZATION FACILITIES; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HEALTH; CANADA; IMPACT; CARE	Background Universal health care systems seek to ensure access to care on the basis of need rather than income and to improve the health status of all citizens. We examined the performance of the Canadian health system with respect to these goals in the province of Ontario by assessing the effects of neighborhood income on access to invasive cardiac procedures and on mortality one year after acute myocardial infarction. Methods We linked claims for payment for physicians' services, hospital-discharge abstracts, and vital-status data for all patients with acute myocardial infarction who were admitted to hospitals in Ontario between April 1994 and March 1997. Patients' income levels were imputed from the median incomes of their residential neighborhoods as determined in Canada's 1996 census. We determined rates of use and waiting times for coronary angiography and revascularization procedures after the index admission for acute myocardial infarction and determined death rates at one year. In multivariate analyses, we controlled for the patient's age, sex, and severity of disease; the specialty of the attending physician; the volume of cases, teaching status, and on-site facilities for cardiac procedures at the admitting hospital; and the geographic proximity of the admitting hospital to tertiary care centers. Results The study cohort consisted of 51,591 patients. With respect to coronary angiography, increases in neighborhood income from the lowest to the highest quintile were associated with a 23 percent increase in rates of use and a 45 percent decrease in waiting times. There was a strong inverse relation between income and mortality at one year (P<0.001). Each $10,000 increase in the neighborhood median income was associated with a 10 percent reduction in the risk of death within one year (adjusted hazard ratio, 0.90; 95 percent confidence interval, 0.86 to 0.94). Conclusions In the province of Ontario, despite Canada's universal health care system, socioeconomic status had pronounced effects on access to specialized cardiac services as well as on mortality one year after acute myocardial infarction. (N Engl J Med 1999;341:1359-67.) (C) 1999, Massachusetts Medical Society.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Clin Epidemiol & Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Cardiol, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Deans Off, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto	Tu, JV (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.			Tu, Jack/0000-0003-0111-722X; Austin, Peter/0000-0003-3337-233X				ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; [Anonymous], 1994, Circulation, V89, P1545; [Anonymous], CARDIOVASCULAR HLTH; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; Beaudet M P, 1996, Health Rep, V7, P11; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Cairney J, 1996, CAN J PUBLIC HEALTH, V87, P199; CarrHill R, 1995, J EPIDEMIOL COMMUN H, V49, pS28, DOI 10.1136/jech.49.Suppl_2.S28; *COMM PROF HOSP AC, 1992, ICD9CM COMM PROF HOS; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; Efron Bradley., 1994, INTRO BOOTSTRAP; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; Evans R. G., 1994, WHY ARE SOME PEOPLE, P3; Every NR, 1997, CIRCULATION, V96, P1770, DOI 10.1161/01.CIR.96.6.1770; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; JAMES SA, 1987, CIRCULATION, V76, P60; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; Katz SJ, 1996, CAN J PUBLIC HEALTH, V87, P253; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Krumholz HM, 1998, CIRCULATION, V98, P2010, DOI 10.1161/01.CIR.98.19.2010; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT MG, 1983, J PSYCHOSOM RES, V27, P377, DOI 10.1016/0022-3999(83)90069-7; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; McIsaac W, 1997, J Health Serv Res Policy, V2, P94; Naylor C D, 1992, Health Econ, V1, P19, DOI 10.1002/hec.4730010106; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; RUBERMAN W, 1984, NEW ENGL J MED, V311, P552, DOI 10.1056/NEJM198408303110902; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399, DOI 10.1136/jech.52.6.399; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Tu JV, 1997, NEW ENGL J MED, V337, P139; Tu JV., 1999, CARDIOVASCULAR HLTH, P83; WEINBLATT E, 1978, NEW ENGL J MED, V299, P60, DOI 10.1056/NEJM197807132990202	40	500	506	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1359	1367		10.1056/NEJM199910283411806	http://dx.doi.org/10.1056/NEJM199910283411806			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536129				2022-12-24	WOS:000083357800006
J	Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A				Protheroe, D; Turvey, K; Horgan, K; Benson, E; Bowers, D; House, A			Stressful life events and difficulties and onset of breast cancer: case-control study	BRITISH MEDICAL JOURNAL			English	Article								Objective To determine the relation between stressful life events and difficulties and the onset of breast cancer. Design Case-control study. Setting 3 NHS breast clinics serving west Leeds. Participants 399 consecutive women, aged 40-79, attending the breast clinics who were Leeds residents. Main outcome measures Odds ratios of the risk of developing breast cancer after experiencing one or more severe life events, severe difficulties, severe 2 year non-personal health difficulties, or severe 2 year personal health difficulties in the 5 years before clinical presentation. Results 332 (83%) women participated. Women diagnosed with breast cancer were no more likely to have experienced one or more severe life events (adjusted odds ratio 0.91, 95% confidence interval 0.47 to 1.81; P = 0.79); one or more severe difficulties (0.86, 0.41 to 1.81; P = 0.69); a 2 year severe non-personal health difficulty (0.53, 0.12 to 2.31; P = 0.4); or a 2 year severe personal health difficulty (2.73, 0.68 to 10.93; P = 0.16) than women diagnosed with a benign breast lump. Conclusion These findings do not support the hypothesis that severe life events or difficulties are associated with onset of breast cancer.	Leeds Gen Infirm, Dept Liaison Psychiat, Leeds LS1 3EX, W Yorkshire, England; Univ Leeds, Nuffield Inst Hlth, Sub Unit Med Stat, Leeds LS2 9PL, W Yorkshire, England	Leeds General Infirmary; University of Leeds; University of Leeds	Protheroe, D (corresponding author), No Hosp, Epping, Vic 3076, Australia.		horgan, kieran/I-3892-2016	House, Allan/0000-0001-8721-8026				BAGHURST KI, 1992, J EPIDEMIOL COMMUN H, V46, P120, DOI 10.1136/jech.46.2.120; BARRACLOUGH J, 1992, BRIT MED J, V304, P1078, DOI 10.1136/bmj.304.6834.1078; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Brown G., 1978, SOCIAL ORIGINS DEPRE; Cassileth BR, 1996, CANCER-AM CANCER SOC, V77, P1015, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1015::AID-CNCR1>3.0.CO;2-G; CHEN CC, 1995, BRIT MED J, V311, P1527, DOI 10.1136/bmj.311.7019.1527; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; GEYER S, 1991, J PSYCHOSOM RES, V35, P355, DOI 10.1016/0022-3999(91)90090-B; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; LESHAN L, 1959, J NATL CANCER I, V22, P1; McGee R, 1996, PSYCHOL MED, V26, P441, DOI 10.1017/S0033291700035522; MECHANIC D, 1972, NEW ENGL J MED, V286, P1132, DOI 10.1056/NEJM197205252862105; Petticrew M, 1999, BRIT J HEALTH PSYCH, V4, P1, DOI 10.1348/135910799168434; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; Reed MJ, 1996, BRIT MED J, V312, P845	15	83	85	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1027	1030		10.1136/bmj.319.7216.1027	http://dx.doi.org/10.1136/bmj.319.7216.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	247FH	10521192	Bronze, Green Published			2022-12-24	WOS:000083210100022
J	Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA				Pouliot, JJ; Yao, KC; Robertson, CA; Nash, HA			Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-DEATH; DRUGS; DISRUPTION; DELETION; PROTEIN; ENZYME	Covalent intermediates between topoisomerase I and DNA can become dead-end complexes that read to cell death. Here, the isolation of the gene for an enzyme that can hydrolyze the bond between this protein and DNA is described. Enzyme-defective mutants of yeast are hypersensitive to treatments that increase the amount of covalent complexes, indicative of enzyme involvement in repair. The gene is conserved in eukaryotes and identifies a family of enzymes that has not been previously recognized. The presence of this gene in humans may have implications for the effectiveness of topoisomerase I poisons, such as the camptothecins, in chemotherapy.	NIMH, Mol Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Nash, HA (corresponding author), NIMH, Mol Biol Lab, Bldg 36,Room 1B08, Bethesda, MD 20892 USA.	nash@codon.nih.gov						BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Brachmann CB, 1998, YEAST, V14, P115; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Larsen AK, 1998, BBA-GENE STRUCT EXPR, V1400, P257, DOI 10.1016/S0167-4781(98)00140-7; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pouliot J. J., UNPUB; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHERMAN F, 1993, EMBO J, V12, P3; TRECO DA, 1991, CURRENT PROTOCOLS MO, V2; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	20	304	313	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					552	555		10.1126/science.286.5439.552	http://dx.doi.org/10.1126/science.286.5439.552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10521354	Green Submitted			2022-12-24	WOS:000083121200066
J	Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T				Jiang, GL; den Hertog, J; Su, J; Noel, J; Sap, J; Hunter, T			Dimerization inhibits the activity of receptor-like protein-tyrosine phosphatase-alpha	NATURE			English	Article							DISULFIDE BOND; KINASE; DOMAIN; FORM; PHOSPHORYLATION; PP60(C-SRC); ACTIVATION	Protein-tyrosine phosphatases (PTPs) are vital for regulating tryosine phosphorylation in many processes, including growth and differentiation(1,2). The regulation of receptor-like PTP (RPTP) activity remains poorly understood, but based on the crystal structure of RPTP alpha domain 1 we have proposed that dimerization can negatively regulate activity, through the interaction of an inhibitory 'wedge' on one monomer with the catalytic cleft of domain 1 in the other monomer(3,4). Here we show that dimerization inhibits the activity of a full-length RPTP in vivo. We generated stable disulphide-bonded full-length RPTP alpha homodimers by expressing mutants with single cysteines at different positions in the ectodomain juxtamembrane region. Expression of wild-type RPTP alpha and Phe135Cys and Thr141Cys mutants in RPTP alpha-null mouse embryo cells increased dephosphorylation and activity of Tyr529 in the protein tyrosine kinase c-Src; in contrast, expression of a Pro137Cys mutant did not. Mutation of Pro 210/211 to leucine in the inhibitory wedge of the Pro137Cys mutant restored its ability to activate c-Src, indicating that dimerization may inhibit full-length RPTP alpha activity in a manner stereochemically consistent with RPTP alpha crystal structures(3). Our results suggest that RPTP alpha activity can in principle be negatively regulated by dimerization in vivo.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Salk Institute; Salk Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); New York University	Jiang, GL (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Noel, Joseph P/A-9459-2009					Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAO HN, 1992, J BIOL CHEM, V267, P20489; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; LEVYTOLEDANO R, 1993, ENDOCRINOLOGY, V133, P1803, DOI 10.1210/en.133.4.1803; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TRACY S, 1995, J BIOL CHEM, V270, P10587, DOI 10.1074/jbc.270.18.10587; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	28	153	159	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 7	1999	401	6753					606	610		10.1038/44170	http://dx.doi.org/10.1038/44170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	244MG	10524630				2022-12-24	WOS:000083054900055
J	Remafedi, G				Remafedi, G			Sexual orientation and youth suicide	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							BISEXUAL YOUTH; RISK-FACTORS; GAY; ADOLESCENTS; BEHAVIOR; HOMOSEXUALITY; SAMPLE; MALES		Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Remafedi, G (corresponding author), Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA.				PHS HHS [5-T71-MC-00006-22] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bagley C, 1997, Crisis, V18, P24, DOI 10.1027/0227-5910.18.1.24; DAUGELLI AR, 1993, AM J COMMUN PSYCHOL, V21, P421, DOI 10.1007/BF00942151; DuRant RH, 1998, J PEDIATR-US, V133, P113, DOI 10.1016/S0022-3476(98)70189-1; Faulkner AH, 1998, AM J PUBLIC HEALTH, V88, P262, DOI 10.2105/AJPH.88.2.262; Garofalo R, 1999, ARCH PEDIAT ADOL MED, V153, P487; Garofalo R, 1998, PEDIATRICS, V101, P895, DOI 10.1542/peds.101.5.895; GIBSON P, 1989, US DEP HLTH HUM SERV, V3; HAMMELMAN TL, 1993, J GAY LESBIAN PSYCHO, V2, P77, DOI DOI 10.1300/J236V02N01_; HARRY J, 1983, J HEALTH SOC BEHAV, V24, P350, DOI 10.2307/2136401; Hershberger SL, 1997, J ADOLESCENT RES, V12, P477, DOI 10.1177/0743554897124004; HUNTER J, 1990, J INTERPERS VIOLENCE, V5, P295, DOI DOI 10.1177/088626090005003004; MUEHRER P, 1995, SUICIDE LIFE-THREAT, V25, P72, DOI 10.1111/j.1943-278X.1995.tb00492.x; Nicholas J., 1998, YOUTH STUDIES AUSTR, V17, P28; PROCTOR CD, 1994, SOC WORK, V39, P504, DOI 10.1093/sw/39.5.504; REMAFEDI G, 1991, PEDIATRICS, V87, P869; REMAFEDI G, 1987, PEDIATRICS, V79, P331; Remafedi G, 1998, AM J PUBLIC HEALTH, V88, P57, DOI 10.2105/AJPH.88.1.57; RICH CL, 1986, SUICIDE LIFE-THREAT, V16, P448; ROESLER T, 1972, J AMER MED ASSOC, V219, P1018, DOI 10.1001/jama.219.8.1018; ROTHERAMBORUS MJ, 1994, J ADOLESCENT RES, V9, P498, DOI 10.1177/074355489494007; SCHNEIDER SG, 1989, SUICIDE LIFE-THREAT, V19, P381; SHAFFER D, 1995, SUICIDE LIFE-THREAT, V25, P64, DOI 10.1111/j.1943-278X.1995.tb00491.x	22	54	55	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1999	282	13					1291	1292		10.1001/jama.282.13.1291	http://dx.doi.org/10.1001/jama.282.13.1291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	241UM	10517437	hybrid			2022-12-24	WOS:000082901100043
J	Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS				Smith, DE; Sjogren, WL; Tyler, GL; Balmino, G; Lemoine, FG; Konopliv, AS			The gravity field of Mars: Results from Mars global surveyor	SCIENCE			English	Article							ORBITER LASER ALTIMETER; IMPACT BASINS; GIANT IMPACT; TOPOGRAPHY; DICHOTOMY; MISSION; MODEL; MOON	Observations of the gravity field of Mars reveal a planet that has responded differently in its northern and southern hemispheres to major impacts and volcanic processes. The rough, elevated southern hemisphere has a relatively featureless gravitational signature indicating a state of near-isostatic compensation, whereas the smooth, Low northern plains display a wider range of gravitational anomalies that indicates a thinner but stronger surface Layer than in the south. The northern hemisphere shows evidence for buried impact basins, although none large enough to explain the hemispheric elevation difference. The gravitational potential signature of Tharsis is approximately axisymmetric and contains the Tharsis Montes but not the Olympus Mons or Alba Patera volcanoes. The gravity signature of Valles Marineris extends into Chryse and provides an estimate of material removed by early fluvial activity.	NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Stanford Univ, Ctr Radio Astron, Stanford, CA 94305 USA; Grp Rech Geodesie Spatiales, Toulouse, France	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Stanford University	Smith, DE (corresponding author), NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Lemoine, Frank/D-1215-2013	Lemoine, Frank G./0000-0002-3051-1456				Acuna MH, 1999, SCIENCE, V284, P790, DOI 10.1126/science.284.5415.790; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; Anderson S, 1998, J GEOPHYS RES-PLANET, V103, P11113, DOI 10.1029/98JE00740; BALMINO G, 1982, J GEOPHYS RES, V87, P9735, DOI 10.1029/JB087iB12p09735; BRATT SR, 1985, J GEOPHYS RES-SOLID, V90, P2415, DOI 10.1029/JB090iB14p12415; Carr M., 1981, SURFACE MARS; COMER RP, 1985, REV GEOPHYS, V23, P61, DOI 10.1029/RG023i001p00061; Connerney JEP, 1999, SCIENCE, V284, P794, DOI 10.1126/science.284.5415.794; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Heiskanen W.A., 1967, PHYS GEODESY; Johnson C., UNPUB; Kaula W.M., 1966, THEORY SATELLITE GEO; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; KONOPLIV AS, 1995, JPL PUBL, V955; Lemoine F., 1998, DEV JOINT NASA GSFC; MCGILL GE, 1989, J GEOPHYS RES-SOLID, V94, P2753, DOI 10.1029/JB094iB03p02753; Melosh H.J., 1989, OXFORD MONOGRAPHS GE; Neumann GA, 1996, J GEOPHYS RES-PLANET, V101, P16841, DOI 10.1029/96JE01246; NEUMANN GA, 1997, LUNAR PLANET SCI C, V28, P1713; SCHULTZ RA, 1990, J GEOPHYS RES-SOLID, V95, P14175, DOI 10.1029/JB095iB09p14175; SENGOR AMC, 1978, GEOPHYS RES LETT, V5, P419, DOI 10.1029/GL005i006p00419; SJOGREN WL, 1999, EOS, V80, P204; Smith DE, 1999, SCIENCE, V284, P1495, DOI 10.1126/science.284.5419.1495; Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SMITH DE, 1999, EOS, V80, P204; SOLOMON SC, 1998, LUNAR PLANET SCI, V29, P1389; Turcotte D. L., 1982, GEODYNAMICS APPL CON, DOI 10.1017/CBO9780511843877; TURCOTTE DL, 1981, J GEOPHYS RES, V86, P3951, DOI 10.1029/JB086iB05p03951; TYLER GL, 1992, J GEOPHYS RES-PLANET, V97, P7759, DOI 10.1029/92JE00513; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1994, SCIENCE, V266, P1839, DOI 10.1126/science.266.5192.1839; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053; Zuber MT, 1998, GEOPHYS RES LETT, V25, P4393, DOI 10.1029/1998GL900129; [No title captured]	37	112	116	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 1	1999	286	5437					94	97		10.1126/science.286.5437.94	http://dx.doi.org/10.1126/science.286.5437.94			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	241WT	10506567				2022-12-24	WOS:000082907400040
J	Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS				Minning, DM; Gow, AJ; Bonaventura, J; Braun, R; Dewhirst, M; Goldberg, DE; Stamler, JS			Ascaris haemoglobin is a nitric oxide-activated 'deoxygenase'	NATURE			English	Article							S-NITROSOHEMOGLOBIN; OXYGEN AVIDITY; HEMOGLOBIN; SUUM; FLAVOHEMOGLOBIN; SUPEROXIDE; BIOSYNTHESIS; EXPRESSION; GLOBIN; GENE	The parasitic nematode Ascaris lumbricoides infects one billion people worldwide. Its perienteric fluid contains an octameric haemoglobin(1-3) that binds oxygen nearly 25,000 times more tightly than does human haemoglobin(4,5). Despite numerous investigations, the biological function of this molecule has remained elusive. The distal haem pocket contains a metal, oxygen and thiol(6), all of which are known to be reactive with nitric oxide. Here we show that Ascaris haemoglobin enzymatically consumes oxygen in a reaction driven by nitric oxide, thus keeping the perienteric fluid hypoxic. The mechanism of this reaction involves unprecedented chemistry of a haem group, a thiol and nitric oxide. We propose that Ascaris haemoglobin functions as a 'deoxygenase', using nitric oxide to detoxify oxygen. The structural and functional adaptations of Ascaris haemoglobin suggest that the molecular evolution of haemoglobin can be rationalized by its nitric oxide related functions.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dep Mol Microbiol & Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Duke Marine Biomed Ctr, Nicholas Sch Environm, Pivers Isl, NC 28516 USA	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Duke University	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.		Gow, Andrew/N-8566-2013; Dewhirst, Mark/Q-1302-2019; Gow, Andrew/AAR-2309-2020	Gow, Andrew/0000-0003-0876-5158; Dewhirst, Mark/0000-0003-3459-6546; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; Balagopalakrishna C, 1998, BIOCHEMISTRY-US, V37, P13194, DOI 10.1021/bi980941c; BASCAL ZA, 1995, J NEUROPHYSIOL, V74, P1880; BLAXTER ML, 1993, PARASITOL TODAY, V9, P353, DOI 10.1016/0169-4758(93)90082-Q; BOWMAN JW, 1995, J NEUROPHYSIOL, V74, P1880, DOI 10.1152/jn.1995.74.5.1880; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DARAWSHE S, 1987, BIOCHEM J, V242, P689, DOI 10.1042/bj2420689; DAVENPORT HE, 1949, PROC R SOC SER B-BIO, V136, P255, DOI 10.1098/rspb.1949.0024; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hardison R, 1998, J EXP BIOL, V201, P1099; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; Maccarrone M, 1997, FEBS LETT, V410, P470, DOI 10.1016/S0014-5793(97)00643-1; Nagashima S, 1998, NAT STRUCT BIOL, V5, P347, DOI 10.1038/nsb0598-347; OKAZAKI T, 1965, BIOCHIM BIOPHYS ACTA, V111, P503, DOI 10.1016/0304-4165(65)90060-7; Peterson ES, 1997, BIOCHEMISTRY-US, V36, P13110, DOI 10.1021/bi971156n; SHARMA VS, 1987, BIOCHEMISTRY-US, V26, P3837, DOI 10.1021/bi00387a015; SHERMAN DR, 1992, SCIENCE, V258, P1930, DOI 10.1126/science.1470914; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Young WK, 1996, BRIT J CANCER, V74, pS256	30	182	192	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 30	1999	401	6752					497	502		10.1038/46822	http://dx.doi.org/10.1038/46822			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243DF	10519555				2022-12-24	WOS:000082981200061
J	Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV				Macarthur, C; Saunders, N; Feldman, W; Ipp, M; Winders-Lee, P; Roberts, S; Best, L; Sherman, P; Pencharz, P; van Zanten, SV			Helicobacter pylori and childhood recurrent abdominal pain: community based case-control study	BRITISH MEDICAL JOURNAL			English	Article							YOUNG MEN; MORTALITY; ALCOHOL		Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada; Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada; Victoria Gen Hosp, Dept Microbiol, Halifax, NS B3H 2Y9, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Dalhousie University; University of Victoria	Macarthur, C (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada.			Sherman, Philip/0000-0002-4733-6690				*ADD RES FDN ONT C, 1994, CAN MED ASS J S, V151; ANDERSON P, 1995, ALCOHOL PUBLIC POLIC, P82; ANDREASSON S, 1988, BRIT MED J, V296, P1021, DOI 10.1136/bmj.296.6628.1021; ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; Edwards G., 1994, ALCOHOL POLICY PUBLI; KAPLAN GA, 1993, SOCIOECONOMIC FACTOR; *NAT BOARD HLTH WE, 1996, DODS 1994; *NAT BOARD HLTH WE, 1996, PAT 1987 1994 KVAL I; Rothman K., 1998, MODERN EPIDEMIOLOGY	9	40	43	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 25	1999	319	7213					822	+		10.1136/bmj.319.7213.822	http://dx.doi.org/10.1136/bmj.319.7213.822			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	241CR	10496827	Green Published, Bronze			2022-12-24	WOS:000082865200025
J	Johnson, RD; Liu, N; Jasin, M				Johnson, RD; Liu, N; Jasin, M			Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination	NATURE			English	Article							EMBRYONIC STEM-CELLS; IONIZING-RADIATION; RAD57 PROTEINS; GENE; RESISTANCE; ENDONUCLEASE; DISRUPTION; EXPRESSION; MEMBER; FAMILY	The repair of DNA double-strand breaks is essential for cells to maintain their genomic integrity. Two major mechanisms are responsible for repairing these breaks in mammalian cells, nonhomologous end-joining (NHEJ) and homologous recombination (HR)(1,2): the importance of the former in mammalian cells is well established(3), whereas the role of the latter is just emerging, Homologous recombination is presumably promoted by an evolutionarily conserved group of genes termed the Rad52 epistasis (4-11). An essential component of the HR pathway is the group strand-exchange protein, known as RecA in bacteria(8) or Rad51 in yeast(6). Several mammalian genes have been implicated in repair by homologous recombination on the basis of their sequence homology to yeast Rad51 (ref. 11): one of these is human XRCC2 (refs 12, 13). Here we show that XRCC2 is essential for the efficient repair of DNA double-strand breaks by homologous recombination between sister chromatids, We find that hamster cells deficient in XRCC2 show more than a 100-fold decrease in HR induced by double-strand breaks compared with the parental cell line. This defect is corrected to almost wild-type levels by transient transfection with a plasmid expressing XRCC2. The repair defect in XRCC2 mutant cells appears to be restricted to recombinational repair because NHEJ is normal. We conclude that XRCC2 is involved in the repair of DNA double-strand breaks by homologous recombination.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	Memorial Sloan Kettering Cancer Center; Cornell University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Jasin, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	m-jasin@ski.mskcc.org						Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Donoho G, 1998, MOL CELL BIOL, V18, P4070, DOI 10.1128/MCB.18.7.4070; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JASIN M, DNA DAMAGE REPAIR, V3; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LIU BL, 1983, PUBL PURPLE MOUNTAIN, V2, P1; Nickoloff JA, 1998, CONT CANC RES, P335; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Smih F, 1995, NUCLEIC ACIDS RES, V23, P5012, DOI 10.1093/nar/23.24.5012; Smith GR, 1998, CONT CANC RES, P135; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vogelstein B., 1998, GENETIC BASIS HUMAN; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	29	277	295	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 23	1999	401	6751					397	399		10.1038/43935	http://dx.doi.org/10.1038/43935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	240JJ	10517641	Bronze			2022-12-24	WOS:000082822600057
J	Sherff, CM; Carew, TJ				Sherff, CM; Carew, TJ			Coincident induction of long-term facilitation in Aplysia: Cooperativity between cell bodies and remote synapses	SCIENCE			English	Article							LOCAL PROTEIN-SYNTHESIS; SENSORY NEURONS; LATE-PHASE; SYNAPTIC FACILITATION; MACROMOLECULAR-SYNTHESIS; CRITICAL PERIOD; POTENTIATION; PLASTICITY; REQUIREMENT; EXPRESSION	Induction of Long-term synaptic changes at one synapse can facilitate the induction of Long-term plasticity at another synapse. Evidence is presented here that if Aplysia sensory neuron somata and their remote motor neuron synapses are simultaneously exposed to serotonin pulses insufficient to induce Long-term facilitation (LTF) at either site along, processes activated at these sites interact to induce LTF. This coincident induction of LTF requires that (i) the synaptic pulse occur within a brief temporal window of the somatic pulse, and (ii) Local protein synthesis occur immediately at the synapse, followed by delayed protein synthesis at the soma.	Yale Univ, Dept Psychol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Sherff, CM (corresponding author), Yale Univ, Dept Psychol, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH012004] Funding Source: NIH RePORTER; NIMH NIH HHS [F32-MH12004, R01MH-14-1083] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARNBRON RT, 1992, J NEUROSCI, V12, P2813; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BAXTER DA, 1990, J NEUROPHYSIOL, V64, P978, DOI 10.1152/jn.1990.64.3.978; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLEARY LJ, 1993, J NEUROPHYSIOL, V70, P1767, DOI 10.1152/jn.1993.70.5.1767; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FREY U, 1989, NEUROSCI LETT, V97, P135, DOI 10.1016/0304-3940(89)90152-3; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1994, J NEUROBIOL, V25, P666, DOI 10.1002/neu.480250608; GUNSTREAM JD, 1995, J NEUROSCI, V15, P439; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; JAFFE DB, 1994, J NEUROPHYSIOL, V72, P471, DOI 10.1152/jn.1994.72.1.471; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; MATTHIES H, 1993, NEUROREPORT, V4, P712, DOI 10.1097/00001756-199306000-00028; Mauelshagen J, 1996, J NEUROSCI, V16, P7099; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; STOOP R, 1995, SCIENCE, V267, P695, DOI 10.1126/science.7839148; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834; XU YL, 1995, J NEUROPHYSIOL, V73, P1313, DOI 10.1152/jn.1995.73.3.1313; Zhang F, 1997, SCIENCE, V275, P1318, DOI 10.1126/science.275.5304.1318	29	72	73	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1911	1914		10.1126/science.285.5435.1911	http://dx.doi.org/10.1126/science.285.5435.1911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489370				2022-12-24	WOS:000082638300050
J	Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF				Floyd, K; Reid, RA; Wilkinson, D; Gilks, CF			Admission trends in a rural south African hospital during the early years of the HIV epidemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESOURCE UTILIZATION; DRUG-USERS; TUBERCULOSIS; INFECTION; RISK; IMPACT; DISTRICT; NAIROBI; COHORT; WOMEN	Context Few studies have attempted to quantify the effect of the epidemic of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) on demand for health care in developing countries. More data are required to improve understanding of its impact and to guide development of appropriate response strategies. Objective To assess the HIV/AIDS epidemic's impact on demand for inpatient hospital care in a rural area of South Africa. Design Retrospective analysis of data from general hospital and individual ward admission registers, a tuberculosis program database, and patient case notes. Setting and Patients Patients admitted between 1991 and 1998 to a 450-bed hospital that serves Hlabisa District, South Africa (population approximate to 200 000), where HIV seroprevalence among antenatal clinic attendees increased from 4% in 1992 to 29% in 1998, Main Outcome Measures Number of admissions to 9 hospital wards, number of clinical AIDS and general medical admissions (both excluding tuberculosis), and number of tuberculosis admissions to adult medical wards during the study period. Results Total hospital admissions increased by 81%, from 6562 in 1991 to 11 872 in 1998, Adult tuberculosis ward admissions increased by 360%, from 303 to 1393, In 1998, tuberculosis patients accounted for 47% and 30% of adult male and female medical ward admissions, respectively, and for 11% of total hospital admissions. Nontuberculosis clinical AIDS cases increased 43-fold, accounting for 4% of adult medical admissions in 1997 vs 0.2% in 1991. Tuberculosis and nontuberculosis clinical AIDS cases were the only types of admission to show a clear and consistent upward trend over the period studied. Patterns in other types of admissions varied more and changes were smaller. Conclusions The HIV/AIDS epidemic has had an important impact on demand for adult tuberculosis and general medical care in a rural South African district hospital. If this impact is shown to extend to other rural South African areas, response strategies are urgently needed.	Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England; Hlabisa Hosp, Hlabisa, South Africa; MRC, Ctr Epidemiol Res S Africa, Mtubatuba, South Africa	Liverpool School of Tropical Medicine; University of Liverpool	Floyd, K (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Div Trop Med, Liverpool L3 5QA, Merseyside, England.	kfloyd@liverpool.ac.uk	Gilks, Charles/B-4184-2012; Wilkinson, David/A-6207-2008	Gilks, Charles/0000-0002-8953-3123; Wilkinson, David/0000-0002-7265-9846				ALLEN S, 1992, AM REV RESPIR DIS, V146, P1439, DOI 10.1164/ajrccm/146.6.1439; [Anonymous], 1997, HUM DEV REP 1997; ARTHUR G, 1998, 12 WORLD AIDS C JUN; BRAUN MM, 1991, AM REV RESPIR DIS, V143, P501, DOI 10.1164/ajrccm/143.3.501; BUVE AMA, 1992, 8 INT C AIDS JUL 19, V2; Coleman RL, 1997, J ACQ IMMUN DEF SYND, V16, P50, DOI 10.1097/00042560-199709010-00008; DUNN DT, 1992, LANCET, V87, P456; FOSTER SD, 1993, COST BURDEN AIDS ZAM; GILKS CF, 1992, Q J MED, V82, P25; Harries A, 1996, TB HIV CLIN MANUAL; Harries AD, 1997, ANN TROP MED PARASIT, V91, P771, DOI 10.1080/00034989760527; HASSIG SE, 1990, AIDS, V4, P883, DOI 10.1097/00002030-199009000-00009; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KARSTAEDT AS, 1996, S AFR MED J, V86, P1490; KING R, 1994, T ROY SOC TROP MED H, V88, P295, DOI 10.1016/0035-9203(94)90083-3; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NUNN P, 1993, TUBERCLE LUNG DIS, V74, P273, DOI 10.1016/0962-8479(93)90054-2; OKELLO DO, 1994, E AFR MED J, V71, P816; *REP S AFR DEP HLT, 1996, EPIDEMIOLOGICAL COMM, V23, P4; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMITH PG, 1994, TUBERCULOSIS PATHOGE, pCH4; *STAT CORP, 1999, STAT STAT SOFTW COMP; TEMBO G, 1994, AIDS, V8, P1169, DOI 10.1097/00002030-199408000-00021; *UNAIDS, UNAIDS9810; WILKINSON D, 1994, LANCET, V343, P647, DOI 10.1016/S0140-6736(94)92640-9; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P420, DOI 10.1016/S0035-9203(97)90263-7; Wilkinson D, 1997, AIDS, V11, P377, DOI 10.1097/00002030-199703110-00016; Wilkinson D, 1997, S AFR MED J, V87, P447; YEUNG S, IN PRESS J TROP PAED	30	45	45	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1999	282	11					1087	1091		10.1001/jama.282.11.1087	http://dx.doi.org/10.1001/jama.282.11.1087			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	234YQ	10493210				2022-12-24	WOS:000082512300036
J	McKenzie, R; Conner, B; Bodeker, G				McKenzie, R; Conner, B; Bodeker, G			Increased summertime UV radiation in New Zealand in response to ozone loss	SCIENCE			English	Article							ULTRAVIOLET-RADIATION; IRRADIANCE; SURFACE	Long-term decreases in summertime ozone over Lauder, New Zealand (45 degrees S), are shown to have Led to substantial increases in peak ultraviolet (UV) radiation intensities. In the summer of 1998-99, the peak sunburning UV radiation was about 12 percent more than in the first years of the decade. Larger increases were seen for DNA-damaging UV radiation and plant-damaging UV radiation, whereas UV-A (315 to 400 nanometers) radiation, which is insensitive to ozone, showed no increase, in agreement with model calculations. These results provide strong evidence of human-induced increases in UV radiation, in a region where baseline levels of UV radiation were already relatively high.	Natl Inst Water & Atmospher Res, NIWA Lauder, Cent Otago, New Zealand	National Institute of Water & Atmospheric Research (NIWA) - New Zealand	McKenzie, R (corresponding author), Natl Inst Water & Atmospher Res, NIWA Lauder, PB 50061 Omakau, Cent Otago, New Zealand.			Bodeker, Gregory/0000-0003-1094-5852; McKenzie, Richard Lloyd/0000-0002-4484-7057				ALBRITTON DL, 1998, SCI ASSESSMENT OZONE; BULLIARD JL, 1996, NZ PUBLIC HLTH REP, V3, P73; CALDWELL MM, 1986, STRATOSPHERIC OZONE, P87; Connor BJ, 1999, GEOPHYS RES LETT, V26, P189, DOI 10.1029/1998GL900250; FORGAN BW, 1997, MISCELLANEOUS SERIES, V49, P51; MADRONICH S, 1995, AMBIO, V24, P143; McKenzie R, 1996, WEATHER CLIM, V16, P17; MCKENZIE RL, 1992, APPL OPTICS, V31, P6501, DOI 10.1364/AO.31.006501; McKenzie RL, 1998, J GEOPHYS RES-ATMOS, V103, P28785, DOI 10.1029/98JD02704; MCKENZIE RL, 1994, OZONE TROPOSPHERE ST, P627; McKinlay AF., 1987, EXCERPTA MED INT C S, V744, P83; Relethford JH, 1998, AM J PHYS ANTHROPOL, V107, P223, DOI 10.1002/(SICI)1096-8644(199810)107:2<223::AID-AJPA9>3.0.CO;2-V; SECKMEYER G, 1992, NATURE, V359, P135, DOI 10.1038/359135a0; SECKMEYER G, 1995, GEOPHYS RES LETT, V22, P1889, DOI 10.1029/95GL01352; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; STAMNES K, 1991, APPL OPTICS, V30, P4418, DOI 10.1364/AO.30.004418; *UN ENV PROGR UNEP, 1998, ENV EFF OZ DEPL 1998; WMO, 1995, SCI ASS OZ DEPL 1994; *WMO, 1994, WMO M EXP UVB MEAS D	20	264	280	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 10	1999	285	5434					1709	1711		10.1126/science.285.5434.1709	http://dx.doi.org/10.1126/science.285.5434.1709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	234EY	10481002				2022-12-24	WOS:000082472600028
J	Henney, JE				Henney, JE			New type 2 diabetes drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item											Henney, JE (corresponding author), HF-1,Room 14-71,5600 Fishers Lane, Rockville, MD 20857 USA.								0	10	10	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1999	282	10					932	932		10.1001/jama.282.10.932	http://dx.doi.org/10.1001/jama.282.10.932			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	231XD	10485665				2022-12-24	WOS:000082335900005
J	Kleiman, FE; Manley, JL				Kleiman, FE; Manley, JL			Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50	SCIENCE			English	Article							PRE-MESSENGER-RNA; POLYMERASE-II; POLY(A) POLYMERASE; SPECIFICITY FACTOR; IN-VITRO; 3'-END CLEAVAGE; BINDING DOMAIN; GLOBIN GENE; DNA-DAMAGE; BRCA1	Polyadenylation of messenger RNA precursors requires a complex protein machinery that is closely integrated with the even more complex transcriptional apparatus. Here a polyadenylation factor, CstF-50 (cleavage stimulation factor), is shown to interact in vitro and in intact cells with a nuclear protein of previously unknown function, BRCA1-associated RING domain protein (BARD1). The BARD1-CstF-50 interaction inhibits polyadenylation in vitro. BARD1, like CstF-50, also interacts with RNA polymerase II. These results indicate that BARD1-mediated inhibition of polyadenylation may prevent inappropriate RNA processing during transcription, perhaps at sites of DNA repair, and they reveal an unanticipated integration of diverse nuclear events.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jlm2@columbia.edu		Manley, James/0000-0002-8341-1459	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28983] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayi TC, 1998, ONCOGENE, V17, P2143, DOI 10.1038/sj.onc.1202123; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Beyer K, 1997, J BIOL CHEM, V272, P26769, DOI 10.1074/jbc.272.42.26769; Chen J., COMMUNICATION; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1997, J BIOL CHEM, V272, P29636, DOI 10.1074/jbc.272.47.29636; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; KLEIMAN FE, UNPUB; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; Takagaki Y, 1998, MOL CELL, V2, P761, DOI 10.1016/S1097-2765(00)80291-9; Takagaki Y, 1996, CELL, V87, P941, DOI 10.1016/S0092-8674(00)82000-0; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yoshio TD, 1997, MOL CELL BIOL, V17, P3907, DOI 10.1128/MCB.17.7.3907	44	139	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 3	1999	285	5433					1576	1579		10.1126/science.285.5433.1576	http://dx.doi.org/10.1126/science.285.5433.1576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232FD	10477523				2022-12-24	WOS:000082359500068
J	Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C				Hopker, VH; Shewan, D; Tessier-Lavigne, M; Poo, MM; Holt, C			Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1	NATURE			English	Article							FIBRONECTIN RECEPTOR COMPLEX; AXON GUIDANCE; CYCLIC-AMP; CELLS; OUTGROWTH; RETINA; ADULT; DCC	Growing axons are guided by both diffusible and substrate-bound factors(1-3). Growth cones of retinal neurons exhibit chemoattractive turning towards the diffusible factor netrin-1 in vitro(4) and are guided into the optic nerve head (ONH) by localized netrin-1 (ref. 5). Here we report that, in Xenopus, laminin-1 from the extracellular matrix (ECM), converts netrin-mediated attraction into repulsion. A soluble peptide fragment of laminin-1 (YIGSR) mimics this laminin-induced conversion. Low levels of cyclic AMP in growth cones also lead to the conversion of netrin-induced attraction into repulsion(6), and we show that the amount of cAMP decreases in the presence of laminin-1 or YIGSR, suggesting a possible mechanism for laminin's effect. At the netrin-1-rich ONH, where axons turn sharply to leave the eye, laminin-1 is confined to the retinal surface. Repulsion from the region in which laminin and netrin are coexpressed may help to drive axons into the region where only netrin is present, providing a mechanism for their escape from the retinal surface. Consistent with this idea, YIGSR peptides applied to the developing retina cause axons to be misdirected at the ONH. These findings indicate that ECM molecules not only promote axon outgrowth, but also modify the behaviour of growth cones in response to diffusible guidance cues.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Cambridge; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Holt, C (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Holt, Christine Elizabeth/0000-0003-2829-121X				Ardini E, 1997, J BIOL CHEM, V272, P2342; Bates CA, 1996, BRAIN RES, V714, P65, DOI 10.1016/0006-8993(95)01468-3; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COHEN J, 1986, NATURE, V322, P465, DOI 10.1038/322465a0; Culotti JG, 1996, CURR OPIN NEUROBIOL, V6, P81, DOI 10.1016/S0959-4388(96)80012-2; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; DECURTIS I, 1993, DEVELOPMENT, V118, P377; Deiner MS, 1997, NEURON, V19, P575, DOI 10.1016/S0896-6273(00)80373-6; Hanson MG, 1998, J NEUROSCI, V18, P7361; HARRIS WA, 1985, J NEUROSCI RES, V13, P101, DOI 10.1002/jnr.490130108; HAUZENBERGER D, 1994, J IMMUNOL, V153, P960; HOLT CE, 1989, J NEUROSCI, V9, P3123; LIESI P, 1988, DEV BIOL, V130, P774, DOI 10.1016/0012-1606(88)90366-1; LILIENBAUM A, 1995, MOL CELL NEUROSCI, V6, P139, DOI 10.1006/mcne.1995.1013; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.3.CO;2-O; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Powell SK, 1997, INT J BIOCHEM CELL B, V29, P401, DOI 10.1016/S1357-2725(96)00110-0; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SONG HJ, 1997, NATURE, V389, P413; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; WEEKS BS, 1991, AM J PHYSIOL, V261, pF688, DOI 10.1152/ajprenal.1991.261.4.F688; Wiemelt AP, 1997, J BIOL CHEM, V272, P31489, DOI 10.1074/jbc.272.50.31489	30	393	394	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					69	73		10.1038/43441	http://dx.doi.org/10.1038/43441			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485706				2022-12-24	WOS:000082374400042
J	Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL				Shimomura, I; Hammer, RE; Ikemoto, S; Brown, MS; Goldstein, JL			Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy	NATURE			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; DIFFERENTIATION; METABOLISM; MOUSE; FAT	Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a paucity of adipose (fat) tissue which is evident at birth and is accompanied by a severe resistance to insulin, leading to hyperinsulinaemia, hyperglycaemia and enlarged fatty liver(1). We have developed a mouse model that mimics these features of CGL(2): the syndrome occurs in transgenic mice expressing a truncated version of a nuclear protein known as nSREBP-1c (for sterol-regulatory-element-binding protein-1c) under the control of the adipose-specific aP2 enhancer. Adipose tissue from these mice was markedly deficient in messenger RNAs encoding several fat-specific proteins, including leptin(2), a fat-derived hormone that regulates food intake and energy metabolism(3). Here we show that insulin resistance in our lipodystrophic mice can be overcome by a continuous systemic infusion of low doses of recombinant leptin, an effect that is not mimicked by chronic food restriction. Our results support the idea that leptin modulates insulin sensitivity and glucose disposal independently of its effect on food intake, and that leptin deficiency accounts for the insulin resistance found in CGL.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.	mbrowl@mednet.swmed.edu; jgolds@mednet.swmed.edu		Ikemoto, Shinji/0000-0002-2291-2735; Hammer, Robert E./0000-0001-5487-7551				Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Harris RBS, 1998, ENDOCRINOLOGY, V139, P8, DOI 10.1210/en.139.1.8; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168; Pardini VC, 1998, J CLIN ENDOCR METAB, V83, P503, DOI 10.1210/jc.83.2.503; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	15	775	812	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1999	401	6748					73	76		10.1038/43448	http://dx.doi.org/10.1038/43448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485707				2022-12-24	WOS:000082374400043
J	Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL				Weber-Ban, EU; Reid, BG; Miranker, AD; Horwich, AL			Global unfolding of a substrate protein by the Hsp100 chaperone ClpA	NATURE			English	Article							REGULATORY SUBUNITS; TAGGING SYSTEM; PROTEASES; BINDING; FAMILY; DEGRADATION	The bacterial protein ClpA, a member of the Hsp100 chaperone family, forms hexameric rings that bind to the free ends of the double-ring serine protease ClpP (refs 1, 2). ClpA directs the ATP-dependent degradation of substrate proteins bearing specific sequences(3-5), much as the 19S ATPase 'cap' of eukaryotic proteasomes functions in the degradation of ubiquitinated proteins(6-8). In isolation, ClpA and its relative ClpX can mediate the disassembly of oligomeric proteinsg(9,10); another similar eukaryotic protein, Hsp104, can dissociate low-order aggregates(11). ClpA has been proposed to destabilize protein structure, allowing passage of proteolysis substrates through a central channel into the ClpP proteolytic cylinder(12-14). Here we test the action of ClpA on a stable monomeric protein, the green fluorescent protein GFP, onto which has been added an Il-amino-acid carboxy-terminal recognition peptide, which is responsible for recruiting truncated proteins to ClpAP for degradation(5,15). Fluorescence studies both with and without a 'trap' version of the chaperonin GroEL, which binds non-native forms of GFP(16), and hydrogen-exchange experiments directly demonstrate that ClpA can unfold stable, native proteins in the presence of ATP.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Horwich, AL (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Genet, 295 Congress Ave, New Haven, CT 06510 USA.			Weber-Ban, Eilika/0000-0002-5773-9274				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; Miranker A, 1996, FASEB J, V10, P93, DOI 10.1096/fasebj.10.1.8566553; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Shtilerman M, 1999, SCIENCE, V284, P822, DOI 10.1126/science.284.5415.822; Wang JM, 1997, CELL, V91, P447, DOI 10.1016/S0092-8674(00)80431-6; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	20	353	357	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					90	93		10.1038/43481	http://dx.doi.org/10.1038/43481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485712				2022-12-24	WOS:000082374400048
J	[Anonymous]				[Anonymous]			Perinatal HIV prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1999	282	7					625	625		10.1001/jama.282.7.625	http://dx.doi.org/10.1001/jama.282.7.625			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226QY	10532854				2022-12-24	WOS:000082033700005
J	Knoll, AH				Knoll, AH			Paleontology - A new molecular window on early life	SCIENCE			English	Editorial Material							ATMOSPHERIC OXYGEN; EARLY EVOLUTION; PALEOSOLS; GA		Harvard Univ, Bot Museum, Cambridge, MA 02138 USA	Harvard University	Knoll, AH (corresponding author), Harvard Univ, Bot Museum, Cambridge, MA 02138 USA.	aknoll@oeb.harvard.edu						Brocks JJ, 1999, SCIENCE, V285, P1033, DOI 10.1126/science.285.5430.1033; Buick R, 1998, AAPG BULL, V82, P50; Canfield DE, 1998, NATURE, V396, P450, DOI 10.1038/24839; Golubic S, 1995, LETHAIA, V28, P285, DOI 10.1111/j.1502-3931.1995.tb01817.x; Hayes J.M., 1994, EARLY LIFE EARTH, V84, P220; Knoll AH, 1999, SCIENCE, V284, P2129, DOI 10.1126/science.284.5423.2129; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; Ohmoto H, 1996, GEOLOGY, V24, P1135, DOI 10.1130/0091-7613(1996)024<1135:EIPGPF>2.3.CO;2; OURLSSON G, 1987, MICROBIOL, V41, P301; Peters K.E., 1993, BIOMARKER GUIDE; Rasmussen B, 1999, GEOLOGY, V27, P115, DOI 10.1130/0091-7613(1999)027<0115:RSOTAA>2.3.CO;2; Rye R, 1998, AM J SCI, V298, P621, DOI 10.2475/ajs.298.8.621; Schopf JW, 1994, EARLY LIFE EARTH, P193; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	16	54	59	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1025	1026		10.1126/science.285.5430.1025	http://dx.doi.org/10.1126/science.285.5430.1025			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10475845				2022-12-24	WOS:000082033100032
J	Annas, GJ				Annas, GJ			The last resort - The use of physical restraints in medical emergencies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1984, TOLEDO LAW REV, V15, P561; BOWMAN C, 1999, BNAS HLTH LAW R 0826, P1405; Donat DC, 1998, J BEHAV THER EXP PSY, V29, P13, DOI 10.1016/S0005-7916(97)00039-6; EVANS LK, 1989, J AM GERIATR SOC, V37, P65, DOI 10.1111/j.1532-5415.1989.tb01571.x; Greenlaw J, 1982, Law Med Health Care, V10, P125; Janelli L M, 1995, J Nurs Care Qual, V9, P86; MILES SH, 1992, GERONTOLOGIST, V32, P762, DOI 10.1093/geront/32.6.762; Parker KP, 1997, J AM GERIATR SOC, V45, P797, DOI 10.1111/j.1532-5415.1997.tb01504.x; PROSSER WL, 1984, TORTS, P117; WEISS EM, 1999, HARTFORD COURAN 0731, pA14; WEISS EM, 1998, HARTFORD COURAN 1011, pA1; 1998, HARTFORD COURAN 1022, pA18; 1998, FED REG, V64, P36070; 1998, HARTFORD COURAN 1011, pA12	14	34	35	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 28	1999	341	18					1408	1412		10.1056/NEJM199910283411820	http://dx.doi.org/10.1056/NEJM199910283411820			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	249XE	10536135	Green Published			2022-12-24	WOS:000083357800028
J	Hensher, M; Fulop, N; Coast, J; Jefferys, E				Hensher, M; Fulop, N; Coast, J; Jefferys, E			The hospital of the future - Better out than in? Alternatives to acute hospital care	BRITISH MEDICAL JOURNAL			English	Article							COST MINIMIZATION ANALYSIS; HOME CARE; AT-HOME; ADMISSIONS; APPROPRIATENESS		Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	Hensher, M (corresponding author), Univ London London Sch Hyg & Trop Med, London Hlth Econ Consortium, Keppel St, London WC1E 7HT, England.		Hensher, Martin C/N-4635-2017	Hensher, Martin C/0000-0001-6444-6827; Fulop, Naomi/0000-0001-5306-6140; Coast, Joanna/0000-0002-3537-5166				ABELSMITH B, 1994, HEALTH POLICY, V28, P89, DOI 10.1016/0168-8510(94)90030-2; Apolone G, 1997, EUR J PUBLIC HEALTH, V7, P34, DOI 10.1093/eurpub/7.1.34; BAKER JE, 1986, J EPIDEMIOL COMMUN H, V40, P117, DOI 10.1136/jech.40.2.117; Coast J, 1998, BRIT MED J, V316, P1802, DOI 10.1136/bmj.316.7147.1802; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; Coast J, 1996, BRIT MED J, V312, P162; HAYES CB, 1995, IRISH MED J, V88, P124; Hensher M, 1996, J ROY SOC MED, V89, P548, DOI 10.1177/014107689608901003; Iliffe S, 1997, J ROY SOC MED, V90, P181, DOI 10.1177/014107689709000401; KNOWELDEN J, 1991, J PUBLIC HEALTH MED, V13, P182, DOI 10.1093/oxfordjournals.pubmed.a042616; Raftery J, 1998, J Health Serv Res Policy, V3, P149; READ S, 1994, PATIENTS MINOR INJUR; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERD S, 1998, COCHRANE LIB; Smith HE, 1997, J ROY COLL PHYS LOND, V31, P527; Steiner A, 1997, INTERMEDIATE CARE CO; Victor C, 1993, Health Trends, V25, P94; VICTOR CR, 1994, J PUBLIC HEALTH MED, V16, P286; Wilson A., 1997, J EPIDEMIOL COMMUNIT, V51, P593	21	37	37	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 23	1999	319	7217					1127	1130		10.1136/bmj.319.7217.1127	http://dx.doi.org/10.1136/bmj.319.7217.1127			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	250ZE	10531112	Green Published			2022-12-24	WOS:000083419500035
J	Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R				Lyden, D; Young, AZ; Zagzag, D; Yan, W; Gerald, W; O'Reilly, R; Bader, BL; Hynes, RO; Zhuang, Y; Manova, K; Benezra, R			Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts	NATURE			English	Article							LOOP-HELIX PROTEIN; MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTORS; EXPRESSION PATTERNS; CELL DEVELOPMENT; E2A PROTEINS; MOUSE EMBRYO; NEURAL-TUBE; GENE FAMILY; T-CELL	Id proteins may control cell differentiation by interfering with DNA binding of transcription factors. Here we show that targeted disruption of the dominant negative helix-loop-helix proteins Id1 and ld3 in mice results in premature withdrawal of neuroblasts from the cell cycle and expression of neural-specific differentiation markers. The ld1-ld3 double knockout mice also display vascular malformations in the forebrain and an absence of branching and sprouting of blood vessels into the neuroectoderm. As angiogenesis both in the brain and in tumours requires invasion of avascular tissue by endothelial cells, we examined the Id knockout mice for their ability to support the growth of tumour xenografts, Three different tumours failed to grow and/or metastasize in ld1(+/-)ld3(-/-) mice, and any tumour growth present showed poor vascularization and extensive necrosis, Thus, the Id genes are required to maintain the timing of neuronal differentiation in the embryo and invasiveness of the vasculature, Because the Id genes are expressed at very low levels in adults, they make attractive new targets for anti-angiogenic drug design.	Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Cytol Core Facil, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; NYU, Kaplan Canc Ctr, Dept Pathol, Div Neuropathol, New York, NY 10016 USA; MIT, Howard Hughes Med Inst Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Max Planck Inst Biochem, Dept Prot Chem, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; New York University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Max Planck Society; Duke University	Benezra, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Cell Biol, 1275 York Ave, New York, NY 10021 USA.			zhuang, yuan/0000-0002-2964-3654				AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Deed RW, 1998, J BIOL CHEM, V273, P8278, DOI 10.1074/jbc.273.14.8278; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DUNCAN M, 1992, DEV BIOL, V154, P1, DOI 10.1016/0012-1606(92)90042-F; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLMEIER W, 1995, DEV DYNAM, V203, P163, DOI 10.1002/aja.1002030205; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jen Y, 1996, DEV DYNAM, V207, P235; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Jen Y, 1997, DEV DYNAM, V208, P92, DOI 10.1002/(SICI)1097-0177(199701)208:1<92::AID-AJA9>3.0.CO;2-X; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KATAGIRI T, 1995, J CELL BIOL, V128, P713; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Manova K, 1998, DEV DYNAM, V213, P293, DOI 10.1002/(SICI)1097-0177(199811)213:3<293::AID-AJA6>3.0.CO;2-D; Martinsen BJ, 1998, SCIENCE, V281, P988, DOI 10.1126/science.281.5379.988; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; NEUMAN T, 1993, DEV BIOL, V160, P186, DOI 10.1006/dbio.1993.1297; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pan LH, 1999, MOL CELL BIOL, V19, P5969; PERLMAN JM, 1986, AM J DIS CHILD, V140, P1122, DOI 10.1001/archpedi.1986.02140250048034; PRICE M, 1991, NATURE, V351, P748, DOI 10.1038/351748a0; QUERTERMOUS EE, 1994, P NATL ACAD SCI USA, V91, P7066, DOI 10.1073/pnas.91.15.7066; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SHERWOOD A, 1978, NEUROPATH APPL NEURO, V4, P245, DOI 10.1111/j.1365-2990.1978.tb00543.x; Shimamura K, 1995, DEVELOPMENT, V121, P3923; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMONSON MS, 1993, NUCLEIC ACIDS RES, V21, P5767, DOI 10.1093/nar/21.24.5767; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WALTHER C, 1991, DEVELOPMENT, V113, P1435; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	51	738	775	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	1999	401	6754					670	677		10.1038/44334	http://dx.doi.org/10.1038/44334			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537105				2022-12-24	WOS:000083207400048
J	Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW				Snijder, HJ; Ubarretxena-Belandia, I; Blaauw, M; Kalk, KH; Verheij, HM; Egmond, MR; Dekker, N; Dijkstra, BW			Structural evidence for dimerization-regulated activation of an integral membrane phospholipase	NATURE			English	Article							ESCHERICHIA-COLI; ENZYMATIC-ACTIVITY; CRYSTAL-STRUCTURES; DIFFRACTION DATA; MOLSCRIPT	Dimerization is a biological regulatory mechanism employed by both soluble and membrane proteins'. However, there are few structural data on the factors that govern dimerization of membrane proteins. Outer membrane phospholipase A (OMPLA) is an integral membrane enzyme which participates in secretion of colicins in Escherichia coli. In Campilobacter(2) and Helicobacter pylori strains(3), OMPLA is implied in virulence. Its activity is regulated by reversible dimerization(4,5) Here we report X-ray structures of monomeric and dimeric OMPLA from E. coli. Dimer interactions occur almost exclusively in the apolar membrane-embedded parts, with two hydrogen bonds within the hydrophobic membrane area being key interactions. Dimerization results in functional oxyanion holes and substrate-binding pockets, which are absent in monomeric OMPLA. These results provide a detailed view of activation by dimerization of a membrane protein.	Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Enzymol & Prot Engn, NL-3584 CH Utrecht, Netherlands	University of Groningen; Utrecht University	Dijkstra, BW (corresponding author), Univ Groningen, BIOSON Res Inst, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Dijkstra, Bauke W./H-4308-2019; Ubarretxena-Belandia, Iban/A-8389-2009; Ubarretxena-Belandia, Iban/AAA-8939-2019	Dijkstra, Bauke W./0000-0001-9731-6586; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLAAUW M, 1995, FEBS LETT, V373, P10, DOI 10.1016/0014-5793(95)01002-V; Brok RGPM, 1996, BIOCHEMISTRY-US, V35, P7787, DOI 10.1021/bi952970i; Brok RGPM, 1995, EUR J BIOCHEM, V234, P934, DOI 10.1111/j.1432-1033.1995.934_a.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Bukholm G, 1997, SCAND J GASTROENTERO, V32, P445, DOI 10.3109/00365529709025079; Dekker N, 1999, J BACTERIOL, V181, P3281, DOI 10.1128/JB.181.10.3281-3283.1999; Dekker N, 1997, J BIOL CHEM, V272, P3179, DOI 10.1074/jbc.272.6.3179; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Grant KA, 1997, INFECT IMMUN, V65, P1172, DOI 10.1128/IAI.65.4.1172-1180.1997; HORREVOETS AJG, 1989, BIOCHEMISTRY-US, V28, P1139, DOI 10.1021/bi00429a031; HORREVOETS AJG, 1991, EUR J BIOCHEM, V198, P247, DOI 10.1111/j.1432-1033.1991.tb16008.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; Merck KB, 1997, J BACTERIOL, V179, P3443, DOI 10.1128/jb.179.11.3443-3450.1997; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pautsch A, 1998, NAT STRUCT BIOL, V5, P1013, DOI 10.1038/2983; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; Ubarretxena-Belandia I, 1999, BIOCHEMISTRY-US, V38, P7398, DOI 10.1021/bi983077x; Ubarretxena-Belandia I, 1998, BIOCHEMISTRY-US, V37, P16011, DOI 10.1021/bi9814181; WEI YY, 1995, NAT STRUCT BIOL, V2, P218, DOI 10.1038/nsb0395-218; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242	29	202	210	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 14	1999	401	6754					717	721		10.1038/44890	http://dx.doi.org/10.1038/44890			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EJ	10537112	Green Published			2022-12-24	WOS:000083207400061
J	Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF				Cate, JH; Yusupov, MM; Yusupova, GZ; Earnest, TN; Noller, HF			X-ray crystal structures of 70S ribosome functional complexes	SCIENCE			English	Review							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA BINDING; NUCLEAR MAGNETIC-RESONANCE; P-SITE; THERMUS-THERMOPHILUS; A-SITE; BACILLUS-STEAROTHERMOPHILUS; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL STRUCTURE; PROMOTES TRANSLOCATION	Structures of 70S ribosome complexes containing messenger RNA and transfer RNA (tRNA), or tRNA analogs, have been solved by x-ray crystallography at up to 7.8 angstrom resolution. Many details of the interactions between tRNA and the ribosome, and of the packing arrangements of ribosomal RNA (rRNA) helices in and between the ribosomal subunits, can be seen. Numerous contacts are made between the 30S subunit and the P-tRNA anticodon stem-loop; in contrast, the anticodon region of A-tRNA is much more exposed. A complex network of molecular interactions suggestive of a functional relay is centered around the Long penultimate stem of 16S rRNA at the subunit interface, including interactions involving the "switch" helix and decoding site of 16S rRNA, and RNA bridges from the 50S subunit.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Lawrence Berkeley Lab, Phys Biosci Div, Macromol Crystallog Facil, Berkeley, CA 94720 USA	University of California System; University of California Santa Cruz; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Cate, JH (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.	cate@wi.mit.edu; marat@darwin.ucsc.edu; harry@nuvolari.ucsc.edu	Yusupova, Gulnara/E-1877-2014; Yusupov, Marat/I-6126-2013	Yusupov, Marat/0000-0001-5544-0597	NIGMS NIH HHS [GM-17129, GM-59140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017129, R01GM017129, R01GM059140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1999, NAT STRUCT BIOL, V6, P643, DOI 10.1038/10695; Agrawal RK, 1999, CURR OPIN STRUC BIOL, V9, P215, DOI 10.1016/S0959-440X(99)80031-1; ALLEN PN, 1989, J MOL BIOL, V208, P457, DOI 10.1016/0022-2836(89)90509-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ban N, 1998, CELL, V93, P1105, DOI 10.1016/S0092-8674(00)81455-5; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Borowski C, 1996, P NATL ACAD SCI USA, V93, P4202, DOI 10.1073/pnas.93.9.4202; BOUSSERT AS, 1977, J MOL BIOL, V116, P577; BOWMAN CM, 1971, P NATL ACAD SCI USA, V68, P964, DOI 10.1073/pnas.68.5.964; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHAPMAN NM, 1977, J MOL BIOL, V109, P131, DOI 10.1016/S0022-2836(77)80049-1; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; CULVER GM, UNPUB; Dallas A, 1997, STRUCTURE, V5, P1639, DOI 10.1016/S0969-2126(97)00311-0; Easterwood TR, 1995, BIOCHEM CELL BIOL, V73, P751, DOI 10.1139/o95-083; Fink DL, 1996, RNA, V2, P851; Fourmy D, 1998, J MOL BIOL, V277, P333, DOI 10.1006/jmbi.1997.1551; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; Frank J, 1995, BIOCHEM CELL BIOL, V73, P757, DOI 10.1139/o95-084; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; Gabashvili IS, 1999, J MOL BIOL, V286, P1285, DOI 10.1006/jmbi.1999.2538; GATE L, UNPUB; GAUTHERET D, 1994, J MOL BIOL, V242, P1, DOI 10.1006/jmbi.1994.1552; GAVRILOVA L P, 1972, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V6, P248; GERSTEIN M, 1992, ACTA CRYSTALLOGR A, V48, P271, DOI 10.1107/S0108767391012680; GOGIYA Z B, 1986, Molekulyarnaya Biologiya (Moscow), V20, P519; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X; Gudkov AT, 1997, FEBS LETT, V407, P253, DOI 10.1016/S0014-5793(97)00361-X; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; GULVER GM, 1999, J MOL BIOL, V286, P355; HANSEN HAS, 1990, BIOCHIM BIOPHYS ACTA, V1050, P1, DOI 10.1016/0167-4781(90)90132-L; HARAUZ G, 1988, METHOD ENZYMOL, V164, P35; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HERR W, 1979, J MOL BIOL, V130, P421, DOI 10.1016/0022-2836(79)90432-7; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Hill WE., 1990, RIBOSOME STRUCTURE F; HINGERTY B, 1978, J MOL BIOL, V124, P523, DOI 10.1016/0022-2836(78)90185-7; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; KASTNER B, 1981, P NATL ACAD SCI-BIOL, V78, P6652, DOI 10.1073/pnas.78.11.6652; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUHLBRANDT W, 1982, J MOL BIOL, V156, P431, DOI 10.1016/0022-2836(82)90259-5; KURLAND CG, 1980, RIBOSOMES STRUCTURE, P597; LAKE JA, 1976, J MOL BIOL, V105, P131, DOI 10.1016/0022-2836(76)90200-X; Lata KR, 1996, J MOL BIOL, V262, P43, DOI 10.1006/jmbi.1996.0497; Leontis NB, 1998, J MOL BIOL, V283, P571, DOI 10.1006/jmbi.1998.2106; LILL R, 1989, EMBO J, V8, P3933, DOI 10.1002/j.1460-2075.1989.tb08574.x; Lodmell JS, 1997, SCIENCE, V277, P1262, DOI 10.1126/science.277.5330.1262; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Mangroo D, 1995, BIOCHEM CELL BIOL, V73, P1023, DOI 10.1139/o95-109; Merryman C, 1999, J MOL BIOL, V285, P97, DOI 10.1006/jmbi.1998.2242; Merryman C, 1999, J MOL BIOL, V285, P107, DOI 10.1006/jmbi.1998.2243; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Moore PB, 1998, ANNU REV BIOPH BIOM, V27, P35, DOI 10.1146/annurev.biophys.27.1.35; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; Newcomb LF, 1999, BIOCHEMISTRY-US, V38, P945, DOI 10.1021/bi981644a; Nikonov SV, 1998, BIOL CHEM, V379, P795, DOI 10.1515/bchm.1998.379.7.795; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1990, RIBOSOME, P73; Noller HF, 1995, BIOCHEM CELL BIOL, V73, P997, DOI 10.1139/o95-107; NOLLER HF, 1986, STRUCTURE FUNCTION G, P143; ODOM OW, 1990, BIOCHEMISTRY-US, V29, P10734, DOI 10.1021/bi00500a004; OFENGAND J, 1979, BIOCHEMISTRY-US, V18, P4322, DOI 10.1021/bi00587a010; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; RADERMACHER M, 1987, EMBO J, V6, P1107, DOI 10.1002/j.1460-2075.1987.tb04865.x; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RHEINBERGER HJ, 1981, P NATL ACAD SCI-BIOL, V78, P5310, DOI 10.1073/pnas.78.9.5310; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; SANTER M, 1977, J BACTERIOL, V130, P900, DOI 10.1128/JB.130.2.900-910.1977; SCHNEIDER G, 1994, ACTA CRYSTALLOGR D, V50, P186, DOI 10.1107/S0907444993009679; SCHWEDLER G, 1993, EUR J BIOCHEM, V217, P361, DOI 10.1111/j.1432-1033.1993.tb18254.x; SPIRIN AS, 1974, FEBS LETT, V40, P38; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; SZEWCZAK AA, 1995, J MOL BIOL, V247, P81, DOI 10.1006/jmbi.1994.0124; TRAKHANOV S, 1989, J MOL BIOL, V209, P327, DOI 10.1016/0022-2836(89)90282-9; TRAKHANOV SD, 1987, FEBS LETT, V220, P319, DOI 10.1016/0014-5793(87)80838-4; TRAUT RR, 1986, STRUCTURE FUNCTION G; VASILIEV VD, 1983, J MOL BIOL, V171, P561, DOI 10.1016/0022-2836(83)90043-8; VASSILENKO SK, 1981, J MOL BIOL, V152, P699, DOI 10.1016/0022-2836(81)90123-6; VONAHSEN U, 1995, SCIENCE, V267, P234, DOI 10.1126/science.7528943; WATSON JD, 1964, B SOC CHIM BIOL, V46, P1399; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOWER J, 1990, BIOCHIM BIOPHYS ACTA, V1050, P38, DOI 10.1016/0167-4781(90)90138-R; YONATH AE, 1980, BIOCHEM INT, V1, P428; YUSUPOV M M, 1987, Doklady Akademii Nauk SSSR, V292, P1271; YUSUPOV MM, 1986, FEBS LETT, V197, P229, DOI 10.1016/0014-5793(86)80332-5; YUSUPOV MM, 1991, BIOCHIMIE, V73, P887, DOI 10.1016/0300-9084(91)90130-S; YUSUPOVA G, 1991, FEBS LETT, V290, P69, DOI 10.1016/0014-5793(91)81228-Z	125	500	525	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1999	285	5436					2095	2104		10.1126/science.285.5436.2095	http://dx.doi.org/10.1126/science.285.5436.2095			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	238VF	10497122				2022-12-24	WOS:000082734300034
J	Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE				Hoppa, GV; Tufts, BR; Greenberg, R; Geissler, PE			Formation of cycloidal features on Europa	SCIENCE			English	Article							TIDAL STRESSES; FRACTURE; SEPARATION; PATTERNS	Cycloidal patterns are widely distributed on the surface of Jupiter's moon Europa. Tensile cracks may have developed such a pattern in response to diurnal variations in tidal stress in Europa's outer ice shell. When the tensile strength of the ice is reached, a crack may occur. Propagating cracks would move across an ever-changing stress field, following a curving path to a place and time where the tensile stress was insufficient to continue the propagation. A few hours Later, when the stress at the end of the crack again exceeded the strength, propagation would continue in a new direction. Thus, one arcuate segment of the cycloidal chain would be produced during each day on Europa. For this model to work, the tensile strength of Europa's ice crust must be Less than 40 kilo-pascals, and there must be a thick fluid Layer below the ice to allow sufficient tidal amplitude.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Hoppa, GV (corresponding author), Univ Arizona, Lunar & Planetary Lab, 1629 E Univ Blvd, Tucson, AZ 85721 USA.							CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; GAMMON PH, 1983, J PHYS CHEM-US, V87, P4025, DOI 10.1021/j100244a004; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Greenberg R, 1998, ICARUS, V135, P64, DOI 10.1006/icar.1998.5986; HEAD JW, IN PRESS J GEOPHYS R; HELFENSTEIN P, 1983, ICARUS, V53, P415, DOI 10.1016/0019-1035(83)90206-3; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1996, LUNAR PLANET SCI C, V30; KADEL SD, 1998, LUNAR PLANET SCI C, V29; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MALIN MC, 1986, SATELLITES, P689; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; NOLAN M, 1987, B AM ASTRON SOC, V19, P860; OJKANGASGW, 1989, ICARUS, V81, P242; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; PEALE SJ, 1979, SCIENCE, V203, P892, DOI 10.1126/science.203.4383.892; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; Smith RA, 1976, J GLACIOL, V17, P223; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; Tufts B. R., 1998, THESIS U ARIZONA TUC; TUFTS BJ, UNPUB; TURTLE EP, 1998, EOS, V79, pS202	24	168	171	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1999	285	5435					1899	1902		10.1126/science.285.5435.1899	http://dx.doi.org/10.1126/science.285.5435.1899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	237CT	10489365				2022-12-24	WOS:000082638300045
J	Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M				Plotnikov, AN; Schlessinger, J; Hubbard, SR; Mohammadi, M			Structural basis for FGF receptor dimerization and activation	CELL			English	Article							FIBROBLAST-GROWTH-FACTOR; LIGAND-BINDING SPECIFICITY; 3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; POINT MUTATION; CELL-ADHESION; FACTOR FAMILY; HEPARIN; AFFINITY; PROTEIN	The crystal structure of FGF2 bound to a naturally occurring variant of FGF receptor 1 (FGFR1) consisting of immunoglobulin-like domains 2 (D2) and 3 (D3) has been determined at 2.8 Angstrom resolution. Two FGF2:FGFR1 complexes form a 2-fold symmetric dimer. Within each complex, FGF2 interacts extensively with D2 and D3 as well as with the linker between the two domains. The dimer is stabilized by interactions between FGF2 and D2 of the adjoining complex and by a direct interaction between D2 of each receptor. A positively charged canyon formed by a cluster of exposed basic residues likely represents the heparin-binding site. A general model for FGF- and heparin-induced FGFR dimerization is inferred from the crystal structure, unifying a wealth of biochemical data.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, New York, NY 10016 USA	New York University; New York University	Mohammadi, M (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		kasaei, fahime/T-7197-2018; Mohammadi, Moosa/ABA-6745-2020	Mohammadi, Moosa/0000-0003-2434-9437; Hubbard, Stevan/0000-0002-2707-9383				AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BATEMAN A, 1995, NAT STRUCT BIOL, V2, P1068, DOI 10.1038/nsb1295-1068; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; DELL KR, 1992, J BIOL CHEM, V267, P21225; Doherty P, 1996, MOL CELL NEUROSCI, V8, P99, DOI 10.1006/mcne.1996.0049; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4327; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KOBRIN MS, 1993, CANCER RES, V53, P4741; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Naski M C, 1998, Front Biosci, V3, pd781; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Noe V, 1999, J CELL SCI, V112, P127; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OTWINOWSKI Z, 1993, P CCP4 STUD WEEK DAR; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGER BA, 1994, J BIOL CHEM, V269, P26879; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; Wang F, 1997, J BIOL CHEM, V272, P23887, DOI 10.1074/jbc.272.38.23887; Wang F, 1999, BIOCHEMISTRY-US, V38, P160, DOI 10.1021/bi981758m; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; Zhu HY, 1997, PROTEIN ENG, V10, P417, DOI 10.1093/protein/10.4.417; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; Zhu HY, 1998, PROTEIN ENG, V11, P937, DOI 10.1093/protein/11.10.937; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	57	481	527	2	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 3	1999	98	5					641	650		10.1016/S0092-8674(00)80051-3	http://dx.doi.org/10.1016/S0092-8674(00)80051-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	233NT	10490103	hybrid			2022-12-24	WOS:000082433500011
J	Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R				Rojas, JR; Trievel, RC; Zhou, JX; Mo, Y; Li, XM; Berger, SL; Allis, CD; Marmorstein, R			Structure of Tetrahymena GCN5 bound to coenzyme A and a histone H3 peptide	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; CRYSTAL-STRUCTURE; IN-VIVO; REFINEMENT; COMPLEXES; PROTEIN; SUPERFAMILY; ACETYLATION; DYNAMICS; ADA	Gene activation is a highly regulated process that requires the coordinated action of proteins to relieve chromatin repression and to promote transcriptional activation. Nuclear histone acetyltransferase (HAT) enzymes provide a mechanistic link between chromatin destabilization and gene activation by acetylating the E-amino group of specific lysine residues within the aminoterminal tails of core histones to facilitate access to DNA by transcriptional activators(1,2). Here we report the high-resolution crystal structure of the HAT domain of Tetrahymena GCN5 (tGCN5) bound with both its physiologically relevant ligands, coenzyme A (CoA) and a histone H3 peptide, and the structures of nascent tGCN5 and a tGCN5/acetyl-CoA complex. Our structural data reveal histone-binding specificity for a random-coil structure Containing a G-K-X-P recognition sequence, and show that CoA is essential for reorienting the enzyme for histone binding. Catalysis appears to involve water-mediated proton extraction from the substrate lysine by a glutamic acid general base and a backbone amide that stabilizes the transition-state reaction intermediate. Comparison with related N-acetyltransferases indicates a conserved structural framework for CoA binding and catalysis, and structural variability in regions associated with substrate-specific binding.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Rochester	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.		li, xinmin/C-6173-2011	Berger, Shelley/0000-0001-5398-4400				Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR MANUAL VERSION; Clements A, 1999, EMBO J, V18, P3521, DOI 10.1093/emboj/18.13.3521; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; FUREY W, 1995, METHOD ENZYMOL, P590; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; Lin YX, 1999, NATURE, V400, P86, DOI 10.1038/21922; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Weston SA, 1998, NAT STRUCT BIOL, V5, P213, DOI 10.1038/nsb0398-213; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	29	225	230	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 2	1999	401	6748					93	98		10.1038/43487	http://dx.doi.org/10.1038/43487			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	232MK	10485713				2022-12-24	WOS:000082374400049
J	Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M				Lenormand, T; Bourguet, D; Guillemaud, T; Raymond, M			Tracking the evolution of insecticide resistance in the mosquito Culex pipiens	NATURE			English	Article							GENE FLOW; HYBRID ZONE; SELECTION; MODEL; CLINE	The evolution of pesticide resistance provides some of the most striking examples of darwinian evolution occurring over a human life span. Identification of resistance alleles opens an outstanding framework in which to study the evolution of adaptive mutations from the beginning of pesticide application(1-3), the evolution of interactions between alleles (dominance(4)) or between loci (epistasis(5,6)). Here we shaw that resistance alleles can also be used as markers to dissect population processes at a microevolutionary scale. We have focused on the antagonistic roles of selection and migration involved in the dynamics of local adaptation with reference to allelic frequencies at two resistance loci in the mosquito Culex pipiens, We find that their frequencies follow an annual cycle of large amplitude (25%), and we precisely unravel the seasonal variation of migration and selection underlying this cycle. Our results provide a firm basis on which to devise an insecticide treatment strategy that will better control the evolution of resistance genes and the growth of mosquito populations.	Univ Montpellier 2, Inst Sci Evolut, Lab Genet & Environm, UMR 5554, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Lenormand, T (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.		Raymond, Michel/C-9049-2015; guillemaud, thomas/B-4899-2012; Lenormand, Thomas/A-5328-2012	guillemaud, thomas/0000-0003-0451-1644; Lenormand, Thomas/0000-0001-8930-5393; Bourguet, Denis/0000-0002-2109-5323; Raymond, Michel/0000-0002-1714-6984				ANDERSON DR, 1994, ECOLOGY, V75, P1780, DOI 10.2307/1939637; BARTON NH, 1989, NATURE, V341, P497, DOI 10.1038/341497a0; BARTON NH, 1982, EVOLUTION, V36, P863, DOI 10.1111/j.1558-5646.1982.tb05452.x; Bourguet D, 1997, GENETICS, V147, P1225; Chevillon C, 1997, GENET RES, V70, P195, DOI 10.1017/S0016672397003029; Cook LM, 1999, P ROY SOC B-BIOL SCI, V266, P293, DOI 10.1098/rspb.1999.0636; Davies AG, 1996, GENETICS, V143, P1321; Guillemaud T, 1998, EVOLUTION, V52, P443, DOI 10.1111/j.1558-5646.1998.tb01644.x; HALDANE JBS, 1948, J GENET, V48, P277, DOI 10.1007/BF02986626; Harrison R.G., 1990, Oxford Surveys in Evolutionary Biology, V7, P69; JAIN SK, 1966, HEREDITY, V21, P407, DOI 10.1038/hdy.1966.42; Kettlewell H. B. D., 1961, Heredity, V16, P403, DOI 10.1038/hdy.1961.49; Lenormand T, 1998, EVOLUTION, V52, P1705, DOI 10.2307/2411343; Lenormand T, 1998, GENETICS, V149, P1383; Lenormand T, 1998, P ROY SOC B-BIOL SCI, V265, P1985, DOI 10.1098/rspb.1998.0529; LENORMAND T, IN PRESS AM NAT; MALLET J, 1990, GENETICS, V124, P921; MALLET J, 1989, TRENDS ECOL EVOL, V4, P336, DOI 10.1016/0169-5347(89)90088-8; MANI GS, 1980, PROC R SOC SER B-BIO, V210, P299, DOI 10.1098/rspb.1980.0135; MAY RM, 1975, AM NAT, V109, P659, DOI 10.1086/283036; McKenzie J., 1996, ECOLOGICAL EVOLUTION; MUTERO A, 1994, P NATL ACAD SCI USA, V91, P5922, DOI 10.1073/pnas.91.13.5922; NAGLAKI T, 1975, GENETICS, V80, P595; Porter AH, 1997, EVOLUTION, V51, P1561, DOI [10.2307/2411208, 10.1111/j.1558-5646.1997.tb01479.x]; RAYMOND M, 1989, GENETICS, V123, P543; SITES JW, 1995, EVOLUTION, V49, P9, DOI 10.1111/j.1558-5646.1995.tb05955.x; SLATKIN M, 1975, GENETICS, V81, P787; SLATKIN M, 1973, GENETICS, V75, P733; SZYMURA JM, 1986, EVOLUTION, V40, P1141, DOI 10.1111/j.1558-5646.1986.tb05740.x	29	161	166	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 26	1999	400	6747					861	864		10.1038/23685	http://dx.doi.org/10.1038/23685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	230CA	10476962				2022-12-24	WOS:000082233200042
J	Kay, S				Kay, S			Brachial palsies from obstetric procedures	LANCET			English	Editorial Material							PLEXUS INJURIES		St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Kay, S (corresponding author), St Jamess Univ Hosp, Dept Plast Reconstruct & Hand Surg, Leeds LS9 7TF, W Yorkshire, England.							Bager B, 1997, ACTA PAEDIATR, V86, P1214, DOI 10.1111/j.1651-2227.1997.tb14849.x; BIRCH R, 1993, J BONE JOINT SURG BR, V75, P346, DOI 10.1302/0301-620X.75B3.8496196; CLARKE HM, 1995, HAND CLIN, V11, P563; GJORUP L, 1966, ACTA NEUROL SCAN S18, V42, P1; Kay SPJ, 1998, BRIT J PLAST SURG, V51, P43, DOI 10.1054/bjps.1997.0166; Mallet J, 1972, REV CHIR ORTHOP S1, V58, P115; Narakas AO., 1987, PARALYSED HAND, P116; Smith B, 1996, BYTE, V21, P145; Tassin GA, 1987, MICRORECONSTRUCTION, P529; TASSIN JL, 1983, THESIS U PARIS 7; Waters PM, 1999, J BONE JOINT SURG AM, V81A, P649, DOI 10.2106/00004623-199905000-00006	11	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 21	1999	354	9179					614	615		10.1016/S0140-6736(99)00222-6	http://dx.doi.org/10.1016/S0140-6736(99)00222-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466658				2022-12-24	WOS:000082214500005
J	Tipton, M; Eglin, C; Gennser, M; Golden, F				Tipton, M; Eglin, C; Gennser, M; Golden, F			Immersion deaths and deterioration in swimming performance in cold water	LANCET			English	Article							THERMAL RESPONSES; EXERCISE; LEG	Background General hypothermia (deep body temperature <35 degrees C) has been implicated in immersion-related deaths, but many deaths occur too quickly for it to be involved. We investigated changes in swimming capability in cold water to find out whether such changes could lead to swim failure and drowning. Methods Ten volunteers undertook three self paced breaststroke swims in a variable-speed swimming flume, in water at 25 degrees C, 18 degrees C, and 10 degrees C, for a maximum of 90 min, During each swim, we measured oxygen consumption, rectal temperature, swim speed and angle, and stroke rate and length. Swim failure was defined as being unable to keep feet off the bottom of the flume. Findings All ten swimmers completed 90 min swims at 25 degrees C, eight completed swims at 18 degrees C, and five at 10 degrees C. In 10 degrees C water, one swimmer reached swim failure after 61 min and four were withdrawn before 90 min with rectal temperatures of 35 degrees C when they were close to swim failure. Swimming efficiency and length of stroke decreased more and rate of stroke and swim angle increased more in 10 degrees C water than in warmer water. These variables seemed to characterise impending swim failure. Interpretation Impaired performance and initial cardiorespiratory responses to immersion probably represent the major dangers to immersion victims. Consequently, treatment should be aimed at symptoms resulting from near-drowning rather than severe hypothermia.	Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England; Natl Def Res Estab, Dept Naval Med, Harsfjarden, Sweden	University of Portsmouth	Tipton, M (corresponding author), Univ Portsmouth, Dept Sport & Exercise Sci, Portsmouth PO1 2DT, Hants, England.	michael.tipton@port.ac.uk		Eglin, Clare Mary/0000-0002-3848-6515; Tipton, Michael/0000-0002-7928-8451				DULAC S, 1987, INT J SPORTS MED, V8, P352, DOI 10.1055/s-2008-1025683; GLASER EM, 1951, J PHYSIOL-LONDON, V115, pP14; Golden F, 1981, HYPOTHERMIA ASHORE A; GOLDEN FS, 1987, J PHYSIOL-LONDON, V391, P399, DOI 10.1113/jphysiol.1987.sp016744; GOLDEN FS, 1986, J PHYSIOL-LONDON, V378, pP94; Golden FS, 1997, BRIT J ANAESTH, V79, P214, DOI 10.1093/bja/79.2.214; GOLDEN FSC, 1982, J PHYSIOL-LONDON, V330, pP60; HOLMER I, 1974, ACTA PHYSIOL SCAND, P1; HOLMER I, 1974, J APPL PHYSIOL, V37, P702, DOI 10.1152/jappl.1974.37.5.702; Home Office, 1977, REP WORK PART WAT SA; HUTCHINSON P, 1998, STAYING ALIVE    SPR, P12; KEATINGE WR, 1969, BRIT MED J, V1, P480, DOI 10.1136/bmj.1.5642.480; NADEL ER, 1974, J APPL PHYSIOL, V36, P465, DOI 10.1152/jappl.1974.36.4.465; PUGH LGC, 1967, BRIT MED J, V2, P333, DOI 10.1136/bmj.2.5548.333; *ROSPA, 1988, DROWN UK 1987; *ROYAL COLL PHYS L, 1966, REP COMM ACC HYP; Scheffe H., 1959, ANAL VARIANCE; TIPTON MJ, 1989, CLIN SCI, V77, P581, DOI 10.1042/cs0770581; TONER MM, 1984, J APPL PHYSIOL, V56, P1355, DOI 10.1152/jappl.1984.56.5.1355	19	51	51	0	40	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 21	1999	354	9179					626	629		10.1016/S0140-6736(99)07273-6	http://dx.doi.org/10.1016/S0140-6736(99)07273-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229UQ	10466663				2022-12-24	WOS:000082214500010
